camptothecin has been researched along with irinotecan in 6320 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (0.11) | 18.7374 |
| 1990's | 596 (9.43) | 18.2507 |
| 2000's | 2938 (46.49) | 29.6817 |
| 2010's | 2636 (41.71) | 24.3611 |
| 2020's | 143 (2.26) | 2.80 |
| Authors | Studies |
|---|---|
| Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL | 1 |
| Pan, X; Wang, HJ; Yang, LX | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| LaVoie, EJ; Li, TK; Liu, A; Liu, LF; Ruchelman, AL; Singh, SK | 1 |
| Friedrich, TD; Guzzo, PR; Jason Herr, R; Nacro, K; Peace, D; Zha, CC | 1 |
| Liu, YQ; Tian, X; Yang, L; Zhan, ZC | 1 |
| Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Che, X; Cheng, P; Dong, G; Feng, H; Guo, W; Liu, W; Luo, C; Miao, Z; Sheng, C; Wang, J; Wang, W; Xu, Y; Yao, J; You, L; Zhang, J; Zhang, W; Zhou, L; Zhu, L | 1 |
| Dong, G; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W | 1 |
| Ahluwalia, D; Bhupathi, D; Cai, X; Duan, JX; Hart, CP; Huang, H; Jiao, H; Jung, B; Jung, D; Liu, Q; Matteucci, J; Matteucci, M; Meng, F; Sun, JD | 1 |
| Kamisuki, S; Kanai, Y; Kusayanagi, T; Manita, D; Matsumoto, Y; Sakaguchi, K; Sugawara, F; Takada, K; Takakusagi, K; Takakusagi, Y; Toba, Y; Tsukuda, S | 1 |
| Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y | 1 |
| Dai, W; Lee, KH; Li, WQ; Liu, YQ; Morris-Natschke, SL; Wang, CY; Yang, L; Yang, XM; Zhou, XW | 1 |
| Chang, LC; Goto, M; Hung, HY; Kuo, DH; Kuo, SC; Lee, KH; Liu, YQ; Morris-Natschke, SL; Nan, X; Pan, SL; Qian, K; Teng, CM; Wang, CY; Wang, MJ; Wu, TS; Wu, YC; Yang, JS; Yang, L; Yang, XM; Zhao, XB; Zhao, YL | 1 |
| Chen, S; Dong, G; Fang, K; Li, J; Liu, N; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W | 1 |
| Goto, M; Lee, KH; Li, L; Liu, H; Liu, YQ; Morris-Natschke, SL; Song, ZL; Wang, CY; Wang, MJ; Wang, YH; Wu, D; Yan, LT; Zhao, YL; Zhu, GX | 1 |
| Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL | 1 |
| Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX | 1 |
| Dong, G; Fang, Y; Liu, N; Liu, Y; Sheng, C; Wu, S; Zhang, W | 1 |
| Goto, M; Hsu, PL; Lee, KH; Liu, YQ; Morris-Natschke, SL; Shang, XF; Song, ZL; Wang, MJ; Yang, CJ; Yang, QR; Zhang, XS | 1 |
| Jiang, J; Jing, D; Liang, X; Liu, X; Rashid, HU; Wang, H; Wang, L; Wu, L; Xie, P; Xu, Y | 1 |
| Fujimoto, M; Fukuda, T; Ishibashi, F; Iwao, M; Nanjo, Y; Natsui, Y; Okazaki, F; To, H; Yoshida, K | 1 |
| Chen, W; Fu, K; Hu, J; Huang, W; Jiang, Z; Li, M; Shi, Y; Ye, W; Zhou, C; Zhou, W | 1 |
| Goon, S; Kundu, B; Mondal, MA; Sarkar, D; Talukdar, A | 1 |
| Fujita, M; Kobayashi, I; Miyamoto, Y; Morishita, Y; Owada, S; Taguchi, T; Takeshita, M | 1 |
| Ariyoshi, Y; Fukuoka, M; Hasegawa, K; Kuriyama, T; Masuda, N; Motomiya, M; Negoro, S; Niitani, H; Nishiwaki, Y; Suzuki, A | 1 |
| Hirabayashi, N; Jinushi, K; Kim, R; Nishiyama, M; Okada, K; Toge, T | 1 |
| Kono, A; Sato, K; Shimazoe, T; Sugimoto, Y; Takeda, S; Tsuruo, T | 1 |
| Eguchi, K; Karato, A; Kojima, A; Kunikane, H; Ohe, Y; Ohmatsu, H; Okamoto, H; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Fukuoka, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Nishioka, M; Takada, M; Takifuji, N | 1 |
| Fukuoka, M; Kishimoto, S; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Kono, A; Kuga, H; Sato, K; Shimazoe, T; Takeda, S | 1 |
| Ariyoshi, Y; Sugiura, T | 2 |
| Fujiwara, Y; Kanzawa, F; Kubota, N; Nishio, K; Ohmori, T; Saijo, N; Takeda, Y; Terashima, Y | 1 |
| Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD | 1 |
| Mukai, K; Nagane, M; Nomura, K; Oyama, H; Shibui, S | 1 |
| Fujiwara, Y; Nakagawa, K; Niimi, S; Nishio, K; Saijo, N; Sugimoto, Y; Terashima, Y; Yokoyama, S | 1 |
| Pautier, P | 1 |
| Abe, R; Akiyoshi, T; Furusawa, M; Matsuoka, H; Sugimachi, K; Ueo, H; Yamamoto, M | 1 |
| Akutsu, M; Inoue, Y; Kano, Y; Miura, Y; Sakamoto, S; Suda, K; Suzuki, K; Yoshida, M | 1 |
| Furuta, T; Miyasaka, T; Nokata, K; Sawada, S; Yaegashi, T; Yokokura, T | 1 |
| Itoh, N; Kondoh, H; Mori, H; Tamaya, T | 1 |
| Armand, JP; Barilero, I; Chabot, GG; Gandia, D; Gouyette, A; Mathieu-Boué, A; Ré, M | 1 |
| Aonuma, M; Hirota, Y; Kawato, Y; Kuga, H; Sato, K | 1 |
| Oguro, M; Seki, Y | 1 |
| Andoh, T; Okada, K | 1 |
| Taguchi, T | 5 |
| Fukuoka, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Niitani, H; Taguchi, T; Takada, M; Takifuji, N | 1 |
| Kado, K; Kaneda, N; Tsuji, T; Tsuru, D; Yokokura, T; Yoshimoto, T | 1 |
| Atsumi, R; Hakusui, H; Suzuki, W | 1 |
| Hanabayashi, T; Itoh, N; Kondoh, H; Mori, H; Sawairi, M; Tamaya, T | 1 |
| Fukuoka, M; Furuse, K; Hara, N; Hasegawa, K; Nakai, H; Nakao, I; Ogura, T; Saito, H; Sakata, Y; Yoshimori, K | 1 |
| Fukuoka, M; Hasegawa, K; Kimura, M; Kurita, Y; Kuriyama, T; Motomiya, M; Nakabayashi, T; Negoro, S; Niitani, H; Suzuki, A | 1 |
| Aonuma, M; Furuta, T; Kawato, Y; Matsumoto, K; Yasuoka, M; Yokokura, T | 1 |
| Akiya, K; Dobashi, K; Fujimoto, S; Hasumi, K; Negishi, Y; Suzuki, M; Takeuchi, S; Tamaya, T; Tanaka, K; Terashima, Y | 1 |
| Hara, Y; Kono, A | 1 |
| Furuta, T; Yokokura, T | 2 |
| Aiyama, R; Furuta, T; Miyasaka, T; Nokata, K; Okajima, S; Sawada, S; Sugino, E; Yamaguchi, K; Yokokura, T | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Noda, K; Ohkawa, T; Sekiba, K; Sugawa, T; Taguchi, T; Takamizawa, H; Takeda, Y; Takeuchi, S; Tamaya, T; Yakushiji, M | 1 |
| Fukuoka, M; Furue, H; Hara, N; Hara, Y; Hasegawa, K; Negoro, S; Niitani, H; Taguchi, T | 1 |
| Bungo, M; Fujiwara, Y; Kanzawa, F; Kasahara, K; Liu, LF; Minato, K; Nakagawa, K; Saijo, N; Sugimoto, Y | 1 |
| Andoh, T; Oguro, M; Okada, K; Seki, Y | 1 |
| Isoe, T; Oh-hara, T; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Arima, T; Ariyoshi, H; Ichimaru, M; Kuramoto, A; Masaoka, T; Oguro, M; Ohno, R; Okada, K; Sakai, Y; Yoshida, Y | 1 |
| Kono, A; Takeda, S | 1 |
| Furuta, T; Kaneda, N; Nagata, H; Yokokura, T | 1 |
| Kaneda, N; Yokokura, T | 1 |
| Furue, H; Hasegawa, K; Hattori, T; Niitani, H; Ohta, K; Taguchi, T; Wakui, A | 1 |
| Koike, K; Mitsuhashi, E; Tagawa, M; Takayanagi, I | 1 |
| Matsushita, M; Matsuzaki, T; Saito, H; Tsuruo, T; Yokokura, T | 1 |
| Matsuzaki, T; Mutai, M; Tsuruo, T; Yokokura, T | 1 |
| Furuta, T; Mutai, M; Yokokura, T | 1 |
| Baba, H; Kunimoto, T; Miyasaka, T; Mutai, M; Nitta, K; Sawada, S; Takeuchi, M; Tanaka, T; Uehara, N; Yokokura, T | 2 |
| Chen, SC; Inoue, K; Itoh, Y; Ogawa, M; Shibata, H; Wang, Y | 1 |
| Bonneterre, J | 1 |
| Fujita, Y; Oyama, H; Sawada, S; Tsuru, D; Yaegashi, T; Yoshimoto, T | 1 |
| Hagiwara, T; Hirohashi, M; Kakihata, K; Kasai, Y; Kitano, Y; Kobayashi, R; Mori, K; Nagai, E; Nomura, M; Takasuna, K | 1 |
| Aburada, M; Hagiwara, H; Kamataki, T; Nagai, E; Narita, M; Yokoi, T | 2 |
| Ikuno, N; Oka, M; Soda, H; Watanabe, M | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Nitta, T; Tamanoi, M; Yana, T | 1 |
| Kato, M; Takada, S; Takayama, S | 1 |
| Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Taguchi, H | 1 |
| Ettinger, DS | 1 |
| Chabot, GG | 3 |
| Hirohashi, M; Kakihata, K; Kasai, Y; Kitano, Y; Mori, K; Nomura, M; Takasuna, K | 1 |
| Burke, TG; Malak, H; Mi, Z | 1 |
| Atsumi, R; Hakusui, H; Okazaki, O | 2 |
| Esaki, T; Fujishima, H; Masumoto, N; Nakano, S; Niho, Y; Tatsumoto, T | 1 |
| Diener, M; Gartmann, V; Sakai, H; Takeguchi, N | 1 |
| Fujiwara, T; Matsumoto, Y; Nagao, S | 1 |
| Arioka, H; Eguchi, K; Karato, A; Lieberman, R; Nakashima, H; Nomura, N; Ohmatsu, H; Shinkai, T; Shiraishi, J; Tamura, T | 1 |
| Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
| Abigerges, D; Armand, JP; de Costa, L; Gonçalves, E | 1 |
| Verweij, J | 2 |
| Hayakawa, S; Sato, S; Takano, T; Wagazuma, S; Yajima, A | 1 |
| Choh, H; Kusano, M; Nakao, K; Shibusawa, M; Takada, M; Tsunoda, A; Yokoyama, N; Yoshizawa, H | 1 |
| Kono, A; Matsuoka, H; Saito, T; Seo, Y; Takiguchi, S; Tomoda, H; Yano, K | 1 |
| Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 2 |
| Grant, SC; Kris, MG | 1 |
| Klastersky, J | 1 |
| Sinha, BK | 1 |
| Armand, JP; Bugat, R; Canal, P; Chatelut, E; Gay, C; Gonçalvès, E; Lokiec, F; Mathieu-Boué, A; Roché, H | 1 |
| Eguchi, K; Hakusui, H; Miya, T; Mizuno, S; Morita, M; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Fujii, H; Hakusui, H; Igarashi, T; Itoh, K; Ohtsu, T; Sasaki, Y; Sudoh, K; Wakita, H; Yoshida, Y | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Miyata, Y; Mizuno, S; Ohtsu, T; Saijo, N; Sasaki, Y; Sekine, I; Wakita, H | 1 |
| Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N | 1 |
| Boorstein, RJ; Chiu, LN; Mahl, E; Mi, LJ | 1 |
| Rivory, LP; Robert, J | 3 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Takifuji, N; Yoshikawa, A | 1 |
| Akiyama, S; Andoh, T; Ito, K; Kodera, Y; Kondou, K; Nagai, S; Nishizawa, M; Satta, T; Takagi, H; Yamauchi, M | 1 |
| Burris, HA; Eckardt, JR; Fields, S; O'Rourke, T; Rodriguez, GI; Rothenberg, ML; Weiss, GR | 1 |
| Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Schellens, JH; Verweij, J | 1 |
| Buitenhuis, M; Catimel, G; Dirix, LY; Mathieu-Boué, A; Siegenthaler, P; Verdonk, HE; Verweij, J; Wagener, DJ | 1 |
| Catimel, G; Chabot, GG; Clavel, M; Cote, C; Dumortier, A; Engel, C; Gouyette, A; Guastalla, JP; Mahjoubi, M; Mathieu-Boué, A | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Hérait, P; Mahjoubi, M | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 8 |
| Kanzawa, F; Kubota, N; Nishio, K; Saijo, N | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Gandia, D; Gouyette, A; Hérait, P | 1 |
| Geoffroy, F; Grem, JL | 1 |
| Fukuoka, M; Yoshikawa, A | 1 |
| Fujimura, T; Kanno, M; Kurosaka, Y; Miwa, K; Miyazaki, I; Nishimura, G; Satou, T; Sugiyama, K; Yonemura, Y; Yoshimitsu, Y | 1 |
| Masuda, N | 4 |
| Saijo, N | 5 |
| Masaoka, T; Ohashi, Y; Ohno, R; Okada, K; Ota, K; Shirakawa, S; Takatsuki, K; Tsuda, H | 1 |
| Atsumi, R; Hakusui, H; Hosokawa, M; Nagai, E; Satoh, T; Suzuki, W | 1 |
| Armand, JP | 3 |
| Aoyama, T; Kaneda, N; Kaneko, M; Komuro, H; Li, P; Nakajima, K; Tsuchida, Y; Yokomori, K | 1 |
| Ishihara, H; Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Arioka, H; Eguchi, K; Karato, A; Nakashima, H; Ohe, Y; Oshita, F; Shinkai, T; Tamura, T; Uenaka, K; Yamamoto, N | 1 |
| Ariyoshi, Y; Ogawa, M | 1 |
| Canal, P; Chatelut, E; Mathieu-Boué, A; Rivory, LP; Robert, J | 1 |
| Ohtsu, A; Ono, K; Saijo, N; Sasaki, Y; Shimada, Y | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Kamataki, T; Sakata, Y; Suzuki, H | 1 |
| Doihara, H; Takashima, S; Yokoyama, N | 1 |
| Gupta, E; Lestingi, TM; Mick, R; Ramirez, J; Ratain, MJ; Vokes, EE | 1 |
| Burris, HA; Fields, SM | 1 |
| Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A | 1 |
| Burris, HA; Degen, D; Hilsenbeck, SG; Rothenberg, M; Shimada, Y; Von Hoff, DD | 1 |
| Aiba, K; Dobashi, N; Funakoshi, S; Hirano, A; Kamada, M; Kuraishi, Y; Mizunuma, N; Ohno, N; Sano, M; Sugimoto, Y | 1 |
| Akutsu, M; Kano, Y; Miura, Y; Suzuki, K; Tsunoda, S | 1 |
| Fujita, F; Fujita, M; Sakamoto, Y | 1 |
| Fukuoka, M; Masuda, N | 2 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD | 1 |
| Funk, LR; Hofmann, GA; Johnson, RK; Mattern, MR; McCabe, FL; Polsky, RM | 1 |
| Kano, E; Kawahara, K; Ueda, K | 1 |
| Green, MR | 2 |
| Akahane, K; Hakusui, H; Hirota, Y; Kawato, Y; Kuga, H; Sato, K; Sekiguchi, M; Suzuki, W; Tsutomi, Y | 1 |
| Tsukagoshi, S | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P | 1 |
| Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P | 1 |
| Arima, T; Hanada, S; Makino, T; Nakahara, K; Shimotakahara, S; Takatsuka, Y; Tokunaga, M; Utsunomiya, A | 1 |
| Kono, A; Shimazoe, T; Takiguchi, S | 1 |
| Furue, H | 3 |
| Fujiwara, T; Honjo, Y; Matsumoto, Y; Nagao, S; Sasaoka, N; Tsuchida, T | 2 |
| Ishida, T; Morimoto, K; Ogawa, M; Ogawa, N; Taguchi, T; Tominaga, T | 1 |
| Futatsuki, K; Kambe, M; Nakao, I; Ogawa, N; Sakata, Y; Shimada, Y; Taguchi, T; Wakui, A; Yoshino, M | 3 |
| Masaoka, T; Ohashi, Y; Ohno, R; Okada, K; Ota, K; Shirakawa, S; Taguchi, T | 1 |
| Burris, HA; Eckardt, JR; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rodriguez, GI; Rothenberg, ML; Smith, LS; Tristan-Morales, M; Weiss, GR | 1 |
| Akiyaya, S; Ito, K; Kodera, Y; Kondou, K; Nagai, S; Satta, T; Takagi, H; Yamauchi, M | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Grochow, LB; Lubejko, BG; Rock, MK; Rowinsky, EK; Sartorius, SE | 1 |
| Kotake, T; Miki, T | 1 |
| Burke, TG; Mi, Z | 2 |
| Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y | 1 |
| Ishida, T; Izuo, M; Nakao, I; Ogawa, M; Oguro, M; Ohkawa, T; Taguchi, T; Tominaga, T; Yoshida, M; Yoshida, Y | 1 |
| Creemers, GJ; Lund, B; Verweij, J | 1 |
| Araki, E; Hoshi, A; Iigo, M; Ishikawa, M; Itabashi, M; Koide, T | 1 |
| Donehower, RC; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Kohno, K; Kuwano, M; Matsuo, K; Sato, S; Tanimura, H; Uchiumi, T; Yamada, Y | 1 |
| Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L | 1 |
| Itoh, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Morino, H; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Nakamura, T; Ueda, T; Wano, Y; Yoshida, A | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Nitta, T; Takifuji, N; Tamanoi, M | 1 |
| Abigerges, D; Armand, JP; Chabot, G; Da Costa, L; De Forni, M; Gandia, D; Herait, P; Mathieu-Boue, A | 1 |
| Funayama, Y; Kubota, N; Miyahara, Y; Nishio, K; Ogasawara, H; Ohira, T; Ohmori, T; Podack, ER; Takahashi, M; Takeda, Y | 1 |
| Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A | 1 |
| Kojima, A; Saijo, N; Shinkai, T | 1 |
| Hata, K; Higuchi, M; Kajino, T; Shibata, N | 1 |
| Fujiwara, Y; Ohune, T; Sumiyoshi, H; Tamura, K; Yamakido, M; Yamaoka, N | 1 |
| Ariyoshi, Y; Hida, T; Miyara, H; Morishita, M; Nishida, K; Sugiura, T; Takahashi, T; Ueda, R | 1 |
| Donehower, RC; Slichenmyer, WJ | 1 |
| Fukuoka, M | 4 |
| Fukuoka, M; Masuda, N; Negoro, S | 1 |
| Terada, K | 2 |
| Chou, TC; Conti, JA; Gonzalez, C; Huang, Y; Kemeny, NE; Pulliam, S; Saltz, LB; Sun, M; Tong, WP | 1 |
| Rowe, PM | 1 |
| Kanematsu, T; Kawanami, K; Kohno, K; Kuwano, M; Taniguchi, K; Wada, M | 1 |
| Arioka, H; Bojanowski, K; Fukuda, M; Ishida, T; Kanzawa, F; Nishio, K; Ogasawara, H; Oka, M; Saijo, N | 1 |
| Sinha, BK; Wang, Z | 1 |
| André, S; Bissery, MC; Lavelle, F; Riou, JF; Roquet, F | 1 |
| Rothenberg, ML | 9 |
| Pommier, Y | 1 |
| Bugat, R; Rougier, P | 1 |
| Bleiberg, H | 3 |
| Gupta, E; Ratain, MJ; Safa, AR; Wang, X | 1 |
| Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Aiba, K | 2 |
| Hasumi, K; Shimizu, Y; Umezawa, S | 3 |
| Gupta, E; Mick, R; Ratain, MJ; Vokes, EE | 1 |
| Ogawa, M | 3 |
| Boisseau, M; Bugat, R; Mahjoubi, M | 1 |
| Dancey, J; Eisenhauer, EA | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Commerçon, A; Haaz, MC; Pond, SM; Riou, JF; Rivory, LP; Robert, J; Sable, S; Vuilhorgne, M | 1 |
| Hagiwara, T; Hirohashi, M; Kamataki, T; Kato, M; Nagai, E; Nomura, M; Takasuna, K; Yokoi, T | 2 |
| Keith, WN; McLeod, HL | 1 |
| Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Bonner, JA; Sawyer, TE | 1 |
| Guffroy, M; Hodge, T | 1 |
| Arioka, H; Funayama, Y; Ishida, T; Kanzawa, F; Kato, H; Nishio, K; Ogasawara, H; Ohe, Y; Ohira, T; Saijo, N | 1 |
| Hidaka, H; Minamino, T; Miyamoto, K; Nakamura, S; Nomura, M; Wakusawa, S | 1 |
| Kato, M; Suzuki, A | 1 |
| Fujii, T; Hirata, K; Kanazawa, H; Katsumoto, E; Kudoh, S; Kurihara, N; Ohtsuka, T; Okishio, K; Shoji, S; Yoshikawa, J | 1 |
| Abiko, Y; Shibata, Y; Takiguchi, H; Tamura, K; Tezuka, M; Yamanaka, K | 1 |
| Kaneko, S; Mizuno, K; Okada, M | 1 |
| Bissery, MC; Chabot, GG; Lavelle, F; Vrignaud, P | 2 |
| Bowles, MR; Pond, SM; Rivory, LP; Robert, J | 1 |
| Hasuo, Y; Imaishi, K; Kataoka, A; Komai, K; Nishida, T; Ookura, N; Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Hanauske, AR | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N | 1 |
| O'Reilly, S; Rowinsky, EK | 2 |
| Adenis, A; Brunet, R; Bugat, R; Canal, P; Dezeuze, A; Douillard, JY; Gay, C; Herait, P; Lokiec, F; Mathieu-Boue, A | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Markham, A; Wiseman, LR | 1 |
| Baranov, AV; Feofanov, AV; Fleury, F; Manfait, M; Nabiev, IR; Riou, JF | 1 |
| Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C | 1 |
| Abigerges, D; Armand, JP; Catimel, G; Clavel, M; Extra, YM; Marty, M | 1 |
| Cunningham, D | 2 |
| von Hoff, D | 1 |
| Pitot, H; Rougier, P; Shimada, Y | 1 |
| Bleiberg, H; Cvitkovic, E | 1 |
| Khayat, D; Saltz, L; Shimada, Y | 1 |
| Mani, S; Ratain, MJ | 1 |
| Miyasaka, T; Sawada, S; Yokokura, T | 1 |
| Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Friedman, HS; Houghton, PJ | 1 |
| Willson, JK | 1 |
| Armand, JP; Couteau, C; Rixe, O; Terret, C | 1 |
| Adenis, A; Becouarn, Y; Bonneterre, J; Brunet, P; Bugat, R; Burki, F; Conroy, T; Culine, S; Douillard, JY; Extra, JM; Ganem, G; Herait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Mousseau, M; Namer, M; Negrier, S; Rougier, P; Seitz, JF; Suc, E; Ychou, M | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Bigner, DD; Elion, GB; Friedman, HS; Hare, CB; Houghton, JA; Houghton, PJ; Keir, S; Marcelli, SL | 1 |
| Hasegawa, Y; Mogi, H; Nomura, F; Saka, H; Shimokata, K; Watanabe, A | 1 |
| Gutzler, F | 1 |
| Ariyoshi, Y; Hotta, T; Kobayashi, T; Ogura, M; Ohashi, Y; Ohnishi, K; Ohno, R; Saito, H; Shirakawa, S; Takeyama, K; Tobinai, K | 1 |
| Bunn, PA | 2 |
| Iino, Y; Kobayashi, I; Maemura, M; Morishita, Y; Ogawa, T; Ohwada, S; Satoh, Y | 1 |
| Mori, K; Ohnishi, T; Tominaga, K; Yokoyama, K | 1 |
| Arioka, H; Nishio, K; Saijo, N | 1 |
| Kojima, Y; Kotake, T; Maeda, O; Miki, T; Nonomura, N; Okuyama, A; Saiki, S; Sawada, M | 1 |
| Boven, E; Giaccone, G; Hulscher, ST; Jansen, WJ; Pinedo, HM; Zwart, B | 1 |
| Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M | 1 |
| Fujiwara, Y; Katoh, O; Ohashi, N; Satow, Y; Yamakido, M; Yamaoka, N | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Hord, M; Kaplan, AL; Kavanagh, JJ; Kieback, D; Kudelka, AP; Levy, T; Llerena, E; Steger, M; Verschraegen, CF | 1 |
| Barnett, GH; Kaakaji, R; Kikuchi, H; Kondo, S; Kondo, Y; Morimura, T; Nakatsu, S; Peterson, JW; Takeuchi, J; Yin, D | 1 |
| Gupta, E; Ramirez, J; Ratain, MJ; Wang, X | 1 |
| Haaz, MC; Jantet, S; Ratanasavanh, D; Rivory, L; Robert, J | 1 |
| Boku, N; Fujii, T; Fukuda, H; Kondo, H; Muro, K; Oda, Y; Ohtsu, A; Oka, M; Ono, H; Saito, D; Shimada, Y; Shirao, K; Watanabe, Y; Yamao, T; Yokoyama, T; Yoshida, S | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Extra, JM; Hérait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Suc, E | 1 |
| Bai, F; Hara, N; Kawasaki, M; Mizuno, K; Nakanishi, Y; Pei, XH; Takayama, K; Tsuruta, N | 1 |
| Chu, XY; Hakusui, H; Kato, Y; Niinuma, K; Sudo, KI; Sugiyama, Y | 1 |
| Kizaki, H; Oguro, M; Onishi, Y | 2 |
| Fujiwara, Y; Fukuoka, M; Kawase, I; Kudoh, S; Okishio, K; Tada, T; Takada, M; Tamura, K; Yamakido, M; Yamaoka, N | 1 |
| Guinan, P; Lievano, G; Mirochnik, Y; Rubenstein, M; Shaw, M | 1 |
| Burke, TG; Warner, DL | 1 |
| Furukawa, M; Harada, T; Kuwano, M; Tanaka, T | 1 |
| Hirose, T; Machida, S; Mori, K; Tominaga, K; Yokoyama, K | 1 |
| Chu, XY; Kato, Y; Sugiyama, Y | 2 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Luo, X; Richmond, L; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Iwasaki, M; Kato, M; Suzuki, A; Wagai, N | 1 |
| Kubota, N; Omura, M; Torigoe, S | 1 |
| Gupta, E; Lestingi, TM; Mick, R; Ramirez, J; Ratain, MJ; Vokes, EE; Wang, X | 1 |
| Shimizu, Y | 1 |
| Bessho, A; Chikamori, K; Harada, M; Kimura, I; Kiura, K; Matsushita, A; Ohnoshi, T; Tabata, M; Ueoka, H; Yamane, H | 1 |
| Saijo, N; Shinkai, T | 1 |
| Crom, WR; Houghton, PJ; Stewart, CF; Zamboni, WC | 1 |
| Andoh, T; Aogi, K; Fujiwara, Y; Hirabayashi, N; Kim, R; Kusano, T; Mizutani, A; Nishiyama, M; Okada, K; Sumiyoshi, H; Toge, T; Yamakido, M | 1 |
| Armand, JP; Couteau, C; Terret, C | 1 |
| O'Reilly, S | 1 |
| Hirota, S; Sadzuka, Y | 1 |
| Misset, JL | 2 |
| Hosokawa, Y; Kaneda, N; Yokokura, T | 1 |
| Ghosh, C; Goldberg, RM; Kirschling, RJ; Knost, JA; Levitt, R; Mailliard, JA; O'Connell, MJ; Pitot, HC; Rubin, J; Schroeder, G; Wender, DB; Windschitl, HE | 1 |
| Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A | 1 |
| Fujiwara, Y; Isobe, T; Sumiyoshi, H; Takahashi, T; Yamakido, M; Yamaoka, N | 1 |
| Haaz, MC; Riché, C; Rivory, LP; Robert, J | 2 |
| Egashira, Y; Hirata, I; Katsu, K; Kawabe, S; Nakagawa, K; Nakagawa, Y; Takao, Y; Takiuchi, H | 1 |
| Koarai, N; Kobayashi, A; Sugizaki, N; Yamaguchi, M | 1 |
| Belani, CP; Ramanathan, RK | 1 |
| Sams, JP; Schaaf, LJ; Slatter, JG; Su, P; Wienkers, LC | 1 |
| de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Murray, N | 1 |
| Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A | 1 |
| Awazu, S; Hosokawa, Y; Kaneda, N; Yokokura, T | 1 |
| Bissery, MC; Boland, I; Gouyette, A; Kalifa, C; Lellouch-Tubiana, A; Morizet, J; Sainte-Rose, C; Santos, A; Terrier-Lacombe, MJ; Vassal, G | 1 |
| Courtney, A; Cox, J; Meyer, W; Mues, G; Nemunaitis, J | 1 |
| Furuse, K | 1 |
| Sasaki, T | 1 |
| Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 3 |
| de Bruijn, P; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Negoro, S | 2 |
| Awazu, S; Hosokawa, Y; Kaneda, N; Kurita, A; Yokokura, T | 1 |
| Fuyuno, G; Horio, H; Kobayashi, R; Morinaga, S; Nomori, H | 1 |
| Bugat, R; Canal, P; Cussac, D; Guichard, S; Hennebelle, I | 1 |
| Boven, E; Erkelens, CA; Jansen, WJ; Kolfschoten, GM; Pinedo, HM; Van Ark-Otte, J | 1 |
| Higuchi, S; Ishizaki, T; Makinosumi, T; Nakano, S; Ogawa, N; Ohdo, S; Yukawa, E | 1 |
| Kaye, SB; Vasey, PA | 1 |
| Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Cvitkovic, E; Goldwasser, F; Lokiec, F; Mahjoubi, M; Misset, JL; Myara, A; Trivin, F; Wasserman, E | 1 |
| Akiyama, S; Kawabe, T; Koike, K; Kuwano, M; Ono, M; Tanaka, T; Toh, S; Uchiumi, T; Wada, M | 1 |
| Hamada, N; Ikari, A; Kakinoki, B; Sakai, H; Sato, T; Takeguchi, N; Yasue, M | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Adachi, J; Arioka, H; Fukumoto, H; Fukuoka, K; Ishida, T; Kurokawa, H; Narita, N; Nishio, K; Nomoto, T; Saijo, N; Tomonari, A; Yokota, J; Yokote, H | 1 |
| Craik, DJ; Dodds, HM; Rivory, LP | 1 |
| Danks, MK; Morton, CL; Pawlik, CA; Potter, PM | 1 |
| Natale, RB | 2 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Hakusui, H; Inaba, M; Ishii, H; Ito, K; Mizuno, N; Ohnishi, Y; Sudoh, K; Sugiyama, Y; Tanioka, Y; Yoshida, Y | 1 |
| Bailey, H; Durivage, HJ; Gelder, M; Irvin, WP; Potkul, RK; Price, FV; Rosenbluth, R | 1 |
| Henja, MH; Kornek, GV; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Haaz, MC; Riché, C; Rivory, L; Robert, J; Vernillet, L | 1 |
| Coffman, BL; Green, MD; Iyer, L; King, CD; Ratain, MJ; Roy, SK; Tephly, TR; Whitington, PF | 1 |
| Hayakawa, T; Kamataki, T; Kase, Y; Togashi, Y | 1 |
| Aburada, M; Hayakawa, T; Kamataki, T; Kase, Y; Komatsu, Y | 1 |
| Boven, E; Giaccone, G; Hulscher, TM; Jansen, WJ; Pinedo, HM; van Ark-Otte, J | 1 |
| Fujiwara, Y; Katoh, O; Mackenzie, PI; Takahashi, T; Watanabe, H; Yamakido, M | 1 |
| Cheng, X; Irie, T; Itamochi, H; Kanamori, Y; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Astoul, C; Ollitrault, N; Salvat, D | 1 |
| Boersma, AW; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Sakata, Y; Tsushima, K | 1 |
| Choi, SH; Tsuchida, Y; Yang, HW | 1 |
| Ariyoshi, Y; Fujiwara, Y; Fukuoka, M; Furuse, K; Kinoshita, A; Kudoh, S; Takada, Y; Yamamoto, H | 1 |
| Bugat, R; Canal, P; Guichard, S; Hennebelle, I | 1 |
| Ardouin, P; Bénard, J; Boland, I; Cappelli, C; Gouyette, A; Hartmann, O; Morizet, J; Pondarré, C; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Cheshire, PJ; Hanna, SK; Houghton, PJ; Lou, X; Richmond, LB; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Araki, S; Asakura, R; Hojo, K; Itoh, A; Kawahara, M; Konishi, T; Nouchi, T; Takeda, Y; Teruya, M | 1 |
| Cheshire, PJ; Hanna, SK; Houghton, JA; Houghton, PJ; Luo, X; McGovren, JP; Poquette, C; Richmond, LB; Stewart, CF; Zamboni, WC | 1 |
| Chang, L; Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Crystal, RG; Hackett, NR; Kojima, A; Ohwada, A | 1 |
| Arbuck, SG; Kieffer, LV; Takimoto, CH | 1 |
| Balis, FM; Blaney, SM; Cole, DE; Godwin, K; Kuttesch, N; McCully, C; Murry, DJ; Takimoto, C | 1 |
| Bigner, DD; Coggins, CA; Colvin, OM; Elion, GB; Friedman, HS; Hare, CB; Houghton, PJ; Keir, S | 1 |
| Berg, D | 2 |
| Fujimoto, M; Fujiwara, M; Hasegawa, S; Ishikawa, H; Kamma, H; Ohtsuka, M; Satoh, H; Yamashita, YT; Yazawa, T | 1 |
| Chourpa, I; Manfait, M; Millot, JM; Pommier, Y; Riou, JF | 1 |
| Belhoussine, R; Carpentier, Y; Dufer, J; Manfait, M; Morjani, H; Palissot, V; Sebille, S | 1 |
| Bunn, PA; Kelly, K | 1 |
| Aschele, C; Baldo, C; Bertino, JR; Bornmann, WG; Debernardis, D; Sobrero, AF | 1 |
| Kunikane, H; Kunitoh, H; Nagatomo, A; Okamoto, H; Watanabe, K | 1 |
| Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G | 1 |
| Hibino, S; Hino, M; Kabe, J; Kamimura, M; Kobayashi, K; Kudo, K; Kudoh, S; Shibuya, M; Shinbara, A; Takeda, Y | 1 |
| Hirota, S; Hirotsu, S; Sadzuka, Y | 2 |
| Dillahey, D; El-Galley, RE; Gomaa, A; Graham, SD; Keane, TE; McGuire, WP; Petros, JA; Sun, C | 1 |
| Ejima, A; Hirota, Y; Kawato, Y; Mitsui, I; Ohsuki, S; Sato, K; Sugimori, M; Terasawa, H; Uoto, K | 1 |
| Danks, MK; Morton, CL; Naeve, CW; Pawlik, CA; Potter, PM | 1 |
| Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Bulusu, VR | 1 |
| Boven, E; Dingemans, AM; Giaccone, G; Jansen, WJ; Kedde, MA; Pinedo, HM; van Ark-Otte, J; van der Vijgh, WJ | 1 |
| Adachi, KI; Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S | 1 |
| Bugat, R; Canal, P; Chatelut, E; Guichard, S; Lochon, I; Mahjoubi, M | 1 |
| Dodds, HM; Haaz, MC; Riou, JF; Rivory, LP; Robert, J | 1 |
| McCann, J | 1 |
| Cuvier, C; Cvitkovic, E; Goldwasser, F; Marty, M; Misset, JL; Wasserman, E | 1 |
| Hirose, T; Machida, S; Mori, K; Tominaga, K | 1 |
| Dodds, HM; Rivory, LP; Robert, J | 1 |
| Kigawa, J; Nishida, T; Okura, N; Sugiyama, T; Terakawa, N; Ushijima, K; Yakushiji, M | 1 |
| Fujita, A; Fukuoka, M; Katakami, N; Kurita, Y; Masuda, N; Nagao, K; Nakagawa, K; Negoro, S; Niitani, H; Nishikawa, H; Tsuchiya, S | 1 |
| Kurita, Y; Matsuda, T; Noda, K; Saijo, N; Shimokata, K; Tamura, T; Yokoyama, A | 1 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| de Bruijn, P; de Jonge, MJ; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 2 |
| Black, JD; Cao, S; Rustum, YM; Troutt, AB | 1 |
| Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G | 1 |
| Crawford, J; Garst, J; Persons, DA; Vollmer, R | 1 |
| Punt, CJ | 4 |
| Kojima, Y; Miki, T; Nishimura, K; Nonomura, N; Okuyama, A; Sawada, M; Takaha, N | 1 |
| Bours, V; Fillet, G; Jerusalem, G | 1 |
| Danks, MK; Morton, CL; Potter, PM; Wierdl, M; Wolverton, JS | 1 |
| Pazdur, R | 2 |
| Cao, S; Minderman, H; Rustman, YM | 1 |
| Eckhardt, SG | 1 |
| Kuhn, JG | 2 |
| Pitot, HC | 1 |
| Saltz, LB | 5 |
| Erlichman, C; Goldberg, RM | 1 |
| Antoine, EC; Bastian, G; Benhammouda, A; Coeffic, D; Gil-Delgado, M; Grapin, JP; Khayat, D | 1 |
| Drengler, RL; Eckhardt, SG; Hammond, L; Kuhn, JG; Miller, LL; Petit, RG; Rothenberg, ML; Rowinsky, EK; Schaaf, LJ; Villalona-Calero, MA; Von Hoff, DD | 1 |
| Hecht, JR | 2 |
| Crawford, J; Devore, R; Dimery, I; Eckardt, J; Eckhardt, SG; Johnson, D | 1 |
| Friedman, HS; Furman, WL; Houghton, PJ; Santana, VM; Stewart, CF; Thompson, J | 1 |
| Kavanagh, JJ; Kudelka, AP; Verschraegen, CF | 1 |
| Rosen, LS | 1 |
| Enzinger, PC; Ilson, DH; Kelsen, DP; O'Reilly, EM; Saltz, LB | 1 |
| Michael, M; Moore, MJ | 1 |
| Benson, AB; Catalano, R; Engelking, C; Field, M; Kornblau, SM; Mitchell, E; Rubin, J; Trotta, P; Vokes, E; Wadler, S | 1 |
| Brown, R; McDonald, AC | 1 |
| Ara, G; Chan, V; Eder, JP; Northey, D; Rizvi, N; Teicher, BA; Wong, J; Wong, YW | 1 |
| Fidler, IJ; Killion, JJ; Kumar, R; Kuniyasu, H; Shinohara, H | 1 |
| Chu, X; Kato, Y; Sugiyama, Y | 1 |
| Kobayashi, A; Yamaguchi, M | 3 |
| Beijnen, JH; Herben, VM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Adhikari, D; Banerjee, D; Bertino, JR; Fu, JZ; Schnieders, B; Zhao, SC | 1 |
| Crystal, RG; Hackett, NR; Kojima, A | 1 |
| Bishop, J; Clarke, S; Findlay, M; Rivory, LP | 1 |
| de Jonge, MJ; Sparreboom, A; Verweij, J | 1 |
| Igarashi, T; Kobayashi, Y; Murayama, T; Ohtsu, T; Sasaki, Y; Tobinai, K | 1 |
| Erlichman, C; Kaufmann, SH; Mullany, S; Svingen, PA | 1 |
| Fukuoka, M; Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Sawaguchi, H; Tada, T; Takeda, K; Takifuji, N; Ushijima, S; Yana, T | 1 |
| Arbuck, SG; Takimoto, CH | 1 |
| Meyer, W; Nemunaitis, J; Ognoskie, N; Singh, A; Tong, A | 1 |
| Goldberg, RM | 4 |
| Henderson, CA | 1 |
| Ando, Y; Asai, G; Kamataki, T; Saka, H; Shimokata, K; Sugiura, S | 1 |
| Blessing, JA; Chafe, W; Kohler, M; Levenback, C; Look, KY; Roman, LD | 1 |
| Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Salonga, D; Schwartz, EL; Wadler, S | 1 |
| O'Connell, MJ | 3 |
| Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J | 1 |
| Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA | 1 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Armand, JP; Canal, P; Haaz, MC; Lokiec, F; Rivory, LP; Robert, J | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| du Sorbier, BM; Lokiec, F; Sanderink, GJ | 1 |
| Chu, XY; Dabbs, JE; Froehlich, R; Green, CE; Kato, Y; Niinuma, K; Sugiyama, Y; Suzuki, H; Tyson, CA; Ueda, K; Weizer, V | 1 |
| Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Milano, G; Pavillard, V; Rostagno, P | 1 |
| Brouwer, E; de Bruijn, P; de Jonge, MJ; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; van Alphen, RJ; Verweij, J | 1 |
| Ajani, JA | 3 |
| Arnera, V; Chollet, DF; Goumaz, L; Mazzo, DJ; Montay, G; Renard, A; Vernillet, L | 1 |
| Honda, T; Koizumi, T; Kubo, K; Sekiguchi, M; Takamizawa, A | 1 |
| Guo, GZ; Hiraoka, M; Nagata, Y; Oya, N; Sasai, K; Shibata, T; Shibuya, K | 1 |
| Albanese, P; Elfring, GL; Eng, M; Hanover, CK; Ilson, D; Kanowitz, J; Kelsen, D; Kemeny, N; Miller, LL; Saltz, LB; Schaaf, LJ; Schwartz, GK; Semple, D; Spriggs, D; Steger, C | 1 |
| Fujimoto, K; Ge, RL; Hanaoka, M; Kaneki, T; Kobayashi, T; Koizumi, T; Kubo, K; Miyahara, T; Sekiguchi, M; Yamamoto, H | 1 |
| Fujikawa, R; Fukushima, J; Goya, T; Koshiishi, Y; Miya, T; Nogami, H | 1 |
| Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E | 1 |
| Danks, MK; Guichard, SM; Krull, EJ; Morton, CL; Potter, PM; Stewart, CF | 1 |
| Ise, M; Kumagai, K; Sakai, C; Takagi, T; Takenouchi, T; Tsujimura, H | 1 |
| Asano, T; Kawaji, K; Kobayashi, M; Mukai, J; Namikawa, O; Sano, T; Yamamoto, A | 1 |
| Aimi, N; Chiba, K; Hosokawa, M; Satoh, T; Takayama, H; Watanabe, A | 1 |
| Cersosimo, RJ | 1 |
| Attar, A; Bloch, F; Bruneval, P; Duong Van Huyen, JP; Kreft, C; Levoir, D; Molina, T | 1 |
| Bishop, JF; Dodds, HM; Rivory, LP | 1 |
| Muggia, FM; O'Leary, J | 1 |
| Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL | 1 |
| Akiyama, S; Chu, XY; Kato, Y; Sugiyama, Y; Suzuki, H; Ueda, K | 1 |
| Canal, P; Chabot, GG; Lokiec, F; Robert, J | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Armand, JP; Boige, V; Raymond, E | 1 |
| Peeters, M; Van Cutsem, E | 1 |
| Ducreux, M; Mitry, E; Rougier, P | 1 |
| André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M | 1 |
| Armand, JP; Couteau, C | 1 |
| Hashimoto, A; Matsuura, T; Murakami, K; Saiki, I; Sakukawa, R; Sano, M; Yamada, Y; Yonekura, K | 1 |
| Katschinski, DM; Robins, HI | 1 |
| O'meara, AT; Sevin, BU | 1 |
| Chikamori, K; Gemba, K; Harada, M; Hiraki, S; Kiura, K; Segawa, Y; Shibayama, T; Tabata, M; Ueoka, H; Yonei, T | 1 |
| Britten, CD; Eckhardt, SG; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S | 1 |
| Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Raderer, M; Scheithauer, W; Valencak, J; Weinländer, G | 1 |
| Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H | 1 |
| Drengler, RL; Elfring, GL; Hammond, LA; Hodges, S; Kraynak, MA; Kuhn, JG; Locker, PK; Miller, LL; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Staton, BA; Stephenson, JA; Villalona-Calero, MA; Von Hoff, DD | 1 |
| Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL | 1 |
| Fukuda, S; Kume, S; Nagamoto, N; Okamura, K; Sakaguchi, T; Tanabe, D | 1 |
| Hamaji, M; Ishida, M; Itoh, T; Kuhara, A; Miyazaki, S; Nishida, Y; Sakaguchi, H | 1 |
| Berger, NA; Whitacre, CM; Willson, JK; Zborowska, E | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakajima, T; Negoro, S; Okishio, K; Tada, T; Takada, M; Takeda, K; Tanaka, M | 1 |
| de Bruijn, P; de Jonge, MJ; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; van Alphen, RJ; Vernillet, L; Verweij, J | 1 |
| Danks, MK; Morton, CL; Potter, PM; Wadkins, RM | 1 |
| Baldwin, AS; Cusack, JC; Liu, R; Wang, CY | 1 |
| Alba, E; Rueda, A; Sevilla Garcia, I | 1 |
| Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J | 1 |
| Cunningham, D; Glimelius, B | 1 |
| Blijham, GH; Van Cutsem, E | 1 |
| Wilke, HJ | 1 |
| Cheshire, PJ; Danks, MK; Houghton, PJ; Krull, EJ; Morton, CL; Naeve, CW; Pawlik, CA; Potter, PM; Richmond, LB | 1 |
| Erlichman, C; Goldberg, RM; O'Connell, MJ; Pitot, HC | 1 |
| Kaneda, N; Kurita, A | 1 |
| Akiyama, SI; Chen, ZS; Furukawa, T; Ono, K; Seto, K; Sumizawa, T; Ueda, K | 1 |
| Amaya, N; Tsutani, H; Ueda, T; Yamauchi, T; Yoshida, A; Yoshio, N | 1 |
| Kumagai, K; Nakaseko, C; Sakai, C; Saotome, T; Takagi, T; Takeshita, A | 1 |
| Kano, Y; Machida, S; Mori, K; Tominaga, K; Yoshida, M; Yoshida, T | 1 |
| Burton, E; Prados, M | 1 |
| Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES | 1 |
| Das, S; Di Rienzo, A; Hall, D; Iyer, L; Kim, S; Mortell, MA; Ramírez, J; Ratain, MJ | 1 |
| Lokiec, F | 1 |
| Cvitkovic, E; Goldwasser, F; Raymond, E; Zeghari-Squalli, N | 1 |
| Chahinian, AP; Higashino, K; Miyake, M; Nakano, T; Ninomiya, K; Shinjo, M; Togawa, N; Tonomura, A; Yamamoto, T | 1 |
| Fujiwara, Y; Isobe, T; Katoh, O; Kurata, T; Miyazaki, M; Oguri, T; Ohashi, N; Takahashi, T; Yamakido, M; Yokozaki, M | 1 |
| Stucky-Marshall, L | 1 |
| Akiyama, S; Chen, ZS; Furukawa, T; Komatsu, M; Ono, K; Sumizawa, T; Tani, A | 1 |
| Miller, M | 1 |
| Basu, N; Brangi, M; Ciotti, M; Owens, IS | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Bugat, R; Canal, P; Chatelut, E; Chevreau, P; Frétigny, E; Guichard, S; Hennebelle, I; Lochon, I; Selves, J; Terret, C | 1 |
| Fujita, A; Igami, Y; Sekine, K; Tagaki, S; Takabatake, H; Yamamoto, R | 1 |
| Gohara, R; Ichiki, M; Kawayama, T; Kinoshita, M; Mitui, T; Oizumi, K; Okubo, Y; Rikimaru, T | 1 |
| Allegrini, G; Antonuzzo, A; Brunetti, I; Cianci, C; Conte, P; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Mangold, G; Manikumar, G; Marty, J; Potter, PM; Vladu, B; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC; Weitman, S | 1 |
| Dörr, T; Kemmeries, G; Petrasch, S | 1 |
| Kitagata, S; Mai, M; Omote, K; Takahashi, Y | 1 |
| Hara, N; Inoue, K; Kawasaki, M; Minami, T; Nakanishi, Y; Osaki, S; Takaki, Y; Takano, K; Takayama, K; Wataya, H | 1 |
| Twelves, C | 1 |
| Boku, N; Hyodo, I; Ohtsu, A; Saito, H; Sakata, Y; Seki, S; Shimada, Y; Shirao, K | 1 |
| Brouwer, E; de Boer-Dennert, MM; de Bruijn, P; de Jonge, MJ; Planting, AS; Sparreboom, A; Stoter, G; van der Burg, ME; Vernillet, L; Verweij, J | 1 |
| Bucana, CD; Fidler, IJ; Killion, JJ; Shinohara, H; Yano, S | 1 |
| Ekimoto, H; Mashiba, H; Matsumoto, S; Okamoto, K | 1 |
| Fujiyoshi, K; Hiura, M; Kumagai, S; Nishida, T; Nishio, S; Okura, N; Sugiyama, T; Umesaki, N; Yakushiji, M | 1 |
| de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Dufer, J; Gorisse, MC; Palissot, V; Trussardi, A | 1 |
| Kigawa, J; Minagawa, Y; Oishi, T; Sugiyama, T; Takahashi, M; Terakawa, N; Yakushiji, M | 1 |
| Chauvergne, J; Chevallier, B; Dieras, V; Fargeot, P; Fumoleau, P; Krakowski, Y; Lentz, MA; Lhommé, C; Matthieu-Boué, A; Mignard, D; Misset, JL; Rebattu, P; Roche, H; Van Glabbeke, M; Vennin, P | 1 |
| DeGroff, J; Enzinger, P; Gollub, M; Gonzalez, G; Huang, Y; Ilson, DH; Kelsen, DP; Kornblith, A; O'Reilly, E; Saltz, L; Schwartz, G | 1 |
| Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD | 1 |
| Cameron, IL; Hardman, WE; Moyer, MP | 2 |
| Bouscarel, B; Ceryak, S; Fromm, H; Kobayashi, K; Kudoh, S; Matsuzaki, Y | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A | 1 |
| Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT | 1 |
| Bayliff, S; Rosoff, PM | 1 |
| Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B | 1 |
| Chen, AY; Choy, H; Rothenberg, ML | 1 |
| Ebuchi, M; Irie, T; Kure, M; Maruyama, M; Nagahama, T; Yoshida, T | 1 |
| Maruyama, M; Nagahama, T; Yuasa, Y | 1 |
| Besmaine, A; Cuvier, C; Cvitkovic, E; Dupont-André, G; Goldwasser, F; Kalla, S; Lokiec, F; Mahjoubi, M; Marty, M; Méry-Mignard, D; Misset, JL; Ouldkaci, M; Wasserman, E | 1 |
| Bowman, LC; Furman, WL; Hoffer, FA; Houghton, PJ; Ma, MK; Meyer, WH; Pappo, AS; Poquette, CA; Pratt, CB; Santana, VM; Stewart, CF; Walter, AW; Zamboni, WC | 1 |
| Beijnen, JH; Gruia, G; Herben, VM; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Vernillet, L | 1 |
| Crawford, J; DeVore, RF; Dimery, IW; Eckardt, J; Eckhardt, SG; Elfring, GL; Garst, J; Hanover, CK; Johnson, DH; Miller, LL; Schaaf, LJ | 1 |
| Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Inai, K; Kishi, S; Morinaga, K; Naiki, H; Tsutani, H; Ueda, T | 1 |
| Adachi, S; Kanazawa, R; Koyama, K; Ogasawara, T; Shibahara, H; Takemura, T; Tsuji, Y; Yamasaki, N | 1 |
| Dodds, HM; Rivory, LP | 2 |
| Avery, R; Bachinski, MS; McNally, P; Sears, S | 1 |
| Adams, DJ; Cohen, DP; Colvin, OM; Flowers, JL; Manikumar, G; Silber, R; Wall, ME; Wani, MC | 1 |
| Bengtson, EM; Rigas, JR | 1 |
| Adjei, AA; Argiris, A; Murren, JR | 1 |
| Bahadori, HR; Eckardt, JR; Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Droege, CM; Hausamen, TU; Lenfers, BH; Loeffler, TM | 1 |
| Joel, SP; te Poele, RH | 1 |
| Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C | 1 |
| Blanke, CD; Rothenberg, ML | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| de Boer-Dennert, MM; de Jonge, MJ; Jacques, C; Planting, AS; Sparreboom, A; ter Steeg, J; van der Burg, ME; Verweij, J | 1 |
| Brouwer, E; de Boer-Dennert, MM; de Bruijn, P; de Jonge, MJ; Jacques, C; Mathijssen, RH; Sparreboom, A; van Alphen, RJ; Vernillet, L; Verweij, J | 1 |
| Borgomastro, A; Magnolfi, E; Zampa, G | 1 |
| Gliniak, B; Le, T | 1 |
| Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
| Sandler, A; van Oosterom, AT | 1 |
| Fukuda, M; Kawabata, S; Kinoshita, A; Kohno, S; Nakatomi, K; Noguchi, Y; Oka, M; Soda, H; Takatani, H; Terashi, K; Tsukamoto, K; Tsurutani, J | 1 |
| Androulakis, N; Aravantinos, G; Bafaloukos, D; Florou, S; Fountzilas, G; Georgoulias, V; Kosmidis, P; Sgouros, I; Skarlos, DV | 1 |
| Al-Zoubi, A; Boucher, J; Savarese, D | 1 |
| Kotake, T; Miki, T; Nakagawa, S; Nakao, M; Nomoto, T; Nonomura, N; Saiki, S; Takada, T | 1 |
| Hatae, M; Hiura, M; Ikeda, M; Kudoh, R; Noda, K; Ohashi, Y; Saji, F; Sato, S; Sugiyama, T; Takahashi, T; Takeuchi, S; Terashima, Y; Tomoda, Y; Umesaki, N; Yajima, A; Yakushiji, M | 1 |
| Van Cutsem, E | 1 |
| Ford, HE; Jackman, AL; Kimbell, R | 1 |
| Bruns, CJ; Davis, DW; Dong, Z; Fidler, IJ; Harbison, MT; Killion, JJ; McConkey, DJ; Nelkin, G; Shinohara, H | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP | 1 |
| Bishop, JF; Clarke, SJ; Dodds, HM; Findlay, M; Rivory, LP; Robert, J | 1 |
| Hotta, T; Ishimoto, K; Iwahashi, M; Matsuda, K; Tanaka, H; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Allegra, CJ; Arbuck, SG; Band, RA; Berger, NA; Berger, SJ; Chen, AP; Cottrell, J; Flemming, D; Gosky, DM; Grem, JL; Guemei, A; Hamilton, JM; Harold, N; Hehman, H; Hirota, H; Ismail, AS; Llorens, V; Monahan, BP; Morrison, G; Quinn, M; Shapiro, JD; Takimoto, CH; Wright, J | 1 |
| André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F | 1 |
| Eriguchi, M; Fujii, Y; Sairenji, T | 2 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E | 1 |
| Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G | 2 |
| Dupuy, JL; Gaulier, JM; Lacassie, E; Lachâtre, F; Lachâtre, G; Marquet, P; Ragot, S; Rousseau, A | 1 |
| Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T | 1 |
| Barbier, M; Boutonnat, J; Grunwald, D; Mousseau, M; Muirhead, K; Ronot, X; Seigneurin, D | 1 |
| Kumagai, K; Sakai, C; Saotome, T; Takagi, T; Tamaru, J | 1 |
| Azrak, RG; Cao, S; Guo, B; Rustum, YM; Tóth, K | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Abad, T; Balcells, M; Dominguez, MS; Dorado, JF; García López, JL; Moyano, AJ; Nogué, M; Seguí, MA; Urruticoechea, L | 1 |
| Danks, MK; Morton, CL; Potter, PM; Wierdl, M | 1 |
| Baker, DS; Bombardt, PA; Cathcart, KS; Compton, LD; Feenstra, KL; Johnson, MG; Lord, RS; Miller, LL; Pearson, LK; Pesheck, CV; Sams, JP; Schaaf, LJ; Slatter, JG; Verburg, MT | 1 |
| Bosron, WF; Dolan, ME; Humerickhouse, R; Li, L; Lohrbach, K | 1 |
| Bras-Gonçalves, RA; Dutrillaux, B; Laurent-Puig, P; Poupon, MF; Rosty, C; Soulié, P | 1 |
| Arioka, H; Fukumoto, H; Fukuoka, K; Ishida, T; Iwamoto, Y; Kurokawa, H; Narita, N; Nishio, K; Saijo, N; Suzuki, T; Tomonari, A; Usuda, J | 1 |
| Hasegawa, S; Ishikawa, H; Kamma, H; Ohtomo, M; Ohtsuka, M; Satoh, H | 1 |
| Kobayashi, T; Maeda, Y; Okamoto, R; Omuro, Y; Sasaki, T; Takeda, N | 1 |
| Kamura, T; Sugiyama, T; Ushijima, K | 1 |
| Fujita, A; Fukuoka, M; Katakami, N; Kurita, Y; Nagao, K; Nakano, M; Negoro, S; Niitani, H; Saito, R | 1 |
| Fujiyoshi, K; Hasuo, Y; Hirai, N; Kamura, T; Kumagai, S; Nishida, T; Nishio, S; Oota, S; Sugiyama, T; Tomioka, Y | 1 |
| Asai, J; Fujimoto, T; Miyo, T; Nagashima, G; Suzuki, R | 1 |
| Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC | 1 |
| Hata, H; Kurita, A; Machida, Y; Morikawa, A; Onishi, H | 1 |
| Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P | 1 |
| Bigner, DD; Castellino, RC; Elion, GB; Friedman, HS; Houghton, PJ; Johnson, SP; Keir, ST | 1 |
| Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C | 1 |
| Benecchi, A; Brianceschi, G; Casati, M; Fraier, D; Frigerio, E; James, C | 1 |
| Hara, N; Nakanishi, Y; Osaki, S; Pei, XH; Takayama, K; Ueno, H | 1 |
| Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M | 1 |
| Kelly, K | 3 |
| Baars, JJ; Huibregtse, K; Pinedo, HM; Stieltjes, H; Van der Vijgh, WJ; van Groeningen, CJ | 1 |
| Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
| Ohtsu, A | 1 |
| Jekunen, A; Knuuttila, A; Linnainmaa, K; Mattson, K; Ollikainen, T; Suhonen, S; Taavitsainen, M | 1 |
| Endo, W; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T | 1 |
| Schallhorn, A | 1 |
| Arbuck, SG; Kieffer, LV; Kieffer, ME; Takimoto, CH; Wright, J | 1 |
| Hiraoka, M; Nihei, K; Ohnishi, T; Sasai, K; Shibuya, K; Tachiiri, S; Xie, X | 1 |
| Allegra, CJ; Grem, JL; Paull, K; Pommier, Y; Voeller, DM | 1 |
| Baldwin, AS; Cusack, JC; Liu, R | 1 |
| Boige, V; Cresteil, T; Deroussent, A; Gouyette, A; Pein, F; Raymond, E; Risse, ML; Santos, A; Vassal, G; Vernillet, L; Zanetta, S | 1 |
| Aldaz, A; Calvo, E; Castellanos, C; Escoriaza, J; Giráldez, J | 1 |
| Archimbaud, Y; Barré, J; Combes, O; Duché, JC; Marietta, MP; Tillement, JP; Urien, S; Vernillet, L | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Lake, RA; McLaren, BR; Robinson, BW | 1 |
| Adjei, AA; Alberts, SA; Burch, PA; Elfring, G; Erlichman, C; Goldberg, RM; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Skaff, PA; Sloan, JA | 1 |
| Jelic, S; Nikolic-Tomasevic, Z; Popov, I; Radosavljevic, D | 1 |
| Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E | 1 |
| Furuhata, T; Hata, F; Hirata, K; Kawasaki, H; Matsunaga, T; Nakagawa, N; Sasaki, K; Shibata, K; Takasaka, H; Yabana, T; Yasojima, T | 1 |
| Fukuoka, M; Nakagawa, K | 1 |
| Halme, M; Jekunen, A; Kivisaari, L; Knuuttila, A; Linnainmaa, K; Mali, P; Mattson, K; Ollikainen, T | 1 |
| Azoulay, D; Goldwasser, F; Gornet, JM; Lévi, F; Misset, JL; Yovine, A | 1 |
| Aherne, GW; Benepal, TS; Cunningham, D; Ford, HE; Gruia, G; Massey, A; Price, T; Rao, S; Ross, PJ; Vernillet, L | 1 |
| Henney, JE | 1 |
| Suzuki, A; Tsutomi, Y | 1 |
| Burtness, BA; Cheng, Y; DiStasio, SA; Leffert, JJ; Li, X; McKeon, A; Murren, JR; Peccerillo, K; Pizzorno, G | 1 |
| de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Cao, S; Rustum, YM | 1 |
| Kikuchi, K; Nakayama, M; Yamahata, T; Yamashita, M | 1 |
| Danks, MK; Guichard, SM; Harris, LC; Iyengar, RV; Khanna, R; Krull, EJ; Mason, SE; Pawlik, CA; Potter, PM | 1 |
| Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Kremos, S; Mavroudis, D; Souglakos, J | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M | 1 |
| Masuda, N; Negoro, S | 1 |
| Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Nakashima, H; Okamura, T; Toh, Y | 1 |
| Ishikawa, N; Isobe, T; Oguri, T | 1 |
| Awad, L; Bleiberg, H; Bugat, R; Culine, S; Droz, JP; Freyer, G; Herait, P; Marty, M; Mignard, D; Rougier, P; Trillet-Lenoir, V | 1 |
| Danks, MK; Eiseman, JL; Ma, MK; Morton, CL; Oliver, L; Potter, PM; Stewart, CF; Wierdl, M | 1 |
| Broadwater, R; Govindarajan, R; Hauer-Jensen, M; Heaton, KM; Lang, NP; Zeitlin, A | 1 |
| Fujito, H; Mori, M; Saita, T | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Fujioka, M; Hashimoto, D; Idezuki, Y; Inokuma, S; Ishida, H; Ishizuka, N; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Okita, H; Suzuki, T; Takahama, T; Takeuchi, I; Yamada, H; Yokoyama, M | 1 |
| Hisano, C; Ishikawa, T; Kaji, Y; Maruyama, T; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Ohkuma, K | 1 |
| Choi, SH; Ham, YA; Im, EO; Im, KS; Jung, JH; Kim, DK; Kim, ND; Lee, JH; Wang, MW; Xu, Y | 1 |
| Balatoni, G; Farczádi, E; Izsó, J; Kofi, AP; Kristó, K; Lohinszky, J; Pintér, T; Szántó, J | 1 |
| Sandler, A | 4 |
| Israel, VP; Miller, L; Natale, RB; Sandler, A; Socinski, M | 1 |
| Chakravarthy, A; Choy, H; Devore, RF; Hande, KR; Jagasia, M; Johnson, DH; Roberts, JR; Yunus, F | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Negoro, S | 1 |
| Rushing, DA | 1 |
| Danks, MK; Khanna, R; Morton, CL; Potter, PM | 1 |
| Ikari, A; Sakai, H; Suzuki, T; Takeguchi, N | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Ratain, MJ | 3 |
| de Bruijn, P; de Jonge, MJ; Kehrer, DF; Sparreboom, A; Verweij, J; Yamamoto, W | 1 |
| Bugat, R; Canal, P; Chatelut, E; Guichard, S; Hennebelle, I; Terret, C | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 2 |
| Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB | 1 |
| Mayer, RJ | 1 |
| Graeven, U; Schmiegel, W | 1 |
| Kitagata, S; Mai, M; Takahashi, Y | 1 |
| Hashimoto, S; Kado, S; Kaneda, N; Kurita, A; Onoue, M; Yokokura, T | 2 |
| Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Kinoshita, H; Kou, M; Morimoto, K | 1 |
| Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P | 1 |
| Ledermann, JA; Napier, MP | 1 |
| Hiramatsu, HP; Kikuchi, Y; Nagata, I; Seto, H | 1 |
| Borsellino, N; Cigolari, S; Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Paoletti, G; Pedicini, T | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 2 |
| Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P | 1 |
| Mitry, E; Rougier, P | 3 |
| Cunningham, D; Sumpter, K | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Bigner, DD; Dolan, ME; Elion, GB; Friedman, HS; Houghton, PJ; Johnson, SP; Keir, S; Patel, VJ; Pegg, AE | 1 |
| Kajiyama, Y; Tsurumaru, M | 1 |
| Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC | 1 |
| Azoulay, D; Duclos-Vallée, JC; Goldwasser, F; Gornet, JM | 1 |
| Boige, V; Borrini, F; Ducreux, M; Fallik, D; Jacob, S; Praz, F; Sabourin, JC | 1 |
| Akamatsu, T; Fujimoto, K; Honda, T; Kaneki, T; Kawashima, A; Koizumi, T; Kubo, K; Tsushima, K | 1 |
| Ebuchi, M; Maruyama, M; Nagahama, T; Yuasa, Y | 1 |
| Baba, H; Ebuchi, M; Kure, N; Maruyama, M; Nagahama, T; Toukairin, Y; Yoshida, T | 1 |
| Goseki, N; Maruyama, M; Nagahama, T | 1 |
| Koshiishi, H; Takahashi, E; Tamamoto, F; Utsumi, K | 1 |
| Fujita, A; Fukuoka, S; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Hill, M; Price, T | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G | 1 |
| Haller, D; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W | 1 |
| Ohtsu, A; Tahara, M | 1 |
| Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S | 1 |
| Innocenti, F; Iyer, L; Ratain, MJ | 2 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Langer, CJ | 4 |
| Bjarnason, GA; Madarnas, Y; Shorter, AM; Webster, P | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Hareyama, M; Imai, K; Itoh, F; Kakiuchi, H; Kobayashi, T; Sasaki, Y; Suzuki, H | 1 |
| Cunningham, D; Waters, J | 1 |
| Maeda, Y; Sasaki, T | 1 |
| Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A | 1 |
| Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S | 1 |
| Kelsen, DP; Kemeny, NE; O'Reilly, EM; Raeburn, L; Saltz, LB; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Stuart, KE | 1 |
| Heinemann, V | 3 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Muro, K; Saitoh, S; Saka, H; Sawa, T; Shimokata, K; Ueoka, H; Yokoyama, A | 1 |
| Baschiera, F; Blandizzi, C; Colucci, R; De Paolis , B; Del Tacca, M; Lazzeri, G | 1 |
| Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB | 1 |
| Doyle, LA; Fukuda, M; Ikegami, Y; Kamihira, S; Kawabata, S; Kohno, S; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Sugahara, K; Tsukamoto, K; Yamada, Y | 1 |
| Flieger, D; Hoff, AS; Sauerbruch, T; Schmidt-Wolf, IG | 1 |
| Iqbal, S; Lenz, HJ | 2 |
| Pelley, RJ | 1 |
| Ohe, Y; Saijo, N | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Messori, A; Trippoli, S; Vaiani, M | 1 |
| Erlichman, C; Goldberg, RM; O'Connell, MJ | 1 |
| Pestalozzi, BC | 1 |
| Ducreux, M; Pignon, JP | 1 |
| Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW | 1 |
| Ahmed, F; Cook, T; Gupta, E; Rubin, E; Sinko, P; Vyas, V | 1 |
| Rivory, LP | 1 |
| Gilbert, BE; Giovanella, B; Jaeckle, K; Knight, V; Verschraegen, CF | 1 |
| Bigg, D; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Lavergne, O; Lesueur-Ginot, L | 1 |
| Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O | 1 |
| Ganapathi, R; Tabata, M | 1 |
| Ajani, JA; Charnsangavej, C; Fairweather, J; Pisters, PW | 1 |
| Köhne, CH; Wilke, HJ; Wils, JA | 1 |
| Enzinger, PC; Ilson, DH | 1 |
| Bahadori, H; Brescia, FJ; Green, MR; Harper, M; Mushtaq, CM; Rocha Lima, CM; Safa, A; Sherman, CA | 1 |
| Ajani, JA; Blumenshein, GR; Fairweather, JS; Feig, BW; Ho, L; Janjan, NA; Komaki, R; Lynch, PM; Pazdur, R; Pisters, PW; Raijman, I; Walsh, GL | 1 |
| Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
| Saltz, L | 2 |
| Douillard, JY | 2 |
| Mitchell, EP | 1 |
| Komura, Y; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S | 1 |
| Chiba, K; Kado, S; Kaneda, N; Kaneko, K; Kato, I; Kurita, A; Miura, K; Onoue, M | 1 |
| Berlin, J | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Govindarajan, R | 2 |
| Fukumoto, H; Kanzawa, F; Koh, Y; Koizumi, F; Nakamura, T; Nishio, K; Saijo, N; Tatsumi, Y; Yoshioka, T | 1 |
| Berg, SL; Bernstein, M; Blaney, S; Luchtman-Jones, L; Pratt, C; Sullivan, J; Weitman, S | 1 |
| Carbone, DP; Cohen, AG; Devore, RF; Jagasia, MH; Johnson, DH; Langer, CJ; Rodgers, JS; Schlabach, LL; Shyr, Y; Yunus, F | 1 |
| Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Milano, G; Rostagno, P | 1 |
| Boushey, RP; Drucker, DJ; Yusta, B | 1 |
| Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY | 1 |
| Sandler, AB | 3 |
| Blum, K; Gallipoli , M; McKeon, A; Murren, JR; Rich, R | 1 |
| Choy, H; MacRae, R | 2 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Johnson, DH | 1 |
| Tamura, T | 1 |
| Ishida, R; Nishida, K; Seto, M | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U | 1 |
| Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D | 1 |
| Aoki, S; Hamamatsu, C; Hirata, K; Hirayama, T; Kawasaki, H; Matsunaga, T; Nakagawa, N; Nakayama, I; Oono, K; Sasaki, K; Shibata, K; Takaoka, A; Takasaka, H; Yabana, T; Yamamoto, Y | 1 |
| Balcells, M; Casal-Rubio, J; Castellanos, J; Constenla, M; Díz, P; Fírvida, JL; Irigoyen, A; Rodríguez, R; Valladares-Ayerbes, M; Vázquez-Estévez, S | 1 |
| Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E | 1 |
| Avallone, A; Biglietto, M; Casaretti, R; Comella, G; Comella, P; De Cataldis, G; De Lucia, L; Di Lullo, L; Maiorino, L; Rivellini, F | 1 |
| Ikeda, T; Mitani, N; Murakami, K; Saiki, I; Yamaura, T | 1 |
| Astrow, AB; Macdonald, JS | 1 |
| Aida, K; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Saito, M; Sanada, Y; Sasaya, S | 1 |
| Akiyama, Y; Handa, S; Kobayashi, K; Kudo, K; Kudoh, S; Soma, T; Takeda, Y | 2 |
| Fujii, H; Goya, T; Igarashi, T; Itoh, K; Minami, H; Miya, T; Ohtsu, T; Sasaki, Y | 1 |
| Agrawal, S; Alford, TL; Bailey, KS; Bono, CP; Chen, SF; Dexter, DL; Hill, B; Hollister, BA; Kandimalla, ER; Knoerzer, DL; Morton, PA; Yu, D | 1 |
| Ilson, DH; O'Reilly, EM | 1 |
| Brescia, FJ; Brunson, CY; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Ajani, JA; Baker, J; Feig, B; Ho, L; Mansfield, PF; Pisters, PW | 1 |
| Burger, RA; Danks, MK; Harris, LC; Iyengar, RV; Krull, EJ; Pawlik, CA; Phelps, DA; Potter, PM | 1 |
| Cunningham, D; James, RD | 1 |
| Abendroth, K; Adams, J; Baldwin, AS; Cusack, JC; Elliott, PJ; Houston, M; Liu, R | 1 |
| Mai, M; Takahashi, Y | 1 |
| Hasuo, Y; Kamura, T; Nishida, T; Sugiyama, T | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N | 1 |
| Bouscarel, B; Ceryak, S; Kobayashi, K; Kudoh, S; Matsuzaki, Y | 1 |
| Band, R; Bowen, D; Cottrell, J; Grem, JL; Guemei, AA; Hehman, H; Ismail, AS; Pavlov, MV; Prudhomme, M; Takimoto, CH; Taylor, RE | 1 |
| Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D | 1 |
| Delitheos, A; Miligkos, V; Papamichael, K; Tiligada, E; Ypsilantis, E | 1 |
| de Bruijn, P; de Jonge, MJ; Kehrer, DF; Nierop, CA; Ruijgrok, EJ; Sparreboom, A; van de Schraaf, J; Verweij, J | 1 |
| Benedetti, F; Bertino, J; Fong, Y; Gonen, M; Jarnagin, W; Kemeny, N; Paty, P; Saltz, L; Schwartz, L; Stockman, J; Sullivan, D; Tong, W | 1 |
| Farabos, C; Gires, P; Haaz, MC; Robert, J | 1 |
| Prescott, LM | 1 |
| Smart, T | 1 |
| Akiyama, Y; Nishio, K; Saijo, N; Shimizu, M; Tamura, T; Yamada, Y | 1 |
| Aiba, K; Akaza, H; Hoctin-Boes, G; Isonishi, S; Kawai, K; Konishi, T; Mikami, O; Miki, T; Noguchi, S; Ohashi, Y; Saeki, T; Saijo, N; Smith, M; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Fujiyoshi, K; Kamura, T; Kumagai, S; Nishida, T; Ota, S; Sugiyama, T; Yoshimura, O | 1 |
| Koda, T; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T | 1 |
| de Bruijn, P; de Jonge, MJ; Kurihara, M; Nishiyama, M; Sparreboom, A; Takano, H; Verweij, J; Yamamoto, W | 1 |
| Kemeny, NE; O'Reilly, E; Raeburn, L; Saltz, LB; Sanz-Altamira, PM; Steger, C; Stuart, KE | 1 |
| Ganser, A; Reinke, F; Schlichting, C; Schöffski, P; van Gennip, AH; van Kuilenburg, AB; Volk, J | 1 |
| Adam, R; Antoine, EC; Bassot, V; Benhammonda, A; Bismuth, H; Castaing, D; Gil-Delgado, MA; Grapin, JP; Guinet, F; Khayat, D | 1 |
| Koda, T; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Wada, M | 1 |
| Sakata, Y | 1 |
| Hiratsuka, N; Sato, A; Tadokoro, K; Takebuchi, K; Ushio, J; Yamamoto, W | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Vassilomanolakis, M | 1 |
| Danks, MK; Harris, LC; Morton, CL; Potter, PM; Weeks, JK; Wierdl, M | 1 |
| Burger, RA; Danks, MK; Guichard, SM; Harris, LC; Krull, EJ; Meck, MM; Potter, PM; Wagner, LM; Wierdl, M | 1 |
| Ando, M; Harada, Y; Koyanagi, Y; Maruyama, S; Ohnuma, S; Sakaniwa, N; Suzuki, K; Tadatomo, H; Tanaka, K; Yamashita, S | 1 |
| Arimoto, Y; Hayashi, S; Komura, H; Kunishige, I; Okuno, Y; Otsuki, Y; Shimoya, K | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H | 1 |
| Fukuda, M; Hayashi, N; Ichiki, M; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Rikimaru, T; Soda, H; Takatani, H | 1 |
| Eguchi, K; Harada, M; Harita, S; Hiraki, S; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Shibayama, T; Tabata, M; Takata, I; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Bokemeyer, C; Honecker, F; Kolb, G; Wedding, U | 1 |
| Rigas, JR | 1 |
| Krieger, G | 1 |
| Louvet, C | 1 |
| Traynor, K | 1 |
| Niedzwiecki, D; O'Connell, MJ; Sargent, DJ; Schilsky, RL | 1 |
| Ledermann, JA; Leonard, P; Seymour, M | 1 |
| Danks, MK; Morton, CL; Oliver, L; Potter, PM; Wadkins, RM; Weeks, JK; Wierdl, M | 1 |
| Bruckner, HW; Evans, A; Kozuch, P; Petryk, M | 1 |
| Lokich, J | 2 |
| Arimori, K; Kikuchi, M; Kumamoto, A; Kumazawa, E; Kuroki, N; Nakano, M; Tanoue, N; Tohgo, A | 1 |
| Aoki, T; Hirai, K; Kawahara, H; Kuroda, H; Ono, M; Sato, K; Suzuki, T | 1 |
| Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Choufani, EB; Hartshorn, KL; Lazar, HL | 1 |
| Bishop, J; Clarke, SJ; Dodds, HM; Ong, SY; Rivory, LP | 1 |
| Bigner, DD; Friedman, HS; Hausheer, F; Keir, ST; Lawless, AA | 1 |
| Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; van Alphen, RJ; Verweij, J | 1 |
| Murren, JR | 1 |
| Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Medeiros, LJ; Mesina, O; Pro, B; Rodriguez, MA; Romaguera, J; Samuels, B; Sarris, AH; Younes, A | 1 |
| Ando, M; Hanioka, N; Jinno, H; Nishimura, T; Ozawa, S; Sawada, J | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Inoue, A; Saijo, N | 1 |
| Chizuka, A; Iijima, K; Niitsu, N | 1 |
| Prados, M | 1 |
| Kimura, T | 1 |
| Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW | 1 |
| Meropol, NJ; Poplin, EA; Rothenberg, ML; Van Cutsem, E; Wadler, S | 1 |
| Ajani, JA; Lozano, R; Pro, B | 1 |
| Fukuoka, M; Negoro, S; Nitta, T; Takeda, K; Takifuji, N; Terakawa, K; Yoshimura, N | 1 |
| Baz, DV; Bofill, JS; Nogueira, JA | 1 |
| Boyd, G; Cummings, J; Jodrell, DI; Smyth, JF | 1 |
| Armand, JP; Becouarn, Y; Ducreux, M; Fizazi, K; Seitz, JF | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y | 1 |
| Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT | 1 |
| Law, S; Wong, J | 1 |
| Cunningham, D; Maroun, J; Van Cutsem, E; Vanhoefer, U | 1 |
| Atherton, P; Erlichman, C; Pitot, HC; Reid, J; Schaaf, L; Sloan, JA | 1 |
| Arnould, S; Bugat, R; Canal, P; Guichard, S; Hennebelle, I | 1 |
| Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS | 1 |
| Kaniwa, N; Ozawa, S; Sai, K; Sawada, JI | 1 |
| Kumazaki, T; Nishiyama, M; Okamoto, R; Sekikawa, T; Takano, H; Tanaka, T; Tanimoto, K; Toyada, M; Ukon, K | 1 |
| Muller, MT; Swaan, PW; Ulukan, H | 1 |
| Saitoh, S; Sakata, Y | 1 |
| Hayasaka, S; Ikegami, Y; Ishikawa, T; Kawabata, S; Kohno, S; Nakatomi, K; Oka, M; Sano, K; Shiozawa, K; Soda, H; Tanabe, S; Yoshikawa, M | 1 |
| Bottero, V; Busuttil, V; Fischel, JL; Loubat, A; Magné, N; Milano, G; Peyron, JF | 1 |
| Ando, M; Hanioka, N; Jinno, H; Ozawa, S; Saito, Y; Sawada, J | 1 |
| Saotome, T; Takagi, T | 1 |
| Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H | 1 |
| Boyer, J; Ferguson, PR; Harkin, DP; Johnston, PG; Latif, T; Longley, DB; Lynch, M; Maxwell, P | 1 |
| Baba, H; Ebuchi, M; Kure, N; Maruyama, M; Nagahama, T; Toukairin, Y | 1 |
| Furukawa, J; Inoue, M; Ishikawa, H; Katsumoto, Y; Nakayama, T; Oshima, S; Sue, F; Yukawa, M | 1 |
| Amaya, K; Miwa, K; Nishijima, K; Nishimura, G; Sasaki, S; Shimizu, K; Tani, T; Terada, I | 1 |
| Fukumoto, S; Habara, K; Iwasaki, T; Kamigaki, T; Ku, Y; Kunimoto, Y; Kuroda, Y; Nakamura, T; Nakamura, Y; Tamura, T | 1 |
| Bécouarn, Y; Bekradda, M; Coudert, B; Gamelin, E; Germa, C; Krisch, C; Mignard, D; Mousseau, M; Négrier, S; Pierga, JY; Provençal, J; Raoul, JL; Rixe, O | 1 |
| Aoki, D; Komuro, Y; Kubota, T; Nozawa, S; Susumu, N; Udagawa, Y | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M | 1 |
| Abe, K; Goto, S; Ihara, Y; Izumi, S; Koji, T; Kondo, T; Urata, Y | 1 |
| Araki, Y; Hayashi, A; Ishibashi, N; Kishimoto, Y; Konishi, J; Matono, K; Mituoka, M; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Blandizzi, C; Colucci, R; Danesi, R; De Paolis, B; Del Tacca, M; Di Paolo, A | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Souglakos, J; Vamvakas, L; Vardakis, N | 1 |
| Caffo, O | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Berg, SL; Blaney, SM; Bomgaars, L | 1 |
| Iwai, T; Kawano, T; Miyake, S; Nagai, K; Nakajima, Y | 1 |
| Gao, JS; Kuang, ZJ; Liu, ZC; Qian, CN; Zeng, YX; Zhang, XS; Zhu, XF | 1 |
| Gonen, M; Jung, C; Motwani, M; Schwartz, GK; Shah, MA; She, Y; Sirotnak, FM | 1 |
| Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Yoshida, M; Yoshida, S | 1 |
| Abrams, SI; Bergmann-Leitner, ES | 1 |
| Bailly, C; Baldeyrou, B; Bigg, DC; Coulomb, H; Demarquay, D; Huchet, M; Laine, W; Lanco, C; Lavergne, O | 1 |
| Azevedo, P; Deavers, MT; Freedman, RS; Kavanagh, JJ; Kudelka, AP; Lu, K; Verschraegen, CF | 1 |
| de Jonge, MJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Arimori, K; Bouscarel, B; Ceryak, S; Ha, L; Ikegami, T; Kobayashi, K; Latham, P; Matsuzaki, Y | 1 |
| Mani, S | 1 |
| Fukuoka, M; Kawahara, M; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K; Yamamoto, S; Yokoyama, A | 1 |
| Carney, DN | 1 |
| Blumenthal, RD; Goldenberg, DM; Lew, W; Modrak, DE; Rodriguez, MD | 1 |
| Agata, H; Fujimoto, T; Hirota, T; Hori, T; Kawai, N; Kitagawa, S; Konno, K; Sawada, K; Tsurusawa, M | 1 |
| Adler, G; Lutz, MP | 1 |
| Douillard, JY; Köhne, CH; Van Cutsem, E | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Ikeda, T; Minami, H; Saka, H; Sakai, S; Sato, M; Sekido, Y; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Aoe, K; Chikamori, K; Chikamori, M; Harada, M; Kawata, K; Kiura, K; Kohara, H; Matsushita, A; Tabata, M; Ueoka, H | 1 |
| Nishiyama, M; Okamoto, R; Okamura, T; Park, JS; Sekikawa, T; Sparreboom, A; Takano, H; Tanimoto, K; Verweij, J; Yamamoto, W | 1 |
| Ando, Y; Hasegawa, Y; Ichiki, M; Shimokata, K; Sugiyama, T; Ueoka, H | 1 |
| Collins, JR; Jerina, DM; Kroth, H; Laco, GS; Luke, BT; Pommier, Y; Sayer, JM | 1 |
| Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G | 1 |
| Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML | 1 |
| Eckhardt, SG; Elfring, GL; Hammond, LA; Hodges, S; Kuhn, JG; Locker, PK; Miller, LL; Petit, RG; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Sharma, A; Villalona-Calero, MA; von Hoff, DD | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Reutova, EV | 1 |
| Amorino, GP; Cao, Q; Choy, H; Kim, JS; Pyo, H | 1 |
| Gall, H; Giaccone, G; Gruia, G; Kedde, MA; Leisink, JM; Pinedo, HM; van der Vijgh, WJ; van Groeningen, CJ; van Riel, JM | 1 |
| Wilke, H | 1 |
| Chin, K; Goto, M; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yamao, T | 1 |
| Fukuoka, M; Hirashima, T; Komiya, T; Nakagawa, K; Nitta, T; Syunichi, N; Tada, H; Tohda, A; Tsurutani, J; Uejima, H | 1 |
| Bleiberg, H; Di Leo, A | 1 |
| Fletcher, L | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J | 1 |
| Aiba, K; Fujiwara, K; Horikoshi, N; Ito, Y; Mizunuma, N; Omachi, K; Saotome, T; Sugiyama, K; Takahashi, S | 1 |
| Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW | 2 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Fujimura, M; Fushiki, H; Izumi, R; Nakashima, A; Saito, S; Yuuki, H | 1 |
| Fukai, H; Idei, T; Matsumoto, H; Nakayama, Y; Ohta, H; Sakamoto, H; Satoh, K; Takami, M; Togo, Y; Yamamoto, T | 1 |
| Bruckner, H; Compton, LD; Dudek, A; Eckardt, J; Elfring, GL; Green, MR; Hainsworth, J; Lester, E; Locker, PK; Miller, LL; Miller, W; Rocha Lima, CM; Savarese, D; Saville, W; Yunus, F | 1 |
| Freund, M; Köhne, CH; Schuff-Werner, P; Steiner, M | 1 |
| Andou, A; Aoe, M; Date, H; Kiura, K; Shibayama, T; Shimizu, N; Tabata, M; Ueoka, H | 1 |
| Dove, A | 1 |
| Cunha, KS; Graf, U; Reguly, ML; Rodrigues de Andrade, HH | 1 |
| Enomoto, T; Murata, Y; Nakajima, Y; Nakamura, T | 1 |
| Wagman, LD | 1 |
| Bilchik, AJ; Chawla, SP; Chung, M; Foshag, LJ; Litvak, DA; Morton, DL; Ramming, KP; Tsioulias, GJ; Wood, TF | 1 |
| Cohen, Y; Lavrenkov, K; Man, S; Mermershtain, W | 1 |
| Hacker, U; Heinemann, V; Schalhorn, A; Stemmler, J; Weise, A | 1 |
| Agrawal, S; Nan, L; Wang, H; Wang, S; Yu, D; Zhang, R | 1 |
| Ando, M; Hanioka, N; Jinno, H; Nishimura, T; Ozawa, S; Sawada Ji, J; Tanaka-Kagawa, T | 1 |
| Hapke, G; Rustum, YM; Tóth, K; Wu, J; Yin, MB | 1 |
| de Bruijn, EA; Dumez, H; Mathijssen, RH; Sparreboom, A; van Oosterom, AT | 1 |
| Adlard, JW; Quirke, P; Richman, SD; Seymour, MT | 1 |
| Kato, Y; Saijo, N | 1 |
| Holen, KD; Saltz, LB | 1 |
| Koda, RT; Li, WY | 1 |
| Cummings, J; Jardine, L; Joel, SP; Okorokov, AL; te Poele, RH | 1 |
| Cerna, C; Davidson, KK; Heise, C; Izbicka, E; Kirn, D; Lawrence, RA; Petit, T; Von Hoff, DD | 1 |
| Agostini, C; Charasson, V; Montaudon, D; Pavillard, V; Richard, S; Robert, J | 1 |
| Bingham, CM; Hossfeld, DK; Iyer, L; Mayer, U; Ramírez, J; Ratain, MJ; Shepard, DR | 1 |
| Chang, W; Kondo, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Oriyama, T | 1 |
| Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M | 1 |
| Kaniwa, N; Ozawa, S; Sai, K; Sawada, J | 1 |
| Mavroudis, D | 1 |
| Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Boyd, G; Cummings, J; Jodrell, DI; Macpherson, JS; Smith, G; Smyth, JF; Wolf, H | 1 |
| Ilson, DH | 3 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Miller, LL; Nelson, G | 1 |
| Brown, MK; Eastman, A; Kohn, EA; Livingstone, M; Ruth, ND | 1 |
| Bissery, MC; D'Attino, RM; Filipski, E; Garufi, C; Granda, TG; Lévi, F; Terzoli, E; Vrignaud, P | 1 |
| Blandizzi, C; Colucci, R; Danesi, R; De Paolis, B; Del Tacca, M; Di Paolo, A; Falcone, A | 1 |
| Fietkau, R; Klautke, G | 2 |
| Giacchetti, S | 1 |
| Bencharit, S; Danks, MK; Howard-Williams, EL; Morton, CL; Potter, PM; Redinbo, MR | 1 |
| Fujita, F; Fujita, M; Koike, M | 1 |
| Hara, H; Hiramatsu, M; Sako, S; Shinohara, H; Tanigawa, N; Toyoda, M | 1 |
| Ando, Y; Figg, WD | 1 |
| Acquaviva, AM; Apicella, A; Di Matola, T; di Palma, A; Pensabene, M; Pignata, S; Ricchi, P; Ruggiero, G; Zanzi, D; Zarrilli, R | 1 |
| Bansback, N; Hummel, S; Lloyd Jones, M; Orr, B; Seymour, M | 1 |
| Das, S; Fleming, GF; Iyer, L; Janisch, L; Karrison, T; Ramírez, J; Ratain, MJ; Schilsky, RL; Vokes, EE; Wen, M | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V | 1 |
| Houghton, PJ; Santana, VM | 1 |
| Asami, K; Kaneko, M; Kishimoto, T; Matsunaga, T; Mimaya, J; Mugishima, H; Sawada, T; Suita, S; Tsuchida, Y; Yagi, K | 1 |
| Boyd, G; Burchell, B; Cummings, J; Ethell, BT; Jodrell, DI; Macpherson, JS; Smyth, JF | 1 |
| Ando, N; Shih, CH | 1 |
| Chamberlain, MC | 4 |
| Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E | 1 |
| Delioukina, ML; Hecht, JR; Parson, M; Prager, D; Rosen, LS; Rosen, P | 1 |
| Bassi, R; Ellis, LM; Hicklin, DJ; Hooper, AT; Prewett, MC; Waksal, HW | 1 |
| Kohno, T; Mizukami, H; Ozawa, K; Saga, Y; Sato, I; Suzuki, M; Urabe, M | 1 |
| Blumenthal, RD; Goldenberg, DM; Leon, E; Reising, A | 1 |
| Dimitrakopoulos, A; Gennatas, K; Giannopoulos, A; Kosmas, Ch; Koufos, Ch; Macheras, A; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, NB; Tsipras, H; Vadiaka, M | 1 |
| Barbarot, V; Bennouna, J; Douillard, JY | 1 |
| Kerr, DJ | 1 |
| Charasson, V; Haaz, MC; Robert, J | 1 |
| Aikawa, M; Dupree, K; Escandón, E; Fox, JA; Lowe, J; Sinicropi, D; Totpal, K; Xiang, H | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Sekido, Y; Shimokata, K | 1 |
| Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N | 1 |
| Tchekmedyian, NS | 1 |
| Kato, H; Tsuboi, M | 1 |
| Dan, T; Kitayama, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Tanabe, H; Yamasaki, H | 1 |
| Adachi, H; Hirata, K; Katsuramaki, T; Kutomi, G; Mukaiya, M; Shimodan, M | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Morales, C; Vaquero, J; Zurita, M | 1 |
| Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Guo, A; Luo, FR; Paranjpe, PV; Rubin, E; Sinko, P | 1 |
| Manzione, L; Reggiardo, G; Rosati, G; Rossi, A | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S | 1 |
| Cunningham, D; Falk, S; Jackson, D | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
| Fujita, M; Kawasaki, M; Shibata, J; Tani, T | 1 |
| Sörenson, S | 1 |
| Ohe, Y | 1 |
| Sakai, H; Yoneda, S | 1 |
| Yokoyama, A | 1 |
| Nokihara, H; Ohe, Y | 1 |
| Kubota, K; Yoh, K | 1 |
| de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J | 1 |
| Ilson, DH; Kelsen, D; Minsky, B | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B | 1 |
| Gershenson, DM | 1 |
| Verschraegen, CF | 1 |
| Minsky, BD | 2 |
| Crane, CH; Janjan, NA; Mason, K; Milas, L | 1 |
| Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Fouladi, M; Gajjar, A; Heideman, RL; Houghton, PJ; Jones-Wallace, D; Stewart, CF; Thompson, SJ | 1 |
| de Bruijn, P; Kehrer, DF; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Buzzi, F; Comella, P; Crucitta, E; De Cataldis, G; De Lucia, L; De Vita, F; Del Gaizo, F; Farris, A; Lannelli, A; Maiorino, L; Mancarella, S; Palmeri, S; Tafuto, S | 1 |
| Commes, T; Motwani, M; Schwartz, GK; She, Y; Sirotnak, FM | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Karlsson, MO; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 2 |
| Ma, MK; McLeod, HL; Xu, G; Zhang, W | 1 |
| Dolan, ME; Humerickhouse, R; Wu, MH; Yan, B | 1 |
| Boltze, C; Halangk, W; Hribaschek, A; Krüger, S; Kuhn, R; Lippert, H; Pross, M; Ridwelski, K | 1 |
| Canal, P; Chatelut, E; Guichard, S; Rouits, E | 1 |
| Fukuda, H; Fukuoka, M; Kudoh, S; Nakagawa, K; Negoro, S; Nishimura, Y; Takeda, K; Tanaka, M; Yamada, M; Yamamoto, N | 1 |
| Murota, M; Sakai, H; Suzuki, T; Takahashi, Y; Takeguchi, N | 1 |
| Mackenzie, PI; Strassburg, CP; Tukey, RH | 1 |
| Belanger, P; Gagné, JF; Gaucher, G; Guillemette, C; Journault, K; Montminy, V | 1 |
| Hasegawa, K; Hiura, M; Ikeda, M; Ishikawa, M; Kamura, T; Kikkawa, F; Noda, K; Ochiai, K; Ohashi, Y; Saji, F; Sato, S; Sugiyama, T; Takahashi, T; Takeuchi, S; Umesaki, N; Yakushiji, M | 1 |
| Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL | 1 |
| Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Mansky, PJ; Straus, SE | 1 |
| de Bruijn, P; Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Carnaghi, C; Fallini, M; Garassino, I; Masci, G; Morenghi, E; Rimassa, L; Santoro, A; Zucali, PA | 1 |
| Di Lauro, C; Gonen, M; Graham, MA; Kemeny, N; Price, C; Saltz, L; Sharma, S; Stockman, J; Teitcher, J; Tong, W; White, P | 1 |
| Berlin, JD | 1 |
| Baidas, S; Marshall, JL; Rizvi, N | 1 |
| Kolesar, JM; Villalona-Calero, MA | 1 |
| Bleyer, AW; Cabanillas, F; Goy, A; Hagemeister, FB; McLaughlin, P; Medeiros, LJ; Mesina, O; Phan, A; Pro, B; Rodriguez, MA; Romaguera, J; Samuels, B; Sarris, AH | 1 |
| Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Ashmun, RA; Burger, RA; Danks, MK; Guichard, SM; Harris, LC; Houghton, PJ; Morton, CL; Potter, PM; Straign, CM; Wagner, LM | 1 |
| Bhonde, MR; Boland, CR; Hanski, C; Hanski, ML; Magrini, R; Notter, M; Scherübl, H; Zeitz, M | 1 |
| Fujimoto, K; Kaneki, T; Koizumi, T; Kubo, K; Urushihata, K; Yamaguchi, S | 1 |
| Hirose, T; Kobayashi, A; Yamada, T | 1 |
| Ayabe, H; Fukuoka, H; Hidaka, S; Nakagoe, T; Nanashima, A; Sawai, T; Shibasaki, S; Tanaka, K; Tsuji, T; Yamaguchi, H; Yamashita, H; Yasutake, T | 1 |
| Arnt, CR; Chiorean, MV; Gores, GJ; Heldebrant, MP; Kaufmann, SH | 1 |
| Hara, N; Harada, T; Inoue, K; Izumi, M; Kimotsuki, K; Minami, T; Nakanishi, Y; Osaki, S; Takano, K; Takayama, K; Wataya, H | 1 |
| Fang, HB; Houghton, PJ; Tan, M; Tian, GL | 3 |
| Depisch, D; Fiebiger, W; Kornek, GV; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Bokemeyer, C; Hentrich, M; Kanz, L; Klaproth, H; Kollmannsberger, C; Kubin, T; Kuczyk, M; Mayer, F; Rick, O; Sayer, HG; Spott, C; Welslau, M | 1 |
| Arnould, S; Bugat, R; Canal, P; Cassar, G; Guichard, S; Hennebelle, I | 1 |
| Atagi, S; Furuse, K; Hosoe, S; Kawaguchi, T; Kawahara, M; Naka, N; Ogawara, M; Okishio, K; Takemoto, Y; Tsuchiyama, T; Ueno, K | 1 |
| de Graaf, M; Gerritsen, WR; Haisma, HJ; Kruyt, FA; Oosterhoff, D; Pinedo, HM; Sone, T; van Beusechem, VW; van der Meulen, IH | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Fujii, H; Konishi, M; Koshiyama, M; Tauchi, K; Yoshida, M | 1 |
| Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E | 1 |
| Ichinose, Y | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Goto, S; Ihara, Y; Kamada, K; Kondo, T; Soh, Y | 1 |
| Deguchi, N; Murai, M; Nonaka, S; Ueno, M; Yamazaki, R | 1 |
| Frank, C; Hapke, G; Rustum, YM; Wu, J; Yin, MB | 1 |
| Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P | 1 |
| Choy, H; Wu, HG | 1 |
| Bleickardt, E; Kwong, MS; Murren, JR | 1 |
| Fukuda, M; Ichiki, M; Kawabata, S; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Nakatomi, K; Narasaki, F; Oka, M; Rikimaru, T; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE | 1 |
| Davis, TW; Durham, WF; Horton, J; Levine, BD; Masferrer, JL; Salazar, VS; Trifan, OC; Zweifel, BS | 1 |
| Hylander, BL; Naka, T; Repasky, EA; Rustum, YM; Sugamura, K; Widmer, MB | 1 |
| Cheshire, P; Dodds, HM; Hanna, S; Houghton, P; Rivory, LP; Stewart, CF; Tobin, PJ | 1 |
| Algarra, SM; Aramendía, JM; Aristu, J; Brugarolas, A; González Cao, M; Martínez Monje, R; Ordoñez, JM; Salgado, E | 1 |
| Baker, C; Chun, HG; Fehn, K; Goel, S; Hoffman, A; Hopkins, U; Jhawer, M; Landau, L; Makower, D; Mani, S; Rajdev, L; Wadler, S | 1 |
| Ang, P; Ang, PT; Au, E; Koo, WH; See, HT | 1 |
| Azuma, T; Hatada, T; Inoue, Y; Kusunoki, M; Miki, C; Mohri, T; Ojima, E | 1 |
| Horikawa, M; Kato, Y; Sugiyama, Y | 1 |
| Kotake, T; Miki, T; Mizutani, Y; Nakao, M; Nomoto, T; Nonomura, N; Okuyama, A; Saiki, S | 1 |
| Hojo, K; Maekawa, R; Maki, H; Sawada, TY; Tanaka, H; Yoshioka, T | 1 |
| Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Jacques, C; Raymond, E; Rixe, O; Sanderink, GJ; Vernillet, L | 1 |
| Bachelot, A; Baudin, E; Docao, C; Gicquel, C; Penfornis, A; Schlumberger, M; Vassal, G | 1 |
| Schmoll, HJ | 1 |
| Needle, MN | 1 |
| Cats, A; van Ruth, S; Zoetmulder, FA | 1 |
| Harper, P; Marx, G | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F | 1 |
| Kawano, Y; Miyakawa, I; Narahara, H; Nasu, K; Takai, N; Utsunomiya, H | 1 |
| Borel, C; Caroli-Bosc, FX; Couteau, C; Desseigne, F; Hua, A; Jacob, JH; Kramar, A; Lefebvre, P; Merrouche, Y; Raoul, JL; Seitz, JF; Ychou, M | 1 |
| Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT | 1 |
| Fukushima, S; Kishimoto, S; Sadzuka, Y; Sonobe, T; Takeuchi, Y; Yamashita, Y | 1 |
| Budman, DR | 1 |
| Fisher, MD | 3 |
| D'Orazio, AI; Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF | 1 |
| Negoro, S; Takeda, K; Takifuji, N; Terakawa, K; Uejima, H; Yoshimura, N | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Erlichman, C; Hobday, TJ | 1 |
| Fisher, MD; Maung, K | 1 |
| Cvitkovic, E; Sutherland, W; Wasserman, E | 1 |
| Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M | 1 |
| Danesi, R; Di Paolo, A | 1 |
| Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J | 1 |
| Chico, IM; Pazdur, R | 1 |
| Chu, E | 3 |
| Blackstock, AW; McMullen, KP | 1 |
| Villalona-Calero, MA; Xu, Y | 1 |
| Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM | 1 |
| Avallone, A; Casaretti, R; Comella, G; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Lapenta, L | 1 |
| Siderov, J | 1 |
| Patel, SR | 1 |
| Kuroiwa, M; Shimada, A; Shitara, T; Suzuki, N; Toki, F; Tsuchida, Y | 1 |
| Cheng, C; Das, S; Di Rienzo, A; Grimsley, C; Innocenti, F; Kuttab-Boulos, H; Ramírez, J; Ratain, MJ | 1 |
| Asami, T; Imada, T; Kokawa, A; Morimoto, M; Saito, T; Shirato, K; Sugimori, K; Tanaka, K; Tomita, N | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S | 1 |
| Haut, PR; Katzenstein, HM; Kletzel, M; Mitchell, TL; Rigsby, C; Shaw, PH | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Imai, Y; Ishikawa, E; Kage, K; Miki, Y; Nakane, M; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Fossella, F; Milas, L; Rosell, R | 1 |
| Bègue, M; Ceccaldi, B; Hauteville, D; Kara, F; Le Marec, E; Mommeja-Marin, H; Saint Blancard, P | 1 |
| Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Goldberg, RM; Hobday, TJ | 1 |
| Calvo, E | 1 |
| Azzariti, A; Church, SW; Colucci, G; Johnston, PG; Lacalamita, R; Paradiso, A; Tommasi, S; Xu, JM | 1 |
| Adachi, A; Hashimoto, D; Ishida, H; Itoyama, S; Murata, N; Sobajima, J | 1 |
| Ebuchi, M; Hasegawa, K; Maruyama, M; Nagahama, T; Natsui, S; Ochiai, T; Takashima, I | 1 |
| Inoue, S; Kagawa, M; Kusanishi, H; Watanabe, Y | 1 |
| Arai, K; Homma, S; Iwasaki, Y; Kimura, Y; Mori, T; Ohue, M; Takahashi, K; Yamaguchi, T | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Kouro, T; Sakita, I; Souma, I; Yoshida, T | 1 |
| Hata, Y; Itoh, T; Maeda, Y; Matsuoka, S; Nakajima, N; Osada, T; Sano, F | 1 |
| Wu, M; Xie, M; Xue, B; Yan, B; Yang, D | 1 |
| Ando, M; Hanioka, N; Ishida, S; Jinno, H; Nishimura, T; Ozawa, S; Saeki, M; Saito, Y; Sawada, J; Tanaka-Kagawa, T | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Randal, J | 1 |
| Atherton, PJ; Gupta, E; Kastrissios, H; Klein, CE; Pitot, HC; Ratain, MJ; Reid, JM; Sloan, JA | 1 |
| Bastidas, JA; Cho, C; Dunphy, EP; Fisher, G; Ford, JM; Jambalos, C; Koong, A; Lin, A; Mehta, VK; Poen, J; Young, H | 1 |
| Akagi, T; Higuchi, S; Inoue, K; Ishizaki, T; Kage, Y; Makinosumi, T; Ohdo, S; Taguchi, Y; Ushinohama, K; Yamauchi, A; Yukawa, E | 1 |
| Albanell, J; Baselga, J | 1 |
| Agrawal, S; Wang, H; Yu, D; Zhang, R | 1 |
| Machida, Y; Onishi, H | 1 |
| Kerr, D | 1 |
| Turrisi, AT | 1 |
| Bodurka, DC; Gano, J; Gershenson, DM; Kavanagh, JJ; Levenback, C; Wharton, JT; Wolf, JK | 1 |
| Gotoh, M; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H | 1 |
| Kwee, JK; Maia, RC; Marques-Santos, LF; Silva, KL; Vasconcelos, FC | 1 |
| Danks, MK; Harris, LC; Morton, CL; Potter, PM; Schuetz, JD; Wierdl, M | 1 |
| Baba, Y; Hayashi, N; Iyama, K; Marutsuka, T; Ogawa, M; Shimada, S; Yokoyama, S | 1 |
| Akbulut, H; Akbulut, KG; Altuntas, F; Cindoruk, M; Icli, F; Ozturk, G; Unal, E | 1 |
| Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C | 1 |
| Beijnen, JH; Jansen, S; Rosing, H; Schellens, JH; Schoemaker, NE | 1 |
| Bilchik, AJ; Cabot, MC; Litvak, DA | 1 |
| Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J | 1 |
| Evans, JF; Kargman, S; Kelly, CR; Kwong, E; Lam, EC; Luk, P; Wolfe, MM; Yao, M; Zheng, Y | 1 |
| Fujitani, K; Hirao, M; Tsujinaka, T | 1 |
| Ariyoshi, Y; Fukuoka, M; Katakami, N; Kudoh, S; Masuda, N; Negoro, S; Niitani, H; Ohashi, Y; Sugiura, T; Takada, Y | 1 |
| Ma, MK; McLeod, HL | 1 |
| Hochster, H | 1 |
| Bonetti, A | 1 |
| Bernstein, ML; Blaney, SM; Dubowy, RL; Hershon, L; McLeod, WD; Souid, AK; Sullivan, J | 1 |
| Artal, A; Balcells, M; Barneto, I; Cardenal, F; Carrato, A; Domine, M; Felip, E; Garrido, P; Juan, O; López-Vivanco, G; Massutí, B; Rosell, R | 1 |
| Bourhis, JH; Damaj, G; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Ravoet, C; Ribrag, V; Suzan, F; Vantelon, JM | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Conroy, T; Gourgou, S; Hua, A; Kramar, A; Mery-Mignard, D; Seitz, JF; Ychou, M | 1 |
| Aoki, F; Kaminishi, M; Mafune, K; Shimizu, N; Shimoyama, S; Tatsutomi, Y | 1 |
| Boku, N; Hyodo, I; Nakamura, A; Ohtsu, A; Saitoh, S; Shimada, Y; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S; Yoshioka, T | 1 |
| Fuchs, CS; Harker, G; Hecht, JR; Moore, MR; Rinaldi, D; Villa, L | 1 |
| Ishikawa, T; Ouchi, KF; Tanaka, Y; Yanagisawa, M | 1 |
| Hiroi, M; Hojyo, T; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Angenault, S; Monneret, C; Pfeiffer, B; Renard, P; Schmidt, F; Thirot, S | 1 |
| McLeod, HL; Watters, JW | 2 |
| Farrell, MP; Kummar, S | 1 |
| Braun, MS; Button, CJ; Cheeseman, SL; Chester, JD; Davis, T; Hall, GD; Joel, SP; Perry, J; Seymour, MT | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Armand, JP; Boige, V; Fabbro, M; Faivre, S; Frenay, M; Germa, C; Raymond, E; Rixe, O; Rodier, JM; Sicard, E; Vassal, G; Vernillet, L | 1 |
| Biloti, DN; Pessine, FB; Santana, MH | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Comte, S; Lebrun, T; Selke, B | 1 |
| Ballesteros, P; Bohn, U; Cassinello, J; Dorta, J; Fernández, JL; Huidobro, G; Jorge, M; López, R; López-Alvarez, P; Martínez-Guisado, A; Pérez-Carrión, R; Sevilla, I; Valladares, M | 1 |
| Crews, KR; Dodds, H; Fricke, K; Hanna, SK; Owens, TS | 1 |
| Funahashi, K; Goto, T; Koike, J; Matsumoto, H; Miki, T; Ryu, M; Shibata, Y; Shiokawa, H; Teramoto, T; Tokuyama, T; Washizawa, N | 1 |
| Akasu, T; Fujita, S; Hosokawa, A; Matsumura, Y; Moriya, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y | 1 |
| Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC | 1 |
| Baldwin, AS; Cusack, JC; Ewend, MG; Weaver, KD; Yeyeodu, S | 1 |
| Anné, PR; Fry, RD; Goldstein, SD; Isenberg, GA; Mahmoud, NN; Mitchell, E; Rose, DG; Stein, DE | 1 |
| Kamiyama, Y; Kano, Y; Kondo, T; Mori, K; Tominaga, K | 1 |
| Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G | 1 |
| Malinovskiĭ, NN; Severtsev, AN; Smirnova, NB | 1 |
| Ator, M; Bihovsky, R; Chatterjee, S; Dionne, C; Hudkins, R; Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Miknyoczki, SJ; Pritchard, S; Ruggeri, B; Wan, W; Zhao, H | 1 |
| Beatrix, O; Dumortier, J; Lapalus, MG; Lombard-Bohas, C; Scoazec, JY; Villarejo, J; Vochelle, V | 1 |
| Fukuoka, M; Kudoh, S; Matsui, K; Mori, K; Nakano, T; Negoro, S; Nishiwaki, Y; Noda, K; Ohsaki, Y; Saijo, N; Sekine, I; Yokoyama, A | 1 |
| Alimonti, A; Burattini, E; Pavese, I; Satta, F; Vecchione, A; Zoffoli, V | 1 |
| Kanishi, Y; Kiguchi, K; Kobayashi, Y; Kondo, H; Okuma, Y; Saito, K; Sato, S | 1 |
| Glimelius, B | 2 |
| Lièvre, A; Mitry, E | 1 |
| Ames, M; Buckner, JC; Cha, S; Erlichman, C; Kaufmann, SH; Miller, LL; O'Fallon, JR; Reid, JM; Schaaf, LJ; Wright, K | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Chen, TC; Fry, D; Liebes, L; Su, S | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Gajjar, A; Jones-Wallace, D; Stewart, CF | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Kuhn, J; Miller, LL; Nelson, G | 1 |
| Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM | 1 |
| Blackburn, A; Cunningham, C; Freeman, S; Gibson, B; Nemunaitis, J; Netto, G; Paulson, AS; Post, L; Randlev, B; Rich, D; Sands, B; Tong, A | 1 |
| Chiba, H; Hirayama, Y; Iyama, S; Niitsu, Y; Oku, T; Sagawa, T; Sakamaki, S; Sato, Y; Takahashi, M; Takayama, T; Takayanagi, N; Tsuji, Y | 1 |
| Ando, M; Hanioka, N; Jinno, H; Kaniwa, N; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yoshida, T | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Urano, M | 1 |
| Aisner, J; Beers, S; Gounder, M; Licitra, EJ; Lin, Y; Musanti, R; Nelson, K; Poplin, E; Rajendra, R; Rubin, EH; Saleem, A; Schaaf, LJ; Smith, S; Thomas, C; Toppmeyer, D; Vyas, V | 1 |
| Ikehara, M; Kato, Y; Noda, K; Nomura, I; Oshita, F; Saito, H; Suzuki, R; Tanaka, G; Yamada, K | 1 |
| Balram, C; Cheung, YB; Lee, EJ; Zhou, QY | 1 |
| Aizawa, H; Gohara, R; Ichiki, M; Kamimura, T; Kawayama, T; Koga, T; Matunami, M; Oshita, Y; Rikimaru, T | 1 |
| Agelaki, S; Alexopoulos, A; Ardavanis, A; Georgoulias, V; Kalbakis, K; Karyda, E; Kouroussis, Ch; Malamos, N; Malas, K; Tselepatiotis, E | 1 |
| Palmer, RD; Williams, DM | 1 |
| Boiocchi, M; Cecchin, E; Corona, G; Toffoli, G | 1 |
| Ansell, W; Nystrom, M; Oliver, RT; Shamash, J; Steele, JP; Wilson, P | 1 |
| Ishikawa, H; Kamakari, K; Noguchi, T; Ono, N; Tashima, M; Terada, Y | 1 |
| Hinkelbein, W; Mühr-Wilkenshoff, F; Ohnesorge, I; Riecken, EO; Scherübl, H; Wolf, KJ; Zeitz, M | 1 |
| Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noguchi, H; Ogura, K; Ohmori, T | 1 |
| Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y | 1 |
| Alberts, SR; Burgart, LJ; Cera, PJ; Fishkin, PA; Goldberg, RM; Johnson, PA; Mahoney, MR; Morton, RF; Nair, S | 1 |
| Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT | 1 |
| Kikuchi, R; Noguchi, T; Oka, Y; Okada, S; Shibata, T; Toyoda, H; Uchida, Y | 1 |
| André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M | 1 |
| Ahmad, A; Ahmad, I; Dahhani, F; Guo, W; Khan, S; Wang, YF | 1 |
| Charuchinda, C; Chitapanarux, I; Lorvidhaya, V; Pukanhapan, N; Sukthomya, V; Tonusin, A | 1 |
| De Boeck, G; de Bruijn, EA; Guetens, G; Landuyt, B; Landuyt, W; van Oosterom, AT; Verbeken, E; Wildiers, H | 1 |
| Friedman, HS; Gilbert, M; Powell, JB; Reardon, DA; Yung, WK | 1 |
| Crane, CH; Liao, Z; Masferrer, J; Mason, KA; Milas, L | 1 |
| Shapiro, CL; Xu, Y | 1 |
| Noda, K; Ochiai, K; Sugiyama, T; Yakushiji, M | 1 |
| Belinson, J; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Kuzur, ME; Miranda, FT; Raefsky, EA; White, MB; Willcutt, NT; Yardley, DA | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Miranda, FT; Shipley, DL; Thompson, DS; Toomey, MA; Willcutt, NT | 1 |
| Hwang, JJ; Marshall, JL; Rizvi, N | 1 |
| Innocenti, F; Ratain, MJ | 4 |
| Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E | 1 |
| Karadeniz, A; Karagol, H; Tas, F; Topuz, E | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Benson, AB; Goldberg, RM | 1 |
| Ishihara, A; Nagao, K; Tanaka, H; Toyoda, N; Umekawa, T | 1 |
| Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M | 1 |
| Bugat, R | 1 |
| Van Cutsem, E; Wilke, HJ | 1 |
| Boku, N; Ikeda, H; Ishikura, S; Ito, Y; Nihei, K; Ogino, T; Ohtsu, A | 1 |
| Gemici, C; Uygur-Bayramiçli, O | 1 |
| Arimori, K; Hidaka, M; Iwakiri, T; Kikuchi, M; Kuroki, N; Nakano, M; Okumura, M; Ono, H; Takamura, N; Yamsaki, K | 1 |
| Haller, DG | 2 |
| Chevreau, C; Culine, S; Droz, JP; Escudier, B; Fizazi, K; Mery-Mignard, D; Rolland, F | 1 |
| Sawabu, N | 1 |
| Artru, P; De Gramont, A; Krulik, M; Louvet, C; Nahon, P; Tournigand, C | 1 |
| Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J | 1 |
| Kobayashi, K | 1 |
| Amano, K; Hanyu, F; Hayashi, T; Imazato, M; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
| Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J | 1 |
| Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM | 1 |
| Cummings, J; Hayward, RL; Jodrell, DI; Macpherson, JS; Monia, BP; Smyth, JF | 1 |
| Chanslip, Y; Pattaranutaporn, P; Suntornpong, N; Thephamongkhol, K | 1 |
| Kosmidis, PA; Manegold, C | 1 |
| Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K | 1 |
| Cohen, Y; Geffen, DB; Gluzman, A; Lavrenkov, K; Man, S | 1 |
| Danks, MK; Morton, CL; Potter, PM; Sampath, J; Schuetz, JD; Wall, A; Wierdl, M | 1 |
| Dvorák, J; Kohout, P; Melichar, B; Melicharová, K; Solichová, D; Zadák, Z | 1 |
| Araya, Y; Fujimoto, T; Inoue, S; Kameyama, M; Kanetoshi, A; Ohtsuka, K; Shida, A; Takaoka, K | 1 |
| Bouzourene, H; Coucke, P; Gillet, M; Leyvraz, S; Matter, M; Stupp, R; Voelter, V | 1 |
| Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M | 1 |
| Bains, M; Coit, D; Gonen, M; Ilson, DH; Karpeh, M; Kelsen, DP; Minsky, BD; O'Reilly, E; Rusch, V; Wilson, K | 1 |
| Aizawa, H; Fujiki, R; Gohara, R; Ichiki, M; Kitajima, T; Rikimaru, T; Shimada, A | 1 |
| Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, J; Meyers, FJ; Tanaka, M; Wang, SE; Wild, CA | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Faust, J; Govindan, R; Mc Leod, H; Read, W | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
| Dueland, S; Lund-Johansen, F; Ostenstad, B; Sauer, T; Tveit, KM | 1 |
| Bleichrodt, RP; Bremers, AJ; Smidt, ML; Wegdam, JA | 1 |
| Lenz, HJ; Park, DJ; Stoehlmacher, J | 1 |
| Almasan, A; Ray, S | 1 |
| Bowen, JM; Cummins, AG; Gibson, RJ; Inglis, MR; Keefe, DM | 1 |
| Batchelor, T; Fisher, JD; Gilbert, MR; Grossman, S; Lesser, G; Piantadosi, S; Supko, JG | 1 |
| Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y | 1 |
| Chen, X; Davis, AJ; Kochman, D; Kusenda, Z; Moore, MJ; Oza, AM; Siu, LL; Yi, QL | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Kato, H; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K | 1 |
| Burnakis, TG | 1 |
| Barceló, R; Ferreiro, J; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Fujiwara, H; Kikuchi, Y; Kita, T; Komiyama, S; Konno, R; Machida, S; Mikami, M; Ohwada, M; Suzuki, M; Takano, M | 1 |
| LaBell, R; Lansdown, R; Ramaswami, R; Romanowski, M; Sweitzer, R; Unger, E; Williams, J | 1 |
| Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Kozakai, I; Motoyama, H; Ohta, T; Saito, Y; Takii, Y | 1 |
| Kinoshita, H; Kitaura, T; Nakae, S; Onoyama, H; Sainoh, K; Saitoh, Y; Shiroiwa, H; Sugihara, S; Takahashi, T; Takao, S; Toyota, J; Urakawa, T; Yamamoto, M | 1 |
| Fukuda, K; Kimura, F; Kokufu, I; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Boven, E; Bras, J; Gerritsen, WR; Haisma, HJ; Kruyt, FA; Molenaar, B; Oosterhoff, D; Pinedo, HM; Schaap, GR; van Beusechem, VW; Witlox, MA; Wuisman, PI | 1 |
| de Gramont, A; Louvet, C | 2 |
| Levin, M | 1 |
| Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S | 1 |
| Fortier, LC; Gagné, JF; Girard, H; Guillemette, C; Villeneuve, L | 1 |
| Blumgart, L; Fong, Y; Gonen, M; Hummer, A; Jarnagin, W; Kemeny, N; Sperber, D; Stockman, J | 1 |
| Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ | 1 |
| Baker, SD; Karlsson, MO; Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Alfonso, R; Díaz-Rubio, E; Flores, L; Macías, JA; Manrique, I; Sastre, J | 1 |
| Koo, WH; Lim, ST; Lim, WT; Wong, NS | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ | 1 |
| Berlin, JD; Rothenberg, ML | 1 |
| Buzzi, F; Comella, P; De Lucia, L; De Vita, F; Farris, A; Gambardella, A; Lorusso, V; Maiorino, L; Mancarella, S; Palmeri, S | 1 |
| Bugat, R; Catane, R; Clemens, M; Di Betta, D; Ducreux, M; Fages, B; Figer, I; Gips, M; Jacques, C; Klein, B; Knuth, A; Köhne, CH; Niederle, N; Preusser, P; Shani, A; Thuss-Patience, P; Wilke, HJ | 1 |
| Abe, S; Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Berney, D; Oliver, RT; Powles, T; Shamash, J | 1 |
| Allouache, J; Bouzy, J; Bugat, R; Coudert, B; Culine, S; Douillard, JY; Fizazi, K; Goupil, A; Kaminsky, MC; Laplanche, A; Lesimple, T; Lortholary, A; Merrouche, Y; Négrier, S; Petrow, P; Pivot, X; Priou, F; Théodore, C; Viala, J; Voigt, JJ | 1 |
| Galle, PR; Haas, U; Heike, M; Hertkorn, C; Hoehler, T; Moehler, M; Schimanski, C; Siebler, J | 1 |
| Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L | 1 |
| Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N | 1 |
| Fuchs, CS | 1 |
| Diasio, R | 1 |
| Venook, AP | 2 |
| Kondo, H; Maeda, Y; Nojima, T; Sato, S; Takenaka, S | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Azuma, M; Higuchi, K; Kitamura, T; Koizumi, W; Nagaba, S; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Sato, A; Shimada, K; Taguchi, S | 1 |
| Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T | 1 |
| de Bruijn, P; de Jong, FA; Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Boige, V; Borrini, F; Ducreux, M; Fallik, D; Jacob, S; Miquel, C; Praz, F; Sabourin, JC; Viguier, J | 1 |
| de Gramont, A; Kuebler, JP | 1 |
| Desai, AA; Innocenti, F; Ratain, MJ | 1 |
| Aghajanian, C; Dizon, DS; Hensley, M; Hummer, A; Leitao, MM; Sabbatini, P; Spriggs, DR; Venkatraman, E | 1 |
| Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D | 1 |
| Doz, F; Frappaz, D; Germa, C; Imadalou, K; Mignard, D; O'Quigley, J; Pein, F; Risse, ML; Santos, A; Sicard, E; Vassal, G | 1 |
| Atalay, G; Bleiberg, H; Cardoso, F; Goldberg, RM; Paesmans, M | 1 |
| Bittorf, B; Brueckl, V; Brueckl, WM; Hahn, EG; Hegewald, J; Hohenberger, W; Jüngert, B; Männlein, G; Mühldorfer, S; Schirner, I; Stickel, F; Wein, A | 1 |
| Chung, C; Fidler, JM; Gao, M; Li, K; Rosen, GD; Ross, JA; Wei, K | 1 |
| Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L | 1 |
| Iwai, T; Ohtsukasa, S; Okabe, S; Sugihara, K; Yamashita, H | 1 |
| Bourhis, JH; Carde, P; Fermé, C; Koscielny, S; Munck, JN; Ribrag, V; Rideller, K; Vantelon, JM | 1 |
| Asada, S; Imai, Y; Ishikawa, E; Miwa, M; Sugimoto, Y; Tsukahara, S | 1 |
| Enomoto, K; Maruyama, K; Matsui, A; Okuda, M; Tsujitsuka, K | 1 |
| de Witte, JH; Keizer, HJ; Peters, WG; ten Bokkel Huinink, WW; van Groeningen, CJ; Voest, EE | 1 |
| Benson, AB; Blanke, CD; Hecht, JR; Lenz, HJ | 1 |
| Haller, D; Sun, W | 1 |
| Ajani, JA; Faust, J; Komaki, R; Putnam, JB; Rice, D; Roth, J; Smythe, R; Stevens, C; Swisher, S; Vaporciyan, A; Walsh, G; Yao, J | 1 |
| Bhargava, P; Jani, CR; O'Donnell, JL; Rocha Lima, CM; Savarese, DM; Stuart, KE | 1 |
| Baker, SD; Faust, J; Govindan, R; Ma, MK; McLeod, HL; Perry, MC; Read, W; Trinkaus, K | 1 |
| Ilson, DH; Minsky, B | 1 |
| Eisenberg, SG; Hwang, JJ; Marshall, JL | 1 |
| Fanucchi, MP; Giblin, J; Khuri, F; Richards, S; Umbreit, JN | 1 |
| Hazama, S; Hinoda, Y; Oka, M | 1 |
| Maeda, Y; Sasaki, E; Sasaki, T | 1 |
| Nagao, M; Nakajima, Y | 1 |
| Hirata, K; Nishikawa, N; Sasaki, K; Takasaka, H; Yoshikawa, T | 1 |
| Kataoka, M; Kondo, K; Shimoyama, S | 1 |
| Motomura, S | 1 |
| Doi, T; Ohtsu, A | 1 |
| Shirao, K; Ura, T | 1 |
| Fukuda, H | 1 |
| Tsunoda, T | 1 |
| Akazawa, S; Murakami, T; Nakazima, T; Sakurai, T; Yamashina, T | 1 |
| Astre, C; Bressolle, F; Culine, S; Malosse, F; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Omura, K | 1 |
| Bosron, WF; Cummings, OW; Davis, WI; Fredenburg, TB; Murry, DJ; Quinney, SK; Sanghani, SP; Seitz, DE; Sun, Z | 1 |
| Bauzon, M; Danks, MK; Dubensky, T; Fattaey, A; Holman, P; Johnson, L; Lemmon, M; Perin, N; Potter, PM; Stubdal, H | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Hiroi, M; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Abad, A; Barnadas, A; Font, A; Manzano, JL; Margelí, M; Martinez-Balibrea, E; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM; Tarón, M | 1 |
| Blay, P; Buesa, JM; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Sánchez, R; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| O'Neil, BH | 1 |
| Willett, CG; Zhu, AX | 2 |
| Soepenberg, O; Sparreboom, A; Verweij, J | 1 |
| Eguchi, K; Kobayashi, K; Matsumoto, T; Morita, S; Ohashi, Y; Sakamoto, J; Shibuya, M; Yamaji, Y | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Komaki, R; Kurie, JM; Lee, JJ; Papadimitrakopoulou, VA; Peeples, BO; Pisters, KM | 1 |
| Bramis, J; Delladetsima, JK; Giannopoulos, A; Kouraklis, G; Polyzos, A; Sfikakis, PP | 1 |
| Pizzolato, JF; Saltz, LB | 1 |
| Hassan, AB; Markham, C; Stocken, DD | 1 |
| Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM | 1 |
| Broggini, M; Colombo, T; Geroni, C; Marchini, S; Sabatino, MA | 1 |
| Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Ebuchi, M; Hasegawa, K; Maruyama, M; Nagahama, T; Takashima, I | 1 |
| Furukawa, J; Ishigami, H; Katsumoto, Y; Kinuta, M; Maruyama, KT; Maruyama, N; Nagai, K; Nakaguchi, K; Tanaka, J; Yokouchi, H | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Oshima, S; Tsujie, M; Yamamoto, H | 1 |
| Hasuike, Y; Kashiwazaki, M; Mishima, H; Nishisyo, I; Takeda, Y; Tsujinaka, T | 1 |
| Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kishi, K; Kitamura, S; Masutani, S; Nakayama, T; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Ohshima, S; Tsujie, M; Yamamoto, H | 1 |
| Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T | 1 |
| Deavers, M; Hunt, K; Le, DT; Malpica, A; Verschraegen, CF | 1 |
| Budman, D; Byrd, J; Enders Klein, C; Fleming, G; Hohl, R; Hollis, D; Kastrissios, H; Leichman, CG; Marshall, J; Ramirez, J; Ratain, MJ; Rosner, GL; Venook, AP; Villalona, M | 1 |
| Bamberg, M; Belka, C; Jendrossek, V | 1 |
| El-Deiry, WS; Wang, S | 1 |
| Hasegawa, R; Itoda, M; Kamakura, S; Kamatani, N; Kaniwa, N; Kitakaze, M; Kitamura, Y; Komamura, K; Minami, H; Ohtsu, A; Ozawa, S; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Ueno, K; Yoshida, T | 1 |
| Ahmad, A; Ahmad, I; Khan, S | 1 |
| Kanzawa, F; Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T; Tsukiyama, S; Ueda, Y | 1 |
| Anderson, SE; Bains, M; Ilson, DH; Kelsen, DP; Minsky, BD | 1 |
| Ikeda, H; Kuroiwa, M; Shitara, T; Tsuchida, Y | 1 |
| Baba, H; Kakeji, Y; Maehara, Y; Oki, E; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
| Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H | 1 |
| Goto, M; Hiraide, Y; Matsumoto, T; Saito, E; Takada, T | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Iyama, S; Kida, M; Kogawa, K; Mezawa, S; Murakami, K; Murase, K | 1 |
| Achille, E; André, T; Buyse, M; Colin, P; Couteau, C; de Gramont, A; Flesh, M; Ganem, G; Landi, B; Lledo, G; Louvet, C; Mery-Mignard, D; Quinaux, E; Tournigand, C | 1 |
| Danks, MK; Potter, PM | 1 |
| Allegrini, G; Calabresi, P; Darnowski, JW; Goulette, FA | 1 |
| Benedicic, Ch; Petru, E; Pickel, H; Seewann, A | 1 |
| Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H | 1 |
| Allen, JD; Boyd, G; Cummings, J; Friedberg, TH; Jodrell, DI; Maliepaard, M; Smyth, JF; Yao, D; Zelcer, N | 1 |
| Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J | 1 |
| Cohen, D; Hiotis, S; Lin, K; Marcus, SG; Newman, E; Potmesil, M; Rothberger, A; Thompson, S; Wong, K | 1 |
| Curley, SA; Ellis, LM; Gentner, B; Parikh, AA; Vauthey, JN; Wu, TT | 1 |
| Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH | 1 |
| Boyd, G; Burchell, B; Cummings, J; Ethell, BT; Jardine, L; Jodrell, DI; Macpherson, JS; Smyth, JF | 1 |
| de Greve, J; Giaccone, G; Gruia, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM | 1 |
| Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| Arciero, C; Peoples, GE; Shriver, CD | 1 |
| Zhang, L | 1 |
| Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D | 1 |
| Viele, CS | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A | 1 |
| Comella, P | 1 |
| Ariyoshi, Y; Fukuoka, M; Hoso, T; Katakami, N; Kawahara, M; Kudoh, S; Matsui, K; Nakagawa, K; Nakano, T; Negoro, SI; Saito, H; Senba, H; Sugiura, T; Takada, Y; Yamamoto, N | 1 |
| Altundag, K; Barista, I; Celik, I; Engin, H; Guler, N; Gullu, I; Kars, A; Oksuzoglu, B; Ozisik, Y; Tekuzman, G; Turker, A; Yalcin, S | 1 |
| Akagi, Y; Hashimoto, Y; Ito, K; Murakami, Y | 1 |
| Vanhoefer, U | 1 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Gill, S; Goldberg, RM | 2 |
| Ahmad, I; Ali, S; Ma, L; Parmar, M; Ugwu, S; Xuan, T; Zhang, JA | 1 |
| Ahmed, B; De Boeck, G; de Bruijn, EA; Guetens, G; Landuyt, W; van Oosterom, AT; Wildiers, H | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 4 |
| Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G | 1 |
| Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E | 1 |
| Davis, ID; Green, M; Jefford, M; McClure, B; Michael, M; Rosenthal, MA; Smith, J; Waite, B; Zalcberg, J | 1 |
| Folprecht, G; Köhne, CH | 5 |
| Berger, MR; Leible, M; Saenger, J; Seelig, MH | 1 |
| Cats, A | 1 |
| Blackman, RK; Bulawa, CE; Charlton, P; Connolly, K; Fleming, JA; McClendon, AK; Osheroff, N; Reimer, C; Rudolph-Owen, LA; Sappal, DS; Thoroddsen, V | 1 |
| Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Aibe, H; Asayama, Y; Honda, H; Irie, H; Kakihara, D; Matake, K; Nakamura, K; Nakayama, T; Nishie, A; Ohga, S; Tajima, T; Yamamoto, N; Yoshimitsu, K | 1 |
| Cohen, MH; Griebel, DJ; Hirschfeld, S; Ibrahim, A; Pazdur, R; Williams, GA | 1 |
| Buster, WP; Gruber, ML | 1 |
| Fakih, M | 2 |
| Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
| Batchelor, TT; Carson, KA; Gilbert, MR; Grossman, SA; Lesser, GJ; Mikkelsen, T; Nabors, LB; Phuphanich, S; Supko, JG | 1 |
| Chang, SM; Cloughesy, TF; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M | 1 |
| Koshimizu, R; Lei, S; Ogiso, Y; Tomida, A; Tsuruo, T; Zhang, HF | 1 |
| Albritton, K; Crews, KR; Fuller, CE; Goldsby, RE; Houghton, PJ; Iacono, LC; McCarville, MB; Santana, VM; Stewart, CF; Wagner, LM | 1 |
| Azrak, RG; Cao, S; Durrani, FA; McLeod, HL; Pendyala, L; Rustum, YM; Slocum, HK; Tóth, K; Yin, MB; Zhang, W | 1 |
| Cloughesy, TF; Liau, LM; Mischel, PS; Wang, Y; Zhu, S | 1 |
| Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS | 1 |
| Morton, CL; Nguyen, NK; Potter, PM; Redinbo, MR; Wierdl, M | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Sasako, M; Ushijima, T | 1 |
| Crawford, J; Govindan, R; Green, MR; Herndon, JE; King, GW; Rizvi, NA; Rocha Lima, CM; Zhang, C | 1 |
| Kitakata, H; Mai, M; Minamoto, T; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K | 1 |
| Abal, M; Bras-Goncalves, R; De Cremoux, P; Fsihi, H; Judde, JG; Louvard, D; Magdelenat, H; Poupon, MF; Robine, S | 1 |
| Carano, RA; Koeppen, H; Ross, AL; Ross, J; Schwall, RH; Van Bruggen, N; Williams, SP | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Tsuzuki, T | 1 |
| Chen, PX; Das, S; Innocenti, F; Iyer, L; Janisch, L; Karrison, T; Kocherginsky, M; Ramírez, J; Ratain, MJ; Rudin, CM; Undevia, SD; Vokes, EE | 1 |
| Barni, S; Cazzaniga, M; Cremonesi, M; Ferretti, G; Ghilardi, M; Mandalà, M; Mary, C; Rezzani, C | 1 |
| Ando, M; Gemma, A; Hibino, S; Kobayashi, K; Kudoh, S; Kurimoto, F; Mizutani, H; Moriyama, G; Nara, M; Okano, T; Seike, M; Shibuya, M; Yoshimura, A | 1 |
| Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G | 1 |
| Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R | 1 |
| Cloughesy, T; Filka, E; Fruehauf, JP; Mehta, R; Parker, RJ | 1 |
| Bae, JM; Choi, IJ; Choi, JY; Chun, JH; Kim, HK; Kim, YW; Lee, HG; Lee, JS; Ryu, KW; Yoon, SM | 1 |
| Bibeau, F; Candeil, L; Copois, V; Del Rio, M; Gourdier, I; Khan, QA; Martineau, P; Orsetti, B; Pau, B; Peyron, D; Pommier, Y; Scheffer, GL; Vezzio, N; Ychou, M | 1 |
| Algars, A; Bendardaf, R; Collan, Y; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Bleiberg, H; Buyse, M; Di Leo, A | 1 |
| Abad, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Gómez, MA; Marcuello, E; Masutti, B; Pronk, L; Ribera, F; Sastre, J | 1 |
| Baker, SD; Brahmer, JR; Carducci, MA; Lee, CK; Sparreboom, A; Verweij, J; Wolff, AC; Zabelina, Y; Zhao, M | 1 |
| Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P | 1 |
| Haraguchi, Y; Nakano, M; Okusawa, A; Shimizu, H; Suzuki, M; Takahashi, M | 1 |
| Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T | 1 |
| Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H | 1 |
| Liang, H; Sha, N | 1 |
| Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ | 1 |
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Limper, AH | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 2 |
| Antony, S; Bates, SE; Kohlhagen, G; Medina-Pérez, WY; Nadjem, T; Pommier, Y; Robey, RW | 1 |
| Cheong, K; Chrystal, K; Harper, P | 1 |
| Bagajevas, A; Cesas, A | 1 |
| de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J; Willems, EW | 1 |
| Barón, MG; Castañón, C; de Tejada, MR; Escudero, P; Feliu, J; López-Gómez, L; Martín, MS; Martínez, MP; Pericay, C; Rodríguez-García, JM; Salud, A; Sánchez, JJ | 1 |
| de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S | 1 |
| Fuchs, CS; Kwok, A; McGovren, JP; Meyerhardt, JA; Ratain, MJ | 1 |
| Bosron, WF; Davis, WI; Fredenburg, TB; Murry, DJ; Quinney, SK; Sanghani, SP | 1 |
| Belmar, N; Buelow, R; Fong, T; Huang, L; Zhao, J | 1 |
| Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A | 1 |
| Barbier, M; Boutonnat, J; Gray, BD; Muirhead, KA; Ronot, X | 1 |
| Inciūra, A; Juozaityte, E | 1 |
| Andoh, T; Takahashi, N; Umemura, K; Yanase, K | 1 |
| Saiki, I | 1 |
| Hayakawa, Y | 1 |
| Hada, M | 1 |
| Lobrinus, JA; Matzinger, O; Michielin, O; Périard, D; Stupp, R; Udry, E | 1 |
| Abbruzzese, JL; Bogaard, KR; Hoff, PM; Lassere, Y; Pazdur, R; Saad, ED; Wolff, R | 1 |
| Aubert, G; Bénard, J; Calvet, L; Larsen, A; Lavelle, F; Morizet, J; Pondarré, C; Santos, A; Terrier-Lacombe, MJ; Vassal, G | 1 |
| Kawada, K; Kawano, T; Miyake, S; Nagai, K; Nakajima, Y; Nishikage, T; Ogiya, K; Tanaka, K; Toukairin, Y | 1 |
| Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Ikehara, M; Noda, K; Nomura, I; Oshita, F; Tanaka, G; Yamada, K | 1 |
| Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L | 1 |
| Alliot, C; Barrios, M | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Itoh, T; Sasaki, K; Takemoto, I | 2 |
| Beroza, P; Damodaran, K; Danks, MK; Hyatt, JL; Lee, RE; Morton, CL; Potter, PM; Wadkins, RM; Yoon, KJ | 1 |
| Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM | 1 |
| Fittkau, M; Holzhausen, HJ; Schmoll, HJ; Voigt, W | 1 |
| Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Becerra, CR; Frenkel, EP; Gaynor, RB; Guo, J; Verma, UN | 1 |
| Abad, A; Antón, A; Carrato, A; Diaz-Rubio, E; Gallego, J; Manzano, JL; Marfa, X; Massutí, B; Yuste, AL | 1 |
| Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ | 1 |
| Nakanishi, Y; Uchino, J | 1 |
| Maeda, K; Okamura, S; Shibuya, T; Suzumiya, J; Suzushima, H; Tamura, K; Utsunomiya, A | 1 |
| Hori, S; Imada, T; Ishiki, K; Ishioka, H; Mizuno, M; Motoi, M; Nagahara, Y; Okamoto, T; Take, S; Yoshida, T | 1 |
| Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S | 1 |
| Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K | 1 |
| Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R | 1 |
| Hasegawa, R; Jinno, H; Kamakura, S; Kamatani, N; Kaniwa, N; Katori, N; Kitakaze, M; Kitamura, Y; Komamura, K; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Ueno, K; Yoshida, T | 1 |
| Morotomi, M; Nomoto, K; Takahashi, T | 1 |
| Asaka-Amano, Y; Kasahara, Y; Kuriyama, T; Kurosu, K; Matsubara, H; Shingyoji, M; Takiguchi, Y; Tanabe, N; Tatsumi, K; Watanabe-Uruma, R | 1 |
| Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM | 1 |
| Bajetta, E; Biasco, G; Brandi, G; Calabrese, C; Di Battista, M; Pantaleo, MA; Poggi, R | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| Fox, R; Melisko, ME; Venook, A | 1 |
| Punt, CJ; van Laarhoven, HW | 1 |
| Fujiwara, K; Hisamoto, A; Hosokawa, S; Hotta, K; Kiura, K; Kozuki, T; Kuyama, S; Satoh, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Gemba, K; Harita, S; Kamei, H; Kiura, K; Nogami, N; Segawa, Y; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Raez, LE; Reis, IM; Rosado, MF; Santos, ES | 1 |
| Isonishi, S; Niimi, S; Ochiai, K; Sasaki, H; Tanaka, T; Yasuda, M | 1 |
| Brem, H; Moriarity, JL; Renard, VM; Storm, PB; Tyler, B; Weingart, JD; Wilentz, RE | 1 |
| Chiriatti, A; Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, J; Zito, A | 1 |
| Awad, L; Cunningham, D; Douillard, JY; Magherini, E; Mery-Mignard, D; Mitry, E; Rougier, P; Van Cutsem, E | 1 |
| Bereder, JM; Bernardini, D; Cals, L; Deplanque, G; Favre, R; François, E; Herait, P; Juin, P; Laadem, A; Merad, L; Rixe, O | 1 |
| Bertagnolio, MF; De Marco, S; Squilloni, E; Sternberg, CN; Vigna, L | 1 |
| Holcombe, RF; Kong, KM; Wimmer, D | 1 |
| Agarwal, R; Ardalan, B; Patel, M | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Grothey, A; Jordan, K; Kegel, T; Kellner, O; Schmoll, HJ | 1 |
| Ohashi, Y; Yamaguchi, T | 1 |
| Humblet, Y | 1 |
| King, CR; Marsh, S; McLeod, HL | 1 |
| Azrak, RG; Cao, S; Durrani, FA; Frank, C; Li, ZR; Rustum, YM; Yin, MB | 1 |
| Hoff, PM; Pazdur, R | 1 |
| Goldberg, RM; Penland, SK | 1 |
| de Jong, FA; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Agelaki, S; Athanasiadis, A; Boukovinas, J; Christophylakis, C; Georgoulias, V; Kouroussis, C; Maltezakis, G; Milaki, G; Pavlakou, G; Syrigos, K; Vardakis, N; Varthalitis, J | 1 |
| Kobayashi, N; Kudo, K; Takeda, Y; Toyota, E; Yonemori, K | 1 |
| Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M | 1 |
| Hiki, N; Imamura, K; Kaminishi, M; Katayama, A; Mafune, K; Motoi, T; Oohashi, K; Shimizu, N; Shimoyama, S; Yamaguchi, H | 1 |
| Chin, K; Ishihara, S; Maruyama, M; Nakajima, T; Ohta, K; Ohyama, S; Takahashi, T; Yamao, T | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Gürkan, A; Kaçar, S; Kahya, M; Karaca, C; Uslu, A; Varilsüha, C | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Ruether, D; Sutherland, F; Walley, B | 1 |
| Aravantinos, G; Economopoulos, T; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Raptis, SA | 1 |
| Hütter, G; Keilholz, U; Krebs, P; Schmittel, A; Schulze, K; Thiel, E | 1 |
| Dakhil, SR; Fitch, TR; Hillman, DW; Ingle, JN; Kardinal, CG; Krook, JE; Kugler, JW; Mailliard, JA; Perez, EA; Rowland, KM; Ryan, JM | 1 |
| Enomoto, T; Hidaka, T; Hori, S; Murata, Y; Nakajima, Y; Nakamura, T; Saito, S | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Boiocchi, M; Campagnutta, E; Cecchin, E; Corona, G; Martella, L; Russo, A; Toffoli, G | 1 |
| Adam, R | 2 |
| Horiike, A; Saijo, N | 2 |
| Cho, LC; Choy, H | 1 |
| Ikegami, Y; Ishikawa, T; Mitomo, H; Sano, K; Sawada, S; Yoshida, H; Yoshikawa, M | 1 |
| Bae, JM; Chang, HJ; Choi, IJ; Chun, JH; Kang, HC; Kim, E; Kim, HK; Kim, IH; Kim, IJ; Kim, JH; Lim, HS; Park, JG; Park, JH | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C | 1 |
| Schrag, D | 1 |
| Bets, D; Bleiberg, H; Chau, I; Cunningham, D; Harstrick, A; Humblet, Y; Khayat, D; Mueser, M; Santoro, A; Siena, S; Van Cutsem, E; Verslype, C | 1 |
| Erlichman, C; Sargent, DJ | 1 |
| Goetz, MP; Grothey, A | 1 |
| Kawabata, Y; Kusumoto, C; Miyamoto, K | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Utkan, G; Yalcin, B | 1 |
| Sulkes, A | 1 |
| Brank, A; Camp, ER; Hochwald, SN; Li, J; MacKay, SL; Minnich, DJ; Moldawer, LL | 1 |
| Androulakis, N; Boukovinas, I; Christophilakis, Ch; Georgoulias, V; Kotsakis, A; Kouroussis, Ch; Polyzos, A; Potamianou, A; Souglakos, J; Syrigos, K; Vardakis, N | 1 |
| Jahnke, K; Keilholz, U; Schmittel, A; Thiel, E | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Kitagawa, C; Mori, A; Sarashina, T; Shimokata, K; Yoneyama, M | 1 |
| Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K | 1 |
| Altés, A; Baiget, M; Del Rio, E; Gómez-Pardo, M; Marcuello, E; Menoyo, A | 1 |
| Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D | 1 |
| Chau, I; Cunningham, D; Dickson, J; Hill, M; Lal, R; Middleton, G; Norman, AR; Oates, J; Ross, PJ; Topham, C | 1 |
| Danesi, R; Figg, WD; Mathijssen, RH; Paoluzzi, L; Price, DK; Singh, AS; Sparreboom, A; Verweij, J | 1 |
| Kiribayashi, Y; Maeda, Y; Murakami, T; Nakamura, M; Ohune, T; Yamasaki, M | 1 |
| Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M | 1 |
| Aubert, G; Bénard, J; Calvet, L; Merlin, JL; Morizet, J; Opolon, P; Santos, A; Schellens, JH; Terrier-Lacombe, MJ; Valent, A; Vassal, G | 1 |
| Hashiguchi, Y; Kawamura, N; Miyama, M; Nakata, S; Negoro, S; Nishimura, S; Tsuda, H | 1 |
| Aliustaoglu, M; Aydin, SZ; Dane, F; Ekenel, M; Gumus, M; Karamanoglu, A; Sengoz, M; Turhal, SN; Yumuk, PF | 1 |
| Blessing, JA; McGehee, R; Monk, BJ; Muggia, FM | 1 |
| Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E | 1 |
| Danks, MK; Hyatt, JL; Lee, RE; Morton, CL; Potter, PM; Yoon, KJ | 1 |
| Ajani, JA; Andrassy, RJ; Blakely, ML; Harting, MT; Herzog, CE; Lally, KP | 1 |
| Beijnen, JH; Borst, P; Breedveld, P; Pluim, D; Schellens, JH; Schinkel, AH; Sönmezer, O; Tibben, MM; van Tellingen, O; Zelcer, N | 1 |
| Ermakova, NA; Mikhaĭlichenko, TD; Moiseenko, VM; Orlova, RV; Protsenko, SA; Teletaeva, GM; Urmancheeva, AF | 1 |
| Alimonti, A; Cognetti, F; Di Palma, M; Ferretti, G; Gelibter, A; Pavese, I; Rasio, D; Satta, F; Vecchione, A | 1 |
| Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB | 1 |
| Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A | 1 |
| Harada, O; Kobayashi, M; Sasamoto, M; Shimaya, S | 1 |
| Beppu, T; Doi, K; Egami, H; Ishiko, T; Morinaga, H; Nakagawa, M; Sugiyama, S; Tanaka, H; Yamane, T | 1 |
| Kitajima, M; Komatsu, Y; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Tanigawara, Y; Toge, T | 1 |
| Cecchin, E; Toffoli, G | 2 |
| Yang, S; Zhang, WN | 1 |
| Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K | 1 |
| de Jong, FA; King, C; Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J | 1 |
| Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R | 1 |
| Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS | 1 |
| Fukuda, M; Inoue, Y; Kasai, T; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsurutani, J | 1 |
| Billard, V; Bourget, P; Drouard-Troalen, L; Ducreux, M; Elias, D; Liberale, G; Matsuhisa, T; Pocard, M; Puizillou, JM; Raynard, B; Sideris, L | 1 |
| Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K | 1 |
| Schwartz, GK; Tse, AN | 1 |
| Liu, JH | 1 |
| Damjanovic, D; Findlay, MP; Thompson, P | 1 |
| Beijnen, JH; Bertelsen, K; Fennelly, D; Garin, A; Glimelius, B; Gruia, G; Kjaer, M; Kuppens, IE; Lefebvre, P; Moiseyenko, V; Mourier, A; Norum, J; Poulsen, JP; Richel, DJ; Schellens, JH; Schoemaker, NE; Sibaud, D; Smaaland, R; Starkhammer, H; ten Bokkel Huinink, WW; Tveit, KM; Voznyi, E | 1 |
| Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K | 1 |
| D'Haene, N; Darro, F; Gaussin, JF; Kiss, R; Mathieu, A; Penant, S; Remmelink, M; Salmon, I; Van Ginckel, R | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kubo, Y; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T; Tubouchi, E | 1 |
| Hada, M; Mizutari, K | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T | 1 |
| Fukuhara, A; Kikuchi, S; Murayama, M; Nakamura, E; Nishimoto, Y; Nozaki, H; Shouda, S; Watanabe, Y; Yagyu, T | 1 |
| Allen, J; Beech, J; Carrington, B; Hogg, M; Saunders, MP; Sjursen, AM; Swindell, R; Valle, JW | 1 |
| Ashkenazi, S; Huppert, D; Leiderman, P; Solntsev, KM; Sullivan, EN; Tolbert, LM | 1 |
| Scheithauer, W | 1 |
| Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E | 1 |
| Acusa, A; Antón, I; Batiste-Alentorn, E; Campos, JM; Guasch, I; Losa, F; Manzano, H; Saigi, E; Salut, A; Vélez de Mendizabal, E | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Gräslund, A; Jarvet, J; Kogner, P; Lindskog, M; Spenger, C | 1 |
| Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G | 1 |
| Boothman, DA; Hwang, A; Meyers, M; Wagner, MW | 1 |
| Marsh, S; McLeod, HL | 1 |
| Delaunoit, T; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, E; Mailliard, JA; Morton, RF; Salim, M; Sargent, DJ; Schaefer, PL; Stella, PJ; Thomas, SP | 1 |
| Filipski, E; Lemaigre, G; Lévi, F; Liu, XH; Mahjoubi, M; Méry-Mignard, D | 1 |
| Martin, MJ | 1 |
| Costa, AF; Picon, PD; Sander, GB | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Bally, MB; Harasym, N; Mayer, LD; Messerer, CL; Ng, R; Ramsay, EC; Simms, EM; Tardi, P; Waterhouse, D | 1 |
| Atsumi, R; Masubuchi, N; May, RD | 1 |
| Chen, P; Cook, EH; Das, S; Dolan, ME; Liu, W; Rosner, GL; Strom, S; Wu, MH; Wu, X | 1 |
| Sharieff, W | 1 |
| Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF | 1 |
| Jung, SH; Kirsh, KL; Loehrer, P; Nagy, C; Navari, RM; Passik, SD; Vinson, J | 1 |
| Briasoulis, E; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Rammou, D; Timotheadou, H | 1 |
| Ahmad, I; Ali, S; Chien, PY; Lei, S; Sheikh, S; Zhang, A | 1 |
| Billups, C; Bjornsti, MA; Houghton, PJ; Liang, H; Peterson, JK; Woo, MH | 1 |
| Earle, CC; Fuchs, CS; Gazelle, GS; Kwok, A | 1 |
| Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF | 1 |
| Detterbeck, FC; Fraser, R; Halle, JS; Hensing, TA; Limentani, SA; Mears, A; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Tynan, M | 1 |
| Brittain, M; Feld, R; Hedley, D; Michael, M; Moore, MJ; Nagai, J; Oza, A; Siu, L | 1 |
| Hejna, M; Raderer, M; Wöhrer, SS | 1 |
| de Bruijn, P; de Jong, FA; Figg, WD; Friberg, LE; Graveland, WJ; Lepper, ER; Mathijssen, RH; Rietveld, T; Sparreboom, A; van Schaik, RH; Verweij, J | 1 |
| Terauchi, F | 1 |
| Kinoshita, K; Tanaka, M; Yoshida, M | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Fushiki, H | 1 |
| Innocenti, F; Mani, S; Prado, M; Ramírez, J; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ | 1 |
| Clarke, S; Rivory, L; Tobin, P | 1 |
| Cantore, M; Del Freo, A; Fiorentini, G; Iacono, C; Mambrini, A; Manni, A; Oliani, C; Rabbi, C; Zamagni, D | 1 |
| Crews, KR; Daw, NC; Liu, T; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Harrington, KJ; Marshall, CJ; Mavria, G; Porter, CD | 1 |
| Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H | 1 |
| Fujiwara, Y; Fukushima, S; Hirohashi, K; Lee, S; Morimura, K; Osugi, H; Suehiro, S; Takemura, M | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Ichikawa, Y; Nishida, M; Tsunoda, H; Yoshikawa, H | 1 |
| Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S | 1 |
| Doi, K; Hashimoto, D; Ishimoto, T; Kikuchi, N; Muranaka, T; Ochiai, T; Ogata, K; Ogawa, M; Ohchi, T | 1 |
| Fukunaga, H; Hata, T; Ikeda, M; Ikenaga, M; Monden, M; Ohue, M; Sekimoto, M; Seshimo, I; Takayama, O; Yamamoto, H; Yasui, M | 1 |
| Ando, M; Maruyama, M; Nagahama, T | 1 |
| Hayashi, N; Koshiishi, H; Koshiishi, Y; Okamura, T; Takahashi, E; Tamamoto, F; Yoshimura, T | 1 |
| Hazama, S; Mori, N; Oka, M; Tamesa, T; Tangoku, A; Watanabe, Y; Yamamoto, S; Yoshimura, K | 1 |
| Reddy, GK | 1 |
| Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Itoh, T; Sumi, Y; Takemoto, I | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D | 1 |
| Geffen, DB; Gluzman, A; Idelevich, E; Lavrenkov, K; Man, S; Shani, A | 1 |
| Akbulut, H; Deisseroth, A; Maynard, J; Pizzorno, G; Tang, Y; Zhang, L | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Delvart, V; Levi, F; Pascal, G; Paule, B | 1 |
| Kitajima, M; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Toge, T | 1 |
| Iishi, H; Narahara, H; Sugimoto, N; Tatsuta, M | 1 |
| Akiyama, Y; Aoki, K; Fujiwara, H; Iwaya, T; Kimura, Y; Nakaya, T; Saito, K | 1 |
| Doggrell, SA | 1 |
| Hasegawa, R; Jinno, H; Kaniwa, N; Kurose, K; Saeki, M; Saito, Y; Sawada, J; Tanaka-Kagawa, T; Tohkin, M | 1 |
| Anderson, KC; Burger, R; Catley, L; Chauhan, D; Denis, L; Hideshima, T; Munshi, NC; Podar, K; Richardson, P; Shringarpure, R; Son, MT; Tai, YT; Tassone, P | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Bonetto, E; Di Carlo, V; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Kamiyama, H; Matsumura, A; Takano, S; Tsuboi, K | 1 |
| Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K | 1 |
| Cunningham, D; Ng, M | 1 |
| Bellott, R; Charasson, V; Gorry, P; Longy, M; Meynard, D; Robert, J | 1 |
| Assadourian, S; Beijnen, JH; Huinink, WW; Kuppens, IE; Lefebvre, P; Sanderink, GJ; Schellens, JH; Schoemaker, NE | 1 |
| Blumenthal, RD; Goldenberg, DM; Hansen, HJ; Hayes, MK; Horak, ID; Osorio, L | 1 |
| Andre, N; Graeven, U; Schmiegel, W | 1 |
| Babic, DR; Grbic, B; Jelic, SB; Matijasevic, MM; Popov, IP | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Tanaka, K; Watanabe, M | 1 |
| Biesma, B; Groen, HJ; Postmus, PE; Schramel, FM; Smit, EF; Stigt, JA; Wachters, FM | 1 |
| Allen, H; Ashkenazi, A; Bedi, A; Jain, AJ; Mayer, EG; Pardoll, DM; Pham, V; Prouser, TS; Ravi, R; Schulick, RD; Yu, H | 1 |
| Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH | 1 |
| Minami, H; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A | 1 |
| Cheung, YB; Chowbay, B; Leong, SS; Poon, D; Tan, EH | 1 |
| Cortés-Funes, H; García-Velasco, A; Gonzalez, E; Gravalos, C; Quintela-Fandino, M | 1 |
| Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A | 1 |
| Paukstadt, W | 1 |
| Dhaliwal, K; Evans, MT; Fennell, DA; Gower, N; Parmar, A; Rudd, R; Shamash, J; Sheaff, MT; Steele, J; Sylvester, R | 1 |
| André, T; de Gramont, A; Gamelin, E; Garcia, ML; Kalla, S; Lenaers, G; Louvet, C; Méry-Mignard, D; Saavedra, A | 1 |
| Hong, Y; McLachlan, AJ; Rivory, LP; Seale, JP; Tobin, PJ | 1 |
| Brufsky, A; Chen, HX; Day, R; Earle, M; Evans, T; Finkelstein, S; Hwang, JJ; Ramanathan, RK; Safran, H; Sinicrope, FA; Troetschel, M; Walko, C; Wong, MK; Zamboni, WC | 1 |
| Carvalho, LP; Fleshman, JW; Glasgow, SC; McLeod, HL; Shannon, WD; Yu, J | 1 |
| Hitre, E; Láng, I | 1 |
| Hassan, MK; Inoue, S; Kanetoshi, A | 1 |
| Gourgou-Bourgade, S; Kramar, A; Ychou, M | 1 |
| Bocci, G; Danesi, R; Di Paolo, A | 1 |
| Abu-Qare, A; Ahmad, A; Ahmad, I; Guo, W; Khan, S; Wang, YF | 1 |
| Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M | 1 |
| Economopoulos, T; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Raptis, SA; Xiros, N | 1 |
| De Jong, FA; Mathijssen, RH; Verweij, J | 1 |
| Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M | 1 |
| Sugiyama, T | 1 |
| Fujii, Y; Yoneto, T; Yoshikawa, K | 1 |
| Chung, KY; Fridman, D; Hamilton, A; Kelsen, DP; Kemeny, NE; Klimstra, DS; Pan, D; Saltz, LB; Schrag, D; Schwartz, GK; Schwartz, L; Shah, M; Shia, J; Tse, A | 1 |
| Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J | 1 |
| Gnad, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kraus-Tiefenbacher, U; Müldner, A; Post, S; von Gerstenberg-Helldorf, B; Wenz, F; Willeke, F | 1 |
| Govindan, R; McLeod, H; Read, W | 1 |
| Hwang, JJ | 1 |
| Gallagher, M; Giantonio, B; Haller, D; Metz, J; O'Dwyer, P; Sun, W; Whittington, R | 1 |
| Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L | 1 |
| Becerra, CR | 1 |
| André, A; Braekman, JC; Bruyneel, F; Darro, F; Decaestecker, C; Dewelle, J; El Yazidi, M; Guissou, P; Kiss, R; Nacoulma, O; Simon, G; Tuti, J; Van Quaquebeke, E | 1 |
| Mayer, RJ; Meyerhardt, JA | 1 |
| Brown, JL; Charlton, PA; Freathy, C; Harris, SM; Mistry, P | 1 |
| Catassi, A; Cesario, A; Ferri, L; Festi, L; Granone, P; Malacarne, D; Margaritora, S; Mulé, A; Russo, P | 1 |
| Belloc, F; Berchem, G; Cotteret, S; Dufer, J; Morjani, H; Palissot, V | 1 |
| Akita, H; Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Meguro, T; Miyagishima, T; Ohizumi, H; Sakata, Y; Takei, M; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S | 1 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Murphy, BA | 1 |
| Seiter, K | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Itoh, T; Shimamoto, S; Sumi, Y; Takemoto, I | 1 |
| Aoyama, N; Hamano, K; Hirohata, S; Horita, K; Ishii, A; Kamigaki, T; Kasuga, M; Nakashima, T; Nishisaki, H; Shirasaka, D; Tamura, T; Yasutake, K | 1 |
| Bugat, R; Conroy, T; Deplanque, G; François, E; Hua, A; Jacob, JH; Magherini, E; Metges, JP; Michel, P; Nasca, S; Paillot, B; Rixe, O; Stein, U | 1 |
| Ansell, W; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Dumontet, C; Sève, P | 1 |
| Boucher, E; Boudjema, K; de Guibert, S; Egreteau, J; Jacquelinet, C; Meunier, B; Raoul, JL | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 2 |
| Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Haller, DG; Sun, W | 1 |
| McLeod, HL; Tan, BR | 1 |
| Grem, JL | 1 |
| Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM | 1 |
| Li, YS | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J | 1 |
| Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J | 1 |
| Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W | 1 |
| Fujita, F; Fujita, M; Fujiwara, T; Kakushima, M; Kawaguchi, T; Kiuchi, S; Koike, M; Kudoh, S; Okuno, S; Sakamoto, Y; Yano, S; Yano, T | 1 |
| Arimochi, H; Bunpo, P; Kataoka, K; Kuwahara, T; Nakayama, H; Ohnishi, Y; Vinitketkumnuen, U | 1 |
| Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S | 1 |
| McLeod, HL; Shannon, WD; Watson, MA; Yu, J | 1 |
| Bertheault-Cvitkovic, F; Bugat, R; Canal, P; Chatelut, E; Cornen, X; Delord, JP; Dieras, V; Guimbaud, R; Lochon, I; Lokiec, F; Mery-Mignard, D; Mouri, Z; Pierga, JY; Turpin, FL | 1 |
| de Graaf, M; Gerritsen, WR; Giaccone, G; Haisma, HJ; Oosterhoff, D; Overmeer, RM; Pinedo, HM; van Beusechem, VW; van der Meulen, IH | 1 |
| Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL | 1 |
| Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J | 1 |
| Vega-Stromberg, T | 1 |
| Dan, S; Fukui, Y; Nakamura, T; Nakatsu, N; Yamazaki, K; Yamori, T; Yoshida, Y | 1 |
| Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M | 1 |
| Berg, S; Blaney, SM; Bomgaars, L; Kerr, J; Klenke, R; Kuttesch, J | 1 |
| Brumshtein, B; Harel, M; Hyatt, JL; Morton, CL; Potter, PM; Silman, I; Sussman, JL; Wadkins, RM; Yoon, KJ | 1 |
| Susman, E | 1 |
| Bernardeschi, P; Cantore, M; Fiorentini, G; Guadagni, S; Rossi, S | 1 |
| Horai, T; Matsuda, M; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Taguch, F | 1 |
| Bresnick, E; Eastman, A; Kohn, EA; Levesque, AA | 1 |
| Feyerherd, P; Fietkau, R; Foitzik, T; Klautke, G; Ludwig, K; Prall, F | 1 |
| Chin, K; Hatake, K; Mizunuma, N; Ohkochi, N; Ota, K; Shinozaki, E; Tanabe, M | 1 |
| Ilson, D; Kelsen, DP; Shah, MA | 1 |
| Arnold, CN; Blum, HE | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM | 1 |
| Bachand, C; Balasubramanian, BN; Beaulieu, F; Eummer, JT; Fairchild, CR; Frennesson, DB; Kramer, R; Langley, DR; Lee, FY; Long, BH; Mahler, M; Martel, A; Naidu, BN; Rose, WC; Ruediger, E; Saulnier, MG; Solomon, C; St Laurent, DR; Stadnick, LK; Stoffan, KM; Vyas, DM; Wong, H; Wright, JJ; Zimmermann, K | 1 |
| Cheung, YB; Chowbay, B; Lee, A; Lee, EJ; Poon, D; Sparreboom, A; Tan, EH; Zhou, Q | 1 |
| Aparicio, J; Balcells, M; Bosch, C; Busquier, I; Campos, JM; Galán, A; Garcerá, S; Llorca, C; López-Tendero, P; Maestu, I; Vicent, JM | 1 |
| Harada, N; Hatano, E; Ikai, I; Koizumi, N; Nitta, T; Shimahara, Y; Tada, M; Taura, K | 1 |
| Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M | 1 |
| Hoshiai, H; Nakai, H; Watanabe, Y | 1 |
| Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C | 1 |
| Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J | 1 |
| Venook, A | 1 |
| Altundag, K; Altundag, O; Gundeslioglu, O; Gunduz, M; Silay, YS; Yigitbasi, OG | 1 |
| Allen, JD; Cohn, SL; Flemming, C; Haber, M; London, WB; Marshall, GM; Norris, MD; Scheffer, GL; Smith, J; Tanabe, K; Tobin, P; Wielinga, P | 1 |
| Alexander, HR; Bartlett, DL; Beresneva, T; Helsabeck, C; Libutti, SK; Pingpank, JF | 1 |
| Asaka, M; Furukawa, S; Fuse, N; Kato, M; Kato, T; Komatsu, Y; Takeda, H; Takei, M; Yuki, S | 1 |
| Ritter, JK; Smith, PC; Tallman, MN | 1 |
| Poston, GJ | 1 |
| Hamanaka, N; Ikehara, M; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Chen, A; Chou, R; Lau, D | 1 |
| Hurwitz, H | 1 |
| Arima, T; Horino, K; Inoue, M; Kaneda, H; Kimura, M; Kuhara, H; Kume, S; Nakano, M; Nishimura, T; Uemura, K | 1 |
| Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D | 1 |
| Bauer, I; Freund, M; Köhne, CH; Schuff-Werner, P; Seule, M; Steiner, B; Steiner, M | 1 |
| Bardelli, A; Benvenuti, S; Di Nicolantonio, F; Gambacorta, M; Marrapese, G; Moroni, M; Sartore-Bianchi, A; Siena, S; Veronese, S | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Imaizumi, K; Kitagawa, C; Sekido, Y; Shimokata, K; Wakai, K | 1 |
| Chen, P; Das, S; Desai, AA; Innocenti, F; Liu, W; Ratain, MJ | 1 |
| Bouzourene, H; Chaubert, P; Sandmeier, D | 1 |
| Kallinowski, B | 1 |
| Galle, PR; Moehler, M; Teufel, A | 1 |
| Cordon-Cardo, C; Drobnjak, M; Gonen, M; Hummer, A; Kemeny, N; Motwani, M; Schwartz, GK; Shah, MA | 1 |
| Abbruzzese, JL; Fidler, IJ; Hamilton, SR; He, J; Kim, SJ; Nam, DH; Rebhun, RR; Thaker, PH; Yazici, S; Yokoi, K | 1 |
| Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J | 1 |
| Fisher, GA; Wakelee, H | 1 |
| Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E | 1 |
| Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, ST; Kim, WS; Lee, J; Lee, SH; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Cunningham, D; Starling, N | 1 |
| Brouwers, JR; Coenen, JL; de Graaf, JC; Idzinga, FS; Jansman, FG; Sleijfer, DT; Smit, WM | 1 |
| Aiko, T; Kitamura, Y; Natsugoe, S; Nishino, S; Shiomori, K; Yoshizawa, H | 1 |
| Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M | 1 |
| Alves, PA; da Rocha, AB; Grass, LB; Grivicich, I; Henriques, JA; Kayser, GB; Regner, A; Schunemann, DP; Schwartsmann, G | 1 |
| Green, MR; Herndon, JE; Kindler, HL; Zhang, C | 1 |
| Amikura, T; Aoki, Y; Fujita, K; Nishino, K; Obata, H; Sekine, M; Tanaka, K; Yahata, T | 1 |
| Agamah, E; Desai, AA; Kindler, HL; Mani, S; Ratain, MJ; Taber, D; Vokes, EE; Wade-Oliver, K | 1 |
| Silberman, H | 1 |
| Azrak, RG; Cao, S; Durrani, FA; Li, X; McLeod, HL; Pendyala, L; Rustum, YM; Shannon, WD; Smith, PF; Yu, J | 1 |
| Brenner, B; Cordon-Cardo, C; Drobnjak, M; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, R; Motwani, M; O'Reilly, E; Saltz, L; Schwartz, GK; Shah, MA; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Chen, LB; Dai, M; Owen, DA; Tai, IT | 1 |
| Jäger, D; Knuth, A; Pestalozzi, BC | 1 |
| Boige, V; Elias, D; Estphan, G; Laplanche, A; Malka, D; Pocard, M; Raynard, B | 1 |
| Cho, KH; Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, JS; Lee, SY | 1 |
| Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM | 1 |
| Ahmad, A; Ahmad, I; Ayoub, J; Bardin, S; Duggan, JX; Guo, W; Johnson, JL; Khan, S | 1 |
| Hasegawa, Y; Hayashi, N; Kato, Y; Wakita, T | 1 |
| Cheshire, PJ; Danks, MK; Houghton, PJ; Hyatt, JL; Iacono, L; Morton, CL; Potter, PM; Stewart, CF; Taylor, KR | 1 |
| Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I | 1 |
| Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM | 1 |
| Di Costanzo, F; Doni, L | 1 |
| Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K | 1 |
| Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ | 1 |
| Chung, G; Mehra, R; Murren, J; Psyrri, A; Smith, B | 1 |
| Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB | 1 |
| Chan, E; Chan, SY; Duan, W; Goh, BC; Hu, Z; Yang, X; Zhou, S | 2 |
| Wu, WQ; Yu, BM | 1 |
| David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW | 1 |
| Anak, O; Bokemeyer, C; El-Serafi, M; Frickhofen, N; Fuchs, R; Genicot, B; Köhne, CH; Langenbuch, T; Lorenz, M; Lutz, MP; Mergenthaler, HG; Müller, L; Nordlinger, B; Reichardt, P; Rougier, P; Rückle-Lanz, H; van Cutsem, E; Vanhoefer, U; Voigtmann, R; Wils, J | 1 |
| Blanke, CD | 1 |
| Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
| Cai, SR; Church, RD; Culverhouse, R; Garbow, JR; McLeod, HL; Shannon, WD; Zhang, W | 1 |
| Mai, M; Takahashi, Y; Yasumoto, K | 1 |
| Aggarwal, S; Chu, E | 1 |
| Anilanmert, B; Ozdemir, FA; Pekin, M | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Chan, E; Chan, SY; Chen, X; Duan, W; Ho, PC; Hu, Z; Huang, M; Li, X; Xu, C; Yang, H; Yang, X; Zhou, S; Zhu, YZ | 1 |
| Fu, ZD; Li, DZ; Liu, HY; Pan, XD; Wang, CY; Wu, S | 1 |
| Baer, MR; Conroy, JM; Li, S; McQuaid, D; Minderman, H; Nowak, NJ; O'Loughlin, KL; Pendyala, L; Quinn, P | 1 |
| Arnold, D; Schmoll, HJ | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Farmakis, D; Pectasides, D; Pectasides, M | 1 |
| Altinbas, M; Coskun, HS; Er, O; Gursoy, S; Kucuk, C; Ozkan, M; Solak, Y | 1 |
| Caponigro, F; Facchini, G; Iaffaioli, RV; Nasti, G | 1 |
| Ueoka, H | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Fujii, M; Kasakura, Y; Kochi, M; Morishita, Y; Sato, K; Takayama, T; Yamagata, M | 1 |
| Fujita, S; Hirota, M; Inoue, Y; Masaki, K; Nomura, M; Sakao, J; Souda, S | 1 |
| Braun-Falco, M; Holtmann, C; Lordick, F; Ring, J | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 2 |
| Agelidou, A; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Ignatiadis, M; Kentepozidis, N; Mylonaki, E; Vossos, A; Zachariadis, E; Ziotopoulos, P | 1 |
| Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD | 1 |
| Ahmad, I; Parmar, M; Peikov, V; Ugwu, S; Zhang, A | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M | 1 |
| Allen, WL; Johnston, PG | 2 |
| Beale, P; Clarke, S; Liddell, S; Noney, L; Rivory, LP; Tobin, PJ | 1 |
| Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Itoh, T; Takemoto, I | 1 |
| Blumgart, L; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Jarnagin, W; Kemeny, N; Leonard, G; Morse, M; Paty, P; Schwartz, L | 1 |
| André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Baer, MR; Ford, LA; Greco, WR; Minderman, H; O'Loughlin, KL; Pendyala, L; Smith, PF; Sweeney, KG; Wetzler, M | 1 |
| Mulder, NH | 1 |
| Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Philip, PA | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Abenhardt, W; Ballo, H; Behrens, R; Behringer, D; Boeck, HP; Braumann, D; Geer, T; Greinwald, R; Karthaus, M; Kindler, M; Kleeberg, U; Messmann, H; Schimke, J; Steinmetz, T | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Ariyoshi, Y; Fukuda, Y; Fukuoka, M; Isobe, T; Katakami, N; Komuta, K; Kudoh, S; Nakamura, S; Nakano, T; Takada, M; Takada, Y | 1 |
| Bourget, P; Gravel, E; Mercier, L; Paci, A | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N; Rontogianni, D | 1 |
| Kim, SR; Kubo, T; Matsumoto, K; Minami, H; Nakajima, T; Ohno, Y; Ohtsu, A; Ozawa, S; Sai, K; Saijo, N; Saito, H; Saito, Y; Sawada, J; Shirao, K; Yamamoto, N; Yoshida, T | 1 |
| Leong, LA; Rosales, J | 1 |
| Aoki, A; Hamada, A; Ito, K; Saito, H; Sasaki, Y; Terazaki, H; Yokoo, K | 1 |
| Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 2 |
| Harada, S; Hashiguchi, K; Hiraki, M; Yakushiji, H | 1 |
| Hirose, K; Nishimura, M; Sawada, T | 1 |
| Hihara, J; Ohta, K; Tanabe, K; Toge, T; Yamaguchi, Y; Yoshida, K | 1 |
| Morikawa, Y | 1 |
| Fujiwara, Y; Kasamatsu, T; Katsumata, N; Tsunematsu, R; Yamada, T; Yamamoto, N; Yonemori, K | 1 |
| Bonnay, M; Delbaldo, C; Dieras, V; Faivre, S; Kovar, A; Laurence, V; Mueser, M; Nolting, A; Pierga, JY; Raymond, E; Vedovato, JC | 1 |
| Liang, H | 2 |
| Chiocca, EA; Danks, MK; Finkelstein, DM; Hyatt, JL; Leroy, S; Potter, PM; Saeki, Y; Terada, K; Tyminski, E | 1 |
| Imamura, F; Kawahara, M; Kubota, K; Mori, K; Negoro, S; Nishiwaki, Y; Noda, K; Saijo, N; Sugiura, T; Tamura, T; Watanabe, K | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY | 1 |
| Almerud, A; Gubanski, M; Lideståhl, A; Lind, PA; Naucler, G | 1 |
| El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V | 1 |
| Bendardaf, R; Elzagheid, A; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Ariyama, H; Baba, E; Harada, M; Kusaba, H; Mitsugi, K; Nakano, S; Qin, B; Shibata, Y; Takii, Y; Tanaka, R | 1 |
| Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY | 1 |
| Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B | 1 |
| Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
| Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J | 1 |
| Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N | 1 |
| Handa, O; Higashihara, H; Ishikawa, T; Kokura, S; Naito, Y; Nakabe, N; Sakamoto, N; Takagi, T; Yoshida, N; Yoshikawa, T | 1 |
| D'Incalci, M; Faircloth, GT; Jimeno, J; Marabese, M; Mazzarella, G; Meco, D; Riccardi, A; Riccardi, R; Ubezio, P | 1 |
| De Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Highley, MS; Maes, RA; van Oosterom, AT | 1 |
| Argiris, A; Avram, MJ; Kut, V; Luong, L | 1 |
| Tyagi, P | 1 |
| Cao, S; Durrani, FA; Fakih, M; Rustum, YM | 1 |
| Aikou, T; Akiyama, S; Aoki, S; Che, XF; Furukawa, T; Goto, S; Haraguchi, M; Igarashi, Y; Kanehisa, M; Kobayashi, M; Mitsuo, R; Nakajima, Y; Noguchi, T; Ren, XQ; Sumizawa, T; Takahashi, H; Tsujikawa, K | 1 |
| Hanioka, N; Jinno, H; Ozawa, S; Saito, Y; Sawada, J; Tanaka-Kagawa, T | 1 |
| Barnes, BJ; Hu, G; Mancl, ME | 1 |
| Araki, H; Ishizaki, M; Kamiyama, Y; Kawaguchi, Y; Komiyama, Y; Nakagawa, A; Nishimura, N; Takahashi, H | 1 |
| Chung, KY; Flombaum, C; Saltz, L; Schrag, D | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Park, CG; Yoon, SM | 1 |
| Chan, AT; Ho, WM; King, A; Koh, J; Lai, P; Leow, CK; Lim, R; Ma, B; Mok, T; Wong, YY; Yeo, W | 1 |
| Eguchi, K; Kobayashi, K; Matsumoto, T; Morita, S; Ohashi, Y; Shibuya, M; Yamaji, Y | 1 |
| Carnahan, MA; Degoricija, L; Finkelstein, S; Grinstaff, MW; Lee, SJ; Morgan, MT; Prata, CA | 1 |
| Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z | 1 |
| Fujimoto, K; Harada, T; Watanabe, K | 1 |
| Akiba, Y; Hibi, T; Higuchi, H; Iizuka, H; Izumiya, M; Nagata, H; Takaishi, H; Yamagishi, Y | 1 |
| Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H | 1 |
| Ando, Y; Araki, K; Endo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 4 |
| Greco, FA; Hainsworth, JD; Kommor, M; Kuzur, ME; Litchy, S; Raefsky, EL; Spigel, DR; Yost, K | 1 |
| Adróver Cebrián, E; Alonso López, C; Alvarez Gallego, J; Arroyo Yustos, M; Barceló Galíndez, R; García Palomo, A; García-Girón, C; León Carbonero, A; Méndez Ureña, M | 1 |
| Bian, JS; Boelsterli, UA; Chan, E; Chan, SY; Duan, W; Ho, PC; Huang, M; Li, X; Tan, TM; Tian, Q; Xiong, W; Yang, H; Zhang, J; Zhou, S; Zhu, YZ | 1 |
| Jones, DH; Lynch, H; Silberstein, PT; Ternet, C | 1 |
| Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M | 1 |
| Fujitani, K; Furukawa, H; Gotoh, M; Iishi, H; Katsu, K; Kawabe, S; Narahara, H; Taguchi, T; Takiuchi, H; Tatsuta, M; Tsujinaka, T | 1 |
| LaVoie, EJ; Liu, AA; Liu, LF; Ruchelman, AL; Zhou, N; Zhu, S | 1 |
| Abbruzzese, JL; Eng, C | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Innocenti, F; Ramirez, J; Ratain, MJ; Yong, WP | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Abali, H; Budakoglu, B; Oksüzoglu, B; Uncu, D; Yildirim, N; Zengin, N | 1 |
| Hakuba, N; Hyodo, M; Sato, H; Yokoi, T | 1 |
| Bhonde, MR; Daniel, PT; Gillissen, BF; Hanski, C; Hanski, ML; Notter, M; Zeitz, M | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Athanasiadis, A; Georgoulias, V; Kalbakis, K; Mavroudis, D; Nikolakopoulos, J; Polyzos, A; Rapti, A; Samonis, G; Syrigos, K; Tselepatiotis, E | 1 |
| Santini, D; Tonini, G; Vincenzi, B | 2 |
| Gupta, S; Inada, M; Joseph, B; Kim, KS | 1 |
| Blankenburg, T; Bork, I; Juergens, S; Nagel, S; Schaedlich, S; Schuette, W; Wollschlaeger, B | 1 |
| Sadzuka, Y; Sonobe, T; Takabe, H | 1 |
| Ko, AH; Tempero, MA | 1 |
| Akasaka, Y; Hata, Y; Honda, S; Ito, T; Matsuoka, S; Nakajima, N; Ohmori, K; Sano, F; Yokoyama, R | 1 |
| Hayashi, Y; Ishida, H; Nakada, H; Ohsawa, T; Okada, N; Shirakawa, K; Yokoyama, M | 1 |
| Mitsugi, K; Nakano, S; Tanaka, R; Ueki, T; Umeno, M | 1 |
| Carrato-Mena, A; Guillén-Ponce, C; Maciá-Escalante, S; Molina-Garrido, MJ | 1 |
| Hasegawa, Y; Ishikawa, K; Kajita, Y; Nabeshima, T; Noda, Y; Yoshida, J | 1 |
| Goetz, MP; Grothey, A; Mandrekar, SJ; Sargent, DJ | 1 |
| Aparicio, J; Díaz, R; Gironés, R; Molina, J; Montalar, J; Palomar, L; Segura, A | 1 |
| Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Houghton, PJ; Iacono, LC; Kocak, M; Krasin, MJ; Kun, LE; Ledet, D; Merchant, TE; Stewart, CF | 1 |
| Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G | 1 |
| Allen, W; Galligan, L; Johnston, PG; Longley, DB; McDermott, U; Wilson, T | 1 |
| Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Braun, AH; Dirsch, O; Hilger, RA; Seeber, S; Stark, K; Vanhoefer, U | 1 |
| Akioka, T; Enomoto, U; Hanafusa, T; Hara, S; Higashi, K; Kiyokane, K; Kusakabe, H; Oka, S; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Chu, KW; Epstein, RJ; Liang, RH; Mok, MY; Yau, TC | 1 |
| Ishiguro, A; Mizuno, Y; Munakata, M; Sakata, Y; Shitara, K; Wada, R | 1 |
| Kato, T; Masuoka, HO; Sato, K; Tamahashi, N; Yano, H | 1 |
| Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
| di Gennaro, G; Schioppa, O; Simonelli, C; Tirelli, U; Vaccher, E | 1 |
| Laurent-Puig, P; Lièvre, A | 2 |
| Graeven, U; Verbeek, W | 1 |
| Balasubramanian, BN; Fairchild, CR; Jang, GR; Long, B; Marathe, PH; Monticello, TM; Rose, WC; Wall, ME; Wani, MC | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Sugimoto, Y | 1 |
| Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X | 1 |
| Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K | 1 |
| Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S | 1 |
| Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM | 1 |
| El-Deiry, WS; Finnberg, N; Furth, EE; Grimberg, A; Kim, SH; Liu, JJ; Piccoli, DA; Russo, P | 1 |
| Antoniou, D; Armenaki, O; Dimitroulis, J; Grigoratou, T; Katis, C; Marosis, C; Michalopoulou, P; Stathopoulos, GP; Stathopoulos, J; Tsavdaridis, D | 1 |
| Kiselyov, A | 1 |
| Brumshtein, B; Harel, M; Hyatt, JL; Morton, CL; Potter, PM; Silman, I; Sussman, JL; Tsurkan, L; Wadkins, RM; Yoon, KJ | 1 |
| Ando, Y; Hasegawa, Y | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Greco, FA; Spigel, DR | 1 |
| Takimoto, CH | 1 |
| Cattarossi, G; Corona, G; Sartor, I; Toffoli, G; Vaccher, E | 1 |
| Ball, DW; Denmeade, SR; Nelkin, BD; Park, JI; Rosen, DM; Ruggeri, B; Strock, CJ | 1 |
| Rosati, G | 1 |
| Castañón, C; Castro, J; Escudero, P; Feliu, J; González, E; González-Barón, M; Juárez, F; Lizón, J; López-Gómez, L; Mel, JR; Pelegrín, A; Ruiz, M; Salud, A | 1 |
| Ando, M; Ando, Y; Hasegawa, Y | 1 |
| Figg, WD; Smith, NF; Sparreboom, A | 1 |
| Fukunaga, H; Ikeda, M; Ikenaga, M; Monden, M; Ohue, M; Sekimoto, M; Seshimo, I; Takayama, O; Yamamoto, H; Yasui, M | 1 |
| Jensen, BV; Pfeiffer, P | 1 |
| Baker, SD; Gelderblom, H; Guchelaar, HJ; Nortier, JW; Rudek, MA; Sparreboom, A; van Erp, NP; Zhao, M | 1 |
| Arimochi, H; Morita, K | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Isomura, M; Miki, Y | 1 |
| Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y | 1 |
| Ichimori, T; Ishikawa, M; Ishikura, H; Kimura, S; Okitsu, H; Sakata, A; Seike, J; Yuasa, Y | 1 |
| Inagaki, J; Inoue, M; Kawa, K; Sakata, N; Yagi, K; Yasui, M | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Hojo, M; Izumi, S; Kamimura, M; Kobayashi, K; Kudo, K; Naka, G; Takeda, Y; Tsuduki, E | 1 |
| Brumshtein, B; Harel, M; Hyatt, JL; Morton, CL; Potter, PM; Silman, I; Sussman, JL; Wadkins, RM | 1 |
| Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D | 1 |
| Cahn, JY; Merrouche, Y; Mugneret, F | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Park, CG | 1 |
| Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS | 1 |
| Andoh, M; Fujiwara, Y; Katsumata, N; Kohno, T; Matsumoto, K; Shimizu, C; Yamanaka, Y; Yonemori, K | 1 |
| Hurwitz, H; Kabbinavar, F | 1 |
| Ando, M; Boku, N; Hasebe, T; Hyodo, I; Miyata, Y; Nagashima, F; Ochiai, A; Ohtsu, A; Saito, H; Sakata, Y; Yoshida, S | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T | 1 |
| Chen, SY; Chen, TH; Gu, MJ; Ma, D; Song, XJ; Wang, CY; Zhang, QH; Zhu, T | 1 |
| Aizawa, M; Ishibashi, K; Itagaki, H; Katsube, T; Kobayashi, R; Naritaka, Y; Ogawa, K; Yokomizo, H; Yoshimatsu, K | 1 |
| Furukawa, H; Imamura, H; Kishimoto, T; Tatsuta, M; Yamamoto, K | 1 |
| Amano, M; Fujita, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 1 |
| Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Ooshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K | 1 |
| Doi, M; Egawa, T; Hayashi, S; Kitano, M; Nagashima, A; Yoshii, H | 1 |
| Ebisui, C; Fujimoto, T; Fujiwara, S; Fukuchi, S; Hasuike, Y; Hayashi, N; Kida, H; Sakita, I; Tsujie, M; Yoshida, T | 1 |
| Eguchi, H; Imaoka, S; Ishikawa, O; Kameyama, M; Kishi, K; Miyashiro, I; Murata, K; Noura, S; Ohigashi, H; Ohue, M; Sasaki, Y; Takachi, K; Tanaka, K; Yamada, T; Yano, M | 1 |
| Amano, S; Enomoto, K; Negishi, N; Sakurai, K | 1 |
| Kitamura, M; Noda, K; Shiba, Y; Umekita, N | 1 |
| Berry, S; Billingsley, K; Croitoru, M; Gallinger, S; Krishnamurthi, S; Mackay, HJ; Pond, GR; Siu, LL; Smith, A; Swanson, PE; Yeung, R | 1 |
| Dimou, E; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Xynotroulas, JP | 1 |
| Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G | 1 |
| Alonso, M; Balcells, M; Barceló, R; Castañón, C; Centelles, M; GarcíaGirón, C; López Vivanco, G; Navalón, M; Ramos, M; Rivera, F | 1 |
| Albritton, K; Goldsby, RE; McAllister, N; McCarville, MB; McNall-Knapp, RY; Rausen, AR; Wagner, LM | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N | 1 |
| Berg, K; Hammond, LA; Izbicka, E; Kuhn, J; Mita, MM; Ochoa, L; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Yeh, IT | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Denis, L; Duncan, BA; Erlichman, C; McGovren, P; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Sharma, A; Sloan, JA; Yin, D | 1 |
| Chiritescu, G; Cripps, C; Fisher, B; Goel, R; Jonker, D; Kocha, W; Lister, D; Malpage, A; Maroun, JA; Seymour, L; Vincent, M | 1 |
| Chua, YJ; Cunningham, D | 2 |
| Grothey, A; Kim, GP | 1 |
| Glisson, BS; Johnson, FM; Krug, LM; Patel, J; Peeples, B; Prieto, VG; Shoaf, S; Tamboli, P; Tran, HT | 1 |
| de Jong, FA; de Jonge, MJ; Mathijssen, RH; Verweij, J | 1 |
| Dong, QM; He, YJ; Li, YH | 1 |
| Ishiguro, A; Munakata, M; Saitoh, S; Sakata, Y; Shitara, K | 1 |
| Kanbe, M; Osada, M | 1 |
| Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ | 1 |
| Gill, S; Ho, C; Ng, K; O'Reilly, S | 1 |
| Grothey, A; Sargent, D | 1 |
| Bae, SH; Baek, JH; Chung, HY; Do, YR; Hyun, MS; Kim, DH; Kim, JG; Kim, MK; Kwon, KY; Lee, KB; Lee, KH; Park, KU; Ryoo, HM; Sohn, SK; Song, HS; Yu, W | 1 |
| Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL | 1 |
| Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
| Asaka-Amano, Y; Itoh, H; Kasahara, Y; Kuriyama, T; Kurosu, K; Takiguchi, Y; Tanabe, N; Tatsumi, K; Uno, T; Uruma, R | 1 |
| Abderrahim, AG; Astre, C; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Arcamone, G; Bertolini, P; Bisogno, G; Carli, M; Paolucci, P; Prete, A; Provenzi, M; Riccardi, R; Ruggiero, A; Surico, G | 1 |
| Abdalla, EK; Vauthey, JN | 1 |
| Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M | 1 |
| Anthoney, DA; Jagdev, S; Seymour, MT; Vasudev, NS | 1 |
| Bhatnagar, P; Levine, E; Saunders, MP; Swindell, R; Valle, JW; Young, E | 1 |
| Boltze, C; Fahlke, J; Hribaschek, A; Kuhn, R; Lippert, H; Meyer, F; Pross, M; Ridwelski, K | 1 |
| Ahmad, I; Xuan, T; Zhang, JA | 1 |
| Beck, S; Bourquin, C; Endres, S; Hartmann, G; Schreiber, S | 1 |
| Barber, SE; Bekele, BN; Jasser, SA; Kim, S; Mandal, M; Myers, JN; Yazici, YD | 1 |
| Leichman, CG | 1 |
| Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S | 2 |
| Kokawa, K; Tanaka, T; Umesaki, N | 1 |
| Hoff, PM; Varadhachary, GR | 1 |
| Marshall, J | 1 |
| Lepere, C; Rougier, P | 1 |
| Barette, M; Bleiberg, H; Cardoso, F; Galdon, MG; Gallez, J; Hendlisz, A; Larsimont, D; Nagy, N; Paesmans, M; Personeni, N; Van Laethem, JL | 1 |
| Hiotis, S; Hochster, H; Marcus, S; Muggia, F; Newman, E; Norwood, B; Potmesil, M; Ryan, T; Wendell, M; Yee, H | 1 |
| Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Bernshausen, A; Bieler, A; Dravits, T; Gansbacher, B; Glockzin, G; Holm, PS; Köhler-Vargas, N; Lage, H; Mantwill, K | 1 |
| Kandabashi, K; Sasaki, T | 1 |
| Amagasa, H; Kusano, M; Nakao, K; Suzuki, N; Tsunoda, A; Yamazaki, K | 1 |
| Han, JY; Ju, SY; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Lim, HS; Park, CG; Park, YH | 1 |
| Boyd, BJ; Davey, G; Khoo, SM; Whittaker, DV | 2 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Michelini, AL; Ryan, DP; Vincitore, MM | 1 |
| Aderka, D; Davidson, T; Goshen, E; Zwas, ST | 1 |
| Fischer von Weikersthal, L; Hortig, P; Keilholz, U; Martus, P; Reeb, M; Schmittel, A; Schulze, K; Sebastian, M; Thiel, E | 1 |
| Das, S; Fackenthal, DL; Graber, AY; Innocenti, F; Komoroski, BJ; Mirkov, S; Ramírez, J; Ratain, MJ; Schuetz, EG; Strom, SC | 1 |
| Hegi, ME; Stupp, R; van den Bent, MJ | 1 |
| Boige, V; Debaere, T; Ducreux, M; Hannoun, L; Hebbar, M; Magherini, E; Malka, D; Mignard, D; Poynard, T; Taïeb, J | 1 |
| Alemany, R; Alonso, MM; Bekele, BN; Curiel, DT; Fueyo, J; Gomez-Manzano, C; Jiang, H; Lang, FF; McCormick, F; Yung, WK; Zhou, X | 1 |
| Bekele, BN; Jasser, SA; Kim, S; Myers, JN; Prichard, CN; Yazici, YD; Younes, MN | 1 |
| Al Rashid, M; Bouscarel, B; Ceryak, S; Ikegami, T; Matsuzaki, Y; Zhang, Y | 1 |
| Camuso, A; Castaneda, S; Fager, K; Flefleh, C; Inigo, I; Kan, D; Luo, FR; McGlinchey, K; Rose, WC; Wild, R | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Akaza, H; Ando, S; Kawai, K; Shimazui, T; Takaoka, E | 1 |
| Hagiwara, T; Kamataki, T; Kumazawa, E; Nagai, E; Onose, S; Takasuna, K; Watanabe, K; Yoshida, S | 1 |
| Fukushima, T; Hirose, Y; Karasawa, H; Kawabata, H; Kawanami, T; Masaki, Y; Ogawa, N; Sawaki, T; Shimoyama, K; Sugai, S; Umehara, H; Wano, Y | 1 |
| Clark, SL; Fong, SE; Koeppen, H; Polakis, P; Ross, S; Rubinfeld, B; Smith, V; Upadhyay, A | 1 |
| Akioka, T; Hanafusa, T; Hara, S; Oka, S; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Billups, C; Crews, KR; Daw, NC; Dome, JS; Furman, WL; Gajjar, AJ; Houghton, PJ; Panetta, JC; Patrick, CC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Wu, J | 1 |
| Hanna, N; Hayostek, C; Mitchell, E; Mohiuddin, M; Nichols, C; Shane, R; Willett, C; Winter, K; Yuen, A | 1 |
| Bhonde, MR; Budczies, J; Cao, M; Daniel, PT; Gillissen, B; Hagemeier, C; Hanski, C; Hanski, ML; Mewes, HW; Moorthy, D; Scherübl, H; Simonetta, F; Truss, M; Zeitz, M | 1 |
| Abbruzzese, JL; Bogaard, K; Hoff, PM; Waldrum, S; Wolff, RA | 1 |
| Donders, RC; Hamberg, P; ten Bokkel Huinink, D | 1 |
| Fujita, J; Hoshimoto, S; Kato, R; Kato, T; Morise, Z; Sugioka, A | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Akaike, A; Matsukawa, M; Sato, A; Sekikawa, T; Ushio, J | 1 |
| Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E | 1 |
| Lane, D | 1 |
| Akiyama, S; Furukawa, T; Gotanda, T; Haraguchi, M; Jueng, HC; Sakata, R; Shimamoto, Y; Sumizawa, T | 1 |
| Baba, H; Endo, K; Haraguchi, M; Kohnoe, S; Maehara, Y; Nishiyama, K; Okamura, T; Toh, Y | 1 |
| Goyle, S; Maraveyas, A | 1 |
| Hata, K; Koyanagi, S; Kuramoto, Y; Ohdo, S; Shimeno, H; Soeda, S | 1 |
| Adami, G; Belvedere, O; Ceschia, T; Fasola, G; Grossi, F; Meduri, S; Recchia, L; Rizzato, S; Rossetto, C; Sacco, C; Sibau, A; Spizzo, R; Tumolo, S; Vigevani, E | 1 |
| de Gramont, A; Tournigand, C | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y | 1 |
| Azrak, RG; Badmaev, V; Creaven, PJ; Fakih, MG; Lawrence, D; Pendyala, L; Prey, JD; Reid, ME; Rustum, YM; Smith, PF | 1 |
| Biasco, G; Brandi, G; Bridonneau, C; Dabard, J; De Vivo, A; Di Battista, M; Morselli Labate, AM; Pantaleo, MA; Pisi, AM; Raibaud, P | 1 |
| Innocenti, F | 1 |
| Alves, PA; da Rocha, AB; Grass, LB; Grivicich, I; Henriques, JA; Kayser, GB; Regner, A; Schwartsmann, G | 1 |
| Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M | 1 |
| Calvet, L; Elie, N; Geoerger, B; Joseph, JM; Machet, L; Morizet, J; Opolon, P; Regairaz, M; Vassal, G | 1 |
| Kawahara, M | 1 |
| Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF | 1 |
| Battistoni, F; Di Cuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B | 1 |
| Beomonte Zobel, B; Coppola, R; Rabitti, C; Santini, D; Tonini, G; Trodella, L; Vincenzi, B | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Bankiewicz, KS; Berger, MS; Drummond, DC; Kirpotin, DB; Krauze, MT; Noble, CO; Park, JW; Saito, R; Yamashita, Y | 1 |
| Bogdanow, M; Gorschlüter, M; Lamberti, C; Lundin, S; Sauerbruch, T; Schmidt-Wolf, IG | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB | 1 |
| Kulka, J; Pintér, T; Sipocz, I | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
| Chen, YC; Chern, YT; Chi, CW; Lee, JY; Wang, JJ | 1 |
| Aoe, K; Hotta, K; Kawata, N; Kiura, K; Kozuki, T; Okada, C; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takeyama, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Fujimura, M; Ishiura, Y; Kasahara, K; Nakamura, H; Saito, K; Terasaki, Y; Yokawa, S | 1 |
| Fukuoka, Y; Hasegawa, Y; Hitsuda, Y; Igishi, T; Kodani, M; Kurai, J; Miyata, M; Shimizu, E; Suyama, H; Touge, H; Yasuda, K | 1 |
| Chang, S; Cloughesy, T; Fine, HA; Fink, K; Greenberg, H; Hess, K; Jaeckle, K; Junck, L; Kuhn, J; Lamborn, K; Mehta, M; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Drummond, DC; Guo, Z; Hong, K; Kirpotin, DB; Noble, CO; Park, JW | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Akiyama, S; Furukawa, T | 1 |
| Biasco, G; Brandi, G; Derenzini, E; Ercolani, G; Grazi, G; Pantaleo, MA; Ravaioli, M | 1 |
| Arakawa, Y; Saito, S; Suzuki, H; Yamada, H | 1 |
| Bernard, O; Gagnon, JF; Guillemette, C; Têtu, B; Villeneuve, L | 1 |
| Chowbay, B; Jada, SR; Wan Teck, DL | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F | 1 |
| Bhattacharya, A; Cao, S; Durrani, FA; Fakih, M | 1 |
| Costanzo, C; Donadelli, M; Moore, PS; Palmieri, M; Piacentini, P; Scarpa, A | 1 |
| Ichikawa, W; Inokuchi, M; Kawano, T; Kojima, K; Nihei, Z; Sugihara, K; Yamada, H; Yamashita, T | 1 |
| Caron, P; Court, MH; Fortier, LC; Girard, H; Greenblatt, DJ; Guillemette, C; Hao, Q; Villeneuve, L; von Moltke, LL | 1 |
| Cannita, K; Cianci, G; De Galitiis, F; De Tursi, M; Di Rocco, ZC; Ficorella, C; Iacobelli, S; Marchetti, P; Morelli, MF; Morese, R; Porzio, G; Ricevuto, E; Tinari, N | 1 |
| Abbruzzese, JL; Bogaard, KR; Dutta, A; Eng, C; Hoff, PM; Jones, D; Lin, E; Wolff, RA; Xiong, H | 1 |
| Assadourian, S; Awada, A; de Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Piccart, M; Semiond, D; van Oosterom, A | 1 |
| Fukutani, K; Kume, H; Takahashi, S; Tomita, K | 1 |
| Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD | 1 |
| Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ | 1 |
| Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H | 1 |
| Ishikawa, T; Kamachi, T; Nakagawa, H; Okura, I; Saito, H; Tamura, A; Watanabe, M | 1 |
| Goto, M; Katsu, K; Kawabe, S; Kii, T; Kuwakado, S; Nishitani, H; Ohta, S; Takiuchi, H; Tanaka, T | 1 |
| Khoukaz, T | 1 |
| András, C; Farczádi, E; Szántó, J | 1 |
| Bonnay, M; Elias, D; Pocard, M; Raynard, B | 1 |
| André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A | 1 |
| Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Chaudhury, P; Hayashi, S; Horton, PJ; Jass, JR; Marcus, VA; Martinie, JB; Metrakos, P; Znajda, TL | 1 |
| Chamberlain, MC; Groshen, S; Tsao-Wei, DD | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Agostara, B; Barone, C; Bordonaro, R; Borsellino, N; Capasso, E; Del Prete, S; Ferraù, F; Gebbia, V; Leonardi, V; Maiello, E; Stinco, S; Tralongo, P; Verderame, F | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Cloughesy, TF; Lai, A; Mischel, P; Nghiemphu, P; Pope, WB | 1 |
| Innocenti, F; Ratain, MJ; Vokes, EE | 1 |
| Han, JY; Jang, IJ; Lee, DH; Lee, JE; Lee, JS; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Büchler, P; Ganten, TM; Haas, TL; Koschny, R; Schader, MB; Schulze-Bergkamen, H; Stremmel, W; Sykora, J; Untergasser, A; Walczak, H | 1 |
| Gandara, DR; Lara, PN; Natale, RB | 1 |
| Crews, KR | 1 |
| Bae, JM; Choi, IJ; Chun, JH; Kim, CG; Kim, HK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW; Yu, MS | 1 |
| Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
| Barten, M; Fietkau, R; Klautke, G; Prall, F; Schiffmann, L; Wöhlke, M | 1 |
| Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N | 1 |
| Baudin, E; Boige, V; de Baere, T; Dromain, C; Ducreux, MP; Duvillard, P; Elias, D; Kergoat, P; Lasser, P; Leboulleux, S; Malka, D; Sabourin, JC; Schlumberger, M | 1 |
| Brunet Vidal, J; Cabezas Montero, I; Gumà Padró, J; Llobera Serentill, M; Manzano Alemany, H; Salud Salvia, A; Servitja Tormo, S; Sopena Bert, E; Valentí Moreno, V | 1 |
| Ansari, R; Beck, T; Bunn, PA; Byrne, M; Einhorn, L; Ellis, P; Guthrie, T; Hanna, N; Hariharan, S; Langer, C; Morrison, M; Sandler, A; Wang, B | 1 |
| Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M | 1 |
| Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G | 1 |
| Kandabashi, K; Maeda, Y; Mikoshiba, M; Okamoto, R; Omuro, Y; Sasaki, E; Sasaki, T | 1 |
| Kobayashi, K; Sutani, A | 1 |
| Akazai, Y; Kimura, H; Nitta, Y | 1 |
| Fujita, A; Hayakawa, T; Hirohata, T; Inotsume, N; Konaka, M; Makino, A; Sato, H; Sato, M; Sekine, K; Totsu, S; Wada, Y | 1 |
| Hoshihara, Y; Hoteya, O; Iizuka, T; Udagawa, H; Yahagi, N; Yamamoto, T | 1 |
| Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T | 1 |
| Duan, W; Kleiber, B; Kuhn, J; Otterson, G; Panico, K; Phillips, G; Schaaf, L; Shah, M; Villalona-Calero, M; Wu, WH; Young, D | 1 |
| Nagata, Y; Shima, M; Shoji, S; Terachi, T; Uchida, T; Usui, Y | 1 |
| Tanaka, T; Umesaki, N; Utsunomiya, T | 1 |
| Borner, MM | 1 |
| Hamaguchi, T; Itoda, M; Kamatani, N; Kaniwa, N; Kubota, K; Kunitoh, H; Maekawa, K; Minami, H; Ohtsu, A; Ozawa, S; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamamoto, N; Yoshida, T | 1 |
| Chen, CS; Chen, TC; Hofman, FM; Kardosh, A; Liu, YT; Petasis, NA; Pyrko, P; Schönthal, AH; Soriano, N; Uddin, J | 1 |
| Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M | 1 |
| Belfiore, P; Croce, AC; Dal Bo, L; Farina, C; Misiano, P; Petrangolini, G; Pratesi, G; Supino, R; Tortoreto, M; Zunino, F | 1 |
| Pujol, JL | 1 |
| Fournel, P | 1 |
| Agrelo, R; Artiga, MJ; Bohr, VA; Castells, A; Cheng, WH; Espada, J; Esteller, M; Fraga, MF; Guerrero, D; Herranz, M; Paz, MF; Ropero, S; Sanchez-Cespedes, M; Setien, F; von Kobbe, C | 1 |
| Bian, JS; Boelsterli, UA; Chan, E; Chan, SY; Chen, YZ; Duan, W; Ho, PC; Hu, ZP; Huang, M; Ng, KY; Yang, XX; Zhou, SF | 1 |
| McLeod, HL | 1 |
| Chu, E; Vokes, EE | 1 |
| Beaven, AW; Goldberg, RM | 1 |
| Inoue, H; Miyashita, T; Takemura, H; Ueda, T; Yoshida, A | 1 |
| Allen, WL; Coyle, VM; Johnston, PG | 1 |
| Büscher, C; Fähndrich, S; Fietkau, R; Klautke, G; Semrau, S; Virchow, C | 1 |
| Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S | 1 |
| Chen, JZ; Liao, WJ; Luo, RC; Zheng, H | 1 |
| Goker, E; Karabulut, B; Korkut, M; Sanli, UA; Uslu, R | 1 |
| Berrocal, DH; Gelpi, RJ; González, GE; Grinfeld, LR; Morales, C | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Akita, H; Ishida, H; Kabuto, T; Nakaguchi, K; Watanabe, Y | 1 |
| Bando, K; Ishizuka, T; Tajiri, T; Yanagi, K; Yoshimura, K; Yoshiyasu, M | 1 |
| Morimoto, N; Shibaki, T | 1 |
| Arimori, K; Hidaka, M; Ikenoue, T; Iwakiri, T; Nagai, K; Nishida, K; Ogikubo, T; Okumura, M; Setoguchi, N; Yamasaki, K | 1 |
| Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK | 1 |
| Lenz, HJ; Park, DJ | 1 |
| Middleton, MR; Sabharwal, A | 1 |
| Assenat, E; Duffour, J; Ychou, M | 1 |
| Konietzny, P; Schmassmann, A; Schmassmann-Suhijar, D; Yoon, S; Zuber, M | 1 |
| Assadourian, S; Beijnen, JH; Bonneterre, J; Bonneterre, ME; Boot, H; Dansin, E; Feger, C; Kuppens, IE; Schellens, JH | 1 |
| Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D | 1 |
| Kawashima, O; Morishita, Y; Nagashima, T; Sugano, M | 1 |
| Hida, N; Kunikane, H; Naoki, K; Narita, Y; Okamoto, H; Watanabe, K | 1 |
| Kovacic, P | 1 |
| Bowen, JM; Cummins, AG; Gibson, RJ; Keefe, DM; Tyskin, A | 1 |
| Eng, C; Shalan, N | 1 |
| Bessho, M; Higashihara, M; Kohuri, M; Niitsu, N | 1 |
| Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J | 1 |
| Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G | 1 |
| Aranda, E; Cervantes, A; Dotor, E; Gallén, M; García, JL; Navarro, M; Rivera, F; Sánchez-Rovira, P; Vega-Villegas, ME | 1 |
| Maitland, ML; Ratain, MJ; Vasisht, K | 1 |
| Bian, JS; Chan, E; Duan, W; Hu, ZP; Huang, M; Li, X; Sheu, FS; Wang, JC; Xu, AL; Yang, XX; Zhang, Q; Zhou, SF; Zhu, YZ | 1 |
| Danks, MK; Hatfield, MJ; Lee, RE; Potter, PM; Qi, J; Remack, JS; Virga, KG; Yoon, KJ | 1 |
| Ando, Y; Hasegawa, Y; Shimokata, K | 1 |
| Chun, JH; Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY | 1 |
| Abe, T; Arai, S; Hagiri, S; Katagiri, M; Kobayashi, H; Kubota, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Goto, A | 2 |
| Iwamoto, S; Yoshioka, K | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| Aulds, S; Clarke, S; Crawford, M; Eyers, T; Gallagher, J; Lee, S; Rivory, L; Seale, JP; Solomon, M; Tobin, P | 1 |
| Lee, SH; Sinko, PJ; Su, Y | 1 |
| In, KH; Jeong, HC; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Meropol, NJ | 2 |
| Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
| Funakoshi, A; Ishii, H; Ishikawa, O; Ohkawa, S; Okusaka, T; Saitoh, S; Ueno, H; Yamao, K | 1 |
| Ijichi, O; Inomata, Y; Ishikawa, S; Kawano, Y; Okamoto, Y; Shinkoda, Y; Takamatsu, H; Tanabe, T | 1 |
| Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG | 1 |
| Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ | 1 |
| Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Ryan, DP; Wu, B; Zhu, AX | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
| Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J | 1 |
| Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ | 1 |
| Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U | 1 |
| Blanchard, RL; Nagar, S | 1 |
| Hasegawa, F; Komatsu, T; Nishio, K; Ochiya, T; Takeshita, F; Takigahira, M; Yanagihara, K | 1 |
| Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H | 1 |
| Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG | 1 |
| Danenberg, KD; Fazzone, W; Gordon, M; Iqbal, S; Lenz, HJ; Rhodes, KE; Schultheis, AM; Sherrod, AE; Vallböhmer, D; Yang, DY; Zhang, W | 1 |
| Kroetz, DL | 1 |
| Clarke, SJ; Di Iulio, J; Ellis, A; Foo, K; Gurtler, V; Hicks, RJ; Hoskins, JM; Jefford, M; Michael, M; Milner, AD; Mitchell, PL; Scott, AM; Tebbut, NC; Thompson, M; Zalcberg, JR | 1 |
| Kudou, T; Munakata, M; Sakata, Y; Shitara, K | 1 |
| Asaka, M; Komatsu, Y; Miyagishima, T; Yuki, S | 1 |
| Narahara, H; Sugimoto, N | 1 |
| Eguchi, T; Shirao, K | 1 |
| Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S | 1 |
| Kamiyama, G; Kusano, M; Nakao, K; Narita, K; Oonaka, T; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K | 1 |
| Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S | 1 |
| Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A | 1 |
| Chowbay, B; Fan, L; Goh, BC; Jada, SR; Lee, SC; Li, HH; Lim, R; Tan, EH; Tham, LS; Wong, CI; Xiang, X; Zhou, QY | 1 |
| Androulakis, N; Aravantinos, G; Boukovinas, J; Fountzilas, G; Georgoulias, V; Kotsakis, A; Papakotoulas, P; Polyzos, A; Potamianou, A; Samonis, G; Stathopoulos, GP; Syrigos, K; Varthalitis, J; Ziras, N | 1 |
| Katakami, N | 1 |
| Fujii, Y; Nakazawa, K; Shuzui, Y; Yoneto, T | 1 |
| Anazawa, S; Eto, K; Kosuge, M; Mitsuyama, Y; Mouri, T; Ogawa, M; Ushigome, T; Watanabe, M; Yamagata, T; Yanaga, K | 1 |
| Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E | 1 |
| Cattan, S; Desauw, C; Hebbar, M; Pruvot, FR; Romano, O; Triboulet, JP; Wacrenier, A | 1 |
| Butler, RN; Davidson, GP; Howarth, GS; Tooley, KL | 1 |
| Adames, V; Chen, J; Fritzky, L; Higgins, B; Kolinsky, K; Linn, M; Mehta, N; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C | 1 |
| Bauer, J; Bouzourene, H; Coucke, P; Leyvraz, S; Matter, M; Stupp, R; Voelter, V; Vuilleumier, H; Zouhair, A | 1 |
| Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R | 1 |
| Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C | 1 |
| Ishihara, A; Kihira, T; Nomura, Y; Tanaka, H | 1 |
| Itoh, T | 1 |
| Creemers, GJ; de Bruijn, P; de Jong, FA; de Jonge, MJ; Eskens, FA; Janssen, JT; Kehrer, DF; Mathijssen, RH; Planting, AS; Ruit, JB; Sparreboom, A; van der Gaast, A; van Schaik, RH; Verweij, J | 1 |
| Chari, RS; Helton, WS; Marsh, RD | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Onozawa, Y; Ueda, S; Yoshino, T | 1 |
| Bartlett, DL; Berlin, J; Lauwers, GY; Messersmith, WA; Petrelli, NJ; Venook, AP | 1 |
| Fuchs, C; Hoff, PM; Mitchell, EP | 1 |
| Adenis, A; Boucher, E; Dahan, L; Di Fiore, F; Galais, MP; Hamidou, H; Hellot, MF; Jacob, JH; Michel, P; Mirabel, X; Paillot, B; Prod'homme, S; Raoul, JL | 1 |
| Nakano, T | 1 |
| Arai, Y; Aramaki, T; Inaba, Y; Matsueda, K; Sato, Y; Seki, H; Takeuchi, Y; Yamaura, H | 1 |
| Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K | 1 |
| Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D | 1 |
| Fujiwara, T; Gouchi, A; Kagawa, S; Matsuoka, J; Nishizaki, M; Tanaka, N; Teraishi, F; Tokunaga, N; Uno, F | 1 |
| Egami, K; Maruyama, H; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Yokoyama, T | 1 |
| Akabane, H; Fujiyoshi, M; Gotoh, J; Hirokata, G; Imai, K; Kawai, T; Kita, K; Nakano, S; Takahashi, M; Yanagida, N | 1 |
| de Bruijn, P; de Jong, FA; Kitzen, JJ; Loos, WJ; Verweij, J | 1 |
| Han, MJ; Kang, WK; Kim, HJ; Kwon, JM; Lee, HR; Lee, J; Lim, HY; Oh, SY; Park, BB; Park, JO; Park, YS | 1 |
| Bankiewicz, KS; Forsayeth, J; Krauze, MT; Park, JW | 1 |
| Dinter, D; Grobholz, R; Heeger, S; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Post, S; Wenz, F; Willeke, F; Woernle, C | 1 |
| Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Kamoto, T; Kawahara, T; Nishiyama, H; Ogawa, O; Yamamoto, S | 1 |
| Danks, MK; Edwards, CC; Hyatt, JL; Potter, PM; Tsurkan, L; Wierdl, M | 1 |
| Kishida, A; Nishino, S; Yoshizawa, H | 1 |
| Kessler, FK; Miles, KK; Nielsen, JN; Ritter, JK; Smith, PC; Tallman, MN; Tian, X | 1 |
| Crawford, J; Dunphy, F; Garst, J; Herndon, JE; Kelley, MJ; Riedel, RF | 1 |
| Adams, DH; Nutt, T | 1 |
| Catalano, RB; O'Dwyer, PJ | 1 |
| Anantha, M; Bally, M; Ramsay, E; Zastre, J | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SK; Lee, CG; Moon, YW; Shin, SJ; Sohn, JH | 1 |
| Furuhashi, S; Hirota, M; Ichihara, A; Kihara, S; Shimada, S; Sugita, H | 1 |
| Hamada, A; Masa, K; Saito, H; Sasaki, Y; Terazaki, H; Watanabe, H; Yokoo, K | 1 |
| Boelsterli, UA; Chan, E; Chan, SY; Duan, W; Ee, PL; Hu, ZP; Huang, M; Koh, HL; Sheu, FS; Wang, JC; Xu, AL; Yang, XX; Zhang, Q; Zhou, SF; Zhu, YZ | 1 |
| Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Nakatani, K; Nobori, T; Ojima, E; Toiyama, Y; Watanabe, H | 1 |
| Allaire, N; Amatucci, J; Bailly, V; Bottiglio, C; Browning, JL; Carmillo, A; Crowell, T; Ding, J; Fawell, S; Garber, E; Griffith, L; Heaney, G; Hoffman, R; Jarpe, M; Kelly, R; LePage, D; Lukashev, M; Lukashin, A; Mackay, F; Meier, W; Miatkowski, K; Ngam-ek, A; Perrin, S; Prentice, H; Reff, M; Silverio, E; Szeliga, K; Violette, SM; Wilson, C; Wortham, K; Xu, X; Yang, D; Yang, W; Zeng, W | 1 |
| Aparicio, J; Díaz, R; Giménez, A; Gómez-Codina, J; Molina, J; Palomar, L; Ponce, J; Segura, A | 1 |
| Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH | 1 |
| Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Semba, H; Takada, M | 1 |
| Gupta, AA; Pappo, AS | 1 |
| Guputa, M; Reddy, GK; Tyagi, P | 1 |
| Gonzalez, MV; Lewis, AL; Stratford, PW; Tang, Y; Taylor, RR | 2 |
| Ishiguro, A; Kasai, M; Munakata, M; Sakata, Y; Shitara, K | 1 |
| Kaneko, H; Koshino, H; Kurihara, A; Otsuka, Y; Takita, W; Tamura, A; Teramoto, T; Tsuchiya, M; Watanabe, M; Yamazaki, K | 1 |
| Ishiguro, A; Kudo, T; Mitobe, S; Munakata, M; Okada, R; Sakata, Y; Shitara, K; Tomioka, R; Yokoyama, S | 1 |
| Hamaguchi, T; Kitagawa, M; Koizumi, F; Matsumoto, S; Matsumura, Y; Negishi, T; Onda, T | 1 |
| Fukushima, M; Hoebe, EK; Peters, GJ; Temmink, OH | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Azarnia, N; Cohn, AL; Gold, P; Khambata-Ford, S; Lenz, HJ; Mauro, DJ; Mayer, RJ; Mirtsching, B; Pippas, AW; Rowinsky, EK; Stella, P; Tsuchihashi, Z; Van Cutsem, E | 1 |
| Feun, LG; Heros, D; Herrera, C; Landy, H; Marini, A; Markoe, A; Robles, C; Savaraj, N | 1 |
| Bessho, M; Higashihara, M; Kohori, M; Niitsu, N | 1 |
| Andres, A; Audard, V; Brezault, C; Chaussade, S; Dousset, B; Giostra, E; Majno, PE; Mentha, G; Roth, AD; Rubbia-Brandt, L; Sartoretti, P; Soubrane, O; Terris, B | 1 |
| Du, J; Feng, G; He, L; Li, X; Qin, S; Wang, L; Xing, Q; Xu, L; Xu, M; Yu, L; Zhang, A | 1 |
| Alnajim, J; Anantha, M; Bally, M; Edwards, K; Karlsson, G; Ramsay, E; Taggar, A; Thomas, A; Webb, M | 1 |
| Atkins, JN; Green, MR; Herndon, JE; Lee, ME; Mauer, A; Rocha-Lima, CM; Vokes, E | 1 |
| Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A | 1 |
| Fujitani, K; Furukawa, H; Ikeda, M; Imamoto, H; Imamura, H; Kato, M; Kobayashi, K; Narahara, H; Takabayashi, A; Tsujinaka, T; Tsukuma, H | 1 |
| Appleman, LJ; Clark, J; Cusack, JC; Dees, EC; Eder, JP; Fidias, P; Kashala, O; O'Neil, BH; Orlowski, RZ; Rocha Lima, CM; Ryan, DP; Supko, JG | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Kigawa, J; Kikuchi, Y; Kuzuya, K; Moriya, T; Sagae, S; Sugiyama, T; Suzuki, M; Takano, M; Takeuchi, S; Tsuda, H; Udagawa, Y; Yaegashi, N | 2 |
| Hahn, KK; Kolesar, JM; Wolff, JJ | 1 |
| Higa, GM | 1 |
| Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D | 1 |
| Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC | 1 |
| Graber, AY; Innocenti, F; Komoroski, BJ; Mirkov, S; Ramírez, J; Ratain, MJ; Strom, SC | 1 |
| Cruz, O; Gala, S; Mora, J; Navarro, R | 1 |
| Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K | 1 |
| Sekine, N; Terada, K | 1 |
| Burke, W; Haga, SB; Thummel, KE | 1 |
| Capanu, M; D'Adamo, D; Ilson, DH; Kelsen, DP; Levnor, A; O'Reilly, E; Ramanathan, RK; Schwartz, GK; Schwartz, L; Shah, MA; Trocola, R; Tse, A | 1 |
| Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K | 1 |
| Ezumi, K; Fujie, Y; Fukunaga, H; Hata, T; Hirota, S; Ikeda, M; Ikenaga, M; Monden, M; Ohue, M; Sekimoto, M; Seshimo, I; Shingai, T; Takayama, O; Takemasa, I; Yamamoto, H; Yasui, M | 1 |
| Bettegowda, C; Cheong, I; Diaz, LA; Huang, X; Kinzler, KW; Vogelstein, B; Zhou, S | 1 |
| Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Norum, J | 1 |
| Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N | 1 |
| Bruckner, HW; Coopeman, AM; Hrehorovich, VR; Meeus, SI; Sawhney, HS | 1 |
| Ahn, JS; Ahn, MJ; Hong, YS; Hwang, IG; Lee, HR; Lee, J; Lee, SC; Lim, HY; Park, BB; Park, K; Park, S | 1 |
| Fuchs, CS; Goldberg, RM; Hurwitz, HI | 1 |
| Aoyagi, Y; Enomoto, T; Nakajima, M; Noguchi, M; Oda, T; Ohkohchi, N; Satake, M; Sugiura, S | 1 |
| Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A | 1 |
| Evans, MT; Fennell, DA; Rudd, RM; Shamash, J; Sheaff, MT; Stebbing, J; Steele, JP; Wells, P | 1 |
| Wang, JW; Zhou, ZT | 1 |
| Bucana, CD; Fidler, IJ; Kitadai, Y; Kuwai, T; Nakamura, T; Sasaki, T | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Desrame, J; Fallik, D; Landi, B; Lecomte, T; Lledo, G; Mansourbakht, T; Spano, JP; Taïeb, J | 1 |
| Bowen, JM; Chan, TW; Cummins, AG; Gibson, RJ; Keefe, DM; Prabowo, AS; Stringer, AM | 1 |
| Chiba, W; Hitomi, S; Yamada, T | 1 |
| Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N | 1 |
| Benedetti, V; Beretta, GL; Carminati, P; Dallavalle, S; De Cesare, M; Merlini, L; Penco, S; Pisano, C; Pratesi, G; Tinelli, S; Zunino, F | 1 |
| Aboody, KS; Bush, RA; Danks, MK; Garcia, E; Gillespie, S; Glackin, CA; Justus, KA; Kim, SU; Metz, MZ; Najbauer, J; Phelps, DA; Potter, PM; Remack, JS; Yoon, KJ | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Hashimoto, N; Imaizumi, K; Shimokata, K | 1 |
| de Jong, FA; Friberg, LE; Kroetz, DL; Marsh, S; Mathijssen, RH; McLeod, HL; Scott-Horton, TJ; Sparreboom, A; Verweij, J | 1 |
| Brocheriou, I; Deray, G; Izzedine, H; Rixe, O | 1 |
| Booth, BP; Gobburu, JV; Ibrahim, A; Innocenti, F; Johnson, JR; Mehta, M; Rahman, A; Ramchandani, RP; Ratain, MJ; Wang, Y | 1 |
| Enomoto, M; Iida, S; Ishiguro, M; Kato, K; Makino, H; Morita, S; Sugihara, K; Takagi, Y; Uetake, H | 1 |
| Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S | 1 |
| Ikami, I; Ishiguro, A; Kasai, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Sakuraba, H; Shitara, K | 1 |
| Arakawa, K; Hamada, K; Kashiwabara, K; Kawate, S; Morishita, Y; Ohwada, S; Sunose, Y; Takeyoshi, I; Tohgo, N; Toya, H; Tsutsumi, H | 1 |
| Bowen, JM; Burns, J; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T | 1 |
| Bally, MB; Gallagher, RC; Harasym, N; Johnstone, S; Mayer, LD; Tardi, PG; Webb, M | 1 |
| Hayashi, T; Kitazaki, T; Kohno, S; Kusakari, C; Matsubara, Y; Nagasaki, T; Nagayasu, T; Nakamura, Y; Nakano, H; Soda, H; Yamaguchi, H | 1 |
| Aboody, KS; Bush, RA; Danks, MK; Garcia, E; Kim, SU; Metz, MZ; Najbauer, J; Potter, PM; Remack, JS; Tsurkan, L; Wierdl, M; Yoon, KJ | 1 |
| Azuma, Y; Hayashi, N; Koshiishi, H; Koshiishi, Y; Ohtsubo, Y; Okamura, T; Takahashi, E; Takahashi, M; Tamamoto, F | 1 |
| Ami, K; Ando, M; Ganno, H; Ito, T; Nagahama, T; Ohbu, M; Taira, M | 1 |
| Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F | 1 |
| Iwazawa, T; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H | 1 |
| Aoyagi, Y; Haku, K; Hayama, T; Matsuda, K; Mimura, T; Nakamura, K; Nozawa, K; Oomi, T; Watanabe, T; Yamada, H | 1 |
| Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Gyôrffy, B; Tegze, B; Tulassay, Z | 1 |
| Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Hashimoto, T; Izumi, Y; Kato, T; Kawada, K; Miura, A; Momma, K; Oota, M | 1 |
| Akamaru, Y; Ito, A; Kasugai, T; Momiyama, T; Nakamura, Y; Ohse, N; Yamamoto, S; Yamasaki, Y; Yumiba, T | 1 |
| Fujioka, T; Hirashima, Y; Kitajima, K; Kumamoto, T; Murakami, K; Sugi, S | 1 |
| Goi, T; Hirono, Y; Iida, A; Ishida, M; Katayama, K; Maeda, H; Murakami, M; Obata, S; Yamaguchi, A | 1 |
| Aoki, T; Hisada, M; Ishizaki, T; Katsumata, K; Mori, Y; Suzuki, S; Tsuchida, A; Wada, T | 1 |
| Crassard, N; Frappaz, D; Marec-Bérard, P; Philip, T; Ranchin, B; Schell, M; Thiesse, P | 1 |
| Miyagi, Y; Noda, K; Oshita, F; Saito, H; Sekiyama, A; Yamada, K | 1 |
| Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH | 1 |
| Lin, GL; Qiu, HZ | 1 |
| Botwood, N; Chau, I; Cunningham, D; Hickish, T; Higgins, L; Massey, A; Osborne, R; Swaisland, A | 1 |
| Ewis, HE; Liu, P; Lu, CD; Tai, PC; Weber, IT | 1 |
| Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF | 1 |
| Cunningham, D; Starling, N; Tilden, D; White, J | 1 |
| Aoyama, C; Hosoya, R; Kamiya, T; Kato, I; Manabe, A; Ogawa, C; Ozawa, M; Takahashi, H; Takusagawa, A; Yokoyama, K | 1 |
| Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N | 1 |
| Hoff, PM; Phan, LK | 1 |
| Beeram, M; Chu, Q; De Bono, J; Forouzesh, B; Hammond, LA; Hong, S; John, W; Latz, JE; Nguyen, B; Rowinsky, EK; Schwartz, G | 1 |
| Falk, S; Glynne-Jones, R; Maughan, TS; Meadows, HM; Sebag-Montefiore, D | 1 |
| Assadourian, S; Bergeron, C; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Morland, B; Orbach, D; Pichon, F; Picton, S; Stockdale, E; Vassal, G | 1 |
| Breitfeld, P; Crews, KR; Donaldson, SS; Houghton, P; Lyden, E; Meyer, WH; Pappo, AS; Parham, D; Wiener, E | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Hiyama, K; Kaneyasu, M; Nishiyama, M; Shimokuni, T; Tanimoto, K | 1 |
| Dicko, A; Mayer, L; Tardi, P; Xie, X | 1 |
| Chan, E; Chen, X; Duan, W; Hu, ZP; Yang, XX; Zhou, SF | 1 |
| Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M | 1 |
| Guichard, SM; Hua, ML; Jodrell, DI; Kang, P; Macpherson, JS | 1 |
| Adachi, M; Ando, K; Hirose, T; Hosaka, T; Ishida, H; Kusumoto, S; Nakashima, M; Ohmori, T; Shirai, T; Sugiyama, T | 1 |
| Guan, ZZ | 1 |
| Birdsall, TC | 1 |
| Yoshida, S | 1 |
| Kitajima, M; Kubota, T; Wada, N | 1 |
| Matsukawa, M; Sato, A | 1 |
| Adena, M; Damianovich, D; Tebbutt, NC | 1 |
| Cai, Y; Chen, Y; Ding, J; Gao, H; Huang, M; Jiang, H; Lin, L; Lu, W; Miao, Z; Shen, H; Zhang, J; Zhang, X; Zhu, H | 1 |
| Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Ojima, E; Toiyama, Y; Watanabe, H; Yanagi, H | 1 |
| Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF | 1 |
| Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Cao, J; Chan, E; Chen, X; Duan, W; Hu, ZP; Huang, M; Wen, JY; Yang, XX; Yu, XQ; Zhou, SF | 1 |
| Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M | 1 |
| Koitz, N; Roth, E; Schmuckenschlager, C; Strasser, EM; Unger-Manhart, N; Wessner, B | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ; Wagner, M | 1 |
| Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Funahashi, M; Murayama, T; Yamada, T | 1 |
| Ono, A; Yamamoto, N | 1 |
| Kuboki, Y; Mizunuma, N | 1 |
| Kabeya, K; Kamoshita, N; Kobayashi, M; Makita, F; Matsuzaki, Y | 1 |
| Kanamori, T; Kawashima, T; Murakami, H; Nakamura, Y | 1 |
| Ansell, W; Berney, D; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Stebbing, J; Walsh, E; Wilson, P | 1 |
| Fukushima, M; Hasegawa, S; Kawashima, K; Matsumoto, S; Nagayama, S; Nomura, A; Okabe, H; Sakai, Y; Satoh, S; Watanabe, G; Yoshibayashi, H | 1 |
| Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B | 1 |
| Chang, J; Choi, BW; Choi, HJ; Chung, KY; Kim, GE; Kim, JH; Kim, SK; Kim, YS; Lee, CG; Moon, YW; Sohn, JH | 1 |
| Chu, DT; Han, FC; Liu, DQ; Xiu, QY; Zhang, XR; Zhu, YZ | 1 |
| Li, J | 1 |
| Chamberlain, MC; Chen, TC; Gupta, V; Hofman, FM; Liebes, LF; Samuelson, CG; Schönthal, AH; Su, YS | 1 |
| Hyodo, I | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ | 1 |
| López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N | 1 |
| Bordovská, S; Meloun, M; Vrána, A | 1 |
| Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K | 3 |
| Battistoni, F; Dicuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Rosaria, VM; Russo, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Dubois, RN; Hatakeyama, N; Horikawa, Y; Jin, M; Komatsu, K; Matsuhashi, T; Odashima, M; Ohba, R; Otaka, M; Oyake, J; Wada, I; Watanabe, S | 1 |
| Cha, HJ; Choi, DH; Ha, JS; Kim, GY; Lee, BJ; Lee, WH; Park, JH; Park, JW; Song, JK | 1 |
| Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W | 1 |
| Cowen, RL; Flint, PJ; Matzow, T; Saunders, MP; Southgate, TD; Telfer, BA; Williams, KJ | 1 |
| de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Ando, Y; Araki, K; Eodo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 1 |
| Berenguer, R; Ferrandini, S; Garberi, J; Politi, P; Trini, E; Valsecchi, M | 1 |
| Asai, G; Fukuoka, M; Kurata, T; Nakagawa, K; Tamura, K; Uejima, H; Yamamoto, N | 1 |
| Choong, NW; Hoffman, PC; Kozloff, M; Mauer, AM; Rudin, CM; Sciortino, DF; Szeto, L; Villano, JL; Vokes, EE; Wade, JL; Winegarden, JD | 1 |
| Mehta, M; Robins, HI; Traynor, AM | 1 |
| Atkins, JN; Bearden, JD; Case, D; Giguere, JK; Miller, AA | 1 |
| Cummings, K; Gao, F; Govindan, R; Hennenfent, KL; Marsh, S; McLeod, HL; Pillot, GA; Read, WL; Viswanathan, A | 1 |
| Bessho, A; Fujimoto, N; Fujiwara, K; Gemba, K; Hotta, K; Kiura, K; Kuyama, S; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Takata, I; Takigawa, N; Tanimoto, M; Tokuda, Y; Ueoka, H | 1 |
| Feigenberg, S; Huang, C; Langer, CJ; Litwin, S; Maiale, C; Millenson, M; Movsas, B; Nicoloau, N; Sherman, E; Somer, R; Treat, J | 1 |
| Basic, I; Benkovic, V; Bevanda, M; Brozovic, G; Dikic, D; Horvat Knezevic, A; Knezevic, F; Orsolic, N | 1 |
| Aiba, K; Arai, K; Fujii, M; Hayashi, K; Ichikawa, W; Katsube, T; Kitajima, M; Kochi, M; Kubota, T; Ogawa, K; Takagi, Y; Terashima, M; Tokunaga, A | 1 |
| Beghelli, S; Dandrea, M; Di Carlo, V; Formicola, R; Mercalli, A; Piemonti, L; Reni, M; Scarpa, A; Sordi, V | 1 |
| Gil Delgado, M; Khayat, D; Spano, JP | 1 |
| Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA | 1 |
| El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S | 1 |
| Almasan, A; Fraizer, GC; Ray, S; Shyam, S | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Funada, R; Harada, K; Hasegawa, K; Homma, N; Ogata, N; Shibasaki, K; Soga, K; Uchida, M; Watanabe, T | 1 |
| Hamano, R; Hirao, T; Kobayashi, T; Masuzawa, T; Shibata, K; Tokuoka, M | 1 |
| Hasegawa, Y; Kataoka, Y; Kawamura, S; Kimura, H; Okumura, S; Shimada, E; Tei, M | 1 |
| Doi, K; Kudo, K; Matsuo, A; Ogata, K; Ohchi, T; Ootao, R | 2 |
| Shoji, Y; Toyooka, M | 1 |
| Wils, J | 1 |
| Gordon, M; Lenz, HJ; Zhang, W | 1 |
| Chijiiwa, K; Igarashi, T; Izumi, H; Kohno, K; Miyamoto, N; Niina, I; Okayasu, R; Onitsuka, T; Shiota, M; Torigoe, T; Uchiumi, T; Wakasugi, T | 1 |
| Andritzky, B; Bokemeyer, C; Burkholder, I; Dürk, H; Edler, L; Elbers, M; Engel-Riedel, W; Fischer, J; Görn, M; Gütz, S; Hossfeld, DK; Kortsik, C; Krüll, A; Laack, E; Meissner, C; Müller, T; Schuch, G; Thöm, I | 1 |
| André, T; de Gramont, A; Larsen, AK; Louvet, C; Tournigand, C | 1 |
| Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y | 1 |
| Alvarez, E; Bowen, JM; Burns, J; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Baudhuin, LM; Highsmith, WE; Holtegaard, L; Moore, BE; O'Kane, DJ; Skierka, J | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Yoon, SJ | 1 |
| Jobo, T | 1 |
| Ilson, DH; Krol, G; Ku, GY | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S | 1 |
| Dulau, A; Huang, CK; Pan, Q; Su-Rick, CJ | 1 |
| Choi, IK; Chun, HJ; Jeen, YT; Kim, JS; Kim, YH; Mok, YJ; Oh, SC; Park, SS; Seo, JH; Shin, SW; Sung, HJ; Sur, HY | 1 |
| Assaraf, YG; Bram, EE; Grimberg, M; Ifergan, I; Lemke, K; Skladanowski, A | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, M; Ohyanagi, F; Okano, Y; Okumura, S; Satoh, Y | 1 |
| Bellott, R; Bonnet, J; Charasson, V; Colotte, M; Klein, K; Laurand, A; Le Morvan, V; Robert, J; Smith, D; Zanger, UM | 1 |
| Harr, MW; Willey, JC | 1 |
| Caron, P; Liu, D; Patel, S; Seiter, K | 1 |
| Benson, AB; Mulcahy, MF; Wisinski, KB | 1 |
| Adoniou, E; Bacoyiannis, C; Felekouras, E; Gryniatsos, J; Kosmas, C; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Sigala, F; Skopelitis, H; Tsavaris, N; Zacharakis, M; Zografos, G | 1 |
| Arima, S; Futami, K; Kamitani, T; Koga, M | 1 |
| Komatsu, Y | 1 |
| Rödel, C; Sauer, R | 1 |
| Kamura, T; Kitagawa, R; Nishio, S; Shouji, T; Sugiyama, T; Ushijima, K; Yoshizaki, A | 1 |
| Motoo, Y | 1 |
| Côté, JF; Diebold, MD; Kirzin, S; Kramar, A; Laurent-Puig, P; Mosnier, JF; Selves, J; Soubeyran, I; Thirouard, AS; Ychou, M | 1 |
| Aikou, T; Akiyama, S; Akune, S; Che, XF; Firth, SD; Furukawa, T; Ikeda, R; Ishizawa, T; Kitazono, M; Komatsu, M; Mercer, JF; Owatari, S; Takeuchi, T; Tsujikawa, K; Yamamoto, M | 1 |
| Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR | 1 |
| Fujimoto, K; Hirao, Y; Matsushita, C; Miyake, M; Tanaka, M; Tanaka, N | 1 |
| Fucić, A; Gamulin, M; Kopjar, N; Milić, M; Pavlica, V; Radić, B; Ramić, S; Vrdoljak, AL; Zeljezić, D | 1 |
| Bayer, W; Hoffmann, D; Wildner, O | 1 |
| Innocenti, F; Kim, TW | 1 |
| Chan, RK; Ericsson, ML; Kung, D; Ruan, DT; Saund, MS | 1 |
| Amado, RG; Berlin, J; Chan, D; Hecht, JR; Hu, E; Malik, I; Posey, J; Tchekmedyian, S; Yang, L | 1 |
| Fakih, MG; Gupta, B; LeVea, C; Litwin, A | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JE; Lee, JS; Lee, SY; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Shi, D; Song, X; Yan, B; Yang, D; Yang, J | 1 |
| Fujimoto, H; Hamada, A; Imai, T; Masa, K; Matsuzaki, T; Saito, H; Watanabe, H; Yokoo, K | 1 |
| Fujiwara, Y; Fukui, T; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Simmyo, Y; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Akerley, W; Atkins, JN; Bearden, JD; Chansky, K; Crowley, JJ; Gandara, DR; Goodwin, JW; Hesketh, PJ; McCoy, J | 1 |
| Hashimoto, H; Hirabayashi, T; Ishikawa, H; Ohi, S; Sugiyama, K; Tachibana, T; Takahashi, N; Yanaga, K | 1 |
| Alessandroni, P; Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Fontana, A; Giustini, L; Graziano, F; Lippe, P; Loupakis, F; Magnani, M; Maltese, P; Mari, D; Menichetti, ET; Pizzagalli, F; Ruzzo, A; Santini, D; Schiavon, G; Testa, E; Tonini, G | 1 |
| Kado, S; Kaneda, N; Kato, I; Kurita, A; Matsumoto, T; Onoue, M; Uchida, K; Yokokura, T | 1 |
| Caca, K; Feisthammel, J; Mössner, J; Schoppmeyer, K; Schulze, M; Wiedmann, M | 1 |
| Oshita, F; Saito, H; Yamada, K | 2 |
| Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M | 1 |
| Hotta, K; Ichimura, K; Kiura, K; Matsuoka, J; Osawa, M; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Hamaguchi, T; Kaniwa, N; Kubota, K; Minami, H; Ohmatsu, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Suzuki, K; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M | 1 |
| Benowitz, NL | 1 |
| de Jong, FA; de Jonge, MJ; Friberg, LE; Loos, WJ; Mathijssen, RH; Planting, AS; Sparreboom, A; van der Bol, JM; van Schaik, RH; Verweij, J | 1 |
| Inokuchi, M; Kawano, T; Kojima, K; Sekita, Y; Sugihara, K; Yamada, H; Yamashita, T | 1 |
| Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 2 |
| Aoki, M; Ishiguro, A; Itoh, J; Munakata, A; Munakata, M; Sakata, Y; Shitara, K; Suzuki, K; Takahata, T | 1 |
| Albritton, K; Crews, KR; Furman, WL; McNall-Knapp, RY; Pappo, AS; Rodriguez-Galindo, C; Stewart, CF; Wagner, LM | 1 |
| Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Ahmad, A; Bilchik, AJ; Chen, SL | 1 |
| Billups, C; Fraga, CH; Furman, WL; Gajjar, A; Liu, T; McGregor, LM; O'Shaughnessy, MA; Owens, T; Panetta, JC; Rodriguez-Galindo, C; Stewart, CF; Throm, SL | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Tsykin, A | 2 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Oka, M; Soda, H; Soejima, Y; Takatani, H | 1 |
| Ando, Y; Fujita, K; Hasegawa, Y; Sasaki, Y | 1 |
| Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y | 1 |
| Benson, A; Wisinski, K | 1 |
| Brito, GA; Carvalho, SB; Cunha, FQ; Melo, ML; Ribeiro, RA; Silva, JV; Soares, PM; Soares, RC; Souza, MH; Vale, ML | 1 |
| Beauvillain, L; Bihannic, R; Bousquet, A; Burnat, P; Ceppa, F; Cremades, S; Fontan, E | 1 |
| Gemma, A; Kawakami, A; Kudoh, S; Li, C; Matsuda, K; Minegishi, Y; Noro, R; Ogawa, N; Seike, Y; Shionoya, A | 1 |
| Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Shu, X; Wong, CI; Zhou, Q | 1 |
| Sargent, D; Schmoll, HJ | 1 |
| Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ | 1 |
| Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C | 1 |
| Deutsch, E; Ducreux, M; Ezra, P; Mangoni, M | 1 |
| Elias, D; Goere, D; Pocard, M | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP | 1 |
| Luan, LB; Wu, QL | 1 |
| Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM | 1 |
| Bosron, WF; Davis, WI; Green, SL; Sanghani, PC; Sanghani, SP; Schiel, MA | 1 |
| Ae, T; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Arai, H; Higashida, T; Imada, T; Kanari, M; Masuda, M; Nakayama, T; Rino, Y; Saeki, H; Sekino, Y; Wada, N; Yamada, T; Yukawa, N | 1 |
| Kohno, H; Ogawa, A; Okajima, A; Taguchi, T; Takenouchi, Y; Tsugane, K | 1 |
| Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D | 1 |
| Akasawa, A; Jinno, H; Kamatani, N; Kaniwa, N; Kim, SR; Matsumoto, K; Minami, H; Ohtsu, A; Ozawa, S; Sai, K; Saijo, N; Saito, H; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yamamoto, N; Yoshida, T | 1 |
| Edelstein, E; Gutman, M; Klein, B; Paran, H | 1 |
| Amessou, M; Decaudin, D; El Alaoui, A; Florent, JC; Johannes, L; Sarr, M; Schmidt, F | 1 |
| Gu, J; Yao, YF | 1 |
| Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Bankiewicz, KS; Drummond, D; Forsayeth, J; Kawaguchi, T; Kirpotin, DB; Krauze, MT; Kullberg, E; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Asaka-Amano, Y; Kawashima, T; Kuriyama, T; Kurosu, K; Moriya, T; Nagao, K; Tada, Y; Takiguchi, Y | 1 |
| Darro, F; Dewelle, J; Dumont, P; El Yazidi, M; Gaussin, JF; Kiss, R; Lefranc, F; Mahieu, T; Mijatovic, T; Ribaucour, F; Sauvage, S; Simon, G; Tuti, J; Van Quaquebeke, E; Van Vynckt, F | 1 |
| Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C | 1 |
| Asakura, T; Kobayashi, S; Kumai, T; Matsumoto, N; Nakano, H; Nakaya, S; Ohtsubo, T; Sekine, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y | 1 |
| Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT | 1 |
| Lagarde, C; Lebrun-Ly, V; Peyronnet, P; Saint-Marcoux, F; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I | 1 |
| Sharma, SP | 1 |
| Albert, M; Biancosino, C; Linder, A | 1 |
| Amado, RG; Berlin, J; Hecht, JR; Malik, I; Meropol, NJ; Navale, L; Patnaik, A; Tchekmedyian, S; Venook, A | 1 |
| Goto, T; Kawakami, T; Kikuchi, K; Kitazawa, E; Miyakawa, H; Mizuguchi, K; Murakawa, Y; Nakano, K; Sato, S; Tajima, Y; Takai, A; Watabe, H; Watanabe, M | 1 |
| Fennell, DA; Rudd, RM; Shamash, J; Sheaff, MT; Slater, SE; Stebbing, J; Steele, JP; Wells, P | 1 |
| Fakih, MG; Ross, ME; Starostik, P | 1 |
| Klek, S; Kulig, J; Popiela, T; Richter, P | 1 |
| Alberts, SR; Delaunoit, T; Dy, GK; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, EM; Krook, JE; Morton, RF; Pitot, HC; Pockaj, BA; Ramanathan, RK; Sargent, DJ; Sticca, RP; Williamson, SK | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 1 |
| Takiuchi, H | 2 |
| Araki, T; Fujii, M; Inoue, S; Kimoto, K; Murakami, M; Ohshiro, Y; Oka, K; Tacho, T; Yano, A | 1 |
| He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L | 1 |
| Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Pectasides, D; Samantas, E; Skarlos, D; Syrigos, K | 1 |
| Ator, M; Chang, H; Deibold, J; Grobelny, J; Hudkins, R; Husten, J; McGann, N; Miknyoczki, S; Parchment, R; Pritchard, S; Ruggeri, B; Worrell, C; Zulli, A | 1 |
| Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Sandanaraj, E; Shu, X; Zhou, Q; Zhou, S | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Sonis, ST; Stringer, AM | 3 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Anderson, P; Curley, S; Green, HL; Hayes-Jordan, A; Herzog, C; Hunt, K; Lally, KP; Mansfield, P | 1 |
| Fuse, ET; Kamimura, M; Kawaishi, M; Kimura, S; Kobayashi, N; Kudo, K; Niino, H; Saito, K; Takeda, Y | 1 |
| Alvarez, E; Bowen, JM; Finnie, J; Gibson, RJ; Keefe, DM | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Berend, S; Fuchs, N; Kopjar, N; Radić, B; Vrdoljak, AL; Zeljezić, D | 1 |
| Bendardaf, R; Korkeila, E; Lamlum, H; Pyrhönen, S; Ristamäki, R; Syrjänen, K | 2 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tomonaga, N | 1 |
| Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N | 1 |
| Goldberg, RM; Hoskins, JM; Ibrahim, JG; McLeod, HL; Qu, P | 1 |
| Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Catalano, V; Falcone, A; Labianca, R; Loupakis, F; Mandolesi, A; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Bender, RA; Liu, JY; Qu, K; Sferruzza, AD | 1 |
| Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR | 1 |
| Noda, K; Oshita, F; Saito, H; Yamada, K | 2 |
| Morris-Stiff, G; Tan, YM; Vauthey, JN | 1 |
| Han, JY; Kim, HT; Lee, JE; Lee, JS; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Bae, SH; Baek, JH; Do, YR; Hur, IK; Hyun, MS; Kim, MK; Kwon, KY; Lee, KH; Lee, WS; Park, KU; Ryoo, HM; Song, HS | 1 |
| Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M | 1 |
| Chak, K; Chan, AT; Chan, G; Ho, S; Ho, WM; Lam, KC; Lee, Y; Mok, TS; Wong, H; Yeo, W; Yim, AP | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Burris, HA; Grapski, R; Greco, FA; Hainsworth, JD; Mallidi, PV; Meng, C; Schreeder, M; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S | 1 |
| Janoff, AS; Mayer, LD | 1 |
| Eigenbrod, T; Klebl, F; Kullmann, F | 1 |
| Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T | 1 |
| Choi, CH; Han, HK; Han, SI; Jung, GR; Kim, KJ; Lee, TB; Lim, SC | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Seto, T | 1 |
| Farhat, FS | 1 |
| Hayakawa, K; Koizumi, W; Kokuba, Y; Okayasu, I; Sato, T; Watanabe, M | 1 |
| de Jong, FA; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathôt, RA; van den Bent, MJ; van der Bol, JM; Verweij, J | 1 |
| Czaykowski, PM | 1 |
| Billups, CA; Danks, MK; McLendon, RE; Wagner, LM; Weiss, BD; Yoon, KJ | 1 |
| Buchsbaum, DJ; DeRosier, LC; Grizzle, WE; Huang, ZQ; Long, JW; Oliver, PG; Sellers, JC; Vickers, SM; Wang, W; Zhou, T; Zinn, KR | 1 |
| Chen, HX; Gonen, M; Hochster, HS; Hoff, PM; Hollywood, EM; Kemeny, NE; Kindler, HL; Lenz, HJ; Morse, M; Quinones, M; Saltz, LB; Wadler, S | 1 |
| Gotoh, M; Hashimoto, Y; Hoshino, Y; Kashimura, S; Kogure, M; Odashima, Y; Osuka, F; Otani, S; Saito, T; Saze, Z; Soeta, N; Terashima, M; Watanabe, K | 1 |
| Astone, A; Barone, C; Basso, M; Cassano, A; D'Argento, E; Giuliante, F; Nuzzo, G; Pozzo, C; Schinzari, G; Trigila, N | 1 |
| Cyrankiewicz, M; Kruszewski, S; Ziomkowska, B | 1 |
| Burioka, N; Fukuoka, Y; Ieiri, I; Kurai, J; Miyata, M; Otsubo, K; Shigeoka, Y; Shimizu, E; Suyama, H; Takane, H | 1 |
| Aravantinos, G; Bamias, A; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Mylonakis, N; Papakostas, P; Pavlidis, N; Samantas, E; Skarlos, D; Varthalitis, I; Xiros, N | 1 |
| Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M | 1 |
| Alnajim, J; Anantha, M; Bally, M; Ramsay, E; Waterhouse, D; Webb, M; Yan, H; Zastre, J | 1 |
| Aoe, M; Date, H; Fujii, T; Fujiwara, Y; Hotta, K; Ichimura, K; Kiura, K; Kobayashi, N; Soh, J; Suehisa, H; Toyooka, S; Yoshino, T | 1 |
| Andrews, M; Daniels, L; Dowlati, A; Green, MR; Leff, R; Willey, J; Yellamraju, L | 1 |
| Allal, AS; Andres, A; Gervaz, P; Giostra, E; Majno, PE; Mentha, G; Morel, P; Roth, AD; Rubbia-Brandt, L; Terraz, S | 1 |
| Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG | 1 |
| Carroll, C; Jones, R; Paisley, S; Tappenden, P | 1 |
| Harasym, NL; Harasym, TO; Harvie, P; Johnstone, SA; Mayer, LD; Tardi, PG | 1 |
| Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T | 1 |
| Kang, HJ; Kim, BS; Kim, WS; Park, YH; Ryoo, BY; Suh, C; Yuh, YJ | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Brandsma, D; De Jong, FA; Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Adam, R; Aloia, T; Azoulay, D; Bouchahda, M; Bralet, MP; Castagne, V; Castaing, D; de Haas, RJ; Ducreux, M; Lévi, F; Machover, D; Paule, B; Wicherts, DA | 1 |
| Adamson, PC; Bernstein, M; Blaney, SM; Bomgaars, LR; Chen, Z; Das, S; Kadota, R; Krailo, M | 1 |
| Haller, DG; Hershock, D; Hewitt, MR; Sun, W; Theobald, MR | 1 |
| Fujii, M; Hirota, M; Matsuda, C; Mikata, S; Morimoto, Y; Nishikawa, K; Tanaka, Y | 1 |
| Han, I; Hatori, S; Iwasaki, H; Murakami, H; Suzuki, M; Takanashi, Y; Yamakawa, M | 1 |
| Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
| Gounder, MK; Kulkarni, D; Nazar, AS; Pungaliya, P; Rubin, EH; Saleem, A; Versace, R | 1 |
| Bendell, JC; Czito, BG; Willett, CG | 1 |
| Bargain, A; Boulaire, JL; Ketata, S; Soulimane, B | 1 |
| Brem, S; Wong, ET | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Delaloye, S; Geist, C; Lai, A; Phelps, ME; Pope, W; Satyamurthy, N; Sayre, J; Silverman, DH | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; Quinn, JA; Reardon, DA; Rich, JN; Sampson, J; Sathornsumetee, S; Vredenburgh, JJ; Wagner, M | 1 |
| Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F | 1 |
| Akiyama, S; Gotoh, H; Gotoh, Y; Nakayama, H; Takami, H | 1 |
| Abad, A; Alonso, V; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massuti, B; Rivera, F; Tabernero, J; Vega, ME; Yuste, AL | 1 |
| Capanu, M; Gallagher, DJ; Kemeny, N; Raggio, G | 1 |
| Meric, JB | 1 |
| Ciardiello, F; Eckhardt, SG; Gustafson, DL; Henthorn, TK; Lockerbie, O; Long, M; Merz, A; Morrow, M; Serkova, NJ; Troiani, T | 1 |
| Cohen, RB; Dahlberg, S; Hidalgo, M; Johnson, DH; Lee, MW; Pandya, KJ; Schiller, JH | 1 |
| Abderrahim, AG; Bressolle, FM; Duffour, J; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Badmaev, V; Brady, W; Creaven, PJ; Fakih, MG; Pendyala, L; Prey, JD; Ross, ME; Rustum, YM; Smith, PF | 1 |
| Fukushima-Uesaka, H; Hamaguchi, T; Kamatani, N; Kaniwa, N; Kunitoh, H; Kurose, K; Minami, H; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Biesmans, B; De Hertogh, G; De Roock, W; De Schutter, J; Humblet, Y; Janssens, M; Peeters, M; Personeni, N; Piessevaux, H; Tejpar, S; Van Cutsem, E; Van Laethem, JL | 1 |
| Fischbach, W; Flieger, D; Hainke, S; Keller, R; Klassert, C; Kleinschmidt, R | 1 |
| Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N | 1 |
| Arnold, D; Lordick, F | 1 |
| Audisio, RA; Bruce, C; Köhne, CH | 1 |
| Hirano, S; Kikuchi, Y; Kouzuma, T; Saito, T; Sato, T | 1 |
| Ako, E; Kanemura, M; Kubo, N; Nishimura, S; Nobuhara, Y; Sunami, T; Yo, T | 1 |
| Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A | 1 |
| Searle, B | 1 |
| Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Sawyer, MB; Xue, H | 2 |
| Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Ando, M; Hirayama, Y; Kohda, K; Konuma, Y; Nakamura, Y; Obata, M; Seki, R; Wada, Y; Yoshida, M | 1 |
| Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
| Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
| Amadio, P; Caputo, G; Condorelli, S; Cordio, S; Germano, D; Manzione, L; Mattina, M; Reggiardo, G; Rosati, G | 1 |
| Carandina, I; Guarino, S; Lelli, G; Modonesi, C; Pedriali, M; Urbini, B | 1 |
| Saito, Y; Sawada, J | 2 |
| Nakano, T; Tomimatsu, H | 1 |
| Hasegawa, H; Kanekiyo, S; Kubo, H; Tada, K; Watanabe, Y | 1 |
| Hirohashi, S; Kaniwa, N; Kurose, K; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shirao, K; Yoshida, T | 1 |
| Abe, T; Goto, J; Hishinuma, T; Kobayashi, M; Mano, N; Okada, M; Takeuchi, T; Unno, M; Yamaguchi, H | 1 |
| Cho, EK; Chung, M; Lee, JH; Lee, SI; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Fan, D; Fidler, IJ; Kim, JS; Kim, SJ; Kitadai, Y; Kuwai, T; Langley, RR; Nakamura, T; Sasaki, T; Tsan, RZ | 1 |
| Mohile, SG; Petrylak, DP; Schleicher, L | 1 |
| Hentrich, M; Hoffmann, U; Lutz, L; Reitmeier, M; Scheidt, B; Schiel, X | 1 |
| Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY | 1 |
| Bendell, JC; Clary, BM; Gan, TJ; Hill, SE; Hurwitz, HI; Morse, MA; Reddy, SK | 1 |
| Curiel, DT; Harada, A; Harada, T; Kuroki, M; Nakanishi, Y; Sone, T; Takayama, K; Uchino, J | 1 |
| Bramhall, SR; Buckels, JA; Coldham, CA; Hubscher, SG; Mayer, AD; Mehta, NN; Mirza, DF; Ravikumar, R; Wigmore, SJ | 1 |
| Choong, NW; Ferguson, MK; Haraf, DJ; Hoffman, PC; Kasza, K; Krauss, SA; Mauer, AM; Rudin, CM; Szeto, L; Tothy, PK; Vokes, EE | 1 |
| Sugarbaker, PH | 1 |
| Bedard, V; Bouzid, T; Duvillard, P; Elias, D; Goere, D; Kohneh-Sharhi, N; Raynard, B | 1 |
| Aegerter, P; Afchain, P; André, T; Bachet, JB; Bouchahda, M; Fermanian, C; Landi, B; Levi, F; Lièvre, A; Louvet, C; Mitry, E; Rougier, P | 1 |
| Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C | 1 |
| de Jong, WK; de Jonge, MJ; Groen, HJ; van der Leest, AH; van Meerbeeck, JP | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 1 |
| Charoentum, C; Chewasakulyong, B; Euathrongchit, J; Munprakan, S; Sorraritchingchai, S; Thongprasert, S | 1 |
| Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S | 1 |
| Cao, Y; Desjardins, A; Dewhirst, MW; Friedman, HS; Herndon, JE; Marcello, JE; McLendon, RE; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Berard, E; Colosetti, P; Czerucka, D; Dreano, M; Fenouille, N; Griessinger, E; Hofman, P; Imbert, V; Lagadec, P; Mari, M; Nawrot, MP; Peyron, JF; Rousseau, D | 1 |
| Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M | 1 |
| Danks, MK; Edwards, CC; Hatfield, MJ; Houghton, PJ; Hyatt, JL; Morton, CL; Potter, PM; Redinbo, MR; Tsurkan, L; Wierdl, M | 1 |
| Fujii, S; Hayashi, R; Kawashima, M; Kiyota, N; Minami, H; Ogino, T; Ohtsu, A; Tahara, M | 1 |
| Aragane, N; Fukuno, Y; Hayashi, S; Kawaura, F; Komiya, K; Tanaka, A | 1 |
| Hatakeyama, K; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Toshima, M; Wakai, T | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Siriwittayakorn, P; Somwangprasert, A; Sukthomya, V; Tharavichitkul, E | 1 |
| Arita, A; Fujimoto, M; Mochizuki, K; Sakai, Y | 1 |
| Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M | 1 |
| Balteskard, L; Braendengen, M; Sørbye, H | 1 |
| Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K | 1 |
| Fujimoto, T; Kuhara, K; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Shimakawa, T; Umehara, A; Yokomizo, H; Yoshimatsu, K | 1 |
| Funahashi, K; Ishii, J; Kaneko, H; Koike, J; Otsuka, Y; Tamura, A; Teramoto, T; Tsuchiya, M; Watanabe, M; Yamazaki, K | 1 |
| Doi, M; Egawa, T; Hayashi, S; Ito, Y; Kitano, M; Nagashima, A; Sekine, K; Shimizu, M; Yoshii, H | 1 |
| Ide, Y; Kinuta, M; Maruyama, K; Murata, K; Ohta, H; Okada, K; Yasumoto, T; Yokouchi, H | 1 |
| Goto, H; Hayashi, N; Koseki, K; Koshiishi, H; Koshiishi, Y; Minami, T; Mori, K; Okamura, T; Sakaniwa, N; Takahashi, E; Tamamoto, F | 1 |
| Baba, M; Hayashi, N; Kakimoto, Y; Koshiishi, H; Koshiishi, Y; Minami, T; Okamura, T; Takahashi, E; Yasui, T | 1 |
| Doi, T; Handa, R; Hoshi, M; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Oshima, K; Oshima, S | 1 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohshiro, R; Ohta, K; Ohzato, H; Takemoto, H; Tatsuta, M | 1 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M | 1 |
| Han, JY; Lee, JS; Lee, SY; Lim, HS; Park, YH | 1 |
| Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G | 1 |
| Ariad, S; Gluzman, A; Lavrenkov, K; Man, S; Mermershtain, W; Rubinov, K | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Kawara, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W | 1 |
| Hamaguchi, T; Kajiwara, T; Kato, K; Matsubara, J; Moriwaki, T; Nakajima, TE; Nishina, T; Oka, T; Okayama, Y; Shimada, Y; Shimoda, T; Shirao, K; Yamada, Y | 1 |
| Barrueco, J; Fuchs, CS; Marshall, J | 1 |
| Chung, ST; Czuczman, PR; Lewis, AL; Tang, Y | 1 |
| Macdonald, JS; Mahtani, RL | 1 |
| Coqueret, O; Gamelin, E; Vigneron, A | 1 |
| Fukuda, S; Kojiro, M; Nakashima, O; Ookawa, K; Sakata, Y; Suto, K; Takahata, T; Tamura, Y; Tanaka, M; Tateishi, T; Yano, H | 1 |
| Isobe, H; Matsui, K; Mori, K; Nakagawa, K; Nishiwaki, Y; Nokihara, H; Saijo, N; Sekine, I; Takeda, K; Tamura, T | 1 |
| Félix, GM; Luis, JV; Sergio, GC | 1 |
| An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Berger, MR; Boleij, A; Eyol, E; Lewis, AL; Taylor, RR | 1 |
| Tang, X; Wang, G; Wang, Z; Wu, H; Wu, Z; Zhu, D | 1 |
| Honda, M; Imutsuka, S; Korenaga, D; Nozoe, T; Yasuda, M | 1 |
| Hahm, JR; Hwang, IG; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, SH; Lee, GW; Lee, JD; Lee, JS | 1 |
| Barrett, J; Bernstein, ML; Blaney, SM; Bomgaars, L; Gupta, M; Mondick, J; Rosner, GL; Thompson, PA; Yu, A | 1 |
| Allegrini, G; Bursi, S; Falcone, A; Fontana, A; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A | 1 |
| Caliendo, V; Ciorba, A; Ciuffreda, L; Clerico, M; Evangelista, W; Facilissimo, I; Fanchini, L; Macripò, G; Milanesi, E; Paris, M; Racca, P; Ritorto, G; Volpatto, R | 1 |
| Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M | 1 |
| Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M | 1 |
| Eastman, A; Fanous, AA; Levesque, AA; Poh, A | 1 |
| Anantha, M; Bally, MB; Meijs, M; Ramsay, EC; Strutt, D; Waterhouse, D; Webb, MS; Zastre, J; Zonderhuis, J | 1 |
| Hazama, S; Oka, M | 2 |
| Kitagawa, Y; Kitajima, M; Kubota, T; Kumagai, K; Kumai, K; Nakamura, R; Saikawa, Y; Takahashi, T | 1 |
| Chinen, T; Hirayasu, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ogawa, K; Ohta, M; Oshiro, Y; Samura, H; Teruya, J; Teruya, T; Uehara, T; Yohena, T | 1 |
| Chen, A; Chen, G; Fehrenbacher, L; Gandara, D; Huynh, M; Lau, D | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| de Jong, FA; Mathijssen, RH; Sparreboom, A; van der Bol, JM; van Gelder, T; Verweij, J; Wiemer, EA | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Barone, C; Kemeny, NE; Pozzo, C | 1 |
| Chen, PM; Chen, WS; Chiou, TJ; Jiang, JK; Lin, JK; Lin, TC; Liu, CY; Liu, JH; Wang, HS; Wang, WS | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S | 1 |
| Cervantes, A; Pfeiffer, P; Tabernero, J | 1 |
| Boige, V; Cohen, M; Delbaldo, C; Faivre, S; Namouni, F; Pautier, P; Peck, R; Raymond, E; Soria, JC | 1 |
| Cunningham, D; Jackson, C | 2 |
| Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK | 1 |
| Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Cabral-Lilly, D; Cafiso, DS; Cho, C; Dicko, A; Ellena, JF; Frazier, AA; Hinderliter, A; Liboiron, BD; Mayer, LD; Tardi, PG; Weber, T; Xie, X | 1 |
| Ahuja, G; Choudhry, I; Cuellar, S; Setty, S; Villano, JL; Yao, M | 1 |
| Blumenthal, DT; Bokstein, F; Shpigel, S | 1 |
| Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Hirao, M; Imano, M; Ishihara, R; Narahara, H; Taguchi, T; Takiuchi, H; Tsujinaka, T; Tsukuma, H; Uedo, N | 1 |
| Jung, SS; Kim, JO; Kim, SY; Lee, JE; Park, HS | 1 |
| Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M | 1 |
| Asano, T; Hayakawa, M; Horiguchi, A; Ito, K; Kakizoe, T; Koizumi, F; Matsumura, Y; Sumitomo, M | 1 |
| Breil, C; Candeil, L; Conseiller, E; Copois, V; Del Rio, M; Denis, V; Fraslon, C; Gongora, C; Martineau, P; Molina, F; Pau, B; Vezzio, N | 1 |
| Altes, A; Baiget, M; Culverhouse, R; Hoskins, JM; Marcuello, E; Marsh, S; Maxwell, T; McLeod, HL; Paré, L; Van Booven, DJ | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Iino, K; Morita, M; Sasaki, H; Tomita, K; Toyoshima, H | 1 |
| Matsuda, T; Shikata, S | 1 |
| Erichsen, TJ; Heinemann, V; Lankisch, TO; Manns, MP; Schulz, C; Strassburg, CP; Zwingers, T | 1 |
| Owzar, K | 1 |
| Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Floriani, I; Fontana, A; Giustini, L; Graziano, F; Humar, B; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Tonini, G; Torresi, U | 1 |
| Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E | 1 |
| Biswas, A; Gollins, S; Haylock, B; Iles, S; Levine, E; Myint, S; Susnerwala, S; Swindell, R | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Murray, D; Sawyer, MB; Xue, H | 1 |
| Hashimoto, K; Igishi, T; Matsumoto, S; Morita, M; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y; Yamasaki, A | 1 |
| Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD | 1 |
| Chu, E; Lee, JJ | 1 |
| Cohen, DJ; Hochster, HS | 1 |
| Allegrini, G; Barletta, MT; Bocci, G; Cerri, E; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Fioravanti, A; Kerbel, RS; Loupakis, F; Masi, G; Orlandi, P | 1 |
| Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M | 1 |
| Gao, Y; Greenberger, LM; Horak, ID; Longley, C; Lozanguiez, Y; Martinez, A; Reddy, P; Rubio, B; Sai, P; Sapra, P; Wu, D; Zhao, H | 1 |
| de Alba, PL; Durán-Merás, I; Martínez, LL; Rodríguez Cáceres, MI; Soto, NE | 1 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Bonnet, S; Boulet, T; Di Pietrantonio, D; Elias, D; Goere, D; Honore, C; Kohneh-Shahri, N; Raynard, B | 1 |
| Arakura, N; Hamano, H; Kawa, S; Komatsu, K; Muraki, T; Ozaki, Y; Tanaka, E | 1 |
| Minami, H; Sai, K; Sawada, J | 1 |
| Aitini, E; Amoroso, V; Ardizzoia, A; Bajetta, E; Bandera, M; Bidoli, P; Cortinovis, D; Cullurà, D; Fusi, A; Lorusso, V; Radula, D; Zilembo, N | 1 |
| Ambrosini, G; Qin, LX; Schwartz, GK; Seelman, SL | 1 |
| Arranz, V; Boukaissi, M; Chéné, AS; de Coupade, C; Dubois, V; Fruchart, JS; Kearsey, J; Meyer-Losic, F; Michel, M; Nicolazzi, C; Quinonero, J; Ravel, D; Ribes, F; Tranchant, I; Zoubaa, I | 1 |
| Buchsbaum, DJ; Kim, H; LoBuglio, AF; Nan, L; Oliver, PG; Wang, W; Zhou, T; Zinn, KR | 1 |
| Ishibashi, M; Kaneko, M; Kaneko, S | 1 |
| Abubakr, YA; Borg, C; Burris, HA; Eng, C; Fehrenbacher, L; Kisker, O; Kopit, J; Kröning, H; Langer, C; Lenz, HJ; Luppi, G; Lutz, MP; Maurel, J; Middleton, G; Prausova, J; Scheithauer, W; Sobrero, AF; Steinhauer, EU; Vega-Villegas, ME; Zubel, A | 1 |
| Chang, HM; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Andre, T; Bachet, JB; Bouchahda, M; Domont, J; Karaboué, A; Landi, B; Levi, F; Lledo, G; Macarulla, T; Rougier, P; Spano, JP; Tabernero, J | 1 |
| Matsumura, Y | 3 |
| Barbet, N; Falandry, C; Freyer, G; Glehen, O; Heudel, P; Romestaing, P; You, B | 1 |
| Allen, J; Kolesar, J; Mrozek, E; Shapiro, CL; Villalona-Calero, M; Young, D | 1 |
| Anzai, N; Hiruma, R; Kamide, T; Kamiya, N; Kotake, Y; Matsumoto, R; Sasaki, H; Shinozaki, H; Tada, A; Wachi, T | 1 |
| Inagaki, D; Katayama, K; Oosawa, H; Shiraishi, R; Tanabe, H; Tani, K; Wada, H; Yasuda, S | 1 |
| Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
| Gorbunova, VA; Kuz'minov, AE; Naskhletashvili, DR | 1 |
| Bodrogi, I; Collette, L; Kerst, JM; Leahy, M; Marréaud, S; Oliver, RDT; Skoneczna, I; Theodore, C; Ven, K | 1 |
| Adenis, A; Bouché, O; Conroy, T; Deligny, N; Di Fioré, F; Fournier, C; Fournier, P; Gasnault, L; Giraud, C; Hebbar, M; Joly, JP; Maes, P; Michel, P; Péreira, R; Rad, E | 1 |
| Innocenti, F; Panetta, JC; Ratain, MJ; Rosner, GL | 1 |
| Durán Merás, I; López de Alba, PL; López Martinez, L; Ornelas Soto, NE; Rodríguez Cáceres, MI | 1 |
| Fricker, J | 1 |
| Hatate, K; Ihara, A; Ikeda, A; Nakamura, T; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamanashi, T | 1 |
| Tanaka, T; Umesaki, N; Utsunomiya, H; Utsunomiya, T | 2 |
| Koga, Y; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M | 2 |
| Elinzano, H; Jin, T; Kang, TY; Peereboom, D | 1 |
| Ghandehari, H; Kolhatkar, RB; Swaan, P | 1 |
| Ahn, JB; Baik, SH; Cheon, SH; Choen, JH; Choi, HJ; Chung, HC; Jeung, HC; Keum, KC; Kim, NK; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Allegrini, G; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Fanelli, G; Fioravanti, A; Kerbel, RS; Naccarato, AG; Orlandi, P; Viacava, P | 1 |
| Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Dickinson, PJ; Drummond, D; Higgins, RJ; Kirpotin, DB; Krauze, M; Larson, RF; LeCouteur, RA; Noble, CO; Park, JW; Roberts, B; Yamashita, Y | 1 |
| Folprecht, G; Goldberg, RM; Köhne, CH; Mitry, E; Rougier, P | 1 |
| D'Angelica, MI; Fong, Y; Jarnagin, WR; Kemeny, NE; Munoz, JA; Raggio, G; Schwartz, LH; White, RR | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Kubota, T; Ochiai, H; Okabayashi, K | 1 |
| Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I | 1 |
| Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S | 1 |
| Kos, M; Mrhar, A; Obradovic, M | 1 |
| Biason, P; Masier, S; Toffoli, G | 1 |
| Atiq, OT; Dragovich, T; Hochster, H; Kozuch, PS; Lenz, HJ; O'Neil, BH; Pipas, JM; Rocha-Lima, CM; Ryan, DP | 1 |
| Feun, L; Savaraj, N | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
| Mayer, RJ; Wolpin, BM | 1 |
| Bar-Eli, M; Fan, D; Fidler, IJ; Kerbel, RS; Kim, SJ; Kuwai, T; Nakamura, T; Sasaki, T; Villares, GJ; Wang, H; Zigler, M | 1 |
| Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z | 1 |
| Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS | 1 |
| Chamberlain, MC; Glantz, MJ | 1 |
| Aulino, JM; Burkey, BB; Chung, CH; Cmelak, A; Gilbert, J; Murphy, BA; Netterville, J; Shyr, Y; Sinard, RJ; Yarbrough, WG | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Song, JE | 1 |
| Hayashi, S; Karaki, H; Sugano, I; Sugimoto, K; Suzuki, H; Takayanagi, H; Yamamori, H; Yamamoto, K | 1 |
| Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
| Ehmer, U; Lankisch, TO; Manns, MP; Strassburg, CP | 1 |
| Friedman, HS; Malone, S; Petros, WP; Schaaf, LJ; Younis, IR | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Ferreud, L; Holmlund, B; Sun, XF; Svanvik, J; Wallin, A | 1 |
| Gao, K; Lam, W; Li, G; Li, J; Lockwood, WW | 1 |
| Chang, HM; Kang, BW; Kang, YK; Kim, JC; Kim, JH; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Yu, CS | 1 |
| Heinemann, V; Moosmann, N | 1 |
| Duffy, A; Fong, Y; Huitzil-Melendez, FD; O'Reilly, EM; Shia, J | 1 |
| Agarwal, M; Beer, TM; Crawford, ED; Goldman, B; Nichols, CR; Petrylak, DP; Ryan, CW | 1 |
| Alami, N; Jerome, L; Leyland-Jones, B; Page, V; Paterson, J; Shiry, L; Yu, Q | 1 |
| Innocenti, F; Perera, MA; Ratain, MJ | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Ames, MM; Dai, NT; Flatten, KS; Gálvez-Peralta, M; Karnitz, LM; Kaufmann, SH; Loegering, DA; Safgren, SL; Wagner, JM | 1 |
| Adlard, JW; Barrett, JH; Braun, MS; Daly, C; Elliott, F; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Selby, P; Seymour, MT; Stephens, RJ | 1 |
| Baba, S; Chin, K; Hatake, K; Hosaka, H; Ishiyama, A; Kozuka, T; Mizunuma, N; Seto, Y; Shinozaki, E; Suenaga, M; Yamamoto, N | 1 |
| Colbeck, M; Hewett, P; Luke, C; Maddern, G; Patterson, W; Pittman, K; Price, T; Rieger, N; Rodda, D; Roder, D; Townsend, A | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Ayadi, M; Bertucci, F; Birnbaum, D; Borg, JP; Delpero, JR; Esterni, B; Esteyries, S; Gonçalves, A; Lagarde, A; Lelong, B; Monges, G; Olschwang, S; Taylor-Smedra, B; Turrini, O; Viens, P; Viret, F | 1 |
| Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Gelderblom, H; Guchelaar, HJ; Kweekel, D | 1 |
| Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
| Aguilar, J; Beviglia, L; Chartier, C; Clarke, MF; Dylla, SJ; Gurney, AL; Hoey, T; Lazetic, S; Lewicki, J; Ngan, L; Park, IK; Pickell, K; Raval, J; Smith-Berdan, S | 1 |
| Georgiades, CC; Geschwind, JF; Hong, K; Lee, KH; Liapi, E | 1 |
| Alvarez Z, M; González D, R; Jarufe C, N; Martínez C, J | 1 |
| Lin, LC; Tsai, TH; Wang, MN | 1 |
| Adamo, V; Battistoni, F; Dicuonzo, G; Fulfaro, F; Galluzzo, S; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB | 1 |
| Creaven, PJ; Gottlieb, RH; Iyer, RV; Khushalani, NI; Ramnath, N; Rustum, YM; Schwarz, JK; Yu, J | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T | 1 |
| Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E | 1 |
| Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
| Banzi, C; Biasco, G; Bonetti, F; Boni, C; Brandes, A; Calandri, C; Carandina, I; Cataldo, S; DI Fabio, F; Lelli, G; Marzola, M; Nanni, O; Negri, F; Panetta, A; Pantaleo, MA; Ravaioli, E; Turci, D; Urbini, B | 1 |
| Berger, MR; Ehrenberg, R; Galle, PR; Heeger, S; Hickmann, L; Moehler, M; Schad, A; Schimanski, CC; Schulze-Bergkamen, H; Urbanik, T; Vick, B; Weber, A | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 1 |
| Barone, C; Pozzo, C | 1 |
| Fakih, MG; Patel, A; Puthillath, A; Yang, G | 1 |
| Awasthi, A; Bansal, T; Jaggi, M; Khar, RK; Talegaonkar, S | 2 |
| Duhoux, F; Mano, MS | 1 |
| Sharma, RI; Smith, TA | 1 |
| Miya, T; Morimoto, Y; Ooi, K; Sasaki, H | 1 |
| Asagawa, T; Higaki, R; Ishii, H; Itou, M; Kobashi, K; Miyazaki, F; Murakami, M; Ninomiya, H; Noguchi, T; Tsunemitsu, K | 1 |
| Aoki, Y; Furuta, R; Hibi, S; Ina, K; Kabeya, M; Kataoka, T; Kawai, M; Kayukawa, S; Kojima, S; Masaki, A; Mori, F; Nagao, S; Yamada, K | 1 |
| Fukazawa, A; Hayashi, T; Konno, H; Kurachi, K; Nakajima, A; Nakamura, K; Nakamura, T; Suzuki, S | 2 |
| Inui, K; Onoue, M | 1 |
| Igarashi, T; Imai, H; Iwabuchi, T; Matsumoto, H; Obana, N; Ooyauchi, M; Sakamoto, K; Satou, Y | 1 |
| Arai, H; Kashiwabara, M; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Mizutani, T; Nishi, Y; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T | 1 |
| Fukai, H; Ichikawa, G; Kita, E; Kuwana, Y; Matsumoto, H; Nakayama, Y; Ohta, Y; Takami, M; Takimoto, T; Yamamoto, T | 1 |
| Ito, N; Kamba, T; Kamoto, T; Kanematsu, A; Masui, K; Nakamura, E; Nishiyama, H; Ogawa, O; Soda, T; Watanabe, J; Yoshimura, K | 1 |
| Bafaloukos, D; Bamias, A; Basdanis, G; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Karanikiotis, C; Kardamakis, D; Karina, M; Koutras, A; Misailidou, D; Papadimitriou, C; Papakostas, P; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Skarlos, DV; Stavropoulos, M; Vourli, G | 1 |
| Cuvillier, O; Doumerc, N; Golzio, M; Kohama, T; Malavaud, B; Naymark, M; Pchejetski, D; Teissié, J; Waxman, J | 1 |
| Healey-Bird, BR; Kemeny, NE; Power, DG | 1 |
| Cianci, G; Cortesi, E; D'Auria, G; Gamucci, T; Grassi, G; Moscetti, L; Nelli, F; Pollera, CF; Sperduti, I; Zeuli, M | 1 |
| Anthony, L | 1 |
| Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW | 1 |
| Dai, H; Liu, Z; Robinson, JT; Sun, X | 1 |
| Bosch, A; Cervantes, A; Chirivella, I; Martín-Martorell, P; Rodríguez-Braun, E; Roselló, S | 1 |
| Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A | 1 |
| Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K | 1 |
| Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I | 1 |
| Ahmad, A; Ali, SA; Bejjani, G; Braffet, M; Friedland, DM; McHayleh, WM; Rahman, M; Sehgal, R | 1 |
| Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M | 1 |
| Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G | 1 |
| Eguchi, K; Isobe, H; Kunikane, H; Masuda, N; Ogura, T; Shibuya, M; Takahashi, T; Takeda, Y; Watanabe, K; Yamamoto, N; Yokoyama, A | 1 |
| Barbas, AS; Bendell, JC; Broadwater, G; Clary, BM; Hurwitz, HI; Morse, MA; Niedzwiecki, D; Reddy, SK | 1 |
| Frei, CR; Greene, RE; Koeller, JM; Kwan, P; McKibbin, T; Simon, J | 1 |
| Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J | 1 |
| Akagi, Y; Ishibashi, N; Mizobe, T; Mori, S; Murakami, H; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Gotoh, M; Hattori, R; Komatsu, T; Matsukawa, Y; Sassa, N; Yamamoto, T; Yoshikawa, Y; Yoshino, Y | 1 |
| Betta, PG; Catalano, A; Lazzarini, R; Moretti, S; Orecchia, S; Procopio, A | 1 |
| Ebi, N; Fukuoka, M; Katakami, N; Kubo, A; Miyazaki, M; Nakagawa, K; Nishimura, T; Okamoto, I; Sugawara, S; Takeda, K; Yoshioka, H | 1 |
| Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
| Andrews, C; Belicha-Villanueva, A; Gibbs, JF; Hylander, BL; Repasky, EA; Sugamura, K | 1 |
| Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M | 1 |
| Deeken, JF; Marshall, JL; Slack, R | 1 |
| Hatfield, JM; Potter, PM; Wadkins, RM; Wierdl, M | 1 |
| Díaz-Rubio, E; García-Saenz, JA; Puente, J; Sastre, J | 1 |
| Komatsu, Y; Munakata, M; Muto, O; Sakata, Y; Shimaya, S; Shitara, K; Yuki, S | 1 |
| Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JS; Lim, KY; Yoon, SJ | 1 |
| Cox, A; Hansen, LT; Helleday, T; Meuth, M; Phear, G; Rodriguez, R; Scorah, J; Spang-Thomsen, M | 1 |
| Buie, LW; Valgus, J | 1 |
| Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA | 1 |
| Ding, J; Iida, S; Inagaki, A; Inagaki, H; Ishida, T; Ito, A; Kayukawa, S; Komatsu, H; Kusumoto, S; Mori, F; Nakagawa, C; Oguri, T; Ri, M; Sanda, T; Suzuki, A; Ueda, R; Yano, H | 1 |
| Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG | 1 |
| Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C | 1 |
| Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ | 1 |
| Aasebø, U; Bergman, B; Bremnes, R; Ek, L; Fluge, S; Hermes, A; Sederholm, C; Sörenson, S; Sundstrøm, S; Thaning, L; Vilsvik, J | 1 |
| Desjardins, A; Friedman, HS; Reardon, DA; Vredenburgh, JJ | 1 |
| Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y | 1 |
| Castellano, V; Moreno, F; Ruiz-Casado, A | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Boisdron-Celle, M; Charasson, V; Chatelut, E; Delord, JP; Fonck, M; Gamelin, E; Laurand, A; Morel, A; Pétain, A; Poirier, AL; Robert, J; Rouits, E | 1 |
| Nariai, H; Natsumeda, T; Oto, Y; Sato, Y; Shitara, T; Taniuchi, M | 1 |
| Abe, T; Fukushima, T; Hamaguchi, Y; Masui, H; Mogaki, M; Nagahori, K; Nagahori, Y | 1 |
| Adachi, K; Arimoto, Y; Nishio, K; Ohba, H; Ohtani, H; Shintani, M; Yui, S | 1 |
| Ishii, Y; Mado, K; Manmoto, J; Masuda, H; Mazaki, T; Okame, H; Suzuki, K; Takayama, T | 1 |
| Jonsson, EN; Karlsson, MO; Kjellsson, MC; Zingmark, PH | 1 |
| Assadourian, S; Brooks, M; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Giammarile, F; Michon, J; Morland, B; Pichon, F; Rubie, H; Schell, M; Stockdale, E; Vassal, G | 1 |
| Asahara, T; Fukui, T; Iwasaki, M; Katono, K; Kurita, A; Masuda, N; Mitsufuji, H; Nishii, Y; Onoda, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yokoba, M | 1 |
| Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK | 1 |
| Alan, H; Chou, TC; Schwartz, GK; Sheikh, TN; Tse, AN | 1 |
| Choi, J; Gump, J; Lacevic, M; Lee, JH; Lush, R; Minton, S; Moulder, S; Munster, P; Neuger, A; Sullivan, D; Valkov, N | 1 |
| Grothey, A; Sargent, DJ | 1 |
| Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO | 1 |
| Ikegami, Y; Ito, A; Kohno, S; Nakamura, Y; Nakano, H; Oka, M; Sano, K; Satake, K; Sawada, S; Soda, H; Yoshida, H; Yoshikawa, M | 1 |
| Arai, T; Boku, N; Inaba, Y; Komatsu, Y; Mizunuma, N; Nishina, T; Sakata, Y; Satoh, T; Shirao, K; Tahara, M; Takiuchi, H; Yamaguchi, K | 1 |
| Berlin, JD; Chan, E; Goff, LW; Lockhart, AC; Roth, BJ; Rothenberg, ML; VerMeulen, WL | 1 |
| Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E | 1 |
| Chang, MH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lee, JK; Lee, KT; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY | 1 |
| Drappatz, J; Norden, AD; Wen, PY | 1 |
| Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M | 1 |
| Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ | 1 |
| Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A | 1 |
| Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J | 1 |
| Aapro, MS; Adenis, A; Aguilar, EA; Esser, R; Glynne-Jones, R; Loos, AH; Preusser, P; Siena, S; Thaler, J; Wilke, H | 2 |
| Ayuso, JR; Castells, A; Conill, C; de Lacy, A; Delgado, S; Gallego, R; Ginés, A; Maurel, J; Miquel, R; Tosca, M; Ugidos, L | 1 |
| Bekaii-Saab, T; Haghighat, P | 1 |
| Allen, WL; Coyle, VM; Fenning, C; Gordon, M; Jithesh, PV; Johnston, PG; Lenz, HJ; Longley, DB; Proutski, I; Stevenson, L; Wilson, RH | 1 |
| Brown, K; Carvajal, R; Chung, K; Egorin, MJ; Gonen, M; Kelsen, D; Klimstra, DS; Lefkowitz, R; Maki, R; Manova-Todorova, K; Mui, J; O'Reilly, E; Schwartz, GK; Shah, M; Sheikh, T; Sikorski, R; Tipian, C; Tse, AN; Wu, N | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Chen, G; Han, X; Liang, F; Liu, Y; Ma, D; Ma, X; Meng, L; Qin, X; Song, X; Wang, S; Weng, D; Weng, Y; Xia, X; Xing, H; Xu, G; Zhou, J | 1 |
| Iwakiri, K; Kobayashi, S; Kuramochi, K; Kusayanagi, T; Manita, D; Miyano, Y; Nakazaki, A; Ozawa, H; Sakaguchi, K; Sugawara, F; Takagi, M; Takakusagi, K; Takakusagi, Y | 1 |
| Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuzawa, T; Mishima, H; Nakamori, S; Takeda, M; Tsujinaka, T | 1 |
| Aoki, Y; Kobayashi, J; Mori, M; Morishima, Y; Nakano, M; Satomi, D; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yoshida, Y | 1 |
| Abdalla, EK; Blazer, DG; Chang, DZ; Chun, YS; Curley, SA; Ellis, LM; Eng, C; Fogelman, D; Glover, KY; Kishi, Y; Kopetz, S; Maru, DM; Overman, MJ; Ribero, D; Vauthey, JN; Wang, H; Wolff, RA; Zorzi, D | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Cardillo, TM; D'Souza, CA; Goldenberg, DM; Govindan, SV; Hansen, HJ; Moon, SJ | 1 |
| Arribas, J; Balmaña, J; Baselga, J; Guzman, M; Saura, C; Scaltriti, M; Tabernero, J; Vilar, E | 1 |
| Gaud, R; Shende, P | 1 |
| D'Esposito, F; Murray, M; Ramzan, I; Tattam, BN | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Anderson, J; Doyle, T; Ellika, S; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Ilson, DH; Kelsen, DP; Kepler, S; O'Reilly, E; Radovich, D; Saltz, LB; Schrag, D; Schwartz, G; Tew, WP | 1 |
| Furukawa, T; Ishikawa, T; Morishima, Y; Nakagawa, H; Osawa, Y; Tamura, A; Wakabayashi, K | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; Quinn, JA; Reardon, DA; Rich, JN; Sampson, J; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K | 1 |
| Li, M; Lou, L; Tang, W; You, T; Zeng, F | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Nakashima, K; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Delattre, JY; Omuro, AM | 1 |
| Hosoi, H; Iehara, T; Misawa, A; Osone, S; Sugimoto, T; Tsuchiya, K | 1 |
| Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA | 1 |
| Kijima, H; Kusumi, T; Nakamura, M; Nishime, C; Ohnishi, Y; Sato, F; Suemizu, H; Tamaoki, N; Ueyama, Y; Yamazaki, H | 1 |
| Higuchi, S; Ieiri, I; Kawamoto, K; Kitano, H; Moriki, K; Otsubo, K; Sasaki, T; Takane, H | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Laurence, J; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Boige, V; Ducreux, M; Laurent-Puig, P; Malka, D | 1 |
| Ducreux, M; Laurent-Puig, P; Lièvre, A; Loriot, MA | 1 |
| Adam, MJ; Anantha, M; Baker, JH; Bally, MB; Co, SJ; Dragowska, WH; Kozlowski, P; Kyle, AH; Lam, J; Minchinton, AI; Ng, SS; Oliver, T; Ramsay, E; Ruth, TJ; Sy, J; Yapp, DT; Yung, A | 1 |
| Hamaguchi, T; Kato, K; Matsumura, Y; Mihara, K; Nakajima, TE; Ochiya, T; Shimada, Y; Takigahira, M; Yamada, Y; Yanagihara, K; Yasunaga, M | 1 |
| Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
| Fujii, Y; Ishiguro, H; Kimura, M; Kuwabara, Y; Mitsui, A; Ogawa, R | 1 |
| Aoki, K; Hoshikawa, K; Nitta, H; Noda, H; Oyama, K; Wakabayashi, G | 1 |
| Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T | 1 |
| Srinivas, NR | 1 |
| Auman, JT; McLeod, HL; Yen-Revollo, JL | 1 |
| Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S | 1 |
| Grunnet, K; Hasselbalch, B; Kosteljanetz, M; Lassen, U; Nelausen, K; Olsen, P; Poulsen, HS; Sorensen, M | 1 |
| Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S | 1 |
| Blumgart, LH; D'Angelica, M; DeMatteo, RP; Fahy, BN; Gonen, M; Jarnagin, WR; Ostrovnaya, I; Weiser, MR | 1 |
| Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL | 1 |
| Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M | 1 |
| Hurwitz, HI; Kabbinavar, FF; Rosen, O; Sarkar, S; Yi, J | 1 |
| Ames, MM; Buckner, JC; Felten, SJ; Galanis, E; Jaeckle, KA; Nikcevich, DA; Reid, JM; Santisteban, M; Scheithauer, BW; Wiesenfeld, M; Wu, W | 1 |
| Cicin, I; Sezer, A; Usta, U | 1 |
| Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S | 1 |
| Huang, S; Okumura, K; Sinicrope, FA | 1 |
| Ando, M; Arioka, H; Fujiwara, Y; Hirakawa, A; Hirata, T; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Tamura, K; Yamanaka, Y; Yonemori, K; Yunokawa, M | 1 |
| Angiolillo, A; Cohen, MB; Gorlick, R; Jakacki, R; Levy, AS; Meyers, PA; Ringuette, SN; Wexler, LH | 1 |
| Jover, R; Sempere, L | 1 |
| Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Khan, AZ; Makuuchi, M; Morris-Stiff, G | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Gerogianni, A; Pallis, AG; Papakotoulas, P; Pavlakou, G; Rapti, A; Varthalitis, I | 1 |
| Mitry, E | 1 |
| Bonastre, J; Brouquet, A; Chevalier, J; Classe, JM; Elias, D; Ferron, G; Goéré, D; Guilloit, JM; Lefevre, JH; Marchal, F; Meeus, P | 1 |
| Assersohn, L; Brown, G; Chong, G; Costello, C; Cunningham, D; Higgins, L; Leary, A; Norman, AR; Oates, J; Ross, PJ | 1 |
| Doi, T; Hoshi, M; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Oshima, S | 1 |
| Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ota, K; Tatsuta, M | 1 |
| Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
| Kanazawa, T; Matsubara, M; Matsushita, K; Mukohara, Y; Nozaki, A; Oka, H; Tokumitsu, S; Tsunashima, T | 1 |
| Fujimoto, T; Nakamura, Y; Ogawa, K; Osawa, G; Otani, T; Tsunoda, T; Yokomizo, H; Yoshimatsu, K | 1 |
| Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M | 1 |
| Amado, RG; Chidiac, T; Cohn, A; Deeter, R; Hagenstad, C; Hecht, JR; Marshall, J; McCollum, D; Mitchell, E; Scroggin, C; Shahin, S; Spigel, D; Stella, P | 1 |
| Albert, PS; Butman, JA; Camphausen, K; Duic, P; Fine, HA; Garren, N; Kim, L; Kreisl, TN; Mackey, M; Moore, K; Park, J; Royce, C; Stroud, I | 1 |
| Hsu, CW; King, TM; Lin, CH; Ou, WC; Wang, HT; Wang, JH | 1 |
| Bradley, LA; Dotson, WD; Douglas, MP; Kolor, K; Palomaki, GE | 1 |
| Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C | 1 |
| Chin, K; Hatake, K; Konishi, F; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T | 1 |
| Eguchi-Nakajima, T; Hamaguchi, T; Hirashima, Y; Kato, K; Morizane, C; Okita, N; Ono, M; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Bansal, T; Jaggi, M; Khar, RK; Mishra, G; Talegaonkar, S | 1 |
| Blaszkowsky, LS; Clark, JW; Earle, CC; Enzinger, PC; Fidias, P; Fuchs, CS; Kulke, MH; Mayer, RJ; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Vincitore, MM; Zhu, AX | 1 |
| Loutfi, R; Mikkelsen, T; Torcuator, R; Zuniga, R | 1 |
| Hurwitz, HI; Ince, W; Novotny, WF; Rosen, O; Yi, J | 1 |
| Batist, G; Chi, KN; Chia, SK; Gelmon, KA; Janoff, AS; Louie, AC; Mayer, LD; Miller, WH; Swenson, CE | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Buffart, TE; Carvalho, B; Eijk, PP; Koopman, M; Meijer, GA; Peters, GJ; Postma, C; Punt, CJ; van Krieken, JH; Ylstra, B | 1 |
| Fukumoto, T; Hachiya, O; Kamio, Y; Kimura, W; Nomura, T; Shibata, K; Takasu, N | 1 |
| Hirano, N; Hoteya, S; Iizuka, T; Kikuchi, D; Yahagi, N | 1 |
| Al-Rejaie, SS; Al-Shabanah, OA; Al-Yahya, AA; Aleisa, AM; Ashour, AE; Attia, SM; Bakheet, SA | 1 |
| André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C | 1 |
| Angeliki, D; Bonakis, A; Christodoulou, C; Drougou, A; Galani, E; Klouvas, G; Skarlos, D | 1 |
| Bibeau, F; Blanchard, F; Boissière-Michot, F; Di Fiore, F; Frébourg, T; Lamy, A; Lopez-Crapez, E; Michel, P; Penault-Llorca, F; Sabourin, JC; Thezenas, S; Ychou, M | 1 |
| Berglund, A; Byström, P; Frödin, JE; Garske, U; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A | 1 |
| Antonini, NF; Hoogerbrugge, N; Koopman, M; Kortman, GA; Ligtenberg, MJ; Mekenkamp, L; Punt, CJ; van Krieken, JH | 1 |
| Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V | 1 |
| Cohen, B; Fisher, MJ; Horn, M; Jakacki, R; MacDonald, T; Packer, RJ; Rood, B; Vezina, G | 1 |
| Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ | 1 |
| Adamson, PC; Blaney, SM; Furman, WL; Ivy, P; Krailo, MD; McGregor, LM; Schaiquevich, P; Speights, R; Spunt, SL; Stewart, CF | 1 |
| Crews, KR; Daldrup-Link, HE; Groshen, S; Hawkins, RA; Jackson, HA; Maris, JM; Matthay, KK; Park, JR; Reynolds, CP; Stewart, CF; Villablanca, JG; Wagner, LM | 1 |
| Mayo, MS; Smith, HJ; Watkins, JF; Williamson, SK | 1 |
| Andersen, RF; Crüger, D; Garm Spindler, KL; Jakobsen, A; Lindebjerg, J; Pallisgaard, N; Rasmussen, AA | 1 |
| Becouarn, Y; Bedenne, L; Bouché, O; Bugat, R; Conroy, T; Douillard, JY; Ducreux, M; Gamelin, E; Gourgou-Bourgade, S; Kramar, A; Mineur, L; Raoul, JL; Seitz, JF; Viret, F; Ychou, M | 1 |
| Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH | 1 |
| Cannone, M; Casaretti, R; Comella, P; Franco, L; Greco, E; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Palmeri, S; Putzu, C; Roselli, M; Sandomenico, C; Vessia, G | 1 |
| Koga, Y; Kuratsu, J; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M | 1 |
| Gaub, MP; Guenot, D; Guérin, E; Larsen, AK; Lelong-Rebel, I; Nicolet, C; Oudet, P; Pencreach, E; Voegeli, AC | 1 |
| Burckhardt, G; Eckardt, R; Grottker, J; Gupta, S; Hagos, Y; Koepsell, H; Müller, GA; Shnitsar, V | 1 |
| Boesler, B; Czock, D; Keller, F; Rasche, FM; Shipkova, M | 1 |
| Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M | 1 |
| Horibe, S; Kitada, N; Nishiguchi, K; Ohnishi, N; Sakaeda, T; Takara, K; Yamamoto, K; Yokoyama, T; Yoshikawa, E | 1 |
| Fakih, MG; Rustum, YM | 1 |
| Bhushan, S; McLeod, H; Walko, CM | 1 |
| Chen, G; Fehrenbacher, L; Gandara, D; Goldstein, D; Huynh, M; Lara, PN; Lau, D; Russin, M; West, H; Yavorkovsky, LL | 1 |
| Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D | 1 |
| Ambrosi, A; Calise, S; Costantino, E; Esposito, F; Fersini, A; Landriscina, M; Maddalena, F; Neri, V; Piscazzi, A; Tirino, V | 1 |
| Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D | 1 |
| Ahn, JS; Ahn, MJ; Chang, MH; Hwang, IG; Ji, SH; Jun, HJ; Kim, HS; Kim, KH; Lee, J; Lim, DH; Park, K; Park, MJ; Park, YH; Uhm, JE; Yi, SY | 1 |
| Bachet, JB; Lièvre, A; Mitry, E; Rougier, P | 1 |
| Fujimoto, H; Kawaguchi, K; Ohta, K; Seo, N; Urayama, M | 1 |
| Katoh, M; Nakajima, M; Saitoh, T; Takahashi, S; Yokoi, T | 1 |
| Honda, Y; Ishida, T; Ishimoto, O; Munakata, M; Sugawara, S | 1 |
| Akagi, T; Aramaki, H; Fujii, A; Fukagawa, T; Higuchi, S; Iba, H; Ikemura, T; Kage, Y; Koyanagi, S; Matsunaga, N; Ohdo, S; To, H; Uchida, A | 1 |
| Ben-Haim, M; Figer, A; Geva, R; Klausner, JM; Lubezky, N; Nakache, R; Shmueli, E | 1 |
| Milicević, M; Popov, I; Radosević-Jelić, Lj | 1 |
| Mehta, RS; Raj, KP; Sanati, H; Zell, JA | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Le Roy, S; Sawyer, MB; Xue, H | 1 |
| Koopman, M; Punt, CJ; Seymour, MT | 1 |
| Alessandroni, P; Baldelli, AM; Bisonni, R; Catalano, V; D'Emidio, S; Falcone, A; Fedeli, SL; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Mari, D; Rossi, D; Silva, RR; Torresi, U | 1 |
| Grènman, S; Miettinen, S; Ylikomi, T | 1 |
| Daidoji, T; Hu, M; Kulkarni, KH; Tang, L; Wang, JR; Wang, SW; Yin, T; Yokota, H | 1 |
| Chung, CH; Kim, DM; Kim, HL; Park, CY | 1 |
| Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS | 1 |
| Fukuda, M; Koike, A; Ohta, T; Takeshita, T; Wu, W | 1 |
| de Stanchina, E; Nair, JS; Schwartz, GK | 1 |
| Cohen, MH; Giusti, RM; Keegan, P; Pazdur, R | 1 |
| Cohen, SJ; Doyle, GV; Gabrail, NY; Iannotti, N; Meropol, NJ; Miller, MC; Mitchell, E; Morse, MA; Picus, J; Punt, CJ; Sabbath, KD; Saidman, BH; Terstappen, LW; Tissing, H | 1 |
| Asahi, D; Doi, T; Hamamoto, Y; Muro, K; Shirao, K; Takiuchi, H; Watanabe, H; Yang, BB; Yoshino, T | 1 |
| Akira, S; Li, L; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Hasegawa, K; Kokawa, K; Konishi, I; Nishida, M; Nishimura, R; Noguchi, H; Saji, F; Takizawa, K; Umesaki, N; Yamamoto, K | 1 |
| Nadai, M; Palù, G; Palumbo, M; Richter, SN | 1 |
| Biasco, G; Brandi, G; de Rosa, F | 1 |
| Fujiwara, K; Furuya, K; Goto, T; Hirata, J; Horie, K; Ishii, K; Kato, M; Kikuchi, Y; Kino, N; Kita, T; Sasaki, N; Takahashi, M; Takano, M; Yokota, H; Yoshikawa, T | 1 |
| Hayashi, Y; Hirato, J; Kuroiwa, M; Park, MJ; Sakamoto, J; Shimada, A; Sotomatsu, M; Suzuki, N | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Dehais, C; Laigle-Donadey, F; Mazeron, JJ; Sanson, M | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Ono, A; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Aoun, N; Baz, W; Burton, J; El-Soueidi, R; Forte, F; Lowry, J; Nakhl, F | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Chen, GQ; Cheng, JK; Han, YH; Liao, SH; Wang, LS; Wang, XL; Xia, L; Zheng, Y | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kolinsky, K; Packman, K; Zhang, YE | 1 |
| Ding, W; Hakoshima, M; Hattori, Y; Kawano, K; Koga, K; Maitani, Y; Shi, L | 1 |
| Eng, C | 4 |
| Castillo, C; Cendoya, I; Fernández, E; Fernández, JL; Gil, A; Gómez Martínez de Lecea, C; Gómez Portilla, A; Guede, N; Kvadatze, M; Larrabide, I; Lirola, A; Magrach, L; Martín, E; Martínez de Lecea, C; Moraza, N; Muriel, J; Olabarría, I; Romero, E; Rua, O; Ruiz de Alegría, N; Ulibarrena, MA; Valdovinos, M | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A | 1 |
| Ando, M; Gemma, A; Hino, M; Isobe, K; Kobayashi, K; Kosaihira, S; Kurimoto, F; Miyanaga, A; Mori, G; Nagai, Y; Sakai, H; Uchida, Y; Yamaguchi, T | 1 |
| Ducreux, M; Hebbar, M; Ychou, M | 1 |
| Gurney, H; Mathijssen, RH | 1 |
| Chen, P; Das, S; Dolan, ME; Innocenti, F; Kroetz, DL; Ramírez, J; Ratain, MJ; Relling, M; Rosner, GL; Schuetz, E | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Fazzone, W; Gordon, M; Iqbal, S; Ladner, RD; Lenz, HJ; Lurje, G; Press, OA; Rhodes, KE; Schultheis, AM; Vallböhmer, D; Yang, D; Zhang, W | 1 |
| Italiano, A; Sablin, MP; Spano, JP | 1 |
| Chang, MH; Ji, SH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lim, DH; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY | 1 |
| Endo, M; Fukuda, H; Itezono, Y; Kawashima, A; Kobayashi, K; Kohchi, M; Miyazaki, Y; Murasaki, C; Murata, T; Nagao, S; Namba, E; Niizuma, S; Ogawa, K; Ohwada, J; Okabe, H; Ori, K; Ozawa, S; Shimma, N; Suda, H; Tanimura, H; Tsukazaki, M; Umeda, I; Ura, M; Yoshinari, K | 1 |
| Hoskins, JM; McLeod, HL | 1 |
| Akaji, K; Dai, P; Harada, Y; Nosaka, K; Ogawa, M; Takamatsu, T; Tanaka, H; Yamaoka, Y | 1 |
| Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL | 1 |
| Biesmans, B; Claes, B; De Roock, W; De Schutter, J; Jacobs, B; Lambrechts, D; Prenen, H; Tejpar, S; Van Cutsem, E | 1 |
| Bonfill Cosp, X; López, JJ; Martin-Richard, M; Roqué I Figuls, M; Solà, I | 1 |
| Chen, KC; Prijovich, ZM; Roffler, SR | 1 |
| Alberts, SR; Fitch, TR; Goldberg, RM; Kim, GP; Mahoney, MR; Mathews, AP; Mitchell, E; Philip, PA; Pitot, HC; Rowland, KM; Sargent, DJ | 1 |
| Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S; Tanaka, S | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Sobrero, A | 1 |
| Fukushima, M; Inui, K; Kanai, M; Katsura, T; Kobayashi, M; Matsumoto, S; Nishimura, T; Onoue, M; Shimizu, A; Terada, T; Teramukai, S; Yanagihara, K | 1 |
| Lai, PS; Lin, FH; Peng, CL; Shieh, MJ; Yueh-Hsiu Wu, S | 1 |
| Campani, D; Canestrari, E; Cascinu, S; Cremolini, C; Falcone, A; Floriani, I; Funel, N; Graziano, F; Loupakis, F; Magnani, M; Masi, G; Petrini, I; Pollina, L; Rulli, E; Ruzzo, A; Santini, D; Scartozzi, M; Schiavon, G; Stasi, I; Tonini, G | 1 |
| Drolet, P; Dubé, P; Leblanc, G; Leclerc, YE; Mitchell, A; Sideris, L | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Bellanger, A; Carpentier, C; Dehais, C; Delattre, JY; Granger, B; Guillevin, R; Hoang-Xuan, K; Laigle-Donadey, F; Marie, Y; Meng, Y; Mokhtari, K; Psimaras, D; Rousseau, A; Sanson, M; Sierra del Rio, M; Taillibert, S; Vincent, LA | 1 |
| Fujishima, M; Hasegawa, H; Kosumi, T; Ohta, Y; Yonekura, T | 1 |
| Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L | 1 |
| Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K | 1 |
| Demetter, P; Geurs, F; Knape, S; Ponette, J; Ponette, S; Vandewaeter, S | 1 |
| Alonso, MM; Bhat, KP; Colman, H; Fueyo, J; Gomez-Manzano, C; Gumin, J; Lang, FF; Lee, OH; Liu, D; Martin, V; Pabbisetty, SK; Xu, J | 1 |
| Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S | 1 |
| James, E; Saif, MW; Waldron-Lynch, MG | 1 |
| Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kaehler, G; Muessle, B; Post, S; Stroebel, P; Wenz, F; Willeke, F; Woernle, C | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Brunetti, IM; Bursi, S; Chiara, S; Cupini, S; Di Donato, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Korbakis, D; Scorilas, A | 1 |
| Blackhall, FH; Ferraldeschi, R; Hadfield, KD; Minchell, LJ; Mullamitha, S; Newman, WG; Roberts, SA; Saunders, M; Tobi, S; Valle, J; Wilson, G | 1 |
| André, T; Aranda, E; Barone, C; Bodoky, G; Bokemeyer, C; Cisar, L; Collette, L; Cunningham, D; Di Costanzo, F; Greil, R; Khayat, D; Labianca, R; Mini, E; Nordlinger, B; Roth, AD; Sobrero, AF; Tabernero, J; Topham, C; Van Cutsem, E; Zhang, X | 1 |
| Polansky, M; Ross, AC | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Holland, D; Koppel, J; Porter, GA; Sutherland, FR | 1 |
| Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S | 1 |
| Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y | 1 |
| Shimizu, H; Yamaguchi, Y; Yoneda, E | 1 |
| Hihara, J; Mizuiri, H; Okada, M | 1 |
| Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T | 1 |
| Buyse, M; De Roock, W; Piessevaux, H; Prenen, H; Schlichting, M; Tejpar, S; Van Cutsem, E | 1 |
| Coward, L; Gary, BD; Gorman, G; Hobrath, JV; Keeton, AB; Li, Y; Mathew, B; Maxuitenko, YY; Piazza, GA; Reynolds, RC; Sani, B; Thaiparambil, J; Tinsley, HN; Whitt, JD | 1 |
| Capanu, M; D'Angelica, M; Fong, Y; Jarnagin, WR; Kemeny, NE; Melendez, FD; Patel, D; Paty, PB; Schwartz, LH | 1 |
| Koopman, M; Nagtegaal, ID; Punt, CJ; van Krieken, JH; Venderbosch, S | 1 |
| Appel, DI; Jiang, Y; Markowitz, JS; Zhu, HJ | 1 |
| Kannerup, AS; Knudsen, AR; Mortensen, FV; Nielsen, DT | 1 |
| Miettinen, S; Ylikomi, T | 1 |
| Endo, M; Miwa, M; Miyazaki, Y; Murata, T; Nagao, S; Nanba, E; Niizuma, S; Ogawa, K; Ohwada, J; Ozawa, S; Shimma, N; Suda, H; Taniguchi, K; Tanimura, H; Tsukazaki, M; Ura, M; Yamada-Okabe, H | 1 |
| Azzariti, A; Berardi, F; Colabufo, NA; D'Incalci, M; Paradiso, A; Perrone, R; Porcelli, L; Quatrale, AE; Simone, GM; Xu, JM; Zucchetti, M | 1 |
| Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA | 1 |
| Goto, K; Kenmotsu, H; Koga, Y; Kuroda, J; Matsumura, Y; Nagano, T; Nishimura, Y; Nishiwaki, Y; Sugino, T; Yasunaga, M | 2 |
| Blinder, V; Gold, HT; Hall, MJ; Schackman, BR | 1 |
| Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M | 1 |
| Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R | 1 |
| Matono, K; Ogata, Y; Shirouzu, K; Torigoe, S | 1 |
| Cortesi, F; Crea, F; Danesi, R; Del Tacca, M; Gallegos Ruiz, MI; Giovannetti, E; Mey, V; Nannizzi, S; Peters, GJ; Ricciardi, S | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Kocák, I; Kocáková, I; Lakomý, R; Nēmecek, R; Poprach, A; Svoboda, M; Vyskocil, J; Vyzula, R | 1 |
| Edwards, CC; Hicks, LD; Hyatt, JL; Potter, PM; Stoddard, S; Tsurkan, L; Wadkins, RM | 1 |
| Addeo, R; Baldi, GG; Del Prete, S; Di Fabio, F; Falcone, A; Loupakis, F; Pinto, C; Rojas Llimpe, FL; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ | 1 |
| Johnstone, E; Kerr, D; Midgley, R; Swanton, C; Tomlinson, I; Walther, A | 1 |
| Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM | 1 |
| Alonso-Orduña, V; Antón, A; Aranda, E; Cardenal, A; Carrato, A; Cervantes, A; Escudero, P; Galán, M; Gallego, J; Giralt, J; Laquente, B; Massutí, B; Rivera, F; Rodríguez, E; Sáenz, A; Tabernero, J; Vega-Villegas, ME; Yuste, AL | 2 |
| Jiang, C; Jin, W; Li, M; Lou, L; Tang, W; You, T; Zheng, C | 1 |
| Hishima, T; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Nunobe, S; Ohashi, M; Suzuki, Y; Takahashi, K; Yamaguchi, T | 1 |
| Bando, H; Doi, T; Fukushima, H; Fuse, N; Kadowaki, S; Ohtsu, A; Okano, S; Tahara, M; Yoda, Y; Yoshino, T | 1 |
| Colcher, D; Davis, ME; Duringer, J; Forman, SJ; Kretzner, L; Numbenjapon, T; Raubitschek, A; Schluep, T; Wang, J; Yen, Y | 1 |
| Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y | 1 |
| Colman, H; Conrad, CA; Emmett, MR; He, H; Ji, Y; Kroes, RA; Lang, FF; Marshall, AG; Moskal, JR; Nilsson, CL | 1 |
| Atyabi, F; Dinarvand, R; Esmaeili, F; Farkhondehfai, A | 1 |
| Chen, BS; Cui, Y; Jiang, T; Li, SW; Qiu, XG; Ren, H; Zhang, W | 1 |
| Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M | 1 |
| Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
| Katoh, M; Nakagawa, N; Yokoi, T; Yoshioka, Y | 1 |
| Kareli, D; Kotsiou, E; Koukourakis, M; Kouskoukis, A; Lialiaris, TS; Makrinou, H; Papachristou, F; Pouliliou, S | 1 |
| Landherr, L; Nagykálnai, T | 2 |
| Li, J; Saif, MW | 1 |
| Chang, HJ; Han, HS; Hong, YS; Jung, KH; Kim, SY; Lee, KS | 1 |
| Chang, HJ; Hong, YS; Jeong, SY; Jung, KH; Park, JG; Shin, YK; Yoo, BC | 1 |
| Gunderson, HD; Leung, N; Shaikh, A; Wiisanen, ME | 1 |
| Abdel-Aziz, H; Abdelfatah, A; Abdelwahab, S; Abdulla, H; Azmy, A; Dwedar, I; Margerges, M; Riad, A; Sharma, V | 1 |
| Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H | 1 |
| Basolo, F; Bencardino, K; Canestrari, E; Catalano, V; Cremolini, C; Falcone, A; Floriani, I; Fontanini, G; Galluccio, N; Graziano, F; Loupakis, F; Magnani, M; Masi, G; Rulli, E; Ruzzo, A; Salvatore, L; Santini, D; Stasi, I; Tonini, G; Vincenzi, B | 1 |
| Hoskins, JM; Innocenti, F; McLeod, HL; Ratain, MJ; Rosner, GL | 1 |
| Daum, S; Ebert, MP; Flieger, D; Galle, PR; Geissler, M; Hoehler, T; Kanzler, S; Moehler, M; Raedle, J; Seufferlein, T | 1 |
| Garcia-Bournissen, F; Ito, S; Kim, R; Nathan, PC; Sakaguchi, S; Schwarz, UI | 1 |
| Kaiser, J; Krämer, I; Thiesen, J | 1 |
| Fujita, Y; Hachino, Y; Hasegawa, K; Horiuchi, T; Matsuura, I; Matsuyama, K; Miyabe, T; Morimoto, S; Nakajima, Y; Shono, Y; Tabuse, K | 1 |
| Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S | 1 |
| Gon, H; Hamabe, Y; Inui, K; Ishida, T; Kanemitsu, K; Nakajima, T; Tanaka, K; Toyokawa, A; Tsukamoto, T; Yamashita, H | 1 |
| Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF | 1 |
| Ambrosini, G; Schwartz, GK; Seelman, SL | 1 |
| Amanze, A; Di Federico, E; Taylor, J; Verschraegen, C | 1 |
| Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW | 1 |
| Cho, SJ; Choi, IJ; Kim, CG; Kim, NK; Kim, YW; Kook, MC; Lee, JH; Lee, JS; Lee, JY; Park, SR; Park, YI; Ryu, KW | 1 |
| Saltz, LB; Segal, NH | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJA | 1 |
| Argiris, A; Axelrod, R; Brockstein, B; Buchanan, A; Forastiere, A; Ghebremichael, M; Hahn, K; Kolesar, J; Pins, M | 1 |
| Ahlawat, P; Srinivas, NR | 1 |
| Barker, JN; Gupta, NK; Noy, A; Young, JW | 1 |
| Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH | 1 |
| Fukumitsu, H; Hirakawa, H; Hoshikawa, T; Makuuchi, H; Mukai, M; Ogoshi, K; Okada, K; Tajima, T; Yazawa, N | 1 |
| Cunningham, D; Okines, A | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, J; Mroue, RM; Nasr, FL; Younes, FC | 1 |
| Fujitani, K; Fukushima, N; Imamura, H; Ito, S; Kawashima, Y; Oshita, H; Sano, T; Sasako, M; Yamamoto, S; Yoshikawa, T | 1 |
| Cheng, YC; Dutschman, GE; Li, X; Ye, M; Zhang, W | 1 |
| Kuebler, JP | 1 |
| Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q | 1 |
| Ho, YH; Lam, AK; Sebesan, S; Weekes, J | 1 |
| Del Monte, G; Formica, V; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A | 1 |
| Berend, S; Kopjar, N; Kuca, K; Mladinić, M; Piljac-Zegarac, J; Plestina, S; Radić, B; Vrdoljak, AL; Zeljezić, D | 1 |
| Axelrod, F; Basi, J; Clarke, MF; Donigian, L; Dylla, S; Fitch-Bruhns, M; Gurney, A; Hoey, T; Lazetic, S; Lewicki, J; Park, IK; Sato, A; Satyal, S; Wang, X; Yen, WC | 1 |
| Lesnaia, NA; Pokrovskiĭ, VS; Romanenko, VI; Treshchalina, EM | 1 |
| Bermudes, DG; Dos Santos, N; Harasym, TO; Johnstone, SA; Mayer, LD; Tardi, PG; Tsang, AW; Zisman, N | 1 |
| Kaneko, M; Kaneko, S; Suzuki, K | 1 |
| Fujita, N; Katayama, R; Koike, S; Sato, S; Sugimoto, Y; Tsuruo, T | 1 |
| Fram, RJ; Yurkovetskiy, AV | 1 |
| Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J | 1 |
| Bosman, FT; Dietrich, D; Fiocca, R; Kennedy, RD; Roth, A; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
| Gollins, SW; Haylock, B; Levine, E; Mason, L; Morris, J; Myint, S; Samuel, L; Susnerwala, S; Swindell, R; Topham, C; Wise, M | 1 |
| Beauchet, A; Brouquet, A; Julie, C; Lot, AS; Nordlinger, B; Penna, C; Prevost, G; Taleb, P | 1 |
| Akashi, R; Kanda, K; Kiyozumi, T; Koba, I; Miyamoto, H; Sagara, K; Yamanouchi, T; Yoshida, M; Zinnouchi, K | 1 |
| Igarashi, T; Kitagawa, Y; Kumagai, K; Nakamura, R; Saikawa, Y; Takahashi, T; Takeuchi, Y | 1 |
| Iwaya, A; Ohta, T; Sato, R; Takii, Y | 1 |
| Gotou, N; Hatori, S; Imada, T; Iwasaki, H; Kawamoto, M; Rino, Y; Samejima, J; Wada, H; Yukawa, N | 1 |
| Bodnar, L; Stec, R; Szczylik, C | 1 |
| Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
| Cha, PC; Furuhata, T; Harada, H; Hirata, K; Kawamoto, S; Mushiroda, T; Nakamura, Y; Nishidate, T; Sasaki, K; Shimoyama, R; Shinoda, N; Zembutsu, H | 1 |
| Hamada, A; Hira, A; Maeda, Y; Saito, H; Sanematsu, E; Sasaki, JI; Yokoo, K | 1 |
| Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N | 1 |
| Saif, MW | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Ehrnrooth, E; Frederiksen, KS; Skak, K; Søndergaard, H | 1 |
| Pappo, A; Paulino, AC | 1 |
| Ballart, C; Branco, CC; Brilhante, MJ; Cabral, R; Mota-Vieira, L; Pacheco, PR; Polena, H; Sigalat, F | 1 |
| Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Falcone, A; Galizia, E; Labianca, R; Loupakis, F; Mandolesi, A; Masi, G; Negri, F; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G | 1 |
| Goldberg, RM; O'Neil, BH | 1 |
| Kim, R; Lee, C; Wesolowski, R | 1 |
| Abrey, LE; Cloughesy, T; Friedman, HS; Huang, J; Jensen, R; Mikkelsen, T; Nicholas, MK; Paleologos, N; Prados, MD; Schiff, D; Vredenburgh, J; Wen, PY; Yung, WK; Zheng, M | 1 |
| Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
| Kemeny, NE; Power, DG | 1 |
| Ahn, JB; Chung, HC; Im, CK; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ | 1 |
| de Gramont, A; Hebbar, M; Pruvot, FR; Romano, O; Triboulet, JP | 1 |
| Biesmans, B; De Hertogh, G; De Roock, W; De Schutter, J; Fieuws, S; Humblet, Y; Jacobs, B; Laurent-Puig, P; Peeters, M; Pénault-Llorca, F; Piessevaux, H; Tejpar, S; Van Cutsem, E; Van Laethem, JL; Van Oirbeek, R; Vandesompele, J | 1 |
| Chang, HM; Jang, SJ; Kang, YK; Kim, JC; Kim, TW; Lee, JL; Lee, JS; Na, YS; Park, HS; Ryu, MH; Sohn, BS | 1 |
| Garcia-Alfonso, P; Gonzalez-Flores, E; Mendez-Ureña, M; Muñoz-Martin, A; Perez-Manga, G; Quiben-Pereira, R | 1 |
| Bhonde, MR; Fechner, H; Hanski, C; Hanski, ML; Jebautzke, B; Lin, WC; Peiró-Jordán, R; Stehr, J; Yokoyama, KK; Zeitz, M | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S | 1 |
| Furuta, R; Hibi, S; Ina, K; Kataoka, T; Kawai, M; Kojima, S | 1 |
| Harada, M; Isobe, H; Izumi, K; Mino, K; Saito, K; Tanaka, H | 1 |
| Hirota, M; Ichihara, T; Nakamura, E; Yamashita, K | 1 |
| Chatelut, E; Ferron, G; Gadiou, M; Gladieff, L; Halilou, MC; Hennebelle, I; Herin, F; Simon, L | 1 |
| Al-Dasooqi, N; Ashton, K; Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Fujii, T; Fukuda, H; Kunikane, H; Kunitoh, H; Mori, K; Okamoto, H; Saijo, N; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Arceci, RJ; Bagatell, R; Boklan, J; Gore, L; Harbison, C; Herzog, C; Hunger, SP; Katzenstein, HM; Kuttesch, J; Langer, C; Lu, H; Smith, AA; Trippett, TM; Weber, M; Whitlock, JA; Wolff, J; Zhou, X | 1 |
| Jang, JS; Kim, BG; Kim, DK; Kim, HJ; Kim, MC; Kim, SG; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY | 1 |
| Boeck, S; Heinemann, V; Schulz, C; Stemmler, HJ | 1 |
| Hamaguchi, T; Kaniwa, N; Kim, SR; Kunitoh, H; Maekawa, K; Matsumura, Y; Minami, H; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J | 1 |
| Bobos, M; Fountzilas, G; Kafiri, G; Karavasilis, V; Karina, M; Kostopoulos, I; Papakostas, P; Pentheroudakis, G; Vrettou, E; Xiros, N | 1 |
| Koopman, M; Punt, CJ | 1 |
| Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N | 1 |
| López-González, A; Provencio, M; Sánchez, A; Yebra, M | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 2 |
| Cunningham, D; Yim, KL | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Hansen, HJ; Moon, SJ | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Hang, M; Hang, X; Li, M; Mao, W; Sun, Q; Xu, W; Zhang, J | 1 |
| Teng, KY; Xu, RH | 1 |
| Burd, R; Daskalakis, C; Dicker, AP; Ryan, A; Wachsberger, P | 1 |
| Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I | 1 |
| Bechi, P; Cipriani, G; Grifoni, R; Molinara, E; Neri, B; Pantaleo, P; Pantalone, D; Rangan, S; Taddei, A; Tonelli, P; Valeri, A; Vannini, A | 1 |
| Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S | 1 |
| Chrisafi, S; Digkas, E; Hatzimichail, A; Kareli, D; Lialiaris, T; Mantadakis, E; Passadaki, T; Vargemezis, V | 1 |
| Hwang, J; Nguyen, HL | 1 |
| Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C | 1 |
| Abdel Karim, N; Flora, D; Gupta, A; Issa, M; Jazieh, AR; Knapp, M; Komrokji, R; Patil, S | 1 |
| Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; Weide, R | 1 |
| Atyabi, F; Azizi, E; Dinarvand, R; Ebrahimnejad, P; Jaafari, MR; Nomani, AR; Rad-Malekshahi, M; Sajadi, A | 1 |
| Hara, Y; Kawano, T; Maekawa, K; Minami, Y; Ueda, S | 1 |
| Ikeda, H; Kanagawa, T; Katoh, H; Kobayashi, K; Kodera, M; Oishi, M; Seshimo, K; Takita, K; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
| Asada, T; Chijiiwa, K; Eto, TA; Futami, S; Hidaka, H; Imada, S; Shibata, N; Shimayama, T; Takaya, T; Tanaka, S | 1 |
| Aguero, EG; Garrett-Mayer, E; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM | 1 |
| Ashwell, S; Brassil, PJ; Dai, J; Garner, CE; Gönen, M; Goteti, K; Kern, SE; Moustakas, DT; Schwartz, GK; Utley, L; Zabludoff, S | 1 |
| Ahlawat, P; Ramesh, M; Srinivas, NR | 1 |
| Drozda, R; Grzegorczyk, K; Kontek, R; Sliwiński, M | 1 |
| Izumi, K; Mouri, H; Ohtsubo, K; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K; Zen, Y | 1 |
| Fujiki, R; Kitamura, T; Matsui, O; Motoo, Y; Mouri, H; Ohtsubo, K; Okai, T; Sanada, J; Sawabu, N; Tokuuye, K; Tsuchiyama, T; Watanabe, H; Yamaguchi, Y | 1 |
| Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA | 1 |
| Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L | 1 |
| Cho, EY; Han, JY; Kim, HT; Lee, GK; Lee, JS; Yoo, SY; Yoon, SJ | 1 |
| Boeck, S; Giessen, C; Heinemann, V; Moosmann, N; Schalhorn, A; Schulz, C; Stemmler, HJ; Zwingers, T | 1 |
| Choi, K; Rineer, J; Sanmugarajah, J | 1 |
| Kirschbaum, M | 1 |
| Barbachano, Y; Chau, I; Cunningham, D; Mikropoulos, C; Petkar, I; Strimpakos, AS | 1 |
| Adam, R; Bonhomme-Faivre, L; Castagne, V; Farinotti, R; Guettier, C; Paule, B; Picard, V; Saffroy, R | 1 |
| Hida, T; Kimura, T; Saga, K | 1 |
| Burris, HA; Farley, C; Greco, FA; Hainsworth, JD; Murphy, PB; Saez, RA; Spigel, DR; Yardley, DA; Zubkus, JD | 1 |
| Arcamone, G; Bisogno, G; Carli, M; Miglionico, L; Riccardi, R; Scagnellato, A | 1 |
| Nishida, T | 1 |
| Itagaki, S | 1 |
| Barrett, JH; Chambers, P; Daly, CL; Elliott, F; Meade, AM; Quirke, P; Richman, SD; Seymour, MT; Taylor, G | 1 |
| Chyi Lee, F; Fekrazad, HM; Rabinowitz, I; Royce, M; Smith, HO; Verschraegen, CF | 1 |
| Chiu, GN; Lin, H; Ling, LU; Tan, KB | 1 |
| Bosnjakovic, P; Martin, RC; O'Hara, R; Padr, R; Robbins, K; Rocek, M; Scupchenko, A; Slauf, F; Tatum, C; Tomalty, D | 1 |
| Kitamura, Y; Kusuhara, H; Sugiyama, Y | 1 |
| Bernheim, J; Buchbut, D; Goldiner, I; Inbar, M; Ish-Shalom, M; Keizman, D; Klein, B; Konikoff, F; Leikin-Frenkel, A; Maimon, N | 1 |
| Kirishima, T; Marui, A; Matsuda, S; Mizumoto, M; Motoyoshi, T; Shintani, H; Takaaki, J; Takai, K; Yamashita, Y; Yoshikawa, T; Yoshinami, N | 1 |
| Bohlin, L; Felth, J; Fryknäs, M; Gullbo, J; Lindskog, M; Rickardson, L; Rosén, J; Wickström, M | 1 |
| Baltas, D; Chatzisotiriou, A; Fountzilas, G; Fragkoulidi, A; Iliadis, G; Kalogera-Fountzila, A; Misailidou, D; Selviaridis, P; Tselis, N; Zamboglou, N | 1 |
| Aida, S; Furuya, K; Goto, T; Kato, M; Kikuchi, Y; Takano, M; Yoshikawa, T; Yoshokawa, T | 1 |
| Derouet, M; Eskelinen, EL; Haniff, M; Rosen, K; Wu, X; Yoo, BH | 1 |
| Akcan, S; Artac, M; Bozcuk, H; Ozdogan, M; Pehlivan, M; Pehlivan, S; Savas, B; Sever, T | 1 |
| Ciardiello, F; Papamichael, D; Tejpar, S | 1 |
| Akasaka, O; Anan, H; Ando, T; Iwase, S; Kasama, M; Koh, R; Matsueda, R; Miwa, H; Morita, S | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Fukumoto, R; Hashimoto, M; Hirabayashi, S; Honda, I; Mase, T; Morioka, Y; Nagata, J; Nakanishi, K; Nishi, T; Onishi, E; Oya, H | 1 |
| Kaiho, T; Miyazaki, M; Nishimura, M; Nomura, S; Okamoto, R; Shinmura, K; Togawa, A; Tsuchiya, S; Yanagisawa, S | 1 |
| Ikeda, N; Saito, H; Sakano, T; Tabira, Y; Urakawa, M; Watanuki, A | 1 |
| Egi, H; Itamoto, T; Kadoya, T; Kohashi, T; Matsugu, Y; Nakahara, H; Ohmori, I; Okajima, M; Takakura, Y; Urushihara, T | 1 |
| Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T | 1 |
| Ahowesso, C; Delaunay, F; Dulong, S; Filipski, E; Hossard, V; Iacobelli, S; La Sorda, R; Lévi, F; Li, XM; Piccolo, E; Tinari, N | 1 |
| Batchelor, TT; Frosch, MP; Gerstner, ER | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Hollis, D; Irahara, N; Mayer, RJ; Meyerhardt, JA; Niedzwiecki, D; Ogino, S; Saltz, LB; Schaefer, P; Whittom, R | 1 |
| Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE | 1 |
| Feilchenfeldt, J; Power, DG | 1 |
| Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME | 1 |
| Aboody, KS; Chen, MY; Gutova, M; Kim, SU; Najbauer, J; Potter, PM | 1 |
| Ardizzoni, A; Bonasoni, MP; Bozzetti, C; Camisa, R; Crafa, P; Lagrasta, CA; Negri, FV; Pedrazzi, G | 1 |
| Hashiguchi, K; Hiraki, M; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Nakamura, J; Noshiro, H; Sumi, K | 1 |
| Chen, XX; Guo, GF; Hu, PL; Jiang, WQ; Liu, MZ; Qiu, HJ; Xia, LP; Zhang, B; Zhou, FF | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Baggstrom, MQ; Fracasso, P; Govindan, R; Morgensztern, D; Pillot, G; Suresh, R; Tan, B; Wildi, J | 1 |
| Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Vasile, E | 1 |
| Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S | 1 |
| Ishizuka, B; Kiguchi, K; Kobayashi, Y; Kondo, H; Ohara, T; Suzuki, N; Yahagi, N | 1 |
| Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K | 1 |
| Baba, N; Ishigami, S; Kitaguchi, K; Nakauchi, M; Nakayama, Y; Ohe, H; Sakikubo, M; Taira, K; Tamura, J; Ura, K; Yoshikawa, A | 1 |
| Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE | 1 |
| Ho, YH; Lam, AK; Ong, K; Sebesan, S; Weekes, J | 1 |
| Prewett, M; Steiner, P; Surguladze, D; Tonra, JR | 1 |
| Benković, V; Dikić, D; Erhardt, J; Knežević, AH; Lisičić, D; Oršolić, N | 1 |
| Brouquet, A; de Chaisemartin, C; Goasguen, N; Julié, C; Laurent-Puig, P; Penna, C; Prevost, GP | 1 |
| Song, ST; Wang, Y; Xu, JM; Xu, QZ; Zhou, PK | 1 |
| Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G | 1 |
| Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S | 1 |
| Bosacki, C; Merrouche, Y; Smith, D | 1 |
| Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kawai, H; Kobayashi, H; Sugihara, K; Uetake, H; Yasuno, M | 1 |
| Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Takaoka, M; Yanagida, N; Yoneya, R | 1 |
| Ide, Y; Mikami, K; Murata, K | 1 |
| Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Ohashi, M; Suzuki, Y; Takahashi, K; Yamaguchi, T | 1 |
| Iida, A; Kaneko, T; Mishima, T; Miyazaki, M; Muto, T; Shimizu, K; Yoshidome, H | 1 |
| Inoue, S; Nasu, K; Noda, K; Umekita, N | 1 |
| Hokama, N; Inokuma, S; Ishibashi, K; Ishida, H; Ishiguro, T; Miyazaki, T; Ohsawa, T; Okada, N; Yokoyama, M | 1 |
| Hirakawa, M; Hirako, T; Koh, Y; Minami, S; Miyajima, N; Saitoh, T; Sasagawa, Y; Takanashi, K; Ueno, Y | 1 |
| Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N | 1 |
| Aoki, T; Igarashi, Y; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Takachi, K; Tanizaki, K; Uemura, Y; Yamanaka, C | 1 |
| Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G | 1 |
| Brady, J; Corrie, PG; Margison, GP; Middleton, MR; Midgley, RS; Mortimer, P; Palmer, C; Sabharwal, A; Watson, AJ | 1 |
| Cho, SH; Go, SI; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Lee, GW | 1 |
| Blobe, GC; Dugan, E; Fernando, NH; Gockerman, JP; Hurwitz, HI; Meadows, KL; Morse, MA; Petros, WP; Truax, R | 1 |
| Choi, SH; Chun, HK; Lee, WS; Lee, WY | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Duan, K; Huang, J; Li, Y; Liu, S; Tang, X; Wang, D; Yu, J; Zhang, X | 1 |
| Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM | 1 |
| Adam, R; Azoulay, D; Castaing, D; de Haas, RJ; Ducreux, M; Flores, E; Lemoine, A; Lévi, F; Paule, B; Wicherts, DA | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, A; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Raynaud, FI; Reader, JC; Valenti, M; Walton, MI; Williams, DH | 1 |
| Ames, MM; Arusell, R; Ballman, KV; Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Hammack, JE; Jaeckle, KA; McGovern, RM; Morton, RF; Nikcevich, DA; Reid, JM; Safgren, SL; Schomberg, PJ; Uhm, JH; Wender, DB | 1 |
| Haugen, M; Katzenstein, HM; Morgan, ER; Powell, C; Qayed, M | 1 |
| Cao, S; Chintala, S; Durrani, FA; Jensen, RL; Rustum, YM; Tóth, K; Vaughan, MM | 1 |
| Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
| Creemers, GJ; de Jong, FA; Friberg, LE; Loos, WJ; Mathijssen, RH; Planting, AS; Sparreboom, A; van der Bol, JM; Verweij, J; Wiemer, EA | 1 |
| Kenmotsu, H; Koga, Y; Kuratsu, J; Kuroda, J; Matsumura, Y; Sugino, T; Yasunaga, M | 1 |
| Attinà, G; Coccia, P; Riccardi, R; Ruggiero, A; Scalzone, M | 1 |
| Inaba, Y; Kawai, H; Muro, K; Najima, M; Sato, Y; Sawaki, A; Shibata, T; Shitara, K; Tajika, M; Takahari, D; Ura, T; Utsunomiya, S; Yamaura, H; Yatabe, Y; Yokota, T | 1 |
| Gerhardt, T; Heller, J; Höblinger, A; Rings, D; Sauerbruch, T; Schepke, M | 1 |
| Belani, CP; Evans, T; Foster, J; Gooding, W; Ramalingam, SS; Sulecki, M | 1 |
| Frese, S; Frese-Schaper, M; Gugger, M; Monestier, M; Zbaeren, J | 1 |
| Barbier, A; Bellanger, A; Capron, F; Domont, J; Genestie, C; Goldmard, JL; Hannoun, C; Khayat, D; Magné, N; Spano, JP; Vaillant, JC | 1 |
| Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yanagi, M | 1 |
| Inokuchi, M; Kato, K; Kawano, T; Kojima, K; Sugihara, K; Yamada, H | 1 |
| Funai, S; Hatabe, S; Inoue, K; Kitano, Y; Tanaka, A | 1 |
| Kitagawa, M; Koh, T; Kondo, Y; Nakagawa, N; Nanri, M; Oguro, A; Yamasaki, J | 1 |
| Abe, T; Fujii, K; Goto, A; Hasegawa, Y; Nishimura, S; Shinomura, Y; Sukawa, Y; Suzuki, K; Yonezawa, K | 1 |
| Baba, K; Ishigami, S; Kitazono, M; Matsushita, D; Natsugoe, S; Ogawa, H; Shinchi, H; Ueno, S | 1 |
| Kubo, N; Matuoka, T; Nobuhara, Y; Yo, T | 1 |
| Cusano, G; D'Incalci, M; Di Francesco, AM; Forestieri, D; Meco, D; Patriarca, V; Pisano, C; Riccardi, R; Servidei, T; Zucchetti, M | 1 |
| Jakubowicz-Gil, J; Kandefer-Szerszen, M; Paduch, R | 1 |
| Bearzi, I; Berardi, R; Biagetti, S; Bisonni, R; Cascinu, S; Falcone, A; Galizia, E; Giampieri, R; Giustini, L; Loupakis, F; Mandolesi, A; Menzo, S; Pierantoni, C; Scartozzi, M; Silva, RR; Zaniboni, A | 1 |
| Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Chen, F; He, Q; Shi, J; Zhang, L; Zhu, M | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ohta, K; Ohzato, H; Shimizu, H; Tatsuta, M | 1 |
| Wagner, LM | 1 |
| Carrie, C; de la Fouchardière, C; Desseigne, F; Labrosse, H; Martel Lafay, I; Méeus, P; Négrier, S; Pérol, D; Petit-Laurent, F; Rivoire, M; Tavan, D | 1 |
| An, X; Ding, PR; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Cai, H; Chen, S; Hotz, K; La Placa, DB; Nguyen, N; Peterkin, V; Stevens, JC; Tukey, RH; Yang, YS | 1 |
| Alberti, DB; Choi, BS; Eickhoff, JC; Holen, KD; Ivy, SP; Kolesar, JM; Marnocha, R; Schelman, WR; Thomas, JP; Wilding, G | 1 |
| DeLisle, S; Mullins, CD; Obeidat, NA; Pradel, FG; Zuckerman, IH | 1 |
| Chinnaiyan, P; Kahali, S; Sarcar, B | 1 |
| Chang, J; Cho, BC; Choi, HJ; Jeong, J; Jung, MK; Kim, JH; Kim, SH; Kim, SK; Lee, YJ; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E | 1 |
| Anderson, J; Doyle, T; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| Fujita, H; Ichimura, K; Ikeda, H; Katoh, H; Kawai, Y; Kodera, M; Maejima, R; Oishi, M; Seshimo, K; Shibagaki, K; Takita, K; Tanaka, N; Toshima, T; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
| Han, N; Liu, ZW; Wang, J; Zhang, ZM | 1 |
| Baltes, S; Brinker, T; Freund, I; Lewis, AL; Nolte, I | 1 |
| Chan, JM; Ho, SH; Tai, IT | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| André, T; Baumgaertner, I; Hannoun, L; Poynard, T; Ratziu, V; Vaillant, JC | 1 |
| Aoki, D; Inaba, N; Noda, K; Ochiai, K; Saito, T; Sugiyama, T; Takahashi, F; Takakura, S; Takano, M | 1 |
| Baylatry, MT; Bengrine-Lefevre, L; Fernandez, C; Joly, AC; Laurent, A; Pelage, JP; Prugnaud, JL | 1 |
| le Deley, MC; Paoletti, X; Raphaël, M; Vassal, G | 1 |
| Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M | 1 |
| Canestrari, E; Catalano, V; Cremolini, C; D'Emidio, S; Falcone, A; Galluccio, N; Giordani, P; Graziano, F; Loupakis, F; Magnani, M; Rocchi, M; Ruzzo, A; Salvatore, L; Santini, D; Spoto, C; Tonini, G; Vincenzi, B | 1 |
| Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H | 1 |
| Furuya, K; Goto, T; Kato, M; Kikuchi, Y; Takano, M; Yoshikawa, T | 1 |
| Glynne-Jones, R; Harrison, M; Mawdsley, S | 1 |
| Francis, P; Nilbert, M; Sun, XF; Svanvik, J; Wallin, A | 1 |
| Kitamura, H; Masumori, N; Matsuda, Y; Sato, S; Takahashi, S; Tanaka, T; Tsukamoto, T | 1 |
| Blair, EA; Haraf, DJ; Pederson, AW; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Bonnans, C; Breuker, C; Brouillet, JP; Evrard, A; Hollande, F; Joubert, D; Kantar, J; Lallemant, B; Leguelinel, G; Lumbroso, S; Pascussi, JM; Poujol, S; Raynal, C | 1 |
| Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Akashi, I; Ashizawa, T; Hama, K; Hirano, T; Iwahori, T; Iwamoto, H; Jyojima, Y; Kihara, Y; Konnno, O; Nagao, T; Nakamura, Y; Segawa, M; Takeuchi, H; Yokoyama, T | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G | 1 |
| Bai, JP | 1 |
| Fang, H; Feng, FY; Wang, JW; Wang, XY | 1 |
| Ahn, JB; Baik, SH; Choen, JH; Choi, HJ; Chung, HC; Im, JS; Jeung, HC; Keum, KC; Kim, HG; Kim, NK; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Ahn, BJ; Choi, MK; Heo, JS; Kang, WK; Kim, S; Lee, J; Lim, HY; Noh, JH; Park, JO; Park, SH; Park, YS; Sohn, TS; Yim, DS | 1 |
| Barth, SW; Briviba, K; Esselen, M; Jäger, N; Marko, D; Watzl, B | 1 |
| Ali, S; Campbell-Baird, C; Harvey, H; Lipton, A; Witters, L | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Boku, N; Fukutomi, A; Hamauchi, S; Hironaka, S; Machida, N; Onozawa, Y; Sakamoto, T; Taku, K; Taniguchi, H; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kikuchi, S; Kokuba, Y; Komiyama, S; Kubota, T; Nakanishi, M; Ochiai, T; Otsuji, E; Sakakura, C; Sonoyama, T | 1 |
| Cao, W; Chen, X; Deng, Z; Gao, Y; Liu, H; Liu, Y; Xu, L | 1 |
| Afchain, P; Aparicio, T; Bonnetain, F; Costes, L; Gauthier, M; Gornet, JM; Lecomte, T; Locher, C; Malka, D; Mitry, E; Moulin, V; Sobhani, I; Taïeb, J; Tougeron, D; Zaanan, A | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN | 1 |
| Dalenc, F; Delannes, M; El Demery, M; Fabbro, M; Gladieff, L; Guichard, F; Kerr, C; Kurtz, JE; Paraiso, D; Pujade-Lauraine, E | 1 |
| Cardenal, F; Cisar, L; Domine, M; Gorbunova, V; Moiseyenko, V; Soria, JC; Szczesna, A; Thomas, M; Zatloukal, P; Zhang, X | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N | 1 |
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
| Fujiwara, Y; Minami, H | 1 |
| Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E | 1 |
| Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY | 1 |
| Fleig, WE; Grothe, W; Grothey, A; Haerting, J; Kleber, G; Unverzagt, S; Wagner, AD | 1 |
| Komatsu, Y; Muro, K; Shibata, T; Shitara, K; Takahari, D; Takiuchi, H; Ura, T; Utsunomiya, S; Yatabe, Y; Yokota, T; Yoshida, M; Yuki, S | 1 |
| D'Andrea, MR; Gasparini, G; Toffoli, G | 1 |
| Aizawa, H; Ichiki, M; Inoue, Y; Nakamura, M; Saitsu, H; Sakata, S; Tokito, T; Wada, Y | 1 |
| Arita, M; Kuga, Y; Miwata, T; Moriya, T; Murakami, E; Nishida, T; Numata, Y; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
| Asaka, M; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Miyazaki, T; Nakatsumi, H; Sasaki, T; Sogabe, S; Takagi, T; Takano, H; Uehata, Y; Yuki, S | 1 |
| Brown, TJ; Clavant, SP; Clingan, PR; Fox, RM; Ganju, V; Gibbs, P; Leung, J; Pho, M; Strickland, AH; Tebbutt, NC; Underhill, CR; Wong, SS | 1 |
| Hu, ZY; Yu, Q; Zhao, YS | 1 |
| Gamulin, M; Kasuba, V; Rozgaj, R; Trosić, I | 1 |
| Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D | 1 |
| Falcone, A; Loupakis, F | 1 |
| Asakawa, N; Kado, S; Kaneda, N; Kato, I; Kurita, A; Matsumoto, T; Onoue, M; Uchida, K; Yokokura, T | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Mehta, SP | 1 |
| Lenz, HJ; Winder, T | 1 |
| Allen, J; Chacko-Mathew, J; Gardner, S; Harter, D; Karajannis, M; Kunnakkat, S; Narayana, A; Raza, S; Weiner, H; Wisoff, J | 1 |
| Arango, D; Armengol, M; Bazzocco, S; Carreras, MJ; Dopeso, H; Elez, E; Espín, E; Hernández-Losa, J; Landolfi, S; Mariadason, JM; Mateo-Lozano, S; Mazzolini, R; Ramon Y Cajal, S; Ramos Pascual, FJ; Rodrigues, P; Schwartz, S; Tabernero, J; Wilson, AJ | 1 |
| Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
| Boehm, KA; Cartwright, T; McCollum, D | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Savva, M; Sivakumar, B; Thakur, R | 1 |
| Ajmi, S; Ben Ahmed, S; Ben Fatma, L; Ben Hadj Hamida, R; Braham, A; Chabchoub, I; Gahbiche, S; Gharbi, O; Hochlef, M; Landolsi, A; Letaief, R; Limam, S; Mokni, M | 1 |
| Heinemann, MH; Ilson, DH; Morris, PG; Oda, J | 1 |
| Barrois, M; Beaune, P; Boige, V; Bouché, O; Castaing, M; Ducreux, M; Laurent-Puig, P; Le Corre, D; Loriot, MA; Malka, D; Mendiboure, J; Miran, I; Mulot, C; Pignon, JP; Trégouët, DA | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Deng, XQ; Li, L; Li, QY; Lv, H; Su, L; Yao, L; Zhang, Y; Zu, YG | 1 |
| Hirakawa, K; Matsuzaki, T; Nishii, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Abbruzzese, A; Arcuri, FP; Caraglia, M; Carducci, A; Correale, P; Del Vecchio, MT; Loiacono, L; Marra, M; Migali, C; Misso, G; Remondo, C; Tagliaferri, P; Tassone, P | 1 |
| Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R | 1 |
| Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L | 1 |
| Heideman, RL; McNall-Knapp, RY; Meyer, WH; Reeves, EN; Williams, CN | 1 |
| Fujita, K; Sparreboom, A | 1 |
| Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M | 1 |
| Alonso, V; Antón, I; Arrivi, A; Cirera, L; Constenla, M; Escudero, P; García, P; Grande, C; Guasch, I; López, LJ; Losa, F; Martin, C; Méndez, M; Moreno, I; Pericay, C; Quintero-Aldana, G; Roca, JM; Salud, A; Vicente, P; Yubero, A | 1 |
| Hatayama, S; Honda, T; Kagabu, M; Kaido, Y; Kumagai, S; Miura, F; Morohara, Y; Murai, M; Omi, H; Satoh, A; Shoji, T; Sugiyama, T; Takatori, E; Yoshizaki, A | 1 |
| Hirata, K; Nakamura, Y; Takashima, T; Tayama, Y | 1 |
| Chen, TC; Ghandi, A; Hofman, FM; Liebes, L; Louie, SG; Schönthal, AH; Wang, W | 1 |
| Caron, J; Chalbos, P; Dereure, O; Duffour, J; Fiess, C; Garcin, A; Gestin-Boyer, C; Guillot, B; Portales, F; Samalin, E; Thézenas, S; Ychou, M | 1 |
| Barrett, JS; Ida, K; Ishida, Y; Kaneko, M; Kashiwase, S; Kimura, T; Kumagai, M; Makimoto, A; Mugishima, H; Nagatoshi, Y; Taga, T | 1 |
| Gallinger, S; Guindi, M; Moore, M; Moulton, CA; Nanji, S; Pollett, A; Ryan, P | 1 |
| Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy | 1 |
| Hashimoto, T; Inoue, K; Kokudo, N; Makuuchi, M; Maruyama, Y; Ogata, S; Sano, K; Takamoto, T; Takemura, T | 1 |
| Aladag, N; Aydinlik, S; Ozkan-Ariksoysal, D; Ozsoz, M; Topkaya, SN | 1 |
| Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M | 1 |
| Dasanu, CA; Trikudanathan, G | 1 |
| Drolet, P; Dubé, P; Sideris, L; Turcotte, S; Younan, R | 1 |
| Choi, JY; Han, JY; Kim, JY; Park, IH | 1 |
| Boyett, JM; Chi, SN; Friedman, HS; Gilbertson, RJ; Gururangan, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Rood, BN; Vajapeyam, S; Young Poussaint, T | 1 |
| Ebi, N; Goto, I; Imamura, F; Iwamoto, Y; Kobayashi, M; Matsui, K; Nakagawa, K; Oizumi, S; Saito, H; Saka, H; Sawa, T; Seki, N; Shibata, K; Takeda, K | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Dickinson, PJ; Drummond, DC; Forsayeth, J; Higgins, RJ; Kirpotin, DB; Krauze, MT; Larson, RF; LeCouteur, RA; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Fukushima, M; Hata, M; Ichikawa, C; Kirii, Y; Miyairi, J; Miyamoto, M; Ota, H; Takagi, H | 1 |
| Andrasina, T; Boudný, J; Bower, M; Martin, RC; Metzger, T; Robbins, K; Tatum, C; Tomalty, D; Válek, V | 1 |
| Bouganim, N; Chaudhury, P; Hassanain, M; Kavan, P; Metrakos, P; Salman, A | 1 |
| Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M | 1 |
| Gallagher, M; Giantonio, B; Haller, DG; Metz, JM; O'Dwyer, PJ; Sun, W; Whittington, R | 1 |
| Katayama, K; Mitsuhashi, J; Noguchi, K; Shigeta, J; Sugimoto, Y | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N | 1 |
| Gallagher, DJ; Kemeny, N | 1 |
| Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L | 1 |
| Bai, J; Chen, J; Duanmu, Z; Gong, Y; Huang, H; Tang, C; Yang, J; Zhou, B; Zhuang, L | 1 |
| Chen, J; Lu, Y; Wolff, JE; Xu, T | 1 |
| Alonso-Varona, A; Caramés, M; García-Alonso, I; Palomares, T | 1 |
| Chen, E; Darling, G; Guindi, M; Haider, M; Horgan, AM; Hornby, J; Keshavjee, S; Knox, JJ; Ringash, J; Visbal, AL; Wong, R; Xu, W | 1 |
| Muro, K | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Moritani, K; Ochiai, H; Okabayashi, K; Watanabe, M | 1 |
| Baiget, M; Barnadas, A; del Rio, E; Espinosa, I; Marcuello, E; Paez, D; Paré, L; Salazar, J | 1 |
| Bhattacharya, A; Cao, S; Chintala, S; Dean, R; Durrani, FA; Ola, MS; Rustum, YM; Slocum, HK; Smith, SB; Tóth, K; Yin, MB; Zinia, TR | 1 |
| Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Meguro, T; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Yuki, S | 1 |
| Guo, C; Hu, ZY; Pei, Q; Yu, Q | 1 |
| Antonijevic, MD; Forster, RE; Heaysman, CL; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Small, SA; Tang, Y | 1 |
| Hata, T; Ishizu, H; Kawamura, H; Kondo, Y; Masuko, H; Okada, K; Tanaka, K; Tanioka, T; Tsunoda, Y; Watarai, H; Yamagami, H; Yokota, K; Yokota, R | 1 |
| Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N | 1 |
| Goto, K; Kenmotsu, H; Koga, Y; Kuroda, J; Matsumura, Y; Nagano, T; Nishiwaki, Y; Takahashi, A; Yasunaga, M | 1 |
| Chau, GY; Chen, WS; Hsieh, YY; Hsu, YN; King, KL; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH | 1 |
| Chang, HJ; Choi, HS; Jeong, SY; Kim, DY; Kim, SY; Oh, JH; Park, JW; Seo, GJ; Shin, A; Yoo, SB | 1 |
| House, L; Liu, Y; Ramírez, J; Ratain, MJ | 1 |
| Fraga, CH; Harstead, KE; Panetta, JC; Schaiquevich, P; Shen, J; Stewart, CF; Tagen, M; Waters, CM; Zhang, F; Zhuang, Y | 1 |
| Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R | 1 |
| Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM | 1 |
| Hoskins, JM; Marsh, S | 1 |
| Chang, HJ; Choi, HS; Hong, YS; Jeong, JY; Jeong, SY; Jung, KH; Kim, DH; Kim, DY; Lim, SB; Park, JG; Sohn, DK | 1 |
| Furuta, T; Hashimoto, S; Matsuzaki, T; Nagata, H; Shishido, Y | 1 |
| Boulens, N; De Baere, T; Denys, A; Doelker, E; Jordan, O | 1 |
| Bjerregaard, JK; Jensen, BV; Jorgensen, TL; Nielsen, D; Pfeiffer, P; Qvortrup, C | 1 |
| Oostendorp, LJ; Ottevanger, PB; Pasker-de Jong, PC; Stalmeier, PF; Van der Graaf, WT | 1 |
| Allegrini, G; Baldi, GG; Canestrari, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Magnani, M; Masi, G; Ruzzo, A; Salvatore, L; Santini, D; Stasi, I; Tonini, G; Vasile, E; Vincenzi, B | 1 |
| Hanioka, N; Jinno, H; Koeda, A; Nagaoka, K; Naito, S; Narimatsu, S; Tanabe, N; Tanaka-Kagawa, T | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N | 1 |
| Chiba, Y; Fukuoka, M; Hida, T; Imamura, F; Iwamoto, Y; Katakami, N; Kawahara, M; Kudo, S; Nakagawa, K; Nishimura, Y; Saka, H; Satouchi, M; Sawa, T; Semba, H; Seto, T; Takeda, K; Tsujino, K; Uejima, H; Yamamoto, N; Yokota, S | 1 |
| Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Ramnath, N; Ruckdeschel, JC; Schneider, BJ; Worden, FP; Wozniak, AJ; Zhang, X | 1 |
| Kalinowska-Lis, U; Kontek, R; Marciniak, B; Matlawska-Wasowska, K | 1 |
| Astier, A | 1 |
| Egashira, Y; Gotoh, M; Higuchi, K; Kawabe, S; Kii, T; Kojima, Y; Kuwakado, S; Takiuchi, H; Tanigawa, N; Yoshida, M | 1 |
| Briasoulis, E; Fountzilas, G; Golfinopoulos, V; Karina, M; Papakostas, P; Pavlidis, N | 1 |
| Edwards, CC; Hatfield, MJ; Hicks, LD; Hyatt, JL; Potter, PM; Tsurkan, L; Wadkins, RM; Yu, X | 1 |
| Czejka, M; Farkouh, A; Gruenberger, B; Kiss, A; Schueller, J | 1 |
| Aoe, K; Hayashi, H; Hotta, K; Kawai, H; Kiura, K; Maeda, T; Matsuo, K; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Hamaguchi, T; Hosokawa, M; Kaniwa, N; Kunitoh, H; Matsumura, Y; Minami, H; Naito, M; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Okuda, H; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Tatewaki, N; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Bachellier, P; Chenard, MP; Jaeck, D; Pessaux, P | 1 |
| Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW | 1 |
| Bosnjakovic, PM; Howard, J; Martin, RC; Padr, R; Robbins, K; Tatum, C; Tomalty, D | 1 |
| Gan, L; Gan, Y; Guo, S; Zhang, X; Zhu, C | 1 |
| Broholm, H; Christensen, IJ; Eriksen, JG; Grunnet, K; Hasselbalch, B; Horsman, MR; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| de Jong, FA; Loos, WJ; Mathijssen, RH; Planting, AS; Schellens, JH; van Aken, MO; van der Bol, JM; Verweij, J; Visser, TJ; Wiemer, EA | 1 |
| Al-Dasooqi, N; Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM | 3 |
| Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z | 2 |
| Casetta, B; Corona, G; Elia, C; Toffoli, G | 1 |
| Sartori, S; Tassinari, D; Tombesi, P | 1 |
| Aigner, A; Czubayko, F; Frömberg, A; Gutsch, D; Schulze, D; Vollbracht, C; Weiss, G | 1 |
| Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP | 1 |
| Bussom, S; Cheng, YC; Chu, E; Dutschman, GE; Jiang, Z; Lam, W; Li, X; Saif, MW; Ye, M; Zhang, W | 1 |
| Abdalla, EK; Agarwal, A; Boonsirikamchai, P; Charnsangavej, C; Chun, YS; Kaur, H; Kopetz, S; Loyer, EM; Maru, DM; Vauthey, JN; Wang, H | 1 |
| Goldberg, RM; McLeod, H; Sargent, DJ | 1 |
| Araki, M; Hasegawa, H; Itoh, M; Kodama, Y; Kuzushita, N; Mano, M; Mita, E; Morita, K; Nakazuru, S; Ohta, M; Ohta, T; Suemura, S; Sueyoshi, Y; Toyama, T; Yoshio, T; Yoshioka, C | 1 |
| Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E | 1 |
| Becherini, P; Cilli, M; Emionite, L; Greenberger, LM; Horak, ID; Loi, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P | 1 |
| Assaraf, YG; Epstein, D; Livney, YD; Shapira, A | 1 |
| Fukui, T; Hakoshima, M; Hattori, Y; Koga, K; Komori, M; Maitani, Y; Narishima, R; Yamasaki, M | 1 |
| Choi, KC; Jeung, EB; Kim, KY; Kim, SU; Leung, PC | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K | 1 |
| Akiyama, F; Kawamata, Y; Matsumura, M; Omatsu, K; Ota, T; Sakamoto, K; Takeshima, N; Takizawa, K; Tanaka, H; Umayahara, K | 1 |
| Díaz-Rubio, E; García-Foncillas, J | 1 |
| d'Esposito, F; Edwards, RJ; Murray, M; Nebot, N | 1 |
| Fukuda, S; Hanada, N; Hirose, K; Ishiguro, A; Itoh, J; Kawasaki, H; Kijima, H; Matsumoto, Y; Saijo, Y; Suzuki, K; Takahata, T; Tanaka, S | 1 |
| Ikeda, H; Ito, T; Kawamoto, K; Ogasahara, K; Yokota, M | 1 |
| Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C | 1 |
| Charles, KA; Chua, W; Clarke, SJ; Kho, PS; Moore, MM | 1 |
| Bussom, S; Cheng, YC; Guan, F; Gullen, EA; Jiang, Z; Lam, W; Liu, SH; Zhang, W | 1 |
| Chansky, K; Crowley, J; Fukuda, H; Gandara, DR; Lara, PN; Natale, R; Redman, MW; Saijo, N; Shibata, T; Tamura, T | 1 |
| Bosnjakovik, P; Derner, M; Joshi, J; Martin, RC; Padr, R; Robbins, K; Rocek, M; Scupchenko, A; Tatum, C; Tomalty, D | 1 |
| Gizewski, ER; Lanzman, RS; Mathys, C; Mödder, U; Rapp, M; Ringelstein, A; Sabel, M; Saleh, A; Schroeteler, J; Turowski, B | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalykaki, A; Karachaliou, N; Kentepozidis, N; Milaki, G; Polyzos, A; Vardakis, N; Ziras, N | 1 |
| Armakolas, A; Batzios, S; Batziou, C; Koutantos, J; Legakis, J; Stathopoulos, GP; Stathopoulos, J; Trafalis, D | 1 |
| Fukuda, H; Fukuoka, M; Kawahara, M; Kudoh, S; Nakagawa, K; Negoro, S; Saijo, N; Sawa, T; Semba, H; Takeda, K; Tanaka, M | 1 |
| Kenmotsu, H; Kinoshita, T; Koga, Y; Kuroda, J; Matsumura, Y; Ohkohchi, N; Takahashi, A; Yasunaga, M | 1 |
| Fukushima, M; Nakagawa, F; Ohshimo, H; Sakamoto, K; Taguchi, T | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Sasaki, Y; Sugiyama, M | 1 |
| Lee, SY; McLeod, HL | 1 |
| Baxevanis, CN; Gritzapis, AD; Kosmas, C; Tsavaris, N; Voutsas, IF | 1 |
| Berglund, A; Fernebro, E; Flygare, P; Glimelius, B; Gubanski, M; Johnsson, A; Kadar, L; Karlberg, I; Lind, PA | 1 |
| Hamaguchi, T; Hirashima, Y; Kato, K; Nishitani, H; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Takeshita, S; Yamada, Y | 1 |
| Jaitner, S; Jung, A; Kirchner, T; Schäffauer, AJ | 1 |
| Ahn, BJ; Choi, MK; Kang, WK; Ko, JW; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Georgoulias, V; Giassas, S; Gioulbasanis, I; Kalbakis, K; Kontopodis, E; Samonis, G; Vardakis, N; Varthalitis, I; Xenidis, N; Ziras, N | 1 |
| Edwards, CC; Garrett, M; Hatfield, MJ; Hicks, LD; Hyatt, JL; Potter, PM; Shaver, TM; Tsurkan, L | 1 |
| Ghandehari, H; Malugin, A; Ray, A; Vijayalakshmi, N | 1 |
| Anderson, JR; Breitfeld, PP; Donaldson, SS; Hawkins, DS; Lyden, ER; Mascarenhas, L; Meyer, WH; Paidas, CN; Parham, DM; Walterhouse, DO | 1 |
| Fratto, ME; Galluzzo, S; Russo, A; Santini, D; Spoto, C; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Breithaupt, K; Thuss-Patience, PC | 1 |
| Hosono, S; Ito, H; Ito, S; Kawai, H; Kawase, T; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajima, K; Takahari, D; Tanaka, H; Ura, T; Watanabe, M; Yatabe, Y; Yokota, T | 1 |
| Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T | 1 |
| Amatu, A; Bernardo, G; Montagna, B; Pagella, C; Poggi, G; Pozzi, E; Quaretti, P; Sottotetti, F; Tagliaferri, B | 1 |
| Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM | 1 |
| Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z | 1 |
| Bruns, H; Büchler, MW; Hoffmann, K; Longerich, T; Mikalauskas, S; Mikalauskiene, L; Nickkholgh, A; Schemmer, P; Strupas, K | 1 |
| Benner, RJ; Benson, AB; Berlin, JD; Denis, LJ; Goff, LW; LoRusso, PM; Rothenberg, ML; Tan, AR; Yin, D | 1 |
| Cho, SJ; Choi, IJ; Kim, CG; Kim, NK; Kim, YW; Kong, SY; Lee, JH; Lee, JY; Park, SR; Park, YI; Rhee, J; Ryu, KW | 1 |
| Khattak, A; Price, TJ; Townsend, AR | 1 |
| Andrasina, T; Dubel, G; Kralj, I; Martin, RC; McMasters, KM; Metzger, T; Schiffman, SC; Scoggins, CR; Tatum, C | 1 |
| Adachi, S; Hiraumi, Y; Itoh, K; Matsubara, H; Naka, N; Nakahata, T; Sano, K; Watanabe, K; Watanabe, M; Yoshioka, K; Yui, Y | 1 |
| Almubarak, M; Altaha, R; Khan, M; Nagaiah, G | 1 |
| Ahn, JB; Hur, H; Keum, KC; Kim, H; Kim, NK; Lee, KY; Min, BS; Yun, M | 1 |
| Chang, HJ; Choi, HS; Hong, YS; Im, SA; Jeong, SY; Jung, KH; Kim, DY; Kim, JH; Kim, SY; Kim, TW; Lee, KS; Lim, SB; Yun, T | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Cai, W; Cui, W; Harutyunyan, N; Ji, L; Keshelava, N; Maldonado, NV; Reynolds, CP; Sposto, R | 1 |
| de Jong, FA; Mathijssen, RH; Sleijfer, S; Sparreboom, A; van Daele, PL; van de Geijn, FE; van der Bol, JM; van Fessem, MA; van Schaik, RH; Verweij, J | 1 |
| Cantor, A; Miley, D; Reddy, V; Robert, F; Rossman, J | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Yataghene, K | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
| Honda, T; Kondo, T; Murakami, S; Nakayama, Y; Noda, K; Ohe, M; Oshita, F; Saito, H; Yamada, K; Yamashita, K | 1 |
| Doi, T; Eguchi-Nakajima, T; Fuse, N; Hamaguchi, T; Kato, K; Matsumoto, S; Matsumura, Y; Ohtsu, A; Shimada, Y; Takanashi, M; Yamada, Y | 1 |
| Ikeda, S; Inagaki, M; Suzuki, K; Takabe, K | 1 |
| Bohn, B; Erben, P; Hanfstein, B; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Popa, J; Post, S; Ströbel, P; Wenz, F | 1 |
| Gleave, M; Gout, PW; Liu, DM; Tung, WL; Wang, Y | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Strassburg, CP | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M | 1 |
| Campanella, C; Cognetti, F; Ettorre, GM; Garufi, C; Mottolese, M; Sperduti, I; Torsello, A; Tumolo, S; Vennarecci, G; Zeuli, M | 1 |
| Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K | 1 |
| Amat, CG; Bermejo, E; Gómez-Ramírez, J; Larrañaga, E; Martín-Pérez, E; Rodríguez, A; Sanz, IG | 1 |
| Bosse, D; Fischer von Weikersthal, L; Giessen, C; Goebeler, M; Grundeis, M; Heinemann, V; Lambertz, H; Maubach, PA; Mittermüller, J; Oruzio, D; Quietzsch, D; Schalhorn, A; Schlag, R; Schulze, M; Stauch, M; Szukics, B; Truckenbrodt, J; Vehling-Kaiser, U; Weigang-Köhler, K; Zwingers, T | 1 |
| Adam, R; Azoulay, D; Castaing, D; Ciacio, O; de Haas, RJ; Giacchetti, S; Guettier, C; Lévi, F; Paule, B; Sebagh, M; Wicherts, DA | 1 |
| Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Oka, M; Shimizu, K; Tanemoto, K; Yukawa, T | 1 |
| Aucélio, RQ; da Cunha, AL; Marques, FF | 1 |
| Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Cao, Y; Fujita, Y; Fukushima, Y; Iwao, H; Jin, ZX; Kawanami, T; Masaki, Y; Miki, M; Nakajima, A; Nakajima, H; Okazaki, T; Sakai, T; Sawaki, T; Tong, XP; Umehara, H; Yue, S | 1 |
| Azuma, M; Bohanes, P; Danenberg, KD; Gerger, A; Gordon, MA; Hollywood, E; Lenz, HJ; Lurje, G; Ning, Y; Pohl, A; Saltz, L; Winder, T; Yang, D; Zhang, W | 1 |
| Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Cho, DH; Hong, YS; Jin, DH; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Na, YS; Ro, S; Ryu, MH; Yang, SJ | 1 |
| Berglund, A; Byström, P; Einarsson, R; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Cho, DH; Hong, YS; Jang, SJ; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Moon, DH; Na, YS; Ryu, MH | 1 |
| Kim, R | 1 |
| Kaufmann, SH; Patel, AG | 1 |
| Jobin, C; Koo, JS; Lane, KT; Mani, S; Orans, J; Redinbo, MR; Scott, JE; Venkatesh, M; Wallace, BD; Wang, H; Yeh, LA | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S; Vincent, J | 1 |
| Ananda, S; Gibbs, P; Heong, V; Tie, J | 1 |
| Haga, T; Kitamura, A; Kuroda, F; Nakajima, Y; Takiguchi, Y; Tatsumi, K | 1 |
| Aguilera, DG; Fangusaro, J; Goldman, S | 1 |
| Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T | 1 |
| Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A | 1 |
| Aguero, EG; Harper, JL; Kearney, PL; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Watkins, JM; Zauls, AJ | 1 |
| Furukawa, K; Kanazawa, Y; Mamada, Y; Uchida, E; Yamada, T; Yokoi, K | 1 |
| Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S | 1 |
| Fukui, M; Matsumoto, M; Omasa, M; Shikuma, K; Taki, T; Tomiyama, K; Ueda, Y; Yutaka, Y | 1 |
| Furuse, J; Hosokawa, Y; Iwamoto, N; Kase, Y; Kitagawa, N; Miyazawa, T; Motoori, S; Saisho, H | 1 |
| Heinemann, V; Hoff, PM | 1 |
| Dong, CM; Kang, MF; Liu, Y; Luo, MQ | 1 |
| Alonso, V; Alonso-Espinaco, V; Castellví-Bel, S; Escudero, P; Fernández-Martos, C; Gallego, R; Garcia-Albeniz, X; Gascón, P; Maurel, J; Pericay, C | 1 |
| Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R | 1 |
| Ghandehari, H; Goldberg, DS; Swaan, PW; Vijayalakshmi, N | 1 |
| Addeo, R; Correale, P; Dicuonzo, G; Falcone, A; Francini, G; Galluzzo, S; Graziano, F; Loupakis, F; Napolitano, A; Rocci, L; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Bagatell, R; Cohn, SL; Kretschmar, C; London, WB; Maris, JM; Stewart, CF; Voss, SD; Wagner, LM | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY | 1 |
| Galle, PR; Geißler, M; Kanzler, S; Kubicka, S; Lordick, F; Moehler, M; Mueller, A; Schwarz, S; Seufferlein, T; Trarbach, T | 1 |
| Apolloni, C; Ditto, A; Frigerio, L; Melpignano, M; Panici, PB; Pignata, S; Raspagliesi, F; Scambia, G; Scollo, P; Selvaggi, L | 1 |
| Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K | 1 |
| Goebel, G; Gotwald, T; Güler, O; Hutterer, M; Kostron, H; Nowosielski, M; Recheis, W; Schocke, M; Stockhammer, G; Tinkhauser, G | 1 |
| Colucci, G; De Vita, F; Giuliani, F; Pisconti, S | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Mizutani, K; Nako, Y; Nei, T; Ozaki, Y; Wakana, K; Yasugi, T | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| El-Hadaad, HA; Halim, AA; Wahba, HA | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Honda, T; Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Asano, K; Ikemura, S; Kawada, I; Morosawa, M; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Chen, JF; Gu, DY; Huang, HY; Wang, DL; Xu, Z | 1 |
| Gmeiner, WH; Pommier, Y; Reinhold, WC | 1 |
| Ait-Arsa, I; Askari, N; Bibeau, F; Boissière, F; Causse, A; Cortijo, C; Del Rio, M; Denis, V; Denouel, A; Gongora, C; Martineau, P; Marzi, L; Mollevi, C; Paillas, S; Pourquier, P; Vezzio-Vié, N | 1 |
| Illum, H | 1 |
| Brundage, RC; Gaber, MW; Hanna, SK; Khatri, A; Kirstein, MN; Naimark, MD; Stewart, CF | 1 |
| Guo, GF; Jiang, WQ; Qiu, HJ; Wang, F; Xia, LP; Xu, RH; Zhang, B; Zhou, FF | 1 |
| Ge, FJ; Li, SS; Li, ZQ; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X | 1 |
| Iwase, Y; Maitani, Y | 3 |
| Nirmala, P; Ramanathan, M | 1 |
| Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Chua, TC; Doerfer, J; Esquivel, J; Germer, CT; Kerscher, AG; Maeder, U; Morris, DL; Pelz, JO; Stojadinovic, A | 1 |
| Iwata, T; Komatsu, M; Kurita, N; Nakao, T; Shimada, M; Utusnomiya, T; Yoshikawa, K | 1 |
| Anantha, M; Bally, M; Patankar, N; Ramsay, E; Waterhouse, D | 1 |
| Atyabi, F; Dinarvand, R; Ebrahimnejad, P; Jafari, MR; Tabasi, SA | 1 |
| Dalla Palma, M; Farina, P; Furini, L; Lombardi, G; Manara, R; Nicoletto, O; Pastorelli, D; Rotilio, A; Zagonel, V; Zustovich, F | 1 |
| De Marchis, ML; Del Monte, G; Formica, V; Grenga, I; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A; Schirru, M | 1 |
| Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Fischer, M; Gurney, A; Hoey, T; Kapoun, AM; Lewicki, J; O'Young, G; Wang, M; Yen, WC | 1 |
| Choijamts, B; Emoto, M; Kawarabayashi, T; Miyamoto, S; Naganuma, Y; Nakajima, K; Tachibana, K | 1 |
| Faybik, P; Fleischmann, E; Gruenberger, T; Herberger, B; Krieger, PM; Maresch, J; Tamandl, D | 1 |
| Buzaid, AC; Esser, R; Fein, L; Hidalgo, J; Lerzo, G; Mathias, Cde C; Murad, AM; Perazzo, F; Senger, S; Simon, SD | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Bearzi, I; Berardi, R; Biagetti, S; Biscotti, T; Bisonni, R; Bittoni, A; Cascinu, S; Galizia, E; Giampieri, R; Giustini, L; Mandolesi, A; Pierantoni, C; Scartozzi, M; Silva, RR; Zaniboni, A | 1 |
| de Bruijn, P; de Jong, FA; Konings, IR; Lam, MH; Loos, WJ; Mathijssen, RH; van der Bol, JM; van Meerten, E; Verweij, J; Wiemer, EA | 1 |
| Arnaud, O; Bates, SE; Boumendjel, A; Di Pietro, A; Dumontet, C; Falson, P; Gèze, A; Guitton, J; Honorat, M; Matera, EL; Payen, L; Stein, WD | 1 |
| Aloyz, R; Amrein, L; Coulombe, Y; Davidson, D; Grenier, J; Hodkinson, K; Martinez-Marignac, VL; Masson, JY; Panasci, L | 1 |
| Toema, BM | 1 |
| Barboriak, DP; Desjardins, A; Friedman, HS; Paldino, MJ; Vredenburgh, JJ | 1 |
| Fujimoto, T; Itagaki, H; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Umehara, A; Yano, Y; Yokomizo, H; Yoshimatsu, K | 2 |
| Doi, K; Hirano, Y; Kudoh, K; Ogata, K; Ohchi, T | 1 |
| Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kojima, O; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T; Yamaguchi, M | 1 |
| Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Maeura, Y; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S | 1 |
| Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T | 1 |
| Asami, S; Idani, F; Kin, H; Komoto, S; Kubo, S; Kubota, T; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yoshioka, T | 1 |
| Akabane, H; Inagaki, M; Nakano, S; Shomura, H; Yanagida, N | 1 |
| Iwanaga, T; Iwasaki, Y; Maeda, Y; Matsumoto, H; Nakano, D; Ohashi, M; Ohhinata, R; Sasaki, E; Takahashi, K; Yamaguchi, T | 1 |
| Aritake, N; Endoh, A; Katsumoto, Y | 1 |
| Akaike, M; Mikayama, Y; Morinaga, S; Shiozawa, M; Tamagawa, H; Tamura, S; Watanabe, T; Yamamoto, N | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Ishii, H; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Uemura, M; Yamamoto, H; Yamashita, S | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S | 1 |
| Ide, Y; Murata, K; Nishigaki, T | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Gotoh, K; Ishikawa, O; Kano, S; Kishi, K; Miyashiro, I; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Kagawa, Y; Kim, HM; Mizushima, T; Mori, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S | 1 |
| Chika, N; Dan, N; Goto, H; Hosokawa, T; Kakimoto, M; Kato, H; Koshiishi, H; Masuda, T; Matsuyama, T; Mitsuhashi, Y; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H; Yoshimura, T | 1 |
| Ng, S; O'bichere, A; Platell, C; Tebbutt, N | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wen, Q; Zhang, Y; Zhou, MQ | 1 |
| Feng, X; Gui, H; Hu, G; Li, Y; Luan, X; Mao, Z; Peng, Y; Shen, J; Yan, B; Yang, J | 1 |
| Brugge, W; Cizginer, S; Kambadakone, A; Karaca, C; Konuk, Y; Macfarlane, C; Mino-Kenudson, M; Sahani, DV; Turner, BG | 1 |
| Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Hori, S; Seki, A | 1 |
| Guo, S; Liang, Y; Zhou, Q | 1 |
| Bot, B; Buyse, M; Cassidy, J; de Gramont, A; Grothey, A; Saltz, L; Sargent, D; Shi, Q; Van Cutsem, E; Wolmark, N; Yothers, G | 1 |
| Callot, V; Chinot, O; Cozzone, PJ; Fellah, S; Girard, N | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S | 1 |
| Endo, I; Kumamoto, T; Nojiri, K; Takeda, K; Tanaka, K | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Basdanis, G; Dimopoulos, MA; Economopoulos, T; Efstratiou, I; Fountzilas, G; Kafiri, G; Kalofonos, HP; Karanikiotis, C; Karina, M; Klouvas, G; Korantzis, I; Makatsoris, T; Malettou, L; Matsiakou, F; Miliaras, D; Papadimitriou, CA; Papakostas, P; Papaspirou, I; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Xiros, N | 1 |
| Brown, MS; Cloughesy, T; Das, A; Goldin, J; Hambleton, J; Huo, J; Kim, HJ; Paton, VE; Pope, WB; Xia, Q | 1 |
| Cai, X; Guo, WJ; Li, J; Liu, X; Tian, S; Zhang, XW | 1 |
| Barnett-Griness, O; Cohen, I; Gruber, SB; Kuten, A; Lejbkowicz, F; Rennert, G; Shulman, K | 1 |
| Bi, F; Chen, X; Chen, Y; Cheng, K; Gao, F; Gong, FM; Liu, JY; Peng, XC; Wei, M; Xu, F | 1 |
| Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH | 1 |
| Saito, Y | 1 |
| Chang, HJ; Choi, HS; Kim, DY; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K | 1 |
| Benoit, JP; Lagarce, F; Roger, E | 1 |
| Fujikawa, K; Hazama, S; Kato, T; Kimura, H; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K | 1 |
| Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S | 1 |
| Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Taniguchi, H; Yamada, Y | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T | 1 |
| Chon, HJ; Chung, HC; Jeung, HC; Kim, HS; Noh, SH; Park, HS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Chin, K; Esaki, T; Furukawa, H; Hamada, C; Iishi, H; Imamoto, H; Imamura, H; Narahara, H; Sakata, Y; Tsuburaya, A | 1 |
| Ito, S; Kawai, H; Kondo, C; Matsuo, K; Mizota, A; Muro, K; Nomura, M; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Chen, KC; Cheng, TL; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Bohoyo Gil, D; Durán-Merá, I; Hurtado Sánchez, MC; Rodríguez-Cáceres, MI | 1 |
| Beretta, G; Biroccio, A; D'Angelo, C; Franceschin, M; Gilson, E; Leonetti, C; Orlandi, A; Passeri, D; Pisano, C; Porru, M; Rizzo, A; Salvati, E; Stevens, MF; Zunino, F; Zupi, G | 1 |
| Bi, F; Chen, J; Chen, X; Chen, XZ; Lang, N; Liu, M; Tang, QL; Zhao, XF | 1 |
| Ito, S; Kawai, H; Muro, K; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Farndon, P; Li-Wan-Po, A | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Sharkey, RM; Trisal, P | 1 |
| Hasselbalch, B; Jakobsen, JN; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
| Kang, SP; Saif, MW | 1 |
| Makrilia, N; Saif, MW; Syrigos, KN | 1 |
| Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
| Alì, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Di Paolo, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
| Aoki, M; Fujii, M; Murata, T; Oda, K | 1 |
| Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M | 1 |
| Arita, M; Fujino, H; Kuga, Y; Miwata, T; Moriya, T; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
| Bjerregaard, JK; De Stricker, K; Gjerstorff, MF; Hansen, TP; Jensen, HA; Pfeiffer, P; Schoennemann, KR; Vestermark, LW | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Mohamed, F; Passot, G; Steghens, A; Tod, M | 1 |
| Asanuma, H; Hasegawa, T; Hirata, K; Hirohashi, Y; Inoda, S; Ishitani, K; Kondo, T; Morita, R; Nakatsugawa, M; Nishizawa, S; Sato, N; Takahashi, A; Tamura, Y; Terui, T; Torigoe, T; Tsuruma, T | 1 |
| Hede, K | 1 |
| Inaba, Y; Kato, M; Kondo, C; Mizota, A; Muro, K; Nomura, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T | 1 |
| Frifeldt, SK; Jakobsen, A; Lindebjerg, J; Pallisgaard, N; Spindler, KL | 1 |
| Abdalla, EK; Andreou, A; Brouquet, A; Cooper, A; Curley, SA; Garrett, CR; Kopetz, S; Loyer, EM; Maru, DM; Overman, MJ; Vauthey, JN | 1 |
| Barriuso, J; Belda, C; Caldés, T; Castro, J; Cuadrado, E; Díaz-Rubio, E; Feliu Batlle, J; González-Barón, M; Martínez Marín, V; Sastre, J | 1 |
| Dumble, M; Greenberger, LM; Horak, ID; Kraft, P; Mehlig, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P; Wang, M | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Antonelli, A; Berti, P; Bocci, G; Canu, B; Cosconati, S; Da Settimo, F; Danesi, R; Di Desidero, T; Fioravanti, A; Frati, R; La Motta, C; Miccoli, P; Mugnaini, L; Orlandi, P; Sartini, S | 1 |
| Borel Rinkes, IH; Clevers, H; Emmink, BL; Govaert, KM; Hoogwater, FJ; Jimenez, CR; Kranenburg, O; Nijkamp, MW; Steller, EJ; Van Houdt, WJ; Verheem, A; Vries, RG | 1 |
| Boot, H; Hompes, D; van Tinteren, H; Verwaal, V | 1 |
| Goldenberg, DM; Govindan, SV; Karacay, H; Sharkey, RM | 1 |
| Aragane, N; Fukushima, N; Hayashi, S; Ide, M; Kimura, S; Mochinaga, S; Nakamura, T; Sueoka, E; Ureshino, N | 1 |
| Anantha, M; Bally, MB; Kozlowski, P; Masin, D; Strutt, D; Verreault, M; Waterhouse, D; Yapp, DT; Yung, A | 1 |
| Manabe, S; Matsumura, Y; Yasunaga, M | 1 |
| Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Andreola, F; Campisi, M; Mercuri, L; Moroni, N; Pierimarchi, P; Psaila, R; Renier, D; Secchieri, C; Serafino, A; Zonfrillo, M | 1 |
| Buchsbaum, DJ; Fineberg, NS; Folks, KD; George, JF; Grizzle, WE; Guo, L; Kim, H; Morgan, DE; Sellers, JC; Stockard, CR; Zinn, KR | 1 |
| Imaoka, S; Kanoh, T; Kimura, Y; Min Kim, H; Monden, T; Nakano, Y; Ohnishi, T; Tono, T; Yano, H | 1 |
| Hadano, N; Imamura, Y; Koyama, M; Kuwada, A; Nakamitsu, A; Taogoshi, H; Uegami, S | 1 |
| Arai, Y; Boku, N; Denda, T; Fujii, H; Hamaguchi, T; Hyodo, I; Iwase, H; Koizumi, W; Ohtsu, A; Saito, H; Shirao, K; Takiuchi, H; Yoshida, M | 1 |
| Barbuzza, O; Guarneri, C; Pollicino, A; Vaccaro, M | 1 |
| Crews, KR; Furman, WL; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tagen, M; Wozniak, A; Wu, J | 1 |
| Kimura, Y; Kitajima, M; Komatsu, Y; Oda, H; Saji, S; Sakamoto, J; Sakata, Y; Sakurai, J; Tajima, Y; Takahashi, M; Takahashi, Y; Tamura, S; Tatebe, S; Wakasugi, T | 1 |
| Dehais, C; Delattre, JY; Golmard, JL; Jouniaux-Delbez, N; Liou, A; Nguyen, BK; Souvannavong, V; Tadrist, C | 1 |
| Dzurenkova, A; Kadasi, L; Minarik, G; Mladosievicova, B; Soltysova, A; Sufliarska, S; Turna, J | 1 |
| Han, JY; Kim, HT; Lee, JS; Lim, KY; Yu, SY; Yun, T | 1 |
| Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K | 1 |
| Advani, S; Bonaventura, A; Cheirsilpa, A; Esser, R; Hsieh, RK; Im, SA; Lim, R; Mueser, M; Sun, Y; Yau, TK | 1 |
| Bjerregaard, JK; Fromm, AL; Hoegdall, E; Jensen, BV; Jørgensen, TL; Larsen, FO; Nielsen, D; Pfeiffer, P; Qvortrup, C; Skougaard, K; Vistisen, K | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Begnami, MD; Cezana, L; Costa, LA; Dettino, AL; Fanelli, MF; Mello, CA; Oliveira, TB; Pinto, CA | 1 |
| Van Loon, K; Venook, AP | 2 |
| Li, Y; Liu, J; Ren, Y | 1 |
| Huang, XE; Li, C; Li, Y | 1 |
| Gelderblom, H; Slingerland, M | 1 |
| Eng, C; Garrett, CR | 1 |
| Bearzi, I; Biscotti, T; Cascinu, S; Falcone, A; Faloppi, L; Galizia, E; Giampieri, R; Labianca, R; Loupakis, F; Mandolesi, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Gemma, A; Kakihata, K; Kon, A; Nagashima, M; Suzuki, T; Yoshii, N | 1 |
| Aiyama, R; Asakawa, N; Furuta, T; Hatano, H; Igarashi, Y; Kodaira, H; Matsuzaki, T; Nishiyama, Y; Sugimoto, Y; Takahashi, H; Yagi, N; Yamazaki, R | 1 |
| Hirano, T; Matsumoto, K; Morisaki, T; Sada, M | 1 |
| Futagami, M; Hakamada, K; Hirakawa, H; Mizunuma, H; Yokoyama, Y | 1 |
| Balivada, S; Basel, MT; Bossmann, SH; Myers, C; Pyle, M; Rachakatla, RS; Seo, GM; Shrestha, TB; Tamura, M; Troyer, DL; Wang, H | 1 |
| Bedognetti, D; Bussom, S; Chen, J; Cheng, YC; Guan, F; Jiang, Z; Lam, W; Marincola, FM; Mark, Y; Quinn, C; Stroncek, DF; Wang, E; White, J; Zhao, Y | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Chen, DY; Qi, Q; Zhao, WY | 1 |
| Lin, CF; Lin, WJ; Luo, TY; Peng, CL; Shieh, MJ; Tsai, HM; Yang, SJ | 1 |
| Ando, T; Fujinami, H; Hasumoto, Y; Hosokawa, A; Itaya, Y; Kajiura, S; Miyazaki, T; Nishikawa, J; Ogawa, K; Sugiyama, T; Suzuki, N; Ueda, A; Yamawaki, H | 1 |
| Sai, K; Saito, Y | 1 |
| Cui, J; Li, C; Li, Y; Wang, C; Wang, P; Wei, N; Xiu, X; Zhang, L | 1 |
| Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Bang, S; Chung, JB; Chung, MJ; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Jerger, K; Kieler-Ferguson, HM; Riviere, K; Szoka, FC | 1 |
| Arimochi, H; Itoh, M; Kashiwagi, M; Morita, K; Nishibori, N | 1 |
| Chang, HJ; Kim, BC; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Ayuzawa, R; Doi, C; Maurya, DK; Tamura, M; Troyer, D | 1 |
| Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C | 1 |
| Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G | 1 |
| Boc, M; Ocvirk, J; Rebersek, M | 1 |
| Deb, J; Dibra, H; Kankipati, CS; Manneh, J; Nicholl, ID; Perry, CJ; Rajan, S; Shan, S | 1 |
| Gotwald, T; Hutterer, M; Jacobs, AH; Kostron, H; Muigg, A; Nowosielski, M; Putzer, D; Staffen, W; Stockhammer, G; Tinkhauser, G; Trinka, E; Virgolini, IJ; Waitz, D | 1 |
| Benković, V; Dikić, D; Karabeg, S; Knežević, AH; Kopjar, N; Lisičić, D; Oršolić, N | 1 |
| Anderson, K; Burris, HA; Jones, S; Marier, JF; Pheng, L; Porubek, D; Trinh, MM; Warner, S | 1 |
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Branda, ME; Goldberg, RM; Grothey, A; Heun, JM; Sargent, DJ | 1 |
| Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M | 1 |
| Bi, F; Chen, X; Chen, Y; Ge, J; Gong, FM; Hou, JM; Liu, JY; Peng, XC; Tan, BX; Xu, F | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Allen, JE; Brown, JM; Daniel, CJ; Dicker, DT; Dolloff, NG; Dorsey, JF; El-Deiry, WS; Furth, EE; Hart, LS; Jee, DI; Klein, PS; Kuribayashi, K; Liu, JJ; Liu, YY; Mayes, PA; Sears, RC | 1 |
| Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM | 1 |
| Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Matsuo, K; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Ura, T; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A | 1 |
| Baylatry, MT; Fernandez, C; Ghegediban, H; Joly, AC; Lacombe, P; Laurent, A; Lewis, A; Pelage, JP; Wassef, M | 1 |
| Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S | 1 |
| Devore, RF; Horn, L; Johnson, D; Laskin, J; Sandler, A; Shyr, Y; Wolff, S; Zhao, Z | 1 |
| Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Takagi, Y | 1 |
| Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J | 1 |
| Chang, SC; Lan, YT; Li, AF; Lin, AJ; Lin, CC; Lin, JK; Yang, SH | 1 |
| Ahowesso, C; Filipski, E; Guettier, C; Hossard, V; Iacobelli, S; La Sorda, R; Lévi, F; Okyar, A; Piccolo, E; Tinari, N | 1 |
| Kabbinavar, F; Kozloff, M | 1 |
| Boisen, MK; Jensen, BV; Johansen, JS; Larsen, O | 1 |
| Fujii, S; Fukahori, M; Godai, TI; Imada, T; Kunisaki, C; Makino, H; Masuda, M; Numata, M; Oshima, T; Rino, Y; Sato, T | 1 |
| Horiba, T; Inoue, T; Masubuchi, M; Matsumura, T; Oomoto, K; Orihara, A; Sato, E; Yagi, Y | 1 |
| Chang, HM; Hong, YS; Jang, SJ; Kang, YK; Kim, JC; Kim, JE; Kim, JH; Kim, MJ; Kim, TW; Lee, JL; Lim, SB; Ryu, MH; Yu, CS | 1 |
| Carnaghi, C; Personeni, N; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC | 1 |
| Kawakami, H; Nakagawa, K; Satoh, T; Shimomura, Y; Sugioka, K; Yonesaka, K | 1 |
| Bonnabry, P; Fleury-Souverain, S; Geiser, L; Hochstrasser, D; Nussbaumer, S; Sadeghipour, F; Veuthey, JL | 1 |
| Baek, JY; Chang, HJ; Chang, HM; Hong, YS; Kang, MJ; Kang, YK; Kim, KP; Kim, MJ; Kim, SY; Kim, TW; Lee, JL; Ryu, MH | 1 |
| Ahowesso, C; Beau, J; Claustrat, B; Delaunay, F; Dulong, S; Filipski, E; Hossard, V; Lévi, F; Li, XM; Peteri-Brunbäck, B; Zampera, S | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Chabot, J; Saif, MW | 1 |
| Ankerst, DP; Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Moosmann, N; Schalhorn, A; Schulz, C; Stintzing, S; von Weikersthal, LF | 1 |
| Basseville, A; Boisdron-Celle, M; Coqueret, O; de Carné Trécesson, S; Gamelin, E; Morel, A; Preisser, L | 1 |
| Li, G; Li, M; Rabba, AK; Si, L; Xue, K | 1 |
| Chen, X; Guo, R; Jin, S; Shu, Y; Sun, J; Wang, T; Xu, B | 1 |
| Amatulli, M; Bassi, R; Deevi, D; Li, H; Paz, K; Prewett, M; Samakoglu, S; Tonra, JR; Wang, S; Witte, L | 1 |
| Esaki, T; Hyodo, I; Ishizuka, N; Kakeji, Y; Koizumi, W; Munakata, M; Nishina, T; Okamura, S; Sakata, Y; Sasaki, Y; Satoh, T; Tsujinaka, T; Ura, T; Yamada, Y; Yamazaki, K | 1 |
| Cao, LP; Liang, LZ; Liu, JH; Min, Z; Xiong, Y | 1 |
| Chen, Y; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Bichev, D; Breithaupt, K; Deist, T; Dogan, Y; Gebauer, B; Hinke, A; Kretzschmar, A; Reichardt, P; Schumacher, G; Thuss-Patience, PC | 1 |
| Abbruzzese, JL; Budillon, A; Carbone, C; Chiao, PJ; Ling, J; Melisi, D; Moccia, T; Paradiso, G; Xia, Q | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Hurtado-Sánchez, Mdel C; Martín-Merás, ID; Rodríguez-Cáceres, MI | 1 |
| Manabe, S; Matsumura, Y; Tarin, D; Yasunaga, M | 2 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Holt, K | 1 |
| Dahan, L; Gasmi, M; Gaudart, J; Norguet, E; Ouafik, L; Seitz, JF | 1 |
| Rocha, JA | 1 |
| Aprile, G; Avallone, A; Bordonaro, R; Butera, A; Cordio, S; De Pauli, F; Di Lucca, G; Parra, HS; Reggiardo, G; Rosati, G | 1 |
| Matsueda, S; Sasaki, H; Tokunaga, Y | 1 |
| Hashimoto, M; Hiraike, M; Honda, S; Misumi, N; Nabeshima, A; Nawata, F; Takase, I; Tanigawa, K | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Saguchi, M; Someno, Y; Takahata, T; Yoshida, T | 1 |
| Dumont, F; Elias, D; Goéré, D; Hessissen, M; Mehta, SS; Quenet, F; Roca, L; Saint-Aubert, B | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, L; Lee, RJ; Meropol, NJ; Mitchell, E; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Winter, K; Wong, SJ | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T | 1 |
| Bocci, G; Danesi, R; Del Re, M; Di Desidero, T; Di Paolo, A; Lastella, M; Polillo, M | 1 |
| Friess, H; Janssen, KP; Johannes, L; Keller, L; Kleeff, J; Langer, R; Maak, M; Nitsche, U; Rosenberg, R; Sarr, M; Thiebaud, M; Wolf, P | 1 |
| Altinbas, M; Camci, C; Dikilitas, M; Kalender, ME; Ozkan, M; Sevinc, A | 1 |
| Billups, CA; Davidoff, AM; Furman, WL; Hawkins, D; Houghton, PJ; Kovach, S; McCarville, MB; McGregor, LM; McPherson, V; Onciu, M; Santana, VM; Stewart, CF; Wu, J | 1 |
| Bosset, JF; Créhange, G; Maingon, P | 1 |
| Bennouna, J; Borg, C; Bouché, O; Delord, JP; Douillard, JY; Faroux, R; François, E; Goldwasser, F; Husseini, F; Kraemer, S; Senellart, H; Trillet-Lenoir, V; Ychou, M | 1 |
| Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ | 1 |
| Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL | 1 |
| Bahary, N; Carneiro, BA; Crandall, TL; Fakih, MG; Krishnamurthi, SS; Lancaster, SL; Lembersky, BC; Pinkerton, RA; Potter, DM; Ramanathan, RK; Schmotzer, AR; Stoller, RG | 1 |
| Chan, RT; Fung, CF; Hung, KN; Leung, GK; Ng, GK; Pu, JK | 1 |
| Iseki, S; Kato, Y; Kijima, A; Nakamichi, N; Shimizu, T; Silver, DL; Sugiura, T; Wakayama, T | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Asai, H; Chin, K; Hatake, K; Matuzaka, S; Mizunuma, N; Nozaki, A; Shinozaki, E; Suenaga, M; Watanabe, T; Yasukawa, M | 1 |
| Fujii, Y; Hamano, K; Hanashima, M; Kuga, T; Oka, K; Yamashita, A | 1 |
| Asaka, M; Fukushima, H; Iwanaga, I; Kawamoto, Y; Kobayashi, Y; Komatsu, Y; Nakatsumi, H; Sasaki, T; Sogabe, S; Takano, H; Uehata, Y; Yuki, S | 1 |
| Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, N | 1 |
| Berglund, Å; Blomqvist, L; Byström, P; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A; Suzuki, C | 1 |
| Choe, CY; Dong, J; Kim, H; Law, PY; Loh, HH; van Wijnen, AJ | 1 |
| Arimori, K; Hirabara, Y; Iwakiri, T; Kawano, Y; Okumura, M; Takagi, A | 1 |
| Antonacopoulou, AG; Bafaloukos, D; Bompolaki, I; Bournakis, E; Briasoulis, E; Dimitrakopoulos, FI; Eleftheraki, AG; Fostira, F; Fountzilas, G; Galani, E; Kalofonos, HP; Kalogeras, KT; Koumarianou, A; Koutras, AK; Pectasides, D; Sgouros, J; Varthalitis, I | 1 |
| Abbott, DH; Ayanian, JZ; Catalano, P; Fouad, MN; Ganz, PA; Grambow, SC; Kahn, KL; Kolimaga, JT; Malin, JL; Provenzale, D; Schrag, D; Wallace, R; Weeks, JC; West, DW; Zafar, SY; Zullig, LL | 1 |
| Liu, GS; Liu, JL; Meng, L; Miu, B; Wang, S; Xi, J; Yao, YS; Yao, ZJ | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Bohn, B; Erben, P; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kähler, G; Kienle, P; Post, S; Schwaab, J; Ströbel, P; Wenz, F | 1 |
| Cohn, AL; Khandelwal, P; Mehta, N; Neubauer, MA; Richards, D; Shumaker, GC; Smith, DA; Watkins, DL; Yassine, MR; Zhang, K | 1 |
| Agarwal, A; Ferrarotto, R; Hoff, PM; Kopetz, S; Maru, D; Overman, M; Pathak, P | 1 |
| Critchfield, GC; Hamilton, SA; Kaldate, RR; Roa, BB; Saam, J; Wenstrup, RJ | 1 |
| Brenckman, W; Cheng, YC; Chu, E; Copur, MS; Jiang, Z; Kummar, S; Liu, SH; O'Rourke, M; Rose, M; Stephenson, J; Su, T; Tilton, R; Wadler, S | 1 |
| André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C | 1 |
| Cohen, EE; House, LK; Innocenti, F; Janisch, L; Karrison, T; Ramírez, J; Ratain, MJ; Wu, K | 1 |
| Farma, JM; Matteotti, RS; Nitzkorski, JR; Sigurdson, ER; Siripurapu, V; Watson, JC; Zhu, F | 1 |
| Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Milella, M; Sperduti, I; Vaccaro, V | 1 |
| Allen, PJ; Brady, MS; Busam, KJ; Chou, JF; Coit, DG; Fields, RC; Kraus, DH; Panageas, KS; Pulitzer, MP | 1 |
| Abe, F; Hasegawa, T; Hotta, K; Kato, A; Kondo, F; Oshima, T; Saito, H; Tsukiyama, I; Ueyama, J | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Dahlbom, M; Huang, SC; Phelps, ME; Satyamurthy, N; Schiepers, C; Wardak, M | 1 |
| Choi, SA; Jin, X; Kim, H; Kim, SK; Kim, SU; Lee, DH; Lee, HJ; Lee, JY; Lim, I; Lim, SH; Phi, JH; Song, JH; Song, SH; Wang, KC | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Rustum, YM; Toth, K | 1 |
| Arai, Y; Ashida, K; Ikeguchi, M; Katano, K; Maeta, Y; Wakatsuki, T | 1 |
| Kotsuji, F; Kurokawa, T; Masada, M; Matsunaga, A; Nakamura, T; Sawamura, Y; Shinagawa, A; Tsuyoshi, H; Yano, R; Yoneda, M; Yoshida, Y | 1 |
| Ikeda, R; Iseki, K; Iwashita, Y; Kondo, T; Osada, T; Shibayama, Y; Sugawara, M; Takeda, Y; Yamada, K; Yoshikawa, Y | 1 |
| Di Fiore, F; Michel, P | 1 |
| Ng, RC; Tantisattamo, E | 1 |
| Angelopoulos, S; Despoudi, K; Kanellos, D; Koliakos, G; Lazaridis, C; Mantzoros, I; Pramateftakis, MG; Raptis, D; Zaraboukas, T | 1 |
| Bhattacharyya, M; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Wilson, P | 1 |
| Arbitrio, M; Cannataro, M; Caraglia, M; Ciliberto, D; Di Martino, MT; Doldo, P; Fabiani, F; Guzzi, PH; Leone, E; Rotundo, MS; Sperlongano, P; Tagliaferri, P; Talarico, D; Tassone, P; Tomaino, V | 1 |
| Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T | 1 |
| Burden, RE; Gazdoiu, M; Gormley, JA; Jaquin, TJ; Johnston, JA; Kuehn, D; Kwok, HF; McClurg, A; Olwill, SA; Scott, CJ; Ward, C | 1 |
| Efrusy, MB; Göke, B; Goldberg, RM; Kirchner, T; Santas, CC; Vijayaraghavan, A | 1 |
| Peeters, M; Price, T | 1 |
| Ko, AH | 2 |
| Kamiyama, H; Kato, T; Koizumi, K; Konishi, F; Maeda, T; Miyaki, Y; Saito, M; Shibata, K; Shiya, N; Suzuki, K | 1 |
| Abbas, M; Auby, D; Azzedine, A; Bedenne, L; Bouché, O; Castaing, M; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lombard-Bohas, C; Malka, D; Mendiboure, J; Michel, P; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E | 1 |
| Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L | 1 |
| Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F | 1 |
| Agostini, V; Biasco, G; Bolondi, L; Borghi, A; Brandi, G; Cappelli, A; Costantini, S; Danesi, R; Derenzini, E; Di Paolo, A; Fanello, S; Giampalma, E; Golfieri, R; Mirarchi, MG; Pini, P; Piscaglia, F | 1 |
| Gen, R; Inoue, N; Nakajima, H; Shibuya, Y; Shikama, Y; Tanzawa, S | 1 |
| Kageyama, S; Katayama, N; Mizuno, T; Nomura, H; Oda, H; Saito, K; Tamaru, S; Yamashita, Y | 1 |
| Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Farrar, WL; Fornaro, L; Frumento, P; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Abbara, C; Ballesta, A; Clairambault, J; Cohen, B; Dulong, S; Levi, F; Okyar, A | 1 |
| Furuta, T; Hashimoto, S; Kodaira, H; Kurita, A; Matsuzaki, T; Nohara, G; Sawada, S; Takagi, A; Ueno, S | 1 |
| Deepak, P; Ehrenpreis, ED | 1 |
| Debelec-Butuner, B; Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Korkmaz, KS; Muhammed Syed, H; Ozmen, B; Varisli, L; Yilmazer-Cakmak, O | 1 |
| Aoki, Y; Arimura, Y; Goto, A; Igarashi, H; Itoh, M; Kaneto, H; Kobayashi, T; Matsunaga, Y; Okuda, H; Onodera, K; Shimizu, H; Shinomura, Y; Sukawa, Y; Suzuki, K; Wakasugi, H; Yawata, A; Yonezawa, K | 1 |
| Capussotti, L; Mellano, A; Muratore, A; Ribero, D; Viganò, L; Zimmitti, G | 1 |
| Alonso, MM; Bandres, E; Bitarte, N; Boni, V; Fortes, P; Garcia-Foncillas, J; Gonzalez-Huarriz, M; Javier Sola, J; Lopez, I; Rodriguez, J; Zarate, R | 1 |
| Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G | 1 |
| Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY | 1 |
| Aoyama, M; Asai, K; Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kubota, E; Mizoshita, T; Mori, Y; Murakami, K; Okamoto, Y; Shimura, T; Tanaka, M; Tanida, S | 1 |
| Czejka, M; Ettlinger, D; Kiss, A; Koessner, C; Schueller, J; Terkola, R | 1 |
| Akie, K; Dosaka-Akita, H; Fujita, Y; Fukumoto, S; Harada, M; Harada, T; Isobe, H; Kikuchi, E; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Ohsaki, Y; Oizumi, S; Shinagawa, N | 1 |
| Dudek, AZ; Graziano, SL; Green, MR; Hodgson, LD; Pang, HH; Ready, NE; Vokes, EE | 1 |
| Allen, PJ; Blumgart, LH; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; House, MG; Jarnagin, WR; Kemeny, NE; Paty, PB | 1 |
| Brinker, T; Glage, S; Hedrich, HJ; Held, N; Lewis, AL | 1 |
| Bosnjak, SM; Hesketh, PJ; Nikolic, V; Rapoport, B | 1 |
| Cheema, TA; Kanai, R; Kim, GW; Martuza, RL; Passer, B; Rabkin, SD; Wakimoto, H | 1 |
| Bulusu, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Chang, CY; Cho, YB; Choi, DH; Chun, HK; Kim, HC; Lee, WY; Park, HC; Park, JO; Park, YS; Yun, SH | 1 |
| Bains, M; Campbell, J; Capanu, M; Ilson, DH; Kelsen, DP; Ku, GY; Minsky, BD; Rizk, N; Rusch, V; Shah, M; Tang, L | 1 |
| Arlt, A; Bauer, I; Ehlers, S; Geismann, C; Grage-Griebenow, E; Kruse, ML; Schäfer, H; Sebens, S | 1 |
| Ackerstaff, E; Chen, JH; Darpolor, MM; Kennealey, PT; Koutcher, JA; Le, HC; Rizwan, A; Sambol, EB; Schwartz, GK; Singer, S; Zakian, KL | 1 |
| Lewis, MR | 1 |
| Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Bhattacharyya, J; Hoshi, M; Kimura, A; Mihara, K; Ohtsubo, M; Sakai, A; Takei, Y; Takihara, Y; Yanagihara, K; Yasunaga, S | 1 |
| Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M | 1 |
| Anantha, M; Bally, MB; Masin, D; Strutt, D; Verreault, M; Waterhouse, D; Yapp, DT | 1 |
| Fourcade, S; Gaudy-Marqueste, C; Grob, JJ; Richard, MA; Tasei, AM | 1 |
| Buhr, HJ; Fusi, A; Hotz, B; Hotz, HG; Keilholz, U | 1 |
| Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M | 1 |
| Bito, T; Fabian, G; Farago, N; Feher, LZ; Katona, RL; Kitajka, K; Kulin, S; Nagy, LI; Puskas, LG; Tiszlavicz, L; Tubak, V | 1 |
| Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, NB | 1 |
| Allen, WL; Carson, G; Coyle, VM; Gordon, MA; Jithesh, PV; Johnston, PG; Lenz, HJ; Longley, DB; Proutski, I; Stevenson, L; Van Schaeybroeck, S | 1 |
| Brem, S; Chinnaiyan, P; Chowdhary, S; Kahali, S; Murtagh, R; Pan, E; Potthast, L; Prabhu, A; Rojiani, A; Sarcar, B; Tsai, YY; Yu, HM | 1 |
| Chen, L; Davis, M; Gaur, S; Wang, Y; Yen, T; Yen, Y; Zhou, B | 1 |
| Bachellier, P; Gaub, MP; Guenot, D; Guérin, E; Larsen, AK; Maier, A; Moras, D; Neuville, A; Oudet, P; Pencreach, E; Petitprez, A; Poch, O; Raffelsberger, W; Rohr, S; Schneider, A | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Sharkey, RM | 1 |
| Takane, H | 1 |
| Ishida, Y; Nakamura, Y; Shimada, S; Yamada, T | 1 |
| Alyasiri, A; Dvorak, A; Fleshman, JW; Hoskins, JM; McLeod, HL; Motsinger-Reif, AA; Myerson, RJ; Roy, S; Tan, BR; Thomas, F | 1 |
| Pauwels, P; Peeters, M; Reutelingsperger, CP; Staelens, S; Van Damme, N; Van de Wiele, C; Vangestel, C | 1 |
| Lansiaux, A; Pourquier, P | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Barroso, E; Carvalho, C; Choti, MA; de Jong, MC; Nobre, AM; Pawlik, TM; Pinto Marques, H; Ribeiro, V | 1 |
| Chikakiyo, M; Higashijima, J; Iwata, T; Kurita, N; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K | 1 |
| Caroli-Bosc, FX; Czerucka, D; Fenouille, N; Grosso, S; Imbert, V; Lagadec, P; Mary, D; Peyron, JF; Pontier-Bres, R; Yunchao, S | 1 |
| Chen, A; Chirmule, N; Gupta, S; Kaliyaperumal, A; Pennucci, JJ; Pérez-Ruixo, JJ; Starcevic, M; Swanson, SJ; Weeraratne, D; Wright, J; Wu, CY; Yang, BB; Zhang, K | 1 |
| Hotta, K; Kiura, K; Matsumura, T; Takigawa, N; Taniguchi, A; Tanimoto, M | 1 |
| Anantha, M; Bally, MB; Sutherland, B; Verreault, M; Waterhouse, DN; Yapp, D | 1 |
| Lee, PL; Sung, C; Tan, LL; Toh, DS | 1 |
| Aboody, KS; Annala, AJ; Garcia, E; Gilchrist, M; Glackin, CA; Gutova, M; Kim, SU; Metz, MZ; Najbauer, J; Polewski, MD; Zhao, D | 1 |
| Chen, MX; Fan, L; Hu, XZ; Jiang, HY; Li, CY; Liang, XB; Ma, JJ; Yan, D | 1 |
| Brito, GA; Cunha, FQ; Figueiredo, AA; Freitas, HC; Leite, CA; Lima-Júnior, RC; Marques-Neto, RD; Medeiros, RP; Melo, ML; Oriá, RB; Ribeiro, RA; Souza, MH; Vale, ML; Wong, DV | 1 |
| He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Anderson, P; Bilton, SD; Chang, EL; Fontanilla, HP; Green, HL; Grosshans, DR; Hayes-Jordan, A; Mahajan, A; McAleer, MF; Pinnix, CC; Subbiah, V; Sulman, EP; Woo, SY | 1 |
| Baba, H; Beppu, T; Hayashi, N; Sawayama, H; Takamori, H; Watanabe, M | 1 |
| Bearzi, I; Biagetti, S; Biscotti, T; Cascinu, S; Falcone, A; Galizia, E; Giampieri, R; Giustini, L; Loupakis, F; Maccaroni, E; Mandolesi, A; Scartozzi, M; Silva, R; Zaniboni, A | 1 |
| Akama, TO; Bobkov, AA; Fukuda, M; Fukuda, MN; Hatakeyama, S; Nakayama, J; Ohyama, C; Shibata, TK; Sugihara, K; Takano, Y; Tamura, N; Wong, SM | 1 |
| Hayashi, H; Masuda, N; Miyazaki, M; Morinaga, R; Nakagawa, K; Nakayama, T; Nishida, Y; Okamoto, I; Okamoto, W; Sakamoto, J; Satoh, T; Terashima, M; Tokunaga, Y; Tominaga, S; Tsurutani, J; Yamaguchi, M | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Fukushima, T; Kaneko, M; Kaneko, S | 1 |
| Kalokairinou, M; Malagari, K; Marinis, A; Moschouris, H; Papadaki, MG; Stamatiou, K | 1 |
| Daimon, T; Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubo, A; Mio, T; Mishima, M; Sasaki, Y | 1 |
| Hantke, T; Lepenies, B; Seeberger, PH; Thang, SH; Tsanaktsidis, J; Vogel, U; Williams, CC | 1 |
| El-Hadaad, HA; Roshdy, S; Wahba, HA | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Hollis, D; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Ng, K; Ogino, S; Saltz, LB; Schaefer, P; Shima, K; Spiegelman, D; Whittom, R | 1 |
| Burckhardt, G; Grottker, J; Hagos, Y; Rosenberger, A | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Alberts, SR; Franko, J; Goldberg, RM; Goldman, CD; Grothey, A; Nelson, GD; Pitot, HC; Pockaj, BA; Sargent, DJ; Shi, Q | 1 |
| Huang, QQ; Lu, W; Luo, Y; Yu, S | 1 |
| Bukofzer, G; Chakravartty, A; Cole, TB; Day, M; Donawho, CK; Fox, GB; Holich, KD; Luo, Y; Mudd, SR; Palma, JP; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| Brünner, N; Jensen, NF; Müller, S; Nielsen, HJ; Nielsen, KV; Nielsen, SL; Rømer, MU | 1 |
| Begg, EJ; Helsby, NA; Jensen, BP | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Brünner, N; Jensen, NF; Nielsen, KV; Nygård, SB; Rømer, MU; Smith, DH | 1 |
| Benhaim, L; Labonte, MJ; Lenz, HJ | 1 |
| Ciccolini, J; Dahan, L; Evrard, A; Iliadis, A; Lacarelle, B; Mbatchi, L; Mercier, C; Norguet, E; Ouafik, L; Ries, P; Seitz, JF; Tibbitts, J | 1 |
| Booth, B | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Miller, G | 1 |
| Bechter, O; Dlaska, M; Eisterer, W; Fridrik, MA; Greil, R; Grünberger, B; Mayrbäurl, B; Obrist, P; Russ, G; Thaler, J; Wöll, E; Zabernigg, A | 1 |
| Aliberti, C; Benea, G; Dallara, S; Fiorentini, G; Muzzio, PC; Pomerri, F; Tilli, M | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Miyoshi, Y; Morimoto, A; Ueda, Y; Yokoyama, T; Yoshino, K | 1 |
| Akiyama, Y; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Burckhardt, G; Gupta, S; Hagos, Y; Henjakovic, M; Koepsell, H; Wulf, G | 1 |
| Danno, K; Imaoka, S; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tohno, T | 1 |
| Iwanaga, T; Iwasaki, Y; Maeda, Y; Ohashi, M; Ohinata, R; Omuro, Y; Onoyama, H; Sasaki, E; Shimoyama, T; Tateishi, Y | 1 |
| Babaya, A; Hamanaka, M; Kamikonya, N; Kuno, T; Matsubara, N; Noda, M; Tomita, N; Tsukamoto, K; Yamagishi, D; Yamano, T | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Gao, J; Liu, D; Liu, Y; Ren, X; Xu, Y; Zhang, C | 1 |
| Antonucci, A; Bruera, G; Cannita, K; Ficorella, C; Giuliante, F; Lanfiuti Baldi, P; Marchetti, P; Nuzzo, G; Ricevuto, E; Vicentini, R | 1 |
| Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S | 1 |
| Furuta, T; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamada, T; Yamade, M | 1 |
| Bedekar, DP; Donohoe, DL; Kurpad, SN; Pechman, KR; Schmainda, KM | 1 |
| Munakata, M; Sakata, Y | 1 |
| Kato, K | 1 |
| Hamamoto, Y; Komaki, T; Nishi, T | 1 |
| Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U | 1 |
| Iwamoto, T; Matsuda, H; Mizutani, H; Okuda, M; Ueno, Y | 1 |
| Albanes, D; Baris, D; Black, A; Burdett, L; Carrato, A; Chanock, SJ; Chatterjee, N; De Vivo, I; Diver, WR; Figueroa, JD; Fraumeni, JF; Fu, YP; Gapstur, SM; Garcia-Closas, M; Garcia-Closas, R; Hall, JL; Hunter, DJ; Hutchinson, A; Jacobs, EJ; Johnson, A; Karagas, MR; Kogevinas, M; Liu, L; Lloreta, J; Malats, N; Myers, T; Porter-Gill, P; Prokunina-Olsson, L; Purdue, MP; Rothman, N; Schned, A; Schwenn, M; Serra, C; Silverman, DT; Tang, W; Tardón, A; Thun, M; Virtamo, J | 1 |
| Jakobsen, A; Pallisgaard, N; Spindler, KL; Vogelius, I | 1 |
| Albertsson, P; Lennernäs, B; Norrby, K | 1 |
| Chang, JE; Chong, S; Chung, SJ; Kim, DD; Kwak, EY; Shim, CK; Shim, WS | 1 |
| Cao, S; Durrani, FA; Rustum, YM; Yu, YE | 1 |
| Balivada, S; Basel, MT; Bossmann, SH; Pyle, MM; Seo, GM; Shrestha, TB; Tamura, M; Troyer, DL | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y | 1 |
| Bjerregaard, JK; Nielsen, KM; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Bai, T; Kobayashi, A; Matsuoka, T; Sasaki, N; Tanaka, J; Tanaka, T; Tanizaki, Y; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yamamoto, M; Yukawa, K | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Carpenter, W; Li, L; Meyerhardt, JA; Sanoff, HK; Schrag, D | 1 |
| Fongsuk, C; Manaspon, C; Nasongkla, N; Nittayacharn, P; Vejjasilpa, K | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Chu, F; Chua, TC; Liauw, W; Morris, DL | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Capussotti, L; Ferrero, A; Langella, S; Lo Tesoriere, R; Russolillo, N; Vigano', L | 1 |
| Blum, HE; Breidert, M; Euringer, W; Fischer, R; Harder, J; Kuhlmann, JB; Spangenberg, HC | 1 |
| Baltes, S; Brinker, T; Geigle, P; Glage, S; Lewis, AL; Mertens, P | 1 |
| Asseburg, C; Bravo Vergel, Y; Manca, A; Meade, A; Parmar, M; Sculpher, MJ; Seymour, MT; Stephens, R | 1 |
| Durán-Merás, I; Hurtado-Sánchez, MC; Jiménez-Girón, A; Olivieri, AC; Rodríguez-Cáceres, MI | 1 |
| Atreya, CE; Bergsland, EK; Ducker, GS; Feldman, ME; Shokat, KM; Warren, RS | 1 |
| Fujii, M; Hamada, N; Hosokawa, S; Hotta, K; Ichihara, E; Ikeda, G; Kiura, K; Kuyama, S; Nogami, N; Osawa, M; Oze, I; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Takata, S; Takigawa, N; Tamaoki, A; Tanimoto, M; Uno, M | 1 |
| Cacciatore, I; Cornacchia, C; Feliciani, F; Mollica, A; Pinnen, F; Stefanucci, A | 1 |
| Aerts, I; André, N; Bourdeaut, F; Corradini, N; Couec, ML; Leblond, P; Marec Bérard, P; Minckes, O; Rialland, X; Thebaud, E | 1 |
| Murayama, J; Okazaki, K; Saito, I; Watanabe, T | 1 |
| Alfaro, R; Chen, X; Figg, WD; Peer, CJ; Spencer, SD; Tian, T | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Saito, I; Shibata, T | 1 |
| Efferth, T; Eichhorn, T; Korn, B; Paulsen, M; Wiench, B | 1 |
| Ahn, YC; Chang, HM; Hong, YS; Jin, DH; Kang, YK; Kim, JC; Kim, KP; Kim, TW; Lee, JL; Na, YS; Park, SJ; Ryu, MH; Yu, CS | 1 |
| Brunet, R; Evrard, S; Kauffmann, A; Laroche-Clary, A; Laurand-Quancard, A; Le Morvan, V; Robert, J; Smith, D | 1 |
| Huang, H; Li, H; Liu, JH | 1 |
| Endo, S; Hidaka, E; Ikehara, K; Ishida, F; Kudo, SE; Omoto, T; Tanaka, J | 1 |
| Abe, T; Ando, M; Kato, T; Nakashima, H; Shindo, J; Shiraki, A; Yamamoto, K; Yukita, Y | 1 |
| Awada, A; Azim, HA | 1 |
| Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S | 1 |
| Asada, M; Kusano, K; Owa, T; Ozawa, Y; Yokoi, A; Yoshimatsu, K | 1 |
| Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K | 1 |
| Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M | 1 |
| Auperin, A; Bize, P; de Baere, T; Denys, A; Deschamps, F; Drouard-Troalen, L; Paci, A; Pascale, F; Rao, PP; Seck, A; Teriitheau, C | 1 |
| Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y | 1 |
| Gibbs, P; Tie, J | 1 |
| Barrie, M; Bequet-Boucard, C; Chinot, O; Colavolpe, C; Figarella-Branger, D; Guedj, E; Mancini, J; Metellus, P; Mundler, O; Tabouret, E | 1 |
| Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y | 1 |
| Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J | 1 |
| Cabral, CB; Fram, RJ; Hanna, SK; Lowinger, TB; Rawal, S; Sen, J; Walsh, MD; Yurkovetskiy, AV; Zamboni, WC | 1 |
| Bachellier, P; Chenard, MP; Fuchshuber, P; Jaeck, D; Narita, M; Nobili, C; Oussoultzoglou, E; Pessaux, P; Rosso, E | 1 |
| Addeo, R; Bronte, G; Cascinu, S; Cicero, G; Falcone, A; Frezza, AM; Garufi, C; Imperatori, M; Maiello, E; Mancuso, A; Masi, G; Recine, F; Russo, A; Santini, D; Scartozzi, M; Schiavon, G; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH | 1 |
| Aboody, KS; Abramyants, Y; Annala, AJ; Barish, ME; Blanchard, MS; D'Apuzzo, M; Gutova, M; Herrmann, KA; Khankaldyyan, V; Kim, SU; Mittelholtz, K; Moats, RA; Najbauer, J; Shackleford, GM; Shi, XH; Synold, TW | 1 |
| Addeo, P; Bachellier, P; Chenard, MP; Fuchshuber, P; Jaeck, D; Narita, M; Oussoultzoglou, E; Rather, M; Rosso, E | 1 |
| Baek, SK; Cho, KS; Jeong, JH; Kim, SY; Yoon, HJ | 1 |
| Hwang, IG; Kang, JH; Kang, WK; Kwon, HC; Lee, J; Lee, SC; Lee, SI; Lim, DH; Lim, HY; Nam, E; Oh, SY; Park, JO; Park, KW; Park, SH; Park, YS; Shin, DB | 1 |
| da Costa Lima, AB; Macedo, LT; Sasse, AD | 1 |
| Attia, S | 1 |
| Asakuma, M; Fukui, T; Igawa, S; Katagiri, M; Katono, K; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Sasaki, J; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yokoba, M | 1 |
| Harling, H; Kirkeby, LT; Mocellin, S; Petersen, SH; Wille-Jørgensen, P | 1 |
| Chesler, L; DuBois, SG; Goodarzian, F; Groshen, S; Hawkins, R; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Shimada, H; Stewart, C; Tagen, M; Tsao-Wei, D; Villablanca, JG; Yanik, G | 1 |
| Ikeda, T; Minamoto, K; Yuasa, I | 1 |
| Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
| Cai, SR; Munir, AZ; Origanti, S; Piwnica-Worms, H; White, LS | 1 |
| Daimon, T; Furuse, K; Kawahara, M; Mio, T; Okishio, K; Yanagihara, K; Yoshioka, H | 1 |
| Coco, C; Ferlini, C; Mariani, M; Martinelli, E; Martino, C; Scambia, G; Shahabi, S; Sieber, S; Sioletic, S; Zannoni, GF | 1 |
| Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W | 1 |
| Carrillo, JA; Munoz, CA | 1 |
| Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC | 1 |
| Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT | 1 |
| Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Shimo, T; Sonoo, H; Yamashita, T | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Calway, T; Du, GJ; Du, W; He, TC; Somogyi, J; Wang, CZ; Wen, XD; Yuan, CS; Zhang, ZY | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Hernandez-Boussard, T; Jarnagin, WR; Kemeny, NE; Klimstra, DS; Poultsides, GA; Saltz, LB; Servais, EL; Shia, J | 1 |
| Abbruzzese, JL; Beeker, T; Benedetti, JK; Blanke, CD; Gold, PJ; Goldman, BH; Lenz, HJ; Mehta, V; Thomas, CR; Tomblyn, MB | 1 |
| Abe, K; Akazawa, Y; Fukuda, Y; Isomoto, H; Mizuta, Y; Nakao, K; Ogihara, K; Shoji, H; Takeshima, F; Tsutsumi, T | 1 |
| Chun, C; Kim, B; Kim, JI; Lee, SH; Song, SC | 1 |
| Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G | 1 |
| Chandrakumaran, K; John, TG; Knowles, B; Rees, M; Welsh, FK | 1 |
| Alfonsi, S; Bearzi, I; Biagetti, S; Bianconi, M; Bittoni, A; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Giustini, L; Loretelli, C; Maccaroni, E; Mandolesi, A; Scartozzi, M | 1 |
| Delattre, JY; Gállego Pérez-Larraya, J; González-Aguilar, A; Guillevin, R; Hoang-Xuan, K; Houillier, C; Lahutte, M; Petrirena, G; Reyes-Botero, G; Sanson, M | 1 |
| Alessandroni, P; Aliberti, C; Catalano, V; Coschiera, P; Fiorentini, G; Giordani, P; Graziano, F; Mambrini, A; Montagnani, F; Mulazzani, L; Tilli, M | 1 |
| Kenmotsu, Y; Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Bellanger, A; Hassani, L; Hassani, Y; Hochart, C; Taillibert, S; Xuan, KH | 1 |
| Chang, LJ; Eastman, A | 1 |
| Chang, HM; Jo, JC; Kang, YK; Kim, HS; Kim, M; Kim, TW; Lee, HJ; Lee, JL; Ryu, MH; Shin, JG | 1 |
| Arcaroli, JJ; Dasari, A; Gao, D; McManus, M; Messersmith, WA; Pitts, TM; Powell, RW; Quackenbush, KS; Spreafico, A; Tan, AC; Touban, BM; Varella-Garcia, M | 1 |
| Abdel-Aziz, H; Abdelwahab, S; Azmy, A; Mahmoud, A; Salim, H | 1 |
| Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Balboa, E; Barros, F; Bernardez, B; Candamio, S; Carracedo, A; Duran, G; Giraldez, JM; Lamas, MJ; Lopez, R; Mosquera, A; Vidal, Y | 1 |
| Ahmad, S; Hughes, MA; Scott, JE; Yeh, LA | 1 |
| Chen, J; Gu, Q; He, C; Huang, M; Xing, JZ | 1 |
| Bachmann, E; Galle, PR; Khillimberger, K; Linnig, M; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Lordick, F | 1 |
| Grunnet, K; Hansen, S; Holmberg, M; Lassen, U; Møller, S; Poulsen, HS; Schultz, H; Sorensen, M | 1 |
| Almeida, L; Ashwell, S; Brassil, P; Breed, J; Deng, C; Gero, T; Grondine, M; Horn, C; Ioannidis, S; Janetka, J; Liu, D; Lyne, P; Newcombe, N; Oza, V; Pass, M; Read, J; Ready, S; Rowsell, S; Su, M; Toader, D; Vasbinder, M; Xue, Y; Yu, D; Yu, Y; Zabludoff, S | 1 |
| Farinotti, R; Fernandez, C; Goldwirt, L; Lemaitre, F; Zahr, N | 1 |
| Abdelhay, ES; Bastos, LG; de-Freitas-Junior, JC; Freire-Neto, CA; Morgado-Díaz, JA; Rocher, BD | 1 |
| Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S | 1 |
| Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P | 1 |
| Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
| Fukuda, Y; Imamura, Y; Kouyama, M; Kuratsune, M; Nakamitsu, A; Ohta, H; Yokoyama, S | 1 |
| Ishibashi, N; Kibe, S; Murakami, N; Ogata, Y; Shirouzu, K; Takahashi, K; Takeuchi, M; Uchida, S; Yahara, T | 1 |
| Itoh, T; Kawamoto, K; Takagi, K | 1 |
| Broadbridge, VT; Karapetis, CS; Price, TJ | 1 |
| Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M | 1 |
| Fujiwara, H; Harada, T; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y | 1 |
| Hiura, M; Kiguchi, K; Kita, T; Kokawa, K; Kubushiro, K; Mizutani, K; Nishimura, R; Sugiyama, T; Takizawa, K; Yaegashi, N; Yamaguchi, S; Yamamoto, K | 1 |
| Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M | 1 |
| Dharmarajan, KV; Wexler, LH; Wolden, SL | 1 |
| Boku, N; Honma, Y; Kato, S; Kawai, H; Morita, S; Nishina, T; Suenaga, M; Taguri, M; Takahashi, H; Tamura, F; Tsushima, T; Ueda, S | 1 |
| Adam, R; Barroso, E; Capussotti, L; Elias, D; Figueras, J; Gigot, JF; Gruenberger, T; Herrera, J; Ijzermans, JN; Isoniemi, H; Laurent, C; Letoublon, C; Lucidi, V; Mirza, DF; Nuzzo, G; Pardo, F; Popescu, I; Poston, G; Sousa, FC; Viganò, L | 1 |
| Brodeur, GM; Brown, JL; Evans, AE; Ho, R; Iyer, R; Light, JE; Minturn, JE; Simpson, AM; Thress, K; Varela, CR; Zhao, H | 1 |
| Andersson, R; Norman, P; Spelt, L; Tingstedt, B; Törnqvist, L | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
| Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G | 1 |
| Gamoh, M; Ishioka, C; Iwama, N; Kato, S; Komine, K; Mori, T; Shimodaira, H; Soeda, H; Suzuki, T; Watanabe, M | 1 |
| Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Yao, J; Zhang, Z | 1 |
| Kunito, S; Nagata, C; Ochiai, K; Okamoto, A; Saito, M; Sasaki, H; Takakura, S; Tanaka, T; Yamada, K; Yanaihara, N | 1 |
| Ernani, V; Hosein, PJ; Kawamura, C; Levi, JU; Loaiza-Bonilla, A; Macintyre, J; Maldonado, JC; Merchan, JR; Narayanan, G; Portelance, L; Ribeiro, A; Rocha-Lima, CM | 1 |
| Cakar, B; Karabulut, B; Karaca, B; Sezgin, C; Uslu, R; Varol, U | 1 |
| Barot, TC; Gulec, SA; Hall, M; Pennington, K; Schwartzentruber, D; Suthar, RR; Wheeler, J | 1 |
| Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A | 1 |
| Arzouk, H; Causse, A; Coquelle, A; de Medina, P; Del Rio, M; Denis, V; Espert, L; Gongora, C; Martineau, P; Marzi, L; Paillas, S; Pattingre, S; Poirot, M; Vezzio-Vie, N | 1 |
| Feusner, JH; Trobaugh-Lotrario, AD | 1 |
| Katzenstein, HM; Trobaugh-Lotrario, AD | 1 |
| Kumar, N; Reddy, SP; Sangeetha, D | 1 |
| Ghang, HY; Han, JY; Hwang, JA; Kim, JY; Kim, SY; Lee, JS; Lee, YS; Shin, ES | 1 |
| Allen, WL; Carson, G; Coyle, VM; Dunne, P; Hector, S; Johnston, PG; Longley, DB; Stevenson, L; Turkington, RC; Van Schaeybroeck, S | 1 |
| Baek, JY; Chang, HJ; Hong, YS; Im, SA; Jung, KH; Kim, DY; Kim, JH; Kim, SY; Kim, TW; Shim, EK; Yeo, HY | 1 |
| Dias, MM; McKinnon, RA; Sorich, MJ | 1 |
| Granot, T; Meruelo, D | 1 |
| Hirota, S; Inoue, K; Ito, Y; Kanazawa, R; Komori, S; Maeda, H; Tsubamoto, H | 1 |
| Colson, YL; Grinstaff, MW; Herrera, VL; Yohe, ST | 1 |
| Boku, N; Doyama, H; Fukutomi, A; Machida, N; Onozawa, Y; Taniguchi, H; Todaka, A; Tsuji, K; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Bach, PB; Conti, RM; Polite, BN; Rosenthal, MB; Shih, YC | 1 |
| Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Garcia-Foncillas, J; Gonzalez-Huarriz, M; Lopez, I; Rodriguez, J; Zarate, R | 1 |
| Hatake, K; Ishikawa, Y; Mishima, Y; Nakano, K; Nishimura, N; Sakajiri, S; Takahashi, S; Tsuyama, N; Yokoyama, M; Yuasa, T | 1 |
| Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX | 1 |
| Agostini, G; Aldrighetti, L; Cappio, S; De Cobelli, F; Del Maschio, A; Losio, C; Orsi, M; Pilla, L; Ratti, F; Venturini, M | 1 |
| Červinka, M; Mls, J; Rudolf, E; Stanislav, J | 1 |
| Pua, U | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Nakao, S; Ohmori, T; Sakai, A; Sone, T | 1 |
| Eckrich, MJ; Engel, ME; Lowas, S; Mixon, BA | 1 |
| Choi, KC; Choi, KJ; Kim, SU; Yi, BR | 1 |
| Edagawa, A; Eguchi, D; Ikeda, Y; Itoh, S; Kawanaka, H; Kawasaki, K; Korenaga, D; Koushi, K; Okuyama, T; Shinohara, S; Takenaka, K | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Aigner, E; Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Perez, R; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
| Cats, A; Ciardiello, F; Gallerani, E; Gelderblom, H; Glimelius, B; Hendlisz, A; Humblet, Y; Moehler, M; Peeters, M; Sagaert, X; Schlichting, M; Tejpar, S; Van Cutsem, E; Vanbeckevoort, D; Vermorken, JB; Viret, F; Vlassak, S | 1 |
| Harada, M; Hato, T; Hishima, T; Horio, H; Okuma, Y; Suzuki, S | 1 |
| Du, F; Guo, Q; Huang, J; Liu, S; Lu, W; Luo, P; Luo, Y; Yu, J | 1 |
| Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H | 1 |
| Alvarez, PJ; Aranega, A; Boulaiz, H; Caba, O; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Rodríguez-Serrano, F | 1 |
| Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T | 1 |
| Boongird, A; Hongeng, S; Manaspon, C; Nasongkla, N | 1 |
| Chargari, C; Deutsch, E; Huguet, F; Levy, A; Védrine, L | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ | 1 |
| Alagoz, M; Chalmers, AJ; El-Khamisy, S; Gilbert, DC | 1 |
| Asukai, K; Hasegawa, I; Horiguchi, N; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Shimizu, S; Togawa, S | 1 |
| Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C | 1 |
| Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S | 1 |
| Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nomura, H; Susumu, N; Tominaga, E; Tsuji, K; Ueki, A; Yamagami, W; Yanokura, M | 1 |
| Blazer, DG; Hsu, D; Papalezova, K; Stinnett, S; Tyler, D; Zani, S | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Ames, MM; Behrens, RJ; Erlichman, C; Foster, NR; Goetz, MP; Graham, DL; Holtan, SG; Medeiros, F; Safgren, SL; Steen, PD | 1 |
| Berthet, C; Bigot, L; Bruno, A; Calvet, L; Dangles-Marie, V; Dartigues, P; De Thé, H; Demers, B; Dessen, P; Duchamp, O; Goéré, D; Gonin, P; Job, B; Julien, S; Lacroix, L; Landron, S; Lantuas, D; Lardier, G; Mariani, P; Merino-Trigo, A; Morgand, L; Nemati, F; Nunes, M; Pham, E; Pierré, A; Pocard, M; Prévost, G; Roman-Roman, S; Soliman, H; Vrignaud, P; Weiswald, LB | 1 |
| Isozaki, M; Kasukawa, H; Kurita, A; Matsuzaki, T; Nakamura, K; Terajima, Y; Yamashita, K; Yoshino, K | 1 |
| Brock, P; Brugières, L; Casanova, M; Child, M; Czauderna, P; de Camargo, B; Maibach, R; Morland, B; Pariente, D; Paris, C; Perilongo, G; Plaschkes, J; Roebuck, D; Ronghe, M; Zimmermann, A; Zsíros, J | 1 |
| Eichler, K; Gallus, C; Gruber-Rouh, T; Hammerstingl, R; Mack, MG; Vogl, TJ; Zangos, S | 1 |
| Chang, H; Cho, BC; Kim, HR; Kim, JH; Kim, SH; Lee, CG; Yoon, SH | 1 |
| Baracos, VE; Bibova, I; Dieleman, LA; Field, CJ; Gänzle, MG; Ketabi, A; Lin, XB; Sawyer, MB; Xue, H | 1 |
| Sakata, Y; Satoh, T | 1 |
| Chen, X; Cheng, L; Dai, L; Deng, H; Fan, P; Li, C; Li, Y; Shi, G; Tian, H; Wei, Y; Yan, N; Yang, Y; Zhang, S; Zhang, X | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Cai, F; Clerc, A; Dupertuis, YM; Granci, V; Lecumberri, E; Pichard, C | 1 |
| Boumendjel, A; Di Pietro, A; Falson, P; Freyer, G; Geze, A; Guitton, J; Honorat, M; Payen, L; Sostelly, A; Tod, M; Valdameri, G | 1 |
| Matsko, MV | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A | 1 |
| Cervinka, M; John, S; Rudolf, E | 1 |
| Durden, BC; Kaplan, AR; Keiser, HE; Levesque, AA; Lippincott, DJ; Lipski, R; Park, JH | 1 |
| Bradbury, J; Cave, J; Crabb, SJ; Johnson, PW; Muthuramalingam, SR; Nolan, L; Ottensmeier, C; Selman, D | 1 |
| Gilbert, KS; Secrist, JA; Waud, WR | 1 |
| Bodnar, L; Charkiewicz, R; Chyczewski, L; Ciechowicz, M; Korniluk, J; Kozłowski, W; Nikliński, J; Rokita, M; Smoter, M; Stec, R; Szczylik, C | 1 |
| Assadourian, S; Billemont, B; Cartot-Cotton, S; Khayat, D; Meric, JB; Rixe, O; Soussan-Lazard, K; Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Arai, Y; Aramaki, T; Boku, N; Hamada, M; Inaba, Y; Kato, K; Morita, S; Muro, K; Ohtsu, A; Satake, M; Sato, Y; Shimada, Y; Takeuchi, Y; Yamada, Y | 1 |
| Deng, L; He, J; Huang, Y; Yi, C; Yu, S; Zhao, F; Zhu, H | 1 |
| Carlsson, G; Holmberg, C; Pettersson, K; Sporrong, SK | 1 |
| Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO | 1 |
| Agatsuma, T; Goya, H; Hirai, K; Ichiyama, T; Kanda, S; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Tateishi, K; Yamamoto, H; Yoshiike, F | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, WC | 1 |
| Kenmotsu, Y; Kondo, T; Murakami, S; Ohe, M; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Degenhardt, YY; Diskin, SJ; Haglund, E; Maris, JM; Mayes, PA; Moy, C; Toporovskya, Y; Wood, A; Wooster, R | 1 |
| Brodowicz, T; Heinemann, V; Jung, A; Kirchner, T; Knittelfelder, R; Kurteva, G; Laubender, RP; Modest, DP; Neumann, J; Ocvirk, J; Papai, Z; Stintzing, S; Zielinski, CC | 1 |
| Fu, FF; Jiang, HP; Jiang, WQ; Li, YX; Teng, LS; Wang, HH; Wang, WB | 1 |
| Hashim, H; Salleh, MZ; Teh, LK; Zakaria, ZA | 1 |
| Gao, F; Linehan, D; Lockhart, AC; Lubner, S; McWilliams, R; Menias, C; Peddi, PF; Picus, J; Sorscher, SM; Suresh, R; Tan, BR; Wang, J; Wang-Gillam, A | 1 |
| Baba, K; Hashida, M; Ikuta, Y; Imahori, H; Kasai, H; Koseki, Y; Murakami, T; Nakanishi, H; Oikawa, H; Okada, M; Shoji, M; Ueda, M | 1 |
| Larsen, AK; Petitprez, A | 1 |
| Berglund, Å; Byström, P; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Date, H; Hotta, K; Kanazawa, S; Katsui, K; Kiura, K; Miyoshi, S; Shien, K; Toyooka, S | 1 |
| Aroulmoji, V; Chinna Babu, P; Murano, E; Sudha, S; Sundaraganesan, N | 1 |
| Köhne, CH | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y | 1 |
| Ishikawa, D; Kumagai, M; Mouri, H; Nanjo, S; Ohtsubo, K; Takeuchi, S; Ueda, Y; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Akimoto, Y; Hamasaki, A; Honda, H; Kaneko, M; Okamoto, K; Oshita, T; Takao, Y; Tanimoto, H; Teramoto, H; Teramoto, M | 1 |
| Chu, Z; Huang, M; Lu, G; Mao, Y; Yuan, B; Zhang, X; Zou, Y | 1 |
| Bucci, F; Cusano, G; Di Francesco, AM; Meco, D; Patriarca, V; Pierri, F; Pisano, C; Riccardi, R; Torella, AR | 1 |
| Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R | 1 |
| Fukuda, M; Hayashi, N; Ikeda, T; Izumikawa, K; Kinoshita, A; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K; Yamaguchi, H | 1 |
| Ahmad, FJ; Ahmad, MZ; Akhter, S; Anwar, M; Kumar, A; Rahman, M; Talasaz, AH | 1 |
| Chung, ST; Czuczman, P; Finnie, J; Foster, D; Holden, RR; Kuchel, T; Lewis, AL; Porter, S | 1 |
| Bekaii-Saab, TS; Bendell, JC; Cohn, AL; Dalal, D; Fish, S; Flick, ED; Grothey, A; Hurwitz, HI; Kozloff, M; Mun, Y; Roach, N; Tezcan, H | 1 |
| Boyett, JM; Fangusaro, J; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Kun, LE; McLendon, R; Onar-Thomas, A; Packer, RJ; Vajapeyam, S; Young Poussaint, T | 1 |
| Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F | 1 |
| Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y | 1 |
| Basu, B; Jodrell, D | 1 |
| Adua, D; Barucca, V; Colonna, M; Di Seri, M; Giannarelli, D; Longo, F; Mottolese, M; Romiti, A; Rossi, L; Ruco, L; Tomao, S; Veltri, E; Zoratto, F; Zullo, A | 1 |
| Antonelli, G; Blandino, R; Calì, S; Ferraù, F; Malaponte, E; Panebianco, V; Vitale, FV | 1 |
| Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F | 1 |
| Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS | 1 |
| Aissat, N; André, T; Artru, P; Bachet, JB; Bennamoun, M; Blons, H; Cayre, A; Chibaudel, B; de Gramont, A; Ebenezer, C; Laurent-Puig, P; Mabro, M; Nguyen, S; Penault-Llorca, F; Tournigand, C | 1 |
| Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K | 1 |
| Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM | 1 |
| Kaneda, N; Konishi, H; Kurita, A; Matsuzaki, T; Takagi, A | 1 |
| Huang, S; Wang, Z; Zhang, G | 1 |
| Higashiyama, K; Iwase, Y; Maitani, Y; Saito, H; Seishi, Y; Sugino, T; Yamauchi, T | 1 |
| Hashimoto, T; Hotta, T; Iwamoto, H; Matsuda, K; Oku, Y; Takifuji, K; Yamaue, H; Yokoyama, S | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y | 1 |
| Aloyz, R; Davidson, D; Panasci, L; Wang, Y | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Bando, H; Fujii, S; Kadowaki, S; Kajiura, S; Nishina, T; Ohtsu, A; Shinozaki, E; Tsuchihara, K; Yamanaka, T; Yamazaki, K; Yoshino, T; Yuki, S | 1 |
| Bander, NH; Farokhzad, OC; Gadde, S; Kantoff, PW; Karnik, R; Langer, R; Lippard, SJ; Perea, B; Pridgen, EM; Sweeney, C; Valencia, PM | 1 |
| Adotevi, O; Borg, C; Degano, SV; Demarchi, M; Dobi, E; Godet, Y; Ivanaj, A; Jary, M; Kantelip, B; Kim, S; Monnien, F; N'Guyen, T; Pivot, X; Thierry-Vuillemin, A | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Adam, R; Andres, A; Barroso, E; Capussotti, L; Gerstel, E; Hubert, C; Majno, PE; Mentha, G; Roth, A; Toso, C | 1 |
| Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L | 1 |
| Kiguchi, K; Kobayashi, Y; Kondo, H; Ohara, T; Suzuki, N; Tozawa, A; Yahagi, N; Yoshida, A; Yoshioka, N | 1 |
| Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Bosman, F; Cisar, L; Cunningham, D; d'Ario, G; Delorenzi, M; Fiocca, R; Klingbiel, D; Labianca, R; Nordlinger, B; Roth, AD; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isikdogan, A; Kaplan, MA; Ozkan, M; Tufan, G | 1 |
| Choe, E; Choi, YH; Jeong, NY; Lee, HJ; Lee, JS; Oh, S; Park, BS; Yoo, KS; Yoo, YH | 1 |
| Curran, D; Folprecht, G; Griebsch, I; Hitre, E; Köhne, CH; Láng, I; Rougier, P; Sartorius, U; Van Cutsem, E | 1 |
| Fujibuchi, W; Miura, K; Unno, M | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Kontek, R; Nowicka, H | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Ding, LY; Guo, M; Liu, YQ; Lu, Y; Ron, WT; Song, FF; Wang, Y; Yu, SQ | 1 |
| Aloia, TA; Boonsirikamchai, P; Charnsangavej, C; Chun, YS; Curley, SA; Kopetz, S; Loyer, EM; Maru, DM; Shindoh, J; Vauthey, JN; Zimmitti, G | 1 |
| Aiba, K; Arakawa, Y | 1 |
| Amano, O; Hashimoto, K; Hirano, K; Kishino, K; Sakagami, H; Shimada, J; Tamura, N | 1 |
| Andoh, A; Shioya, M | 1 |
| Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M | 1 |
| Ding, LL; Dou, W; Zhang, JJ | 1 |
| Bertarelli, G; Biondani, P; Cortinovis, D; de Braud, F; Di Bartolomeo, M; Fanetti, G; Mariani, L; Melotti, F; Milione, M; Perrone, F; Pietrantonio, F | 1 |
| Happold, C; Hundsberger, T; Seystahl, K; Weller, M; Wick, A; Wick, W; Wiestler, B | 1 |
| Douillard, JY; Peeters, M; Siena, S; Van Cutsem, E; Wiezorek, J; Williams, R; Zhang, K | 1 |
| Cho, EK; Chung, M; Hong, J; Kim, HS; Lee, JH; Lee, WK; Park, J; Park, SH; Park, YH; Shin, DB; Sym, SJ | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR | 1 |
| Ilson, DH; Ku, GY | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Chang, YL; Cheng, AL; Liau, JY; Lin, LI; Lin, YL; Ou, DL; Tseng, LH; Yeh, KH; Yu, SC | 1 |
| Cubillo, A; De Vicente, E; García-García, E; Hernando-Requejo, O; Hidalgo, M; López, U; López-Ríos, F; Morelli, P; Muro, A; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Rubio, C | 1 |
| Campbell, JC; Capanu, M; Ilson, DH; Janjigian, YY; Kelsen, DP; Ku, GY; Shah, MA | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Dunne, D; Fenwick, SW; Gruenberger, T; Jones, RP; Koelblinger, C; Malik, HZ; O'Grady, E; Poston, GJ; Stättner, S; Stremitzer, S; Sutton, P; Terlizzo, M | 1 |
| Jaggi, M; Negi, LM; Talegaonkar, S | 2 |
| Dvorák, J; Krajina, A; Malírová, E; Melichar, B; Nová, M; Ryska, A; Voboril, Z; Weiner, P | 1 |
| Barthel, B; Koch, TH; Shi, D; Xiao, D; Yan, B; Yang, D | 1 |
| Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K | 1 |
| Gou, L; Kang, T; Su, X; Wang, Y; Xie, Y; Yang, J; Yao, Y; Yi, C | 1 |
| Hezel, AF; Katz, AW; Mondo, EL; Noel, MS; Schoeniger, LO | 1 |
| Benhaim, L; Boige, V; Bonnet, S; De Baere, T; Deschamps, F; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Faron, M; Goéré, D; Lefèvre, JH; Malka, D | 1 |
| Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N | 1 |
| Chaudhary, UB; Gudena, V; Keane, T; Verma, N | 1 |
| Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER | 1 |
| Cinar, V; Erdik, B; Oyan, B; Ozturk, MA; Ozveren, O | 1 |
| Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S | 1 |
| de la Fouchardière, C; Derbel, O; Méeus, P; Orlandini, F; Penet, AS; Pérol, M; Péron, J; Stella, M | 1 |
| Bankiewicz, K; Berger, MS; Butowski, N; Chen, PY; Drummond, DC; Fitzgerald, JB; Forsayeth, JR; James, CD; Kalra, A; Kirpotin, DB; Ozawa, T; Prados, MD; Wei, KC | 1 |
| Huang, J; Mao, W; Shen, Y; Sui, M; Wang, J; Wu, X; Zhang, H | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Aoyagi, H; Hasegawa, K; Isogai, J; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Yoshida, T | 1 |
| Kataoka, M; Miyazawa, K; Oeda, Y; Tonooka, T; Wakatsuki, K; Yoshioka, S | 1 |
| Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Nagase, H; Oshima, S; Sakamoto, T | 1 |
| Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Tomita, Y; Ueda, N | 1 |
| Cong, X; Gunturu, KS; Hochster, HS; Lacy, J; Stein, SM; Thumar, JR; Yao, X | 1 |
| Baechler, S; Barth, SW; Briviba, K; Esselen, M; Marko, D; Skrbek, S; Watzl, B; Winkler, S | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Kawabe, Y; Mori, N; Murakami, T; Yokooji, T | 1 |
| Edwards, CC; Hatfield, MJ; Hyatt, JL; Jeffries, C; Lemoff, A; Potter, PM; Tsurkan, LG; Yan, B | 1 |
| Chen, DY; Zhao, WY | 1 |
| Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY | 1 |
| Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS | 1 |
| Al-Kasspooles, MF; Decedue, CJ; Henry, D; Howell, J; Niu, F; Roby, KF; Williamson, SK | 1 |
| Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
| Assadourian, S; Bloch, J; Cartot-Coton, S; Khayat, D; Soussan-Lazard, K; Spano, JP; Tejpar, S; Van Cutsem, E; Vandecaveye, V; Verslype, C | 1 |
| Hui, C; McVey, M; South, A; Thomas, AM | 1 |
| Cha, H; Cho, WJ; Lee, HY; Lee, JC; Lee, SJ; Lee, YH; Min, YJ; Moon, CH; Park, HJ; Park, JW; Seo, J; Song, HT | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Fakih, MG; Fora, AA; Groman, A; Ma, WW; McMahon, JA; Romano, KS; Wilding, G | 1 |
| Fujioka, M; Hasegawa, T; Katoh, M; Nadai, M; Onishi, K; Sakakibara, Y; Tanaka, Y | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Arce Abaitua, B; Blumenfeld Olivares, JA; Cormenzana Carpio, M; Hernández-Marqués, C; Lassaletta-Atienza, A; Madero Lopez, L; Ruiz Hernández, A | 1 |
| Alonso, V; Codony-Servat, J; Escudero, P; Fernández-Martos, C; Gallego, R; Garcia-Albeniz, X; Martinez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Pericay, C | 1 |
| Conroy, T; Ducreux, M; Gavoille, C; Samalin, E; Ychou, M | 1 |
| Behera, D; Das, A; Madan, K; Singh, N | 1 |
| Asakawa, M; Fujine, N; Kogiso, M; Kon, M; Maitani, Y; Nakamura, Y; Sanada, E; Shimizu, T; Sumiyoshi, K | 1 |
| Choi, EW; Cusack, JC; Donahue, JM; Fuchs, BC; Kasuya, H; Kawasaki, H; Kulu, Y; Kuruppu, DK; Tanabe, KK | 1 |
| Shimada, T; Watanabe, A | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Antón, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Constenla, M; Dueñas, R; Escudero, P; Gallego, J; Gómez, A; González, E; Grávalos, C; Losa, F; Manzano, JL; Marcuello, E; Massuti, B; Maurel, J; Rivera, F | 1 |
| Gleyzer, N; Scarpulla, RC | 1 |
| Charpentier, M; Guo, L; Lu, W; Xiao, D; Yan, B; Yang, D | 1 |
| Commes, T; Hammers, H; Kachhap, SK; Kaelber, NS; Kant, H; Kim, E; Liu, JO; Mendonca, J; Shim, JS; Van Diest, PJ; Wissing, MD | 1 |
| Boumendjel, A; Di Pietro, A; Falson, P; Freyer, G; Gèze, A; Guitton, J; Honorat, M; Payen, L; Sostelly, A; Tod, M | 1 |
| Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G | 1 |
| Gan, Y; Guo, SY; Li, FF; Zhang, XX | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M | 1 |
| Kutner, A; Maciejewska, M; Milczarek, M; Psurski, M; Rosinska, S; Wietrzyk, J | 1 |
| Akman, T; Aktas, B; Alacacioglu, A; Balakan, O; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Engin, H; Gunaydin, Y; Harputluoglu, H; Kaplan, MA; Karaca, H; Ozdemir, NY; Sevinc, A; Sonmez, OU; Tonyali, O; Tufan, G; Tugba Unek, I | 1 |
| Cardic, MB; Chao, Y; Chen, LT; Cunningham, D; de Gramont, A; Kang, YK; Kujundzic, M; Lim, HY; Park, SR; Ramos, FJ; Rees, C; Roy, AC; Tabernero, J; Yeh, CG | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Cardillo, TM; Gold, DV; Goldenberg, DM; Govindan, SV; Sharkey, RM; Tat, F | 1 |
| Bueno, R; Choi, NC; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Hong, TS; Jaklitsch, MT; Kwak, EL; Lanuti, M; Lee, MS; Mamon, HJ; Meyerhardt, JA; Rattner, DW; Ryan, DP | 1 |
| Calis, S; Dimchevska, S; Geskovski, N; Goracinova, K; Kajdžanoska, M; Kuzmanovska, S; Petruševski, G; Simonoska Crcarevska, M; Ugarkovic, S | 1 |
| Berlin, J; Chan, E; Ciombor, KK | 1 |
| Bauernhofer, T; Hubmann, E; Jilek, K; Keil, F; Leitner, G; Pichler, A; Pichler, M; Rabl, H; Tinchon, C; Uggowitzer, M | 1 |
| Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X | 1 |
| Aparicio, T; Bouché, O; Breysacher, G; Charneau, J; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Le Brun-Ly, V; Lecomte, T; Locher, C; Mitry, E; Ramdani, M; Seitz, JF; Stefani, L; Subtil, F; Teillet, L | 1 |
| Beijnen, JH; Iusuf, D; Lin, F; Marchetti, S; Mazzanti, R; Pluim, D; Schellens, JH; van Tellingen, O | 1 |
| Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A | 1 |
| Alvarez-Velilla, R; Balaña-Fouce, R; Calvo-Álvarez, E; Desideri, A; Escudero-Martínez, JM; Ordóñez, C; Pérez-Pertejo, Y; Prada, CF; Prieto, C; Reguera, RM; Requena, JM | 1 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Ghang, HY; Han, JY; Hong, SH; Hwang, JA; Kim, JY; Lee, JS; Lee, YS; Nam, S; Shin, ES; Yoon, SJ | 1 |
| Fischer von Weikersthal, L; Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, UR; Modest, DP; Schalhorn, A; Stintzing, S | 1 |
| Hashimoto, K; Inoue, M; Inoue, Y; Koike, Y; Kusunoki, M; Matsushita, K; Mohri, Y; Okugawa, Y; Otake, K; Saigusa, S; Tanaka, K; Uchida, K; Ueeda, M | 1 |
| Arakawa, A; Itani, Y; Ito, K; Kawaguchi, R; Shiozaki, T; Tabata, T; Takeuchi, S; Toyoda, S; Tsubamoto, H | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Kubota, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Uematsu, K; Yamamoto, K; Yoshimura, A | 1 |
| Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U | 1 |
| Boukouris, AE; Buitrago-Molina, LE; Hegermann, J; Kirstein, MM; Kühnel, F; Manns, MP; Marhenke, S; Orlik, J; Pothiraju, D; Schütt, J; Vogel, A | 1 |
| Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Gao, B; Gao, Z; Gavine, PR; Ji, J; Ji, Q; Kilgour, E; Liu, K; Shen, D; Su, X; Tang, L; Xie, L; Xu, Y; Yin, X; Zhang, J; Zhang, L; Zhang, X; Zhou, M | 1 |
| Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y | 1 |
| Akashi, Y; Matsuura, M; Saito, T; Satohisa, S; Suzuki, M; Suzuki, T; Tanaka, R; Teramoto, M | 1 |
| Cao, Y; Cheng, Q; Lu, H; Zhang, H | 1 |
| Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J | 1 |
| Andersen, RF; Havelund, BM; Jakobsen, AK; Lassen, U; Pallisgaard, N; Ploen, J; Sorensen, MM; Spindler, KL | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Cheng, D; Kuang, Q; Liu, G; Liu, X; Xu, W | 2 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW | 1 |
| Ding, Y; Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yang, Y; Yu, L; Yue, G; Zou, Z | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL; Kulikowski, G; Merz, AL; Pitts, TM; Selby, H; Serkova, NJ; Weekes, CD | 1 |
| Banfi, R; Cecchi, M; Ceroti, M; Vaiani, M | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Bellet, D; Bièche, I; Cottu, P; Dangles-Marie, V; Guinebretière, JM; Laurendeau, I; Marangoni, E; Massonnet, G; Nemati, F; Richon, S; Vacher, S; Validire, P; Weiswald, LB | 1 |
| El-Rayes, B; Gao, H; Landry, J; Shelton, JW; Shu, HK; Wang, L; Waxweiler, TV; Xu, Y | 1 |
| Beeram, M; Bekaii-Saab, T; Buchbinder, A; Lokiec, FM; Papadopoulos, KP; Patnaik, A; Rezaï, K; Schaaf, LJ; Tahiri, S; Tolcher, AW; Urien, S | 1 |
| Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H | 1 |
| Cortejoso, L; Escolar, F; García, MI; García-Alfonso, P; González-Haba, E; López-Fernández, LA; Sanjurjo, M | 1 |
| Hanna, N; Hayostek, C; Mitchell, E; Mohiuddin, M; Nichols, R; Paulus, R; Willett, C; Yalavarthi, S; Yuen, A | 1 |
| Bastian, G; Escargueil, AE; Guérin, E; Larsen, AK; Ouaret, D; Petitprez, A; Poindessous, V; Regairaz, M | 1 |
| Fukuhara, T; Inoue, A; Ishimoto, O; Maemondo, M; Matsubara, N; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Tanaka, M; Watanabe, K | 1 |
| Matsuzaki, T; Nagaoka, M; Shishido, Y; Ueno, S; Yamazaki, R | 1 |
| Alcindor, T; Moreau, LC; Rajan, R; Thirlwell, MP | 1 |
| Choi, DR; Choi, HC; Kim, B; Kim, HS; Kim, JH; Kwon, JH | 1 |
| Albares, MP; del Carmen Leiva-Salinas, M; Frances, L; Guijarro, J; Ramon, R | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Diasio, RB | 1 |
| Hendel, HW; Jensen, BV; Nielsen, D; Skougaard, K | 1 |
| Cassidy, J; Hochster, H | 1 |
| Fujinaga, M; Hashimoto, H; Hatori, A; Kawamura, K; Kumata, K; Ogawa, M; Wakizaka, H; Xie, L; Yamasaki, T; Yui, J; Zhang, MR | 1 |
| Fujii, H; Horie, H; Inoue, T; Kotake, K; Miyakura, Y; Sugano, K; Tahara, M; Yasuda, Y | 1 |
| Colson, YL; Grinstaff, MW; Kopechek, JA; Porter, TM; Yohe, ST | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Goel, S; Mani, S; Swami, U | 1 |
| Hu, J; Kinn, J; Norstedt, G; Sherif, A; Wikström, AC; Winqvist, O; Zirakzadeh, AA | 1 |
| Fukami, K; Hasegawa, J; Hirose, K; Kaneda, N; Kitamura, M; Maeda, Y; Maruo, E; Takada, H; Yamashita, K | 1 |
| Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS | 1 |
| Cripe, T; Geller, J; Nagarajan, R; Turpin, B; Wagner, L; Weiss, B | 1 |
| Filip, S; Grim, J; Paulík, A | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Arora, G; Barbery, K; Guerrero, G; Narayanan, G; Suthar, R | 1 |
| Akiyoshi, K; Furuta, K; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Taniguchi, H; Yamada, Y | 1 |
| Jett, JR; Kalemkerian, GP; Kesler, KA; Schild, SE | 1 |
| Bruno, R; Claret, L; Gupta, M; Han, K; He, J; Joshi, A; Powell, B; Sarapa, N | 1 |
| Campolo, F; Dolci, S; Dorio, AS; Graziani, G; Lacal, PM; Leonetti, C; Muzi, A; Porru, M; Praz, F; Tentori, L; Vernole, P | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Dias, LE; Faris, JE; Fernandez-del Castillo, C; Ferrone, CR; Guimaraes, AR; Hong, TS; Huynh, MA; Kwak, EL; Lillemoe, KD; McDermott, S; Murphy, JE; Ryan, DP; Sahani, DV; Szymonifka, J; Thayer, SP; Wargo, JA; Wo, JY; Zhu, AX | 1 |
| Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R | 1 |
| Huppert, P; Wenzel, T; Wietholtz, H | 1 |
| Gan, Y; Guo, SY; Li, FF; Li, J; Zhang, XX | 1 |
| Bouakaz, A; Escoffre, JM; Lecomte, T; Novell, A; Serrière, S | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX | 1 |
| Galazios, G; Kareli, D; Karelis, A; Lialiaris, T; Liberis, V; Nikas, I; Nikolettos, N; Pouliliou, S; Psillaki, A | 1 |
| Gao, J; Jia, R; Li, Y; Lu, M; Shen, L; Zhou, J | 1 |
| Mani, S; Redinbo, MR; Roberts, AB; Venkatesh, MK; Wallace, BD | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Guo, M; Hou, J; Lu, Y; Rong, WT; Wang, DF; Wang, Y; Xu, Q; Yu, SQ | 1 |
| Bekaii-Saab, T; Goldberg, RM | 1 |
| Chauffert, B; Ghiringhelli, F; Wiazzane, N | 1 |
| Graham, J; Lindsay, CR; Roxburgh, P | 1 |
| Asada, K; Hamaguchi, T; Ito, Y; Iwasa, S; Kato, K; Shimada, Y; Ushijima, T; Yamada, Y | 1 |
| Huang, S; Park, JM; Sinicrope, FA; Tougeron, D | 1 |
| Hummon, AB; Liu, X; Weaver, EM | 1 |
| Aksu, G; Bilici, A; Cabuk, D; Gumus, M; Kaya, S; Oven Ustaalioglu, BB; Seker, M; Temiz, S; Uygun, K; Yildiz, R | 1 |
| Benstead, K; Brown, SR; Chambers, P; Chau, I; Dawson, L; Falk, S; Gwyther, S; Hill, M; Lowe, C; Maisey, N; Marshall, H; Maughan, T; Middleton, G; Napp, V; O'Callaghan, A; Oliver, A; Quirke, P; Richman, S; Seligmann, JF; Seymour, MT; Wadsley, J | 1 |
| de Gramont, A; Green, E; Haller, DG; McCleary, NJ; Meyerhardt, JA; O'Connell, M; Saltz, LB; Sargent, DJ; Twelves, CJ; Van Cutsem, E; Yothers, G | 1 |
| Coward, L; Darby, A; Gorman, GS; Rasberry, B | 1 |
| Gu, Z; Mao, W; Shen, Y; Sui, M; Sun, W; Sun, X; Tang, J; Wang, J | 1 |
| Arrowsmith, ER; Bajetta, E; Del Prete, SA; Fuchs, CS; Hwang, J; Jin, J; Malek, K; Ng, K; Ryan, DP; Sedova, M; Sharma, S; Tabernero, J | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY | 1 |
| Liu, JL; Palakurthi, S; Vangara, KK | 1 |
| Hirano, K; Isayama, H; Kogure, H; Koike, K; Nakai, Y; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Yamamoto, N; Yatomi, Y | 1 |
| Autran, D; Barrie, M; Boucard, C; Chinot, O; Loundou, A; Matta, M; Tabouret, E; Thiebaut, A | 1 |
| Carr, DF; Fenwick, SW; Ghaneh, P; Greensmith, RM; Hamlett, J; Jenkins, R; Jones, RP; Kitteringham, NR; Malik, HZ; O'Grady, E; Park, BK; Poston, GJ; Rowe, C; Santoyo-Castelazo, A; Sutton, P; Terlizzo, M | 1 |
| Cheng, H; Cream, LV; Drabick, JJ; El-Deiry, WS; Gallant, JN; Harouaka, R; Harvey, HA; Kumar, SM; Kunkel, M; Lamparella, NE; Matthew, EM; Robertson, GP; Truica, CI; Yang, Z; Zheng, S | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Chen, J; Chen, Z; Cheng, P; He, Z; Liu, Z; Qi, Z; Yang, R; Zhang, S | 1 |
| Brown, GW; Giaever, G; Lee, AY; Nislow, C; Torres, NP | 1 |
| Biasco, G; Brandi, G; de Rosa, F; Derenzini, E; Di Girolamo, S; Ercolani, G; Falcone, A; Grazi, GL; Loupakis, F; Masi, G; Pantaleo, MA; Pietrabissa, A; Pinna, AD | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Ishii, G; Ishikawa, Y; Kenmotsu, H; Nagai, K; Nakajima, R; Niho, S; Noguchi, M; Oshita, F; Sekine, I; Tada, H; Watanabe, S | 1 |
| Ebara, K; Ichimura, E; Miyakawa, Y; Miyazaki, O; Morino, T; Nagai, D; Nakajima, N; Okamoto, K; Onda, T; Sekine, K | 1 |
| Bilska, K; Chaber, R; Drabko, K; Pogorzala, M; Polczyńska, K; Raciborska, A; Rodriguez-Galindo, C; Rogowska, E; Wozniak, W; Wyrobek, E | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
| Furuya, K; Goto, T; Hirata, J; Horie, K; Kikuchi, Y; Kino, N; Kudoh, K; Takahashi, M; Takano, M; Yokota, H | 1 |
| Gao, J; Li, Y; Peng, Z; Shen, L; Wang, X; Zhou, J | 1 |
| Ahn, JH; Kang, HW; Kim, H; Lee, KA; Suk, HJ | 1 |
| Blaum, M; Galldiks, N; Heinzel, A; Langen, KJ; Mottaghy, FM; Müller, D; Verburg, FA | 1 |
| Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Bains, MS; Gerber, N; Goodman, KA; Ilson, DH; Janjigian, YY; Kelsen, DP; Rizk, N; Rusch, VW; Wu, AJ; Zhang, Z; Zheng, J | 1 |
| Biondi, M; Fusco, S; Lewis, AL; Netti, PA | 1 |
| Miura, Y; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A | 1 |
| Dang, YZ; Gao, J; Li, J; Li, YY; Shen, L; Sun, ZW; Wang, XC | 1 |
| Huang, XE; Huo, JG; Tang, JH; Wang, XN; Wei, GL | 1 |
| Alberts, SR; Blanke, CD; Cassidy, J; Cheung, WY; Kerr, DJ; Meyers, J; O'Connell, M; Sargent, DJ; Shi, Q; Van Cutsem, E; Yothers, G | 1 |
| Yokooji, T | 1 |
| Del Bene, F; Germani, M; Magni, P; Terranova, N | 1 |
| Antoniotti, C; Basolo, F; Bocci, G; Canu, B; Cremolini, C; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Faviana, P; Fioravanti, A; Fontanini, G; Loupakis, F; Lupi, C; Masi, G; Orlandi, P; Salvatore, L; Schirripa, M; Sensi, E | 1 |
| Bontempi, G; De Jay, N; El-Hachem, N; Haibe-Kains, B; Olsen, C; Papillon-Cavanagh, S | 1 |
| Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U | 1 |
| Dufas, T; Eichler, K; Gruber-Rouh, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Maillet, M; Mir, O | 2 |
| Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Negi, LM; Talegaonkar, S; Tariq, M | 1 |
| De Marchis, ML; Ferroni, P; Formica, V; Guadagni, F; La Farina, F; Laudisi, A; Ludovici, G; Palmirotta, R; Peeters, M; Rolfo, C; Roselli, M; Russo, A | 1 |
| Doki, Y; Furukawa, H; Kudo, T; Kurokawa, Y; Nishikawa, K; Oka, Y; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T | 1 |
| Aerts, I; Bailey, S; Breazna, A; Cañete, A; Cisar, L; de Toledo Codina, JS; Dorman, A; Estlin, E; Geoerger, B; Gesner, L; Grill, J; Grundy, RG; Hargrave, D; Leblond, P; Madero, L; Nicolin, G; Perek, D; Verlooy, J | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F; Zaniboni, A | 1 |
| Gao, Y; Han, L; Hou, P; Huang, B; Liu, X; Lu, J; Lu, Y; Shi, X; Tian, B; Wang, X; Zhang, Y; Zhao, L | 1 |
| Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S | 1 |
| Akatsuka, S; Arioka, H; Azuma, T; Egawa, M; Hibi, K; Ito, T; Kenmochi, T; Koizumi, W; Nagashima, A; Nemoto, H; Sasaki, T; Shimada, K; Soda, H; Takinishi, Y | 1 |
| Katayama, K; Nishino, T; Okitsu, H; Okitsu, N; Takahashi, Y; Tanaka, T | 1 |
| Ohishi, K; Ori, T; Sunayama, K; Takeda, M | 1 |
| Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M | 1 |
| Kadoya, N; Munemoto, M; Murata, S; Saito, H; Yoshimoto, K | 1 |
| Gao, J; Gong, JF; Li, J; Li, Y; Lu, M; Lu, ZH; Shen, L; Wang, XC; Zhang, XT; Zhou, J | 1 |
| Chang, J; Wang, LZ; Zhang, YT; Zhong, XD | 1 |
| Fujitani, K | 1 |
| Aljuffali, IA; Fang, JY; Huang, YJ; Sung, CT; Wen, CJ | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
| Chen, LT; Dito, E; Ko, AH; Lin, YL; Ong, A; Shan, YS; Su, WC; Tempero, MA; Wang, YW; Yeh, CG | 1 |
| Eguchi, T; Fujitake, S; Fujiwara, M; Ishigure, K; Ito, S; Kinoshita, T; Kodera, Y; Kojima, H; Mochizuki, Y; Ohashi, N | 1 |
| Amagai, K; Boku, N; Denda, T; Fujita, Y; Hamamoto, Y; Kawai, H; Konishi, K; Mizusawa, J; Nakamura, K; Nishina, T; Nishisaki, H; Ohkawa, S; Ohtsu, A; Takashima, A; Tsuji, A; Tsuji, Y; Yamada, Y; Yamaguchi, K | 1 |
| Chen, H; Deng, X; Jin, J; Li, H; Peng, C; Shen, B; Zhan, Q; Zhang, X | 1 |
| Lam, VW; Laurence, JM; Richardson, AJ | 1 |
| Cai, X; Cao, W; Ding, H; Liu, T; Wang, L; Wang, M; Xu, Q; Zhao, Z; Zhong, M; Zhou, X | 1 |
| Davidson, TB; Malogolowkin, M; Mascarenhas, L; May, W; Sposto, R; Venkatramani, R | 1 |
| Chen, JS; Chou, WC; Hsu, HC; Liau, CT; Lin, YC; Shen, WC; Wu, CE; Yang, TS | 1 |
| Araki, A; Eto, R; Hazama, S; Hinoda, Y; Kanekiyo, S; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Uchiyama, T; Yamamoto, T; Yoshida, S; Yoshino, S | 1 |
| Duvillard, P; Gouy, S; Lhomme, C; Morice, P; Pautier, P; Uzan, C | 1 |
| Fujita, K; Kato, Y; Kawara, K; Nakamichi, N; Okumura, H; Sasaki, Y; Shimada, K; Sugiura, T; Sunakawa, Y; Suzuki, H; Umeda, S; Watanabe, Y | 1 |
| Doi, T; Feng, HP; Fuse, N; Muro, K; Noguchi, K; Ohtsu, A; Shimamoto, T; Takahari, D; Ura, T; Yoshino, T | 1 |
| Bala, V; Boyd, BJ; Prestidge, CA; Rao, S | 1 |
| Dunne, DF; Fenwick, SW; Jones, RP; Malik, HZ; O'Grady, E; Poston, GJ; Smethurst, A; Stättner, S; Terlizzo, M | 1 |
| Chiou, YC; Lee, PC; Peng, CL; Shieh, MJ; Wong, JM | 1 |
| Baek, SK; Kim, HJ; Kim, HS; Kim, SY; Kim, TY; Lee, KW; Nam, BH; Ryu, MH; Zang, DY | 1 |
| Blake, D; Bridgewater, J; Brown, S; Chau, I; Gollins, S; Gwyther, S; Hill, M; Lowe, C; Maisey, N; Marshall, H; Maughan, T; Middleton, G; Myint, S; Napp, V; Oliver, A; Richman, S; Seymour, M; Slater, S; Wadsley, J; Wagstaff, J | 1 |
| Bahary, N; Boone, BA; Gibson, MK; Krasinskas, AM; Lembersky, BC; Steve, J; Stoller, RG; Zeh, HJ; Zureikat, AH | 1 |
| Goi, T; Katayama, K; Koneri, K; Sawai, K; Yamaguchi, A | 1 |
| Baiget, M; Barnadas, A; Berenguer-Llergo, A; Del Río, E; Lasa, A; Martín-Richard, M; Páez, D; Paré-Brunet, L; Salazar, J; Sebio, A; Tobeña, M | 1 |
| Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M | 1 |
| Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Schalhorn, A; Schulz, C; Stintzing, S | 1 |
| Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A | 1 |
| García, R; Giammaria, F; Gómez, F; Marqués, A | 1 |
| Dishman, AF; Lahann, J; Park, TH; Rahmani, S | 1 |
| Lopes, Gde L | 1 |
| Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L | 1 |
| Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW | 1 |
| Chen, HL; Dang, HW; Fu, Y; Wang, XY; Wei, SJ; Yang, FY; Yang, XY; Zhang, WP; Zhang, YX | 1 |
| Xu, JM | 1 |
| Fu, YL; Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Yao, K; Zhao, CH | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Andronescu, E; Ficai, A; Ghitulica, CD; Hoteteu, M; Iliescu, RI; Voicu, G | 1 |
| Burtness, B; Chun, YS; Cohen, SJ; Hall, MJ; Nagorney, DM; Sigurdson, ER; Thomay, AA; Truty, MJ | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Blasius, E; Boström, J; Glas, M; Greschus, S; Herrlinger, U; Kebir, S; Landwehr, C; Mack, F; Rasch, K; Schäfer, N; Schaub, C; Scheffler, B; Seifert, M; Simon, M; Stuplich, M; Urbach, H; Vilz, B; Waha, A | 1 |
| Chen, CP; Chen, HH; Chen, JS; Hsieh, RK; Huang, CC; Huang, JS; Huang, WT; Hwang, WS; Jeng, HH; Kao, RH; Lee, YC; Lin, CJ; Lin, PC; Lu, YC; Uen, WC; Wang, HM; Wu, HC; Yeh, CH | 1 |
| Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V | 1 |
| Morland, B; Platt, K; Whelan, JS | 1 |
| Komatsu, Y; Muro, K; Sameshima, S; Satoh, T; Sugihara, K; Yamaguchi, K; Yasui, H | 1 |
| Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R | 1 |
| Hao, X; Hu, X; Li, J; Shi, Y; Wang, H; Wang, Y; Xu, J; Yu, S; Zhang, X | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Boige, V; Borget, I; Caramella, C; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Farron, M; Goéré, D; Honoré, C; Malka, D; Pottier, E | 1 |
| Capussotti, L; De Rosa, G; De Saussure, WO; Mentha, G; Rubbia-Brandt, L; Viganò, L | 1 |
| Honda, R; Inoue, S; Nagashima, K; Ohsaki, Y; Onodera, H; Tanno, S | 1 |
| Blüml, S; Brown, RJ; Dhall, G; Finlay, JL; Wellner, M; Zaky, W | 1 |
| Akmese, B; Can, A; Dogan-Topal, B; Karadas, N; Ozkan, SA; Sanli, S | 1 |
| Anghileri, E; Bertolini, F; Bruzzone, MG; Calleri, A; Ceroni, M; Cuppini, L; Di Stefano, AL; Eoli, M; Finocchiaro, G; Mancuso, P; Pellegatta, S; Porrati, P; Prodi, E | 1 |
| Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ | 1 |
| Alameddine, R; Mukherji, D; Shamseddine, A; Temraz, S | 1 |
| Akahane, T; Aoki, D; Hirasawa, A; Kataoka, F; Kosaki, K; Makita, K; Nomura, H; Okubo, K; Saito, K; Susumu, N; Tanigawara, Y; Tominaga, E; Zama, T | 1 |
| Brünner, N; Nielsen, DL | 1 |
| Awada, A; Barrett-Lee, PJ; Chan, S; Chia, YL; Cocquyt, V; Coleman, RE; Garcia, AA; Hamm, JT; Hannah, AL; Hoch, U; Huizing, MT; Jerusalem, GH; Mehdi, A; O'Reilly, SM; Perez, EA; Sideras, K; Young, DE; Zhao, C | 1 |
| Funahashi, H; Ishiguro, H; Kimura, M; Matsuo, Y; Miyai, H; Takeyama, H; Wakasugi, T | 1 |
| Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR | 1 |
| Dasanu, CA; Joseph, R | 1 |
| Banerjee, A; Boyett, JM; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Warren, KE; Wu, S | 1 |
| Bekaii-Saab, TS; Buchbinder, A; Clive, S; Fisher, GA; Garrett, CR; Goldberg, RM; Kavan, P; Ryan, T; Shacham-Shmueli, E | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD | 1 |
| Cereda, V; di Bari, MG; Ferroni, P; Formica, V; Grenga, I; Guadagni, F; Raffaele, P; Roselli, M; Tesauro, M | 1 |
| Malogolowkin, MH; Mascarenhas, L; Venkatramani, R | 1 |
| Guren, T; Ikdahl, T; Kjersem, JB; Kure, EH; Lingjaerde, OC; Tveit, KM | 1 |
| Fan, WF; Liu, BR; Meng, LJ; Shen, J; Wang, J; Wang, L | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Ahn, G; Cho, JY; Jang, IJ; Kim, HK; Kim, HY; Lee, DS; Park, DM; Park, JW; Rhee, SJ | 1 |
| Fukuoka, T; Hasegawa, T; Hirakawa, K; Matsuzaki, T; Morisaki, T; Nishii, T; Yashiro, M | 1 |
| Bellister, S; Bhattacharya, R; Bollu, LR; Dupre, E; Ellis, LM; Fan, F; Gao, G; Lu, J; Tozzi, F; Weihua, Z; Xia, L; Ye, X; Zhou, Y | 1 |
| Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA | 1 |
| Bellemare, J; Guillemette, C; Roberge, J; Rouleau, M | 1 |
| Cai, J; Chen, J; Dai, J; Feng, J; Ge, S; Huang, L; Li, M; Liao, X; Ma, H; Qin, K; Wang, Q; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T | 1 |
| Abou Taleb, H; Baba, T; Hamanishi, J; Kido, A; Konishi, I; Matsumura, N; Togashi, K; Yamaguchi, K; Yamanoi, K; Yoshioka, Y | 1 |
| Carberry, M; Damjanov, N; Giantonio, BJ; Jacobs-Small, M; Mykulowycz, K; O'Dwyer, PJ; Sepulveda, A; Sohal, DP; Sun, W; Teitelbaum, UR; Uehara, T; Wissel, P | 1 |
| Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK | 1 |
| Delaunay, F; Dulong, S; Dumitru, M; Filipski, E; Guettier, C; Lévi, F; Li, XM; Mohammad-Djafari, A; Mteyrek, A; Scaglione, F; Siffroi-Fernandez, S | 1 |
| Hasegawa, M; Hattori, S; Ide, H; Kikuchi, E; Miyajima, A; Oya, M; Yasumizu, Y | 1 |
| Boelsterli, UA; Mani, S; Redinbo, MR | 1 |
| Chowbay, B; Sutiman, N | 1 |
| Boku, N; Fukuda, H; Kato, K; Mizusawa, J; Nakamura, K; Ohtsu, A; Shimada, Y; Shirao, K; Takashima, A | 1 |
| Aboody, KS; Abramyants, Y; Barish, ME; Brown, CE; Ghoda, LY; Gilchrist, M; Gutova, M; Lacey, SF; Metz, MZ; Najbauer, J; Portnow, J; Potter, PM; Synold, TW; Tirughana, R; Vo, T | 1 |
| Ikehata, M; Iwakawa, S; Ogawa, M; Tanaka, S; Ueda, K; Yamada, Y | 1 |
| Dong, S; Qi, B; Qu, H; Tang, N; Tong, X; Wang, L; Yu, B; Yu, M; Zhang, C; Zhang, N | 1 |
| Ba, Y; Bai, YX; Deng, T; Han, Y; Li, YH; Liu, XJ; Wang, Y; Xu, JM; Zhang, L | 1 |
| Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A | 1 |
| Baek, JY; Chang, HJ; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Lee, SU; Oh, JH; Park, JW | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Chen, X; He, D; Huang, T; Luo, W; Tan, X; Wang, C; Wang, R; Wu, X; Yu, Y; Zeng, X | 1 |
| Barbier, O; Bigo, C; Chen, S; Karin, M; Nguyen, N; Tukey, RH; Wang, K; Yueh, MF | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Elbatsh, A; Iusuf, D; Lin, F; Ludwig, M; Schinkel, AH; van de Steeg, E; van der Valk, M; van Esch, A; van Tellingen, O; Wagenaar, E | 1 |
| Asano, T; Ishii, M; Iwata, K; Kobayashi, H; Kobayashi, S; Koizumi, S; Okamura, R; Otsubo, T; Saji, O; Sumiyoshi, K | 1 |
| Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Quietzsch, D; Schalhorn, A; Schulz, C; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; von Weikersthal, LF | 1 |
| Duffy, AG; Greten, TF | 1 |
| Ford, JM; McPherson, LA; Shen, Y | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Lenz, HJ; Stintzing, S | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Imamura, Y; Liao, X; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Mowat, RB; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Spiegelman, D; Whittom, R; Yamauchi, M | 1 |
| Brown, KM; Gajjar, A; Han, Y; Parmar, AD; Riall, TS; Sheffield, KM; Vargas, GM | 1 |
| Bezan, A; Greil, R; Hauser-Kronberger, C; Hohla, F; Hopfinger, G; Rinnerthaler, G; Romeder, F; Stättner, S; Ulmer, H | 1 |
| Doki, Y; Fukunaga, M; Hasegawa, J; Hata, T; Ide, Y; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohashi, I; Sekimoto, M; Takemasa, I; Takemoto, H; Tamagawa, H; Yamamoto, H; Yasumasa, K | 1 |
| Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
| Brünner, N; Christensen, IJ; Nielsen, HJ; Nielsen, SL; Nygård, SB; Spindler, KL | 1 |
| Fujita, K; Sasaki, Y | 1 |
| Andersen, RF; Appelt, AL; Jakobsen, A; Pallisgaard, N; Spindler, KG | 1 |
| Armstrong, AE; Cohn, RA; Dargart, J; Gosiengfiao, Y; Matossian, D; Reichek, J; Walterhouse, DO | 1 |
| D'Incalci, M; Grohar, PJ; Helman, LJ; Mendoza, A; Pommier, Y; Segars, LE; Yeung, C | 1 |
| Jakubczak, M; Kontek, R; Matlawska-Wasowska, K | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Bécouarn, Y; Bénichou, J; Bernard, O; Fourrier-Réglat, A; Guimbaud, R; Moore, N; Noize, P; Ravaud, A; Rouyer, M; Smith, D | 1 |
| Chen, X; He, Y; Li, C; Li, N; Qiu, Z; Ren, S; Tian, F; Wang, X; Zhang, Y; Zhao, D; Zhou, S | 1 |
| Chen, YJ; Chu, L; Fang, JM; Hu, F; Li, CY; Xu, Q; Zhang, X | 1 |
| Harada, M; Hida, T; Imamura, F; Ishikura, S; Kawahara, M; Kubota, K; Matsui, K; Mizusawa, J; Nakagawa, K; Negoro, S; Nishio, M; Okamoto, H; Saijo, N; Sakai, H; Shibata, T; Shinkai, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Banerjee, A; Boyett, JM; Fahey, F; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Vajapeyam, S; Wu, S | 1 |
| Al-Dasooqi, N; Bateman, E; Bowen, JM; Gibson, RJ; Shirren, J; Stansborough, R; Sultani, M; Wardill, HR | 1 |
| Inoue, K; Kobayashi, H; Murata, S; Naitoh, H; Tani, T; Yamamoto, H | 1 |
| Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G | 1 |
| Jin, J; Joo, KM; Kang, W; Kim, KH; Kim, SU; Lee, JI; Nam, DH; Seol, HJ; Yang, H | 1 |
| Arif, Q; Bharti, A; Brand, TM; Dhanasingh, I; Hembrough, T; Husain, AN; Kanteti, R; Nandi, S; Rolle, CE; Salgia, R; Surati, M; Tretiakova, M; Vokes, EE; Wheeler, DL; Yala, S | 1 |
| Besznyák, I; Bursics, A; Dede, K; Fekete, A; Kőszegi, G; Láng, I; Mersich, T; Mester, G; Pörneczi, B | 1 |
| Hida, N; Horiike, A; Ishii, M; Kenmotsu, H; Misumi, Y; Murakami, H; Nishio, M; Ohyanagi, F; Okamoto, H; Shimokawa, T; Takahashi, T; Yamamoto, N | 1 |
| Burnouf, PA; Prijovich, ZM; Roffler, SR | 1 |
| Adams, R; Becker, M; Bhargava, A; Ellinghaus, P; Hoffmann, J; Kahmann, N; Müller, T; Rosenthal, A; Schmieder, R; Scholz, A; Thierauch, KH; Wilhelm, SM; Zopf, D | 1 |
| Liu, B; Shen, J; Wang, J; Wang, L; Xie, L | 1 |
| Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D | 1 |
| Borg, C; Cléau, D; Curtit, E; Demarchi, M; Dobi, E; Fratte, S; Guiu, B; Heyd, B; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Monnien, F; Nerich, V; Nguyen, T | 1 |
| Fujii, T; Kimura, H; Nakayama, H; Sakai, Y | 1 |
| Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P | 1 |
| Fejerskov, B; Jensen, NB; Städler, B; Teo, BM; Zelikin, AN | 1 |
| Cao, DY; Dun, JN; Fang, Y; Wang, J; Xiang, B; Xue, GQ; Zhang, L | 1 |
| Hamada, A; Harada, T; Kudoh, S; Maeno, K; Miyawaki, H; Moriyama, A; Nakagawa, K; Nakanishi, Y; Saeki, S; Shimokawa, M; Takayama, K | 1 |
| Berland, E; Filipski, E; Guettier, C; Lévi, F; Okyar, A; Ozturk, N; van der Horst, GT | 1 |
| Benković, V; Blažević, AS; Knežević, AH; Lisičić, D; Mihaljević, J; Oršolić, N; Ðikić, D | 1 |
| Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T | 1 |
| Ishimoto, T; Kinoshita, O; Kishimoto, M; Konishi, E; Kuriu, Y; Masuzawa, N; Murayama, Y; Nakanishi, M; Otsuji, E; Yanagisawa, A; Yasukawa, S | 1 |
| Kwon, AH; Motohiro, T; Nakatake, R; Saito, T; Tanaka, H; Ueda, A; Yamamichi, K | 1 |
| Asaoka, T; Fujitani, K; Hirao, M; Ikeda, M; Ikenaga, M; Miyamoto, A; Nakamori, S; Sekimoto, M; Takeoka, T; Yamamoto, K | 1 |
| Aoyagi, H; Hasegawa, K; Isogai, J; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T | 1 |
| Arita, K; Haruki, S; Hiranuma, S; Ito, K; Matsumoto, A; Suzuki, K; Takiguchi, N; Usui, S | 1 |
| Iwanaga, T; Iwasaki, Y; Karasawa, K; Kawasaki, K; Maeda, Y; Oohinata, R; Yajima, K; Yuu, K | 1 |
| Hakamada, K; Kawasaki, H; Kimura, A; Muroya, T; Nagase, H; Nakai, M; Nakayama, Y; Okano, K; Wajima, N; Yonaiyama, S | 1 |
| Fukunaga, M; Kaido, M; Kawabata, R; Kawase, T; Kimura, Y; Nakajima, Y; Ninomiya, H; Ohzato, H | 1 |
| Aoki, T; Chono, T; Hyuga, S; Kobayashi, K; Matsumoto, T; Moon, JH; Nishioka, K; Takachi, K; Takemoto, H; Tsukao, Y; Uemura, Y; Watanabe, R | 1 |
| Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M | 1 |
| Dasanu, CA; Nandy, N | 1 |
| Cho, YB; Chun, HK; Huh, JW; Kim, HC; Lee, WY; Park, YA; Yun, SH | 1 |
| Berthou, J; Bichard, D; Borg, C; Facy, O; Ghiringhelli, F; Heyd, B; Ladoire, S; Lakkis, Z; Limat, S; Lorgis, V; Nerich, V; Orry, D; Ortega-Deballon, P; Rat, P; Vincent, J | 1 |
| Amaral, SS; Besnard, AG; Beyaert, R; Braun, H; Cunha, FQ; Graham, GJ; Guabiraba, R; Jabir, MS; Liew, FY; Lima-Junior, RC; Menezes, GB; Ribeiro, RA; Secher, T; Teixeira, MM | 1 |
| Chen, XW; Ju, YL; Ou Yang, MZ; Wang, JZ; Zhang, WJ; Zhu, DJ | 1 |
| Brito, GA; Cunha, FQ; Freitas, HC; Leite, LL; Lima-Júnior, RC; Magalhães, PJ; Miranda, SP; Nunes, LG; Ribeiro, RA; Souza, MH; Teixeira, MM; Wanderley, CW; Wong, DV | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Abbasi, T; Bharati, IS; Chao, Y; Cong, X; Fogal, V; Gallagher, M; Jiang, P; Kesari, S; Makale, M; Mukthavaram, R; Mukthavavam, R; Nomura, N; Pastorino, S; Pingle, SC; Vali, S | 1 |
| Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I | 1 |
| Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS | 1 |
| Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C | 1 |
| Chen, X; Li, J; Ouyang, XN; Peng, YH; Wang, WW; Xie, FW; Yu, ZY | 2 |
| Cheng, L; Dong, XL; Hu, J; Li, M; Liu, BR; Qian, XP; Ren, W; Sun, ZP; Xie, L; Xu, GX | 1 |
| Agu, RU; Feridooni, T; Mac Donald, C; Shao, D; Yeung, P | 1 |
| Baracos, V; Dieleman, L; Farhangfar, A; Gänzle, MG; Lin, XB; Sawyer, MB; Schieber, A; Valcheva, R | 1 |
| Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C | 1 |
| Ikegami, Y; Inoue, Y; Ishikawa, T; Nakagawa, H; Nakamura, Y; Sano, K; Suzuki, T; Yoshida, H | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Ahn, G; Cho, JY; Jang, IJ; Kim, HK; Kim, HY; Park, DM; Park, JW; Rhee, SJ | 1 |
| Chaudhury, A; Chiu, GN; Liu, Y; Shaikh, IM; Tan, BJ; Tan, BM; Tan, KB | 1 |
| Gemeinhart, RA; Köllmer, M; Liu, Y; Nitsche, LC; Sharma, V; Szymusiak, M | 1 |
| Guo, Y; Shen, X; Shi, M; Yang, C; Yang, L; Zhang, J | 1 |
| Chen, X; Gan, Y; Guo, S; Li, F; Li, J; Wang, X; Zhang, X | 1 |
| Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ | 1 |
| Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE | 1 |
| Cho, YB; Do, IG; Han, SW; Hong, JY; Hong, YS; Kang, HJ; Kang, WK; Kim, HC; Kim, KM; Kim, KP; Kim, SH; Kim, TW; Kim, TY; Lee, J; Lee, WY; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, I; Yun, SH | 1 |
| Aster, RH; Curtis, BR; George, JN; Mirtsching, BC | 1 |
| Chen, YL; Chiang, JH; Chueh, FS; Chung, JG; Hsueh, SC; Lee, CS; Lu, CC; Lu, HF; Yang, JS | 1 |
| Asamura, H; Eba, J; Katayama, H; Kenmotsu, H; Niho, S; Shibata, T; Tamura, T; Tsuboi, M; Watanabe, S; Yamamoto, N | 1 |
| Akashi, K; Ariyama, H; Baba, E; Ijichi, K; Komoda, M; Kubo, N; Kusaba, H; Tamura, S; Tsuchihashi, K; Uchino, K | 1 |
| Ali, HI; Kolluru, S; Liu, JL; Lu, D; Palakurthi, S; Vangara, KK | 1 |
| Hamaguchi, T; Kubo, T; Matsumura, Y; Ochiya, T; Takigahira, M; Yanagihara, K | 1 |
| Bankiewicz, KS; Berger, MS; Beyer, J; Drummond, DC; Forsayeth, J; Hadaczek, P; Hayes, ME; Kirpotin, DB; Krauze, MT; Noble, CO; Park, JW | 1 |
| Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V | 1 |
| Furuse, J; Kishiki, T; Masaki, T; Ohkura, Y; Ohnishi, H; Ohtsuka, K; Sugiyama, M; Watanabe, T | 2 |
| Böning, L; Jehn, CF; Kröning, H; Lüftner, D; Pezzutto, A | 1 |
| Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Iijima, S; Imamura, H; Imano, M; Kurokawa, Y; Shimokawa, T; Sugimoto, N; Uedo, N | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Moloney, J; Schrag, D | 1 |
| Endo, S; Hirai, S; Hirose, M; Hyodo, I; Saito, R; Suzuki, H; Ueno, T; Yamato, K | 1 |
| Antoniotti, C; Benhaim, L; Bohanes, P; Cremolini, C; El-Khoueiry, R; Falcone, A; Graziano, F; Lenz, HJ; Loupakis, F; Marmorino, F; Masi, G; Ning, Y; Ricci, V; Ruzzo, A; Salvatore, L; Schirripa, M; Wakatsuki, T; Yang, D; Zhang, W | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
| Álvarez, R; Cubillo, A; de Vicente, E; García, E; Hernando, O; Hidalgo, M; López-Ríos, F; Perea, S; Plaza, C; Quijano, Y; Rodriguez-Pascual, J; Rubio, C; Sanchez, G | 1 |
| Gao, Y; Liu, M; Xiao, L | 1 |
| An, GY; Gong, LL; Guo, CL; Han, FF; Li, GR; Liu, H; Liu, LH; Lv, YL; Yu, D; Zhu, J | 1 |
| Chen, Q; Li, A; Ni, P; Qiang, F; Røe, OD; Wang, M; Wang, S; Wu, X; Xu, S; Xu, W; Zhang, J; Zhang, R; Zhang, Y; Zhou, J | 1 |
| Bitzer, M; König, C; Malek, NP; Plentz, RR; Schempf, U; Sipos, B | 1 |
| Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK | 1 |
| Burdach, S | 1 |
| Hamilton, G; Klameth, L; Rath, B; Thalhammer, T | 1 |
| Konagaya, A; Kusuhara, H; Maeda, K; Yoshida, K | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Altundag, K; Babacan, T; Balakan, O; Dag, MS; Dilli, I; Turkbeyler, IH | 1 |
| Amagai, K; Azuma, M; Higuchi, K; Hosaka, H; Kanda, T; Koizumi, W; Moriwaki, T; Nakayama, N; Sakuyama, T; Sasaki, E; Sasaki, T; Sekikawa, T; Shimada, K; Takahashi, F; Takeda, Y; Takeuchi, M; Tanabe, S | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Shimizu, K; Yasuda, K; Yukawa, T | 1 |
| Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Arita, J; Inoue, Y; Ono, Y; Saiura, A; Takahashi, M; Takahashi, Y | 1 |
| Wang, L; Wei, Y; Xie, H; Yao, W; Zeng, C; Zhou, H | 1 |
| Ando, Y; Fujii, T; Fujiwara, M; Hayashi, N; Kanda, M; Kobayashi, D; Kodera, Y; Koike, M; Mashita, N; Nakayama, G; Nomoto, S; Sugimoto, H; Tanaka, C; Uehara, K; Yamada, S | 1 |
| Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ | 1 |
| Bai, L; Su, D | 1 |
| Fujii, H; Horie, H; Inoue, T; Kotake, K; Miyakura, Y; Sato, F; Sugano, K; Tahara, M; Yasuda, Y | 1 |
| Aliberti, C; de Baere, T; Garcia-Monaco, R; Lencioni, R; Martin, RC; Narayanan, G; O'Grady, E; Rilling, WS; Walker, D | 1 |
| Fujimori, K; Kaido, Y; Kaiho, M; Mizunuma, H; Nishiyama, H; Omi, H; Otsuki, T; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Yaegashi, N; Yokoyama, Y | 1 |
| Bertaut, A; Ghiringhelli, F; Ladoire, S; Lorgis, V; Rambach, L; Vincent, J | 1 |
| Abbara, C; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Gonin, P; Polrot, M; Tandia, M | 1 |
| Aoyama, T; Hamano, T; Hashimura, T; Kawai, J; Kimura, H; Uegaki, M | 1 |
| Cloughesy, TF; Dahlbom, M; Huang, SC; Phelps, ME; Schiepers, C; Wardak, M | 1 |
| Chen, Q; Ha, MW; Li, P; Wang, YD | 1 |
| Cao, S; Durrani, FA; Rustum, YM; Tóth, K | 1 |
| Baba, H; Baba, Y; Etoh, K; Ishimoto, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Murata, A; Sakamoto, Y; Shigaki, H; Sugihara, H; Watanabe, M; Yoshida, N | 1 |
| Gong, T; Liao, L; Liu, H; Lu, H; Zhang, X; Zhang, Z | 1 |
| McGregor, N; Pienta, KJ; Wang, X; Wu, M; Zhang, J | 1 |
| Glimelius, B; Gubanski, M; Lind, PA | 1 |
| Fukita, S; Saitoh, M; Takeda, S; Takeda, T | 1 |
| Allard, MA; Malka, D | 1 |
| Ando, M; Atagi, S; Fukuda, H; Hida, T; Ichinose, Y; Kimura, T; Kotani, Y; Minato, K; Nakagawa, K; Nishio, M; Ohe, Y; Saijo, N; Satouchi, M; Shibata, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Bhuniya, S; Hong, KS; Kim, EJ; Kim, JS; Lee, H; Maiti, S; Sessler, JL | 1 |
| Allen, PJ; Capanu, M; Cercek, A; Chou, JF; Correa-Gallego, C; DeMatteo, RP; DʼAngelica, MI; Fong, Y; Gewirtz, AN; Jarnagin, WR; Kemeny, N; Kingham, TP; Paty, PB | 1 |
| Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nishiyama, H; Suetomi, T; Takaoka, E; Uchida, M | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Boschetti, G; Cotte, E; Decullier, E; Fontaine, J; Gilly, FN; Glehen, O; Isaac, S; Maurice, C; Passot, G; Vaudoyer, D; You, B | 1 |
| Boku, N; Fukase, K; Goto, M; Koizumi, W; Mizusawa, J; Nishina, T; Ohtsu, A; Takahari, D; Takashima, A; Tamura, T; Tsuji, A; Yamada, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Anghileri, E; Aquino, D; Bruzzone, MG; Cuppini, L; Di Stefano, AL; Eoli, M; Finocchiaro, G; Scotti, A | 1 |
| Cheng, L; Feng, L; Gong, H; Gu, X; Liu, T; Liu, Z; Shi, X; Sun, B; Wang, C | 1 |
| Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L | 1 |
| Ishikawa, Y; Ito, T; Kenmotsu, H; Kubota, K; Nagai, K; Niho, S; Noguchi, M; Oshita, F; Sekine, I; Tada, H; Watanabe, S; Yamamoto, N; Yoshimura, M | 1 |
| Chan, GL; Gao, J; Han, W; Qian, L; Wang, X; Wu, M; Yu, Y; Zhang, Y; Zhu, S | 1 |
| Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M | 1 |
| Benson, AB; Berlin, J; Burtness, B; Catalano, P; Chapman, AE; Liles, DK; Mitchell, E; Powell, M | 1 |
| Bendell, JC; Berlin, JD; El-Rayes, BF; George, TJ; Hart, LL; Kingsley, CD; Lenz, HJ; Marshall, JL; Modiano, MR; Nakashima, D; Ryan, T | 1 |
| Bando, H; Fukunaga, M; Hazama, S; Iwamoto, S; Kato, T; Matsuda, C; Mishima, H; Miyake, Y; Oba, K; Sakamoto, J | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Deng, D; Fang, HB; Tan, M; Zhang, T | 1 |
| Gillmore, R; Suarez Martinez-Falero, B | 1 |
| Antoun, S; Barret, M; Dalban, C; Latko, E; Malka, D; Mansourbakht, T; Taieb, J; Zaanan, A | 1 |
| Boige, V; Dias, MM; Glimelius, B; Karapetis, CS; Kweekel, DM; Lara, PN; Laurent-Puig, P; Martinez-Balibrea, E; McKinnon, RA; Páez, D; Pignon, JP; Punt, CJ; Redman, MW; Sorich, MJ; Toffoli, G; Wadelius, M | 1 |
| Cao, W; Cheng, C; Huo, BL; Wang, YH; Zhang, E | 1 |
| Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH | 1 |
| Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J | 1 |
| Blaszkowsky, LS; Cashavelly, BJ; Kim, CY; Penson, RT; Riley, JP; Ryan, DP; Schapira, L; Wold, MC | 1 |
| Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I | 1 |
| Chen, MC; Ho, TJ; Hsu, HH; Huang, CY; Kuo, CH; Kuo, WW; Lee, NH; Lin, YM; Tsai, CH; Tsai, FJ | 1 |
| Anders, HJ; Frese, S; Frese-Schaper, M; Gugger, M; Huynh-Do, U; Keil, A; Kocher, GJ; Körner, M; Schiffer, L; Schmid, RA; Steiner, SK | 1 |
| Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P | 1 |
| Doherty, GA; Lee, CS; Ryan, EJ | 1 |
| Abal, M; Barbazán, J; Candamio, S; Cano, A; Casares de Cal, Mde L; Díaz-López, A; Gómez-Tato, A; López-López, R; Muinelo-Romay, L; Vieito, M | 1 |
| Misawa, S; Miyamoto, M | 1 |
| Ahmad, S; Kong, R; Liu, T; Phan, AT; Scott, JE; Williams, AL; Wong, ST; Yeh, LA; Zhao, H; Zhu, X | 1 |
| Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
| Ge, X; Jiang, H; Li, F; Shen, J; Wei, S; Zhou, J; Zhou, L | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Yano, S | 1 |
| Augustine, TA; Coffey, MC; Goel, S; Klampfer, L; Maitra, R; Mariadason, JM; Seetharam, R; Tesfa, L | 1 |
| Alexander, HR; Culpepper, WJ; El-Kamary, SS; Jiang, Y; Lane, BF; Mindikoglu, AL; Reddy, SK; Reilly, C; Zhan, M | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Boisselier, B; Chinot, O; Delattre, JY; Di Stefano, AL; Ducray, F; Farina, P; Figarella-Branger, D; Gallego Perez-Larraya, J; Honnorat, J; Idbaih, A; Laffaire, J; Marie, Y; Sanson, M; Vintonenko, N | 1 |
| Arao, T; Hamaguchi, T; Hayashi, H; Hirashima, Y; Honma, Y; Horita, Y; Iwasa, S; Kato, K; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Okita, NT; Shimada, Y; Takashima, A; Togashi, Y; Yamada, Y | 1 |
| Kræmer, PC; Ladekarl, M; Schmidt, HH | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wang, L; Wu, XY; Xiang, J | 1 |
| Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G | 1 |
| Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T | 1 |
| Aichler, M; Buck, A; Eickelberg, O; Fernandez, IE; Hauck, SM; Huber, K; Janssen, KP; Keller, U; Li, Z; Sun, N; Walch, A; Zitzelsberger, H | 1 |
| Kagabu, M; Kumagai, S; Miura, F; Omi, H; Sato, A; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Takahashi, N; Taniguchi, H; Yamada, Y | 1 |
| Brunner, T; Grabinger, T; Kostadinova, F; Leist, M; Luks, L; Medema, JP; Zimberlin, C | 1 |
| Chung, HY; Kang, BW; Kim, JG; Kwon, OK; Yu, W | 1 |
| Gao, YJ; Han, JC; Yu, J | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Chang, J; Feng, LH; Wang, LZ; Zhang, YT; Zhong, XD | 1 |
| Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS | 1 |
| Gilbert, CW; Hukuoka, Y; Kichikawa, K; Masada, T; Nishiofuku, H; Obayashi, C; Sato, T; Takano, M; Tanaka, T | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L | 1 |
| Barni, S; Borgonovo, K; Coinu, A; Ghidini, A; Petrelli, F | 1 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 1 |
| Atyabi, F; Dinarvand, R; Ghahremani, MH; Khoshayand, MR; Montazeri, H; Ostad, SN; Rouhani, H; Sepehri, N; Tavassolian, F | 1 |
| Bergamo, F; De Paoli, A; De Salvo, GL; Di Grazia, L; Esposito, G; Griguolo, G; Indraccolo, S; Lonardi, S; Mescoli, C; Nardin, M; Rugge, M; Zagonel, V; Zulato, E | 1 |
| Amini, M; Dinarvand, R; Ghahremani, MH; Ghanbarpour, AR; Gharghabi, M; Ostad, SN; Rouhani, H; Sepehri, N; Tavassolian, F | 1 |
| Bian, T; Chen, C; Chen, Y; Jin, T; Lin, A; Wang, H | 1 |
| Amini, M; Atyabi, F; Azhdarzadeh, M; Dinarvand, M; Ghasemi, Z; Mollarazi, E; Sayari, E | 1 |
| Konno, F; Matsumoto, H; Mitsui, K; Namiki, K; Takahashi, T; Yoshida, R | 1 |
| Rovere, RK | 1 |
| Kjaer, A; Kristoffersen, K; Lassen, U; Madsen, J; Michaelsen, SR; Nedergaard, MK; Poulsen, HS; Stockhausen, MT | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Cho, AR; Heo, JH; Hwhang, TH; Kim, WM; Lee, DH; Park, DJ; Won, JH; Yun, HJ | 1 |
| Ema, A; Naito, M; Nakamura, T; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Teng, HW; Tzeng, CH; Yang, SH; Yang, YH; Yen, CC | 1 |
| Delorenzi, M; Høgdall, E; Jensen, BV; Johansen, JS; Kruhøffer, M; Nielsen, DL; Pfeiffer, P; Rossi, S; Schou, JV; Tejpar, S; Yilmaz, M | 1 |
| Hendel, HW; Høgdall, EV; Jensen, BV; Johannesen, HH; Nielsen, D; Schou, JV; Skougaard, K | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
| Arifa, RD; de Paula, TP; Fagundes, CT; Lima, RL; Madeira, MF; Menezes-Garcia, Z; Rachid, MA; Ryffel, B; Souza, DG; Tavares, LD; Teixeira, MM; Zamboni, DS | 1 |
| Phelps, MA; Sparreboom, A | 1 |
| Das, S; House, LK; Innocenti, F; Janisch, L; Karrison, T; Maitland, ML; Marsh, R; Ramírez, J; Ratain, MJ; Salgia, R; Schilsky, RL; Turcich, M; Undevia, S; Wu, K | 1 |
| Cai, SJ; Huang, LY; Li, XX; Liang, L; Peng, JJ; Shi, DB; Zheng, HT | 1 |
| Amagai, K; Ando, H; Gamoh, M; Ishioka, C; Isobe, H; Kakudo, Y; Kato, S; Mori, T; Shimodaira, H; Soeda, H; Suto, T; Takahashi, S; Watanabe, M; Yamaguchi, T | 1 |
| Chen, Q; Chen, S; Huang, C; Li, J; Liao, J; Liu, F; Su, G; Tang, W; Ye, Y | 1 |
| Tadje, M | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Bouquié, R; Boyer, JC; Broly, F; Etienne-Grimaldi, MC; Gagnieu, MC; Gaub, MP; Ged, C; Ghiringhelli, F; Le Guellec, C; Le Morvan, V; Loriot, MA; Philibert, L; Picard, N; Poncet, D; Quaranta, S; Thomas, F | 1 |
| Chen, L; Ci, T; Ding, J; Yu, L | 1 |
| Bi, F; Chen, X; Liu, Z; Wei, W | 1 |
| Merali, Z; Paré, G; Ross, S | 1 |
| Hongeng, S; Manaspon, C; Nasongkla, N; Nittayacharn, P | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Cabral, H; Kataoka, K | 1 |
| Bae, SK; Choi, EJ; Park, JB; Yoon, KD | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Coban, E; Demir, L; Dirican, A; Erten, C; Koyuncu, B; Kucukzeybek, Y; Somali, I; Tarhan, MO; Varol, U; Yildiz, Y | 1 |
| Abramson, V; Anders, C; Berg, J; Carey, LA; Carpenter, JT; Deal, AM; Karginova, O; Kelly Marcom, P; Lin, NU; Liu, MC; Melhem-Bertrandt, A; Melisko, M; Nanda, R; Parker, J; Perou, CM; Peterman, A; Prat, A; Puhalla, S; Smith, JK; Stearns, V; Storniolo, AM; Van Poznak, C; Winer, EP; Wolff, AC | 1 |
| Hong, SM; Ihn, MH; Kang, SB; Kim, DW; Lee, SY; Oh, HK | 1 |
| Aoki, T; Fukayama, M; Hamada, T; Hasegawa, K; Isayama, H; Koike, K; Kokudo, N; Morikawa, T; Nakai, Y; Sakamoto, Y; Sasaki, T; Tanaka, M | 1 |
| Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J | 1 |
| Bayraktar, S; Broome, P; de Queiroz Marques Junior, E; Leslie, M; Nowacki, M; Rocha-Lima, CM; Susnerwala, S; Weissman, C | 1 |
| Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N | 1 |
| Abei, M; Endo, S; Hirai, S; Hirose, M; Hyodo, I; Saito, R; Suzuki, H; Ueno, T; Yamato, K | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T | 1 |
| Blackmon, SH; Correa, AM; Eng, C; Kee, B; Subbiah, IM; Swisher, SG; Vaporciyan, AA | 1 |
| Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S | 1 |
| Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M | 1 |
| Goto, K; Matsumoto, S; Morise, M; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K | 1 |
| Asahara, H; Ishikawa, T; Itamochi, H; Kigawa, J; Kuroki, M; Manabe, S; Miyamoto, S; Miyata, K; Nam, SO; Odawara, T; Takada, S; Yotsumoto, F | 1 |
| Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
| Cai, P; Gao, F; Gao, L; Gao, X; Huang, G; Liang, J; Liu, R; Wang, Y; Wei, Y; Yuan, Q; Zhu, H | 1 |
| Agarwal, S; Dasari, A; Eng, C; Fogelman, D; Garrett, C; Jiang, ZQ; Kee, B; Kopetz, S; Maru, D; Morris, V; Overman, MJ; Wolff, R | 1 |
| Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S | 1 |
| Chang, BW; Johung, KL; Saif, MW | 1 |
| Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
| Aragão, KS; Costa, ML; de Almeida, PR; de Castro Brito, GA; de Mesquita Neto, JW; de Sá Grassi, L; de Souza, MH; Leite, LL; Lima-Júnior, RC; Marques-Neto, RD; Medeiros, RP; Nunes, LG; Ribeiro, RA | 1 |
| Billard, V; Blot, F; Cloutier, AS; Dartigues, P; Ducreux, M; Dumont, F; Elias, D; Goéré, D; Honoré, C; Mariani, A | 1 |
| Hu, Y; Liu, X; Song, S; Tian, L; Wang, Y; Xu, J; Xu, X | 1 |
| Casadó, A; Mora, M; Sagristá, ML | 2 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Hirakawa, K; Ikeya, T; Maeda, K; Nagahara, H; Ohtani, H; Shibutani, M; Sugano, K | 1 |
| Doi, A; Doi, T; Hamaguchi, T; Ichinohe, R; Kaniwa, N; Matsumura, Y; Odaka, Y; Ohtsu, A; Okuda, H; Okuyama, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shimada, Y; Takahashi, A; Takahashi, H; Yoshida, T; Yoshino, T | 1 |
| Inoue, D; Ishii, H; Kanda, H; Matsuyama, M; Muramatsu, Y; Ozaka, M; Yamada, I | 1 |
| Melichar, B; Mohelnikova-Duchonova, B; Soucek, P | 1 |
| Liu, X; Xu, W | 1 |
| Bišof, V; Dedić Plavetić, N; Krpan, AM; Ozretić, D; Rakušić, Z; Simetić, L | 1 |
| Cereda, V; Cunningham, D; Ferroni, P; Formica, V; Guadagni, F; Luccchetti, J; Nardecchia, A; Roselli, M; Smyth, EC; Tesauro, M | 1 |
| Kasperczyk, S; Malinowska-Borowska, J; Nowak, P; Rogalska, A; Świętochowska, E; Słomian, G | 1 |
| Chen, X; Gan, Y; Jia, Z; Li, FF; Li, J; Zhang, XX; Zhao, YN | 1 |
| Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY | 1 |
| Coward, L; Gorman, G; Grappe, F; Nance, G | 1 |
| Crocenzi, T; Esparaz, B; Fisch, MJ; Glover, K; Jones, D; Kee, BK; Morris, JS; Overman, M; Slack, RS; Wen, S; Wong, L | 1 |
| Joo, J; Kwon, MM; Lim, KY; Park, BK; Park, HJ; Park, SY; Yoon, JH | 1 |
| Feng, JF; Huang, XE; Liu, J | 1 |
| Chan, RL; Cho, CH; Hu, T; Li, M; Lu, L; Shen, J; To, KK; Wang, L; Yeung, JH; Zhang, L | 1 |
| Fujita, Y; Hamamoto, Y; Hazama, S; Inoue, Y; Kanekiyo, S; Mishima, H; Oba, K; Oka, M; Okayama, N; Sakamoto, J; Suehiro, Y; Tsunedomi, R; Yamasaki, T; Yoshino, S | 1 |
| Tong, Y; Zheng, Y; Zhou, J | 1 |
| Fuse, N; Kim, JM; Kim, SY; Kim, TY; Kim, YH; Komatsu, Y; Lee, KH; Morita, S; Munakata, M; Nishio, K; Park, SH; Rha, SY; Saitoh, S; Sakata, Y; Sasaki, Y; Satoh, T; Ura, T; Yamada, Y; Yamaguchi, K; Yamamoto, E; Yasui, H; Zhang, Q | 1 |
| Ghazaly, E; Joel, S; Kitromilidou, C; Perry, J; Powles, T | 1 |
| Wang, H; Wei, X; Wu, J; Xie, H; Xu, X; Zheng, S; Zhou, L | 1 |
| Cruz, JE; Hermes-DeSantis, E; Jabbour, SK; Moss, RA; Nosher, JL; Saksena, R | 1 |
| Akiyama, S; Arima, K; Chen, ZS; Furukawa, T; Horikuchi, F; Kamijo, Y; Kawahara, K; Minami, K; Nakagawa, M; Nishizawa, Y; Seki, N; Shinsato, Y; Tabata, S; Tachiwada, T; Takeda, Y; Tsujikawa, K; Yamamoto, M | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Okita, N; Okuma, HS; Shimada, Y; Shoji, H; Takashima, A; Yamada, Y | 1 |
| Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K | 1 |
| Fung, KP; Lau, CB; Leung, PC; Leung, PS; Li, L; Yue, GG | 1 |
| Elvin, P; Gallick, G; Jiang, ZQ; Kopetz, S; Maru, D; Morris, VK; Overman, MJ; Parikh, N | 1 |
| Dimchevska, S; Djurdjic, B; Gancheva, V; Georgiev, G; Geskovski, N; Goracinova, K; Petrov, P; Petrusevska, M | 1 |
| Al-Azri, AR; Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM | 1 |
| Pang, LQ; Qin, ZS; Wu, K; Xia, TF; Zhang, XS; Zhao, ZQ | 1 |
| Jaggi, M; Joshi, V; Negi, LM; Ronodip, K; Talegaonkar, S | 1 |
| Eldon, MA; Hoch, U; Johnson, RK; Staschen, CM | 1 |
| Dang, HW; Wang, XY; Yang, FY; Yang, WC; Zhang, WP | 1 |
| Bhuniya, S; Cheong, C; Hong, KS; Kim, EJ; Kim, HM; Kim, JS; Lee, H; Maiti, S | 1 |
| Hayashi, A; Higashi, Y; Hori, Y; Kishimoto, K; Maeda, N; Morii, E; Ohashi, F; Osuga, K; Tanaka, K; Tomiyama, N | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Bennouna, J; Botbyl, J; de Labareyre, C; Delord, JP; Deslandres, M; Ruiz-Soto, R; Senellart, H; Suttle, AB; Wixon, C | 1 |
| Ito, S; Masui, H; Minami, Y; Mogaki, M; Morita, T; Takagawa, R; Watanabe, J | 1 |
| Ilhan, IE; Kurucu, N; Sari, N | 1 |
| Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J | 1 |
| Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM | 1 |
| Bauer, S; Formentini, A; Galle, PR; Hoffman, A; Kittner, JM; Kornmann, M; Link, KH; Maderer, A; Moehler, M; Neumann, W; Rey, JW; Schad, A; Schwarz, M; Thomaidis, T; Trautmann, M; Weinmann, A | 1 |
| Cain, J; Drummond, DC; Fitzgerald, JB; Kalra, AV; Kim, J; Klinz, SG; Nielsen, UB; Paz, N | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
| Boucher, E; Boudjema, K; Hénno, S; Le Prisé, E; Levi Sandri, GB; Meunier, B; Sulpice, L; Turner, K | 1 |
| Arnold, D; Boxberger, F; Herrenberger, J; Hinke, A; Hoeffkes, HG; Kutscheidt, A; Leutgeb, B; Petersen, V; Schroeder, J; Schulze, M; Seraphin, J; Stein, A; Valdix, AR | 1 |
| Bertagnolli, MM; Caracol, A; Emond, M; Foster, NR; Goldberg, RM; Grady, WB; Lao, VV; Maizels, N; Monnat, RJ; Niedzwiecki, D; Pavelitz, T; Rabinovitch, PS; Renfro, L; Saltz, LB; Welsch, P | 1 |
| Aichler, M; Buck, A; Feuchtinger, A; Halbritter, S; Janssen, KP; Späth, C; Walch, A; Zitzelsberger, H | 1 |
| Bokemeyer, C; Bruns, R; Csőszi, T; Élez, E; Höhler, T; Kocáková, I; Martens, UM; Melichar, B; Orlova, R; Quaratino, S; Rivera, F; Smakal, M; Straub, J; Tabernero, J; Tjulandin, S; Topuzov, E; Van Cutsem, E | 1 |
| Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D | 1 |
| Cohen, D; Cohen, S; Denlinger, C; Gold, PJ; Hochster, HS; Leichman, CG; Leichman, L; Lenz, HJ; Messersmith, W; ONeil, BH; Uboha, N | 1 |
| Graf, A; Gruenberger, B; Gruenberger, T; Singh, J; Starlinger, P; Stift, J; Stremitzer, S; Tamandl, D | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Kirstein, MM; Kubicka, S; Lange, A; Manns, MP; Prenzler, A; Vogel, A | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR | 1 |
| Battat, E; Bitterman, H; Brenner, B; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A | 1 |
| Cheng, L; Jia, J; Li, Q; Tu, L; Wang, X; Yan, D; Zheng, X | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Mishra, MN; Palakurthi, S; Vangara, KK | 1 |
| Gerken, M; Glockzin, G; Klinkhammer-Schalke, M; Lang, SA; Piso, P; Schlitt, HJ | 1 |
| Fujii, T; Ikeda, T; Kimura, H; Nakayama, H; Sakai, Y | 1 |
| Bosch, LJ; Haan, JC; Israeli, D; Kabbarah, O; Koopman, M; Labots, M; Meijer, GA; Mekenkamp, LJ; Nagtegaal, ID; Punt, CJ; Qu, X; Rausch, C; Tol, J; van de Wiel, MA; van Essen, HF; van Grieken, NC; Verheul, HM; Voorham, QJ; Ylstra, B | 1 |
| Brodeur, GM; Croucher, JL; Gordon, WP; Iyer, R; Li, N; Liu, B; Loren, J; Molteni, V; Tuntland, T | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; McBride, WJ; Rossi, EA; Sharkey, RM; Trisal, P | 1 |
| Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R | 1 |
| Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG | 1 |
| Badreldin, W; Berney, D; Chowdhury, S; Frampton, AE; Harding, V; Harland, SJ; Krell, J; Mazhar, D; Shamash, J; Stebbing, J; Wilson, P | 1 |
| Benson, AB; Chan, AT; Chan, JA; Fuchs, CS; Giovannucci, EL; Goldberg, RM; Hantel, A; Mayer, RJ; Meyerhardt, JA; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Sato, K; Schaefer, PL; Venook, AP; Whittom, R | 1 |
| Azuma, S; Kawato, N; Makihara, K; Nakata, I; Ueno, H | 1 |
| Bujok, K; Fromm, MF; Glaeser, H; Mandery, K; Rau, TT; Schmidt, I; Schuh, W | 1 |
| Chow, L; DeWire, M; Fouladi, M; Goldman, S; Hummel, T; Lane, A; Leach, J; Miles, L; Salloum, R; Stevenson, C; Sutton, M | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J | 1 |
| Fan, S; He, X; Liu, M; Shi, W; Wu, D; Yao, Y; Yu, H; Zhang, P; Zhong, B; Zhou, M | 1 |
| Chau, I; Cunningham, D; Khan, K; Moorcraft, SY; Peckitt, C; Rao, S; Watkins, D | 1 |
| Bas, SZ; Maltas, E; Ozmen, M; Tamyurek, E; Yildiz, S | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, LA; Lee, RJ; Meropol, NJ; Mitchell, EP; Moughan, J; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Wong, SJ | 1 |
| Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Nakamura, K; Saitou, M; Satoh, T; Shibata, T; Takano, T; Yunokawa, M | 1 |
| Conghua, X; Haifeng, Y; Haiyan, Y; Lei, G; Lulu, M; Tao, L; Yun, F; Zhiyu, H | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Dobhal, S; Jaggi, M; Kumar, V; Negi, LM; Talegaonkar, S; Verma, AK; Verma, R | 2 |
| Arndt, GM; Cheung, L; Failes, TW; Fletcher, JI; Neiron, Z; Yu, DM | 1 |
| Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL | 1 |
| Cho, HJ; Choi, HG; Choi, JY; Kim, JO; Ramasamy, T; Shin, BS; Umadevi, SK; Yong, CS | 1 |
| Bouard, C; Boumendjel, A; Di Pietro, A; Gauthier, C; Gervot, H; Guitton, J; Honorat, M; Lecerf-Schmidt, F; Payen, L; Peres, B; Puisieux, A; Rioufol, C; Terreux, R | 1 |
| Baylin, SB; Dobromilskaya, I; Easwaran, H; Huang, P; Poirier, JT; Rudin, CM; Topper, M; Vendetti, FP; Wrangle, J | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV; Müller, J | 1 |
| Anantha, M; Bally, MB; Gill, N; Karim, T; Neijzen, R; Ng, SS; Strutt, D; Tai, IT; Wang, H; Waterhouse, D; Wong, MQ; Yapp, DT | 1 |
| Gao, P; Li, X; Liu, D; Lu, J; Xu, Y; Zhang, C | 1 |
| Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Cheng, YC; Chu, E; Guan, F; Hu, R; Jiang, Z; Lam, W; Liu, SH | 1 |
| Kamei, T; Miwa, I; Nakamura, Y; Sakamoto, Y; Shinagawa, M | 1 |
| Ino, K; Kobayashi, A; Mabuchi, Y; Minami, S; Tanizaki, Y; Yahata, T | 1 |
| Borrero-Palacios, A; Cebrian, A; del Puerto-Nevado, L; Fernandez-Aceñero, MJ; Garcia-Foncillas, J; Gomez del Pulgar, T; Martinez-Useros, J; Moreno, I; Perez, N; Puime-Otin, A; Rodriguez-Remirez, M; Rojo, F; Senin, C; Soengas, MS; Vega-Bravo, R; Zazo, S | 1 |
| Aliberti, C; Bazzi, M; Campana, LG; Chiarion-Sileni, V; Midena, E; Parrozzani, R; Pigozzo, J; Pilati, P; Valpione, S | 1 |
| Chalmers, A; El-Khamisy, SF; Gilbert, DC; Gollins, S; Haley, V; Meisenberg, C; Ward, SE | 1 |
| Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X | 1 |
| Deng, Y; Li, J; Qin, S; Zhang, Z | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Kang, T; Lee, BJ; Oh, E; Park, C; Vo, CL | 1 |
| Adam, R; Bridgewater, J; Chau, I; García Alfonso, P; Gruenberger, T; Hermann, F; Lasserre, S; Mudan, S; Rivoire, M; Waterkamp, D | 1 |
| Choi, KC; Kim, SU; Yi, BR | 1 |
| Bernard, AC; Coqueret, O; De Carné Trécesson, S; Gamelin, E; Guette, C; Henry, C; Jonchère, B; Juin, P; Lam, D; Toutain, B; Vétillard, A | 1 |
| Chai, K; Jiang, K; Li, F; Meng, G; Wang, W; Yang, S | 1 |
| Chang, JY; Chang, TC; Chen, LT; Cheng, AL; Chiang, NJ; Shen, BN; Shiah, HS; Wang, YW; Yang, CH; Yeh, CG; Yeh, KH | 1 |
| Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R | 1 |
| Beaty, K; Choe, JH; Eng, C; Fournier, KF; Mansfield, PF; Ohinata, A; Overman, MJ; Phillips, JK; Rafeeq, S; Royal, RE; Wolff, RA | 1 |
| De Castro-Prado, MA; De Sant'anna, JR; Dos Santos, PA; Esquissato, GN; Franco, CC; Rosada, LJ | 1 |
| Baroian, N; Buchner, P; Czejka, M; Dittrich, C; Sahmanovic, A; Schreiber, V | 1 |
| Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A | 1 |
| Imai, H; Nishi, K; Ohori, H; Sasaki, T; Sato, A; Sawada, K; Takahashi, T | 1 |
| Fukunaga, K; Ikuta, S; Kakuno, A; Morita, M; Murao, S; Sonoda, T; Tani, S; Yamagishi, S; Yamanaka, N | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Deshpande, V; Faris, JE; Fernández-del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Kwak, EL; Lillemoe, KD; Marchegiani, G; McDonnell, EI; Murphy, JE; Ryan, DP; Sabbatino, F; Santos, DD; Ting, DT; Warshaw, AL; Wo, JY; Zhu, AX | 1 |
| Erickson, BA; Evans, DB; Ritch, PS | 1 |
| Bai, H; Liu, Y; Ma, N; Ren, Z; Wang, F; Xu, S | 1 |
| Fukushima, K; Hayama, Y; Higashiguchi, M; Hirata, H; Hoshino, S; Inoue, K; Kida, H; Kijima, T; Kinehara, Y; Kumanogoh, A; Minami, T; Miyake, K; Morimura, O; Nagatomo, I; Otsuka, T; Takeda, Y; Takeuchi, Y | 1 |
| Allen, S; Bent, M; Courtier, J; DuBois, SG; Hawkins, R; Hilton, JF; Hollinger, F; Matthay, KK; Mosse, YP | 1 |
| Hummon, AB; Liu, X | 1 |
| Lan, H; Li, Y; Lin, CY | 1 |
| Anchisi, S; Baertschi, D; Betticher, DC; Borner, M; Brauchli, P; Dietrich, D; Frueh, M; Herrmann, R; Hess, V; Koeberle, D; Kollar, A; Kueng, M; Matter, K; Moosmann, P; Popescu, RA; Roth, A; Saletti, P; Schacher, S; von Moos, R; Winterhalder, R | 1 |
| Brünner, N; Christensen, IJ; Jakobsen, A; Nielsen, HJ; Spindler, KL | 1 |
| Nygren, P | 1 |
| Choi, YH; Kim, RB; Lenehan, J; Parfitt, J; Teft, WA; Welch, S; Winquist, E | 1 |
| Arai, D; Betsuyaku, T; Ikemura, S; Ishioka, K; Kabata, H; Kamata, H; Kawada, I; Miyata, J; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Alexandru-Abrams, D; Bota, DA; Hsu, FP; Paff, M | 1 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Hofheinz, RD; Khazzaka, E; Mai, S; Reis, T; Welzel, G; Wenz, F | 1 |
| Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C | 1 |
| Hou, J; Lu, Y; Qi, SS; Rong, WT; Wang, DF; Xiao, Q; Xu, Q; You, J; Yu, SQ; Zhang, J | 1 |
| Bonifacio, A; Sergo, V; Toffoli, G; Vicario, A | 1 |
| Barboriak, DP; Boxerman, JL; Gilbert, MR; Prah, M; Schmainda, KM; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Ardelt, MA; Brandl, L; De Toni, EN; Ehrlich, SM; Gerbes, AL; Kirchner, T; Lehr, T; Liebl, J; Mayr, D; Vollmar, AM; Zahler, S | 1 |
| Bhardwaj, RD; Nakaji, P; Ponce, FA; Rosenfeld, A; Xu, DS | 1 |
| Dropkin, E; Strickler, JH; Strosberg, JR; Zhu, J | 1 |
| Hayakawa, Y; Lou, C; Saiki, I; Yokoyama, S | 1 |
| Uwagawa, T; Yanaga, K | 1 |
| Berman, J; Bradford, WD; Chen, G; Conkright, J; Haug, JS; Kucharavy, A; Li, R; McCroskey, S; Mulla, WA; Rubinstein, B; Seidel, CW; Tsai, HJ; Weems, L | 1 |
| Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW | 1 |
| Alferiev, IS; Brodeur, GM; Chorny, M; Croucher, JL; Iyer, R; Kolla, V; Levy, RJ; Mangino, JL | 1 |
| Chen, KC; Cheng, CM; Cheng, TL; Hsieh, YT; Roffler, SR; Tao, MH | 1 |
| Marangon, E; Mazzega, E; Posocco, B; Toffoli, G | 1 |
| Herman, JM; Katz, MH; Marsh, Rde W; Talamonti, MS | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Bellemann, N; Gnutzmann, DM; Gockner, TL; Kauczor, HU; Köhler, K; Kortes, N; Krone, D; Mechel, J; Mokry, T; Radeleff, BA; Schmitz, A; Sommer, CM; Stampfl, U | 1 |
| Bossi, I; Cappelletti, V; Daidone, MG; de Braud, F; Di Bartolomeo, M; Di Buduo, E; Iacovelli, R; Maggi, C; Martinetti, A; Musella, V; Pietrantonio, F; Sottotetti, E | 1 |
| Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R | 1 |
| Hakamada, K; Hui, FM; Kijima, H; Kudo, D; Miura, T; Morohashi, S; Nanashima, N; Sawano, T; Shimizu, T; Tsuchida, S; Yamada, T | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kirschbrown, WP; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Adachi, S; Arakawa, Y; Heike, T; Hiramatsu, H; Mizowaki, T; Nishiuchi, R; Saida, S; Shibata, H; Umeda, K; Watanabe, K | 1 |
| Gil-Ranedo, J; Mendiburu-Eliçabe, M | 1 |
| Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J | 1 |
| Choi, HG; Choi, JY; Kim, JH; Kim, JO; Ku, SK; Ramasamy, T; Ruttala, HB; Tran, TH; Yong, CS | 1 |
| Atasoy, A; Babacan, NA; Cihan, S; Kos, TF; Yildirim, Y | 1 |
| Chen, TC; Golden, EB; Gong, A; Hofman, FM; Howard, A; Jhaveri, N; Louie, SG; Schönthal, AH; Sivakumar, W; Torres, S; Vaikari, VP; Wang, W | 1 |
| Fujita, S; Hirose, H; Michiura, T; Miyazaki, S; Miyazaki, Y; Nagaoka, M; Sugimoto, S; Yamabe, K | 1 |
| Inada, K; Maeshiro, T; Matsuoka, Y; Miyamoto, S; Nasu, K; Seyama, Y; Takahashi, M; Tani, K; Tanizawa, T; Umekita, N; Wada, I; Warabi, M | 1 |
| Aoyama, T; Hayashi, S; Hayashi, T; Kanazawa, A; Kunisaki, C; Masuda, M; Oshima, T; Rino, Y; Sato, T; Segami, K; Sugano, N; Yamamoto, N; Yoshikawa, T; Yukawa, H | 1 |
| Asaoka, T; Endo, S; Fujitani, K; Fukuda, Y; Fukui, A; Fushimi, H; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Iwase, K; Kawada, J; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takagi, M; Yamamoto, K | 1 |
| Calderon, RI; Cruz, RE; Drummond, DC; Fitzgerald, JB; Hall, CP; Hindle, A; Kang, MH; Ko, W; Lee, JS; Makena, MR; Paz, N; Reynolds, CP; Song, MM; Triche, TJ; Wang, J | 1 |
| André, T; Buyse, M; Delbaldo, C; Douillard, JY; Dupuis, O; Faroux, R; Guerin-Meyer, V; Jouhaud, A; Piedbois, P; Quinaux, E; Rougier, P; Ychou, M; Zawadi, A | 1 |
| Hoffmann, OI; Ilmberger, C; Jauch, KW; Joka, M; Magosch, S; Mayer, B | 1 |
| Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J | 1 |
| Beck, JT; Brandt, U; Davidson, SJ; Garrett, CR; Hecht, JR; Mackenzie, MJ; Reid, TR; Rizvi, S; Sharma, S | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Aldrighetti, L; Cipriani, F; Ferrero, A; Langella, S; Ratti, F; Russolillo, N; Viganò, L | 1 |
| Andersen, CL; Beck, MK; Belling, KC; Bosman, F; Brünner, N; Budinská, E; Delorenzi, M; Do, KN; Gupta, R; Hanáková, B; Hansen, TP; Jensen, NF; Moreira, JM; Nygård, SB; Pfeiffer, P; Rasmussen, MH; Roth, A; Rømer, MU; Stenvang, J; Tarpgaard, LS; Tejpar, S; Viuff, B | 1 |
| Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH | 1 |
| Arora, K; Buddington, RK; de Jonge, HR; Moon, C; Naren, AP; Parthasarathi, K; Ren, A; Schuetz, JD; Shanmukhappa, SK; Shata, MT; Sinha, C; Valasani, KR; Woodrooffe, K; Yarlagadda, S; Zhang, W | 1 |
| Adamo, RF; Alferiev, IS; Brodeur, GM; Chorny, M; Croucher, JL; Fishbein, I; Iyer, R; Kolla, V; Levy, RJ; Mangino, JL; Zhang, K | 1 |
| Carcaboso, AM; Glisoni, R; Lavarino, C; Monterrubio, C; Mora, J; Paco, S; Rodríguez, E; Schaiquevich, P; Sosnik, A; Vila-Ubach, M | 1 |
| Li, Y; Lin, X; Lu, S; Zhang, MQ | 1 |
| Boerner, JL; Boerner, SA; Burger, A; Heilbrun, L; LoRusso, PM; Mueller, KL; Nechiporchik, N; Polin, L; Stark, K; Zoratti, GL | 1 |
| Cecchin, E; Chen, S; Court, MH; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Laverdiere, I; Lévesque, E; Toffoli, G; Tourancheau, A; Villeneuve, L | 1 |
| Frese, S; Frese-Schaper, M; Keil, A; Körner, M; Schmid, RA; Steiner, SK | 1 |
| Akiyama, H; Kurosu, T; Miura, O; Murakami, N; Sakashita, C; Umezawa, Y; Yamamoto, M | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C | 1 |
| Akamaru, Y; Fujitani, K; Inagaki, H; Ishiguro, T; Miyashita, Y; Morita, S; Nakamura, M; Nishikawa, K; Sakamoto, J; Shigematsu, T; Sugimoto, N; Takagi, M; Tamura, S; Tokunaga, S; Tsuburaya, A; Tsujinaka, T; Yoshikawa, T | 1 |
| Barone, C; Basso, M; Bonomo, L; Cassano, A; Cerchiaro, E; Devicienti, E; Guerra, A; Iezzi, R; Marsico, VA; Rodolfino, E | 1 |
| Burdach, S; D'Incalci, M; DaPrada, GA; Fregoni, V; Grohar, PJ; Pavesi, L; Riccardi, A; Tancredi, R; Zambelli, A | 1 |
| Hassan, AS; Naicker, M; Wan Ishak, WZ; Yusof, KH | 1 |
| Cassinelli, G; De Cesare, M; Lanzi, C; Zaffaroni, N; Zuco, V | 1 |
| Ise, Y; Kitagawa, C; Saka, H | 1 |
| Arakawa, Y | 1 |
| Berntzen, DT; Carling, U; Dorenberg, EJ; Dueland, S; Edwin, B; Eide, NA; Haugvik, SP; Røsok, B | 1 |
| Kaku, Y; Kanno, T; Nishizaki, T; Tsuchiya, A | 1 |
| Hicklin, DJ | 1 |
| Chin, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Cheng, G; Gao, Y; Liu, J; Liu, Y; Piao, H; Tang, B; Tian, Y; Wang, L; Xu, C; Zou, M | 1 |
| Christie, M; Desai, J; Diaz, LA; Gibbs, P; Karapetis, CS; Kinde, I; Kinzler, KW; Papadopoulos, N; Roebert, J; Singh, M; Strausberg, RL; Tacey, M; Tie, J; Tran, B; Vogelstein, B; Wang, Y; Wong, HL; Wong, R | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Elmali, F; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M | 1 |
| Atyabi, F; Dinarvand, M; Dinarvand, R; Esmaeili, A; Kiani, M; Mirzaie, Z; Mirzazadeh, F; Soleimani, M | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KH; Lee, KW; Oh, DY | 1 |
| Gruenberger, B; Gruenberger, T; Singh, J; Starlinger, P; Stift, J; Stremitzer, S; Tamandl, D | 1 |
| Ananda, S; Chapman, M; Field, K; Gibbs, P; Guerrieri, M; Jones, I; Kosmider, S; Skinner, I; Tran, B | 1 |
| Crona, DJ; de Graan, AJ; Innocenti, F; Mathijssen, RH; Qiao, W; Ramirez, J; Ratain, MJ; Rosner, GL; van Schaik, RH | 1 |
| Aitini, E; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Lonati, V; Petrelli, F | 1 |
| Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S | 1 |
| Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY | 1 |
| Chen, Y; Cheng, Y; Jiang, H; Ma, L; Yang, C; Zhu, J | 1 |
| Ando, Y; Fujita, K; Ichikawa, W; Minamimura, K; Miyauchi, H; Morita, S; Moriwaki, T; Nakamura, M; Ohashi, Y; Okutani, Y; Sadahiro, S; Sakata, Y; Shinozaki, K; Sugihara, M; Sugiyama, T; Takahashi, T; Takii, Y; Tanaka, C; Tsuji, A; Uehara, K | 1 |
| Almeida, GS; deSouza, NM; Jamin, Y; Papaevangelou, E; Robinson, SP | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, D; Stenvang, J | 1 |
| Bencsikova, B; Bortlicek, Z; Dusek, L; Halamkova, J; Kiss, I; Melichar, B; Ostrizkova, L; Pavlik, T; Valik, D; Vyzula, R; Zdrazilova-Dubska, L | 1 |
| Cai, G; Cai, S; Gu, W; Hu, W; Palmer, JD; Xu, Y; Zhang, Z; Zhu, J | 1 |
| Duchêne, B; Jonckheere, N; Skrypek, N; Van Seuningen, I; Vasseur, R; Vincent, A | 1 |
| Au-Yeung, TT; Fleisig, HB; Hukezalie, KR; Ludlow, AT; Thompson, CA; Wong, JM; Zhao, CR | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Addeo, A; Bini, R; Comelli, S; Leli, R; Savio, D; Vana, F; Vaudano, GP; Viora, T | 1 |
| Baba, H; Denda, T; Hata, T; Ina, K; Inukai, M; Iwamoto, S; Kato, T; Kunieda, K; Kurachi, K; Mishima, H; Morita, Y; Munemoto, Y; Nagata, N; Nakamura, M; Oba, K; Ooshiro, M; Sakamoto, J; Shimoyama, T; Takahashi, T; Tamagawa, H | 1 |
| Guo, D; Han, X; Ling, Y; Luo, J; Shi, C; Wang, L; Xu, G | 1 |
| Arrojo, R; Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; Liu, D; Rossi, EA; Sharkey, RM; Trisal, P | 1 |
| Mukai, S; Naito, Y; Nojima, H; Ohno, S; Yabuta, N | 1 |
| Li, W; Liu, Y; Xing, Y | 1 |
| Bellevicine, C; Bianco, A; Cacciola, NA; Calabrese, C; Carlomagno, C; De Stefano, A; Federico, A; Fusco, A; Malapelle, U; Milone, F; Milone, M; Pallante, P; Pellino, G; Quintavalle, C; Selvaggi, F; Sepe, R; Sgariglia, R; Troncone, G; Uchimura Bastos, A | 1 |
| Aranda, E; Chaves, M; Garcia-Alfonso, P; García-Gonzalez, M; Gómez, MJ; González-Flores, E; Grávalos, C; López-Ladrón, A; Losa, F; Massuti, B; Muñoz, A; Oltra, A; Queralt, B; Salud, A | 1 |
| Del Rio, M; Gongora, C; Jin, C; Lam, H; Li, F; Ling, X; Wani, M; Welch, J; Westover, D | 1 |
| Matsui, H; Nagasaki, Y; Vong, LB; Yoshitomi, T | 1 |
| Abouelkhair, KM; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Ibrahim, EM; Loretelli, C; Mandolesi, A; Maristella, B; Scarpelli, M; Scartozzi, M | 1 |
| Kaniwa, N | 1 |
| Cheng, LW; Cheng, Y; Chi, ZC; Li, Z; Liu, XW; Sun, BS | 1 |
| Ghegediban, SH; Laurent, A; Maeda, N; Namur, J; Osuga, K; Paci, A; Pascale, F; Reb, P; Seck, A; Sterba, M; Verret, V; Wassef, M | 1 |
| Bijman-Lagcher, W; de Bruin, RW; Huisman, SA; IJzermans, JN; Smits, R | 1 |
| Kakuta, S; Kou, T; Sugaya, M; Takayama, W; Yanagibashi, H; Yoneyama, Y | 1 |
| Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E | 1 |
| Ahmadipour, F; Houshmand, M; Kamalidehghan, B; Meng, GY; Shakibi, R | 1 |
| Amzerin, M; Errihani, H; Mokrim, M; Piccart, MJ | 1 |
| Cho, YB; Choi, SH; Hong, HK; Lee, WY; Yoo, HY | 1 |
| Ames, MM; Berg, AK; Buckner, JC; Galanis, E; Jaeckle, KA; Reid, JM | 1 |
| Juvale, K; Lamprecht, A; Singh, MS; Wiese, M | 1 |
| Ashton, A; Gupta, S; Kaseb, A; Odisio, BC; Tam, AL; Vauthey, JN; Wallace, MJ; Wei, W; Yan, Y | 1 |
| Ayez, N; Eggermont, AM; Grünhagen, DJ; Rothbarth, J; van der Stok, EP; van Meerten, E; Verhoef, C | 1 |
| Brünner, N; Bunch, L; Christensen, S; Jensen, AA; Jensen, NF; Pedersen, SF; Pedraz-Cuesta, E; Romer, MU; Stenvang, J | 1 |
| Azuma, Y; Hanashiro, K; Nakachi, A; Nishiki, T; Ota, M; Shimabuku, M; Shimabukuro, N; Shiroma, H; Teruya, T; Toritsuka, D | 1 |
| Cline-Burkhardt, M; Cohn, A; Dakhil, S; Go, WY; Hecht, JR; Piperdi, B; Saleh, M; Tian, Y | 1 |
| Gao, SR; Li, LM; Wang, AR; Wang, GM; Xia, HP; Xu, HY | 1 |
| Chen, HL; Cheng, PL; Gao, WJ; Goto, M; Lee, KH; Liu, YQ; Morris-Natschke, SL; Song, ZL; Wang, MJ; Wang, YH; Zhu, GX | 1 |
| Bidyasar, S; Fu, S; Hong, DS; Janku, F; Kee, BK; Kurzrock, R; Lim, J; Naing, A; Piha-Paul, SA; Said, R; Tsimberidou, AM; Wallace, M; Wheler, JJ | 1 |
| Andersen, CL; Belling, K; Bolund, L; Brünner, N; Jensen, NF; Li, J; Lin, X; Rasmussen, MH; Stenvang, J; Tarpgaard, LS; Yang, G; Zhu, S | 1 |
| Acuna, SA; Angarita, FA; McCart, JA; Ottolino-Perry, K; Sellers, C; Tang, N; Zerhouni, S | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Li, FY; Liu, L; Liu, ZQ; Lu, L; Peng, XJ; Qi, XX; Shi, J; Wang, Y; Zhou, FY; Zhou, J | 1 |
| Cao, YF; Fang, ZZ; Hong, M; Meng, DL; Qi, JQ; Sun, DX; Sun, XY | 1 |
| Bianco, R; Cardone, C; Ciardiello, D; Ciardiello, F; Fenizia, F; Formisano, L; Lambiase, M; Martinelli, E; Martini, G; Morgillo, F; Napolitano, S; Normanno, N; Troiani, T; Vitagliano, D | 1 |
| Goldstein, SR; Hierro, LC; O'Dwyer, PJ; Selvakumaran, M; Vasilevskaya, IA; Winkler, JD | 1 |
| Babel, I; Capello, M; Fleming, JB; Hanash, SM; Katz, MH; Lee, M; Maitra, A; Taguchi, A; Tian, W; Wang, H | 1 |
| Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; McSherry, F; Miller, E; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Ayadi, M; Bouygues, A; Chouaib, S; Ferrand, N; Larsen, AK; Muchardt, C; Ouaret, D; Sabbah, M; Thiery, JP | 1 |
| Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Abu-Amna, M; Bar-Sela, G; Hadad, S; Haim, N; Hassoun, G | 1 |
| Beniak, J; Bystricky, B; Chovanec, J; Drgona, L; Konkolovsky, P; Lagin, A; Mardiak, J; Medvecova, L; Mego, M; Mikulova, M; Miskovska, V; Reckova, M; Spanik, S; Svetlovska, D; Vochyanova-Andrezalova, I; Zajac, V | 1 |
| Dalla Pozza, L; Heath, JA; Kalra, M; Kellie, SJ; McCowage, GB; Stevens, MM; Swamy, S | 1 |
| Abraham, WD; Bustamante López, SC; Huang, B; Irvine, DJ; Luo, SS; Zheng, Y | 1 |
| Liang, G; Xu, T; Yang, L; Zhang, F | 1 |
| Boongird, A; Hongeng, S; Israsena, N; Larbcharoensub, N; Manaspon, C; Nasongkla, N; Vejjasilpa, K | 1 |
| Bateman, E; Keefe, D; Klein, G; Mayo, B; Plews, E; Weaver, E; White, I; Wignall, A; Wozniak, B | 1 |
| Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI | 1 |
| Kang, JH; Kim, B; Kim, HM; Kim, JJ; Lee, SJ; Oh, SH; Park, BH; Shin, KJ; Song, SW; Woo, JK | 1 |
| Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B | 1 |
| Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L | 1 |
| Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Rossi, EA; Sharkey, RM | 1 |
| Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; McBride, WJ; Rossi, EA; Sharkey, RM; Wang, Y | 1 |
| Bowman, KJ; Jones, GD; Smith, AJ; Thomas, AL; Wood, JP | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Chin, K; Fujii, M; Ichikawa, W; Kakeji, Y; Kawase, T; Kochi, M; Kunisaki, C; Matsuhashi, N; Nakajima, T; Nishikawa, K; Ohno, T; Takagane, A; Takeuchi, M; Tanabe, K; Terashima, M; Tsuji, A; Yoshida, K | 1 |
| Chen, D; Gao, K; Li, L; Liu, C; Wang, H; Yang, Z; Yao, D; Yu, J; Zhang, J | 1 |
| Fujisawa, M; Miyake, H; Nishikawa, M | 1 |
| Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Ding, YY; Song, LX; Xu, JF; Xu, Q | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Chia, WT; Chung, MF; Lin, KJ; Liu, HY; Sung, HW | 1 |
| Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E | 1 |
| Ballesta, A; Dulong, S; Lévi, F; Okyar, A | 1 |
| Kapesa, L; Liu, W; Ma, J; Shen, H; Zeng, M; Zeng, S; Zhang, Y | 1 |
| Cui, H; Lock, LL; Mao, W; Shen, Y; Sui, M; Sun, W; Tang, J; Wang, J; Xu, D | 1 |
| Crocenzi, TS; Garcia-Monaco, RD; Kelly, LR; Laing, CJ; Martin, RC; Rilling, WS; Schreeder, M; Scoggins, CR; Sharma, VR; Strasberg, SM; Tatum, CM | 1 |
| Colson, YL; Falde, EJ; Freedman, JD; Grinstaff, MW; Herrera, VL; Yohe, ST | 1 |
| Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T | 1 |
| Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ | 1 |
| Fukagawa, S; Katsuda, T; Kondo, H; Maehara, M; Miyahara, D; Miyamoto, S; Miyata, K; Nam, SO; Ueda, T | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Cirkel, GA; Daenen, LG; Gerrits, J; Houthuijzen, JM; Huitema, AD; Ishihara, K; Oosterom, I; Roodhart, JM; van Tinteren, H; Verhoeven-Duif, NM; Voest, EE | 1 |
| Andréasson, H; Bjersand, K; Graf, W; Larsson, R; Mahteme, H; Nygren, P; Sundström Poromaa, I | 1 |
| Holcombe, RF; Planoutene, MV; Planoutis, KS; Planutis, AK | 1 |
| Chan, MT; Li, Z; Wu, WK; Yu, J; Yu, X | 1 |
| Fu, LW; Lin, G; Poon, DC; To, KK; Wang, F; Wei, Y | 1 |
| Palakurthi, S | 1 |
| Aljubran, A; Alzahrani, A; Bazarbashi, S; Mohieldin, A; Shoukri, M; Soudy, H | 1 |
| Barceló-Batllori, S; Berdasco, M; Borck, G; Carneiro, F; de la Torre, C; Esteller, M; Gomez, A; Heyn, H; Iwakawa, R; Kohno, T; Martínez-Cardús, A; Moran, S; Moura, CS; Moutinho, C; Pastorino, U; Pérez-Salvia, M; Roz, L; Savola, S; Setien, F; Simó-Riudalbas, L; Soler, M; Szakszon, K; Vaquero, A; Vidal, A; Vidal, E; Villanueva, A; Yokota, J; Zondervan, I | 1 |
| Chang, TM; Kau, YC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, TC | 1 |
| Dartigues, P | 1 |
| Cacciola, NA; De Stefano, A; Federico, A; Forzati, F; Fusco, A; Malapelle, U; Pallante, P; Pellecchia, S; Rocco, D; Sepe, R | 1 |
| Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H | 1 |
| Arantes, RME; Bastos, RW; Cardoso, VN; Cartelle, CT; Generoso, SV; Martins, FS; Nicoli, JR; Oliveira, JS; Pedroso, SHSP; Soares, PMG; Teixeira, MM; Vieira, AT | 1 |
| Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG | 1 |
| André, T; Bennouna, J; Borg, C; Bouché, O; Jary, M; Kim, S | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Cai, Q; Shao, N | 1 |
| Gjerset, RA; Zhao, M | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Cuddington, BP; Ketela, T; Moffat, J; Mossman, KL; Workenhe, ST | 1 |
| Bachet, JB; Blanc, JF; Coriat, R; Cunha, AS; Hentic, O; Innominato, P; Laurent, C; Marthey, L; Pietrasz, D; Raoul, JL; Regenet, N; Taieb, J; Terrebonne, E; Trouilloud, I; Turrini, O; Wagner, M | 1 |
| Acquaviva, J; Astsaturov, I; Bates, RC; Chimmanamada, D; He, S; Inoue, T; Jimenez, JP; Khazak, V; Ogawa, LS; Osman, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Ying, W; Zhang, C; Zhang, J | 1 |
| Chen, YH; Hwang, WL; Lin, CH; Teng, CL; Wang, CY | 1 |
| Chan, DL; Karapetis, CS; Pavlakis, N; Price, TJ; Segelov, E; Shapiro, J; Tebbutt, NC | 1 |
| Almeida, DS; Caeiro, C; Carvalho, BF; Castro, L; Costa, A; Damasceno, M; Fernandes, AC; Linhares, P; Osório, L; Sampaio, LV; Vaz, RC | 1 |
| Crispin, A; Fischer von Weikersthal, L; Giessen-Jung, C; Heinemann, V; Held, S; Holch, J; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Quietzsch, D; Schalhorn, A; Stahler, A; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, JC | 1 |
| Dicker, DT; El-Deiry, WS; Hong, B; Kline, CL; Kopelovich, L; Prabhu, VV; van den Heuvel, AP; Warfel, NA; Zhang, S; Zhou, L | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Balestra, A; Becouarn, Y; Fourrier-Réglat, A; Guimbaud, R; Jové, J; Laurent, C; Michel, P; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N | 1 |
| Badr, G; Chaturvedi, SK; Ishtikhar, M; Khan, MV; Khan, RH; Khan, S; Mahmoud, MH | 1 |
| Amini, M; Atyabi, F; Azhdarzadeh, M; Dinarvand, R; Esfandyari-Manesh, M; Hosseinzadeh, H; Mirzaie, ZH; Ostad, SN; Vafaei, SY; Varnamkhasti, BS | 1 |
| Cheng, PC; Kuo, MY; Lai, JK; Liang, KH; Liao, MY; Lin, CW; Lu, RM; Wu, HC | 1 |
| Jabbar, AA; Zahir, MN | 1 |
| Ágoston, EI; Baranyai, Z; Bodoky, G; Bursics, A; Dede, K; Harsányi, L; Kulka, J; Szász, AM | 1 |
| Asaishi, K; Goto, M; Higuchi, K; Kii, T; Kurisu, Y; Kuwakado, S; Miyamoto, T; Nishitani, H; Shimamoto, F; Terazawa, T | 1 |
| Kanamori, M; Kawashima, R; Mano, Y; Saito, R; Sonoda, Y; Sumiyoshi, A; Tominaga, T; Zhang, R | 1 |
| de Bruijn, P; de Bruin, RW; Ghobadi Moghaddam-Helmantel, IM; Huisman, SA; IJzermans, JN; Mathijssen, RH; Wiemer, EA | 1 |
| Gandhi, A; Ghose, R; Mallick, P; Shah, P | 1 |
| Atanackovic, D; Bluemner, E; Bokemeyer, C; Brugger, W; Hapke, G; Hildebrandt, B; Illerhaus, G; Steffens, CC; Stein, A; Stöhlmacher, J; Stübs, P | 1 |
| Akiyama, Y; Fujita, K; Kato, Y; Kawara, K; Kitamura, M; Kunishima, M; Masuo, Y; Okumura, H; Sasaki, Y; Shimada, K; Sunakawa, Y; Suzuki, H; Watanabe, Y | 1 |
| Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A | 1 |
| Guo, GL; Schumacher, JD | 1 |
| Agarwal, P; He, X; Lu, X; Wang, H; Xu, RX; Yu, J; Zhao, S | 1 |
| Agostini, M; Calandra, E; Crotti, S; Marangon, E; Nitti, D; Posocco, B; Roverso, M; Toffoli, G; Traldi, P | 1 |
| Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M | 1 |
| Braren, R; Erkan, M; Esposito, I; Friess, H; Holzapfel, K; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Schlitter, AM; Siveke, JT; Stöß, C; Wenzel, P | 1 |
| Kimura, T; Matsuzaki, S; Ogita, K; Sawada, M; Ueda, Y; Yoshida, S; Yoshino, K | 1 |
| Cecchin, E; Chen, S; Couture, F; Guillemette, C; Innocenti, F; Jonker, D; Laverdière, I; Lévesque, E; Toffoli, G; Villeneuve, L | 1 |
| Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Aihara, T; Beppu, N; Doi, H; Kamikonya, N; Kimura, F; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H; Yoshie, H | 1 |
| Biernat, KA; Cohen, RD; Dollinger, M; Figueroa, E; Frye, SV; Guthrie, L; Ingle, JD; Jin, J; Kelly, L; Mani, S; McShane, SR; O'Neal, SK; Pellock, SJ; Pepe-Ranney, C; Pollet, RM; Redinbo, MR; Roberts, AB; Robinson, SJ; Venkatesh, MK; Wallace, BD; Zamboni, WC | 1 |
| Caro, MS; Durán, FJ; Geller, FC; Kratz, JM; Lang, KL; Marostica, LL; Persich, L; Schenkel, EP; Silva, IT; Simões, CM | 1 |
| Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH | 1 |
| Daoud, J; Essa, S; Lafleur, M; Martel, S; Tabrizian, M | 1 |
| Advani, PP; Crozier, JA; Hobday, T; Jaslowski, AJ; LaPlant, B; Moreno-Aspitia, A; Perez, EA | 1 |
| Leung, WW; Ng, SS; To, KK | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ | 1 |
| De Haan, AF; Dijkstra, JR; Faber, C; Koopman, M; Mekenkamp, LJ; Nagtegaal, ID; Punt, CJ; Simmer, F; Venderbosch, S; Vink-Börger, EM | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Ayers, M; Clarke, SJ; Cunningham, D; Ferry, D; Frödin, JE; Guren, TK; Hawkes, E; Kim, SY; Kim, TW; Kim, TY; Loboda, A; Mauro, DJ; Nebozhyn, M; Park, YS; Peckitt, C; Roh, JK; Schmoll, HJ; Sclafani, F; Tabernero, J; Watkins, DJ | 1 |
| Aravantinos, G; Gazouli, M; Isaakidou, A; Karantanos, T; Pektasides, D; Sioziou, A; Theodoropoulos, GE | 1 |
| Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K | 1 |
| Choate, KA; Ko, CJ; Lim, YH; Odell, ID | 1 |
| Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J | 1 |
| Gu, Y; Li, L; Li, Q; Wang, W; Wu, X; Xu, Q; Zhang, X | 1 |
| Baker, L; Bedford, S; Browne, H; Christie, M; Drysdale, MJ; Fallowfield, M; Fiumana, A; Foloppe, N; Massey, AJ; Scrace, S; Stokes, S; Webb, P; Wood, M | 1 |
| Chen, H; Chen, X; Cheng, X; Gou, L; Li, W; Su, X; Wang, Y; Wei, X; Wei, Y; Wu, Y; Xie, Y; Yang, J; Yao, Y; Yu, L; Zhang, B; Zhang, H; Zhang, R; Zhang, Y | 1 |
| Almeida, PR; Batista, GL; Bem, AX; Borges, VF; Brito, GA; Carvalho, CB; Cunha, FQ; Cunha, TM; Leite, CA; Lima-Júnior, RC; Ribeiro, RA; Silva, RL; Teixeira, MA; Wanderley, CW; Wong, DV | 1 |
| Adamson, C; Agarwal, VJ; Babu, R; Britt, D; Friedman, AH; Grossi, PM; Iyer, A; Karikari, IO; Komisarow, JM; Rahimpour, S; Thomas, S | 1 |
| Canon, JL; Carrasco, J; Chapaux, X; Danse, E; Gigot, JF; Gizzi, M; Hubert, C; Humblet, Y; Jouret-Mourin, A; Lannoy, V; Lefesvre, P; Navez, B; Pairet, G; Sempoux, C; Tinton, N; Van den Eynde, M | 1 |
| Adkins, CE; Eldon, MA; Hoch, U; Hye, T; Lockman, PR; Mohammad, AS; Mohan, NK; Nounou, MI; Terrell-Hall, T | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Bang, YJ; Kim, TY; Oh, DY | 1 |
| Hu, S; Lee, DH; Lee, E; Li, X; Li, Y; Liu, X; Shen, Y; Tang, J; Wang, C; Wang, J; Zhou, Z | 1 |
| Choi, M; Kim, R; Mahipal, A | 1 |
| Bosenberg, MW; Held, MA; Iyidogan, P; Langdon, CG; Levy, F; Mamillapalli, R; Platt, JT; Stern, DF; Theodosakis, N; Vuagniaux, G; Wang, S; Wiedemann, N | 1 |
| Bernard, AC; Campone, M; Coqueret, O; Fontanel, S; Guette, C; Henry, C; Jonchère, B; Moreau, M; Toutain, B; Vétillard, A | 1 |
| Ahn, TJ; Do, IG; Kang, WK; Kim, HC; Kim, SH; Kim, ST; Lee, E; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I | 1 |
| Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J | 1 |
| Kim, SH; Ku, JL; Moon, HH | 1 |
| Ban, LY; Fang, FQ; Guo, HS; Liu, JW; Yu, PY; Zhang, J | 1 |
| Fry, AM; Jones, GD; Sabir, SR; Sahota, NK | 1 |
| Anderson, JR; Arndt, CA; Hawkins, DS; Lyden, E; Meyer, WH; Michalski, JM; Parham, DM; Rodeberg, DA; Weigel, BJ | 1 |
| Delestre, L; Dewitte, A; Lansiaux, A; Lepretre, F; Pham, MH; Wattez, N | 1 |
| Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A | 1 |
| Li, H; Li, X; Ni, S; Su, W; Wang, B; Wang, J; Xia, T; Yao, Q; Zhu, X | 1 |
| Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS | 1 |
| Grapsa, D; Saif, MW; Syrigos, K | 1 |
| Andersen, RF; Appelt, AL; Hoegdall, EV; Jakobsen, A; Jensen, BV; Johansen, JS; Nielsen, D; Pallisgaard, N; Pfeiffer, P; Schou, JV; Spindler, KL; Yilmaz, M | 1 |
| Chen, BM; Hsieh, YT; Huang, PT; Lin, HP; Roffler, SR | 1 |
| Ao, L; Cai, H; Chi, P; Guan, Q; Guo, Y; Guo, Z; Li, M; Li, X; Lu, X; Tong, M; Yan, H; Zheng, W | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Higashi, T; Igarashi, T; Iwasaki, H; Kamitani, Y; Kodawara, T; Masada, M; Nakamura, T; Negoro, Y; Tsukamoto, H; Watanabe, K; Yano, R | 1 |
| Danbara, N; Horitani, S; Ikeura, T; Kwon, AH; Masuda, M; Miyoshi, H; Nakamaru, K; Okazaki, K; Satoi, S; Takaoka, M; Toyokawa, H; Uemura, Y; Yamada, Y | 1 |
| Fujita, D; Nakanishi, T; Saito, Y; Tamai, I | 1 |
| Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT | 1 |
| Inoue, H; Inui, T; Ishibashi, O; Ishida, A; Kohno, M; Nakatsuji, M; Saito, M; Shimizu, S; Tsuge, S | 1 |
| He, XH; Huang, MY; Liang, YD; Ouyang, DY; Pan, H; Wei, HX; Xu, LH; Zha, QB | 1 |
| Dangi, JS; Prasad, S | 1 |
| Bartnik, CM; Flowers, CR; Goldstein, DA; Neustadter, E; Zeichner, SB | 1 |
| Bosman, F; Brünner, N; Budinska, E; Delorenzi, M; Nielsen, SL; Nygård, SB; Roth, A; Tejpar, S; Vainer, B | 1 |
| Argiles, G; Elez, ME; Grasselli, J; Sanz-Garcia, E; Tabernero, J | 1 |
| Barbuti, R; Cerone, A; Danesi, R; Del Re, M; Milazzo, P; Sameen, S | 1 |
| Blay, J; Cutler, MJ; Hajducek, DM; Lowthers, EL; Richard, CL; Spagnuolo, PA | 1 |
| Bisgin, A; Helmfors, L; Meng, WJ; Nandy, SK; Pathak, S; Ping, J; Sun, XF; Waldmann, P | 1 |
| Beccaria, K; Canney, M; Carpentier, A; Chapelon, JY; Fernandez, C; Goldwirt, L; Lafon, C; Perier, MC; Piquet, J | 1 |
| Collier, AB; Gresh, RC; Kamara, DF; Kolb, EA; Sampson, VB; Vetter, NS | 1 |
| Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V | 1 |
| Adam, R; Afshar, M; Ajavon, Y; Boige, V; Bouchahda, M; Carvalho, C; Castaing, D; De Baere, T; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Kunstlinger, F; Lepère, C; Lévi, FA; Rougier, P; Smith, D; Truant, S; Tumolo, S | 1 |
| Authier, N; Durando, X; Eschalier, A; Herviou, P; Libert, F; Pinguet, J; Richard, D; Roche, L | 1 |
| Ahn, JB; Baik, SH; Hong, SP; Hur, H; Jung, I; Jung, M; Keum, KC; Kim, H; Kim, NK; Kim, TI; Koom, WS; Lim, JS; Min, BS; Park, YS; Roh, JK; Shin, SJ | 1 |
| Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X | 1 |
| Ando, Y; Matsuoka, A | 1 |
| Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Le Dret, L; Opolon, P; Pagès, M; Vassal, G; Vievard, A; Villa, I; Zopf, D | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Fujita, K; Ishida, H; Kubota, Y; Sasaki, Y | 1 |
| Esin, E; Yalcin, S | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Bala, V; Li, P; Prestidge, CA; Rao, S; Wang, S | 1 |
| Ikeda, M; Ishida, K; Kume, K; Nishizuka, SS; Shimura, T; Takemoto, K; Young, L | 1 |
| Backus, L; Chow, LM; DeWire, M; Doughman, R; Drissi, R; Fouladi, M; Goldman, S; Grimme, L; Hummel, TR; Kumar, S; Lane, A; Leach, J; Miles, L; Pai, A; Pruitt, D; Salloum, R; Sobo, M; Stevenson, C; Sutton, M | 1 |
| Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A | 1 |
| Hosomi, Y; Igawa, S; Iwasawa, S; Katono, K; Kishi, K; Kondo, T; Kurimoto, R; Masuda, N; Murakami, S; Ohba, M; Okamoto, H; Oshita, F; Saito, H; Shimokawa, T; Takagi, Y; Takiguchi, Y; Watanabe, K; Yamada, K; Yamamoto, M | 1 |
| Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Alsina, MA; Casadó, A; Castelli, F; Giuffrida, MC; Mora, M; Pujol, M; Sagristá, ML | 1 |
| Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV | 1 |
| Annaratone, L; Bonin, S; Bussolati, G; Capella, C; Chiaravalli, AM; Donada, M; Hoefler, G; Nardon, E; Pichler, M; Stanta, G | 1 |
| Li, CY; Wang, D; Xu, MF; Yang, XQ; Zhao, H | 1 |
| Caine, M; Dreher, MR; Dunn, A; Fowers, KD; Grey, D; Hall, B; Johnson, CG; Lewis, AL; O'Byrne, V; Sharma, KV; Tang, Y; Wood, BJ | 1 |
| Fukushima, M; Nukatsuka, M; Shimamoto, Y; Takechi, T | 1 |
| Deng, B; Jia, LQ; Pan, L; Tan, HY; Wang, J; Yu, LL | 1 |
| Imyanitov, EN; Iyevleva, AG; Krasnova, ME; Mitiushkina, NV; Raskin, GA; Silkin, SV; Sokolenko, AP; Startsev, SS | 1 |
| Cano, F; Carcaboso, AM; Manzanares, A; Monterrubio, C; Mora, J; Pascual-Pasto, G; Schaiquevich, P; Sosnik, A; Tornero, JA; Vila-Ubach, M | 1 |
| Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Groot Koerkamp, B; Jarnagin, WR; Kemeny, NE; Kingham, TP; Klimstra, DS; Konstantinidis, IT | 1 |
| Cao, YF; Chen, Q; Chen, Y; Fang, ZZ; Gonzalez, FJ; Jiang, C; Lu, D; Sun, DX; Tanaka, N; Wang, H; Xie, C; Zhang, D | 1 |
| Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T | 1 |
| Akinwande, O; Bhutiani, N; Martin, RC | 1 |
| Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z | 1 |
| Amitesh, R; Beeke, C; Karapetis, C; Lo, L; Maddern, G; Moore, J; Padbury, R; Price, TJ; Roder, D; Townsend, AR | 1 |
| Chiang, CT; Ebrahim-Zadeh, N; Goldschmidt, R; Hasan, T; Huang, HC; Liu, J; Mai, Z; Mallidi, S; Rizvi, I | 1 |
| Blumenthal, DT; Bokstein, F; Mendel, L | 1 |
| Chacorovska, M; Dimchevska, S; Geskovski, N; Goracinova, K; Hristov, DR; Koliqi, R; Pejova, B; Petruševski, G; Ugarkovic, S | 1 |
| Ikeda, S; Ikegami, N; Murayama, JI; Sakamaki, H; Shimizu, H; Yajima, S | 1 |
| Emi, Y; Ikeda, Y; Ishibashi, T; Nakao, S | 1 |
| Cheng, Y; Wang, C; Wang, X; Wang, Y; Xiao, J; Zhang, J; Zhang, Q | 1 |
| Amagai, K; Azuma, M; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
| Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A | 1 |
| Guo, QL; Hu, G; Huang, XF; Liu, W; Ning, R; Qi, Q; Wang, XP; Yang, J; Zhan, YR | 1 |
| Chen, M; He, Q; Luo, P; Peng, X; Shao, J; Xu, L; Xu, Z; Yang, B; Zhu, H; Zhu, Y | 1 |
| Chang, LL; Dai, XY; Gai, RH; He, QJ; Wang, DD; Yang, B; Zhou, TY; Zhu, DF; Zhu, H; Zhuang, LH | 1 |
| Auzolle, C; Bonnetain, F; Bouché, O; Brieau, B; Coriat, R; Ducreux, M; Goujon, G; Lecomte, T; Marthey, L; Pozet, A; Prieux, C; Rougier, P; Soibinet, P; Taieb, J; Tougeron, D; Zaanan, A | 1 |
| Battiste, JD; Bonney, PA; Maurer, AJ; McNall-Knapp, RY; Santucci, JA; Sughrue, ME | 1 |
| Fujiwara, H; Ikai, A; Kishimoto, M; Otsuji, E; Sakai, T; Sowa, Y; Watanabe, M; Yanagisawa, A | 1 |
| Brodeur, GM; Cam, N; Croucher, JL; Golden, RL; Guan, P; Hornby, Z; Iyer, R; Kolla, V; Li, G; MacFarland, SP; Naraparaju, K; Wehrmann, L; Wei, G | 1 |
| Aluzaite, K; Brünner, N; Damsgaard, B; Do, KN; Foekens, J; Fogh, L; Gajjar, M; Hamerlik, P; Hansen, SN; Jandu, H; Knudsen, BR; Martens, J; Moreira, J; Nielsen, SL; Noer, JB; Pommier, Y; Proszek, J; Schrohl, AS; Smid, M; Stenvang, J; Stougaard, M; Thrane, SW | 1 |
| Akiyama, Y; Hasuike, Y; Higuchi, I; Ishikawa, A; Miyamoto, M; Okada, A; Tanigawa, T | 1 |
| Hayashida, H; Higaki, N; Miyake, Y; Nakane, S; Nezu, R; Oka, Y; Okada, K; Ueshima, S | 1 |
| Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 1 |
| Hama, N; Haraguchi, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takeda, T; Uemura, M; Yamamoto, K | 1 |
| André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG | 1 |
| Cheong, PF; Fan, L; Goh, BC; Hee, KH; Lee, LS; Lee, SC; Sapari, NS; Seng, KY; Soh, TI; Soo, R; Soong, R; Wang, LZ; Wong, A; Yong, WP | 1 |
| Hashida, K; Hattori, K; Itou, T; Kai, C; Kawamoto, K; Matsuba, Y; Nagahisa, Y; Sakurai, R | 1 |
| Huang, CW; Lin, YW; Lu, CY; Sung, YC; Tang, HC; Tsai, HL; Wang, JH; Wang, JY; Wu, CC; Yeh, YS | 1 |
| Li, J; Lin, G; Wang, L; Xie, J; Yi, L; Zhang, K; Zhang, R | 1 |
| Adachi, N; Aoyama, H; Fujibayashi, Y; Furukawa, T; Saga, T; Wakizaka, H; Yoshii, Y; Zhang, MR | 1 |
| Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Broholm, H; Christensen, IJ; Dahlrot, RH; Grunnet, K; Hansen, S; Kosteljanetz, M; Larsen, VA; Lassen, U; Michaelsen, SR; Poulsen, HS; Toft, A; Urup, T | 1 |
| Atasilp, C; Chamnanphon, M; Chansriwong, P; Puangpetch, A; Reungwetwattana, T; Sirachainan, E; Sukasem, C; Wongwaisayawan, S | 1 |
| Al-Ghafari, AB; Carrier, DJ; Coyle, B; Hussein, D; Kerr, ID; Punjaruk, W; Storer, LC | 1 |
| Allen, PJ; Boucher, TM; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Fong, YC; Jarnagin, WR; Kemeny, NE | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Abiko, K; Abou-Taleb, HA; Baba, T; Hamanishi, J; Horikawa, N; Kitamura, S; Konishi, I; Koshiyama, M; Matsumura, N; Murakami, R; Taha, AA; Yamaguchi, K; Yamanoi, K | 1 |
| Li, K; Wang, S | 1 |
| Cho, SY; Han, JY; Kang, J; Kang, W; Kwon, JY; Lee, A; Lee, C; Min, S; Park, H | 1 |
| Chang, CH; Donahue, T; Kang, Y; Liao, Y; Liu, X; Meng, H; Nel, AE; Situ, A; Villabroza, KR | 1 |
| Bell, T; Boerner, JL; Boerner, SA; Bowditch, A; Burger, A; Cai, D; Chen, AP; Cleary, JM; Ferry-Galow, K; Heilbrun, LK; Ji, J; Kinders, RJ; Li, J; LoRusso, PM; Marrero, AM; Parchment, RE; Pilat, MJ; Rubinstein, L; Sausville, EA; Shapiro, GI; Smith, D; Tolaney, SM; Wolanski, A; Zhang, J; Zhang, Y | 1 |
| Amendola, V; Litti, L; Meneghetti, M; Toffoli, G | 1 |
| Bartlett, JM; Boutros, PC; Braunstein, M; Kalatskaya, I; Krzyzanowski, PM; Liao, L; Lobo, N; Lyttle, N; Marcellus, R; Spears, M; Stein, LD; Taylor, KJ; Twelves, CJ; Yao, CQ | 1 |
| Liu, JY; Nie, YL; Wang, XF; Wei, LM; Yan, L; Zhang, LR | 1 |
| Ando, Y; Hirata, E; Hirata, K; Ikeda, T; Minegishi, Y; Morita, S; Ohashi, Y; Sakata, Y; Shimada, M; Sugihara, M; Sugiyama, T; Tabata, T; Takano, M; Yamada, K; Yamamoto, K; Yokoyama, T | 1 |
| Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N | 1 |
| Huang, J; Lyu, X; Tao, Y; Tian, Y; Wang, W; Wu, D; Yang, L | 1 |
| Cherubini, G; Halldén, G; Lemoine, NR; Pantelidou, C | 1 |
| Debus, J; Ho, AD; Huber, PE; Nicolay, NH; Perez, RL; Rühle, A; Saffrich, R; Schmezer, P; Sisombath, S; Trinh, T; Weber, KJ | 1 |
| Ambrosio, L; Biondi, M; Borzacchiello, A; De Rosa, G; Giarra, S; Mayol, L; Russo, L; Serri, C; Zeppetelli, S | 1 |
| Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L | 1 |
| Barni, S; Bendell, JC; Bessudo, A; Bolotin, E; Eng, C; Gladkov, O; Hart, LL; Hsu, C; Kopp, MV; Kotiv, B; Langdon, R; Müller, L; Schwartz, B; Severtsev, A; Vladimirov, V; von Roemeling, R | 1 |
| Alifieris, C; Sitaras, N; Stathopoulos, GP; Trafalis, DT | 1 |
| Basu, S; Gao, S; Hu, M; Yin, T; Zeng, M | 1 |
| Chen, KC; Lee, SY; Peng, CL; Shieh, MJ; Wei, MF; Yang, CY; Yao, CJ | 1 |
| Edenfield, WJ; Koch, MD; Ramirez, KG | 1 |
| Killock, D | 1 |
| Abdallah, EA; Abdon Lopes de Mello, C; Alves, Vda S; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Ocea, LM; Piana de Andrade, V; Souza E Silva, V; Tariki, MS | 1 |
| Chiba, Y; Chikumi, J; Harada, T; Itamochi, H; Komatsu, H; Kudoh, A; Nonaka, M; Oishi, T; Oumi, N; Sato, S; Shimada, M; Sugiyama, T | 1 |
| Anne, PR; Benson, AB; Catalano, PJ; Forastiere, AA; Keller, SM; Kleinberg, LR; Mitchel, EP | 1 |
| Belka, C; Brehmer, S; Dunkl, E; Fietkau, R; Friedrich, F; Gerlach, R; Glas, M; Goldbrunner, R; Grau, S; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Kohnen, R; Kortmann, RD; Krex, D; Leutgeb, B; Maciaczyk, J; Mack, F; Mayer-Steinacker, R; Mehdorn, M; Pietsch, T; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Stuplich, M; Tüttenberg, J; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A | 1 |
| Arifa, RDN; Barcelos, LS; Garcia, ZM; Krambrock, K; Ladeira, LO; Lima, RL; Madeira, MFM; Paula, TP; Pinheiro, MVB; Pinho, V; Souza, DG; Teixeira, MM; Ÿvila, TV | 1 |
| Chen, J; Jia, H; Lee, RJ; Lu, L; Qin, L; Weng, S; Yu, B; Zhang, X; Zheng, Y; Zhu, W | 1 |
| Ahn, DH; Bekaii-Saab, T; Bupathi, M; Ciombor, KK; Goldstein, DA; Reardon, J; Stephens, JA; Wu, C | 1 |
| Fujiwara, Y; Kishi, K; Motoori, M; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Chang, IH; Chi, BH; Choi, SS; Kim, KD; Kim, SU; Lee, HJ; Lee, SR | 1 |
| Boustani, AM; Cha, CH; Chang, B; Cong, X; Deng, Y; Hochster, HS; Indukala, D; James, ES; Kortmansky, JS; Lacy, J; Li, J; Patel, V; Salem, RR; Staugaard, C; Stein, SM | 1 |
| Bai, X; Gao, S; Li, G; Liang, T; Lou, J; Ma, T; Que, R; Shen, S; Su, R; Wei, Q; Yu, R; Yuan, Y | 1 |
| Agama, K; Brünner, N; Doroshow, JH; Jensen, NF; Knudsen, BR; Pfister, TD; Pommier, Y; Roy, A; Rømer, MU; Smith, DH; Stenvang, J; Zhang, HL | 1 |
| Granovetter, M | 1 |
| Bowen, JM; Gibson, RJ; Logan, RM; Secombe, KR; Van Sebille, YZ; Wardill, HR | 1 |
| André, N; Dory-Lautrec, P; Figarella-Branger, D; Gentet, JC; Heng, MA; Padovani, L; Pasquier, E; Scavarda, D; Verschuur, A | 1 |
| Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A | 1 |
| Lim, K; Ur Rehman, SS; Wang-Gillam, A | 1 |
| Dang, H; Gan, M; Wei, S; Zhang, W | 1 |
| He, MM; Jin, Y; Li, YH; Li, ZZ; Luo, HY; Pan, ZZ; Qiu, MZ; Ren, C; Ren, J; Shao, JY; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, ZC; Zhao, Q | 1 |
| Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Chen, MC; Chen, RJ; Ho, TJ; Hsu, HH; Huang, CY; Kuo, WW; Lee, NH; Lin, YM; Tu, CC; Viswanadha, VP | 1 |
| Akinwande, O; Hahl, M; Kelly, L; Martin, RC; McMasters, KM; Philips, P; Scoggins, CR; Tatum, C | 1 |
| Chen, Y; Lu, W; Ma, L; Wang, L; Xie, S | 1 |
| Anthony Greco, F; Barton, JH; Bendell, JC; Burris, HA; Infante, JR; Jones, SF; Nambu, Y; Thompson, DS; Watanabe, N | 1 |
| Arcaroli, JJ; Bagby, S; Blatchford, P; Capasso, A; Eckhardt, SG; Gao, D; Greene, J; Kim, J; Messersmith, WA; Nguyen, A; Pitts, TM; Purkey, A; Quackenbush, KS; Schreiber, A; Schuller, AG; Tai, WM; Wang, G | 1 |
| Bao, B; Fang, Y; Liu, Y; Lu, W; Tang, K; Wang, H; Zhang, X | 1 |
| Chen, EX; Hagerman, L; Jonker, DJ; Keller, D; McKeever, K; Seymour, L; Siu, LL; Wells, J | 1 |
| Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G | 1 |
| Arihara, Y; Hayashi, T; Hirakawa, M; Iyama, S; Kato, J; Kobune, M; Miyanishi, K; Okagawa, Y; Ono, M; Osuga, T; Sato, T; Sato, Y; Takada, K; Takimoto, R; Tamura, F; Uemura, N; Yoshida, M | 2 |
| Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G | 1 |
| Endlicher, E; Gelbmann, C; Klebl, F; Kullmann, F; Messmann, H; Rogler, G; Schnoy, E; Troppmann, M | 1 |
| Chang, PM; Chen, SC; Yang, MH | 1 |
| Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM | 1 |
| Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A | 1 |
| Ghandehari, H; Jaafari, MR; Mahmoudi, A; Malaekeh-Nikouei, B; Mosallaei, N; Yellepeddi, VK | 1 |
| Alzghari, SK; Chee, W; La-Beck, NM; Petersen, GH; Sankari, SS | 1 |
| Campion, L; Carrie, C; Dubois, N; Ferchaud-Roucher, V; Gaugler, MH; Krempf, M; Mahé, M; Mirabel, X; Paris, F; Rio, E; Ripoche, N | 1 |
| Chantrill, LA; Ciardiello, F; Desai, J; Elez, E; Gebski, VJ; Haydon, A; Jefford, M; Karapetis, CS; Khasraw, M; Lunke, S; Nott, LM; Pavlakis, N; Price, TJ; Robledo, KP; Segelov, E; Shapiro, JD; Simes, J; Thavaneswaran, S; Underhill, C; van Hazel, G; Waring, PM; Wasan, H; Wilson, K | 1 |
| Boyer, JC; Del Rio, M; Evrard, A; Gassiot, M; Mbatchi, LC; Robert, J; Thomas, F; Tubiana, N; Ychou, M | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Bosch, LJ; Carvalho, B; Grady, WM; Herman, JG; Koopman, M; Lao, VV; Luo, Y; Meijer, GA; Mongera, S; Monnat, RJ; Nagtegaal, ID; Punt, CJ; Snaebjornsson, P; Tang, W; Trooskens, G; van Criekinge, W; Vlassenbroeck, I; Welcsh, P | 1 |
| Hu, GY; Huang, L; Li, QX; Li, ZH; Liao, X; Liu, B; Qiu, H; Yu, QQ; Yuan, XL; Zhang, MS | 1 |
| Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS | 1 |
| Arantes, RM; Bastos, RW; Cardoso, VN; Cartelle, CT; França, CS; Generoso, SV; Martins, FS; Moreira, LM; Neves, MJ; Nicoli, JR; Pedroso, SH; Vieira, AT | 1 |
| Han, J; Kim, JH; Kim, JS; Kumar, R; Shin, WS; Verwilst, P | 1 |
| Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG | 1 |
| Amini, M; Atyabi, F; Baharian, A; Dinarvand, R; Ghahremani, MH; Gharghabi, M; Mehdizadeh, M; Ostad, SN; Rouhani, H; Sepehri, N; Varshochian, R | 1 |
| Esaki, T; Fujiya, T; Furukawa, H; Horita, Y; Imamoto, H; Imamura, H; Kimura, Y; Morita, S; Ninomiya, M; Nishikawa, K; Oono, R; Sasako, M; Sugimoto, N; Taguri, M; Takayama, O; Tan, P; Tsuburaya, A; Tsujinaka, T; Yabusaki, H; Yamada, Y | 1 |
| Carmeli, B; Farkash, A; Katzir, I; Lomnicky, Y; Parush-Shear-Yashuv, N; Rotem Rabinovich, H; Siegelmann-Danieli, N; Vesterman Landes, J | 1 |
| Diaz-Serrano, A; Garcia-Carbonero, R; Riesco-Martinez, MC | 1 |
| Barile, R; Barone, C; Basso, M; Cassano, A; D'Argento, E; Martini, M; Rossi, S; Schinzari, G; Strippoli, A | 1 |
| Bennouna, J; Cabart, M; Campion, L; Douillard, JY; Dupuis, O; Frénel, JS; Hiret, S; Ramée, JF; Senellart, H | 1 |
| Cai, Y; Chen, J; Feng, J; Fu, Q; Fu, S; Hong, Q; Huang, L; Li, J; Liu, S; Xie, C; Xu, M; Yu, Q; Yuan, X; Zang, A; Zhang, M; Zhang, T | 1 |
| Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A | 1 |
| Bosman, F; Brunner, N; Buhl, IK; Delorenzi, M; Gerster, S; Hansen, A; Jensen, PB; Jensen, T; Knudsen, S; Roth, A; Tejpar, S | 1 |
| Jensen, HA; Krogh, M; Pfeiffer, P; Qvortrup, C; Sorbye, H; Vestermark, LW; Winther, SB; Zubcevic, K | 1 |
| Chang-Claude, J; Kap, EJ; Popanda, O | 1 |
| Cho, YH; Kim, SN; Yoon, SY | 1 |
| Cha, Y; Choi, B; Choi, SH; Heo, DS; Kim, CY; Kim, DW; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Park, CK | 1 |
| Bähr, O; Banat, M; Filmann, N; Fimmers, R; Franz, K; Glas, M; Herrlinger, U; Kebir, S; Mack, F; Mittelbronn, M; Rieger, J; Schäfer, N; Schaub, C; Steinbach, JP; Thiepold, AL; Tichy, J; Waha, A | 1 |
| Abdullah, S; Abi-Jaoudeh, N; Anderson, V; Duffy, AG; Figg, WD; Fioravanti, S; Greten, TF; Lee, S; Levy, E; MacLeod, AR; Makarova-Rusher, OV; Peer, CJ; Raffeld, M; Rahma, OE; Revenko, AS; Steinberg, SM; Tomita, Y; Trepel, JB; Ulahannan, SV; Walker, M; Wood, BJ | 1 |
| Bowen, JM; Coller, JK; Gibson, RJ; Hutchinson, MR; Logan, RM; Manavis, J; Secombe, KR; Staikopoulos, V; Van Sebille, YZ; Wardill, HR; White, IA | 1 |
| Heller, AA; Hummon, AB; LaBonia, GJ; Lockwood, SY; Spence, DM | 1 |
| Cao, Z; Chen, Y; Gao, J; Jiang, Q; Li, Y; Liu, J; Luo, H; Xu, R; Yang, Z | 1 |
| Cardillo, TM; Chang, CH; Goldenberg, DM; Liu, D; Wang, Y; Zalath, M | 1 |
| Hu, J; Tan, X | 1 |
| Lee, RJ; Teng, L; Teng, M; Xie, J; Yang, S; Yu, B; Zhang, X | 1 |
| Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN | 1 |
| Keyoumu, S; Qu, Y; Tang, X; Tang, Y; Xu, C; Zhou, N | 1 |
| Agostini, M; Calandra, E; Crotti, S; Giodini, L; Marangon, E; Nitti, D; Posocco, B; Toffoli, G; Traldi, P | 1 |
| Bala, V; Prestidge, CA; Rao, S | 1 |
| Chantrill, L; Ciardiello, F; Day, F; Desai, J; Elez, E; Gebski, V; Haydon, A; Jefford, M; Joubert, W; Karapetis, C; Khasraw, M; Nott, L; Pavlakis, N; Price, T; Segelov, E; Shapiro, J; Tebbutt, N; Tejpar, S; Thavaneswaran, S; Underhill, C; van Hazel, G; Waring, P; Wasan, H; Wilson, K | 1 |
| Ambati, SR; Chaudhry, A; Lopes, EC; Moore, MA; Pera, B; Saxena, A; Shieh, JH; Su, TL; Wong, EW | 1 |
| Ali, MA; Itai, S; Iwao, Y; Noguchi, S; Oka, T | 1 |
| Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Perez, MVR; Pratt, M; Roife, D | 1 |
| Boumber, Y; Cai, KQ; Deneka, A; Duncan, JS; Duncan, KE; Egleston, BL; Gaponova, AV; Golemis, EA; Khazak, V; Kopp, MC; Kudinov, AE; Nikonova, AS; Ogawa, LS; Proia, DA; Skobeleva, N | 1 |
| Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP | 1 |
| Spindler, A; Stefan, K; Wiese, M | 1 |
| Biffoni, M; Buccarelli, M; Cappellari, M; De Luca, G; Fanciulli, M; Goeman, F; Melucci, E; Pilozzi, E; Ricci-Vitiani, L; Signore, M | 1 |
| Chen, Z; Lan, S; Shi, W; Tai, J; Wei, Z; Wu, D; Yu, H; Zhao, D; Zhao, J; Zhong, B | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Baba, H; Hayakawa, K; Hiraoka, M; Ikushima, H; Kamikonya, N; Kato, D; Nemoto-Murofushi, K; Noda, M; Oya, M; Oya, N; Sakai, Y; Sato, T; Shimada, M; Takeuchi, M; Tomita, N; Watanabe, M; Watanabe, T | 1 |
| Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R | 1 |
| Gao, Q; Ma, J; Shen, H; Zeng, S | 1 |
| Havre, RF; Kalaitzakis, E; Meisner, S; Willemoe, GL | 1 |
| Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K | 1 |
| Bakrin, N; Bonnefoy, I; Cotte, E; Glehen, O; Kepenekian, V; Kim, BJ; Passot, G; Vaudoyer, D | 1 |
| Lee, PC; Lee, SY; Lin, CY; Lin, SY; Luo, TY; Ning, ST; Peng, CL; Shieh, MJ; Shih, YH; Tsai, MH; Wei, MF | 1 |
| Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A | 1 |
| Pan, Z; Peng, J | 1 |
| Akinwande, O; Martin, RC; Scoggins, C | 1 |
| Aliberti, C; Carandina, R; Catalano, V; Coschiera, P; Felicioli, A; Fiorentini, G; Mulazzani, L; Sarti, D | 1 |
| Hamaguchi, T; Honma, Y; Ikezawa, N; Iwasa, S; Kato, K; Nagashima, K; Okita, N; Shimada, Y; Shoji, H; Takashima, A; Yamada, Y; Yamaguchi, T | 1 |
| Besselink, MG; Mohammad, NH; Molenaar, IQ; Rombouts, SJ; van Rijssen, LB; van Santvoort, HC; Vogel, JA; Walma, MS; Wilmink, JW | 1 |
| Han, J; Kim, JH; Kim, JS; Kumar, R; Lee, GG; Sessler, JL; Shin, WS | 1 |
| Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN | 1 |
| Antoniotti, C; Battaglin, F; Berenato, R; Bergamo, F; Borelli, B; Caporale, M; Cremolini, C; De Braud, F; Falcone, A; Fontanini, G; Lonardi, S; Loupakis, F; Marmorino, F; Marsico, VA; Masi, G; Mennitto, A; Moretto, R; Pietrantonio, F; Rossini, D; Salvatore, L | 1 |
| Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X | 1 |
| Arcaroli, JJ; Bagby, SM; Bradshaw-Pierce, EL; Capasso, A; Davis, SL; Diamond, JR; Eckhardt, SG; Ecsedy, JA; Hyatt, SL; Klauck, PJ; McPhillips, K; Messersmith, WA; Pitts, TM; Purkey, A; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ | 1 |
| Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME | 1 |
| Allorge, D; Barthelemy, C; Bonnabry, P; Décaudin, B; Humbert, L; Lebecque, M; Odou, P; Pinturaud, M; Richeval, C; Sidikou, O; Simon, N; Soichot, M; Vasseur, M | 1 |
| Bouchahda, M; Chatelut, E; Etienne-Grimaldi, MC; Focan, C; Innominato, P; Karaboué, A; Lévi, F; Milano, G; Paintaud, G | 1 |
| Alexandre, J; Aoki, D; Aotani, E; Enomoto, T; Fujiwara, K; Green, J; Hamano, T; Isonishi, S; Kato, K; Kim, BG; Kim, JW; Mikami, M; Nishino, K; Nomura, H; Okamoto, A; Pignata, S; Sugiyama, T; Suzuki, N; Tanabe, H; Terao, Y; Terauchi, F; Yaegashi, N; Yokoyama, Y; Yoshikawa, H | 1 |
| Lee, JR; Oh, PJ | 1 |
| Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J | 1 |
| Cruise, GM; Pereira, PL; Plotkin, S; Sommer, CM; Sutter, A; Wu, Y; Yu, R | 1 |
| Billadeau, DD; Cristofanilli, M; Cryns, VL; Gaisina, I; Giles, F; Jain, S; Kozikowski, A; Mazar, AP; O'Halloran, T; Ugolkov, A; White, K; Zhang, JS | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Wu, D; Zhang, J | 1 |
| Bahary, N; Bartlett, DL; Choudry, MH; Clifford, AK; Dhir, M; Hogg, ME; Holtzman, MP; Jones, HL; Perkins, S; Pingpank, JF; Shuai, Y; Steve, J; Zeh, HJ; Zureikat, AH | 1 |
| Garg, S; Song, Y; Wang, T; Xiao, Y; Yang, S; Zhang, B; Zhang, N | 1 |
| Ball, A; Bowers, M; Bridgewater, JA; Corkhill, A; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Maishman, T; Maughan, TS; O'Reilly, DA; Primrose, JN; Pugh, SA; Radford, M; Rees, C; Rees, M; Siriwardena, AK; Stanton, L; Valle, JW | 1 |
| Inoue, M; Ishioka, C; Komine, K; Ouchi, K; Shimodaira, H; Soeda, H; Takahashi, H; Takahashi, M; Takahashi, S; Zhang, X | 1 |
| Boku, N; Fukahori, M; Hamaguchi, T; Honda, K; Honma, Y; Iwasa, S; Okita, NT; Sasaki, Y; Shimada, Y; Shoji, H; Sudo, K; Takahashi, N; Takashima, A; Yamada, T; Yamada, Y | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Hirano, A; Hiroshima, Y; Ishida, Y; Kasahara, K; Kawaguchi, D; Kikuchi, Y; Koda, K; Kosugi, C; Matsuo, K; Mori, M; Murakami, T; Shuto, K; Tanaka, K; Yamada, M; Yamazaki, K | 1 |
| Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A | 1 |
| Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
| Bhuniya, S; Han, J; Hong, KS; Kim, EJ; Kim, HM; Kim, JS; Kumar, R; Lee, H; Shin, WS | 1 |
| Brünner, N; Guo, J; Huang, X; Li, L; Liu, S; Pan, Q; Ren, Y; Ren, Z; Stenvang, J; Wen, B; Wu, L; Xu, S; Zhang, C; Zhou, R; Zi, J | 1 |
| Guo, B; Qian, SY; Sun, M; Yang, X; Zhang, Q | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Lopes, F; Mitchell, RT; Nash, S; Smith, R; Spears, N | 1 |
| Brutcher, E; Cassidy, RJ; Chen, Z; El-Rayes, BF; Hawk, N; Kooby, D; Landry, J; Maithel, SK; Sarmiento, JM; Shaib, WL; Zhang, C | 1 |
| Hayakari, M; Hosoi, K; Nakagawa, J; Terui, K; Ueno, K; Yokoyama, Y | 1 |
| Bien, H; Choi, M; Mackenzie, GG | 1 |
| Huang, YC; Lee, WH; Liu, SC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, ST | 1 |
| Boongird, A; Chaimongkolnukul, K; Hongeng, S; Kengkoom, K; Manaspon, C; Nasongkla, N; Nittayacharn, P; Vejjasilpa, K | 1 |
| Motoshita, J; Nakagawa, T; Nakano, T; Nakashima, T; Okabe, M; Shiratsuchi, H; Tamae, A; Tanaka, R; Yasumatsu, R | 1 |
| Bateman, E; Bowen, JM; Campbell, JM; Keefe, DM; Peters, MD; Stephenson, MD | 1 |
| Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D | 1 |
| Han, M; Jin, Y; Ma, Y; Qin, H; Rao, Z; Shi, A; Wang, X; Wang, Y; Wu, X; Zhang, G | 1 |
| Garcia, P; John, J; Lewis, AL; Swaine, T; Tang, Y; Waters, LJ | 1 |
| Byrne, A; Dean, A; Hayden, I; Marinova, M | 1 |
| Dong, Y; Fang, T; Lin, L; Wang, H; Xie, K; Zhang, X | 1 |
| Chen, S; Chowbay, B; Khor, CC; Lam, S; Sutiman, N; Yu, Y; Zhang, CZ | 1 |
| Choi, HG; Gupta, B; Kim, JO; Poudel, BK; Ramasamy, T; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Agostini, G; Aldrighetti, L; Cereda, S; De Cobelli, F; Del Maschio, A; Marra, P; Reni, M; Sallemi, C; Venturini, M | 1 |
| Adam, R; Albiol, M; Awad, S; Fenwick, SW; Figueras, J; Gruenberger, T; Jones, RP; Malik, HZ; O'Grady, E; Plant, G; Poston, GJ; Rees, M; Stremitzer, S; Terlizzo, M | 1 |
| Fukutomi, A; Hamauchi, S; Kawahira, M; Kawai, S; Kawakami, T; Kito, Y; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ | 1 |
| Bodoky, G; Ciuleanu, T; Clingan, P; Cohn, A; Garcia Alfonso, P; Garcia-Carbonero, R; Kim, TW; Lonardi, S; Nasroulah, F; Obermannová, R; Portnoy, D; Prausová, J; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yang, L; Yoshino, T | 1 |
| Choi, HG; Choi, Y; Jeong, JH; Kim, JO; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Bednarek, E; Bocian, W; Kawęcki, R; Kozerski, L; Naumczuk, B; Sitkowski, J | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Crea, F; Danesi, R; De Gregorio, V; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Vivaldi, C | 1 |
| Abrey, LE; Aftab, DT; Cloughesy, TF; Ellingson, BM; Harris, RJ; Hessel, C; Lai, A; Leu, K; Mason, WP; Nghiemphu, PL; Pope, WB; Sahebjam, S; Schwab, GM; Wen, PY; Woodworth, DC; Zaw, O | 1 |
| Bala, V; Bateman, E; Keefe, D; Prestidge, CA; Rao, S; Wang, S | 1 |
| Dröge, P; Ivanyi-Nagy, R; Peter, S; Yu, H | 1 |
| Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T | 1 |
| Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV | 1 |
| Cheung, YK; Mao, X | 1 |
| Baumgart, JT; Edessa, LD; Helman, LJ; Heske, CM; Lee, S; Mendoza, A; Neckers, L; Proia, DA; Trepel, J | 1 |
| Caparello, C; Falcone, A; Funel, N; Garajova, I; Giovannetti, E; Kazemier, G; Le Large, TY; Meijer, LL; Peters, GJ; Vasile, E | 1 |
| Hsueh, CT; Selim, JH; Tsai, JY | 1 |
| Krishnan, V; Liem, N; Peethala, PC; Subhash, VV; Tan, SH; Yan, FL; Yeo, MS; Yong, WP | 1 |
| Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E | 1 |
| Al-Dasooqi, N; Bennett, C; Bowen, J; Finnie, J; Gibson, R; Keefe, D | 1 |
| Balasubramanian, P; Chen, AP; Evrard, YA; Kinders, RJ; Kummar, S; Wang, L | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Ayers, M; Clarke, SJ; Cunningham, D; Ferry, D; Frodin, JE; Guren, TK; Hawkes, E; Kim, SY; Kim, TW; Kim, TY; Loboda, A; Nebozhyn, M; Park, YS; Peckitt, C; Roh, JK; Schmoll, HJ; Sclafani, F; Tabernero, J; Watkins, DJ | 1 |
| Aviles, PM; Boguslawski, EA; Bowman, MJ; D'Incalci, M; Easton, MK; Galmarini, CM; Grohar, PJ; Guillen Navarro, MJ; Harlow, ML; Hostetter, G; Johnson, BK; Kitchen-Goosen, SM; Madaj, ZB; Maloney, N; Roland, J; Turner, L; Winn, ME | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C | 1 |
| Alcaide, J; Díez de Corcuera, I; Feliu, J; García García, T; Manzano, JL; Sastre, J; Valladares-Ayerbes, M; Vera, R | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Atkins, J; Bellido, J; El Osta, B; Fogelman, D; Fu, S; Hong, DS; Huang, H; Janku, F; Kee, B; Kopetz, S; Lanman, R; Meric-Bernstam, F; Morris, VK; Overman, MJ; Piha-Paul, S; Shureiqi, I; Sommer, N; Sorokin, AV; Subbiah, V; Tarcic, G; Tsimberidou, AM | 1 |
| Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K | 1 |
| Chen, HJ; Fang, S; Huang, ZH; Lin, XH; Yu, JL; Zou, ZW | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Bateman, EH; Bowen, JM; Keefe, DM; Mayo, BJ; Stringer, AM | 1 |
| Frese, S; Hall, SR; Herrmann, M; Keil, A; Körner, M; Schmid, RA | 1 |
| Andersen, CL; Lyskjær, I; Rasmussen, MH | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Jia, J; Liu, C; Shen, L; Sun, Z; Wang, X; Zhang, X | 1 |
| Cheng, SY; Du, J; Li, J; Li, KC | 1 |
| Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Yang, L; Zhang, X; Zhou, J | 1 |
| Itai, S; Iwao, Y; Noguchi, S; Oka, T; Ranneh, AH | 1 |
| Flint, S; Galvin, S; Nestor, LA | 1 |
| Fujita, KI; Ikegami, Y; Inoue, Y; Kitazawa, T; Nanbo, I; Onozuka, M; Saito, KI; Sakamoto, T; Sano, K; Sasaki, Y; Tatebayashi, E; Yoshida, H | 1 |
| Amano, R; Fukuoka, T; Hirakawa, K; Ikeya, T; Iseki, Y; Kimura, K; Maeda, K; Matsutani, S; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tanaka, H; Toyokawa, T | 1 |
| Terada, T | 1 |
| Ding, Y; Li, DD; Li, JJ; Liu, W; Peng, RQ; Wen, XZ; Wu, XJ; Xie, B; Zhang, X; Zhang, XS; Zhu, SG | 1 |
| Aparicio, T; Auby, D; Bachet, JB; Bouché, O; Boulat, O; Breysacher, G; Cretin, J; Faroux, R; Gargot, D; Gasmi, M; Genet, D; Jouve, JL; Khemissa, F; Lecomte, T; Lepère, C; Locher, C; Maillard, E; Mitry, E; Ramdani, M; Seitz, JF; Sobhani, I; Stefani, L; Teillet, L | 1 |
| Alvarenga, EM; Araújo, AR; Araújo, TS; de C Brito, GA; Martins, CS; Medeiros, JV; Nogueira, KM; Pacífico, DM; Sousa, DP; Sousa, FB; Souza, EP; Souza, LK | 1 |
| Cleary, JM; Czibere, A; Kearns, JD; Korn, WM; MacBeath, G; Mathews, S; McRee, AJ; Nering, R; O'Neil, BH; Shapiro, GI; Sharma, S; Tolaney, SM | 1 |
| Boku, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishimura, T; Okita, N; Shimada, Y; Takashima, A; Yamada, Y | 1 |
| Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T | 1 |
| Fan, WF; Meng, LJ; Pu, XL; Wang, J; Yang, M | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Carter, KA; Geng, J; Lovell, JF; Luo, D; Ortega, J; Razi, A; Shao, S | 1 |
| Jin, DY; Lou, WH; Rong, YF; Wu, W; Xu, XF; Zhang, L | 1 |
| Ålgars, A; Carpen, O; Jokilehto, T; Kaare, M; Kytölä, S; Lintunen, M; Orpana, A; Österlund, P; Ristamäki, R; Ristimäki, A; Sundström, J; Vainionpää, R | 1 |
| Chong, Z; Feng, B; Meng, Q; Mengyi, Z; Ming, L; Qiulin, T; Ruihua, H; Xin, M | 1 |
| Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M | 1 |
| Aragão, KS; da Silveira Bitencourt, F; de Alencar, NM; de Castro Brito, GA; de Figueiredo, IS; de Freitas, AP; Lima-Júnior, RC; Luz, PB; Magalhães, PJ; Ramos, MV; Ribeiro, RA | 1 |
| Chacorovska, M; Dimchevska, S; Geskovski, N; Goracinova, K; Petruševski, G; Popeski-Dimovski, R; Ugarkovic, S | 1 |
| Belanger, B; Chen, LT; Hubner, R; Pipas, JM; Siveke, J; Von Hoff, D; Wang-Gillam, A | 1 |
| Blank, SV; Boyd, L; Curtin, J; Goldberg, JD; Li, X; Ling, HT; Muggia, F; Musa, F; Pothuri, B; Speyer, JL; Tiersten, A | 1 |
| Chen, SH; Chern, CS; Chiang, WH; Chiu, HC; Huang, CW; Huang, WC; Lo, CL | 1 |
| Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS | 1 |
| Alex, SM; Bhuniya, S; Bobba, KN; Dutta, D; Maiti, KK | 1 |
| Finel, M; Ge, GB; Järvinen, E; Troberg, J; Yang, L | 1 |
| Chen, Q; Cheng, M; Wang, Z; Zhao, S | 1 |
| Benahim, E; Boige, V; de Baere, T; Deschamps, F; Ducreux, M; Goéré, D; Malka, D; Tselikas, L | 1 |
| Adams, R; Brown, S; Cheadle, J; Elliott, F; Fisher, D; Maughan, T; Middleton, G; Quirke, P; Richman, SD; Seligmann, JF; Seymour, M; Smith, CG | 1 |
| Anderson, RG; Bischak, MM; Broskin, SA; Campbell, CA; Foltz, LE; Higby, KJ; Koper, JA; Nickle, AC; Resendes, KK | 1 |
| D'Souza, D; Flanagan, S; Golzarian, J; Young, S | 1 |
| Gloor, B; Rau, T; Vinzens, S; Wochner, A; Zindel, J; Zweifel, M | 1 |
| Ball, IA; Bowen, JM; Coller, JK; Gibson, RJ; Lightwala, Z; Secombe, K; Shirren, J; Stansborough, RL; van Sebille, YZ; Wardill, HR; Wignall, A | 1 |
| Khan, SA; Paty, PB; Shia, J; Zeng, Z | 1 |
| Du, XL; Lairson, DR; Parikh, RC; Robert, MO | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Ahrendt, SA; Bahary, N; Bartlett, DL; Choudry, HA; Dhir, M; Hogg, ME; Holtzman, MP; Pingpank, JF; Singhi, AD; Zeh, HJ; Zureikat, AH | 1 |
| Aroldi, F; Beretta, GD; Bertocchi, P; Meriggi, F; Prochilo, T; Zaniboni, A | 1 |
| Fukuoka, Y; Kichikawa, K; Masada, T; Matsushima, S; Nishiofuku, H; Ohbayashi, C; Sato, T; Sho, M; Takano, M; Tanaka, T; Tatsumoto, S; Yamato, I; Yasuda, S | 1 |
| Alexander, C; Ashford, MB; Barnes, J; Barry, ST; England, RM; Hare, JI; Kemmitt, PD; Smith, A; Strittmatter, N; Waring, MJ; Wilson, J | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Bosserhoff, A; Dietrich, P; Hellerbrand, C; Koch, A; Lee, S; Luehrmann, A; Mahli, A; Müller, M; Saugspier, M; Schulze-Luehrmann, J; Sommer, J; Thasler, R; Thasler, WE | 1 |
| Bodoky, G; Harsanyi, L; Hegyi, P; Lakatos, G; Nehéz, L; Petranyi, A; Szűcs, A | 1 |
| Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G | 1 |
| Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S | 1 |
| Brünner, N; Høgdall, EV; Jensen, BV; Linnemann, D; Nielsen, DL; Palshof, JA; Pfeiffer, P; Poulsen, TS; Stenvang, J; Tarpgaard, LS; Yilmaz, M | 1 |
| Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T | 1 |
| Cabal-Hierro, L; O'Dwyer, PJ | 1 |
| An, HJ; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, Y; Lim, KY; Moon, SH; Nam, BH; Yun, T | 1 |
| Binder, RJ; Bollinger, JC; Bowling, J; Chen, J; Chi, L; Fratt, EM; Hatfield, MJ; Hyatt, JL; Jeffries, C; Potter, PM; Scarborough, J | 1 |
| Chen, X; Chen, ZS; Cheng, C; Guo, HQ; Kathawala, RJ; Li, T; Yang, D; Yang, DH | 1 |
| Baretta, Z; Bonfill Cosp, X; Hallum, S; Martin-Richard, M; Mocellin, S; Roqué I Figuls, M; Solà, I | 1 |
| Chang, H; Chen, P; Li, B; Luo, X; Nie, P; Shi, X; Wu, B; Xu, W; Yu, X; Zou, Z | 1 |
| Akamatsu, H; Furukawa, K; Ikehara, M; Kishi, K; Koh, M; Masuzawa, T; Suzuki, Y; Tanemura, M; Tei, M; Tsukada, R | 1 |
| Abe, N; Abe, S; Aoto, K; Kawana, S; Murakami, F; Ohtake, T; Okano, M; Suzuki, O; Tachibana, K; Takenoshita, S; Tasaki, K | 1 |
| Ando, T; Hirose, Y; Ishikawa, H; Kameyama, H; Katada, T; Kobayashi, T; Miura, K; Ohashi, T; Sakata, J; Soma, D; Takano, K; Takizawa, K; Toge, K; Wakai, T; Yuza, K | 1 |
| Fujiwara, T; Kagawa, S; Kikuchi, S; Kuroda, S; Nishizaki, M | 1 |
| Hagihara, K; Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Uemura, M; Yamamoto, K | 1 |
| Iijima, S; Nishioka, K; Oshima, S; Takachi, K; Takemoto, H; Tsujimura, N; Uemura, Y | 1 |
| Byer, J; Chang, YD; Kim, DW; Kim, RD; Kothari, N; Mahipal, A | 1 |
| Alharbi, SA; Chan, CEL; Chinnathambi, A; Goh, BC; Ho, PC; Lee, LS; Lee, SC; Lim, SW; Sethi, G; Soo, R; Wang, L; Wong, AL; Wong, FC; Yong, WP | 1 |
| Loreni, G; Miele, V; Ramponi, S; Rastelli, M; Scevola, G; Sposato, S | 1 |
| Gress, TM; Rinke, A | 1 |
| Caroen, S; Carter, C; Cho-Phan, C; Fanger, G; Fisher, G; Knox, S; Kunz, P; Ning, S; Oronsky, B; Parker, C; Reid, T; Scicinski, J | 1 |
| Akahane, T; Aoki, D; Hirasawa, A; Kataoka, F; Mushiroda, T; Nanki, Y; Nomura, H; Susumu, N; Tominaga, E; Yamagami, W; Yoshihama, T | 1 |
| Ashour, ME; Downs, JA; El-Khamisy, SF; El-Shafie, L; Hodgson, A; Khurram, SA; Liao, C; Meisenberg, C; Pilborough, A; Ward, SE | 1 |
| Choi, HG; Choi, JY; Din, FU; Kim, DS; Kim, DW; Kim, JO; Ku, SK; Mustapha, O; Oh, KT; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Ashrafi, K; Blino, D; Britton, H; Bushby, AJ; den Hartog, M; Domenge, O; Dreher, MR; Krishnasamy, V; Levy, EB; Lewis, AL; Mikhail, AS; Negussie, AH; Radaelli, A; Shuturminska, K; Tang, Y; Willis, SL; Wood, BJ; Woods, DL | 1 |
| Alsaied, O; Arora, N; Banerjee, S; Dauer, P; Dudeja, V; Giri, B; Majumder, K; Modi, S; Saluja, A; Von Hoff, D | 1 |
| Di Pietro, A; Guitton, J; Hénin, E; Honorat, M; Payen, L; Tod, M | 1 |
| Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Berry, S; Chan, KK; Earle, C; Jerzak, KJ; Ko, YJ | 1 |
| Basu, S; Ghose, R; Mallick, P; Moorthy, B | 1 |
| Amano, F; Kanai-Mori, A; Koike, A; Morishige, Y; Tamaki, R; Yanagihara, K | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Barrie, M; Boucard, C; Campello, C; Chinot, O; Farina, P; Girard, N; Graillon, T; Lehmann, P; Petrirena, G; Tabouret, E | 1 |
| Chen, M; He, Q; Li, G; Luo, P; Shao, J; Xu, L; Xu, Z; Yan, H; Yang, B; Zhu, Y | 1 |
| Alles, EJ; Bamber, JC; Cox, TR; Elyas, E; Erler, JT; Papaevangelou, E; Robinson, SP | 1 |
| Bijari, N; Derakhshandeh, K; Ghobadi, S | 1 |
| Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M | 1 |
| Choi, HG; Choi, JY; Din, FU; Kim, DS; Kim, DW; Kim, JO; Ku, SK; Mustapha, O; Oh, KT; Oh, YK; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Qin, HY; Shi, AX; Wang, YP; Wu, XA; Zhang, XY; Zhao, YS; Zhou, Y | 1 |
| Dawson, DW; Donahue, TR; Hines, OJ; Muthusamy, VR; Reber, HA; Sugimoto, M | 1 |
| Cho, DH; Kim, CW; Kim, JC; Kim, MB; Kim, TW; Roh, SA; Yoon, YS | 1 |
| Furukubo, T; Hojyo, A; Izumi, S; Kambara, K; Katsube, Y; Koide, H; Minegaki, T; Nishiguchi, K; Ochiai, M; Ogawa, K; Shima, D; Torii, N; Tsujimoto, M; Yamakawa, T | 1 |
| Ahn, S; Hwang, JH; Kim, HW; Kim, J; Kim, JW; Kim, YH; Lee, J; Lee, JC; Paik, KH | 1 |
| Behera, D; Sharma, S; Singh, A; Singh, N | 1 |
| Hu, ZW; Hua, F; Shang, S | 1 |
| Fang, L; Song, S; Tao, X; Wang, L; Wu, Z; Yao, C | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Jin, C; Lu, W; Zhang, Q | 1 |
| Bezdenezhnykh, N; Kocherga, R; Kovalova, O; Kudryavets, Y; Lykhova, O; Maksimyak, GI; Vorontsova, A; Zhylchuk, V | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Brito, GA; Castelucci, P; Coelho-Aguiar, JM; Costa, DV; Gomes, AS; Leitão, RF; Lima-Júnior, RC; Martins, CS; Moura-Neto, V; Nogueira, LT; Silva, AM | 1 |
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Matsunaga, T; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Tsujino, T; Uchimoto, T; Yoshikawa, Y | 1 |
| Atasilp, C; Chansriwong, P; Prommas, S; Puangpetch, A; Rerkarmnuaychoke, B; Reungwetwattana, T; Sirachainan, E; Sirilerttrakul, S; Sukasem, C; Wongwaisayawan, S | 1 |
| Hosokawa, M; Sugiyama, Y; Tomaru, A; Toshimoto, K | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Chen, QK; Chen, XW; Huang, YF; Liao, NZ; Liu, CC; Luo, ZT; Wang, GX; Zhang, WJ; Zhu, DJ | 1 |
| Adam, R; Barroso, E; Capussotti, L; Elias, D; Giuliante, F; Gruenberger, T; Guglielmi, A; Hubert, C; Innominato, PF; Isoniemi, H; Lapointe, R; Laurent, C; Lin, JK; Lopez-Ben, S; Regimbeau, JM; Skipenko, OG; Yi, B | 1 |
| Bi, A; Ding, H; Ding, J; Geng, M; Huang, M; Lian, Q; Sun, B; Sun, X; Xu, J; Yan, S | 1 |
| Carcaboso, AM; Castillo-Ecija, H; Cheung, NKV; Cuadrado-Vilanova, M; de Torres, C; Ferrandiz, MM; Glisoni, R; Jungbluth, A; Kuplennik, N; Lavarino, C; Monterrubio, C; Mora, J; Olaciregui, NG; Paco, S; Pascual-Pasto, G; Sosnik, A; Vila-Ubach, M | 1 |
| Chang, CH; Donahue, T; Jiang, J; Liao, YP; Lin, J; Lin, P; Liu, X; Meng, H; Nel, AE; Perrett, I; Wainberg, Z; Wu, N | 1 |
| Amlashi, FG; Blum Murphy, M; Bozkurt, M | 1 |
| Kashihara, H; Kono, T; Kurita, N; Shimada, M; Takasu, C; Yismaw, WG; Yoshikawa, K | 1 |
| Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K | 1 |
| Garg, S; Liu, Y; Song, Y; Wang, T; Yang, S; Zhang, B; Zhang, J; Zhang, N | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Keyvani-Ghamsari, S; Rabbani-Chadegani, A; Sargolzaei, J; Shahhoseini, M | 1 |
| A Guzzetta, A; Abdelfatah, E; Ahuja, N; Azad, N; B Baylin, S; Hu, Y; Kerner, Z; Sharma, A; Singh, J; Vatapalli, R; Wyatt McMahon, K; Yerram, S; Zahnow, C | 1 |
| Deneka, AY; Gaponova, AV; Golemis, EA; Haber, L; Kopp, MC; Nikonova, AS | 1 |
| Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L | 1 |
| Almeida, PRC; Lima-Júnior, RCP; Malveira, LRC; Marcolino Assis-Júnior, E; Melo, AT; Moreira, LS; Oliveira, CMG; Pereira, VBM; Sousa, NRP; Souza, MHLP; Wong, DVT | 1 |
| Khorrami, S; Malekzadeh, R; Mowla, SJ; Rakhshani, N; Soleimani, M; Zavaran Hosseini, A | 1 |
| Kara, D; Karadaş, C; Uysal, D | 1 |
| Barbier, O; Chen, S; Lu, W; Paszek, M; Rettenmeier, E; Trottier, J; Tukey, RH; Yueh, MF | 1 |
| Hazama, S; Nagano, H; Oka, M; Okayama, N; Tsunedomi, R | 1 |
| Carie, A; Semple, JE; Sill, KN; Sullivan, B | 1 |
| Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY | 1 |
| Dicker, DT; El-Deiry, WS; Zhang, J; Zhao, S; Zhou, L | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M | 1 |
| Ames, MM; Foster, NR; Goetz, MP; Hobday, TJ; Horvath, LE; Jatoi, A; Mahoney, MR; McWilliams, RR; Meyers, JP; Murray, JA; Schneider, DJ; Smyrk, TC | 1 |
| Guo, H; Han, K; Tang, H; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhuang, K | 1 |
| Chen, X; Deng, Q; Guo, M; Guo, Z; He, J; He, Q; Huang, L; Liang, W; Liu, L; Liu, Y; Pan, H; Tang, H | 1 |
| Sahota, S; Vahdat, LT | 1 |
| Eng, C; Fournier, K; Mann, GN; Mansfield, P; Morris, J; Overman, MJ; Qiao, W; Raghav, K; Royal, RE; Uemura, M; Wolff, RA | 1 |
| Doki, Y; Fukunaga, M; Hata, T; Ikeda, M; Kato, T; Kim, HM; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nishimura, J; Sueda, T; Yamamoto, H | 1 |
| Gu, Z; Liao, C; Pang, J; Wu, F; Zhang, S | 1 |
| Kalluri, R; Kurywchak, P | 1 |
| Colville-Ebeling, B; Jensen, BV; Larsen, FO; Markussen, A; Nielsen, D; Riis, LB | 1 |
| Hashimoto, Y; Hirata, Y; Ishizaki, Y; Kitamura, S; Kuga, Y; Miwata, T; Mouri, T | 1 |
| Astafiev, S; Gul, S; Hapiak, Y; Kaur, G; Loers, G; Mishra, B; Saini, V; Schachner, M; Theis, T | 1 |
| Chi, SN; Cohen, KJ; DiRenzo, J; Donson, AM; Dunkel, IJ; Etzl, MM; Foreman, NK; Gore, L; Kieran, MW; Kuei, MC; MacDonald, TJ; Macy, ME; Narendran, A; Ostrovnaya, I; Smith, AA; Trippett, TM | 1 |
| Hosomi, Y; Ishii, M; Kato, T; Masuda, N; Minato, K; Misumi, Y; Miura, Y; Nagamata, M; Naoki, K; Ogura, T; Okamoto, H; Okuma, Y; Otani, S; Sasaki, J; Sata, M; Shimokawa, T; Takakura, A; Takata, S; Watanabe, K; Yokoyama, T | 1 |
| Dimchevska, S; Dimovski, A; Geskovski, N; Gomez Vallejo, V; Goracinova, K; Hristov, DR; Koliqi, R; Llop, J; Matevska-Geskovska, N; Monopoli, MP; Petruševski, G; Sebastian, ES; Szczupak, B; Ugarkovic, S | 1 |
| Bardia, A; Goldenberg, DM; Govindan, SV; Guarino, M; Isakoff, SJ; Maliakal, P; Mayer, IA; Messersmith, WA; Ocean, AJ; Picozzi, VJ; Sharkey, RM; Starodub, AN; Vahdat, LT; Wegener, WA | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T | 1 |
| Bastide, S; Cousin, C; Favier, M; Leguelinel-Blache, G; Loriot, V; Obled, S; Phouttasang, V; Thibault, V; Wolf, P | 1 |
| Crispin, A; Fischer von Weikersthal, L; Giessen-Jung, C; Haas, M; Heinemann, V; Holch, JW; Jung, A; Kirchner, T; Kruger, S; Michl, M; Modest, DP; Neumann, J; Quietzsch, D; Schalhorn, A; Stahler, A; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, J | 1 |
| Chen, XM; Kong, SJ; Yin, JF; Zhang, HY; Zhang, J; Zhang, X | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Chang, GJ | 1 |
| Abdel-Rahman, WM; Al-Khayyal, NA; Aravind, SR; Nair, VA; Saber-Ayad, M | 1 |
| Andreou, A; Bahra, M; Beierle, AS; Duwe, G; Knitter, S; Lohneis, P; Öllinger, R; Pesthy, S; Pratschke, J; Raschzok, N; Sauer, IM; Schmelzle, M; Schmuck, RB; Sinn, M; Struecker, B | 1 |
| Emami, J; Hasanzadeh, F; Maghzi, P; Mirian, M; Rostami, M; Sadeghi, H | 1 |
| Chen, X; Huang, Y; Luo, Y; Su, P; Wang, G; Wang, Q; Yang, Y; Zhu, D | 1 |
| Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P | 1 |
| Barni, S; Ghidini, A; Inno, A; Labianca, R; Petrelli, F; Rimassa, L; Tomasello, G | 1 |
| Ahmad, T; Ahmed, M; Czejka, M; Fan, Y; Khan, RA; Mansoor, N; Sharib, S; Yang, DH | 1 |
| Gao, J; Li, J; Li, Y; Liu, D; Shen, L; Yang, R | 1 |
| Collado, MC; Forsgård, RA; Frias, R; Korpela, K; Korpela, R; Marrachelli, VG; Monleon, D; Österlund, P; Spillmann, T | 1 |
| Akimoto, S; Hasegawa, H; Ishida, T; Ishii, Y; Kitagawa, Y; Koishikawa, K; Okabayashi, K; Tsuruta, M | 1 |
| Kim, SH; Komuta, K; Minami, S; Ogata, Y; Yamamoto, S | 1 |
| Bisra, G; Chandrawati, R; de Oliveira, MG; Guex, AG; Marini, TCC; Olesen, MTJ; Stevens, MM; Zelikin, AN | 1 |
| He, Y; Jia, B; Lac, D; Lam, KS; Li, Y; Lin, TY; Luo, Y; Xiao, K; Xue, X; Yang, X; Zhang, H | 1 |
| Peng, CL; Shieh, MJ; Tsai, MH; Yang, SJ | 1 |
| Cinar, P; Ko, AH | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Makihara, K; Miyagi, K; Nakamura, S; Nakata, I; Ueno, H | 1 |
| Bai, XL; Chen, YG; Gao, SL; Guo, CX; Li, GG; Li, X; Liang, TB; Lou, JY; Ma, T; Que, RS; Shen, YN; Sun, PW; Wei, QC; Wei, SM; Yu, RS; Yuan, Y; Zhang, Q; Zhang, Y; Zheng, L | 1 |
| Korzhikov-Vlakh, VA; Korzhikova-Vlakh, EG; Lavrentieva, A; Orlova, RV; Rühl, E; Scheper, T; Tarasenko, II; Tennikova, TB; Volokitina, MV; Zashikhina, NN | 1 |
| Acedo, P; Cañete, M; Casadó, A; Mora, M; Rello-Varona, S; Sagristá, ML; Stockert, JC; Villanueva, A | 1 |
| Bilancia, D; Cascinu, S; Corsi, DC; Ferraú, F; Galli, F; Giordano, M; Iaffaioli, RV; Labianca, R; Leone, F; Lonardi, S; Marchetti, P; Nasti, G; Ronzoni, M; Rosati, G; Scartozzi, M; Zagonel, V; Zaniboni, A | 1 |
| Allan, S; Byrne, JA; Cheung, L; Eden, GL; Flemming, CL; Fletcher, JI; Gamble, LD; Gifford, AJ; Haber, M; Hanssen, KM; Henderson, MJ; Murray, J; Norris, MD; Ruhle, M; Saletta, F; Schuetz, JD; Tan, A; Tivnan, A; Truong, AM; Valli, E; Yu, DMT | 1 |
| Andreatos, N; Buettner, S; Damaskos, C; Deshwar, A; Ghasebeh, MA; Kamel, IR; Margonis, GA; Pawlik, TM; Pour, MZ; Rezaee, N; Sasaki, K; Wang, J; Weiss, MJ; Wolfgang, CL | 1 |
| Bettinger, J; Karhan, B; Peters, SS; Philip, J; Wrzesinski, SH | 1 |
| Bagatell, R; Gupta, AA; Lysecki, D; Mascarenhas, L; Miller, A; Nicholls, L; Okcu, F; Setty, BA; Stanek, JR | 1 |
| Chang, YJ; Chu, CM; Makondi, PT; Wei, PL | 1 |
| Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y | 1 |
| Chiba, Y; Fukagawa, D; Itamochi, H; Kawamura, H; Kojima-Chiba, A; Muraki, Y; Sato, S; Suga, Y; Sugai, T; Sugiyama, T; Yoshino, N | 1 |
| Cohen, D; Ghaffaripour, T; Stoner, P | 1 |
| Monchusi, B; Ntwasa, M | 1 |
| Akashi, K; Arimizu, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Inadomi, K; Kajitani, T; Komoda, M; Kusaba, H; Kuwayama, M; Makiyama, A; Makiyama, C; Matsushita, Y; Oda, H; Ohmura, H; Shinohara, Y; Shirakawa, T; Uchino, K | 1 |
| Akinwande, O; Dendy, M; Kim, HS; Ludwig, JM | 1 |
| Chen, M; Dong, Y; Gao, J; Hua, Y; Li, W; Li, Y; Zhang, H; Zhang, X; Zhao, L; Zheng, A | 1 |
| Berlin, JD; Cohen, SJ; Dotan, E; Goldberg, RM; Goldenberg, DM; Govindan, SV; Guarino, MJ; Hecht, JR; Lieu, CH; Marshall, JL; Messersmith, WA; Sharkey, RM; Simpson, PS; Starodub, AN; Wegener, WA | 1 |
| Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J | 1 |
| Kamimura, S; Kinoshita, M; Miyachi, M; Moritake, H; Sawa, D; Yamada, A | 1 |
| Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V | 1 |
| Liu, X; Lu, Z; Miao, Y; Shen, Y; Sui, M; Tang, J; Wang, L; Wang, W; Zheng, M; Zhou, Q; Zhou, Z | 1 |
| Gao, Z; Hui, Y; Ma, X; Ren, S; Wang, Y | 1 |
| Grothe, W; Ho, J; Moehler, M; Syn, NL; Tai, BC; Unverzagt, S; Wagner, AD; Yong, WP | 1 |
| Bahrami, A; Blankenship, K; Bradley, C; Chen, X; Clay, MR; Dapper, J; Downing, J; Dyer, MA; Easton, J; Federico, SM; Freeman, BB; Gordon, B; Honnell, V; Karlstrom, A; Mardis, ER; Ocarz, M; Pappo, A; Shelat, AA; Stewart, E; Twarog, NR; Wilson, RK; Wu, J; Xu, B; Zhang, J; Zhou, X | 1 |
| DeLuca, JG; Herman, JA; Lee, E; Paddison, P; Pain, M; Toledo, CM; Wang, H; Yong, RL; Zhu, J | 1 |
| Bunn, PA; Chan, DC; Drummond, DC; Fitzgerald, JB; Gaddy, DF; Hendriks, BS; Kalra, AV; Klinz, SG; Lee, H; Leonard, SC; Paz, N | 1 |
| Beare, S; Bottomley, D; Chambers, P; Essapen, S; Gollins, S; Hemmings, G; Lawrie, E; Lopes, A; Myint, AS; Quirke, P; Samuel, L; Saunders, M; Sebag-Montefiore, D; Sizer, B; Southward, K; Susnerwala, S; Taylor, M; Tinkler-Hundal, E; West, N; Worlding, J | 1 |
| Liauw, SL | 1 |
| Duan, Z; Pan, D; Peng, H; Wei, X; Wen, J | 1 |
| Brünner, N; Nielsen, DL; Palshof, JA; Stenvang, J; Viuff, BM | 1 |
| Chen, D; Jin, R; Kang, Y; Li, W; Liang, G; Qiu, P; Wang, J; Wu, J; Xu, Q; Zhang, S; Zhou, P; Zhou, Y; Zhu, M | 1 |
| Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F | 1 |
| Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC | 1 |
| Allen, JN; Berger, D; Blaszkowsky, LS; Clark, JW; Collura, C; Deshpande, V; Ferrone, CR; Lillemoe, KD; Miller, CL; Murphy, JE; Parikh, AR; Qadan, M; Ryan, DP; Smalley, R; Tanabe, KK; Taylor, MS; Worthington, S | 1 |
| Doi, H; Inui, T; Kataoka, Y; Kida, T; Nakatsuji, M; Nishino, K; Sakamoto, S; Shimizu, S; Tamura, Y; Teraoka, Y | 1 |
| Dunn, SP; Finegold, MJ; Furman, WL; Gao, Y; Katzenstein, HM; Krailo, MD; Langham, MR; Malogolowkin, M; McCarville, MB; McGahren, ED; Meyers, RL; O'Neill, AF; Ranganathan, S; Rodriguez-Galindo, C; Tiao, GM; Towbin, AJ; Weldon, CB; Xia, C | 1 |
| Ambudkar, SV; Chufan, EE; Fukuda, M; Ishida, M; Iwabuchi, Y; Kanehara, K; Kudoh, K; Murakami, M; Naitoh, T; Ohnuma, S; Shibata, H; Sugisawa, N; Unno, M | 1 |
| Gao, Z; Li, Z; Wang, P; Yan, J | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
| Diness, LV; Larsen, FO; Markussen, A; Nielsen, D | 1 |
| Alvarenga, EM; Araújo, AR; Brito, GAC; de Araújo, S; Iles, B; Júnior, JLP; Medeiros, JVR; Pacífico, DM; Sousa, DP; Sousa, NA; Souza, EP | 1 |
| Battisti, A; Berti, F; Buzzo, M; Giodini, L; Gladich, I; Guida, F; Laio, A; Marangon, E; Toffoli, G | 1 |
| Alì, G; Antonelli, A; Basolo, F; Bocci, G; Di Desidero, T; Ferrari, SM; Fioravanti, A; Fontanini, G; Francia, G; Orlandi, P | 1 |
| Hawkins, CJ; Miles, MA | 1 |
| Aoki, I; Bakalova, R; Higashi, T; Nikolova, B; Shibata, S; Zhelev, Z | 1 |
| Eisterer, W; Fridrik, MA; Greil, R; Gruenberger, B; Hejna, M; Huemer, F; Keil, F; Thaler, J; Trommet, V; Ulmer, H; Weiss, L; Wöll, E | 1 |
| Baiocchi, M; De Angelis, ML; De Maria, R | 1 |
| Bracke, B; Chapelle, T; Driessen, A; Francque, S; Hartman, V; Huyghe, I; Morrison, S; Op de Beeck, B; Roeyen, G; Ysebaert, D | 1 |
| Bai, R; Cao, X; Deng, X; Wang, S; Wu, Q; Ye, T | 1 |
| Biondi, RM; Gatterdam, V; Gerlach, K; Hahn, S; Khageh Hosseini, S; Kolterer, S; Proschak, E; Schulze, JO; Steiner, M; Steinhilber, D; Tampé, R; Trojan, J; von Manstein, V; Waidmann, O; Zeuzem, S; Zörnig, M | 1 |
| Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K | 1 |
| Berger, MD; Cao, S; Falcone, A; Heinemann, V; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Soni, S; Stintzing, S; Suenaga, M; Sunakawa, Y; Yang, D; Zhang, W | 1 |
| Arimori, K; Ashizawa, K; Fukuda, M; Honda, T; Ikeda, T; Iwakiri, T; Kobayashi, K; Matsuo, N; Mukae, H; Nakatomi, K; Okumura, M; Senju, H; Takemoto, S; Yamaguchi, H | 1 |
| Das, K; Imamura, H; Nishikawa, K; Sugimoto, N; Taguri, M; Tan, P; Tsuburaya, A; Yoshida, K | 1 |
| Arrieta, O; Cardona, AF; Carranza, H; Corrales, L; Cuello, M; Martín, C; Otero, J; Pino, LE; Reguart, N; Rojas, L; Rolfo, C; Rosell, R; Ruiz-Patiño, A; Vargas, C; Wills, B; Zatarain-Barrón, ZL | 1 |
| Arita, S; Baba, E; Esaki, T; Kajitani, T; Makiyama, A; Oda, H; Shimokawa, H; Shirakawa, T | 1 |
| Alsina, M; Braña, I; Britten, CD; Del Conte, G; Ezeh, P; Houk, B; Kern, KA; Leong, S; Pathan, N; Pierce, KJ; Siu, LL; Soares, HP; Tabernero, J; Vermette, J; Wainberg, ZA | 1 |
| Cao, Y; Ge, G; Li, C; Li, W; Sun, X; Xiao, L; Zhu, L | 1 |
| Bergeron, C; Brok, J; Catania, S; Graf, N; Hol, JA; Howell, L; Kager, L; Mavinkurve-Groothuis, AMC; Pritchard-Jones, K; Spreafico, F; van den Heuvel-Eibrink, MM; van Tinteren, H; Verschuur, A | 1 |
| Benasutti, H; Groman, E; Saba, L; Scheinman, R; Simberg, D; Vu, VP; Wang, G | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Chen, YL; Cheng, KW; Cheng, TC; Cheng, TL; Chuang, YC; Leu, YL; Lu, YC; Tseng, CH; Tzeng, CC; Wang, JY; Yang, CN | 1 |
| Hou, YC; Lei, CS; Lin, MT; Pai, MH; Yeh, SL | 1 |
| Singh, KK; Taneja, N | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Matsubara, Y; Mihara, H; Nakata, N; Nanjo, S; Sugiyama, T; Takagi, H; Yoshita, H | 1 |
| Bähr, O; Breuer, S; Burger, MC; Cieplik, HC; Franz, K; Harter, PN; Steinbach, JP | 1 |
| Blocker, SJ; Chen, W; Douglas, KA; Hendriks, BS; Lalo, E; Lee, H; Polin, LA; Shields, AF | 1 |
| Allen, PJ; Balachandran, VP; Boucher, T; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Jarnagin, WR; Kemeny, NE; Kingham, TP; Pak, LM | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Guan, Y; Hafiz, MZ; He, S; Li, X; Liu, W; Wu, L; Xiong, J; Yan, B; Yang, J | 1 |
| Anbil, S; Baglo, Y; Fitzgerald, J; Hasan, T; Hayden, D; Huang, HC; Kalra, A; Lee, H; Liu, J; Paz, N; Pereira, S; Pogue, BW; Rizvi, I | 1 |
| Chen, HM; Cheng, AL; Lai, MS; Liang, YH; Shao, YY; Yeh, KH | 1 |
| Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N | 1 |
| Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D | 1 |
| Gu, HW; Liu, XL; Wu, HL; Yin, XL; Zhang, SH | 1 |
| Andriguetti, NB; Antunes, MV; Arnhold, PC; Bastiani, MF; da Silva, ACC; Dos Reis, SL; Hahn, RZ; Kael, I; Klück, HM; Linden, R; Schneider, A; Schwartsmann, G | 1 |
| Jiang, X; Li, C; Liang, L; Liu, L; Lu, P; Qiao, Y; Wang, L; Xia, Y; Yang, T | 1 |
| Bao, WG; Li, YQ; Shi, WG; Tu, ZK; Wu, D; Yin, QL; Yu, H; Yu, YY; Zhao, DW; Zhong, BH | 1 |
| Chang, W; Li, R; Liu, W; Shen, Q; Tao, K; Tao, R; Xie, G; Yin, Y; Zhang, P | 1 |
| Ebadi, M; Field, CJ; Lehner, R; Mazurak, VC | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Almeida, PRC; Câmara, LMC; Cândido, AGF; Falcão, RB; Fernandes, C; Lima-Júnior, RCP; Muniz, HA; Silva, CMS; Souza, MHLP; Souza, NRP; Teixeira, MA; Wanderley, CWS | 1 |
| Fujikawa, T; Ikarashi, N; Kato, S; Kimura, H; Kon, R; Machida, Y; Matsunaga, Y; Minami, M; Murakami, Y; Sakurai, R; Sugiyama, K; Tomimoto, R; Tsubota, Y | 1 |
| Akamatsu, W; Andoh-Noda, T; Chung, XKW; Mao, D; Okano, H; Qin, Y; Sato, SI; Takemoto, Y; Uesugi, M | 1 |
| Guldin, S; Krol, S; Salvati, E; Serrano, LA; Stellacci, F; Yang, Y | 1 |
| Hosoda, Y; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 1 |
| Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Larsen, VA; Lassen, U; Lukram, B; Michaelsen, SR; Poulsen, HS; Toft, A; Urup, T | 1 |
| Endo, K; Imano, H; Kido, T; Kimura, Y; Morimoto, Y; Saito, R; Sasaki, T; Toda, H; Yoshino, K | 1 |
| Chouda, Y; Inoue, H; Ishida, M; Kanazawa, T; Kubota, S; Miyake, S | 1 |
| Abe, T; Baba, J; Hirata, A; Ichikawa, K; Kikuchi, T; Kondo, R; Koya, T; Makino, M; Maruyama, Y; Sato, K; Shoji, S; Tanaka, H; Tanaka, J; Terada, M; Tsukada, H; Watanabe, S; Yoshizawa, H | 1 |
| Artru, P; Bennouna, J; Ducreux, M; Lievre, A; Lledo, G | 1 |
| Baumann, AB; D'Anastasi, M; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Reiser, MF; Ricard, I; Sommer, WH; Stintzing, S | 1 |
| Alberts, SR; Hartgers, ML; Hassan, M; Jin, Z; Mahipal, A; Muppa, P; Nagorney, DM; Sanhueza, CT; Shubert, CR; Smyrk, TC; Truty, MJ | 1 |
| Liu, B; Liu, S | 1 |
| Anan, C; Katada, E; Mitsui, A; Sasaki, S; Uematsu, N | 1 |
| Price, TJ | 1 |
| Chia, YL; Eldon, MA; Gordi, T; Hoch, U; Sy, SKB | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Geredeli, C; Yasar, N | 1 |
| Chen, H; Chen, Y; Gu, Y; Hoffman, RM; Li, Y; Wang, H; Wang, W; Wu, M; Xu, M; Yang, Z; Zhu, P | 1 |
| Chang, B; Jiang, X; Kariminia, S; Li, Q; Li, Y; Yan, H; Yang, L; Zhen, H | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Afkham, A; Afkham, NM; Aghebati-Maleki, L; Ahmadi, M; Akbarzadeh, P; Dolati, S; Jadidi-Niaragh, F; Sadreddini, S; Siahmansouri, H; Younesi, V; Yousefi, M | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
| Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H | 1 |
| Bejrowska, A; Mazerska, Z; Mróz, A; Pawłowska, M | 1 |
| Hirayu, N; Imamura, T; Shiota, K; Sou, H; Taketani, S; Taniwaki, S; Uchino, Y | 1 |
| Kitamura, S; Kuga, Y; Miwata, T; Mouri, T; Nishida, T; Sakimoto, H | 1 |
| Aldaz Pastor, A; Garcia-Del-Barrio, MA; Martin-Algarra, S | 1 |
| Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L | 1 |
| Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
| Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J | 1 |
| Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T | 1 |
| Ciftci, O; Taslıdere, A; Turkmen, NB | 1 |
| Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T | 1 |
| di Nunzio, MR; Douhal, A; Douhal, Y; Organero, JA | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Aparicio, T; Baconnier, M; Barbier, E; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; Francois, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J | 1 |
| Chuang, CH; Fang, YP; Lin, HC; Lu, YC; Wu, YJ | 1 |
| Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tadevosyan, SS; Tsygankov, АY; Zhil'tsova, MG | 1 |
| Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
| Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A | 1 |
| Kopetz, S | 1 |
| Chen, Z; Gao, J; Li, S; Li, Y; Lin, X; Lu, Z; Shen, L; Zhang, C; Zou, J | 1 |
| Brčić Karačonji, I; Čanović, S; Fuchs, N; Jurič, A; Kopjar, N; Lucić Vrdoljak, A; Micek, V; Mikolić, A; Mršić, G; Neuberg, M; Prester, L; Žunec, S | 1 |
| Ahmad, N; Ahmad, R; Alam, MA; Jalees Ahmad, F; Umar, S | 1 |
| Deng, X; Shang, L; Wang, S; Wu, Y; Ye, T | 1 |
| Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W | 1 |
| Gao, S; Ghose, R; Hu, M; Ittmann, MM; Mallick, P; Shah, P; Trivedi, M | 1 |
| Cao, Y; Chen, Y; Jiang, J; Kang, A; Qin, Y; Shi, Y; Tang, Y; Wang, H; Wang, J; Wei, W; Zhou, G | 1 |
| Chen, X; Ju, Y; Su, P; Wang, G; Yang, Y | 1 |
| Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L | 1 |
| Bai, S; Gao, YE; Hou, M; Kang, Y; Ma, X; Shi, X; Xiao, B; Xu, Z; Xue, P; Zhang, T | 1 |
| Alvau, MD; Casetta, B; Meneghello, A; Polo, F; Tartaggia, S; Toffoli, G | 1 |
| Celia, C; Cilurzo, F; Cosco, D; Costa, N; Di Marzio, L; Di Tullio, A; Fresta, M; Locatelli, M; Malatesta, L; Paolino, D | 1 |
| Choi, HG; Gautam, M; Jin, SG; Kim, JO; Ku, SK; Nguyen, HT; Oh, KT; Ou, W; Soe, ZC; Thapa, RK; Yong, CS | 1 |
| Hirao, J; Iguchi, T; Mori, K; Nishiya, T; Saitoh, W; Shirai, M; Takada, S; Tsuji, M | 1 |
| Deguchi, T; Hanaki, T; Ichikawa, T; Kobayashi, D; Masubuchi, M; Shibata, A; Takase, T; Yaguchi, T | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Ishikura, K; Mizukami, Y; Okuyama, H; Tamura, K | 1 |
| Hur, SK; Jo, S; Kim, D; Kim, KS; Whang, CH; Yoo, E | 1 |
| Chuma, M; Fujino, H; Fukushima, K; Hamano, H; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kirino, Y; Mitsui, M; Nakamura, T; Nimura, T; Okada, N; Takechi, K; Tamaki, T; Teraoka, K; Yanagawa, H; Zamami, Y | 1 |
| Benoit, LT; Cochran, JH; Emmerton, KK; Lau, UY; Senter, PD; Stevens, NS; Zaval, M | 1 |
| Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC | 1 |
| Deng, W; Hu, R; Liang, L; Shen, L; Wang, Y; Yang, L; Yang, W; Yao, Y; Zhang, H; Zhang, J; Zhang, Z; Zhou, M | 1 |
| Jiang, S; Lan, S; Ma, D; Mao, D; Shi, K; Yang, X | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Atis, S; Combès, E; Del Rio, M; Gabanou, M; Gongora, C; Jarlier, M; Larbouret, C; Martineau, P; Mollevi, C; Pérez-Gracia, E; Torro, A; Tosi, D; Vié, N | 1 |
| Chi, Y; Jiang, ZC | 1 |
| Aliberti, C; Carandina, R; Felicioli, A; Fiorentini, G; Guadagni, S; Mulazzani, L; Sarti, D | 1 |
| Ding, HF; Huang, YQ; Ji, M; Qian, G; Song, YS; Wang, JL; Yuan, JD; Zhang, Y | 1 |
| Fujita, KI; Ishida, H; Iwai, S; Kamei, D; Kubota, Y; Sasaki, Y; Taki-Takemoto, I; Tsuboya, A | 1 |
| Eskens, FALM; Groot Koerkamp, B; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Akahori, D; Amano, T; Hasegawa, H; Kakutani, T; Koda, K; Kunimoto, Y; Matsui, T; Niwa, H; Ozawa, Y; Suda, T; Tanahashi, M; Yamada, K; Yokomura, K | 1 |
| Bengrine, L; Collot, T; Fumet, JD; Ghiringhelli, F; Klopfenstein, Q; Vincent, J | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W | 1 |
| Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
| Bi, Y; Lee, RJ; Li, C; Li, L; Sun, Y; Teng, L; Wang, M; Wang, X; Xie, J | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Freiberg-Richter, J; Giessen-Jung, C; Graeven, U; Heinemann, V; Held, S; Jung, A; Kirchner, T; Modest, DP; Peuser, B; Peveling Genannt Reddemann, C; Schenk, M; Schuch, G; Schwaner, I; Stahler, A; Stintzing, S; Uhlig, J; Vehling-Kaiser, U | 1 |
| Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD | 1 |
| Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
| Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM | 1 |
| Deng, T; Jiang, ZX; Mao, X; Xiao, Y; Yang, Z; Zheng, X | 1 |
| Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O | 2 |
| Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
| Abramson, VG; Bardia, A; Diamond, JR; Goldenberg, DM; Iannone, R; Isakoff, SJ; Kalinsky, K; Mayer, IA; Moroose, RL; O'Shaughnessy, J; Rugo, HS; Santin, AD; Shah, NC; Sharkey, RM; Sweidan, AM; Tolaney, SM; Vahdat, LT; Washkowitz, S; Wegener, WA | 1 |
| Gallego, I; García, G; García-Alfonso, P; Lloansí, A; Muñoz, A; Ortega, L; Sandoval, C; Torres, G | 1 |
| Bang, OS; Hong, S; Kim, HY; Kim, J; Kim, NS; Kim, YA; Shin, S | 1 |
| Argilés Martínez, G; Carmona-Bayonas, A; Castañón López, C; Fernández Montes, A; Gallego Plazas, J; García Paredes, B; Gutiérrez Abad, D; Jiménez Fonseca, P; Juez Martel, I; Llorente Ayala, B; López Doldán, MC; López Flores, M; López López, C; López Muñoz, AM; Martínez de Castro, E; Páez López, D; Sánchez Cánovas, M; Tobeña Puyal, M | 1 |
| Ishigame, T; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Suzushino, S; Tsukida, S | 1 |
| Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L | 1 |
| Auerbach, C; Cheron, R; Natarajan, E; Pashankar, F | 1 |
| Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A | 1 |
| Gong, C; Hu, M; Huang, X; Lin, Y; Shu, Y; Song, L; Wu, Q; Xie, Y; Zeng, A | 1 |
| Kanno, M; Kichikawa, K; Koyama, F; Marugami, N; Masada, T; Nishiofuku, H; Otsuji, T; Sato, T; Sho, M; Tanaka, T; Tatsumoto, S | 1 |
| Chen, P; Gu, N; Ji, M; Sun, C; Wang, Z; Xing, J; Zhang, H; Zhang, X; Zhou, G | 1 |
| Bafaloukos, D; Bamia, C; Bombolaki, I; Chatzopoulos, K; Chrisafi, S; Efstratiou, I; Fountzilas, G; Kafiri, G; Koliou, GA; Kotoula, V; Kourea, HP; Makatsoris, T; Mauri, D; Mavroeidis, L; Papadopoulou, K; Papakostas, P; Papatsibas, G; Pectasides, D; Pentheroudakis, G; Petraki, K; Samantas, E | 1 |
| Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB | 1 |
| Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L | 1 |
| Guo, T; Huang, S; Lai, R; Li, H; Liu, T; Shi, F; Sun, R; Tang, Z; Ying, Y | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Jiang, L; Liu, Y; Luan, X; Wang, L; Wang, S; Wang, X; Wang, Z; Xia, Y; Zhang, Z | 1 |
| Alessandroni, P; Bergamo, F; Borelli, B; Catalano, V; Cremolini, C; Falcone, A; Giordani, P; Graziano, F; Intini, R; Lonardi, S; Mattioli, R; Negri, F; Rocchi, MBL; Rossini, D; Santini, D; Sarti, D; Stragliotto, S; Vincenzi, B; Zagonel, V | 1 |
| Ashley, GW; Fontaine, SD; Reid, R; Santi, AD; Santi, DV; Smith, PC | 1 |
| Antista, M; Barault, L; Corallo, S; de Braud, F; Di Bartolomeo, M; Di Maio, M; Di Nicolantonio, F; Farina, G; Fucà, G; Gori, S; Guarini, V; Lobefaro, R; Lonardi, S; Longarini, R; Macagno, M; Martinetti, A; Milione, M; Morano, F; Mosconi, S; Murgioni, S; Pagani, F; Palermo, F; Perrone, F; Petrelli, F; Pietrantonio, F; Raimondi, A; Randon, G; Rimassa, L; Sartore-Bianchi, A; Tamborini, E; Tomasello, G | 1 |
| Brenner, AJ; Chiou, J; Gruslova, A; Pandey, R; Tiziani, S | 1 |
| Chang, S; Chen, Z; Kong, R; Liu, J; Piao, L; Xu, X | 1 |
| Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS | 1 |
| Altwerger, G; Azodi, M; Bellone, S; Bianchi, A; Bonazzoli, E; Buza, N; Han, C; Huang, GS; Hui, P; Lopez, S; Manara, P; Manzano, A; Menderes, G; Perrone, E; Ratner, E; Santin, AD; Scambia, G; Schwartz, PE; Silasi, DA; Tymon-Rosario, J; Zammataro, L; Zeybek, B | 1 |
| Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R | 1 |
| Boeing, T; Cury, BJ; da Silva, LM; de Andrade, SF; de Souza, P; Desreumax, P; Dubuqoy, L; Ferreira Dos Anjos, M; Mariano, LNB; Quintão, NLM; Somensi, LB; Speca, S | 1 |
| Abe, S; Hatano, A; Ikeda, Y; Izumi, T; Miyamoto, L; Okuno, H; Tsuchihashi, Y; Tsuchiya, K; Tsunematsu, H; Yamane, M; Yasuoka, T | 1 |
| Cai, X; Chen, Y; Fang, H; Fang, W; Li, H; Li, Q; Lin, X; Ma, D; Nie, Y; Peng, C; Shen, L; Wang, N; Wang, W; Xu, R; Zhao, Q; Zhu, B; Zhu, L | 1 |
| Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Chen, S; Feng, C; Guo, C; Hua, L; Huang, H; Li, G; Lin, Z; Mo, Q; Shen, Y; Wei, M; Xu, J | 1 |
| Aranda, E; Balbín, M; Bando, I; Bellosillo, B; Calle, SG; Díaz-Rubio, E; García-Alfonso, P; Llovet, P; Lopez, C; Martínez, A; Mediero, B; Moral, VM; Orden, V; Ortiz-Morales, MJ; Palanca, S; Peligros Gomez, MI; Quintero, G; Salud, A; Sastre, J; Viéitez, JM | 1 |
| Li, J; Lu, M; Peng, Z; Shen, L; Wang, X; Zhang, P; Zhang, X; Zhou, J | 1 |
| Beijnen, JH; Gan, C; Martínez-Chávez, A; Rosing, H; Schinkel, AH; Wang, Y | 1 |
| Bang, YJ; Chung, HC; Iwasa, S; Kamio, T; Kawaguchi, Y; Kawakami, H; Kojima, A; Lee, J; Ryu, MH; Saito, K; Sakai, D; Shitara, K; Sugihara, M; Sugimoto, N; Yabusaki, H; Yamaguchi, K | 1 |
| Asaro, F; Fortuna, S; Garziera, M; Geremia, S; Scarabel, L; Toffoli, G | 1 |
| Ueno, M | 1 |
| Hartmann, G; Holdenrieder, S; Kalthoff, S; Paulusch, S; Rupp, A; Strassburg, CP | 1 |
| Aprile, G; Belfiore, A; Boccaccino, A; Brich, S; Cattaneo, L; Centonze, G; Cillo, U; Corallo, S; Cremolini, C; De Braud, F; Falcone, A; Fassan, M; Fontanini, G; Germani, MM; Lonardi, S; Loupakis, F; Marmorino, F; Milione, M; Morano, F; Morelli, L; Moretto, R; Pietrantonio, F; Prisciandaro, M; Rossini, D; Urbani, L | 1 |
| Kasi, A; Paluri, RK; Posey, JA; Young, C | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Fischer von Weikersthal, L; Fraccaroli, A; Haas, M; Heinemann, V; Heinrich, K; Held, S; Holch, JW; Jung, A; Kullmann, F; Modest, DP; Moehler, M; Scheithauer, W; Schulz, C; Stintzing, S; von Einem, JC | 1 |
| Chen, JB; Chen, TL; Huang, CW; Huang, HY; Ke, TW; Lin, YW; Sung, YC; Tang, HC; Tsai, CS; Tsai, HL; Wang, HM; Wang, JH; Wang, JY; Wu, CC | 1 |
| Borg, C; Chevalier, H; Edeline, J; El Hajbi, F; Hammel, P; Lièvre, A; Meurisse, A; Neuzillet, C; Peugniez, C; Turpin, A; Vernerey, D; Vienot, A | 1 |
| Balachandran, VP; Boerner, T; Buisman, FE; D'Angelica, MI; Drebin, JA; Gonen, M; Jarnagin, WR; Kemeny, NE; Kingham, TP; Narayan, RR; Seier, K; Srouji, RM; Wei, A | 1 |
| Foster, L; Lamarca, A; Satyadas, T; Siriwardena, A; Valle, JW | 1 |
| Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A | 1 |
| Al-Rajabi, R; Carroll, E; Diab, O; Kasi, A; Melancon, T; Rawlley, B | 1 |
| Bhargava, P; Choudhari, A; Goel, M; Gupta, S; Jadhav, P; Mandavkar, S; Ostwal, V; Parulekar, M; Patkar, S; Ramaswamy, A; Sharma, A; Srinivas, S | 1 |
| Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E | 1 |
| Baloni, P; Bergey, D; Hood, LE; Jabbari, N; Kenerson, HL; Lausted, C; Meng, C; Pillarisetty, VG; Sullivan, KM; Tian, Q; Yan, X; Yeung, RS | 1 |
| Chen, X; Fang, S; Han, W; Jin, J; Li, T; Wan, J; Wang, H; Wang, Y; Xie, B; Xie, H; Yang, B; Ying, K | 1 |
| Ayukawa, H; Endo, S; Furuse, J; Furuta, T; Hirano, R; Kaneko, S; Kawai, K; Kobayashi, T; Minowa, Y; Nagashima, F; Naruge, D; Okano, N; Shibasaki, H; Yokokawa, A | 1 |
| Kang, J; Kim, SY; Kim, TW; Lee, JS; Morita, S; Muro, K; Park, YS; Sakamoto, J; Xu, RH | 1 |
| Bandyopadhyay, A; Behera, D; Sharma, S; Singh, N | 1 |
| Ando, K; Bharti, A; Fujimoto, Y; Hisamatsu, Y; Hu, Q; Jogo, T; Kimura, Y; Mori, M; Nakanishi, R; Oki, E | 1 |
| Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S | 1 |
| Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Cheng, L; Du, Y; He, W; Li, X; Wang, J; Wang, T | 1 |
| Ghaedi, K; Majd, A; Miralaei, N; Peymani, M; Safaei, M | 1 |
| Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S | 1 |
| Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF | 1 |
| Jiang, Z; Li, Y; Luo, W; Wang, C; Yu, C; Zhang, H; Zhang, W | 1 |
| Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
| Chen, Y; Cheng, Z; Huang, Y; Lu, W; Wang, L; Yang, B; Yu, J | 1 |
| Boku, N; Esaki, T; Izawa, N; Kawakami, K; Kawakami, T; Komoda, M; Makiyama, A; Masuishi, T; Mitani, S; Moriwaki, T; Nagashima, K; Nakajima, TE; Okuda, H; Tsuji, Y; Yamamoto, S; Yamamoto, Y; Yamazaki, K | 1 |
| Chen, Y; Huang, Q; Li, K; Liu, X; Shen, Y; Sui, M; Wang, H; Zhang, Q; Zhu, Q | 1 |
| Dou, W; Gao, R; Wang, Z; Yue, B | 1 |
| Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N | 1 |
| Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A | 1 |
| Innocenti, F; Karas, S | 1 |
| Aranda, E; Díaz, IA; Élez, E; García-Alfonso, P; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Martínez de Castro, E; Ortiz-Morales, MJ; Polo, E; Riesco, MDC; Rodriguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, J; Toledano-Fonseca, M; Valladares-Ayerbes, M | 1 |
| Arifa, RDN; Barcelos, LS; Brito, CB; Cassini-Vieira, P; da Silva, JM; da Silva, TA; de Paula, TP; Fagundes, CT; Lima, RL; Menezes-Garcia, Z; Queiroz-Junior, CM; Souza, DG; Teixeira, MM; Vilas Boas, FA | 1 |
| Ito, Y; Kobuchi, S; Sakaeda, T; Sakai, S | 1 |
| Bins, S; Creemers, GJ; de Man, FM; de With, M; Deenen, MJ; Deiman, BALM; Gelderblom, H; Guchelaar, HJ; Houterman, S; Houtsma, D; Hövels, AM; Hulshof, EC; Koolen, SLW; Laven, MMJ; Luelmo, SAC; Mathijssen, RHJ; McLeod, HL; Shulman, K; Swen, JJ; Thijs, AMJ; van Schaik, RHN | 1 |
| Iga, N; Ishizaki, M; Kawai, H; Miyauchi, S; Mizuno, D; Nishi, H; Suemori, K; Uno, F; Yamashita, K; Yoshida, R | 1 |
| Coburn, N; David, E; Kiss, A; Ni, T; Pugash, R; Raphael, MJ; Voizard, N | 1 |
| Dai, WP; Jiao, XD; Li, XN; Liu, K; Qin, BD; Qin, WX; Sun, L; Wang, MM; Wang, Z; Ye, CY; Yuan, LY; Zang, YS | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Huang, CW; Li, CC; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ | 1 |
| Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T | 1 |
| Andre, N; Beccaria, K; Bertozzi, AI; Boddaert, N; Bourdeaut, F; Butel, T; Cuinet, A; De Carli, E; de Marcellus, C; Dufour, C; Figarella-Branger, D; Fouyssac, F; Grill, J; Leblond, P; Pasqualini, C; Puget, S; Robert, MP; Tauziède-Espariat, A; Valteau-Couanet, D; Varlet, P | 1 |
| Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Agarwal, N; Mathew Thomas, V; Swami, U; Tripathi, N | 1 |
| Coward, LU; Crane, RA; Gorman, GS; Grubb, ES | 1 |
| Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H | 1 |
| Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S | 1 |
| Lin, GH; Wang, BC; Xiao, BY | 1 |
| Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ | 1 |
| Balachander, A; Biswas, SK; Chen, S; Choo, SP; Chowbay, B; Guo, YA; Lam, J; Lee, B; Lee, SS; Leong, WF; Lim, TKH; Ng, M; Ong, WS; Seet, A; Skanderup, AJ; Sutiman, N; Tai, D; Yeong, J | 1 |
| Chityala, PK; Ghose, R; Li, L; Lin, Z; Tao, G | 1 |
| Crocenzi, TS; Driscoll, M; Hansen, P; Kelly, LR; Martin, RCG; McMasters, KM; Philips, P; Rocha, F; Scoggins, CR; Sharma, VR; Simo, KA; Tatum, CM | 1 |
| Kong, L; Rong, L; Wang, M | 1 |
| Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y | 1 |
| Antunes, MV; Basso, J; Hahn, RZ; Ibaldi, MR; Linden, R; Pavei, CC; Schaefer, VD; Schwartsmann, G | 1 |
| Li, Y; Shi, W; Wu, D; Yu, H; Zhang, G; Zhao, D; Zhong, B | 1 |
| Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S | 1 |
| Giuliani, J | 1 |
| Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H | 1 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
| Ahmed, MA; Basaran, M; Dogan, I; Iribas, A | 1 |
| Ikushiro, S; Maruo, Y; Mimura, Y; Tagawa, K | 1 |
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S | 1 |
| Bardia, A; Ciruelos, E; Cortes, J; Dalenc, F; Delaney, R; Fu, O; Jhaveri, KL; Lin, L; Loirat, D; Marmé, F; Pardo, PG; Rugo, HS; Schmid, P; Tolaney, SM; Trédan, O; Verret, W | 1 |
| Barzi, A; McCombs, JS; Zheng, H | 1 |
| Afable, M; Gathirua-Mwangi, W; Khan, T; Wu, Y; Yang, T | 1 |
| Furlanetto, J; Loibl, S; Marmé, F | 1 |
| Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA | 1 |
| García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P | 1 |
| Meyers, PA; Slotkin, EK | 1 |
| Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A | 1 |
| Jiang, W; Liu, Q; Yang, D; Yang, SB | 1 |
| Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S | 1 |
| Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW | 1 |
| Betrian, S; Brac De La Perriere, C; Chaltiel, L; Delord, JP; Sarradin, V | 1 |
| Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M | 1 |
| Buunk, AM; de Boer-Veger, NJ; Deenen, MJ; Deneer, VHM; Guchelaar, HJ; Houwink, EJF; Hulshof, EC; Nijenhuis, M; Risselada, A; Rongen, GAPJM; Soree, B; Swen, JJ; Touw, DJ; van der Weide, J; van Schaik, RHN; van Westrhenen, R | 1 |
| Brien, DO; Drummond, DC; Hayes, ME; Huang, ZR; Kesper, K; Kirpotin, DB; Moore, D; Noble, CO; Wani, K | 1 |
| André, N | 1 |
| Chang, JS; Chen, LT; Chiang, NJ; Hwang, DY; Li, YJ; Shan, YS; Shen, BN; Su, YY; Wang, YW | 1 |
| Abu, YF; Chen, C; Meng, J; Ramakrishnan, S; Roy, S; Tao, J; Xie, Y; Yan, Y; Zhang, Y; Zhou, Y | 1 |
| Chen, BS; Cheng, TC; Chiang, CH; Chiu, JH; Hsieh, CL; Luan, YZ; Ma, KS; Peng, CM | 1 |
| Cai, Z; Guo, W; Liang, X; Liu, K; Sun, X; Tang, X; Xie, L; Xu, J | 1 |
| Chen, Y; Du, C; Jiang, X; Li, S; Luo, Y; Wang, Y; Wu, L; Xie, Y; Zhang, R | 1 |
| Fushiki, K; Hamauchi, S; Kawakami, T; Onozawa, Y; Oshima, K; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Gao, F; Guo, J; Li, X; Wang, T; Wu, M; Zhang, F | 1 |
| Chang, PY; Chang, WC; Chen, PK; Chiu, SH; Hsu, TF; Ko, KH; Lin, HH | 1 |
| Duan, HQ; Duan, XC; Li, XZ; Liu, JT; Qin, N; Zhong, ZX | 1 |
| He, Z; Jia, L; Wang, Y; Yang, J | 1 |
| Fukuda, M; Hosoe, T; Ikarashi, N; Kamei, J; Kon, R; Miyaoka, K; Noguchi, H; Sakai, H; Teshima, Y; Tomimoto, R; Yamaguchi, A; Yamaguchi, T | 1 |
| Chen, JH; Huang, CI; Huang, YK; Lee, HM; Lin, PM; Su, YC | 1 |
| Dai, QL; Jia, HJ; Rui Bai, S; Wang, XB; Xia, J; Yue He, S; Zhou, M | 1 |
| Kumar, S; Sherman, MY | 1 |
| Chen, Y; Dai, Y; Ye, T; Zhang, Y | 1 |
| Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y | 1 |
| Li, J; Qin, J; Sun, M; Wang, D; Zhen, Y | 1 |
| Barlesi, F; Gazzah, A; Mahjoubi, L; Parisi, C | 1 |
| Alexandrov, IA; Gahramanov, V; Gerlitz, G; Kaczmarczyk, L; Kumar, S; Patel, S; Salmon-Divon, M; Sherman, MY; Yaglom, J | 1 |
| Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C | 1 |
| Chen, M; Han, J; He, G; Huang, R; Li, W; Liu, J; Song, Q; Xu, Y; Yu, Z; Zhang, C; Zhao, L | 1 |
| Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K | 1 |
| Chang, CK; Chiu, PF; Hsu, LC; Huang, PS; Liang, PH; Lin, CS; Lin, YY; Yang, HY; Yu, LC | 1 |
| Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K | 1 |
| Dai, Y; Li, Y; Qian, M | 1 |
| Deenen, MJ; Gelderblom, H; Guchelaar, HJ; Hulshof, EC; Mathijssen, RH; Peeters, SL; Swen, JJ; Thijs, AM | 1 |
| Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Jimbo, R; Kobayashi, Y; Sano, T; Sato, R; Sato, T; Yokoyama, J | 1 |
| Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Kimura, M; Kotani, M; Nakabori, T; Nozaki, K; Ohkawa, K; Seiki, Y; Takada, R; Takagi, M; Uehara, H; Urabe, M; Watsuji, K; Yagi, T; Yamai, T | 1 |
| Cao, Z; Chen, L; Chen, S; Chen, Y; Huang, W; Jiao, S; Li, Z; Liu, Y; Sun, L; Wang, W; Yang, Z; Zhang, L | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Bins, S; de Neijs, MJ; de With, M; Kloet, E; Mathijssen, RHJ; Matic, M; Oomen-de Hoop, E; van Doorn, L; van Meerten, E; van Schaik, RHN; van Veggel, A | 1 |
| Kim, KP; Lee, BK; Yoon, S | 1 |
| Mellinghoff, IK | 1 |
937 review(s) available for camptothecin and irinotecan
| Article | Year |
|---|---|
Topoisomerase I inhibitors: Challenges, progress and the road ahead.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Irinotecan; Poisons; Topoisomerase I Inhibitors | 2022 |
[DNA topoisomerase inhibitor].
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan | 1992 |
Clinical trials with the topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1992 |
[Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1991 |
[Mechanisms of acquired resistance to DNA topoisomerase I inhibitors].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Resistance; Humans; Irinotecan; Leukemia, Experimental; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1991 |
[DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dogs; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Mice; Neoplasms, Experimental; Topoisomerase I Inhibitors | 1991 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
[Treatment of adult T-cell leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Leukemia, T-Cell; Pentostatin; Piperazines; Prednisone; Vincristine | 1995 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
[Chemotherapy of uterine endometrial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Invasiveness; Paclitaxel | 1995 |
Clinical studies of CPT-11 in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Uterine Neoplasms | 1995 |
New chemotherapeutic agents in non-small-cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
New antineoplastic agents in lung cancer 1988-1993.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Teniposide; Vinblastine; Vinorelbine | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1995 |
[Recent advance in chemotherapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids | 1994 |
New anticancer agents.
Topics: Adenine; Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Imides; Indoles; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pyridines; Topotecan; Vinblastine; Vinorelbine | 1994 |
DNA topoisomerase inhibitors.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
Chemotherapy of advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Digestive System Neoplasms; Double-Blind Method; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Immunologic Factors; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 1994 |
[Therapeutic strategy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
[Phase III trial of new anticancer agents from a medical oncologists viewpoint].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Protocols; Clinical Trials, Phase III as Topic; Humans; Irinotecan; Neoplasms; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 1995 |
[Strategies for the overcoming of drug resistance].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance; Humans; Irinotecan; Neoplasms; Tumor Cells, Cultured | 1995 |
[New promising anticancer drugs for lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Clinical trials of new antitumor drugs in hematopoietic malignancies].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Doxorubicin; Ethics, Medical; Humans; Idarubicin; Irinotecan; Leukemia; Lymphoma | 1994 |
[New antitumor drugs for malignant lymphoma: a review].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carubicin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Piperazines | 1994 |
Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1994 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
New directions for chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
[Recent development of new anticancer drugs in Japan].
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Cisplatin; Cytarabine; Irinotecan; Methotrexate; Paclitaxel; Tretinoin; Tubulin Modulators; Vinblastine; Vinorelbine | 1993 |
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan | 1993 |
[Irinotecan hydrochloride (CPT-11)].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Leukemia L1210; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1994 |
Topoisomerase I inhibitors: topotecan and irenotecan.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1994 |
The current status of camptothecin analogues as antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; DNA Topoisomerases, Type I; Forecasting; Humans; Irinotecan; Topotecan | 1993 |
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
Recent clinical advances with camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan | 1995 |
[Current status and problems in clinical trial for new anticancer drug in Japan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Informed Consent; Irinotecan; Japan; Neoplasms | 1996 |
[Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Quality Control | 1996 |
[Development of new anti-cancer agents in Europe].
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Europe; Female; France; Humans; Irinotecan; Japan; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1996 |
Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Drug Resistance; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms, Experimental; Topoisomerase I Inhibitors | 1996 |
CPT-11: an original spectrum of clinical activity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Topoisomerase I Inhibitors | 1996 |
CPT-11: clinical experience in phase I studies.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 1996 |
Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Topoisomerase I Inhibitors | 1996 |
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors | 1996 |
Role of chemotherapy for advanced colorectal cancer: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
[Recent advance in chemotherapy for advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Quinazolines; Remission Induction; Thiophenes; Thymidylate Synthase | 1996 |
[Chemotherapy of solid tumor].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Paclitaxel; Survival Rate | 1996 |
Current perspectives on camptothecins in cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
Irinotecan (CPT-11): pharmacology and clinical applications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Neoplasms, Experimental | 1996 |
The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms | 1996 |
New systemic drugs in the treatment of gastrointestinal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Docetaxel; Gastrointestinal Neoplasms; Humans; Irinotecan; Paclitaxel; Quinazolines; Taxoids; Thiophenes; Thymidylate Synthase | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Europe; Humans; In Vitro Techniques; Irinotecan; Japan; Tissue Distribution; Treatment Outcome; United States | 1996 |
Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan | 1996 |
Future directions for clinical research with CPT-11 (irinotecan).
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Research; Topoisomerase I Inhibitors | 1996 |
Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 1996 |
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Middle Aged; Neutropenia | 1996 |
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan | 1996 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Clinical pharmacology and pharmacodynamics of irinotecan. A review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan | 1996 |
Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Irinotecan; Mice | 1996 |
Topoisomerase-I inhibitors in the management of colon cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1996 |
The current status of irinotecan (CPT-11) in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Irinotecan; Neoplasms; United States; United States Food and Drug Administration | 1996 |
CPT-11. The European experience.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Europe; Humans; Irinotecan; Neoplasms | 1996 |
Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Irinotecan; Japan; Neoplasms | 1996 |
[Apoptosis and chemosensitivity].
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Genes, bcl-2; Humans; Irinotecan; Neoplasms; Tumor Cells, Cultured | 1997 |
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Mutation; Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
Chemotherapy for gastric cancer in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Stomach Neoplasms | 1997 |
[Chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Paclitaxel | 1996 |
[Chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic | 1996 |
CPT-11: the European clinical development.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | 1996 |
Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drugs, Investigational; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Metalloendopeptidases; Platinum Compounds; Thymidylate Synthase; Topoisomerase I Inhibitors | 1997 |
[A case of solitary metastatic splenic tumor of ovarian carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Hysterectomy; Irinotecan; Ovarian Neoplasms; Splenectomy; Splenic Neoplasms | 1997 |
Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Clinical pharmacokinetics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[New anti-cancer drugs for gastrointestinal cancers].
Topics: Amino Acids; Antidotes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Irinotecan; Leucovorin; Paclitaxel; Taxoids | 1997 |
[Promising new drugs for gynecological cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan | 1997 |
Topoisomerase I inhibitors: review and update.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Continuing the fight against advanced colorectal cancer: new and future treatment options.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Chemotherapy of gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Methotrexate; Stomach Neoplasms | 1998 |
DNA topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Gastrointestinal Diseases; Humans; Irinotecan; Neutropenia; Patient Care Planning; Topoisomerase I Inhibitors | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Hospitalization; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Pharmacology of irinotecan.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Humans; Irinotecan | 1998 |
Irinotecan in the first-line treatment of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans; Irinotecan | 1998 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; North America | 1998 |
European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Therapy, Combination; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycins | 1998 |
Alternative dosing schedules for irinotecan.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan | 1998 |
Gastrointestinal toxicity or irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Diarrhea; Gastrointestinal Diseases; Humans; Irinotecan | 1998 |
Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; Irinotecan; Lung Neoplasms | 1998 |
Irinotecan in cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 1998 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
Irinotecan and cisplatin in upper gastrointestinal malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Irinotecan | 1998 |
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal Agents; Humans; Irinotecan; Octreotide; Practice Guidelines as Topic | 1998 |
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Topics: Animals; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biotransformation; Camptothecin; Carrier Proteins; Glucuronates; Humans; Irinotecan; Liver; Rats | 1998 |
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1998 |
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Paclitaxel; Topoisomerase I Inhibitors; Topotecan | 1998 |
An overview of topoisomerase I-targeting agents.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Irinotecan; Liver Neoplasms; Topoisomerase I Inhibitors; Treatment Failure; Trimetrexate | 1998 |
Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Humans; Irinotecan; Neoplasm Metastasis; Salvage Therapy; Topoisomerase I Inhibitors | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia | 1998 |
Camptothecins: a review of their development and schedules of administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan | 1998 |
[Irinotecan pharmacokinetics].
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Blood Proteins; Body Fluid Compartments; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Half-Life; Humans; Inactivation, Metabolic; Irinotecan; Liver; Mice; Models, Biological; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Prodrugs; Rats; Tissue Distribution; Topoisomerase I Inhibitors | 1998 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1998 |
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Europe; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Palliative Care; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Europe; Fluorouracil; Irinotecan; Japan; Leucovorin; Mitomycin; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Gastrointestinal cancer and oral anticancer agents].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Drug Combinations; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 1999 |
Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Fluorouracil; Humans; Irinotecan; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 1999 |
Novel anticancer drugs in Japan.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Japan; Neoplasms | 1999 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Oncology Nursing; Pancreatic Neoplasms | 1999 |
CPT-11 in gastrointestinal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Pancreatic Neoplasms; Stomach Neoplasms | 1999 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting.
Topics: Adenocarcinoma; Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colitis; Colonoscopy; Female; Gastrointestinal Hemorrhage; Humans; Intestinal Mucosa; Irinotecan; Liver Neoplasms; Middle Aged; Neoplasm Staging; Sigmoid Neoplasms; United States; United States Food and Drug Administration | 1999 |
Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms | 1999 |
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
Irinotecan in cancers of the lung and cervix.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Uterine Cervical Neoplasms | 1999 |
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1999 |
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
[New regimens for the treatment of gynecologic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 2000 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
[Adjuvant chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2000 |
DNA topoisomerase I poisons.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan | 1999 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Small-cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
[Pharmacology of camptothecin and its derivatives].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Irinotecan; Mutation; Topotecan | 1995 |
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2000 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Mitomycin; Stomach Neoplasms | 2000 |
[CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Irinotecan; Male; Neoplasms | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
Extensive small-cell lung cancer: a treatment overview.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2000 |
Irinotecan in small-cell lung cancer--Japanese trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Leucovorin; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2000 |
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2000 |
[Irinotecan hydrochloride for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Topoisomerase I Inhibitors | 2000 |
Novel chemotherapeutic agents in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Thymidylate Synthase | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Current treatment options for advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Colorectal cancer chemotherapy: irinotecan.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors | 2000 |
[Outpatient treatment for gastrointestinal tract cancer in the Department of Surgery].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Quality of Life | 2000 |
[Latest progress on chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2000 |
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Topics: Adenine; Antineoplastic Agents; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Imides; Irinotecan; Isoquinolines; Mercaptopurine; Methyltransferases; Naphthalimides; Organophosphonates; Oxidoreductases; Pharmacogenetics; Phenotype | 2000 |
The role of irinotecan in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Patient Selection; Topoisomerase I Inhibitors; Treatment Outcome | 1999 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
The role of new agents in advanced non-small-cell lung carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2000 |
The changing face of chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Thymidylate Synthase; Topoisomerase I Inhibitors | 2001 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Irinotecan; Lung Neoplasms | 2001 |
Determinants of prognosis and response to therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2001 |
Oxaliplatin: a new agent for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2001 |
Topoisomerase I targeting agents in small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; DNA Topoisomerases, Type I; Humans; Irinotecan; Lung Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors | 2001 |
Metabolism of CPT-11. Impact on activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Enzyme Inhibitors; Glucuronides; Humans; Irinotecan; Oxidation-Reduction; Prodrugs | 2000 |
Alternative administration of camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Routes; Enzyme Inhibitors; Humans; Irinotecan | 2000 |
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 2000 |
Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Stomach Neoplasms | 2000 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Irinotecan in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Paclitaxel; Topoisomerase I Inhibitors | 2000 |
Irinotecan in the management of patients with pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Irinotecan; Multicenter Studies as Topic; Pancreatic Neoplasms | 2000 |
Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Staging; Radiation Dosage; Radiotherapy, Adjuvant; Stomach Neoplasms | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2000 |
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2000 |
Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Radiation Dosage; Rectal Neoplasms; Treatment Outcome | 2000 |
Second-line therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Efficacy of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Treatment Outcome | 2000 |
Irinotecan in small-cell lung cancer: the US experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate; United States | 2001 |
Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Vindesine | 2001 |
Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids | 2001 |
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2001 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Irinotecan: summary and future directions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Forecasting; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; United States | 2001 |
Current status of irinotecan in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2001 |
New state of the art in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Survival Rate | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Treatment Outcome | 2001 |
Adjuvant therapy of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2001 |
Cisplatin and irinotecan in upper gastrointestinal malignancies.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Irinotecan | 2001 |
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms | 2001 |
Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Stomach Neoplasms | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[Platinum compounds in cancer therapy--past, present, and future].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Forecasting; Humans; Irinotecan; Medical Oncology; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum | 2001 |
[Chemotherapy of irinotecan (CPT-11) combined with cisplatin in patients with advanced gastric cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2001 |
[Irinotecan (CPT-11) therapy for advanced gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Humans; Irinotecan; Mitomycin; Stomach Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
[Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Endpoint Determination; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Quality of Life; Stomach Neoplasms | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
[New chemotherapies for colorectal cancer treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Irinotecan; Oxidoreductases, N-Demethylating; Prodrugs; Topoisomerase I Inhibitors | 2001 |
The emerging world role of irinotecan in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Drug Synergism; Humans; Irinotecan; Japan; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; United States | 2001 |
Irinotecan and radiation in combined-modality therapy for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2001 |
Role of topoisomerase I inhibitors in small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
Irinotecan-induced dysarthria.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia, Broca; Bone Neoplasms; Camptothecin; Dysarthria; Enzyme Inhibitors; Fatal Outcome; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Organoplatinum Compounds; Oxaliplatin; Premedication; Sigmoid Neoplasms | 2001 |
[Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
New adjuvant therapies for esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2001 |
Optimizing the use of irinotecan in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
[Standard therapy of CPT-11 for colorectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Salvage Therapy; Topoisomerase I Inhibitors | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
The development of camptothecin analogs in childhood cancers.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; HeLa Cells; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |
[Chemotherapy of colorectal carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Folic Acid; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2001 |
Quantitation of camptothecin and related compounds.
Topics: Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2001 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Prediction of the response of colorectal cancer to systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Trimetrexate; Uracil | 2001 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
New developments in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Humans; Irinotecan; Paclitaxel; Survival Rate | 2002 |
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; England; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes; Treatment Outcome; Wales | 2001 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel | 2002 |
Update on European adjuvant trials with irinotecan for colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Humans; Irinotecan; Survival Rate; Treatment Outcome | 2002 |
Irinotecan/thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Thalidomide | 2002 |
Capecitabine/irinotecan combination regimens in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan | 2002 |
Irinotecan therapy for small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Japan; Lung Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; United States | 2002 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Therapy; Humans; Incidence; Irinotecan; Japan; Lung Neoplasms; Radiation Pneumonitis; Radiotherapy; Thorax | 2002 |
[Irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2002 |
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
[New treatment strategy for stage III non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy; Taxoids; Treatment Outcome; Vinblastine | 2002 |
Irinotecan, cisplatin, and radiation in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Forecasting; Humans; Irinotecan | 2002 |
Irinotecan in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Irinotecan; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Topoisomerase I Inhibitors | 2002 |
Irinotecan for the treatment of cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Female; Gastrointestinal Diseases; Humans; Irinotecan; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2002 |
Combined-modality therapy for rectal cancer using irinotecan.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Preoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2002 |
Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Digestive System Surgical Procedures; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Preoperative Care; Prostaglandin-Endoperoxide Synthases; Rectal Neoplasms | 2002 |
Irinotecan in the treatment of small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Survival Rate | 2001 |
Therapeutic advances in the management of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Methotrexate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2001 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2002 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Palliative Care; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Treatment Outcome | 2002 |
[Randomized controlled trials in Japan--lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2002 |
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic | 2002 |
Camptothecin and taxane regimens for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Small Cell; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Irinotecan plus cisplatin in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2002 |
Current role of irinotecan in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Taxoids | 2002 |
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2002 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Resistance; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retreatment | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2001 |
Review of the role of CPT-11 in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Adjuvant therapy of colon cancer: a review.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging | 2002 |
Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2001 |
Chemoradiation with novel agents for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2002 |
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Topics: Animals; Apoptosis; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; NF-kappa B; Risk Assessment; Sensitivity and Specificity; Topoisomerase I Inhibitors | 2002 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
[A case of AFP-producing gastric cancer with multiple liver metastases responding to CPT-11 and cisplatin combination chemotherapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endonucleases; ErbB Receptors; Humans; Irinotecan; Lung Neoplasms; Predictive Value of Tests; Protein Biosynthesis; Proteins; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2002 |
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
Limited stage small cell lung cancer: treatment and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Treatment Outcome | 2003 |
Lessons learned from the irinotecan metabolic pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Biotransformation; Camptothecin; Carboxylic Ester Hydrolases; Carrier Proteins; Cytochrome P-450 CYP3A; Diarrhea; Glucuronides; Humans; Irinotecan; Oxidoreductases, N-Demethylating | 2003 |
The role of pemetrexed in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Folic Acid Antagonists; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Cancer pharmacogenomics: current and future applications.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA Adducts; DNA Repair; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Organoplatinum Compounds; Oxidoreductases; Pharmacogenetics; Polymorphism, Genetic; Thymidylate Synthase | 2003 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
Chemotherapy for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan | 2003 |
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Levamisole; Palliative Care; Quality-Adjusted Life Years; Quinazolines; Thiophenes | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 2003 |
[Chemotherapy for colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Pharmacogenetics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Neoplasms; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2003 |
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Glioma; Humans; Irinotecan; United States | 2003 |
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Radiotherapy | 2003 |
Rationale for mitomycin and irinotecan use in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mitomycin; Women's Health | 2003 |
Japanese ovarian trials: focus on irinotecan.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Japan; Ovarian Neoplasms; United States; Women's Health | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Syndrome | 2003 |
Optimal use of the combination of irinotecan and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan | 2003 |
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Survival Analysis | 2003 |
Irinotecan in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2003 |
Current treatments and future perspectives in colorectal and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2003 |
[Chemotherapy-induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Diarrhea; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2003 |
Advanced NSCLC: new cytostatic agents.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2003 |
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Celecoxib; Cisplatin; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2003 |
The global role of irinotecan in the treatment of lung cancer: 2003 update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vindesine | 2003 |
Tailoring chemotherapy in advanced colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Helicases; DNA Repair; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Platinum Compounds; Proteins; Thymidylate Synthase; Transcription Factors; Xeroderma Pigmentosum Group D Protein | 2003 |
Colorectal cancer: integrating oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides | 2003 |
Alternative schedules with irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2003 |
Induction therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Floxuridine; Fluorouracil; Forecasting; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quinazolines; Thiophenes | 2003 |
[Controversial issues in chemotherapy for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2003 |
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Reproducibility of Results | 2003 |
Pharmacology of intraperitoneal CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Risk Assessment; Sensitivity and Specificity | 2003 |
Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2003 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Life Style; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Neoplasm Invasiveness; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Prodrugs; Prognosis; Risk Factors | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2003 |
[Application and problems in hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interleukin-2; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy | 2003 |
[Home chemotherapy and outpatient treatment for metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Home Care Services; Humans; Infusions, Intravenous; Irinotecan; Levamisole; Liver Neoplasms; Middle Aged; Quality of Life | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; United States | 2003 |
[Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Prognosis; United States | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
[Radiotherapy for locally relapsed rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy, High-Energy; Rectal Neoplasms | 2003 |
[Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Informed Consent; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Receptors, Growth Factor; Rectal Neoplasms | 2003 |
Clinical studies of camptothecin and derivatives.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mutagens; Topotecan | 2003 |
Irinotecan (Campto) in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Irinotecan; Pancreatic Neoplasms | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Differentiation; Dacarbazine; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Signal Transduction; Temozolomide | 2003 |
[Chemotherapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Meta-Analysis as Topic; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2003 |
Palliative cytostatic treatment of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Mitomycin; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Survival Analysis; Uterine Cervical Neoplasms; Vindesine | 2003 |
Progress in treatment of small-cell lung cancer: role of CPT-11.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Neoplasms; Nurse-Patient Relations; Nursing Assessment; Nursing Methodology Research; Octreotide; Oncology Nursing; Quality of Life | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
[Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Staging; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2004 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadherins; Camptothecin; Carcinogens; Docetaxel; Fluorouracil; Gerbillinae; Herpesvirus 4, Human; Humans; Irinotecan; Lymphatic Metastasis; Mice; Mice, Transgenic; Models, Animal; Mutation; Neoplasm Staging; Neoplasms, Experimental; Rats; Stomach Neoplasms; Taxoids | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Survival Analysis; Survival Rate; United States | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
Chemotherapy-induced lung disease.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bleomycin; Busulfan; Camptothecin; Cyclophosphamide; Humans; Iatrogenic Disease; Interferons; Irinotecan; Lung Diseases; Methotrexate; Mitomycin; Nitrosamines; Respiratory Function Tests; Tretinoin | 2004 |
Chemotherapy of small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2004 |
[Combined treatment of esophageal cancer: a review].
Topics: Adenocarcinoma; Alcohol Drinking; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diet; Dihematoporphyrin Ether; Esophageal Neoplasms; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Palliative Care; Photochemotherapy; Platinum Compounds; Postoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Taxoids; Time Factors | 2004 |
[The guidelines for diagnostics and treatment of cervical cancer].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Palliative Care; Practice Guidelines as Topic; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors; Uterine Cervical Neoplasms | 2004 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
[A case of gastric metastasis of small cell cancer of the lung, regression of the gastric lesion after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Fatal Outcome; Gastroscopy; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Stomach Neoplasms | 2004 |
[Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
"Irinogenetics" and UGT1A: from genotypes to haplotypes.
Topics: Animals; Camptothecin; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan | 2004 |
Systemic treatment of advanced colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2004 |
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Current approaches to first-line treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Current status of second-line therapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy | 2004 |
Progress in the development of novel treatments for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
[New therapy options in colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2004 |
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan | 2004 |
Developments in combination chemotherapy for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pyrimidines; Stomach Neoplasms; Taxoids | 2004 |
Integration of novel agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Humans; Irinotecan; Vascular Endothelial Growth Factor A | 2004 |
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronides; Glucuronosyltransferase; Humans; Intestines; Irinotecan; Loperamide; Topoisomerase I Inhibitors | 2004 |
Pharmacogenomics and stomach cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Humans; Irinotecan; Pharmacogenetics; Stomach Neoplasms; Taxoids | 2004 |
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
New options and old dilemmas in the treatment of patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Signal Transduction | 2004 |
Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Role of DNA mismatch repair in apoptotic responses to therapeutic agents.
Topics: Alkylating Agents; Antineoplastic Agents; Apoptosis; Base Pair Mismatch; Camptothecin; Cisplatin; DNA Adducts; DNA Repair; Floxuridine; Fluorouracil; Guanine Nucleotides; HCT116 Cells; Humans; Irinotecan; Radiation, Ionizing; Thionucleotides | 2004 |
Pharmacogenetics of irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Pharmacogenetics | 2004 |
Current perspectives in the treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2004 |
Palliative chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epirubicin; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Treatment Outcome | 2004 |
[Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Irinotecan; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytokines; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Hematopoiesis; Humans; Irinotecan; Leukopenia; Lymphocyte Activation; Mice; Nausea; Peripheral Nervous System Diseases; Phytotherapy; Thrombocytopenia; Vomiting; Weight Loss | 2004 |
Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Which drug combination for colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Combined Modality Therapy; ErbB Receptors; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2004 |
[Colorectal cancer: current treatment options].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Fluorouracil; Humans; Irinotecan; Mass Screening; Organoplatinum Compounds; Oxaliplatin; Risk; Survival Rate | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2004 |
Pemetrexed in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Folic Acid Antagonists; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2004 |
[Topoisomerase I inhibitor (irinotecan hydrochloride)].
Topics: Antineoplastic Agents, Phytogenic; Biomarkers; Camptothecin; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Humans; Immunohistochemistry; Irinotecan; Prodrugs; Reference Values | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life; Survival Rate; Tegafur; Uracil | 2005 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Combined-modality therapy of rectal cancer with irinotecan-based regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Sensitivity and Specificity; Toxicogenetics | 2004 |
Systemic therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Prodrugs; Pyridines | 2005 |
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan | 2005 |
Toxicity of the topoisomerase I inhibitors.
Topics: Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Renal Insufficiency; Topoisomerase I Inhibitors; Topotecan | 2005 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
Adjuvant therapy of colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2005 |
Combined modality treatment for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Transforming Growth Factor alpha | 2005 |
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genes, p53; Genes, ras; Genomic Instability; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Thymidylate Synthase | 2005 |
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
[Chemotherapy of advanced stomach cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2004 |
Small-cell lung cancer: current therapy and novel agents.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis | 2005 |
Advances in colon cancer chemotheapy: nursing implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Community Health Nursing; Deoxycytidine; Drug Monitoring; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Nurse's Role; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2005 |
[Colon cancer: molecular markers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Feces; Fluorouracil; Genes, ras; Genes, Tumor Suppressor; Genetic Markers; Humans; Irinotecan; Microsatellite Repeats; Mutation; Oncogenes; Polymerase Chain Reaction; Prognosis; Prospective Studies; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Critical evaluation of current treatments in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Medical Oncology; Neoplasm Metastasis; Vascular Endothelial Growth Factors | 2005 |
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quinazolines; Thiophenes; United Kingdom | 2005 |
New combinations in metastatic colorectal cancer: what are our expectations?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
Benefit-risk assessment of irinotecan in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index | 2005 |
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
New chemotherapeutic strategies in colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2005 |
Cetuximab in previously treated colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Salvage Therapy | 2005 |
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2005 |
Perioperative adjunctive treatment in the management of operable gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Adjuvant therapy in colon cancer: which treatment in 2005?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2005 |
Current therapies for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
(Neo-)adjuvant treatments in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2005 |
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2005 |
Gastric cancer. Treatment of advanced disease and new drugs.
Topics: Antineoplastic Agents; Camptothecin; Docetaxel; Drug Therapy; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2005 |
Novel agents that potentially inhibit irinotecan-induced diarrhea.
Topics: Animals; Antidiarrheals; Camptothecin; Diarrhea; Enzyme Inhibitors; Humans; Irinotecan | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
[Treatment of small cell lung cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Role of genomic markers in colorectal cancer treatment.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; Oncogenes; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
[Childhood rhabdomyosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Humans; Irinotecan; Radiotherapy Dosage; Rhabdomyosarcoma; Risk; Vincristine | 2005 |
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine | 2005 |
Cetuximab therapy and symptomatic hypomagnesemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fatigue; Humans; Hypocalcemia; Incidence; Irinotecan; Magnesium; Magnesium Deficiency; Male; Severity of Illness Index | 2005 |
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Fluorouracil; Forecasting; Gene Expression Profiling; Genomics; Humans; Irinotecan; Loss of Heterozygosity; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
New developments in the treatment of esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Esophageal Neoplasms; Esophagectomy; Forecasting; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Topoisomerase II Inhibitors | 2004 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomedical Research; Camptothecin; Chromosomal Instability; Chromosomes, Human, 16-18; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Clinical Trials as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA, Neoplasm; Fluorouracil; Forecasting; Genes, Tumor Suppressor; Genetic Markers; Humans; Immunohistochemistry; Irinotecan; Molecular Biology; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Prognosis; Stomach Neoplasms | 2005 |
[Which role do new therapeutic options play in palliative care of colorectal cancer?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
[Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents].
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Humans; Irinotecan; Neoplasm Proteins; Polymorphism, Single Nucleotide | 2005 |
Metastatic colorectal cancer: is there one standard approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Clinical pharmacogenetics of irinotecan (CPT-11).
Topics: Camptothecin; Humans; Irinotecan; Pharmacogenetics | 2005 |
Evolving role of irinotecan in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms | 2003 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Vitamin B Complex | 2005 |
Pharmacogenetics of irinotecan metabolism and transport: an update.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmacogenetics; Phenotype; Prodrugs | 2006 |
[Drug therapy of patients with metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Prognosis; Survival Rate | 2005 |
[SNPs associated with adverse effects].
Topics: Antineoplastic Agents; Camptothecin; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Pyrimidines; Treatment Outcome | 2005 |
[Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoembryonic Antigen; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Skin Neoplasms | 2005 |
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; ErbB Receptors; Humans; Irinotecan; Panitumumab | 2005 |
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome | 2005 |
Role of pharmacogenetics in irinotecan therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Camptothecin; Forecasting; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
[Progression of adjuvant chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2005 |
[Recent progress of chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Rate | 2005 |
Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2006 |
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
The role of bevacizumab as first-line therapy for colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2005 |
Second-line treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2005 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temozolomide | 2006 |
[Successful treatment of refractory mantle cell lymphoma with irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Humans; Irinotecan; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome | 2005 |
[Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2006 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Patient Compliance; Quality of Life | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Mechanisms of substrate transport by ABC transporter, MRP1/ABCC1].
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Binding Sites; Camptothecin; Glutathione; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; Nucleotides; Phosphoric Acids; Point Mutation; Protein Binding; Protein Transport | 2006 |
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cryosurgery; Decision Trees; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Risk Factors; Treatment Failure; Treatment Outcome | 2006 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
Administration of anti-EGFR therapy: a practical review.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Clinical Protocols; Decision Trees; Drug Monitoring; ErbB Receptors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Nursing Assessment; Oncology Nursing; Risk Assessment; Risk Factors | 2006 |
[The modern treatment of colorectal cancer. Present and future].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2006 |
Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Tissue Distribution | 2006 |
[Non-surgical treatment for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Tegafur | 2006 |
Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium Bicarbonate | 2006 |
[Lung carcinoma].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quality of Life; Vinblastine; Vinorelbine | 2006 |
[Prevention of anticancer drug-induced premature ovarian failure].
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Freezing; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Irinotecan; Leuprolide; Organ Preservation; Ovary; Primary Ovarian Insufficiency | 2006 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
Individualizing cancer chemotherapy.
Topics: Camptothecin; Enzyme Inhibitors; Genetic Testing; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Toxicogenetics | 2006 |
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases | 2006 |
Nondermatologic adverse events associated with anti-EGFR therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic | 2006 |
Predicting the outcome of chemotherapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2006 |
Determinants of chemosensitivity in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Glutathione S-Transferase pi; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Stomach Neoplasms; Taxoids; Thymidylate Synthase; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2006 |
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
[Irinotecan for the treatment of metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Irinotecan; Maximum Tolerated Dose; Multicenter Studies as Topic; Pharmacogenetics | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Topics: Camptothecin; Dihydrouracil Dehydrogenase (NADP); Genotype; Glucuronosyltransferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Pharmacogenetics; Treatment Outcome | 2006 |
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biological Assay; Camptothecin; Gene Frequency; Genotype; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Models, Genetic; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Technology, Pharmaceutical | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Oxonic Acid; Survival Rate; Tegafur | 2006 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Models, Biological; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Stomatitis; Tegafur | 2006 |
[Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Remission Induction; Survival Rate; Tegafur | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
[Pharmacokinetic study of cancer chemotherapy].
Topics: Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Flavonoids; Glucuronides; Humans; Ileum; Irinotecan; Male; Rats; Rats, Wistar; Sulfobromophthalein | 2006 |
Irinotecan in the treatment of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis | 2006 |
[Malignant mesothelioma--diagnosis and treatment strategies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asbestos; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Interleukin-6; Irinotecan; Mediastinal Neoplasms; Mesothelioma; Pleural Neoplasms; Tomography, X-Ray Computed | 2006 |
[Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Oxonic Acid; Tegafur | 2006 |
Real-time imaging and quantification of brain delivery of liposomes.
Topics: Animals; Blood-Brain Barrier; Brain; Camptothecin; Convection; Drug Delivery Systems; Fluorescence; Gadolinium; Humans; Irinotecan; Liposomes; Magnetic Resonance Imaging | 2006 |
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics | 2006 |
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2006 |
Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms | 2007 |
Pharmacogenetics and irinotecan therapy.
Topics: Antineoplastic Agents; Bilirubin; Biomarkers; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Labeling; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Practice Guidelines as Topic; Risk Assessment | 2006 |
Adding pharmacogenetics information to drug labels: lessons learned.
Topics: Antineoplastic Agents; Camptothecin; Drug Labeling; Genetic Variation; Glucuronosyltransferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Pharmacogenetics; United States; United States Food and Drug Administration | 2006 |
The role of targeted therapy in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Epidermal Growth Factor; Humans; Irinotecan; Neovascularization, Pathologic; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
[Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Postoperative Care; Treatment Outcome | 2006 |
[Thymic basaloid carcinoma].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Basal Cell; Chemotherapy, Adjuvant; Diagnosis, Differential; Fatal Outcome; Humans; Irinotecan; Male; Radiotherapy, Adjuvant; Thymus Neoplasms | 2006 |
Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Vaccines; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Humans; Hungary; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[Application of Camptosar in neoadjuvant chemotherapy for rectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Remission Induction | 2006 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Survival Analysis | 2006 |
[Basic strategies on first- and second-line chemotherapy for advanced gastric cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Survival Rate; Taxoids | 2007 |
[Up to date chemotherapy for colon cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Rate | 2007 |
[Clinical development of chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
[Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
[Standard chemotherapy for colonic neoplasms].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
Cetuximab plus irinotecan in refractory colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chronic Disease; Colorectal Neoplasms; Humans; Irinotecan | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Adjuvant treatment of colon cancer: past, present and future.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Panitumumab | 2006 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Europe; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Staging; Oxonic Acid; Practice Guidelines as Topic; Rectal Neoplasms; Tegafur; United States; Uracil | 2007 |
Integration of novel agents into combined-modality treatment for rectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2007 |
[Diagnosis of and therapy for pancreatic neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Diabetes Complications; Drug Combinations; Early Diagnosis; Gemcitabine; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tegafur | 2007 |
Insights, challenges, and future directions in irinogenetics.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Liver; Neoplasms; Pharmacogenetics; Phenotype; Polymorphism, Genetic | 2007 |
Reducing irinotecan-associated diarrhea in children.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cephalosporins; Child; Diarrhea; Genetic Predisposition to Disease; Humans; Irinotecan | 2008 |
UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2007 |
Radiotherapy for localized rectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Rectum; Survival Analysis; Treatment Outcome | 2007 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Treatment Outcome | 2007 |
[Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Analysis | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Cetuximab].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Approval; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Mice | 2007 |
Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fatty Liver; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Optimizing combination chemotherapy by controlling drug ratios.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Humans; Irinotecan; Liposomes; Neoplasms | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Routes; Drug Administration Schedule; Humans; Irinotecan; Neoadjuvant Therapy; Prognosis; Stomach Neoplasms | 2007 |
Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2007 |
Targeted therapy in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central Nervous System; Colorectal Neoplasms; Cytotoxins; Deoxycytidine; Dexamethasone; Dysarthria; Female; Fluorouracil; Granisetron; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Sarcoma, Small Cell; Serotonin Antagonists; Topoisomerase I Inhibitors | 2008 |
Combined-modality therapy for rectal cancer: future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Metachronous metastasis to the penis from a rectal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Palliative Care; Penile Neoplasms; Prognosis; Rectal Neoplasms | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2007 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Stents | 2007 |
[Prediction of adverse drug reactions based on genomic information].
Topics: Anti-Infective Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Arylamine N-Acetyltransferase; Asian People; Azathioprine; Camptothecin; Cytidine Deaminase; Deoxycytidine; Forecasting; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Polymorphism, Genetic; Prodrugs; Sulfamethoxazole | 2007 |
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Survival Rate | 2008 |
[Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclin D1; Drug Eruptions; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Dosage; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Mutation; Neoplasm Proteins; Panitumumab; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Vascular Endothelial Growth Factor A | 2008 |
Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Humans; Irinotecan; Treatment Outcome | 2008 |
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Sulfonamides | 2008 |
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Time Factors | 2008 |
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2008 |
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2007 |
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2007 |
A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Failure; Vascular Endothelial Growth Factor A | 2007 |
[Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28].
Topics: Antineoplastic Agents; Asian People; Camptothecin; Genetic Markers; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic | 2008 |
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Clinical Trials as Topic; Drug Carriers; Drug Evaluation, Preclinical; Humans; Irinotecan; Micelles; Nanoparticles; Paclitaxel; Particle Size; Polymers | 2008 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
[Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glycosides; Humans; Irinotecan; Lung Neoplasms; Male; Methylnitrosourea; Middle Aged; Taxoids; Treatment Outcome | 2007 |
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2008 |
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Neoplasm Metastasis; Neoplasms; Neutropenia; Polymorphism, Genetic | 2008 |
Topoisomerase I inhibitors for the treatment of brain tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2008 |
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
Systemic treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2008 |
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Topics: Antineoplastic Agents, Phytogenic; Atazanavir Sulfate; Bilirubin; Camptothecin; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Irinotecan; Isoenzymes; Jaundice; Neoplasms; Oligopeptides; Pharmacogenetics; Pyridines; Risk Factors; Terminology as Topic | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2008 |
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Protease Inhibitors | 2008 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Pharmacology, Clinical; Risk Assessment; Sex Distribution; Survival Analysis; Treatment Outcome | 2008 |
Drug-eluting particles for interventional pharmacology.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Drug Carriers; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Microspheres | 2007 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Floxuridine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoplasm Staging; Prognosis; Survival Rate; Time Factors | 2008 |
Neoadjuvant chemoradiation for rectal cancer: is more better?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2008 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; ErbB Receptors; Genetic Predisposition to Disease; Humans; Irinotecan; Neutropenia | 2007 |
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Liver | 2006 |
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Irinotecan; Metabolic Networks and Pathways; Models, Biological; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Risk Assessment | 2008 |
Modifications of human carboxylesterase for improved prodrug activation.
Topics: Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Carboxylic Ester Hydrolases; Drug Design; Humans; Hydrolysis; Irinotecan; Liver; Mutagenesis; Prodrugs; Solubility | 2008 |
Irinotecan in the treatment of elderly patients with advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Health Services for the Aged; Humans; Irinotecan; Male | 2008 |
Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Panitumumab | 2008 |
Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2008 |
Experience with irinotecan for the treatment of malignant glioma.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioma; Humans; Irinotecan; Topoisomerase I Inhibitors | 2009 |
Antiangiogenic therapy in malignant gliomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Disease-Free Survival; Glioma; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Neoplasm Metastasis; Quality of Life; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Polymeric micellar delivery systems in oncology.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cisplatin; Clinical Trials as Topic; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Irinotecan; Micelles; Nanocapsules; Paclitaxel; Particle Size; Permeability; Polyglutamic Acid; Polymers | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Glass; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Microspheres; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Pharmacogenomics of tamoxifen and irinotecan therapies.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome | 2008 |
[New perspectives in predicting response to chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Repair; Drug Monitoring; ErbB Receptors; Genes, Tumor Suppressor; Humans; Irinotecan; Neoplasm Proteins; Oncogenes; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors | 2008 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Floxuridine; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Risk Factors | 2009 |
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Topics: Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Does celecoxib have a role in the treatment of patients with colorectal cancer?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2009 |
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Irinotecan; Microsatellite Repeats; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2009 |
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Metastasis; Palliative Care | 2009 |
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Irinotecan; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Eruptions; Evidence-Based Medicine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Risk Factors | 2009 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Europe; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Treatment Outcome | 2009 |
[Colorectal cancers: prognostic and predictive factors of response to treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chromosome Deletion; Chromosomes, Human, Pair 18; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Prognosis | 2009 |
Second-line chemotherapy in advanced and metastatic CRC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2009 |
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Irinotecan; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate | 2009 |
Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2009 |
What's new in ... colorectal cancer. Meaningful progress in therapy options.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2009 |
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2009 |
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Irinotecan; Mitomycin; Prospective Studies; Purpura, Thrombotic Thrombocytopenic | 2010 |
[Pharmacogenomics].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Clopidogrel; Humans; Irinotecan; Pharmacogenetics; Tegafur; Ticlopidine | 2009 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypertension; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2010 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Profiling; Genes, APC; Genes, p53; Genomic Instability; Humans; Irinotecan; Microsatellite Instability; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
[Chemotherapy of elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Comorbidity; Cooperative Behavior; Decision Making; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Life Expectancy; Organoplatinum Compounds; Oxaliplatin; Patient Care Team | 2009 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Humans; Irinotecan; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2009 |
A novel K-ras mutation in colorectal cancer. A case report and literature review.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Tumor Suppressor Protein p53 | 2009 |
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Delayed-Action Preparations; Humans; Irinotecan; Neoplasms; Polymers; Prodrugs; Topoisomerase I Inhibitors | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
Is there a role for second-line chemotherapy in advanced gastric cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Platinum Compounds; Salvage Therapy; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors | 2009 |
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Pharmacological; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Models, Biological; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Racial Groups | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Vascular Endothelial Growth Factor A | 2004 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Precision Medicine; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Treatment of metastatic colorectal cancer in the elderly.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Comorbidity; Drug Delivery Systems; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2009 |
Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Prodrugs; Tandem Mass Spectrometry; Topoisomerase I Inhibitors | 2010 |
[Intestinal absorption and secretion mechanism of carboxylate drugs].
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents, Phytogenic; Benzimidazoles; Benzoates; Camptothecin; Coumaric Acids; Cyclohexanes; Drug Interactions; Flavonoids; Food-Drug Interactions; Functional Food; Humans; Hypoglycemic Agents; Intestinal Absorption; Irinotecan; Monocarboxylic Acid Transporters; Nateglinide; Phenols; Phenylalanine; Polyphenols; Telmisartan | 2009 |
[Histological complete response in a case of advanced gastric endocrine carcinoma treated by irinotecan plus cisplatin].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Male; Stomach Neoplasms | 2009 |
Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Peritoneal Neoplasms | 2009 |
Palliative treatment of unresectable metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care | 2010 |
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Genetic Markers; Humans; Irinotecan; Mutation; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2010 |
[Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fatty Liver; Hepatic Veno-Occlusive Disease; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2010 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure | 2010 |
Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.
Topics: Administration, Oral; Camptothecin; Clopidogrel; Drug Evaluation; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Membrane Transport Proteins; Models, Biological; Models, Statistical; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic; Ticlopidine | 2010 |
An overview of the recent progress in irinotecan pharmacogenetics.
Topics: Alleles; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Dinucleotide Repeats; Drug-Related Side Effects and Adverse Reactions; Gene Frequency; Glucuronosyltransferase; Haplotypes; Homozygote; Humans; Irinotecan; Models, Biological; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2010 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2010 |
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Molecular predictive and prognostic markers in colon cancer.
Topics: Camptothecin; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); ErbB Receptors; Genes, ras; Genomic Instability; Humans; Irinotecan; Loss of Heterozygosity; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Thymidylate Synthase | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Pharmacogenetics of irinotecan disposition and toxicity: a review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic | 2010 |
Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan | 2010 |
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2010 |
Metastatic colorectal cancer: from improved survival to potential cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Catheter Ablation; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Medical Oncology; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2010 |
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Spheroids, Cellular; Survival Rate; Treatment Outcome | 2010 |
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Evidence-Based Medicine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
[Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate | 2010 |
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
Topics: Animals; Camptothecin; Capillary Permeability; Clinical Trials as Topic; Drug Evaluation, Preclinical; Extravasation of Diagnostic and Therapeutic Materials; Humans; Irinotecan; Micelles; Neoplasms | 2011 |
Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic | 2010 |
Irinotecan pharmacogenomics.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Forecasting; Glucuronosyltransferase; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Genetic | 2010 |
Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Meta-Analysis as Topic; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2010 |
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Signal Transduction | 2010 |
Consequences of chemotherapy on resection of colorectal liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Delivery Systems; Fatty Liver; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Liver Regeneration; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prognosis; Survival Rate; Tomography, X-Ray Computed | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Vitamin B Complex | 2010 |
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Risk Factors; Treatment Outcome | 2011 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
[Metastatic gastric cancer: does second-line chemotherapy make sense?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Palliative Care; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retreatment; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Drug Implants; Female; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oligodendroglioma | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diagnosis, Differential; Genetic Predisposition to Disease; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia, Hereditary; Irinotecan; Jaundice, Chronic Idiopathic; Neoplasms | 2010 |
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Approval; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Organoplatinum Compounds; United States; United States Food and Drug Administration | 2010 |
Maintenance therapy in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2010 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pilot Projects; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Therapy, Combination; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate | 2010 |
Irinotecan and radiosensitization in rectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Humans; Irinotecan; Meta-Analysis as Topic; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Rectal Neoplasms | 2011 |
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Disease-Free Survival; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Pyrimidines; Research Design; Time Factors; Treatment Outcome | 2011 |
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Topics: Antineoplastic Agents; Camptothecin; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic | 2011 |
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Middle Aged; Recurrence; Survival Analysis | 2011 |
[A case of recurrent gastric cancer with lymph node metastasis successfully treated by CPT-11/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Remission Induction; Salvage Therapy; Stomach Neoplasms | 2011 |
[A case report of primary duodenal adenocarcinoma responding to chemotherapy with S-1 and irinotecan].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Duodenal Neoplasms; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Remission Induction; Tegafur | 2011 |
Adjuvant treatment of colon cancer: what is next?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds | 2011 |
Cetuximab in the treatment of patients with colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Evidence-Based Medicine; Humans; Irinotecan; Mutation; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Ethnicity; Gemcitabine; Genetic Markers; Genotype; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Single Nucleotide; Tamoxifen | 2011 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Complementary Therapies; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2011 |
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Polymorphism, Genetic; Precision Medicine | 2011 |
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors; Treatment Outcome | 2011 |
[A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dysarthria; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Sigmoid Neoplasms | 2011 |
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Irinotecan; Topoisomerase I Inhibitors | 2011 |
[Chemotherapy and rectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2011 |
Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diabetes Mellitus, Type 2; Fatal Outcome; Gout; Humans; Hyperlipidemias; Hypertension; Hypophosphatemia; Inappropriate ADH Syndrome; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Osteomalacia; Paraneoplastic Syndromes; Risk Factors; Small Cell Lung Carcinoma | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
Diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colitis; Colon; Colonoscopy; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Enterocolitis, Pseudomembranous; Gastrointestinal Motility; Humans; Irinotecan; Muscle Contraction; Sodium-Potassium-Exchanging ATPase; Steatorrhea | 2011 |
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
[Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents, Phytogenic; Camptothecin; Carbamates; Haplotypes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Piperidines; Polymorphism, Genetic | 2011 |
[Molecular determinants of response to topoisomerase I inhibitors].
Topics: Camptothecin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2011 |
Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.
Topics: Aryl Hydrocarbon Hydroxylases; Azathioprine; Camptothecin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Enzymes; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Methyltransferases; Mixed Function Oxygenases; Prodrugs; Tamoxifen; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2012 |
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic | 2012 |
[A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Stomach Neoplasms | 2011 |
[Chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin | 2011 |
[Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2011 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan | 2012 |
[A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Organoplatinum Compounds; Panitumumab; Tomography, X-Ray Computed | 2012 |
Clinical development of new formulations of cytotoxics in solid tumors.
Topics: Aminopterin; Anthracyclines; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Folic Acid Antagonists; Humans; Irinotecan; Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 2012 |
Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Compassionate Use Trials; Cost Sharing; Drug Industry; ErbB Receptors; Female; Health Services Accessibility; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Second-line chemotherapy for advanced gastric cancer in Korea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Republic of Korea; Stomach Neoplasms; Taxoids | 2012 |
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis | 2012 |
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Topics: Antineoplastic Agents; Biological Products; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2012 |
Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cisplatin; Glioma; Humans; Irinotecan; Nitrosourea Compounds | 2012 |
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Cetuximab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Liver Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Relapsed hepatoblastoma.
Topics: Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Hepatoblastoma; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Radiotherapy; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Male; Neoplasm Metastasis; Risk Factors; Survival Rate; Transplantation, Homologous | 2012 |
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; Camptothecin; Diarrhea; Genetic Association Studies; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Neutropenia | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Topics: Breast Neoplasms; Camptothecin; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Ganciclovir; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Humans; Irinotecan; Prodrugs; Stem Cells; Thymidine Kinase | 2012 |
DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.
Topics: Biomarkers; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA Repair Enzymes; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors | 2012 |
S-1 for the treatment of gastrointestinal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Practice Guidelines as Topic; Tegafur | 2012 |
Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Humans; Induction Chemotherapy; Irinotecan; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2013 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Codon; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Treatment Outcome | 2012 |
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Transcriptome; Vascular Endothelial Growth Factor A | 2012 |
Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Signal Transduction; src-Family Kinases; Topoisomerase I Inhibitors; Up-Regulation | 2013 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome | 2012 |
A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2012 |
Splice isoforms as therapeutic targets for colorectal cancer.
Topics: Alternative Splicing; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Glucuronosyltransferase; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Pregnane X Receptor; Protein Isoforms; Receptors, Steroid; Survivin; Vascular Endothelial Growth Factor A | 2012 |
[Predictive biomarkers for response to irinotecan, platinum drugs, and taxanes].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Humans; Irinotecan; Neoplasms; Platinum Compounds; Taxoids | 2012 |
Chemotherapeutic options for gastroesophageal junction tumors.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Palliative Care; Stomach Neoplasms; Taxoids | 2013 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Coronary Angiography; Diagnostic Errors; Docetaxel; Electric Countershock; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Myocardial Infarction; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Takotsubo Cardiomyopathy; Taxoids; Ventricular Fibrillation | 2013 |
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2013 |
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Second-line therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2013 |
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2013 |
Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Odds Ratio; Polymorphism, Single Nucleotide; Treatment Outcome; White People | 2013 |
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
Topics: Aged; Alleles; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Single Nucleotide; Risk Factors; White People | 2014 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Hospitalization; Humans; Irinotecan; Molecular Targeted Therapy; Multidrug Resistance-Associated Protein 2; Severity of Illness Index; Topoisomerase I Inhibitors | 2013 |
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Neutropenia; Pharmacogenetics | 2012 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
[Role of ABC efflux transporters in the oral bioavailability and drug-induced intestinal toxicity].
Topics: Animals; ATP-Binding Cassette Transporters; Biological Availability; Camptothecin; Genistein; Intestines; Irinotecan; Methotrexate; Multidrug Resistance-Associated Proteins; Rats | 2013 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; ErbB Receptors; Humans; Irinotecan; Mutation; Neoplasm Metastasis; Prodrugs; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Carriers; Humans; Irinotecan; Liver Neoplasms; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Humans; Irinotecan; Nanomedicine; Neoplasms; Prodrugs | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2013 |
[Relationship between UGT1A and irinotecan-related toxicity].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Single Nucleotide | 2013 |
Methods of overcoming treatment resistance in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Rectum | 2014 |
Understanding and modulating mammalian-microbial communication for improved human health.
Topics: Animals; Anti-Inflammatory Agents; Camptothecin; Disease Models, Animal; Enteritis; Eosinophilia; Gastritis; Gastrointestinal Tract; Glucuronidase; Humans; Irinotecan; Lipopolysaccharides; Mammals; Microbiota | 2014 |
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2014 |
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytotoxicity, Immunologic; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Taxoids; Tumor Escape; Tumor Microenvironment | 2014 |
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur | 2014 |
The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Risk | 2014 |
[A case of neuroendocrine cell carcinoma of the esophagus with lung metastases successfully treated with CPT-11/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy | 2013 |
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2014 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate; Treatment Outcome | 2014 |
[Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2014 |
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Topics: Alleles; Amino Acid Sequence; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Molecular Sequence Data; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Topoisomerase I Inhibitors | 2014 |
Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Irinotecan; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2014 |
[Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Creutzfeldt-Jakob Syndrome; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Phosphopyruvate Hydratase; Prostate; Prostatic Neoplasms; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic | 2014 |
Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2014 |
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Survival Analysis | 2014 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; PubMed; Pyridines; Retreatment; Salvage Therapy; Treatment Failure; Triazines | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Inflammation; Intestinal Mucosa; Irinotecan; Mucositis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin | 2014 |
[Case report of chemotherapeutic control of a gastric cancer producing granulocyte-colony stimulating factor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fatal Outcome; Gastroscopy; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Patient Selection; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiotoxicity; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Liver; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; France; Gastrointestinal Neoplasms; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Pharmacovigilance; Phenotype; Polymorphism, Genetic; Treatment Outcome; United States; White People | 2014 |
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Aspirin; Benzimidazoles; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Central Nervous System Stimulants; Clopidogrel; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Imidazolidines; Irinotecan; Isoenzymes; Methylphenidate; Oseltamivir; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Pyridines; Ticlopidine | 2014 |
Progress of drug-loaded polymeric micelles into clinical studies.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Epirubicin; Humans; Irinotecan; Micelles; Neoplasms; Paclitaxel; Platinum Compounds; Polymers | 2014 |
Efficacy of S-1 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectum; Tegafur | 2014 |
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Precision Medicine; Treatment Outcome | 2014 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Humans; Infant; Irinotecan; Male; Retrospective Studies; Sarcoma, Ewing; Survival Rate; Temozolomide | 2015 |
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Vascular Endothelial Growth Factor A | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cancer Vaccines; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Irinotecan; Mice; Temozolomide; Vaccination; Vaccines, Subunit | 2014 |
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
Pancreatic cancer and FOLFIRINOX: a new era and new questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Care Planning; Postoperative Care; Preoperative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
[A case of gastric small cell carcinoma with liver and lymph node metastases responding to CPT-11 plus CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Etoposide; Everolimus; Humans; Irinotecan; Pancreatic Neoplasms | 2015 |
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Deoxycytidine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Genomics; Glucuronosyltransferase; HLA Antigens; Humans; International Cooperation; Irinotecan; Japan; Pharmacogenetics; Precision Medicine; Prodrugs; Product Surveillance, Postmarketing | 2015 |
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Mammary Neoplasms, Experimental; Methotrexate; Mice; Mucositis; Rats | 2015 |
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2015 |
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; MicroRNAs; Organoplatinum Compounds; Oxaliplatin | 2015 |
Challenges in SN38 drug delivery: current success and future directions.
Topics: Animals; Camptothecin; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Immunoconjugates; Irinotecan; Nanoparticles; Neoplasms; Prodrugs; Solubility | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Treatment Outcome | 2015 |
Mechanistic review of drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Camptothecin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fatty Liver; Hepatocytes; Humans; Irinotecan; Lipid Metabolism; Liver; Methotrexate; Mitochondria, Liver; Organoplatinum Compounds; Oxaliplatin; Perhexiline; Tamoxifen; Tetracycline; Valproic Acid | 2015 |
Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Jaw Diseases; Middle Aged; Osteonecrosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, X-Ray Computed | 2016 |
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2016 |
Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glioblastoma; Humans; Irinotecan; Prospective Studies; Salvage Therapy; Survival Analysis | 2015 |
Capecitabine for the treatment of gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2015 |
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asian People; Camptothecin; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Pyridines; Ramucirumab; Stomach Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quality-Adjusted Life Years; Treatment Outcome; United States | 2016 |
Current and advancing treatments for metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pyrrolidines; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Therapies, Investigational; Thymine; Trifluridine; Uracil; Vascular Endothelial Growth Factor A | 2016 |
[UGT1A1 Genotyping for Proper Use of Irinotecan].
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic | 2015 |
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Dosage Calculations; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Treatment Outcome | 2015 |
Maintenance strategy in metastatic colorectal cancer: A systematic review.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Disease-Free Survival; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Irinotecan; Maintenance Chemotherapy; Male; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Organoplatinum Compounds; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2016 |
Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Treatment Outcome | 2015 |
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
[A Case of Rectal Cancer Completely Resected after Successful Treatment with Irinotecan plus Cetuximab-Induced Interstitial Pneumonia with Steroid Pulse Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Rectal Neoplasms; Saponins | 2015 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts.
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Biphenyl Compounds; Camptothecin; Drug Synergism; Graft Survival; Humans; Irinotecan; Mice; Mice, Nude; Mice, SCID; Molecular Targeted Therapy; Nitrophenols; Piperazines; Precision Medicine; Stomach Neoplasms; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Nanoparticles; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Liposomes; Nanomedicine; Nanotechnology; Pancreatic Neoplasms | 2016 |
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Camptothecin; Cisplatin; Doxorubicin; Humans; Irinotecan; Neoplasms; Paclitaxel; Polyethylene Glycols; Treatment Outcome | 2016 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Ramucirumab; Survival Rate; Treatment Outcome | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Endonucleases; Fluorouracil; Genetic Markers; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Xeroderma Pigmentosum Group D Protein | 2016 |
Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Irinotecan; Neoplasm Staging; Proportional Hazards Models; Publication Bias; Retreatment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2017 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Survival Rate | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Drug Compounding; Drug Resistance, Neoplasm; Humans; Irinotecan; Liposomes; Pancreatic Neoplasms; Patents as Topic; Treatment Outcome | 2016 |
Primary combined small cell carcinoma and squamous cell carcinoma of the oropharynx with special reference to EGFR status of small cell carcinoma component: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; ErbB Receptors; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oropharyngeal Neoplasms; Otorhinolaryngologic Surgical Procedures | 2017 |
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Meta-Analysis as Topic; Neutropenia; Odds Ratio; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Systematic Reviews as Topic; Treatment Outcome | 2017 |
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Topics: Antineoplastic Agents; Asian People; ATP-Binding Cassette Transporters; Camptothecin; Docetaxel; Doxorubicin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Solute Carrier Proteins; Taxoids; Treatment Outcome; White People | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Fluorouracil; Humans; Intestinal Diseases; Irinotecan; Mucositis; Receptors, Cytokine | 2016 |
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Precision Medicine; Translational Research, Biomedical; Vascular Endothelial Growth Factor A | 2016 |
Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; CA-19-9 Antigen; Camptothecin; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Nanoparticles; Paclitaxel; Pancreatic Neoplasms | 2016 |
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Cyclophosphamide; Epithelial Cell Adhesion Molecule; Humans; Irinotecan; Neoplasms; Neoplastic Cells, Circulating; Reproducibility of Results; Software; Specimen Handling; Treatment Outcome | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.
Topics: Anti-Bacterial Agents; Antidiarrheals; Apoptosis; Camptothecin; Cholinergic Antagonists; Gastrointestinal Microbiome; Glucagon-Like Peptide 2; Humans; Irinotecan; Mucositis | 2017 |
Pharmaceutical Investigation for Individualized and Optimal Cancer Pharmacotherapy.
Topics: Antineoplastic Agents; Camptothecin; Drug Monitoring; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Outpatients; Pharmacy Service, Hospital; Polymorphism, Genetic; Precision Medicine | 2016 |
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Treatment Outcome | 2016 |
The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Panitumumab; Prognosis; Survival Rate; Treatment Outcome | 2016 |
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2017 |
Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms | 2017 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Second-line systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
[A Case of Primary Poorly Differentiated/Small Cell Carcinoma of the Breast in a Patient with Von Recklinghausen's Disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neurofibromatosis 1 | 2016 |
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Seeking new anti-cancer agents from autophagy-regulating natural products.
Topics: Antineoplastic Agents; Autophagy; Biological Products; Camptothecin; Humans; Irinotecan; Molecular Structure; Paclitaxel; Resveratrol; Stilbenes | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Platinum Compounds; Ramucirumab; Stomach Neoplasms; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
[Long-Term Survival of a Gastric Neuroendocrine Carcinoma Patient with Extra-Regional Lymph Node Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Stomach Neoplasms; Time Factors | 2017 |
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Polymorphism, Genetic; Treatment Outcome | 2017 |
Sacituzumab govitecan: an antibody-drug conjugate.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms | 2017 |
UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Risk Factors | 2017 |
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2017 |
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy | 2017 |
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gentamicins; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Practice Guidelines as Topic; Treatment Outcome; United States | 2017 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Palliative Care; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2017 |
Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Epidemiologic Methods; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Microspheres | 2017 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2017 |
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Colorectal Neoplasms; Humans; Immunohistochemistry; Irinotecan | 2017 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Glioma; Humans; Irinotecan; Neoplasm Grading; Neoplasm Recurrence, Local; Prevalence; Survival Rate | 2018 |
[Metastatic colorectal cancer: To stop or not to stop?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Withholding Treatment | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2018 |
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2018 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Docetaxel; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Immunotherapy; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Quality of Life; Taxoids; Thymine; Trifluridine; Uracil | 2018 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
FOLFOXIRI plus biologics in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2019 |
The Emerging Role of the SLCO1B3 Protein in Cancer Resistance.
Topics: Androgen Antagonists; Antineoplastic Agents; Biological Transport; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Protein Conformation; Signal Transduction; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Taxoids | 2020 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment | 2020 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms | 2020 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Dacarbazine; Humans; Irinotecan; Neoplasms; Temozolomide; Vincristine | 2021 |
Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Gastrointestinal Microbiome; Irinotecan | 2021 |
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2022 |
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Diarrhea; Humans; Immunoconjugates; Irinotecan; Neutropenia; Urinary Bladder Neoplasms | 2022 |
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Hormones; Humans; Immunoconjugates; Irinotecan; Triple Negative Breast Neoplasms | 2022 |
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin | 2022 |
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing; Temozolomide | 2023 |
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2022 |
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.
Topics: Camptothecin; Drug Interactions; Genotype; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic | 2023 |
Recent advances in SN-38 drug delivery system.
Topics: Camptothecin; Drug Delivery Systems; Irinotecan; Micelles; Prodrugs | 2023 |
Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us.
Topics: Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Irinotecan; Topoisomerase I Inhibitors | 2023 |
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Irinotecan; Lung Neoplasms | 2023 |
Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Neoplasms; Solubility | 2023 |
1625 trial(s) available for camptothecin and irinotecan
| Article | Year |
|---|---|
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1992 |
Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Diarrhea; Drug Evaluation; Esophageal Neoplasms; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Middle Aged; Pharyngeal Neoplasms | 1992 |
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Evaluation; Drug Resistance; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome | 1992 |
[Advances in lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1992 |
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1991 |
[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1991 |
[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
[An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Uterine Neoplasms | 1991 |
[Phase I clinical study of CPT-11. Research group of CPT-11].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms | 1990 |
Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1994 |
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Sampling Studies | 1995 |
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1993 |
A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Japan; Kinetics; Leukopenia; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Kinetics; Lactones; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Blood Specimen Collection; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Prospective Studies; Regression Analysis | 1995 |
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 1995 |
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Treatment Outcome | 1995 |
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Alopecia; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Prodrugs; Salvage Therapy; Treatment Outcome | 1995 |
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Topics: Adult; Aged; Bone Marrow Diseases; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Prodrugs; Treatment Outcome | 1995 |
[Pilot study of irinotecan in refractory small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1995 |
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Vomiting | 1995 |
[Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Rectal Neoplasms | 1995 |
Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged | 1994 |
CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.
Topics: Bayes Theorem; Camptothecin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Metabolic Clearance Rate | 1994 |
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 1994 |
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Glucuronates; Humans; Irinotecan | 1994 |
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia | 1994 |
Clinical studies of irinotecan alone and in combination with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1994 |
Preclinical and phase I trials of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neoplasms | 1994 |
Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Vindesine | 1994 |
[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged | 1994 |
[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 1994 |
[A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1994 |
[Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Phase I and pharmacokinetic trial of weekly CPT-11.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Irinotecan; Least-Squares Analysis; Male; Middle Aged; Neoplasms | 1993 |
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Feasibility Studies; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Muscle Cramp; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia | 1994 |
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan | 1993 |
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1993 |
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Organ Specificity; Vomiting | 1993 |
High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Spectrophotometry, Infrared | 1995 |
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adenocarcinoma; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Irinotecan; Loperamide; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Remission Induction; Survival Rate | 1996 |
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Topics: Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms | 1996 |
[Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis | 1996 |
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms | 1996 |
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms | 1996 |
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Survival Rate; Treatment Outcome | 1996 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction | 1997 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Vomiting | 1996 |
A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Incidence; Irinotecan; Middle Aged; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1997 |
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Thrombocytopenia | 1997 |
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1997 |
A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1997 |
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 1997 |
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Patient Satisfaction; Pilot Projects; Platinum Compounds; Remission Induction; Safety; Uterine Cervical Neoplasms; Vomiting | 1998 |
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis | 1998 |
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1998 |
Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1998 |
[Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1998 |
Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1998 |
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1998 |
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Topics: Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Feces; Glucuronates; Humans; Irinotecan; Pilot Projects; Reproducibility of Results; Topoisomerase I Inhibitors | 1998 |
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Prospective Studies; Thiorphan | 1998 |
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Interactions; Etoposide; Humans; Irinotecan; Liver; Lymphoma, Non-Hodgkin; Middle Aged; Topoisomerase I Inhibitors | 1998 |
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 1998 |
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Survival Rate | 1998 |
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Probability; Quality of Life; Survival Analysis; Treatment Failure | 1998 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; France; Glucuronates; Humans; Irinotecan; Metabolic Clearance Rate; Models, Biological; Neoplasms | 1997 |
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Chromatography, High Pressure Liquid; Feces; Female; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Tumor Cells, Cultured | 1998 |
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1998 |
[Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Safety | 1998 |
A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Survival Rate; Time Factors | 1998 |
Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemoglobins; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count | 1999 |
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin | 1999 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 1999 |
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting | 1999 |
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Treatment Outcome | 1999 |
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Predictive Value of Tests; Reproducibility of Results | 1999 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome | 1999 |
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prospective Studies; Quality of Life; Survival Analysis; Topoisomerase I Inhibitors | 1999 |
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Quality of Life; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure | 1999 |
A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1999 |
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1999 |
Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Injections, Intravenous; Irinotecan; Male; Mesothelioma; Middle Aged; Pilot Projects; Pleural Diseases | 1999 |
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Northern; Camptothecin; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Glutamate-Cysteine Ligase; Humans; Irinotecan; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Tumor Cells, Cultured | 1999 |
[Period of time patients with advanced non-small cell lung cancer could remain at home during CIC--therapy (cisplatin + ifosfamide + CPT-11)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Outpatient Clinics, Hospital; Survival Rate | 1999 |
Phase I study of a combination of irinotecan and ifosfamide in advanced primary lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1999 |
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 1999 |
[Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Quality of Life; Time Factors | 1999 |
Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1999 |
UFT plus calcium folinate/irinotecan in colorectal cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Irinotecan; Leucovorin; Tegafur; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 1999 |
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 1999 |
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Topics: Adult; Aged; Camptothecin; Cisplatin; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Topoisomerase I Inhibitors | 1999 |
Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Uterine Cervical Neoplasms | 1999 |
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1999 |
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome | 1999 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Severity of Illness Index; Survival Rate; Treatment Outcome | 1999 |
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Radioimmunotherapy | 1999 |
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Gilbert Disease; Glucuronates; Glucuronides; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Treatment Outcome | 1999 |
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Neoplasms; Neuroblastoma; Subrenal Capsule Assay; Treatment Outcome | 1999 |
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Digestive System; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Glucuronates; Glucuronides; Hematopoiesis; Humans; Infusions, Intravenous; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasms; Treatment Outcome | 1999 |
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1999 |
A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Pilot Projects | 1999 |
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Diarrhea; Female; Fluorouracil; Glucocorticoids; Humans; Irinotecan; Loperamide; Male; Middle Aged; Treatment Failure | 1999 |
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Least-Squares Analysis; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Topoisomerase I Inhibitors | 2000 |
Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies | 1999 |
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 1999 |
[The salvage chemotherapy for refractory testicular cancer with novel anticancer agents].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Male; Organoplatinum Compounds; Salvage Therapy; Testicular Neoplasms | 1999 |
Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Prospective Studies; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 2000 |
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 1999 |
Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Doxorubicin; Drug Administration Schedule; Humans; Irinotecan; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Recurrence | 2000 |
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamide; Irinotecan; Male; Middle Aged; Neoplasms; Salvage Therapy | 2000 |
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Feces; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Mass Spectrometry; Middle Aged; Neoplasms | 2000 |
[A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2000 |
[Neoadjuvant chemotherapy with cisplatin and CPT-11 for advanced cervical cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Uterine Cervical Neoplasms | 2000 |
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Complex and Mixed; Neoplasms, Connective and Soft Tissue; Neoplasms, Glandular and Epithelial; Neutropenia; Time Factors | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate | 2000 |
Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis | 2000 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Administration Schedule; Female; Fluorouracil; France; Health Care Costs; Hospital Costs; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Salvage Therapy; Sensitivity and Specificity; Survival Analysis | 2000 |
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome | 2000 |
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Topics: Adolescent; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Irinotecan; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Neoplasms; Topoisomerase I Inhibitors | 2000 |
Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
Topics: Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Half-Life; Humans; Indicators and Reagents; Infusions, Intravenous; Irinotecan; Reproducibility of Results; Spectrometry, Fluorescence; Topoisomerase I Inhibitors | 2000 |
[A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Pilot Projects; Salvage Therapy | 2000 |
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Area Under Curve; Atropine; Camptothecin; Colorectal Neoplasms; Dexamethasone; Digestive System; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Follow-Up Studies; Gallbladder Neoplasms; Glucuronates; Humans; Irinotecan; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2000 |
Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Colorectal Neoplasms; Creatinine; Diarrhea; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Risk Factors; Urea | 2000 |
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Length of Stay; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Time Factors; Treatment Failure | 1999 |
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Feasibility Studies; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2000 |
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 2000 |
[Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Thiorphan | 2000 |
Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Digestive System; Humans; Irinotecan; Pilot Projects; Thalidomide | 2000 |
[Combination chemotherapy with irinotecan hydrochloride plus carboplatin for patients with advanced or recurrent colorectal cancer--a pilot study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Survival Analysis | 2000 |
Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2000 |
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis | 2000 |
Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Quality of Life; Stomatitis; Survival Analysis | 2000 |
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2000 |
[Evaluation of bronchial arterial infusion (BAI) for high risk lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2000 |
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Treatment Outcome; Uracil | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2000 |
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2000 |
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Thiophenes; Treatment Failure | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infections; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Sensation Disorders; Treatment Outcome | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Palliative Care; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2000 |
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Diarrhea; Fatigue; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Prognosis; Treatment Outcome; Vomiting | 2001 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Irinotecan and thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Thalidomide | 2000 |
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Tests; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Topoisomerase I Inhibitors; Toxicity Tests; Treatment Outcome | 2001 |
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2001 |
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2001 |
Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2001 |
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome | 2001 |
Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Bone Marrow; Buffers; Camptothecin; Case-Control Studies; Defecation; Diarrhea; Digestive System; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Risk Factors; Sodium Bicarbonate; Ursodeoxycholic Acid | 2001 |
Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Butyrylcholinesterase; Butyrylthiocholine; Camptothecin; Carboxylic Ester Hydrolases; Humans; Hydrolysis; Irinotecan; Nitrophenols; Predictive Value of Tests | 2001 |
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Diarrhea; Humans; Irinotecan; Middle Aged; Neomycin; Neoplasms | 2001 |
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma; Colonic Neoplasms; Cryosurgery; Dexamethasone; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed | 2001 |
A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; CA-19-9 Antigen; Camptothecin; Female; Gallbladder Neoplasms; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Survival Rate; Treatment Outcome | 2001 |
Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2001 |
Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Synergism; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging | 2001 |
Phase I clinical trial of weekly combined topotecan and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2001 |
Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2001 |
Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Camptothecin; Female; Glucuronates; Humans; Infusions, Intravenous; Irinotecan; Male; Models, Statistical; Neoplasms; Sampling Studies | 2001 |
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2001 |
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Tegafur; Uracil | 2001 |
Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis | 2001 |
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Survival Rate; Thiophenes | 2002 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2002 |
[Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Irinotecan; Neuroblastoma | 2001 |
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2001 |
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Analysis | 2002 |
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Glucuronates; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2002 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2001 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Treatment Outcome | 2002 |
Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2002 |
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Treatment Outcome | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Safety; Survival Rate; Treatment Outcome | 2002 |
Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radiotherapy; Remission Induction; Survival Rate; Treatment Outcome | 2002 |
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Disease-Free Survival; Floxuridine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Multivariate Analysis; Proportional Hazards Models; Survival Rate | 2002 |
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors | 2002 |
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adult; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors | 2002 |
Chronotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rats | 2002 |
Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Japan; Leiomyosarcoma; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Proteins; Neuroblastoma; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Supratentorial Neoplasms; Thrombocytopenia | 2002 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Pilot Projects | 2002 |
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Neoplasm; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Quality of Life; Survival Analysis | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2002 |
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; England; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2002 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms | 2002 |
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Topoisomerase I Inhibitors | 2002 |
Modulation of irinotecan metabolism by ketoconazole.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Ketoconazole; Leukocyte Count; Leukocytes; Liver; Male; Middle Aged; Mixed Function Oxygenases; Neutrophils; Prodrugs | 2002 |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Italy; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies; Treatment Outcome | 2002 |
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Quinazolines; Thiophenes; Treatment Outcome | 2002 |
Effects of St. John's wort on irinotecan metabolism.
Topics: Antidepressive Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Confidence Intervals; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Hypericum; Irinotecan; Mixed Function Oxygenases; Topoisomerase I Inhibitors | 2002 |
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Prognosis; Quinazolines; Severity of Illness Index; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Probability; Prognosis; Pyridines; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Mitomycin as a modulator of irinotecan anticancer activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Patient Selection; Recurrence; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2002 |
Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.
Topics: Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Multidrug Resistance-Associated Protein 2; Phenytoin; Probability; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2002 |
Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Treatment Outcome | 2002 |
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Topics: Adult; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Germany; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 2002 |
Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Thrombocytopenia | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Polypharmacy; Prospective Studies; Salvage Therapy | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Analysis; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival; Treatment Outcome | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Vomiting | 2002 |
Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2002 |
Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2002 |
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Hyperbilirubinemia; Irinotecan; Male; Middle Aged; Predictive Value of Tests | 2002 |
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Failure | 2002 |
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Safety; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Stomatitis; Treatment Outcome | 2002 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Cryosurgery; Disease-Free Survival; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Prodrugs; Survival Analysis; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Probability; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Pyridines; Survival Analysis | 2002 |
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
Topics: Adult; Aged; Camptothecin; Canada; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Probability; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Probability; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Salvage Therapy; Survival Analysis; Treatment Failure | 2002 |
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Creatinine; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucuronates; Humans; Infusions, Intravenous; Irinotecan; Kidney Function Tests; Liver Function Tests; Male; Oxidoreductases; Predictive Value of Tests; Reproducibility of Results | 2002 |
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Conformal; Rectal Neoplasms; Ultrasonics | 2003 |
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Camptothecin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms | 2003 |
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2003 |
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Cohort Studies; DNA Adducts; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Metabolic Clearance Rate; Neoplasms; Safety | 2003 |
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2003 |
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Blast Crisis; Bone Marrow; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Time Factors | 2003 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2003 |
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Prospective Studies; Quality of Life; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
[A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytopenia | 2003 |
Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cyclosporine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2003 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome; Vomiting | 2003 |
Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Medicine, Kampo; Middle Aged; Treatment Outcome | 2003 |
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome | 2003 |
[Cytoreductive surgery of liver metastasis from colorectal cancer: principles of intra-arterial regional chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Female; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure | 2003 |
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Cytokines; Female; Fluorouracil; Genetic Therapy; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Irinotecan; Male; Middle Aged; Neoplasms; Pilot Projects; Tumor Suppressor Protein p53; Viral Vaccines; Virus Replication | 2003 |
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Cohort Studies; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate | 2003 |
Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Middle Aged; Treatment Outcome | 2003 |
IPM chemotherapy in cytokine refractory renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kidney Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival; Treatment Outcome | 2003 |
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; United States | 2003 |
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin | 2003 |
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Camptothecin; Carcinoma; Female; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2002 |
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2002 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxyurea; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2003 |
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Women's Health | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Pain; Pelvic Neoplasms; Radiotherapy Dosage; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of irinotecan in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Renal Cell; Female; Humans; Irinotecan; Kidney Neoplasms; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Odds Ratio; Probability; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2003 |
Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Postoperative Complications; Rectal Neoplasms | 2003 |
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome; United Kingdom; Uracil | 2003 |
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2003 |
Population-based maximum tolerated dose of irinotecan and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2003 |
Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2003 |
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Time Factors | 2003 |
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2003 |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Rate | 2003 |
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary | 2003 |
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pilot Projects; Prospective Studies; Stomach Neoplasms | 2003 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rectal Neoplasms; Topoisomerase I Inhibitors | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids | 2003 |
A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Drug Administration Schedule; Humans; Infant; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Neoplasms; Neutropenia | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Recurrence; Salvage Therapy; Survival Analysis; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Pancreatic Neoplasms; Research Design | 2003 |
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant | 2003 |
Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Irinotecan in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Radiotherapy, Adjuvant; Treatment Outcome | 2003 |
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Stability; Glucuronates; Humans; Irinotecan; Neoplasm Metastasis; Reproducibility of Results; Saliva; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Confidence Intervals; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Proportional Hazards Models; Survival Analysis; Taxoids | 2003 |
Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Linear Models; Lung Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Vindesine; Vomiting, Anticipatory | 2003 |
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2003 |
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Retrospective Studies | 2003 |
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Pelvis; Radiotherapy | 2003 |
Current treatment and future directions in neuroblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Endostatins; Humans; Infant; Irinotecan; Neoplasm Staging; Neuroblastoma; Prospective Studies; Survival Rate | 2003 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Spain; Treatment Outcome; Vomiting | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2004 |
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Spain; Survival Analysis; Treatment Outcome | 2003 |
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2004 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Tegafur; Treatment Outcome; Uracil | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2004 |
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Recurrence; United States; United States Food and Drug Administration | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
Topics: Adult; Brain Neoplasms; Camptothecin; Confidence Intervals; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Statistics, Nonparametric | 2004 |
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Mismatch; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Repair; Female; Humans; Immunohistochemistry; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Time Factors | 2004 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Dehydrogenase (NADP); Middle Aged; Neoplasms; Polymorphism, Genetic; Tablets; Tegafur; Treatment Outcome; Uracil | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Stomach Neoplasms | 2004 |
Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.
Topics: Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Neutropenia; Sodium Bicarbonate; Survival Analysis; Treatment Outcome; Water | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2004 |
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2004 |
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Taxoids | 2004 |
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome | 2004 |
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2004 |
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Confidence Intervals; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Oligodendroglioma | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 2004 |
Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Treatment Outcome | 2004 |
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2004 |
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Female; Humans; Irinotecan; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Treatment Outcome | 2004 |
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis | 2004 |
A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel | 2004 |
Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids | 2004 |
Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2004 |
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Gene Expression Profiling; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Multivariate Analysis; Prognosis; Thymidylate Synthase; Treatment Outcome | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2004 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged | 2004 |
Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Genes, erbB-1; Head and Neck Neoplasms; Humans; Immunoglobulin G; Irinotecan; Lung Neoplasms; Male; Mice | 2004 |
A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
The toxicity rates of two different regimens of irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Topoisomerase I Inhibitors | 2003 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life | 2004 |
Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Testicular Neoplasms; Treatment Failure | 2004 |
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiography; Thrombocytopenia; Treatment Outcome | 2004 |
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Topoisomerase I Inhibitors | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome | 2004 |
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Single-Blind Method; Survival Analysis; Topoisomerase I Inhibitors | 2004 |
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Survival Analysis; TATA Box | 2004 |
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Prospective Studies; Thymidylate Synthase | 2004 |
Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
Topics: Adsorption; Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon; Defecation; Diarrhea; Female; Humans; Irinotecan; Male; Microspheres; Middle Aged; Neoplasms; Oxides; Time Factors; Treatment Outcome | 2004 |
Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recombinant Proteins; Recurrence; Uterine Cervical Neoplasms | 2004 |
The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Male; Middle Aged; Muscarinic Antagonists; Neoplasm Metastasis | 2004 |
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Survival Rate | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Survival Analysis; Survival Rate | 2004 |
A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2004 |
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia | 2004 |
Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms | 2004 |
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prospective Studies; Uterine Cervical Neoplasms | 2004 |
Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prospective Studies; Safety; Time Factors | 2004 |
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prognosis; Survival Rate | 2004 |
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzodiazepines; Camptothecin; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mood Disorders; Nausea; Neoplasms; Olanzapine; Organoplatinum Compounds; Time Factors; Treatment Outcome; Vomiting | 2004 |
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Greece; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Patient Selection; Taxoids; Time Factors; Treatment Outcome; Withholding Treatment | 2004 |
Two schedules of second-line irinotecan for metastatic colon carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colonic Neoplasms; Cost Savings; Drug Administration Schedule; Female; Health Care Costs; Humans; Irinotecan; Male; Middle Aged; Quality of Life | 2004 |
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Charcoal; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endpoint Determination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Irinotecan; Lymphoma; Male; Middle Aged; Neoplasms; Phenobarbital | 2004 |
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2004 |
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Drug Interactions; Female; Humans; Ifosfamide; Irinotecan; Male; Osteosarcoma; Pharmacokinetics | 2004 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Interactions; Female; Floxuridine; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Up-Regulation | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasms; Camptothecin; Celecoxib; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Infusions, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Pyrazoles; Risk Assessment; Statistics, Nonparametric; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Temozolomide; Treatment Outcome | 2005 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Israel; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2004 |
Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2004 |
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2005 |
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Time Factors; Treatment Outcome | 2004 |
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Pilot Projects | 2004 |
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Quality of Life; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2005 |
A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Rectal Neoplasms | 2004 |
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Treatment Outcome | 2005 |
Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2005 |
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Rectal Neoplasms; Treatment Outcome | 2005 |
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors | 2004 |
Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Radiotherapy, Adjuvant; Treatment Outcome; Upper Gastrointestinal Tract | 2004 |
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2004 |
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Male; Treatment Outcome | 2004 |
Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Placebos; Quality of Life; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Patient Selection; Prodrugs; Safety | 2005 |
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Failure | 2005 |
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Transplantation, Heterologous | 2005 |
A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2006 |
Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2005 |
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Humans; Incidence; Irinotecan; Risk Factors; Stomach Neoplasms; Thromboembolism; Thrombophilia | 2005 |
First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Neutropenia; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting | 2005 |
Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia | 2005 |
Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Time Factors; Treatment Outcome | 2004 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Topics: Aged; Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; ErbB Receptors; Female; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Panitumumab | 2005 |
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids | 2005 |
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytoprotection; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplasm Metastasis | 2005 |
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2005 |
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Female; Heart Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Prospective Studies | 2005 |
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Cyclosporine; Drug Interactions; Female; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged | 2005 |
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Drug Administration Schedule; Drug Interactions; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucose; Hemodilution; Humans; Hyperthermia, Induced; Hypoalbuminemia; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Period; Prospective Studies; Red-Cell Aplasia, Pure; Treatment Outcome | 2005 |
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Geriatric Assessment; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Invasiveness; Neoplasm Staging; Probability; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2005 |
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiology Phenomena; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2005 |
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome | 2006 |
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Caco-2 Cells; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Induction; Female; Flavonoids; Glucuronates; Glucuronosyltransferase; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pilot Projects | 2006 |
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cytarabine; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Irinotecan; Leukemia, Myeloid; Male; Middle Aged; Recurrence | 2006 |
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids | 2005 |
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Korea; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2005 |
A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms | 2005 |
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cetuximab; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged | 2005 |
Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Taxoids | 2006 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis | 2005 |
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; CD3 Complex; CD4 Antigens; CD8 Antigens; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Humans; Immunodominant Epitopes; Immunotherapy; Interferon-gamma; Interleukin-2; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Prospective Studies; T-Lymphocytes; Treatment Outcome | 2005 |
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis; Treatment Outcome | 2005 |
Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2005 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Prospective Studies; Survival Analysis | 2005 |
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Survival Rate; Tegafur; Uracil; Vomiting, Anticipatory | 2005 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Weight Loss | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Camptothecin; Hematologic Diseases; HIV Infections; Humans; Irinotecan; Male; Middle Aged; Sarcoma, Kaposi; Treatment Outcome | 2005 |
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Lactones; Middle Aged; Neoplasm Metastasis; Sulfones | 2005 |
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2006 |
Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Humans; Irinotecan; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2005 |
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Topoisomerases, Type I; Drug Therapy, Combination; Follow-Up Studies; Humans; Irinotecan; Treatment Outcome | 2005 |
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2005 |
Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Granisetron; Humans; Irinotecan; Male; Middle Aged; Nausea; Pilot Projects; Vomiting | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cholagogues and Choleretics; Cisplatin; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Maximum Tolerated Dose; Middle Aged; Sodium Bicarbonate; Survival Analysis; Ursodeoxycholic Acid | 2005 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure | 2006 |
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2005 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis | 2006 |
Same-day pegfilgrastim and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; Disease-Free Survival; DNA, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hepatectomy; Humans; Irinotecan; Life Tables; Liver Neoplasms; Male; Microsatellite Repeats; Middle Aged; Neoplasm Proteins; Neutropenia; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Italy; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Survival Analysis | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Time Factors; Treatment Outcome | 2005 |
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Leukocytes, Mononuclear; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oligonucleotides, Antisense; Thionucleotides | 2006 |
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Powders; Sensitivity and Specificity | 2006 |
A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2006 |
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Dose-Response Relationship, Drug; Female; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Time Factors; Treatment Outcome; Vitamins | 2005 |
Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms | 2005 |
Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate | 2005 |
Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Saliva; Tissue Distribution | 2006 |
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neutropenia; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2006 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2006 |
Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Uterine Cervical Neoplasms | 2005 |
Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophagectomy; Esophagogastric Junction; Female; Floxuridine; Gastrectomy; Humans; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Treatment Outcome | 2005 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome | 2006 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Sex Factors; Treatment Outcome | 2006 |
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Terminally Ill; Treatment Outcome | 2005 |
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Cirrhosis; Liver Neoplasms; Male | 2006 |
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cefixime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Diarrhea; Feces; Female; Glucuronidase; Humans; Irinotecan; Lactones; Male; Neoplasms; Severity of Illness Index | 2006 |
Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2006 |
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2006 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Italy; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Selenomethionine; Treatment Outcome | 2006 |
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis | 2005 |
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Epilepsy; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2006 |
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2006 |
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Safety; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2006 |
Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2006 |
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Survivors; Tegafur; Treatment Outcome | 2006 |
New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Vascular Endothelial Growth Factor A | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
Salvage chemotherapy with CPT-11 for recurrent meningioma.
Topics: Aged; Agranulocytosis; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Male; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Failure | 2006 |
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2006 |
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administration Schedule; Enteroendocrine Cells; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium Bicarbonate | 2006 |
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2006 |
Irinotecan for children with relapsed solid tumors.
Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor | 2006 |
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Diarrhea; Disorders of Excessive Somnolence; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2006 |
Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Disease Progression; Dose Fractionation, Radiation; Esophagitis; Feasibility Studies; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Thrombocytopenia; Treatment Outcome | 2006 |
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Outpatients; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2007 |
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Gastrointestinal Tract; Half-Life; Humans; Irinotecan; Male; Neoplasm Metastasis; Neoplasms | 2006 |
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection | 2006 |
A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Prospective Studies; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Natriuretic Peptide, Brain; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Prognosis; Recurrence; Rituximab; Survival Analysis; Survival Rate; Treatment Outcome; Troponin T | 2006 |
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2006 |
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Fecal Incontinence; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Pancytopenia; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2006 |
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2007 |
Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Radiotherapy; Recurrence; Time Factors; Treatment Outcome | 2006 |
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome | 2007 |
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Digestive System Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Massachusetts; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2006 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capsules; Diarrhea; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Nausea; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Remission Induction; Tegafur | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur; Vomiting, Anticipatory | 2006 |
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asia; Camptothecin; Female; Genotype; Half-Life; Haplotypes; Humans; Inactivation, Metabolic; Irinotecan; Leukocyte Count; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organic Anion Transporters | 2006 |
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Compliance | 2006 |
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2006 |
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Rectal Neoplasms; Recurrence; Treatment Outcome | 2006 |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2006 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Japan; Mitomycin; Ovarian Neoplasms; Pilot Projects; Salvage Therapy; Uterine Cervical Neoplasms | 2006 |
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Mass Screening; Middle Aged; Neomycin; Placebos; Stomach Neoplasms | 2006 |
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome | 2006 |
A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Camptothecin; Colorectal Neoplasms; Cytokines; Dietary Proteins; Dietary Supplements; Eicosapentaenoic Acid; Energy Intake; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Male; Malnutrition; Middle Aged; Nutritional Status; Nutritional Support; Phospholipids; Quality of Life; Treatment Outcome; Vitamin B Complex | 2007 |
Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2006 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2006 |
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Teniposide; Tomography, X-Ray Computed | 2007 |
Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, T-Cell; Male; Mitoxantrone; Natriuretic Peptides; Neoplasm Recurrence, Local; Stroke Volume; Troponin T; Ventricular Function, Left | 2007 |
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2007 |
Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2006 |
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Pyrazines | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2007 |
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2007 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2006 |
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Ontario; Time Factors; Treatment Outcome | 2007 |
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Paris; Prospective Studies; Time Factors; Treatment Outcome | 2007 |
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; HT29 Cells; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Treatment Outcome | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2007 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2007 |
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Male; Middle Aged; Mutation; Quinazolines | 2007 |
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Irinotecan; Neoplasm Metastasis; Salvage Therapy; Survival Analysis | 2007 |
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Tegafur; Uracil | 2007 |
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dietary Supplements; Drug Interactions; Female; Glutamates; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Vitamins | 2007 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Rectal Neoplasms; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Rhabdomyosarcoma; Survival Analysis; Treatment Outcome | 2007 |
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Metastasis; Rhabdomyosarcoma; Treatment Outcome; Vincristine | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2007 |
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies | 2007 |
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Follow-Up Studies; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Analysis; Testicular Neoplasms; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome | 2007 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Vitamin B Complex | 2007 |
Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2007 |
[Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Survival Rate | 2006 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Patient Compliance; Quality of Life; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2007 |
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Sample Size; Survival Rate; Treatment Failure | 2007 |
Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2006 |
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thalidomide | 2006 |
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pharmacogenetics; Probability; Survival Analysis; Treatment Outcome | 2006 |
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids | 2007 |
Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging | 2007 |
Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Tegafur | 2007 |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors | 2008 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 2007 |
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate | 2008 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Survival Analysis | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2007 |
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2008 |
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Compliance | 2007 |
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Taxoids | 2007 |
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Topics: Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Treatment Outcome | 2007 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Vitamin B Complex | 2007 |
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Gene Frequency; Genotype; Haplotypes; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Treatment Outcome | 2007 |
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Vitamin B Complex | 2007 |
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Topics: Adult; Aged; Area Under Curve; Camptothecin; Cytochrome P-450 CYP3A; Drug Interactions; Female; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Smoking; Treatment Failure | 2007 |
[Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Treatment Outcome | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis | 2007 |
HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Drug Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2007 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Odds Ratio; Rectal Neoplasms; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2007 |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil | 2007 |
Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Topics: Alleles; Animals; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carboxylesterase; Chlorocebus aethiops; COS Cells; Haplotypes; Humans; Hypersensitivity; Irinotecan; Linkage Disequilibrium; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs; RNA, Messenger; Sequence Analysis, DNA | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2007 |
Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2007 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Floxuridine; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2007 |
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2007 |
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Skin Diseases; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate | 2007 |
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Topics: Adult; Aged; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2007 |
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Tegafur; Uracil | 2007 |
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Genotype; Haplotypes; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Lung Neoplasms; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Treatment Outcome | 2008 |
A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2008 |
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Follow-Up Studies; Hong Kong; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prodrugs; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Virginia | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2007 |
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2007 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin | 2008 |
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2007 |
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Rituximab; Salvage Therapy; Vincristine | 2008 |
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Safety | 2007 |
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatoblastoma; Humans; Infant; Irinotecan; Male; Medulloblastoma; Neoplasms; Treatment Outcome | 2007 |
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2007 |
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2007 |
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2008 |
Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Quinazolines | 2008 |
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Survival Rate; Treatment Outcome | 2007 |
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Selenomethionine; Treatment Outcome | 2008 |
Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antidiarrheals; Camptothecin; Cholestyramine Resin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Levofloxacin; Male; Middle Aged; Ofloxacin; Time Factors | 2007 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2007 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Rectal Neoplasms | 2007 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival; Time Factors; Treatment Outcome | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2007 |
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Vaccines, DNA | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Thrombospondins; Vascular Endothelial Growth Factor A | 2007 |
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2007 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2008 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate | 2008 |
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis | 2008 |
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 2008 |
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
Topics: Adult; Aged; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organic Chemicals; Proliferating Cell Nuclear Antigen | 2008 |
Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy | 2008 |
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids | 2008 |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Irinotecan; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Female; Humans; Hypoxia; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Proportional Hazards Models; Radiography; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2007 |
[A pilot study of irinotecan hydrochloride(CPT-11)and cisplatin(CDDP)combination chemotherapy for previously treated non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Survival Rate | 2008 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Palliative Care; Survival Analysis | 2008 |
[Evaluation of bronchial arterial infusion (BAI) for lung cancer with carcinomatous pleuritis].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Pleurisy; Tomography, X-Ray Computed | 2007 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2007 |
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2008 |
Activated charcoal to prevent irinotecan-induced diarrhea in children.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Charcoal; Child; Child, Preschool; Diarrhea; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Treatment Outcome | 2008 |
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan | 2008 |
Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Sulfonamides | 2008 |
Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.
Topics: Anti-Infective Agents, Local; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Skin Diseases | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxaloacetates; Treatment Failure; Treatment Outcome | 2008 |
Chemotherapy for brain metastases in small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cranial Irradiation; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2008 |
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Disease Progression; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Analysis; Taxoids | 2008 |
Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Rate; Tegafur; Uracil | 2008 |
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Epothilones; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Paresthesia; Vomiting | 2008 |
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide | 2008 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Approval; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate; United States; United States Food and Drug Administration | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Tandem Repeat Sequences; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2007 |
Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2007 |
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein | 2008 |
Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Survival Rate | 2008 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide | 2008 |
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quality of Life | 2008 |
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms | 2008 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Gene Expression; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Feasibility Studies; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Penile Neoplasms; Time Factors; Treatment Outcome | 2008 |
Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Rectal Neoplasms; Tegafur | 2008 |
Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Tegafur; Uracil | 2009 |
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Pyrazines; Survival Rate | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide | 2008 |
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms | 2008 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2008 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms | 2008 |
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2008 |
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Radiotherapy, Adjuvant; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Time Factors; Treatment Outcome | 2008 |
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged; Survival Analysis; Thalidomide | 2008 |
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2008 |
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; T-Lymphocytes; Treatment Outcome; Viral Vaccines | 2008 |
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome | 2008 |
Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Treatment Outcome | 2009 |
Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Spain; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Tegafur; Treatment Outcome | 2008 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate; Vomiting; Young Adult | 2008 |
Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2008 |
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Selection; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; DNA Adducts; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2008 |
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Glutathione S-Transferase pi; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic | 2008 |
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic | 2008 |
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infant; Injections, Intravenous; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Prospective Studies; Thoracic Neoplasms; Treatment Outcome; Young Adult | 2008 |
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged | 2008 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome | 2008 |
Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2008 |
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms | 2009 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Survival Analysis | 2009 |
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2008 |
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2009 |
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 2009 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis | 2008 |
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Genotype; Haplotypes; Humans; Inactivation, Metabolic; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Linkage Disequilibrium; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2008 |
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2009 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Treatment Outcome | 2008 |
A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; Female; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Survival Analysis; Treatment Outcome | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Placebos; Retrospective Studies; Survival Rate | 2009 |
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Glucuronides; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Tegafur; Uracil | 2009 |
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Rate | 2009 |
Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2009 |
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2009 |
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy; Irinotecan; Male; Oxonic Acid; Peptides; Tegafur; Tomography, X-Ray Computed | 2008 |
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2009 |
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nausea; Proctitis; Rectal Neoplasms; Remission Induction; Vomiting | 2009 |
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2009 |
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Predictive Value of Tests | 2009 |
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Floxuridine; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2009 |
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis | 2009 |
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure; Treatment Outcome | 2009 |
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Adenosquamous; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Incidence; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Prognosis; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2009 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Simvastatin | 2009 |
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Recurrence; Temozolomide | 2009 |
Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Celecoxib; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2009 |
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Recurrence; Risk Assessment | 2009 |
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Rate | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Digestive System Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome; Vitamin B Complex | 2010 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome | 2009 |
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Survival Analysis | 2009 |
Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Analysis; Young Adult | 2009 |
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Japan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pyrimidines | 2009 |
Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Uterine Cervical Neoplasms | 2009 |
Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2009 |
A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nimustine; Paclitaxel; Small Cell Lung Carcinoma; Survival Analysis | 2009 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colorectal Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Metastasis; Organic Anion Transporters; Polymorphism, Genetic; Prospective Studies; Retrospective Studies | 2007 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vomiting | 2009 |
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Cohort Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2009 |
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Drug Interactions; Female; Fluorouracil; Gastrointestinal Tract; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2009 |
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Camptothecin; DNA Topoisomerases, Type I; Humans; Intestinal Mucosa; Irinotecan; Neoadjuvant Therapy; Neoplasm Invasiveness; Prospective Studies; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Treatment Outcome | 2009 |
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Humans; Irinotecan; Multivariate Analysis; Radiography; Regression Analysis; Treatment Outcome | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Uracil | 2009 |
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Capecitabine; Cell Cycle Proteins; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Fluorouracil; Humans; Irinotecan; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2009 |
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Preoperative Period; Prospective Studies; Remission Induction; Spain; Stomach Neoplasms; Survival Rate | 2009 |
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors | 2010 |
Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Immunohistochemistry; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Young Adult | 2009 |
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Palliative Care; Quality of Life; Stomach Neoplasms; Young Adult | 2009 |
Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 2009 |
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate | 2009 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms | 2010 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Colitis; Dacarbazine; Diarrhea; Female; Humans; Irinotecan; Male; Neutropenia; Pneumonia; Recurrence; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Adjuvant; Stomach Neoplasms | 2010 |
Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Epidemiologic Methods; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2009 |
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Australia; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Microspheres; Middle Aged; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Yttrium Isotopes | 2009 |
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Complementarity Determining Regions; Female; Fluorouracil; Genes, T-Cell Receptor beta; Hematuria; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Proteinuria; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult | 2009 |
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Microsatellite Instability; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Smad4 Protein; Telomerase; Tumor Suppressor Protein p53 | 2009 |
Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Rectal Neoplasms | 2009 |
A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Division; Colorectal Neoplasms; Drug Monitoring; Drug Resistance, Neoplasm; HT29 Cells; Humans; Irinotecan; Ki-67 Antigen; Liver Neoplasms; Polyhydroxyethyl Methacrylate; Radiography; Topoisomerase I Inhibitors | 2011 |
[Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2009 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome | 2010 |
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult | 2009 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2009 |
[Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2009 |
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2010 |
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Single Nucleotide | 2010 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2010 |
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2010 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Deoxycytidine; Diarrhea; Fecal Incontinence; Female; Fluorouracil; Gangrene; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Proctitis; Pyrazoles; Radiation Injuries; Radiation-Sensitizing Agents; Rectal Neoplasms; Sulfonamides | 2010 |
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Male; Middle Aged; Oxonic Acid; Proportional Hazards Models; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome; Young Adult | 2009 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States | 2009 |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Predictive Value of Tests; Probability; Survival Analysis; Thymidylate Synthase; Time Factors; Treatment Outcome | 2009 |
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2009 |
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Microsatellite Instability; Mutation; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Precision Medicine; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Gemcitabine; Humans; Irinotecan; Life Expectancy; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Piperidines | 2010 |
Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Registries; Treatment Outcome | 2009 |
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Genes, ras; Humans; Irinotecan; Male; Microsatellite Repeats; Middle Aged; Mutation; Oncogene Protein p21(ras); Proportional Hazards Models; Treatment Outcome | 2009 |
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2009 |
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cytokines; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2010 |
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2010 |
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Purines; Treatment Outcome | 2010 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate | 2009 |
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carmustine; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Radiotherapy; Statistics as Topic; Time Factors; Young Adult | 2010 |
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Female; Humans; Individuality; Irinotecan; Male; Midazolam; Middle Aged; Models, Biological; Neoplasm Metastasis; Phenotype; Precision Medicine; Prodrugs | 2010 |
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2011 |
Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recurrence; Retreatment; Small Cell Lung Carcinoma | 2010 |
Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Survival Analysis | 2010 |
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polymorphism, Genetic; Pyridines; Thiosemicarbazones; Treatment Outcome | 2010 |
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Topoisomerase I Inhibitors | 2010 |
[Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2010 |
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Operating characteristics of two independent sample design in phase I trials in paediatric oncology.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Models, Statistical; Odds Ratio; Research Design; Sample Size; Treatment Outcome | 2010 |
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thymidylate Synthase; Treatment Outcome | 2011 |
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Topics: 3' Untranslated Regions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Genotype; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy | 2010 |
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Follow-Up Studies; Humans; Irinotecan; Stomach Neoplasms; Survival Rate | 2011 |
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Kidney Failure, Chronic; Leukopenia; Male; Middle Aged; Rectal Neoplasms; Renal Dialysis; Stomach Neoplasms | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Recombinant Proteins; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2010 |
Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gastrectomy; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Neoplasms; Stomach Neoplasms | 2011 |
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Celecoxib; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Radiotherapy; Uterine Cervical Neoplasms | 2010 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2010 |
Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Longitudinal Studies; Male; Middle Aged; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur; Time Factors; Treatment Outcome | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Decision Making; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Research Personnel; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2011 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2010 |
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Carriers; Female; Humans; Hyaluronic Acid; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Risk Factors; Survival; Treatment Outcome | 2011 |
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Confidence Intervals; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vitamin B Complex | 2010 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Chronotherapy; ErbB Receptors; Female; Fluorouracil; Gene Amplification; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Young Adult | 2010 |
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2010 |
Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Female; Humans; Irinotecan; Leukocyte Count; Male; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Neutrophils; Nonlinear Dynamics; Regression Analysis | 2010 |
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recombinant Proteins | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Brain Stem Neoplasms; Camptothecin; Child; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Phosphorylation; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Conformal | 2010 |
Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Time Factors; Treatment Outcome | 2010 |
Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2010 |
Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Preoperative Period; Rectal Neoplasms; Remission Induction; Survival Rate | 2011 |
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Survival; Tegafur; Treatment Outcome | 2010 |
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Radiotherapy, Adjuvant; Vindesine | 2010 |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Patient Selection; Polymorphism, Genetic; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2010 |
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2010 |
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Colorectal Neoplasms; Confidence Intervals; Digestive System Diseases; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hypertension; Irinotecan; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Registries; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2010 |
Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Iodized Oil; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult | 2011 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur | 2010 |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biliary Tract Neoplasms; Camptothecin; Cholangiocarcinoma; Common Bile Duct Neoplasms; Female; Gallbladder Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2010 |
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophagitis; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Severity of Illness Index | 2011 |
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Lymphocyte Culture Test, Mixed; Male; Middle Aged; T-Lymphocytes; Time Factors; Treatment Outcome | 2012 |
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Statistics as Topic; Stomach Neoplasms; Surveys and Questionnaires; Survival Analysis; Taxoids; Time Factors; Vitamin B Complex | 2010 |
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Recurrence; Rhabdomyosarcoma; Risk Factors; Time Factors; Treatment Outcome; United States; Vincristine | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2012 |
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Preoperative Care; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Radiotherapy Dosage; ras Proteins; Rectal Neoplasms; Remission Induction | 2011 |
Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Recurrence | 2010 |
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nanoparticles; Neoplasms | 2010 |
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction | 2011 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Research Design; Time Factors; Treatment Outcome | 2010 |
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
[Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Female; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Treatment Outcome | 2010 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Young Adult | 2011 |
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Prospective Studies; Renal Dialysis; Renal Insufficiency | 2011 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Japan; Leukopenia; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Craniotomy; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Glucocorticoids; Humans; Injections, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Burden; Young Adult | 2012 |
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Survival Rate; Young Adult | 2010 |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Blood Chemical Analysis; Camptothecin; Disease Progression; Docetaxel; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Taxoids; Upper Gastrointestinal Tract | 2010 |
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Intra-Abdominal Fat; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur | 2010 |
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Levoleucovorin; Male; Middle Aged; Treatment Outcome | 2011 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Humans; Infant; Irinotecan; Male; Neuroblastoma; Temozolomide | 2011 |
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2011 |
A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Tumor Burden | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Small Cell Lung Carcinoma | 2012 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2011 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2010 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tegafur; Treatment Failure | 2012 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure | 2012 |
Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2010 |
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Tumor Cells, Cultured | 2011 |
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Recombinant Proteins; Remission Induction | 2011 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Greece; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult | 2011 |
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Topoisomerase I Inhibitors; Treatment Outcome | 2011 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Oxonic Acid; Patient Selection; Salvage Therapy; Serum Albumin; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2011 |
Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Genetic Linkage; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Salvage Therapy; Treatment Outcome | 2011 |
Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Medical Oncology; Safety; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2011 |
Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Japan; Male; Methotrexate; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
Topics: Adolescent; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cefpodoxime; Ceftizoxime; Child; Child, Preschool; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Topoisomerase I Inhibitors; Young Adult | 2012 |
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2011 |
A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lipids; Lipoproteins; Lung Neoplasms; Male; Middle Aged; Simvastatin; Small Cell Lung Carcinoma; Smoking | 2011 |
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2011 |
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dipeptides; Drug Resistance, Neoplasm; Humans; Irinotecan | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Positron-Emission Tomography; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chemistry, Pharmaceutical; Emulsions; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Succinates; Technology, Pharmaceutical; Vitamin E | 2011 |
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Vitamin B Complex | 2011 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Young Adult | 2012 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2011 |
Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2011 |
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Gastrointestinal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Polymorphism, Single Nucleotide | 2011 |
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Germany; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Vitamin B Complex | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Rectal Neoplasms | 2012 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia | 2012 |
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Gefitinib; Homovanillic Acid; Humans; Immunohistochemistry; Infant; Infant, Newborn; Irinotecan; L-Lactate Dehydrogenase; Male; Neoplasm Proteins; Neuroblastoma; Pilot Projects; Quinazolines; Risk Factors; Treatment Outcome; Tumor Burden; Vanilmandelic Acid | 2012 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Splenic Neoplasms; Treatment Outcome | 2011 |
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2012 |
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Genotype; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Vascular Endothelial Growth Factor A | 2012 |
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Real-Time Polymerase Chain Reaction; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Half-Life; Humans; Irinotecan; Leucovorin; Male; Mice; Middle Aged; Phytotherapy | 2011 |
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2011 |
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Humans; Irinotecan; Neoplasms; Thalidomide | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Metastasis; Quality of Life | 2011 |
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2013 |
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2012 |
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Catheterization; Diarrhea; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Rate; Young Adult | 2011 |
Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.
Topics: Aged; Biotransformation; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Infusions, Intra-Arterial; Irinotecan; Middle Aged; Neoplasm Metastasis; Time Factors | 2011 |
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Platelet-Derived Growth Factor; Proportional Hazards Models; Vascular Endothelial Growth Factor A | 2011 |
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2011 |
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2012 |
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Neoplasms, Squamous Cell; Positron-Emission Tomography | 2012 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Polymerase Chain Reaction; Premedication; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Skin Diseases; Survival Rate; Young Adult | 2011 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2011 |
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 5; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Proteomics; Vorinostat | 2012 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Genotype; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Radiation-Sensitizing Agents; Rectal Neoplasms; Treatment Outcome; Young Adult | 2011 |
Immunogenicity of panitumumab in combination chemotherapy clinical trials.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Hypersensitivity; Humans; Incidence; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Severity of Illness Index | 2011 |
[Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2011 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2011 |
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Topoisomerase Inhibitors; Young Adult | 2013 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate | 2012 |
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins B-raf | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Peritoneal Neoplasms; Prospective Studies | 2012 |
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2011 |
Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.
Topics: Aged; Aged, 80 and over; Arteries; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prospective Studies; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Withholding Treatment | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Stomach Neoplasms; Survival Analysis | 2012 |
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Deoxycytidine; Epidemiologic Methods; Female; Gelatin Sponge, Absorbable; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate | 2012 |
Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Ovarian Neoplasms; Research Design; Taxoids | 2012 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2012 |
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vitamin B Complex | 2012 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment Outcome | 2012 |
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platinum Compounds; Proportional Hazards Models; Prospective Studies; Pyrimidines; Republic of Korea; Risk Assessment; Risk Factors; Salvage Therapy; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins | 2012 |
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Iodine Radioisotopes; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Prognosis; Tissue Distribution; Vincristine; Young Adult | 2012 |
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Topics: Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2012 |
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2012 |
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thoracic Neoplasms | 2012 |
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Thymidylate Synthase | 2012 |
Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prospective Studies | 2012 |
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms | 2012 |
Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Rectal Neoplasms; Skin Diseases; Treatment Outcome | 2012 |
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2012 |
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Standard of Care; Survival Rate; Young Adult | 2012 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Treatment Outcome | 2012 |
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Polymorphism, Genetic; Tegafur; Treatment Outcome | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Phosphorylase; Treatment Outcome | 2012 |
Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genetic Variation; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds | 2012 |
Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Uterine Cervical Neoplasms; Young Adult | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution | 2013 |
Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Child; Female; Humans; Irinotecan; Male; Pilot Projects; Rhabdomyosarcoma; Soft Tissue Neoplasms | 2013 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2013 |
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Retrospective Studies; Signal Transduction; Skin; Treatment Outcome | 2013 |
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Preoperative Care; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2013 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Delayed-Action Preparations; Diffusion Magnetic Resonance Imaging; Female; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Angiography; Male; Melanoma; Microspheres; Middle Aged; Prognosis; Treatment Outcome; Uveal Neoplasms | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Irinotecan; Male; Middle Aged | 2012 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2012 |
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2012 |
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Isosorbide Dinitrate; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; Treatment Outcome | 2012 |
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Treatment Outcome | 2012 |
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Hepatectomy; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Small Cell Lung Carcinoma; Thrombosis | 2012 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Young Adult | 2013 |
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Radiography, Interventional; Time Factors; Treatment Outcome | 2012 |
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Treatment Outcome | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prealbumin; Predictive Value of Tests; Prognosis; Receptors, Albumin; Sensitivity and Specificity; Serum Amyloid A Protein; Sweden; Tissue Inhibitor of Metalloproteinase-1; Tissue Polypeptide Antigen | 2012 |
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Prospective Studies; Tegafur; Young Adult | 2012 |
Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2012 |
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2012 |
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Ependymoma; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Salvage Therapy; Young Adult | 2012 |
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Disease Progression; Drug Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2013 |
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 18; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Loss of Heterozygosity; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Research Design; Smad4 Protein | 2012 |
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
Topics: Aged; Camptothecin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Small Cell Lung Carcinoma | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged | 2013 |
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2013 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Radiotherapy, Intensity-Modulated; ras Proteins; Rectal Neoplasms; Treatment Outcome | 2014 |
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2014 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Carriers; Europe; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Time Factors; Treatment Outcome | 2013 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2013 |
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Genes, p53; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mutation; Ribosomal Protein S6; Staurosporine; Treatment Outcome | 2013 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tissue Distribution | 2013 |
A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; fas Receptor; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Panitumumab; Prospective Studies; ras Proteins; Time Factors; Treatment Outcome | 2013 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Markers; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index | 2013 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Camptothecin; Docetaxel; Drug Carriers; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nanocapsules; Stomach Neoplasms; Survival Rate; Taxoids | 2013 |
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoradiotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prospective Studies; Stomach Neoplasms; Young Adult | 2013 |
Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Temozolomide; Treatment Outcome | 2013 |
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cognition Disorders; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Geriatric Assessment; Health Services for the Aged; Humans; Irinotecan; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2013 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2013 |
Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Genotype; Humans; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Treatment Outcome | 2013 |
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Treatment Outcome | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Outcome | 2013 |
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Prodrugs; Treatment Outcome | 2013 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2013 |
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; DNA; Female; Genotype; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Retrospective Studies | 2013 |
Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Rectal Neoplasms; Survival Rate; Treatment Failure; Young Adult | 2013 |
Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Survival Rate; Treatment Outcome | 2013 |
Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2013 |
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Denmark; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Republic of Korea; Young Adult | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cefixime; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Pilot Projects; Sarcoma, Ewing; Temozolomide; Vincristine | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2013 |
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Panitumumab; Proportional Hazards Models; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins B-raf; Pyrimidines; Sirolimus; Treatment Outcome | 2013 |
Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Blotting, Western; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Drug Delivery Systems; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver; Liver Neoplasms; Mass Spectrometry; Microsomes; Neoplasm Proteins; Prospective Studies; Reproducibility of Results | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2013 |
Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Male; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Survival Rate; Temozolomide; Time Factors; Vincristine | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Imaging, Three-Dimensional; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Organoplatinum Compounds; Pemetrexed; Stomach Neoplasms; Treatment Outcome | 2013 |
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Sex Factors; Survival Rate; Young Adult | 2013 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Polymorphism, Genetic; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study.
Topics: Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Survival Analysis; Tomography, X-Ray Computed | 2013 |
A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Patient Selection; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2013 |
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Irinotecan; Male; Medulloblastoma; Temozolomide | 2013 |
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Liposomes; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Sucrose; Treatment Outcome | 2013 |
CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression; Humans; Irinotecan; Male; Oxonic Acid; Prognosis; RNA, Messenger; Stomach Neoplasms; Survival; Tegafur; Thymidylate Synthase; Vascular Endothelial Growth Factor A | 2013 |
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Recurrence; Temozolomide; Vincristine; Young Adult | 2013 |
UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Interactions; Female; Humans; Irinotecan; Japan; Male; Maximum Tolerated Dose; Middle Aged; Receptor, IGF Type 1; Treatment Outcome | 2013 |
Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
Topics: Adult; Aged; Angiography; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Contrast Media; Disease Progression; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Camptothecin; Colorectal Neoplasms; Cyclosporine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Odds Ratio; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Survival Analysis; Young Adult | 2013 |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pharmacogenetics; Polymorphism, Genetic; Tegafur | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Tegafur | 2013 |
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Liposomes; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2013 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Camptothecin; Child; Humans; Irinotecan; Risk; Sarcoma, Ewing | 2014 |
Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Glucuronides; Humans; Irinotecan; Male; Middle Aged | 2013 |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; UDP-Glucuronosyltransferase 1A9 | 2013 |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Oxaloacetates | 2013 |
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Polyethylene Glycols; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; United States | 2013 |
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Fatigue; Hemorrhage; Humans; Hypertension; Infant; Injections, Intravenous; Irinotecan; Neoplasm Recurrence, Local; Proteinuria; Young Adult | 2013 |
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Young Adult | 2013 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2013 |
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectum; Treatment Outcome | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Metastasis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Reduced Folate Carrier Protein; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2013 |
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Young Adult | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Young Adult | 2014 |
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2013 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; DNA, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Outcome | 2013 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2014 |
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2014 |
A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2013 |
A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Protective Agents; Treatment Outcome | 2014 |
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib | 2014 |
Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate | 2013 |
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Postoperative Period; Preoperative Period; Stomach; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Temozolomide; Treatment Outcome | 2014 |
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Simvastatin; Treatment Outcome | 2014 |
A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Clinical Protocols; Disease-Free Survival; Etoposide; Female; Humans; Incidence; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Patient Selection; Survival Analysis; Treatment Outcome | 2014 |
Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Decision-Making; Colorectal Neoplasms; Decision Trees; Disease-Free Survival; DNA Mutational Analysis; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinase; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms | 2014 |
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Creatinine; Disease-Free Survival; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2014 |
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2014 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Japan; Male; Neoplasm Metastasis; Prognosis; Risk Factors; Stomach Neoplasms | 2014 |
A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Pilot Projects; Pneumonectomy; Young Adult | 2014 |
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cetuximab; Diarrhea; Disease-Free Survival; Docetaxel; Enoxaparin; Female; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids; Thromboembolism | 2016 |
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Membrane Glycoproteins; Middle Aged; Young Adult | 2014 |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Tumor Burden | 2014 |
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Recurrence; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide | 2014 |
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Retrospective Studies; Transcriptome | 2014 |
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids | 2014 |
Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child, Preschool; Disease-Free Survival; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Survival Rate; Time Factors; Vincristine | 2015 |
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; CpG Islands; Disease-Free Survival; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Phenotype; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2014 |
Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; GTP Phosphohydrolases; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Gastrins; Humans; Infusions, Intravenous; Injections, Intramuscular; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Vomiting | 2014 |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Maximum Tolerated Dose; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Survival Rate; Tegafur | 2015 |
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Topics: Adipokines; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Prognosis; Prospective Studies; Survival; Treatment Outcome | 2014 |
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Aluminum Silicates; Antineoplastic Agents, Phytogenic; Camptothecin; Clay; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Placebos; Treatment Outcome; Young Adult | 2015 |
A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Ewing; Taxoids; Young Adult | 2014 |
Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Stomach Neoplasms; Treatment Outcome | 2014 |
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genes, ras; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Receptor, ErbB-2; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2015 |
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sulfonamides; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Female; Fluorouracil; Follow-Up Studies; Genetic Association Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; MRE11 Homologue Protein; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome; Young Adult | 2014 |
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Integrin alphaV; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Female; Humans; Irinotecan; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Neoplasm Proteins; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Topoisomerase I Inhibitors | 2015 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Genomic landscape of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Camptothecin; Chromosomes, Human, Pair 6; Colorectal Neoplasms; DNA Copy Number Variations; Drug Resistance, Neoplasm; Genes, Neoplasm; Genome, Human; Humans; Irinotecan; Treatment Outcome | 2014 |
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Rabbits | 2015 |
A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Republic of Korea; Young Adult | 2015 |
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms; Salvage Therapy; Survival Analysis | 2015 |
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Young Adult | 2015 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2014 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2015 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Pharmacogenetics; Treatment Outcome | 2015 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Radiotherapy Dosage; Vincristine; Young Adult | 2015 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2015 |
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Young Adult | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Diarrhea; Female; Follow-Up Studies; Humans; Intestine, Small; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rectal Neoplasms | 2015 |
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Cortex; Contrast Media; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Everolimus; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus | 2015 |
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Failure | 2015 |
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease-Free Survival; Drug Delivery Systems; Feasibility Studies; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2015 |
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Young Adult | 2015 |
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Stomach Neoplasms | 2015 |
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quality of Life; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Topics: Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Gene Dosage; Genetic Markers; Humans; Irinotecan; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pelvic Neoplasms; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Remission Induction; Survival Rate; Young Adult | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2015 |
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Drug Interactions; Enzyme Induction; Female; Glioma; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Phenobarbital; Phenytoin | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate | 2015 |
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide; Treatment Outcome | 2015 |
Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.
Topics: Aged; Aged, 80 and over; Camptothecin; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Probiotics | 2015 |
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2015 |
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2015 |
The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Uterine Cervical Neoplasms; Young Adult | 2016 |
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Hypersensitivity; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2015 |
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Thymine; Trifluridine; Uracil | 2015 |
The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Treatment Outcome | 2015 |
Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.
Topics: Academic Medical Centers; Animals; Antineoplastic Agents; Biomarkers; Camptothecin; Cell Line, Tumor; Cisplatin; Dietary Supplements; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acids; Fish Oils; Fishes; Food-Drug Interactions; Health Care Surveys; Humans; Irinotecan; Mice, Inbred BALB C; Neoplasms; Netherlands; Organoplatinum Compounds; Oxaliplatin; Seafood; Surveys and Questionnaires; Tumor Burden; Up-Regulation | 2015 |
Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Genes, ras; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Intention to Treat Analysis; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Quality of Life; Tegafur; Young Adult | 2015 |
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids | 2016 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting | 2016 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Hyperglycemia; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor, IGF Type 1; Up-Regulation | 2015 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome | 2015 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multivariate Analysis; Proportional Hazards Models; Treatment Outcome | 2016 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vincristine | 2016 |
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Republic of Korea; Simvastatin; Survival Analysis; Treatment Outcome | 2015 |
Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Outcome Assessment, Health Care; Paraffin Embedding; Prognosis; Proportional Hazards Models; Prospective Studies; Proto-Oncogene Proteins p21(ras); Tissue Fixation | 2015 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2016 |
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2015 |
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2016 |
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Retreatment; Sucrose; Treatment Outcome | 2016 |
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Phenotype; Raltegravir Potassium | 2016 |
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies | 2016 |
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle Proteins; DNA Repair; Female; Histones; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Topics: Adult; Anthracyclines; Apoptosis; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Irinotecan; MCF-7 Cells; Middle Aged; Signal Transduction; Young Adult | 2016 |
Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cisplatin; Drug Dosage Calculations; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Glucuronosyltransferase; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Stomach Neoplasms; Tomography, X-Ray Computed | 2016 |
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines | 2016 |
Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recurrence; Small Cell Lung Carcinoma | 2016 |
Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcom
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Survival Rate | 2016 |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Costs and Cost Analysis; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2016 |
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Macrophages; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Pyrrolidines; Receptors, CCR2 | 2016 |
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Carriers; Female; Glucuronosyltransferase; Homozygote; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Micelles; Middle Aged; Neoplasms; Polymers | 2016 |
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Phthalazines; Piperazines; Treatment Outcome | 2016 |
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Tegafur; Uracil | 2016 |
Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan.
Topics: Adult; Aged; Biomarkers; Camptothecin; Ceramides; Combined Modality Therapy; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiosurgery; Treatment Outcome | 2016 |
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quality of Life | 2016 |
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Constitutive Androstane Receptor; Drug Interactions; Female; France; Genetic Markers; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Xenobiotics | 2016 |
Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Biomarkers, Tumor; Camptothecin; Chi-Square Distribution; China; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Logistic Models; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenomic Variants; Phenotype; Predictive Value of Tests; Prospective Studies; ROC Curve; Treatment Outcome; Young Adult | 2016 |
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dihydrouracil Dehydrogenase (NADP); DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Combinations; Fatigue; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Eukaryotic Initiation Factor-4E; Female; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides; RNA, Messenger | 2016 |
Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Humans; Irinotecan; Metabolic Clearance Rate; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; GTP Phosphohydrolases; Humans; Irinotecan; Membrane Proteins; Mutation; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Research Design | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Psychometrics; Quality of Life; Temozolomide | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate | 2016 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Radiotherapy Planning, Computer-Assisted; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Panitumumab; Proto-Oncogene Proteins p21(ras); Survival Rate; Tegafur | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure | 2016 |
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Chronotherapy; Europe; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2016 |
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Chemoradiotherapy; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cyclooxygenase 2 Inhibitors; Deglutition Disorders; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging | 2016 |
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2016 |
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2016 |
PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Metastasectomy; Microspheres; Middle Aged; Neoadjuvant Therapy; Treatment Outcome | 2016 |
The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Health Status; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Retrospective Studies; Surveys and Questionnaires; Survival Analysis | 2016 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Ramucirumab | 2016 |
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Molecular Imaging; Necrosis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Uterine Cervical Neoplasms | 2016 |
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Exons; Female; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Irinotecan; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Receptor, IGF Type 1 | 2017 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Ramucirumab | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cisplatin; Female; Humans; Induction Chemotherapy; Intestinal Neoplasms; Irinotecan; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2017 |
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2017 |
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; ErbB Receptors; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Receptor, ErbB-3; Treatment Outcome; Young Adult | 2017 |
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2017 |
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2017 |
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2017 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; ErbB Receptors; Female; Florida; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Panitumumab; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2017 |
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Nitro Compounds; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Survival Rate | 2015 |
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome | 2017 |
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Care Facilities; Capecitabine; Databases, Factual; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2017 |
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2017 |
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Small Cell Lung Carcinoma | 2017 |
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion Molecules; Female; Glucuronosyltransferase; Half-Life; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Response Evaluation Criteria in Solid Tumors; Time Factors | 2017 |
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neuregulin-1; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Retrospective Studies | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Treatment of Locally Advanced Rectal Cancer: Turning Good Rationale Into Good Evidence?
Topics: Antineoplastic Agents; Camptothecin; Chemoradiotherapy; Colectomy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Care Management; Patient Selection; Rectal Neoplasms | 2017 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Rhabdomyoma; Survival Rate; Temozolomide; Vinculin | 2018 |
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2017 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Catecholamine Plasma Membrane Transport Proteins; Cetuximab; Colorectal Neoplasms; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Glucuronosyltransferase; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Vitamin K Epoxide Reductases | 2017 |
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Female; Follow-Up Studies; GTP Phosphohydrolases; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Postoperative Care; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms; Retrospective Studies; Survival Rate | 2017 |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms | 2017 |
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies | 2018 |
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2017 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Population Groups; Prognosis; Protein Serine-Threonine Kinases; Survival Rate | 2017 |
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Wnt-5a Protein | 2018 |
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Diphenylamine; Female; Humans; Irinotecan; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; TOR Serine-Threonine Kinases; Triazines | 2017 |
Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.
Topics: Adolescent; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Irinotecan; Kidney Neoplasms; Male; Risk Factors; Wilms Tumor | 2018 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxyuridine; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care | 2018 |
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pilot Projects; Pyridines; Treatment Outcome | 2017 |
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Survival Rate; Young Adult | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2018 |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth Processes; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2018 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult | 2017 |
A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma; Diarrhea; Disease-Free Survival; DNA-Binding Proteins; Endometrial Neoplasms; Endonucleases; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate; Thrombocytopenia; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2018 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Male | 2019 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate | 2019 |
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Progression-Free Survival; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide | 2019 |
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cohort Studies; Colorectal Neoplasms; Drug Dosage Calculations; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Survival Analysis | 2019 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Quality of Life; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2020 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Phenylurea Compounds; Precision Medicine; Prodrugs; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Time Factors; Young Adult | 2019 |
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nivolumab; Prognosis; Progression-Free Survival; Retrospective Studies; Stomach Neoplasms | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Bone Neoplasms; Camptothecin; Cell Count; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins; Risk Assessment; Young Adult | 2020 |
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2020 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Camptothecin; Esophageal Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypercalciuria; Irinotecan; Leucovorin; Magnesium; Male; Nephrocalcinosis; Prognosis; Renal Tubular Transport, Inborn Errors; Retrospective Studies; Survival Rate | 2020 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras) | 2020 |
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Proto-Oncogene Proteins p21(ras); Quality of Life; Retrospective Studies | 2021 |
Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Middle Aged; Quality of Life; Young Adult | 2021 |
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proton Pump Inhibitors | 2021 |
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Topoisomerase I Inhibitors | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Dietary Supplements; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Pilot Projects; Prospective Studies; Protective Agents; Silymarin; Treatment Outcome; Young Adult | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Prospective Studies; Retrospective Studies; Risk Factors; Survival Rate; Weight Loss | 2022 |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2022 |
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proto-Oncogene Proteins B-raf; Vemurafenib | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Rectal Neoplasms; Retrospective Studies | 2023 |
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorouracil; Humans; Immunity; Irinotecan; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Prospective Studies; Treatment Outcome | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2022 |
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Cyclin-Dependent Kinase 4; Female; Humans; Immunoconjugates; Irinotecan; Middle Aged; Receptor, ErbB-2; Vinorelbine | 2022 |
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms | 2023 |
Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Vascular Endothelial Growth Factor A | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
3772 other study(ies) available for camptothecin and irinotecan
| Article | Year |
|---|---|
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1991 |
Novel camptothecin derivatives. Part 1: oxyalkanoic acid esters of camptothecin and their in vitro and in vivo antitumor activity.
Topics: Acids; Alkanes; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Screening Assays, Antitumor; Esters; Humans; In Vitro Techniques; Tumor Cells, Cultured | 2002 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
Topics: Amines; Antineoplastic Agents; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Naphthyridines; Nitro Compounds; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrroles; Quinones; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2007 |
First synthesis of novel spin-labeled derivatives of camptothecin as potential antineoplastic agents.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Survival; Humans; Mice; Molecular Structure; Spin Labels; Structure-Activity Relationship | 2008 |
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2008 |
11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Leukemia, Lymphoid; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Esters; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Molecular Structure; Pharmaceutical Solutions; Phosphates; Structure-Activity Relationship | 2010 |
Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Plant Extracts; Protein Binding; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2010 |
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Brain; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2011 |
Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.
Topics: Amino Acid Sequence; Animals; Binding Sites; Camptothecin; DNA Topoisomerases, Type I; Drosophila melanogaster; Gene Knockout Techniques; HeLa Cells; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Humans; Molecular Sequence Data; Peptide Library; Protein Binding; Quartz Crystal Microbalance Techniques; Topoisomerase I Inhibitors | 2011 |
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship | 2012 |
Design and one-pot synthesis of new 7-acyl camptothecin derivatives as potent cytotoxic agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Humans; KB Cells; Molecular Structure; Structure-Activity Relationship | 2012 |
Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
Topics: Amidines; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms, Experimental; Structure-Activity Relationship; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Cycle; Cell Line, Tumor; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Evodia; Humans; Models, Molecular; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators | 2015 |
Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2016 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil | 2017 |
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones | 2017 |
Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
Topics: Anthraquinones; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Design; Humans; Molecular Docking Simulation; Neoplasms; Thiadiazoles; Topoisomerase I Inhibitors | 2017 |
Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorine; Humans; Structure-Activity Relationship; Topotecan | 2017 |
Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Drug Design; Female; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2018 |
Lamellarin-inspired potent topoisomerase I inhibitors with the unprecedented benzo[g][1]benzopyrano[4,3-b]indol-6(13H)-one scaffold.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Coumarins; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Male; Mice, Inbred BALB C; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2019 |
Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred ICR; Molecular Structure; Oligosaccharides; Solubility; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2020 |
[The effect of CPT-11 in combination with interferon-alpha against human colon carcinoma heterotransplanted in nude mice: preliminary report].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Humans; Interferon-alpha; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1992 |
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase II Inhibitors; Transplantation, Heterologous | 1992 |
Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Blotting, Northern; Camptothecin; Cell Division; Cell Line; DNA Topoisomerases, Type I; Drug Resistance; Gene Expression; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Molecular Sequence Data; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger | 1992 |
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1992 |
Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Cell Division; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Pancreatic Neoplasms; Thymidine; Tumor Cells, Cultured | 1992 |
Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Oligodeoxyribonucleotides; Point Mutation; Polymerase Chain Reaction; RNA, Neoplasm; Tumor Cells, Cultured | 1992 |
Intracellular distribution of CPT-11 in CPT-11-resistant cells with confocal laser scanning microscopy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Nucleus; Cytoplasm; Cytoplasmic Granules; Fluorescence; Humans; Image Processing, Computer-Assisted; Irinotecan; Lasers; Lung Neoplasms; Microscopy, Electron; Nuclear Envelope; Tumor Cells, Cultured; Ultrasonography | 1992 |
Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance; Female; Gene Expression; Genes, myc; Glutathione; Glutathione Transferase; Humans; In Vitro Techniques; Irinotecan; Membrane Glycoproteins; Ovarian Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1992 |
[Cytotoxic effect of CPT-11 against human recurrent carcinoma cells primarily cultured on contact-sensitive plates: preliminary report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Culture Media; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Metastasis; Recurrence; Tumor Cells, Cultured | 1992 |
Effects of CPT-11 in combination with other anti-cancer agents in culture.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Humans; In Vitro Techniques; Irinotecan; Leukemia, Lymphoid; Tumor Cells, Cultured | 1992 |
Chemical modification of an antitumor alkaloid, 20(S)-camptothecin: glycosides, phosphates and sulfates of 7-ethyl-10-hydroxycamptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Glycosides; Irinotecan; Leukemia L1210; Mice; Mice, Inbred Strains; Phosphates; Sulfates | 1992 |
Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged | 1992 |
Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Irinotecan; Time Factors | 1992 |
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; DNA Damage; DNA Replication; DNA, Single-Stranded; Irinotecan; Kinetics; Leukemia P388; Mice; RNA, Neoplasm; Thymidine; Topoisomerase I Inhibitors; Uridine | 1991 |
CPT-11 converting enzyme from rat serum: purification and some properties.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Hydrogen-Ion Concentration; Hydrolysis; Irinotecan; Isoelectric Point; Kinetics; Male; Molecular Weight; Prodrugs; Rats; Rats, Inbred Strains | 1991 |
Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.
Topics: Animals; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Enterohepatic Circulation; Feces; Glucuronidase; Hydrolysis; Intestinal Diseases; Irinotecan; Lactones; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Rats; Rats, Inbred Strains; Spectrometry, Fluorescence | 1991 |
Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Drug Synergism; Female; Genital Neoplasms, Female; Humans; Irinotecan; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1991 |
[An early phase II study of CPT-11 in primary lung cancer].
Topics: Adenocarcinoma; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 1991 |
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 1991 |
[Conversion of CPT-11 into SN-38 in human tissues].
Topics: Animals; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Liver; Lung; Pancreatic Neoplasms; Rats | 1991 |
[Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L 1210 leukemia].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Female; Irinotecan; Leukemia L1210; Methotrexate; Mice; Mitomycin; Mitomycins; Thioinosine | 1991 |
Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbamates; Female; Irinotecan; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Solubility; Water | 1991 |
[A phase I study of weekly administration of CPT-11 in lung cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1990 |
Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Lung Neoplasms; Tumor Cells, Cultured | 1990 |
Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Irinotecan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; T-Lymphocytes; Topoisomerase II Inhibitors | 1990 |
Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Humans; Immunoblotting; Irinotecan; Mice; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1990 |
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Female; Humans; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged | 1990 |
[Inhibitory effects of CPT-11 on liver metastases in nude mice injected with human pancreatic tumor cells into their spleens].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Depression, Chemical; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Spleen; Tumor Cells, Cultured | 1990 |
[Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fibrosarcoma; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Leukemia L1210; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental | 1990 |
Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Cell Division; Irinotecan; Kinetics; Leukemia L1210; Mice; Mice, Inbred Strains; Tissue Distribution; Tumor Cells, Cultured | 1990 |
Nonlinear pharmacokinetics of CPT-11 in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile; Biotransformation; Camptothecin; Glucuronates; Irinotecan; Male; Rats; Rats, Inbred Strains | 1990 |
Some pharmacological properties of a new antitumor drug, CPT-11, in isolated muscle preparations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aorta, Thoracic; Camptothecin; Female; Guinea Pigs; Heart; Ileum; In Vitro Techniques; Irinotecan; Male; Muscle, Smooth; Muscle, Smooth, Vascular; Rabbits; Rats; Rats, Inbred Strains; Trachea; Uterine Contraction; Vas Deferens | 1989 |
Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Resistance; Irinotecan; Leukemia P388; Neoplasms, Experimental; Tumor Cells, Cultured; Vincristine | 1988 |
Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.
Topics: Animals; Camptothecin; Clone Cells; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Metastasis | 1988 |
[Antitumor activity of CPT-11 against rat Walker 256 carcinoma].
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma 256, Walker; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Rats | 1988 |
[Antitumor activity of new derivatives of camptothecin].
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Irinotecan; Lethal Dose 50; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred ICR; Neoplasms, Experimental | 1987 |
[Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Female; Irinotecan; Ovarian Neoplasms; Tumor Stem Cell Assay | 1987 |
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Irinotecan; Mice; Mice, Inbred Strains; Neoplasms, Experimental | 1987 |
Partial purification and characterization of an esterase acting on the anticancer pro-drugs, 7-ethylcamptothecin derivatives.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Esterases; Irinotecan; Liver; Male; Pancreas; Prodrugs; Rats; Rats, Wistar | 1995 |
Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Cecum; Diarrhea; Drugs, Chinese Herbal; Enzyme Inhibitors; Flavonoids; Glucuronidase; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 1995 |
Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.
Topics: Animals; Camptothecin; Drugs, Chinese Herbal; Enzyme Inhibitors; Glucuronates; Glucuronosyltransferase; Irinotecan; Kinetics; Male; Microsomes, Liver; Nitrophenols; Rats; Rats, Wistar | 1995 |
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cecum; Cisplatin; Diarrhea; Enzyme Inhibitors; Hyperplasia; Ileum; Intestinal Mucosa; Irinotecan; Male; Mice; Mucins; Proliferating Cell Nuclear Antigen; Serotonin; Topoisomerase I Inhibitors; Vasoactive Intestinal Peptide | 1995 |
Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.
Topics: Administration, Oral; Animals; Bleomycin; Camptothecin; Cartilage, Articular; Chondroitin Lyases; Ciprofloxacin; Collagenases; Cycloheximide; Ethylmaleimide; Etoposide; Fluorescent Dyes; Hydroxyurea; Injections, Intra-Articular; Iodoacetates; Iodoacetic Acid; Irinotecan; Levofloxacin; Male; Ofloxacin; Papain; Rats; Rats, Sprague-Dawley; Rhodamines; Topoisomerase I Inhibitors | 1994 |
[Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].
Topics: Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Body Water; Camptothecin; Diarrhea; Intestinal Absorption; Irinotecan; Male; Rats; Rats, Wistar | 1995 |
Reduced albumin binding promotes the stability and activity of topotecan in human blood.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; DNA, Neoplasm; Drug Stability; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescence Polarization; HL-60 Cells; Humans; Irinotecan; Lactones; Molecular Structure; Serum Albumin; Topoisomerase I Inhibitors; Topotecan | 1995 |
Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma 256, Walker; Cattle; Chromatography, High Pressure Liquid; Female; Irinotecan; Ovarian Neoplasms; Rats; Rats, Wistar; Tumor Cells, Cultured | 1995 |
Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Humans; Irinotecan; Tongue Neoplasms; Tumor Cells, Cultured | 1995 |
Eicosanoid-mediated Cl- secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chloride Channels; Chlorides; Colon; Eicosanoids; Female; In Vitro Techniques; Intestinal Mucosa; Irinotecan; Parasympathomimetics; Patch-Clamp Techniques; Rats; Rats, Inbred Strains | 1995 |
Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Flow Cytometry; Glioma; Glutathione; Glutathione Transferase; Humans; Irinotecan; Nucleic Acid Conformation; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bayes Theorem; Camptothecin; Drug Monitoring; Humans; Irinotecan; Neoplasms | 1995 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neprilysin; Randomized Controlled Trials as Topic; Thiorphan | 1995 |
Topoisomerase I inhibitors and other new cytotoxic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Organoplatinum Compounds; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1995 |
[A model for sensitivity determination of anticancer agents against chemical-induced colon cancer in rats].
Topics: Animals; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Dimethylhydrazines; Drug Screening Assays, Antitumor; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 1995 |
Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Colony-Forming Units Assay; Gastrointestinal Neoplasms; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Survival Analysis; Thymidine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
Topics: Antineoplastic Agents, Phytogenic; Bile; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 1995 |
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 1995 |
Toxicity of camptothecin to Chinese hamster cells containing 5-hydroxymethyl-2'-deoxyuridine in their DNA.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line; Cricetinae; Cricetulus; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Irinotecan; Lung; Naphthoquinones; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; S Phase; Thymidine; Topoisomerase I Inhibitors | 1995 |
Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Glucuronates; Glucuronidase; Humans; Irinotecan; Middle Aged; Time Factors | 1995 |
Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Humans; Irinotecan; Male; Mice; Mice, Nude; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Topoisomerase I inhibition: a new target or new missiles?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1995 |
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
Topics: Antineoplastic Agents; Camptothecin; Carbazoles; Carcinoma, Small Cell; Cell Nucleus; Drug Resistance; Glucosides; Humans; In Vitro Techniques; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Reproducibility of Results | 1994 |
Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylic Ester Hydrolases; Cattle; Cricetinae; Dogs; Guinea Pigs; Haplorhini; Humans; Hydrolysis; Irinotecan; Isoenzymes; Kinetics; Mice; Microsomes, Liver; Nitrophenols; Organophosphorus Compounds; Rabbits; Rats; Species Specificity | 1994 |
CPT-11: a novel antitumor drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Irinotecan; Mice; Mice, Inbred C3H; Molecular Structure; Neoplasms, Experimental; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromosomes, Human, Pair 20; DNA Topoisomerases, Type I; Female; Genes, myc; Humans; Injections, Intraperitoneal; Irinotecan; Lethal Dose 50; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
Topics: Camptothecin; Cisplatin; Drug Resistance; Etoposide; Glutathione; HeLa Cells; Humans; In Vitro Techniques; Irinotecan; Methionine | 1994 |
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Half-Life; Humans; Irinotecan; Male; Middle Aged; Prodrugs | 1994 |
[Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1994 |
[Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan)].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Soft Tissue Neoplasms | 1994 |
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Topics: Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Neoplastic Stem Cells; Topoisomerase I Inhibitors | 1994 |
[Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA, Superhelical; Drug Screening Assays, Antitumor; Humans; Irinotecan; Tumor Cells, Cultured | 1994 |
[Effects of SN-38 in combination with other anticancer agents against Dauji cells].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Camptothecin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Tumor Cells, Cultured | 1994 |
[Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Interferon-alpha; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplantation; Transplantation, Heterologous | 1994 |
In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; CHO Cells; Cricetinae; DNA Damage; Drug Resistance; Female; Irinotecan; Leukemia P388; Mice; Topotecan | 1993 |
Effect of peplomycin or camptothecin-11 on X-ray skin injuries of ICR hairless mice.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Irinotecan; Male; Mice; Mice, Hairless; Mice, Inbred ICR; Peplomycin; Radiation Dosage; Radiation Injuries, Experimental; Radiation-Sensitizing Agents; Skin; Skin Diseases; Thigh; Topoisomerase I Inhibitors; X-Rays | 1994 |
Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.
Topics: Animals; Camptothecin; Cholinesterase Inhibitors; Defecation; Diarrhea; Dogs; Injections, Intravenous; Irinotecan; Male; Rats; Receptors, Cholinergic; Topoisomerase I Inhibitors; Vomiting | 1993 |
[Successful treatment of chemotherapy-resistant adult T cell leukemia/lymphoma by irinotecan hydrochloride (CPT-11)].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Infusions, Intravenous; Irinotecan; Leukemia-Lymphoma, Adult T-Cell; Male; Remission Induction | 1994 |
[Antitumor effect of camptothecin analog on liver metastatic model of human colon cancer in nude mice].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Tumor Cells, Cultured | 1994 |
[Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Glioma; Humans; Irinotecan; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
[Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Testicular Neoplasms; Transplantation, Heterologous | 1993 |
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.
Topics: Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Half-Life; Irinotecan; Kinetics; Lactones; Molecular Structure; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Topotecan | 1994 |
Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Enterocolitis; Injections, Intraperitoneal; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude | 1993 |
Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Half-Life; Humans; Irinotecan; Lactones; Serum Albumin; Structure-Activity Relationship | 1993 |
Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
Topics: Camptothecin; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Hot Temperature; Humans; Irinotecan; KB Cells; Neoplasms; RNA, Messenger; Teniposide | 1993 |
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Humans; Injections, Intraperitoneal; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1993 |
Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Glioma; Humans; Irinotecan; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1993 |
DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells.
Topics: Camptothecin; Cell Death; DNA Damage; DNA Repair; DNA, Neoplasm; DNA, Single-Stranded; Humans; Irinotecan; Leukemia, Promyelocytic, Acute; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Zinc | 1993 |
CPT-11-induced cholinergic effects in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Parasympathomimetics | 1993 |
Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cell Death; DNA Damage; DNA, Neoplasm; Doxorubicin; Humans; Irinotecan; Lung Neoplasms; Mice; Mitomycin; Molecular Sequence Data; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured | 1993 |
Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucuronates; Glucuronidase; Irinotecan; Kinetics; Substrate Specificity; Time Factors | 1993 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1993 |
Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromosome Aberrations; Dose-Response Relationship, Drug; Humans; Irinotecan; Lymphocytes; Mutagens; Neoplasms; Sister Chromatid Exchange; Time Factors | 1993 |
Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Bile; Camptothecin; Carbon Radioisotopes; Feces; Irinotecan; Male; Rats; Rats, Wistar; Tissue Distribution | 1995 |
[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Thrombocytopenia | 1996 |
Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 1996 |
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Liver; Lung; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Survival Analysis | 1996 |
Camptothecins: new enthusiasm for an old drug.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Topoisomerase I Inhibitors | 1996 |
Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Topics: Antibiotics, Antineoplastic; Benz(a)Anthracenes; Camptothecin; Carcinoma, Squamous Cell; Dactinomycin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; KB Cells; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carbazoles; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cell Survival; Cisplatin; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Glucosides; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Nucleus; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Female; Humans; Interleukin-1; Irinotecan; Mice; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Protein Biosynthesis; Recombinant Proteins; Transcription, Genetic; Transplantation, Heterologous | 1996 |
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Camptothecin; Cyclosporine; Female; Irinotecan; Rats; Rats, Wistar | 1996 |
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1996 |
Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11)
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Fatal Outcome; Female; Humans; Irinotecan; Tumor Lysis Syndrome | 1996 |
Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cholinesterase Inhibitors; DNA; Humans; Irinotecan; KB Cells; Microsomes, Liver | 1996 |
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Glucuronidase; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 1996 |
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genetic Variation; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Karyotyping; Kinetics; Nuclear Proteins; Tumor Cells, Cultured | 1996 |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1996 |
The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Buthionine Sulfoximine; Camptothecin; Cell Survival; Cells, Cultured; Cricetinae; Drug Interactions; Enzyme Inhibitors; Glutathione; Irinotecan; Topoisomerase I Inhibitors | 1996 |
Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Atrophy; Camptothecin; Cecum; Cisplatin; Diarrhea; Ileum; Intestinal Mucosa; Irinotecan; Mice | 1996 |
Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors.
Topics: 3T3 Cells; Animals; Camptothecin; Cell Line, Transformed; DNA Topoisomerases, Type I; Enzyme Inhibitors; Genes, ras; Guanosine Diphosphate; Guanosine Triphosphate; Immunoblotting; Irinotecan; Mice; Phosphorylation; ras Proteins; Topoisomerase I Inhibitors | 1996 |
Inhibition of P-glycoprotein-dependent multidrug resistance by an isoquinolinesulfonamide compound H-87 in rat ascites hepatoma AH66 cells.
Topics: Affinity Labels; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Camptothecin; Dihydropyridines; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Irinotecan; Isoquinolines; Protein Binding; Protein Kinase Inhibitors; Rats; Sulfonamides; Tritium; Tumor Cells, Cultured; Vinblastine | 1996 |
Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm.
Topics: Amino Acid Sequence; Animals; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 1; Cell Extracts; Cell Nucleus; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Cytoplasm; Dactinomycin; DNA; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Molecular Sequence Data; Oligopeptides; Protein Synthesis Inhibitors; Rats; Tumor Cells, Cultured | 1996 |
[Small-cell lung cancer and subacute sensory neuropathy in a patient positive for the anti-Hu antigen].
Topics: Acute Disease; Antibodies, Anti-Idiotypic; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Biomarkers, Tumor; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Diseases | 1996 |
Stimulation of interleukin-1beta-converting enzyme activity during growth inhibition by CPT-11 in the human myeloid leukemia cell line K562.
Topics: Apoptosis; Base Sequence; Camptothecin; Caspase 1; Cysteine Endopeptidases; Gene Expression Regulation, Leukemic; Humans; In Situ Hybridization; Irinotecan; Leukemia, Myeloid; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1996 |
Irinotecan shown to be effective against colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Humans; Irinotecan; Treatment Outcome | 1996 |
Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum.
Topics: Adenosine; Animals; Antihypertensive Agents; Caffeine; Camptothecin; Dopamine; Enzyme Inhibitors; Extracellular Space; Irinotecan; Male; Microdialysis; Neostriatum; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P1; Theobromine; Vasodilator Agents | 1996 |
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Sensitivity and Specificity; Taxoids; Vincristine | 1996 |
Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Kinetics; Liver | 1996 |
DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA, Viral; Irinotecan; Oligodeoxyribonucleotides; Simian virus 40; Spectrum Analysis, Raman; Topoisomerase I Inhibitors | 1996 |
Synthesis of CPT-11 (irinotecan hydrochloride trihydrate).
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Screening Assays, Antitumor; Irinotecan | 1996 |
Schedule-dependent efficacy of camptothecins in models of human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Treatment of central nervous system xenografts with camptothecins.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous | 1996 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1997 |
[New drugs. Topoisomerase inhibitors].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Future directions in therapeutic approaches for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Forecasting; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 1996 |
Irinotecan for metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; Drug Therapy; Humans; Irinotecan | 1997 |
[Caring for patients treated with Campto (CPT-11)].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Monitoring; Humans; Irinotecan; Nursing Records | 1996 |
Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Interferon-alpha; Interferon-beta; Interferon-gamma; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Recombinant Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Teratocarcinoma; Testicular Neoplasms; Topoisomerase I Inhibitors; Transplantation, Heterologous; Vinblastine | 1997 |
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutagenesis; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Prognosis; RNA, Messenger | 1996 |
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Flow Cytometry; Glioblastoma; Humans; Irinotecan; Kinetics; Tumor Cells, Cultured | 1997 |
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Female; Glucuronates; Glucuronosyltransferase; Irinotecan; Metabolic Clearance Rate; Phenobarbital; Rats; Rats, Wistar; Valproic Acid | 1997 |
Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Detergents; Glucuronates; Humans; Individuality; Irinotecan; Liver; Microsomes, Liver | 1997 |
Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Topics: Adenosine Triphosphate; Animals; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Bile; Bile Canaliculi; Camptothecin; Carrier Proteins; Hyperbilirubinemia; Irinotecan; Male; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley | 1997 |
A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lymphoma, T-Cell; Piperidines; Tumor Cells, Cultured | 1997 |
Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1997 |
Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1996 |
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Ethylamines; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Osmolar Concentration; Topotecan | 1997 |
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Carboxylic Acids; Glutathione; Hyperbilirubinemia; Irinotecan; Lactones; Male; Rats; Rats, Sprague-Dawley | 1997 |
Efficacy of oral irinotecan against neuroblastoma xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infant; Irinotecan; Mice; Mice, Inbred CBA; Neuroblastoma; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1997 |
Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling.
Topics: Animals; Apoptosis; Camptothecin; Carboxylic Acids; Caspase 1; Cells, Cultured; Ceramides; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblasts; Fumonisins; Irinotecan; Mice; Oligopeptides; Signal Transduction; Topoisomerase I Inhibitors | 1997 |
SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids.
Topics: Adenocarcinoma; Camptothecin; Cell Survival; Colonic Neoplasms; Humans; Irinotecan; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Topics: Antineoplastic Agents; Area Under Curve; Camptothecin; Female; Humans; Irinotecan; Male; Neoplasms; Phenotype; Racial Groups; Severity of Illness Index; Sex Characteristics; Topoisomerase I Inhibitors | 1997 |
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Proteins; Camptothecin; Female; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; Protein Binding | 1997 |
Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Biological Transport; Camptothecin; Cell Membrane; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Irinotecan; Mammary Neoplasms, Experimental; Mice; Tumor Cells, Cultured | 1997 |
Efficacy of camptothecin in progressive multifocal leucoencephalopathy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Leukoencephalopathy, Progressive Multifocal | 1997 |
Effect of CPT-11 on lipid peroxide level in mouse tissues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Camptothecin; Glutathione Peroxidase; Irinotecan; Kinetics; Lipid Peroxides; Lung; Male; Mice; Microsomes, Liver; Myocardium; NADP; Rats; Rats, Wistar | 1997 |
[Chemotherapy of advanced colorectal cancers after failure of a treatment with fluoropyrimidine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Thymidylate Synthase; Treatment Failure | 1997 |
Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography.
Topics: Animals; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Irinotecan; Lactones; Rats | 1997 |
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water | 1997 |
Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Saliva | 1997 |
The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Topics: Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Drug Interactions; Humans; Irinotecan; Kinetics; Microsomes, Liver | 1997 |
[A case of recurrent advanced colon cancer treated with CPT-11 for second-line chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1997 |
Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylic Ester Hydrolases; Drug Interactions; Humans; Irinotecan; Microsomes, Liver | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Topics: 1-Octanol; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Buffers; Camptothecin; Drug Interactions; Injections, Intravenous; Irinotecan; Male; Rats; Rats, Wistar | 1997 |
Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Medulloblastoma; Mice; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1997 |
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Codon; Colonic Neoplasms; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Female; Fluorouracil; Forecasting; Genes, ras; Guanine; Humans; Irinotecan; Male; Middle Aged; Mutation; Prognosis; Retreatment; Sequence Analysis, DNA; Survival Rate; Thymine; Treatment Failure | 1997 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Pleurisy; Retrospective Studies; Survival Rate | 1997 |
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Male; Reference Standards; Reproducibility of Results; Spectrometry, Fluorescence | 1997 |
Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chromatography, High Pressure Liquid; Glucuronidase; Injections, Intravenous; Irinotecan; Kinetics; Liver; Male; Rats; Rats, Sprague-Dawley | 1997 |
[Long-term survival after multimodal therapy for lung cancer with pleural dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pleural Neoplasms; Radiosurgery; Survivors | 1997 |
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Topoisomerase I Inhibitors | 1997 |
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Sarcoma; Sarcoma, Experimental; Tumor Cells, Cultured | 1997 |
Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Cell Cycle; Circadian Rhythm; Irinotecan; Leukocyte Count; Male; Mice; Mice, Inbred ICR; Time Factors; Weight Loss | 1997 |
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1997 |
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.
Topics: Bilirubin; Camptothecin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1997 |
A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells.
Topics: Anion Transport Proteins; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carrier Proteins; Cisplatin; DNA, Antisense; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glutathione Transferase; Humans; Irinotecan; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Transfection; Tumor Cells, Cultured; Vincristine | 1997 |
Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzimidazoles; Benzoxepins; Camptothecin; Carbachol; Chloride Channels; Chlorides; Colon; Cyclooxygenase Inhibitors; Dinoprostone; Female; Imidazoles; Indomethacin; Intestinal Mucosa; Irinotecan; Membrane Potentials; Nitrobenzoates; Patch-Clamp Techniques; Rats; Rats, Wistar; Receptors, Thromboxane; Tetrodotoxin; Thromboxane A2; Thromboxane-A Synthase | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 1997 |
Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Irinotecan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Photolysis; Solutions; Water | 1997 |
Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Cell Division; Drug Screening Assays, Antitumor; Humans; Irinotecan; Liver; Prodrugs; Rabbits; Rhabdomyosarcoma; Tumor Cells, Cultured | 1998 |
Pharmacokinetics of CPT-11 in rhesus monkeys.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dogs; Female; Humans; Infusions, Intravenous; Irinotecan; Macaca mulatta; Metabolic Clearance Rate; Mice; Rats; Species Specificity | 1998 |
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atropine; Blood Pressure; Camptothecin; Cholinergic Fibers; Colorectal Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Parasympatholytics; Salivation; Topoisomerase I Inhibitors | 1998 |
Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Biotransformation; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Irinotecan; Ketoconazole; Microsomes, Liver; Molecular Structure; Oxidoreductases, N-Demethylating; Recombinant Proteins; Structure-Activity Relationship; Transfection; Troleandomycin | 1998 |
[Evaluation of a new anti-cancer drug regimen for endometrial cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Irinotecan; Lethal Dose 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel | 1998 |
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Causality; Crigler-Najjar Syndrome; Glucuronosyltransferase; Guanine; Humans; Irinotecan; Isoenzymes; Microsomes, Liver; Nitrophenols; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Uridine Diphosphate; Zidovudine | 1998 |
Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colon; Diarrhea; Dinoprostone; Enzyme Inhibitors; Intestinal Absorption; Intestine, Large; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water | 1997 |
Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Diarrhea; Dinoprostone; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Eating; Intestinal Absorption; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water; Weight Gain | 1997 |
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Mice; Multidrug Resistance-Associated Proteins; RNA, Messenger; Tumor Cells, Cultured; Verapamil | 1998 |
The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Southern; Camptothecin; Drug Resistance, Neoplasm; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; RNA, Messenger; Tumor Cells, Cultured | 1997 |
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; HeLa Cells; Humans; Irinotecan; Isoenzymes; Neoplasm Proteins; Tumor Cells, Cultured | 1997 |
[Derivatives of camptothecin. A new class of antineoplastic agents].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan | 1997 |
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Irinotecan; Topotecan; Tumor Cells, Cultured | 1998 |
Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Injections, Intraperitoneal; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neuroblastoma | 1998 |
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; S Phase; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Ganglioneuroblastoma; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Remission Induction; Topotecan; Transplantation, Heterologous | 1997 |
Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Injections, Intravenous; Irinotecan; Male; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; Prodrugs; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Injections, Intravenous; Irinotecan; Metabolic Clearance Rate; Mice; Mice, Inbred CBA; Models, Biological; Neoplasm Transplantation; Thymectomy; Transplantation, Heterologous | 1998 |
Clonal analysis of cancer cells that survived anticancer drug treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1997 |
In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Prodrugs; Tumor Cells, Cultured | 1998 |
Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Irinotecan; Macaca mulatta; Male; Nausea; Vomiting | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1998 |
[Evaluation of a new anti-cancer drug regimen for surface epithelial-stromal ovarian cancer].
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
[Pilot study of cisplatin, ifosfamide and irinotecan (CPT-11) with granulocyte colony-stimulating factor support (CIC-regimen) in relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects | 1998 |
Angiocytotoxic therapy in human non-small cell lung cancer cell lines--advantage of combined effects of TNP-470 and SN-38.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cyclohexanes; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured | 1998 |
Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Topics: Camptothecin; DNA Topoisomerases, Type I; DNA, Viral; Hydrolysis; Irinotecan; Kinetics; Lactones; Oligonucleotides; Simian virus 40; Spectrometry, Fluorescence; Topoisomerase I Inhibitors | 1998 |
Resistance to apoptosis induced by topoisomerase I inhibitors in multidrug-resistant HL60 leukemic cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Drug Resistance, Multiple; Enzyme Inhibitors; HL-60 Cells; Humans; Hydrogen-Ion Concentration; Irinotecan; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Vincristine | 1998 |
Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1998 |
[New cancer therapies: balancing risk and benefit].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Neoplasms; Risk | 1998 |
Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile; Body Weight; Camptothecin; Carcinoma, Ehrlich Tumor; Drug Carriers; Feces; Irinotecan; Liposomes; Liver; Male; Mice; Neoplasm Transplantation; Water | 1998 |
4-Piperidinopiperidine-resistant lymphoma cells were resistant to dexamethasone- and A23187-induced apoptosis.
Topics: Apoptosis; Calcimycin; Camptothecin; Dexamethasone; DNA Fragmentation; Drug Resistance; Humans; Irinotecan; Lymphoma; Piperidines; Tumor Cells, Cultured | 1998 |
Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Staging; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1998 |
Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Leukemia P388; Mice; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Survival; COS Cells; DNA, Complementary; Glioma; Humans; Irinotecan; Liver; Molecular Sequence Data; Prodrugs; Rabbits; Sequence Alignment; Sequence Homology, Amino Acid; Tumor Cells, Cultured | 1998 |
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan | 1998 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Irinotecan and 5-fluorouracil in colorectal cancer: time for a pause?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; DNA, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Treatment Outcome | 1998 |
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Paclitaxel; Tumor Cells, Cultured | 1998 |
Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred BALB C | 1998 |
Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Humans; Irinotecan; Leukemia P388; Microsomes, Liver; Tumor Cells, Cultured | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinergic Fibers; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Parasympathomimetics; Receptors, Cholinergic; Syndrome | 1998 |
The detection of photodegradation products of irinotecan (CPT-11, Campto, Camptosar), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Atmospheric Pressure; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mass Spectrometry; Photochemistry; Spectrometry, Fluorescence | 1998 |
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1998 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Irinotecan; Isoenzymes; Ketoconazole; Kinetics; Microsomes, Liver; Troleandomycin | 1998 |
Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Drug Interactions; Duodenum; Female; Interleukin-15; Intestinal Mucosa; Irinotecan; Paraffin Embedding; Rats; Rats, Inbred F344 | 1998 |
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Tumor Lysis Syndrome | 1998 |
Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Renal Cell; Humans; Irinotecan; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; COS Cells; Culture Media, Serum-Free; Endoplasmic Reticulum; Genetic Vectors; Humans; Irinotecan; Mutagenesis, Site-Directed; Polymerase Chain Reaction; Rabbits; Species Specificity; Transfection | 1998 |
Irinotecan: toward clinical end points in drug development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Randomized Controlled Trials as Topic | 1998 |
Rational design of irinotecan administration based on preclinical models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Dose-Response Relationship, Drug; Female; HL-60 Cells; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Nucleic Acid Synthesis Inhibitors | 1998 |
Irinotecan: a review of the initial phase I trials.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Hodgkin Disease; Humans; Irinotecan; Japan; Leukemia; Lymphoma, Non-Hodgkin; United States | 1998 |
US pivotal studies of irinotecan in colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; United States | 1998 |
Extending principles learned in model systems to clinical trials design.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Models, Biological; Research Design | 1998 |
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Male; Outcome Assessment, Health Care; Palliative Care; Prostatic Neoplasms; Quality of Life; Research Design | 1998 |
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1998 |
Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Bacteria; Camptothecin; Diarrhea; Enzyme Inhibitors; Glucuronidase; Injections, Intravenous; Intestine, Large; Intestine, Small; Irinotecan; Male; Penicillins; Rats; Rats, Wistar; Streptomycin | 1998 |
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; DNA, Neoplasm; Doxorubicin; Drug Interactions; Etoposide; Female; Irinotecan; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Intestinal Diseases; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms, Experimental; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C | 1998 |
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1998 |
Role of E2F-1 in chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Cloning, Molecular; Culture Media, Serum-Free; DNA-Binding Proteins; Doxorubicin; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Fibrosarcoma; Humans; Irinotecan; Paclitaxel; Recombinant Proteins; Retinoblastoma-Binding Protein 1; Tetrahydrofolate Dehydrogenase; Transcription Factor DP1; Transcription Factors; Transfection; Tumor Cells, Cultured | 1998 |
Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.
Topics: Adenocarcinoma; Adenoviruses, Human; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Division; Cell Survival; Clone Cells; DNA Topoisomerases, Type I; DNA, Complementary; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Irinotecan; Lung Neoplasms; Recombinant Proteins; Transfection; Tumor Cells, Cultured | 1998 |
Trace analysis of SN-38 in human plasma by high-performance liquid chromatography.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Reproducibility of Results; Spectrometry, Fluorescence | 1998 |
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Survival; Deoxyuracil Nucleotides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Thymidylate Synthase; Thymine Nucleotides; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 1998 |
Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-fos; Survival Analysis; Treatment Failure | 1998 |
Managing the side effects of chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drugs, Investigational; Fluorouracil; Humans; Irinotecan; Patient Care Team; Quality of Life | 1998 |
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; TATA Box | 1998 |
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; RNA, Messenger; Thymidine Phosphorylase; Thymidylate Synthase | 1998 |
Irinotecan may extend survival in people with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 1998 |
Irinotecan for colorectal cancer: a small step forward.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Survival Rate; Topoisomerase I Inhibitors | 1998 |
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Recurrence, Local; Neuroblastoma; Thymectomy; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Irinotecan (CPT-11) metabolites in human bile and urine.
Topics: Antineoplastic Agents, Phytogenic; Bile; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Mass Spectrometry; Middle Aged; Neoplasm Metastasis | 1996 |
Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Bile; Bile Canaliculi; Camptothecin; Humans; Irinotecan; Leukotriene C4; Rats; Rats, Sprague-Dawley | 1998 |
Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 1998 |
Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography.
Topics: Animals; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Dogs; Female; Irinotecan; Lactones; Light; Male; Rats; Rats, Sprague-Dawley; Reference Standards | 1998 |
[A case of relapsed thymic carcinoma that responded remarkably to chemotherapy with CPT-11].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Humans; Irinotecan; Male; Middle Aged; Thymus Neoplasms | 1998 |
Effects of SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; CHO Cells; Cricetinae; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Camptothecin; Infusions, Intravenous; Irinotecan; Lung; Lymph; Sheep | 1998 |
Bradycardia induced by irinotecan: a case report.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bradycardia; Camptothecin; Cholinergic Agents; Colonic Neoplasms; Diarrhea; Electrocardiography; Humans; Irinotecan; Male | 1998 |
Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Division; Culture Media; Humans; Irinotecan; Liver; Mass Spectrometry; Rabbits; Substrate Specificity; Tumor Cells, Cultured | 1998 |
[Successful treatment with CPT-11 and adriamycin for hemophagocytic syndrome associated with intravascular lymphomatosis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Doxorubicin; Histiocytosis, Non-Langerhans-Cell; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Vascular Neoplasms | 1998 |
Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases.
Topics: Animals; Camptothecin; Carboxylic Ester Hydrolases; Esters; Fatty Acids; Humans; In Vitro Techniques; Irinotecan; Prodrugs; Rats; Swine | 1998 |
Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11).
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colonic Neoplasms; Fatal Outcome; Humans; Intestinal Mucosa; Irinotecan; Liver Neoplasms; Male; Middle Aged | 1998 |
More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinesterase Inhibitors; Drug Administration Schedule; Drug Synergism; Humans; Infusions, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Sialorrhea | 1999 |
Clinical Status and Future Directions of Irinotecan. Proceedings of a symposium. Houston, Texas, USA. January 21-23, 1998.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan | 1998 |
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine | 1999 |
Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; KB Cells; Lactones | 1999 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight; Camptothecin; Carcinoma, Hepatocellular; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Specific Pathogen-Free Organisms; Survival Rate; Trimethylsilyl Compounds; Tumor Cells, Cultured | 1998 |
Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Division; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Fibrosarcoma; Hot Temperature; Humans; Hyperthermia, Induced; Irinotecan; Kinetics; Lung Neoplasms; Mice; Topoisomerase I Inhibitors | 1999 |
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Flow Cytometry; Humans; In Vitro Techniques; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors | 1999 |
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous | 1999 |
Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Sensitivity and Specificity | 1999 |
[A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Remission Induction; Stomach Neoplasms | 1999 |
[Thermo-chemotherapy using low-dose CPT-11 in a patient with local recurrence of rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Hyperthermia, Induced; Irinotecan; Middle Aged; Pelvic Neoplasms; Rectal Neoplasms | 1999 |
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biopsy; Camptothecin; Caspases; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Camptothecin; Glutathione; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Substrate Specificity | 1999 |
Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carcinoma, Lewis Lung; Drug Carriers; Irinotecan; Liposomes; Male; Mice; Tissue Distribution | 1999 |
The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Binding Sites; Butyrylcholinesterase; Camptothecin; Cholinesterase Inhibitors; COS Cells; Eels; Humans; Irinotecan; Mice; Models, Molecular; Prodrugs | 1999 |
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA-Binding Proteins; Drug Resistance; Female; Genetic Therapy; I-kappa B Proteins; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; NF-kappa B; NF-KappaB Inhibitor alpha; Recombinant Proteins; Tumor Necrosis Factor-alpha | 1999 |
Irinotecan-induced central nervous system toxicity: a case report.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Central Nervous System; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged | 1999 |
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Catalysis; Cell Division; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred CBA; Molecular Sequence Data; Neoplasm Transplantation; Neoplasms, Experimental; Nitrobenzenes; Phenylacetates; Prodrugs; Rabbits; Tumor Cells, Cultured | 1999 |
Optimum doses of irinotecan.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Topoisomerase I Inhibitors | 1999 |
High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase ext
Topics: Animals; Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Glucuronates; Irinotecan; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Spectrometry, Fluorescence | 1999 |
ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
Topics: Adenosine Triphosphate; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Biological Transport; Buthionine Sulfoximine; Camptothecin; Carrier Proteins; Cell Line; Cell Survival; Culture Media; Cyclic P-Oxides; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Irinotecan; Isoenzymes; KB Cells; Multidrug Resistance-Associated Proteins; Nicotinic Acids; Propionates; Quinolines | 1999 |
Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Salvage Therapy | 1999 |
[Improvement of quality of life (QOL) and life prolongation by CPT-11 + adriamycin (ADM) therapy: report of 4 cases of non-Hodgkin's lymphoma refractory to conventional chemotherapies].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Doxorubicin; Drug Administration Schedule; Humans; Irinotecan; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Quality of Life | 1999 |
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver; Phenotype; Polymorphism, Genetic; Promoter Regions, Genetic | 1999 |
[Usefulness of a pharmacokinetic approach for clinical antineoplastic chemotherapy evaluation].
Topics: Antineoplastic Agents; Area Under Curve; Camptothecin; Half-Life; Humans; Irinotecan; Metabolic Clearance Rate | 1999 |
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Colonic Neoplasms; Cross-Linking Reagents; DNA Adducts; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mammary Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Organoplatinum Compounds; Oxaliplatin; RNA, Neoplasm; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |
An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Camptothecin; Cisplatin; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; KB Cells; Leukotriene C4; Multidrug Resistance-Associated Proteins | 1999 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 1999 |
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus.
Topics: Animals; Camptothecin; COS Cells; Glucuronidase; Glucuronosyltransferase; Humans; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Monosaccharide Transport Proteins | 1999 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Topoisomerase I Inhibitors | 1999 |
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cholinesterase Inhibitors; Drug Screening Assays, Antitumor; Esters; Female; Glycine; Humans; Infant, Newborn; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
[Low-dose CPT-11 against a recurrent rectal cancer--a case report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms | 1999 |
Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cell Survival; Cytoprotection; Ileum; Immunohistochemistry; Interleukin-15; Intestinal Mucosa; Irinotecan; Lipopeptides; Lipoproteins; Macrophages; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Transplantation; Rats; Specific Pathogen-Free Organisms | 1999 |
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Floxuridine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Skin; Transplantation, Heterologous; Uterine Neoplasms | 1999 |
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Factors contributing to the resistance to apoptosis induced by topoisomerase I inhibitors in vincristine resistant cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Drug Resistance, Multiple; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, MDR; HL-60 Cells; Humans; Irinotecan; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Vincristine | 1999 |
Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms | 1999 |
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured | 1999 |
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Corn Oil; Drug Synergism; Duodenum; Female; Fish Oils; Gastrointestinal Diseases; Humans; Irinotecan; Lipid Peroxidation; Mice; Mice, Nude; Muscle, Smooth; Thiobarbituric Acid Reactive Substances; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Topics: 2,4-Dinitrophenol; Animals; Antineoplastic Agents, Phytogenic; Biological Transport, Active; Camptothecin; Cricetinae; Dose-Response Relationship, Drug; HT29 Cells; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Irinotecan; Isomerism; Mesocricetus; Time Factors; Topoisomerase I Inhibitors | 1999 |
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Successful clinical response to irinotecan in desmoplastic round blue cell tumor.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Desmin; Female; Humans; Irinotecan; Male; Prognosis; Treatment Outcome | 1999 |
[Three cases of multiple liver metastases of gastric cancer responding to tegafur/low-dose CDDP/CPT-11 combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms; Tegafur | 1999 |
[Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
Topics: Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Tumor Cells, Cultured | 1999 |
[Liver concentration of CPT-11, SN-38 and SN-38 GLU in intraperitoneal and intravenous administration of CPT-11].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Liver; Mice; Mice, Inbred ICR | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms | 1999 |
Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fatal Outcome; Humans; Irinotecan; Liver; Liver Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Rupture; Tumor Lysis Syndrome | 1999 |
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Topics: Acetylcholinesterase; Acylation; Alzheimer Disease; Binding, Competitive; Butyrylcholinesterase; Camptothecin; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Humans; Hydrolysis; Irinotecan; Kinetics; Neostigmine; Propidium; Substrate Specificity; Tacrine | 1999 |
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Drug Screening Assays, Antitumor; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleic Acid Synthesis Inhibitors; RNA, Neoplasm; Tumor Cells, Cultured | 1999 |
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; History, 20th Century; Humans; Irinotecan; Lung Neoplasms; Medical Oncology; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; DNA Topoisomerases, Type I; Flow Cytometry; Humans; Irinotecan; Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured | 1999 |
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Statistics, Nonparametric; Topoisomerase I Inhibitors | 2000 |
Premedication for irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Muscarinic Antagonists; Premedication; Scopolamine; Topoisomerase I Inhibitors | 2000 |
Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Colonic Neoplasms; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Membrane Glycoproteins; Mice; Mice, SCID; Neoplasm Transplantation; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 1999 |
Glutamine for irinotecan diarrhea.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Glutamine; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2000 |
Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Drug Therapy, Combination; Humans; In Situ Nick-End Labeling; Injections, Intralesional; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms; Lymph Nodes; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pancreatic Neoplasms; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Mass Spectrometry; Piperidines | 2000 |
In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Coloring Agents; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
[A case of advanced gastric cancer with lung and liver metastasis responding remarkably to combination chemotherapy with CDDP and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2000 |
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Treatment Outcome | 1999 |
Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 1999 |
Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.
Topics: Acetonitriles; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Irinotecan; Male; Mass Spectrometry; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 1999 |
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Stomach Neoplasms; Survival Rate | 1999 |
Response of chemosensitive and chemoresistant leukemic cell lines to drug therapy: simultaneous assessment of proliferation, apoptosis, and necrosis.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Camptothecin; Cell Division; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Irinotecan; Leukemia, Myeloid; Necrosis; Propidium; Tranexamic Acid; Tumor Cells, Cultured; Vincristine | 2000 |
Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase: evidence for CPT-11 drug activation.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Blotting, Northern; Butyrylcholinesterase; Camptothecin; COS Cells; DNA, Complementary; Horses; Humans; Irinotecan; Liver; Molecular Sequence Data; Prodrugs; Protein Biosynthesis; Sequence Homology, Amino Acid; Transfection | 2000 |
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Enzyme Inhibitors; Humans; Hydrolysis; Irinotecan; Isoenzymes; Liver; Molecular Sequence Data; Sequence Alignment | 2000 |
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Primers; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Microsatellite Repeats; Mutation; Phenotype; Tumor Suppressor Protein p53 | 2000 |
Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aspartic Acid; Camptothecin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase Inhibitors; Caspases; Cyclin A; Cyclin-Dependent Kinase Inhibitor p16; DNA Fragmentation; DNA, Complementary; Enzyme Activation; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Protease Inhibitors; S Phase; Time Factors; Transfection; Tumor Cells, Cultured | 2000 |
Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Large Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Neoplasm Transplantation; Rats; Sarcoma, Yoshida; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |
[Irinotecan (topoisomerase-I inhibitor) for the treatment of recurrent primary intracranial malignant lymphoma].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cerebellar Neoplasms; Cranial Irradiation; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |
Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Enzyme Inhibitors; Glucuronates; Irinotecan; Male; Microscopy, Electron, Scanning; Microspheres; Models, Biological; Rats; Rats, Wistar; Topoisomerase I Inhibitors | 2000 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Drug Synergism; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2000 |
Determination of MAG-camptothecin, a new polymer-bound camptothecin derivative, and free camptothecin in dog plasma by HPLC with fluorimetric detection.
Topics: Acrylamides; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Fluorometry; Injections, Intravenous; Irinotecan; Linear Models; Reproducibility of Results | 2000 |
Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Combined Modality Therapy; DNA, Recombinant; DNA, Viral; Drug Resistance, Neoplasm; Fluorouracil; Gene Transfer Techniques; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Female; Fever; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Practice Guidelines as Topic; Sleep | 2000 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2000 |
New drugs for colorectal cancer based on Japanese experience.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Humans; Irinotecan; Japan; Organoplatinum Compounds; Oxaliplatin | 2000 |
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Transformed; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Docetaxel; Epithelial Cells; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
[Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase | 2000 |
P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line; DNA; G1 Phase; Humans; Irinotecan; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2000 |
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Phosphorylation; Thymidine Kinase; Thymidylate Synthase; Time Factors; Topotecan; Tumor Cells, Cultured; Zidovudine | 2000 |
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Topics: Adenoviridae; Animals; Apoptosis; Breast Neoplasms; Camptothecin; Cell Nucleus; Colorectal Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Humans; I-kappa B Proteins; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Time Factors; Transgenes; Tumor Cells, Cultured | 2000 |
In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.
Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Blood Cells; Blood Platelets; Blood Proteins; Camptothecin; Humans; In Vitro Techniques; Irinotecan; Protein Binding; Ultrafiltration | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
FDA approves irinotecan as first-line therapy for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Quality of Life; Surveys and Questionnaires; Topoisomerase I Inhibitors; United States; United States Food and Drug Administration | 2000 |
New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Line; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Interleukin-6; Irinotecan; Mesothelioma | 2000 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lymph Node Excision; Lymphatic Metastasis | 2000 |
[Current problems of early phase clinical trials for new anticancer agents in Japan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Japan; Medical Oncology; Neoplasms; Workforce | 2000 |
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sigmoid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
From the Food and Drug Administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fetal Monitoring; Humans; Irinotecan; Oximetry; United States; United States Food and Drug Administration | 2000 |
Inductions of fibroblast-like morphology and high growth activity by low-dose CPT-11 in PC12 cells: role of tenascin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylic Acids; Caspase Inhibitors; Caspases; Cell Division; Cell Nucleus; Cell Survival; Cell Transformation, Neoplastic; Culture Media, Conditioned; Dactinomycin; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblasts; Fumonisins; Irinotecan; Oligopeptides; PC12 Cells; Rats; Tenascin; Tumor Necrosis Factor-alpha | 2000 |
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Irinotecan; Kinetics; Maximum Tolerated Dose; Neoplasm Transplantation; Rats; Rats, Inbred F344; Time Factors | 2000 |
[Recent advances in surgical treatment for primary lung cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pneumonectomy; Taxoids; Thoracic Surgery, Video-Assisted | 2000 |
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Topics: Animals; Blotting, Northern; Blotting, Southern; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Genetic Vectors; Humans; Irinotecan; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Tumor Cells, Cultured | 2000 |
[Clinical development of antitumor agent in Europe and USA--experience on CPT-11 development].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Approval; Europe; Humans; Irinotecan; Technology, Pharmaceutical; United States | 2000 |
Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Crosses, Genetic; Enzyme Inhibitors; Esterases; Gene Expression; Irinotecan; Kinetics; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Prodrugs; Tissue Extracts; Topoisomerase I Inhibitors | 2000 |
Development of ELISAs for irinotecan and its active metabolite SN-38.
Topics: Antibody Specificity; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme-Linked Immunosorbent Assay; Horseradish Peroxidase; Irinotecan | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged | 2000 |
Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomerase I inhibitor.
Topics: Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Plant Extracts; Plants, Medicinal; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
[Irinotecan--experience with second-line treatment in advanced colorectal cancer] .
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure; Treatment Outcome | 2000 |
Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylic Ester Hydrolases; Cell Division; COS Cells; DNA, Complementary; Humans; Intestines; Irinotecan; Liver; Molecular Sequence Data; Rabbits; Sequence Homology, Amino Acid; Transfection | 2000 |
Inhibition of thromboxane A(2)-induced Cl(-) secretion by antidiarrhea drug loperamide in isolated rat colon.
Topics: Animals; Antidiarrheals; Calcium; Camptothecin; Chlorides; Colon; Dinoprostone; Female; In Vitro Techniques; Irinotecan; Loperamide; Naloxone; Rats; Rats, Wistar; Thromboxane A2 | 2000 |
Cost-effectiveness of irinotecan in advanced colorectal cancer.
Topics: Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Irinotecan; Survival Analysis | 2000 |
Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan | 2000 |
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biotransformation; Caco-2 Cells; Camptothecin; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Feces; Female; Glucuronidase; Half-Life; Humans; Irinotecan; Male; Middle Aged; Oxidation-Reduction | 2000 |
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Humans; Irinotecan; Kinetics; Liver; Nitrophenols; Rats; Substrate Specificity; Topoisomerase I Inhibitors | 2000 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia | 2000 |
[Weekly chemotherapy with alternating low-dose CPT-11 and low-dose FP against a far advanced pancreatic cancer--a case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Male; Pancreatic Neoplasms | 2000 |
Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Cecum; Diarrhea; Drug Administration Schedule; Glucuronates; Ileum; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 2000 |
Camptosar plus cisplatin increase survival in small-cell lung cancer study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Irinotecan; Paclitaxel; Tumor Cells, Cultured | 2000 |
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nervous System Neoplasms; Temozolomide; Time Factors; Tumor Cells, Cultured | 2000 |
Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11.
Topics: alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Combined Modality Therapy; DNA Topoisomerases, Type I; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Remission Induction | 2000 |
[Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): implications of the mismatched base repair system].
Topics: Adaptor Proteins, Signal Transducing; Adult; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; Camptothecin; Carrier Proteins; Colonic Neoplasms; DNA Repair; DNA-Binding Proteins; Humans; Irinotecan; Microsatellite Repeats; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Rectal Neoplasms; Retrospective Studies | 2000 |
Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Radiography | 2000 |
[Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Infusions, Intravenous; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms | 2000 |
[Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
Topics: Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Humans; Infusions, Parenteral; Irinotecan; Peritoneal Neoplasms; Stomach Neoplasms | 2000 |
[Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics].
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile; Camptothecin; Injections, Intraperitoneal; Irinotecan; Peritoneum; Rats; Rats, Sprague-Dawley | 2000 |
Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Radiosurgery; Radiotherapy, Adjuvant; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Irinotecan-associated pulmonary toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged | 2000 |
Identification of genes highly expressed in G2-arrested Chinese hamster ovary cells by differential display analysis.
Topics: Animals; Arylamine N-Acetyltransferase; Camptothecin; CHO Cells; Cloning, Molecular; Cricetinae; DNA; DNA Damage; DNA, Complementary; Enzyme Inhibitors; Etoposide; Eukaryotic Initiation Factor-4A; G2 Phase; Gene Expression; Irinotecan; Isoenzymes; Nucleic Acid Synthesis Inhibitors; Peptide Initiation Factors; Ribosomal Proteins; RNA, Messenger; Topoisomerase I Inhibitors; X-Rays | 2000 |
[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Male; Tegafur; Uracil | 2000 |
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Case-Control Studies; Female; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Promoter Regions, Genetic; Retrospective Studies; Risk Factors | 2000 |
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antineoplastic Agents; Camptothecin; Colon; Colorimetry; Electric Stimulation; Electrophorus; Enzyme Inhibitors; Gastric Acid; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Irinotecan; Male; Muscle Contraction; Muscle, Smooth; Parasympathetic Nervous System; Rats; Rats, Wistar; Topoisomerase I Inhibitors | 2001 |
Irinotecan: a new agent comes of age.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Humans; International Cooperation; Irinotecan; Male; Ovarian Neoplasms; Uterine Cervical Neoplasms | 2001 |
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Northern; Caco-2 Cells; Camptothecin; DNA, Antisense; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; RNA, Messenger; Transfection; Tumor Cells, Cultured | 2001 |
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Cytokines; Epithelial Cell Adhesion Molecule; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HT29 Cells; Humans; Interferons; Interleukins; Irinotecan; Lewis Blood Group Antigens; Macrophage Colony-Stimulating Factor; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Value of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life | 2001 |
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Pharmacokinetics of orally administered camptothecins.
Topics: Administration, Oral; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Biological Transport, Active; Biotransformation; Caco-2 Cells; Camptothecin; Carrier Proteins; Cell Membrane Permeability; Colonic Neoplasms; Enzyme Inhibitors; Humans; Hydrolysis; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Liver; Liver Neoplasms; Probenecid; Prodrugs; Rectal Neoplasms | 2000 |
The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Enzyme Inhibitors; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 2000 |
[A case of small cell carcinoma of esophagus successfully treated by chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged | 2001 |
No toxicity caused by organ accumulation of CPT-11 on multiple injections under clinical regimens in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Injections; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2000 |
In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Thiazoles; Thiazolidinediones; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.
Topics: 3T3 Cells; Animals; Camptothecin; Cell Survival; Chromosome Segregation; Diketopiperazines; DNA; Enzyme Inhibitors; Flow Cytometry; G1 Phase; Irinotecan; Mice; Mitosis; Piperazines; S Phase; Topoisomerase II Inhibitors | 2001 |
[Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report].
Topics: Adult; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms | 2001 |
Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Berberine; Camptothecin; Carcinoma, Lewis Lung; Disease Models, Animal; Female; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Mediastinal Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Transplantation; Transcription Factor AP-1 | 2001 |
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Topics: Adenine; Antineoplastic Agents; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pharmacogenetics; Polymorphism, Genetic | 2001 |
[A case of AFP-producing gastric cancer responding to low-dose CPT-11 and low-dose cisplatin combination chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Stomach Neoplasms | 2001 |
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole | 2001 |
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Mass Index; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasms; Sex Factors | 2001 |
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Nuclear Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Glioblastoma; Humans; Immunoblotting; Irinotecan; MyoD Protein; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Transgenes; Tumor Cells, Cultured | 2001 |
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
[Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Male; Proteoglycans; Stomach Neoplasms | 2001 |
Impact on survival following successful neoadjuvant chemotherapy and radical surgery for Stage IIb bulky and Stage IIIb cervical cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Peplomycin; Uterine Cervical Neoplasms | 2001 |
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 2001 |
Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Acids and Salts; Biological Transport, Active; Camptothecin; Cholic Acid; Cricetinae; Enzyme Inhibitors; Hydrogen-Ion Concentration; In Vitro Techniques; Intestinal Mucosa; Intestines; Irinotecan; Mesocricetus; Micelles; Taurocholic Acid; Topoisomerase I Inhibitors | 2001 |
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin | 2001 |
Anticancer drugs as inducers of thermotolerance in yeast.
Topics: Antineoplastic Agents; Bleomycin; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Fluorouracil; Hot Temperature; Irinotecan; Methotrexate; Mitomycin; Saccharomyces | 2000 |
Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver.
Topics: Animals; Biliary Tract; Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans; In Vitro Techniques; Irinotecan; Liver; Male; Metabolic Clearance Rate; Perfusion; Rats; Rats, Sprague-Dawley | 2001 |
PML and a tale of two drug companies.
Topics: AIDS-Related Opportunistic Infections; Albendazole; Blood-Brain Barrier; Camptothecin; Drug Industry; Humans; Irinotecan; JC Virus; Leukoencephalopathy, Progressive Multifocal; Microsporidiosis; Polymerase Chain Reaction; Topotecan | 1995 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Making inroads on PML.
Topics: Acquired Immunodeficiency Syndrome; Camptothecin; HIV Protease Inhibitors; Humans; Irinotecan; Leukoencephalopathy, Progressive Multifocal; Topotecan | 1996 |
CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Cytosol; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Fluorouracil; Immunohistochemistry; Irinotecan; Kinetics; Liver; Male; Mice; Mice, Inbred C57BL; Oxidoreductases; RNA, Messenger | 2001 |
[A modified administrated schedule for combination therapy with irinotecan and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical cancer--a report of 2 cases as a pilot study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Neoadjuvant Therapy; Pilot Projects; Uterine Cervical Neoplasms | 2001 |
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Biological Transport; Biotransformation; Caco-2 Cells; Camptothecin; Cell Survival; Chromatography, High Pressure Liquid; Cyclosporine; Humans; Intestinal Mucosa; Irinotecan; Quinolines; RNA, Messenger; Verapamil | 2001 |
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Quinazolines; Thiophenes | 2001 |
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Prospective Studies; Treatment Failure | 2001 |
Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; DNA, Complementary; Drug Screening Assays, Antitumor; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Liver; Rabbits; Rhabdomyosarcoma; Transduction, Genetic; Tumor Cells, Cultured | 2001 |
A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
Topics: Adenoviridae; Antigens, CD34; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biotransformation; Bone Marrow Purging; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; DNA, Complementary; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Irinotecan; Leukocytes, Mononuclear; Neuroblastoma; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Transduction, Genetic; Tumor Cells, Cultured | 2001 |
[A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2001 |
[A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant | 2001 |
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Researchers urge caution with standard regimen for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Catalysis; COS Cells; Esterases; Esters; Humans; Irinotecan; Kinetics; Models, Molecular; Molecular Sequence Data; Prodrugs; Protein Conformation; Rabbits; Recombinant Fusion Proteins; Sequence Homology, Amino Acid | 2001 |
Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.
Topics: Animals; Camptothecin; Diarrhea; Digestive System; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Incidence; Irinotecan; Male; Mice; Mice, Inbred BALB C; Rats; Rats, Wistar; Sarcoma, Experimental; Tissue Distribution | 2001 |
[Usefulness of chemotherapy with CPT-11 in clinic for three colorectal cancer in terminal stage].
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Terminal Care | 2001 |
Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 2. Chemotherapy-responsive right artial metastasis from colon carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Heart Atria; Heart Neoplasms; Humans; Irinotecan; Male; Middle Aged; Ultrasonography | 2001 |
Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Chemical and Drug Induced Liver Injury; Humans; Irinotecan; Kidney; Kidney Diseases; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 2001 |
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2001 |
High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.
Topics: Camptothecin; Chromatography, High Pressure Liquid; Glucuronides; Humans; Irinotecan; Microsomes, Liver; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2001 |
Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects | 2001 |
In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Fluorouracil; Gastrointestinal Diseases; Guidelines as Topic; Irinotecan; Leucovorin; Mortality; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Time Factors; Vascular Diseases | 2001 |
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Octreotide; Treatment Outcome | 2001 |
Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan | 2001 |
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.
Topics: Camptothecin; Cell Extracts; Chromatography, High Pressure Liquid; Colonic Neoplasms; Culture Media; Drug Stability; HT29 Cells; Humans; Irinotecan; Lactones; Reproducibility of Results; Sensitivity and Specificity; Sonication; Time Factors | 2001 |
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2001 |
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2001 |
[A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged | 2001 |
Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Adducts; DNA Repair; DNA-Binding Proteins; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Endonucleases; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerases; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Xeroderma Pigmentosum Group A Protein | 2001 |
A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Insecta; Irinotecan; Microsomes, Liver; Mixed Function Oxygenases | 2001 |
Unique action determinants of double acting topoisomerase inhibitor, TAS-103.
Topics: Aminoquinolines; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Buthionine Sulfoximine; Camptothecin; Drug Resistance; Enzyme Inhibitors; Etoposide; Fungal Proteins; Glutamate-Cysteine Ligase; Glutathione; GTP-Binding Proteins; Humans; Indenes; Irinotecan; Mitochondrial Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
Downregulation of topoisomerase I in differentiating human intestinal epithelial cells.
Topics: Caco-2 Cells; Camptothecin; Cell Differentiation; DNA Damage; DNA Topoisomerases, Type I; Down-Regulation; G1 Phase; Humans; Intestinal Mucosa; Irinotecan | 2001 |
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Membrane; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Glucuronides; Humans; Irinotecan; Kinetics; Lung Neoplasms; Neoplasm Proteins; Secretory Vesicles; Tumor Cells, Cultured | 2001 |
Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Camptothecin; Cell Survival; Cycloheximide; DNA Damage; DNA-Binding Proteins; Doxorubicin; Enzyme Activation; Enzyme Inhibitors; Gene Expression; HeLa Cells; Humans; I-kappa B Kinase; I-kappa B Proteins; Irinotecan; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.
Topics: Animals; Camptothecin; Enzyme Inhibitors; Glucuronides; Glucuronosyltransferase; Humans; Insecta; Irinotecan; Isoenzymes; Kinetics; Microsomes, Liver | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cisplatin; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Fluorouracil; Folic Acid Antagonists; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Tetracycline; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
[Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Injections, Intraperitoneal; Irinotecan; Male; Middle Aged; Neoplasm Seeding; Peritoneal Neoplasms; Stomach Neoplasms | 2001 |
[Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Middle Aged; Sigmoid Neoplasms; Starch | 2001 |
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2001 |
[Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male | 2001 |
Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cell Division; Cisplatin; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Ouabain; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured | 2001 |
Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Blotting, Western; Camptothecin; Cell Nucleus; Cell Size; Cisplatin; Cytoplasm; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Isoenzymes; Lectins; Time Factors; Tumor Cells, Cultured | 2001 |
[A case of lung metastasis from colon cancer treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged | 2001 |
Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents, Phytogenic; Atropine; Blood Pressure; Camptothecin; Cardiovascular System; Cholinesterase Inhibitors; Erythrocytes; Heart Atria; Heart Rate; Irinotecan; Male; Physostigmine; Rats; Rats, Wistar; Statistics, Nonparametric; Vagus Nerve | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
Topics: Blotting, Western; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Irinotecan; Neoplasms, Squamous Cell; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capillaries; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelium, Vascular; Epirubicin; Humans; Irinotecan; Paclitaxel; Phenotype; Skin; Vascular Endothelial Growth Factor A | 2001 |
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Flavonoids; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2001 |
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; CD8-Positive T-Lymphocytes; Cell Survival; Chromium; Cisplatin; Colonic Neoplasms; Cytotoxicity, Immunologic; fas Receptor; Flow Cytometry; Fluorouracil; Humans; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Interferon-gamma; Irinotecan; Recombinant Proteins; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2001 |
A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; DNA, Neoplasm; DNA, Superhelical; Doxorubicin; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; Plasmids; Topoisomerase I Inhibitors | 2001 |
Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Mixed Tumor, Mesodermal; Ovarian Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2001 |
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Body Surface Area; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan | 2002 |
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Body Constitution; Body Surface Area; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Multivariate Analysis; Netherlands; Retrospective Studies | 2002 |
Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylic Acids; Cell Cycle; Cell Division; Cricetinae; Diarrhea; Glucuronides; HT29 Cells; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Intestines; Irinotecan; Lactones; Male; Mesocricetus; Sodium Bicarbonate | 2002 |
UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2001 |
Lung cancer--time to move on from chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Smoking; Survival Rate | 2002 |
Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Signal Transduction; Sphingomyelins; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin | 2001 |
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Survival; Cisplatin; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Formazans; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Tetrazolium Salts; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Enzyme Inhibitors; Female; Glucuronates; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Polymorphism, Genetic | 2002 |
Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Topics: Binding Sites; Binding, Competitive; Camptothecin; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Hydrogen Bonding; Irinotecan; Models, Molecular; Molecular Conformation; Nucleic Acid Heteroduplexes; Structure-Activity Relationship; Substrate Specificity; Thermodynamics; Topoisomerase I Inhibitors | 2002 |
Nothing succeeds like failure.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Industry; Humans; Irinotecan | 2002 |
[Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Rectal Neoplasms; Thiophenes; Time Factors | 2001 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Topoisomerases, Type I; DNA, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutagenesis; Point Mutation; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2002 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Syndrome; Thrombosis | 2002 |
ImClone BLA is declined.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Industry; Humans; Irinotecan; United States; United States Food and Drug Administration | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
[Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Neoplasms | 2002 |
[A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinosarcoma; Cisplatin; Drug Administration Schedule; Female; Humans; Hysterotomy; Irinotecan; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms | 2002 |
Combined chemotherapy trials require combined pharmacogenetic approaches.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Oxidoreductases Acting on CH-NH Group Donors; Polymorphism, Genetic; Quinazolines; Thiophenes | 2002 |
Promising drug is victim of bad business.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Clinical Trials as Topic; Colonic Neoplasms; Drug Approval; Drug Industry; ErbB Receptors; Humans; Irinotecan; Patents as Topic; Recombinant Fusion Proteins; United States; United States Food and Drug Administration | 2002 |
Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination.
Topics: Animals; Camptothecin; Clinical Trials as Topic; DNA Damage; Drosophila melanogaster; Enzyme Inhibitors; Female; Irinotecan; Male; Mutagenicity Tests; Mutation; Recombination, Genetic; Topoisomerase I Inhibitors; Topotecan; Wings, Animal | 2002 |
Loss of one allele of the p53 gene in the lens epithelial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT-11).
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Eye Neoplasms; Genotype; In Situ Nick-End Labeling; Irinotecan; Lens, Crystalline; Mice; Mice, Transgenic; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Fighting wars, winning battles.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Disease-Free Survival; Floxuridine; Humans; Irinotecan; Liver Neoplasms | 2002 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2002 |
Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Patient Compliance; Retrospective Studies | 2002 |
Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Irinotecan; Kidney Failure, Chronic; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Renal Dialysis | 2002 |
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Female; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Nuclear Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2002 |
Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Topics: Antineoplastic Agents, Phytogenic; Binding, Competitive; Camptothecin; Catalase; Cell Line; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Deferoxamine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Isoenzymes; Microsomes; Mixed Function Oxygenases; Protein Binding | 2002 |
Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
Topics: Aphidicolin; Apoptosis; Camptothecin; Cell Division; DNA Damage; DNA Fragmentation; DNA Ligases; DNA Repair; DNA Topoisomerases, Type I; Drug Interactions; Electrophoresis, Gel, Pulsed-Field; Enzyme Activation; Enzyme Inhibitors; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Altered irinotecan metabolism in a patient receiving phenytoin.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Interactions; Glioma; Humans; Irinotecan; Phenytoin; Topoisomerase I Inhibitors | 2002 |
Stability of irinotecan hydrochloride in aqueous solutions.
Topics: Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Glucose; Humans; Hydrogen-Ion Concentration; Hydrolysis; Infusions, Intravenous; Irinotecan; Pharmaceutical Solutions; Phosphates; Serum Albumin; Sodium Chloride; Temperature | 2002 |
DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Breast Neoplasms; Camptothecin; Cell Cycle; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Etoposide; Humans; Irinotecan; Neoadjuvant Therapy; Tumor Suppressor Protein p53 | 2002 |
Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Mutation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Catalysis; Colorectal Neoplasms; DNA Topoisomerases, Type I; HT29 Cells; Humans; Irinotecan; Neoplasm Proteins; Tumor Cells, Cultured | 2002 |
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Transport; Camptothecin; Female; Glucuronides; Irinotecan; Mice | 2002 |
[A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Hysterectomy; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Middle Aged; Neoplasm Invasiveness; Rectal Neoplasms; Sigmoid Neoplasms | 2002 |
An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Mass Spectrometry; Microsomes, Liver; Reference Standards; Sensitivity and Specificity; Spectrometry, Fluorescence | 2002 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection | 2002 |
Factors influencing the cellular accumulation of SN-38 and camptothecin.
Topics: Adenocarcinoma; Biological Transport; Camptothecin; Colonic Neoplasms; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Kinetics; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.
Topics: Alkaloids; Breast; Camptothecin; cdc25 Phosphatases; Cell Cycle Proteins; Cell Death; Cells, Cultured; Cyclin A; Cyclin B; DNA Damage; Enzyme Inhibitors; Female; G1 Phase; Genes, cdc; Humans; Irinotecan; Kinetics; Mitosis; Protein Serine-Threonine Kinases; S Phase; Staurosporine; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Dinoprostone; Duodenum; Fatty Acids, Omega-3; Irinotecan; Liver; Male; Membrane Lipids; Mice; Organ Size | 2002 |
Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Camptothecin; Drug Administration Schedule; Irinotecan; Male; Mice; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin | 2002 |
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Cholinesterase Inhibitors; Colorectal Neoplasms; Confidence Intervals; Female; Humans; Irinotecan; Male; Middle Aged; Physostigmine | 2002 |
[Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
Third Wave, Daiichi to develop personalized cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Polymorphism, Single Nucleotide | 2002 |
Structural insights into CPT-11 activation by mammalian carboxylesterases.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Asparagine; Binding Sites; Camptothecin; Carboxylic Ester Hydrolases; Crystallography, X-Ray; Glycosylation; Irinotecan; Liver; Models, Molecular; Molecular Sequence Data; Pliability; Prodrugs; Rabbits; Structure-Activity Relationship | 2002 |
[Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2002 |
[A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 2002 |
Irinotecan in small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Glucuronosyltransferase; Irinotecan; Lung Neoplasms; Polymorphism, Genetic; Prodrugs | 2002 |
Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caco-2 Cells; Camptothecin; Cell Survival; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nitrobenzenes; Sulfonamides; Topoisomerase Inhibitors | 2002 |
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Topics: Adult; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Polymorphism, Genetic | 2002 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures | 2002 |
Clinical trials using irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2002 |
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Topics: Anthraquinones; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Glucuronates; Glucuronides; HT29 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Metabolic Clearance Rate; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine | 2002 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Treatment Outcome | 2002 |
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; Drug Therapy, Combination; ErbB Receptors; Female; HT29 Cells; Humans; Irinotecan; Ki-67 Antigen; Mice; Mice, Nude; Neoplasm Transplantation; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Female; Gene Expression; Genetic Vectors; Humans; Inhibitory Concentration 50; Irinotecan; Ovarian Neoplasms; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequence Analysis, DNA; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Division; Cell Survival; Culture Media, Conditioned; Cyclophosphamide; Cytokines; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Inhibitory Concentration 50; Interleukin-1; Interleukin-3; Interleukin-6; Irinotecan; Membrane Proteins; Mice; Mice, Inbred Strains; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Isogeneic; Tumor Cells, Cultured | 2002 |
Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Glucuronates; Humans; In Vitro Techniques; Irinotecan; Microsomes, Liver; Oxidoreductases, N-Demethylating | 2002 |
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carcinoma; Caspases; Cell Cycle; Cells, Cultured; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Humans; Irinotecan; Kinetics; Membrane Glycoproteins; Neoplasms; Receptors, Tumor Necrosis Factor; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2002 |
Thalidomide and irinotecan-associated diarrhea.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Rectal Neoplasms; Thalidomide | 2002 |
[A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Rectal Neoplasms; Tegafur; Uracil | 2002 |
[Usefulness of low-dose irinotecan for multiple lung metastases of cholangiocellular carcinoma after operation--a case report].
Topics: Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Hepatectomy; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2002 |
Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cell Division; Irinotecan; Neuroectodermal Tumors; Rats; Rats, Wistar; Time Factors | 2002 |
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |
Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Camptothecin; Cell Line; Diffusion Chambers, Culture; Dogs; Dose-Response Relationship, Drug; Humans; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis | 2002 |
[Irinotekan in spread small cell lung cancer. More studies are required to change the practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2002 |
[Small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Radiotherapy, Adjuvant; Treatment Outcome | 2002 |
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2002 |
ERBITUX as a single agent and in combination in colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Interactions; Female; Fluorouracil; Glutamates; Guanine; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Transplantation, Heterologous | 2002 |
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA, Antisense; DNA, Complementary; Drug Synergism; Flavonoids; GTP-Binding Proteins; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Another NICE mess.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Legislation, Drug; Organizational Policy; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; State Medicine; United Kingdom | 2002 |
[A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Topics: Administration, Oral; Antacids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Defecation; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Sodium Bicarbonate; Ursodeoxycholic Acid | 2002 |
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chi-Square Distribution; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Tissue Distribution | 2002 |
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Topics: Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cytosol; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Irinotecan; Kinetics; Liver; Microsomes, Liver; Neoplasms; Protein Isoforms; Tumor Cells, Cultured | 2002 |
Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylic Ester Hydrolases; Cloning, Molecular; Colorectal Neoplasms; DNA, Complementary; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Gene Library; Humans; Hydrolysis; Irinotecan; Isoelectric Focusing; Kinetics; Protein Isoforms; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin.
Topics: Anesthesia; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Injections, Intraperitoneal; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Rats; Tumor Cells, Cultured | 2002 |
Non-linear pharmacokinetics of irinotecan in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Dose-Response Relationship, Drug; Female; Irinotecan; Mice; Mice, Inbred BALB C; Nonlinear Dynamics | 2002 |
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Thorax; Treatment Failure | 2002 |
Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2.
Topics: Animals; Camptothecin; Chlorides; Colon; Cyclic GMP; Enzyme Inhibitors; Female; Gene Expression; Imidazoles; Intestinal Mucosa; Irinotecan; Membrane Potentials; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Parasympathomimetics; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; RNA, Messenger; Thromboxane A2 | 2002 |
Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Interactions; Enzyme Activation; Flavonoids; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics | 2002 |
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Topics: Camptothecin; Catalysis; Cells, Cultured; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Microsomes, Liver; Polymorphism, Genetic; Recombinant Proteins; UDP-Glucuronosyltransferase 1A9 | 2002 |
St. John's Wort: more implications for cancer patients.
Topics: Antidepressive Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Humans; Hypericum; Irinotecan; Mixed Function Oxygenases; Neoplasms | 2002 |
Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
Topics: Adenoviridae; Animals; Bone Marrow; Bone Marrow Purging; Camptothecin; Carboxylic Ester Hydrolases; DNA, Complementary; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Pilot Projects; Prodrugs | 2002 |
Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Caffeine; Camptothecin; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Colonic Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Gene Deletion; Humans; Irinotecan; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Hodgkin Disease; Humans; Irinotecan; Male; Radiography; Recurrence; Salvage Therapy; Topoisomerase I Inhibitors | 2002 |
[Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Cisplatin; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Tegafur | 2002 |
[CPT-11 hepatic arterial injection plus oral UFT administration for liver metastasis of rectal cancer--report of two cases].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tegafur; Uracil | 2002 |
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carrier Proteins; Caspase 3; Caspase 7; Caspase 9; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Peptides; Protein Binding; Protein Structure, Tertiary; Proteins; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2002 |
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Camptothecin; Dacarbazine; Humans; Irinotecan; Longitudinal Studies; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide; Xenograft Model Antitumor Assays | 2002 |
Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Thiophenes; Treatment Failure | 2002 |
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Cell Survival; Colonic Neoplasms; Drug Interactions; Flow Cytometry; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Peptide Hydrolases; Poly(ADP-ribose) Polymerases | 2002 |
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chi-Square Distribution; Diarrhea; Dose-Response Relationship, Drug; Female; Glucuronates; Humans; Irinotecan; Male; Middle Aged | 2002 |
Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Adhesion Molecules; Cell Division; Chlorocebus aethiops; Colonic Neoplasms; COS Cells; Drug Screening Assays, Antitumor; Gene Expression Regulation; Humans; Immunoenzyme Techniques; Irinotecan; Lymphokines; Plasmids; Polymerase Chain Reaction; Prodrugs; Sialoglycoproteins; Tumor Cells, Cultured | 2002 |
Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Camptothecin; Cell Nucleus; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Irinotecan; Isoenzymes; Lectins; Tumor Cells, Cultured | 2002 |
SN-38 induces cell cycle arrest and apoptosis in human testicular cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line; Cisplatin; DNA; Etoposide; G1 Phase; Humans; In Situ Nick-End Labeling; Irinotecan; Male; Testicular Neoplasms; Tetrazolium Salts; Thiazoles | 2002 |
Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; DNA Damage; DNA Fragmentation; DNA-Binding Proteins; Enzyme Inhibitors; G2 Phase; Head and Neck Neoplasms; Humans; Irinotecan; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins; Serine; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 2002 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome | 2002 |
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Dinoprostone; Drug Administration Schedule; Drug Synergism; HT29 Cells; Humans; Irinotecan; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Colonic Neoplasms; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Mice; Mice, SCID; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2002 |
The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Chromatography, High Pressure Liquid; Female; Glucuronidase; Humans; Irinotecan; Kinetics; Mice; Mice, SCID; Microdialysis; Neoplasm Transplantation; Neuroblastoma; Transplantation, Heterologous | 2002 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Floxuridine; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tegafur; Uracil | 2002 |
Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Topics: Animals; Bile; Camptothecin; Digestive System; Dose-Response Relationship, Drug; Drug Interactions; Irinotecan; Male; Probenecid; Rats; Rats, Sprague-Dawley | 2002 |
Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Germinoma; Humans; Irinotecan; Male; Pilot Projects; Salvage Therapy | 2002 |
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Disease Models, Animal; Humans; Irinotecan; Liver Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Sulfonamides; Transplantation, Heterologous | 2002 |
[Gastrointestinal toxicity caused by irinotecan in the case of preexistent passage problems].
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fever; Humans; Intestinal Obstruction; Irinotecan; Leukopenia; Middle Aged; Stents | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
[Glutamate transporter mediated increase of antitumor activity by theanine, an amino acid in green tea].
Topics: Amino Acid Transport System X-AG; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Depression, Chemical; Drug Synergism; Drug Therapy, Combination; Glutamates; Glutathione; Irinotecan; Male; Mice; Neoplasm Transplantation; Sarcoma, Experimental; Tea; Tissue Distribution | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
Perspectives in colorectal cancer meeting. Miami, Florida. September 28-29, 2001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Guanylate Cyclase; Humans; Irinotecan; Microsatellite Repeats; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Receptors, Enterotoxin; Receptors, Guanylate Cyclase-Coupled; Receptors, Peptide | 2001 |
Capecitabine combinations in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Lessons learned from the Saltz and Mayo Clinic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration | 2002 |
Pharmacokinetics of irinotecan and its metabolites.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Irinotecan; Isotonic Solutions; Light; Neoplasms; Research Design; Sodium Chloride | 2002 |
Successful clinical response to irinotecan in relapsed neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Infant; Irinotecan; Lung Neoplasms; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Neuroblastoma; Radiography; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
Topics: Base Sequence; Bilirubin; Black or African American; Camptothecin; Genotype; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Microsomes, Liver; Molecular Sequence Data; Phenobarbital; Polymorphism, Genetic; Promoter Regions, Genetic; Topoisomerase I Inhibitors; White People | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Tegafur; Uracil | 2002 |
Novel therapeutic approaches in the treatment of children with hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Hepatoblastoma; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local | 2002 |
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Blotting, Northern; Blotting, Western; Camptothecin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Heterozygote; Homozygote; Irinotecan; Mice; Mitoxantrone; Molecular Sequence Data; Mutation; Neoplasm Proteins; Polymorphism, Genetic; RNA, Messenger; Sequence Analysis, DNA; Topotecan; Transfection; Tumor Cells, Cultured | 2002 |
[Dysarthria during irinotecan administration].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Diagnosis, Differential; Dysarthria; Endometrial Neoplasms; Female; Humans; Irinotecan; Magnetic Resonance Imaging | 2002 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2002 |
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Thymidylate Synthase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
[A case of postoperative liver metastasis of alpha-fetoprotein producing gastric cancer successfully treated with intrahepatic chemotherapy (adriamycin, cisplatin, irinotecan hydrochloride)].
Topics: alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Gastrectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2002 |
[Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Bile; Camptothecin; Glucuronides; Humans; Infusions, Parenteral; Irinotecan; Male; Stomach Neoplasms | 2002 |
[A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Therapy, Combination; Female; Humans; Injections, Intralesional; Injections, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritonitis | 2002 |
[Hepatic arterial infusion with irinotecan for the colorectal cancer patient with liver metastasis--a case report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Rectal Neoplasms | 2002 |
[A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colectomy; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Sigmoid Neoplasms | 2002 |
[A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Stomach Neoplasms | 2002 |
Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Humans; Hydrolysis; Irinotecan; Kidney; Lipase; Liver; Mice; Molecular Sequence Data; Peptide Fragments; Prodrugs; Sequence Homology, Amino Acid; Substrate Specificity | 2003 |
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Topics: Amino Acid Substitution; Animals; Arginine; Aspartic Acid; Camptothecin; Chlorocebus aethiops; COS Cells; Genetic Variation; Glucuronides; Glucuronosyltransferase; Glutamine; Glycine; Humans; Irinotecan; Proline; Tyrosine | 2003 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
Erbitux trial flawed from the beginning, committee finds.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Drug Synergism; Humans; Irinotecan; Research Design; Treatment Outcome; United States; United States Food and Drug Administration | 2002 |
Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; Camptothecin; Cell Cycle; DNA; Esterases; Hydroxyurea; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Sarcoma 180 | 2003 |
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Fluorouracil; Genetic Therapy; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2003 |
Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dosage Forms; Growth Inhibitors; Irinotecan; Lactates; Male; Mice; Microspheres; Nanotechnology; Polyethylene Glycols; Rats; Rats, Wistar; Sarcoma 180; Xenograft Model Antitumor Assays | 2003 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Europe; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Outpatients; Oxonic Acid; Paclitaxel; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2002 |
CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Cells; Bone Marrow Cells; Camptothecin; Cell Death; Drug Resistance, Multiple; Female; Humans; Interphase; Irinotecan; Leukemia; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phenotype; Rhodamine 123; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2003 |
p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11).
Topics: Animals; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Liver; Rabbits; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Fluorouracil; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Life Tables; Lymphokines; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Nitrates; Nitric Oxide; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Reproducibility of Results | 2003 |
Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Ceramides; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fumonisins; Glucosylceramides; Humans; Irinotecan; Morpholines; Protein Kinase C; Sphingolipids; Sphingosine; Tumor Cells, Cultured | 2003 |
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Salvage Therapy; Time Factors | 2002 |
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Camptothecin; Cell Division; Colorectal Neoplasms; Cyclin D1; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoskeletal Proteins; Dinoprostone; Drug Synergism; Endothelial Growth Factors; Fluorouracil; Intercellular Signaling Peptides and Proteins; Interleukin-10; Interleukin-12; Irinotecan; Isoenzymes; Lactones; Liver Neoplasms, Experimental; Lymphokines; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Prostaglandin-Endoperoxide Synthases; Sulfones; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Time Factors; Topoisomerase I Inhibitors | 2003 |
Hepatic artery infusion for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
[Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Floxuridine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 2003 |
Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
Topics: Antineoplastic Agents; Camptothecin; Glucuronidase; Glucuronides; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Prodrugs | 2003 |
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drugs, Chinese Herbal; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Concern about similarity of manuscripts.
Topics: Camptothecin; Humans; Irinotecan; Periodicals as Topic | 2003 |
Lipid membrane with low proton permeability.
Topics: Aminacrine; Camptothecin; Fluorescent Dyes; Hydrogen-Ion Concentration; Irinotecan; Liposomes; Membrane Lipids; Permeability; Protons; Spectrometry, Fluorescence | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Irinotecan; Lactones; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
[A case of metastatic liver tumor of colorectal cancer responding to low-dose CPT-11 chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2003 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vomiting, Anticipatory | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Middle Aged; Nausea; Pilot Projects; Rectal Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 2003 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergism; Genetic Therapy; Glioma; Humans; I-kappa B Proteins; Irinotecan; NF-kappa B; NF-KappaB Inhibitor alpha; Repressor Proteins; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Time Factors | 2003 |
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Line; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Kinetics; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Time Factors | 2003 |
[Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].
Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Camptothecin; Colitis; Cytomegalovirus Infections; Ganciclovir; Humans; Immunocompromised Host; Irinotecan; Male; Quinazolines; Rectal Neoplasms; Sigmoid Neoplasms; Thiophenes | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neomycin | 2003 |
Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Culture Techniques; Cell Division; Cisplatin; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Karyotyping; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Ovarian Neoplasms; Tumor Cells, Cultured | 2002 |
Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioblastoma; Glioma; Humans; Irinotecan | 2003 |
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Camptothecin; Cell Line; Glioblastoma; Humans; Irinotecan; Naphthalenes; Perylene; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2003 |
Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Safety | 2003 |
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Safety; Treatment Outcome | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; Colonic Neoplasms; Drug Evaluation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2003 |
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Asparagine; Aspartic Acid; Camptothecin; COS Cells; Exons; Genetic Variation; Glucuronates; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Japan; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Transfection; UDP-Glucuronosyltransferase 1A9 | 2003 |
Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; Hyperthermia, Induced; Irinotecan; Melphalan; Mice; Mice, Inbred C3H; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2003 |
Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.
Topics: Administration, Oral; Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Charcoal; Diarrhea; Drug Interactions; Irinotecan; Male; Models, Animal; Rats; Rats, Sprague-Dawley | 2002 |
Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11).
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Hepatoblastoma; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary | 2003 |
[A case of paraneoplastic syndrome improved following chemoradiotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Gait Ataxia; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Polyneuropathy; Paresthesia; Radiotherapy, Adjuvant; Treatment Outcome | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2003 |
Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Enzyme Inhibitors; Irinotecan; Liposomes; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Camptothecin; Cell Division; Colonic Neoplasms; Endothelial Growth Factors; HT29 Cells; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Lymphokines; Mice; Mice, Nude; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Phlebitis due to irinotecan.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Arm; Camptothecin; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Phlebitis; Rectal Neoplasms | 2003 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Sampling Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Is liver disease an octreotide side effect?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Agents; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Octreotide | 2003 |
Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Bile; Camptothecin; Chromatography, High Pressure Liquid; Cyclosporine; Digestive System; Epithelium; Immunosuppressive Agents; In Vitro Techniques; Irinotecan; Liver; LLC-PK1 Cells; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Perfusion; Rats; Rats, Wistar; Swine; Tissue Distribution | 2003 |
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Synergism; Irinotecan; Mice; Models, Biological; Models, Statistical; Neoplasms, Experimental; Research Design; Sample Size; Statistics, Nonparametric; Temozolomide | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed | 2003 |
[A case of gastric cancer with multiple liver metastasis responding to combination therapy of CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2003 |
Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; beta-Galactosidase; Camptothecin; Cell Cycle; Cell Division; Cell Line, Tumor; Cellular Senescence; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Fluorescent Dyes; Genes, p53; Humans; Immunoblotting; Irinotecan; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Time Factors; Topoisomerase I Inhibitors | 2003 |
Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer.
Topics: Adult; Camptothecin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2003 |
Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Camptothecin; Carboxylic Ester Hydrolases; Cell Division; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Rabbits; Tumor Cells, Cultured | 2003 |
Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Intestinal Mucosa; Irinotecan; Male; Middle Aged; Permeability; Quinazolines; Thiophenes | 2003 |
Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Male; Microscopy, Confocal; Middle Aged; Prodrugs; Topoisomerase I Inhibitors | 2003 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
Epidermal growth factor receptor inhibition induces trichomegaly.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; ErbB Receptors; Eyelashes; Female; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis | 2003 |
Missing evidence for the adequacy of a 1-cm distal margin in resected rectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Digestive System Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Rectal Neoplasms; Treatment Outcome | 2003 |
Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Diseases; Camptothecin; Diarrhea; Infusions, Intravenous; Intestines; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 2003 |
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Caspase 3; Caspase 7; Caspases; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Membrane Glycoproteins; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2003 |
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Diarrhea; Intestine, Small; Irinotecan; Male; Neoplasm Transplantation; Rats; Severity of Illness Index | 2003 |
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan | 2003 |
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 2003 |
Comment: Usefulness of herbal and dietary supplement references.
Topics: Benzamides; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dietary Supplements; Drug Interactions; Humans; Hypericum; Imatinib Mesylate; Irinotecan; Phytotherapy; Piperazines; Plant Preparations; Pyrimidines; Reference Books | 2003 |
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nail Diseases; Nails | 2003 |
Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Drug Delivery Systems; Enzyme Inhibitors; Half-Life; HT29 Cells; Humans; Injections, Intravenous; Irinotecan; Lactones; Light; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Particle Size; Scattering, Radiation; Serum Albumin; Topoisomerase Inhibitors | 2003 |
[A case of multiple lung metastases from colon cancer after sigmoidectomy treated effectively by chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Sigmoid Neoplasms; Tegafur; Uracil | 2003 |
[A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Silicates; Stomach Neoplasms; Titanium | 2003 |
[A case of effective weekly paclitaxel administration for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2003 |
Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Mice, Nude; Osteosarcoma; Prodrugs; Transduction, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Advances in colon cancer.
Topics: Camptothecin; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Pyridines; Treatment Outcome | 2003 |
A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Luminescent Proteins; Male; Mice; Mice, Nude; Models, Animal; Neoplasm Metastasis; Pancreatic Neoplasms; Predictive Value of Tests; Red Fluorescent Protein; Transduction, Genetic; Tumor Cells, Cultured | 2003 |
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Topics: Alleles; Amino Acid Sequence; Antineoplastic Agents; Binding, Competitive; Black People; Blotting, Western; Camptothecin; Flavonoids; Glucuronates; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Kinetics; Molecular Sequence Data; Mutation, Missense; Piperidines; Polymorphism, Genetic; Recombinant Proteins; Sequence Homology, Amino Acid; Subcellular Fractions; UDP-Glucuronosyltransferase 1A9; White People | 2003 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Fluorouracil; Humans; Irinotecan; Leucovorin; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Survival Analysis; Wound Healing | 2003 |
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Endothelial Growth Factors; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphokines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis | 2003 |
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Topics: Adenosine Triphosphate; Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA-Binding Proteins; Female; Gene Frequency; Genotype; Glucuronates; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Male; Membrane Transport Proteins; Middle Aged; Models, Biological; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phenotype; Polymorphism, Genetic; Protein Binding; X-ray Repair Cross Complementing Protein 1 | 2003 |
CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Palliative Care; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Topics: Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Germany; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 2003 |
SNP analysis by using ferrocenyl naphthalene diimide (FND)-based electrochemical hybridization assay (EHA).
Topics: Antineoplastic Agents; Base Sequence; Camptothecin; DNA Probes; Electrochemistry; Ferrous Compounds; Imides; Irinotecan; Nucleic Acid Hybridization; Polymorphism, Single Nucleotide | 2003 |
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Erythrocytes; Humans; Irinotecan; Reproducibility of Results; Sensitivity and Specificity; Topoisomerase I Inhibitors | 2003 |
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carrier Proteins; Colorectal Neoplasms; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Exons; Female; Gene Deletion; Genomic Instability; Humans; Irinotecan; Male; Middle Aged; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2003 |
Pharmacogenomics: road to anticancer therapeutics nirvana?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Repair; Drug Design; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Thymidylate Synthase | 2003 |
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Retrospective Studies | 2003 |
Apoptotic pathways of epothilone BMS 310705.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Vomiting | 2003 |
PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Epoxy Compounds; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Phenanthrenes; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; Humans; Irinotecan; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Up-Regulation | 2003 |
Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Membrane; DNA, Complementary; Drug Resistance, Multiple; Fibroblasts; Humans; Irinotecan; Kinetics; Mice; Mitoxantrone; Neoplasm Proteins; Recombinant Proteins; Transfection | 2003 |
Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Approval; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Netherlands; Program Evaluation; Treatment Outcome | 2003 |
Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan | 2003 |
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2003 |
Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Citalopram; Depressive Disorder; Drug Interactions; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Rhabdomyolysis; Selective Serotonin Reuptake Inhibitors | 2003 |
Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Topics: Blotting, Northern; Blotting, Western; Brain; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hydrolases; Hydrolysis; Irinotecan; Liver; Male; Reverse Transcriptase Polymerase Chain Reaction; RNA; Umbelliferones | 2003 |
A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Topics: Adenoviridae; Animals; Camptothecin; Carboxylesterase; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Rabbits; Transgenes; Virus Replication; Xenograft Model Antitumor Assays | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
[The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Taxoids; Thrombopoietin | 2003 |
[Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2003 |
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Irinotecan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Taxoids | 2003 |
Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Humans; Ileal Neoplasms; Irinotecan; Jejunal Neoplasms; Male; Salvage Therapy; Survival Analysis; Treatment Outcome | 2003 |
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; DNA; Doxorubicin; Female; Glutathione; Glutathione Transferase; Guanidines; Irinotecan; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred DBA; Mice, Nude; Pyrroles; Transplantation, Heterologous | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
[Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Infusions, Intravenous; Injections, Intraperitoneal; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Spinal Neoplasms | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Rectal Neoplasms; Tegafur; Uracil | 2003 |
[A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Sigmoid Neoplasms | 2003 |
[A case of spinal infarction related to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infarction; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Spine | 2003 |
[Long-term survival after neck lymph node metastases from sigmoid colon cancer--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Neck; Sigmoid Neoplasms; Survivors; Tegafur; Uracil | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2003 |
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Irinotecan; Luciferases; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Base Sequence; Camptothecin; DNA Primers; Genes, MDR; Genotype; Haplotypes; Humans; Irinotecan; Japan; Kidney | 2003 |
A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).
Topics: Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Liposomes; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
Combined modality therapy in esophageal cancer: the Memorial experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel | 2003 |
[A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Ovarian Neoplasms; Prognosis; Quality of Life; Skin Neoplasms; Stomach Neoplasms | 2003 |
Enzyme-prodrug systems: carboxylesterase/CPT-11.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Irinotecan; Liver; Molecular Sequence Data; Neoplasms; Prodrugs; Rabbits; Sequence Alignment; Sequence Homology, Amino Acid | 2004 |
Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cells, Cultured; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HT29 Cells; Humans; Irinotecan; Kinetics; Mice; Mice, Nude; Thrombospondin 1; Xenograft Model Antitumor Assays | 2004 |
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Topics: Anthraquinones; Antigens, CD; Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Carrier Proteins; Colonic Neoplasms; Drug Interactions; Drug Resistance; Glucuronides; HT29 Cells; Humans; Irinotecan; Membrane Glycoproteins; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Propionates; Quinolines; Tetraspanin 29; Tumor Cells, Cultured; Tyrosine | 2004 |
Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cisplatin; Female; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Stomach Neoplasms; Treatment Outcome | 2003 |
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Folic Acid; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Retrospective Studies | 2003 |
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Topics: Anthraquinones; Biopsy; Camptothecin; Catalysis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Food Additives; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Propofol; Topoisomerase I Inhibitors; Tyrosine | 2003 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
Presentations from the Walter Reed Army Medical Center. Case 1: rectal carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Patient Care Planning; Rectal Neoplasms; Rectum; Ultrasonography | 2003 |
[Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Female; Humans; Intestinal Neoplasms; Irinotecan; Male; Middle Aged | 2003 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Analysis | 2003 |
[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Quality of Life; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2003 |
Development and characterization of a novel liposome-based formulation of SN-38.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Stability; Female; Hydrogen-Ion Concentration; Injections, Intravenous; Irinotecan; Liposomes; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Time Factors; Transplantation, Heterologous | 2004 |
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Drug Interactions; Drug Synergism; Humans; Irinotecan; Neoplasm Transplantation; Rats; Rhabdomyosarcoma; Stilbenes; Time Factors; Tumor Cells, Cultured | 2004 |
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan | 2004 |
[Principles of postoperative therapy in rectal carcinoma].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors | 2004 |
Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Irinotecan; Luminescent Measurements; Male; Microspheres; Rats; Rats, Inbred Strains | 2004 |
Biological characterization of MLN944: a potent DNA binding agent.
Topics: Animals; Antigens, Neoplasm; Camptothecin; Catalysis; Cell Cycle; Cell Line, Tumor; Cluster Analysis; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; G1 Phase; G2 Phase; Gene Expression Profiling; HCT116 Cells; Humans; Intercalating Agents; Irinotecan; Male; Mice; Mice, Nude; Mitosis; Mutation; Neoplasms, Experimental; Phenazines; Transplantation, Heterologous; Xenograft Model Antitumor Assays; Yeasts | 2004 |
[A case of isolated hepatic malignant lymphoma representing characteristic findings on radiological imaging].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Irinotecan; L-Lactate Dehydrogenase; Liver Neoplasms; Lymphoma; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prednisolone; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Health Care Costs; Hepatic Artery; Humans; Immunosuppressive Agents; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Patient Selection; Treatment Outcome | 2004 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Models, Biological; Ovarian Neoplasms; Paclitaxel | 2004 |
Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.
Topics: Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cullin Proteins; Cysteine Endopeptidases; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; Multienzyme Complexes; Proteasome Endopeptidase Complex; RNA, Small Interfering; S Phase; Ubiquitin | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Irinotecan; Kinetics; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2004 |
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cellular Senescence; DNA Damage; Enzyme Inhibitors; Exons; Gene Deletion; Glioblastoma; Humans; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2004 |
Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.
Topics: Animals; Arginine; Bacillus subtilis; Bacterial Proteins; Camptothecin; Carboxylic Ester Hydrolases; Catalysis; Computer Simulation; COS Cells; DNA Mutational Analysis; Humans; Irinotecan; Kinetics; Leucine; Models, Molecular; Mutagenesis, Site-Directed; Rabbits; Serine; Viscosity | 2004 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.
Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; Mutation; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2004 |
Quantification of tumor tissue populations by multispectral analysis.
Topics: Adipose Tissue; Animals; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; fas Receptor; Female; Humans; Irinotecan; Ligands; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Membrane Glycoproteins; Mice; Mice, Nude; Necrosis; Neoplasm Transplantation; Remission Induction; Skin Neoplasms; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Necrosis Factor-alpha | 2004 |
Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Mitomycin; Oxonic Acid; Pyridines; Radiography; Stomach Neoplasms; Tegafur; Treatment Failure | 2004 |
Irinotecan pharmacogenetics: is it time to intervene?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Risk; Topoisomerase I Inhibitors | 2004 |
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Neutropenia; Prospective Studies; Risk; Topoisomerase I Inhibitors | 2004 |
Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gilbert Disease; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies | 2004 |
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colon; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2004 |
Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ploidies; Predictive Value of Tests; Treatment Outcome | 2004 |
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Genes, p53; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Tumor Suppressor Protein p53 | 2004 |
[Two cases of metastatic or recurrent rectal cancer responding to combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Floxuridine; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Quality of Life; Rectal Neoplasms | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Tumor Cells, Cultured | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pleurisy; Quality of Life; Tegafur; Uracil | 2004 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Topoisomerase I Inhibitors | 2004 |
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Topics: Camptothecin; Chromatography, High Pressure Liquid; Glucuronidase; Humans; Irinotecan; Time Factors | 2004 |
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors | 2004 |
Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly e
Topics: Amino Acid Sequence; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cloning, Molecular; Gene Expression Regulation, Enzymologic; Humans; Hydrolysis; Irinotecan; Isoenzymes; Liver; Molecular Sequence Data; Oxidation-Reduction | 2004 |
Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytokines; Digestive System; Dose-Response Relationship, Drug; Female; Fluorouracil; Histocompatibility Antigens Class I; Intestinal Mucosa; Irinotecan; Jejunum; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Peptides; Time Factors | 2004 |
A flow cytometric assay for simultaneous assessment of drug efflux, proliferation, and apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Irinotecan; K562 Cells; Predictive Value of Tests; Staining and Labeling | 2004 |
[Screening of DNA topoisomerase inhibitors].
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; DNA Topoisomerases; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2004 |
[Screening for inhibitors of tumor invasion into basement membranes].
Topics: Animals; Basement Membrane; Berberine; Camptothecin; Carcinoma, Lewis Lung; Cell Movement; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lymphatic Metastasis; Mice; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Saponins; Tumor Cells, Cultured | 2004 |
[Structure-activity relationship analysis].
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine | 2004 |
[Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Carcinoma, Signet Ring Cell; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Pyrazoles; Sigmoid Neoplasms; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Diagnosis, Differential; Frontal Lobe; Glioblastoma; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Radiography; Temozolomide | 2004 |
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Differentiation; Cell Division; Child; Child, Preschool; Diterpenes; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Retinaldehyde; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2004 |
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
Topics: Adenovirus E1A Proteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Camptothecin; Carcinoma, Squamous Cell; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; DNA Topoisomerases, Type I; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Irinotecan; Nuclear Proteins; Proto-Oncogene Proteins p21(ras); Repressor Proteins; Tumor Cells, Cultured | 2004 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Costs; Humans; Hypoalbuminemia; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Prognosis; Sample Size | 2004 |
Biliary excretion of irinotecan and its metabolites.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Carboxylic Acids; Glucuronides; Irinotecan; Lactones; Male; Rats; Rats, Wistar | 2004 |
Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Diarrhea; Enzyme Inhibitors; Humans; Intestines; Irinotecan; Models, Molecular; Quantitative Structure-Activity Relationship; Rabbits; Sulfonamides | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2004 |
Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Glucuronidase; Intestinal Mucosa; Irinotecan; Jejunum; Lactones; Rats; Rats, Wistar; Sugar Acids | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2004 |
Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.
Topics: Agar; Animals; Antineoplastic Agents, Phytogenic; Baculoviral IAP Repeat-Containing 3 Protein; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Genes, Reporter; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Mice; Neoplasm Transplantation; NF-kappa B; Oligonucleotides; Proteins; RNA; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Ubiquitin-Protein Ligases | 2004 |
[Chemotherapy for small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Quality of Life | 2004 |
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
Topics: Aged; Bilirubin; Camptothecin; Female; Genetic Linkage; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide | 2004 |
A novel mouse model of rectal cancer established by orthotopic implantation of colon cancer cells.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Rectal Neoplasms; Transplantation, Heterologous | 2004 |
In vitro conversion of irinotecan to SN-38 in human plasma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged | 2004 |
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Irinotecan; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
Two new drugs for colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms | 2004 |
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fluorouracil; Hepatitis C; Humans; Immunocompromised Host; Irinotecan; Leucovorin; Male; Recurrence | 2004 |
Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2004 |
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Topics: Animals; Brain Neoplasms; Camptothecin; Carmustine; Cell Line, Tumor; Enzyme Inhibitors; Female; Gliosarcoma; Irinotecan; Neoplasm Transplantation; Rats; Rats, Inbred F344; Topoisomerase I Inhibitors | 2004 |
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Camptothecin; Colonic Neoplasms; Dysarthria; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Male | 2004 |
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Irinotecan; Nucleic Acids; Organoplatinum Compounds; Oxaliplatin; Uridine | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2004 |
Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carbon-Sulfur Lyases; Caspase 3; Caspases; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Cysteine; DNA Fragmentation; Drug Interactions; Enzyme Activation; Gene Expression; Humans; Irinotecan; Minichromosome Maintenance Complex Component 2; Nuclear Proteins; Organoselenium Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Saccharomyces cerevisiae Proteins; Selenocysteine | 2004 |
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Surface Area; Camptothecin; Dose-Response Relationship, Drug; Female; Glucuronates; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Models, Statistical; Neoplasms | 2004 |
Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.
Topics: Antibiotics, Antitubercular; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Interactions; Glucuronates; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mycobacterium avium-intracellulare Infection; Rifampin; Tuberculosis, Pulmonary | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2004 |
[Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Carcinoma, Signet Ring Cell; Cholecystectomy; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasms, Multiple Primary; Splenectomy; Stomach Neoplasms | 2004 |
Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Glucuronides; Irinotecan; Male; Rats; Rats, Wistar; Sulfobromophthalein | 2004 |
A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Gastrectomy; Humans; Irinotecan; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Preoperative Care; Stomach Neoplasms | 2004 |
Cisplatin enhances the p53-independent apoptosis induced by a topoisomerase I inhibitor (CPT-11) in the lens epithelial tumors in transgenic mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cisplatin; Drug Synergism; Enzyme Inhibitors; Epithelium; Genotype; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Lens, Crystalline; Mice; Mice, Transgenic; Mutation; Polymerase Chain Reaction; Signal Transduction; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
UGT1A1*28 polymorphism in ovarian cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Estrogens; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Loss of Heterozygosity; Odds Ratio; Ovarian Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Protein Isoforms; Regression Analysis | 2004 |
[Resection of liver metastasis of colorectal origin following chemotherapy with irinotecan].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Survival Rate | 2004 |
Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Membrane; Cells, Cultured; Drug Resistance; Glucuronides; Humans; Irinotecan; Mutation; Neoplasm Proteins; Quercetin | 2004 |
Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Metallothionein; Middle Aged; Oligonucleotide Array Sequence Analysis; Stomach Neoplasms | 2004 |
The price tag on progress--chemotherapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Costs; Humans; Irinotecan; Medicare; Neoplasm Metastasis; United States | 2004 |
New treatment options for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Exanthema; Humans; Irinotecan; Research Design; Topoisomerase I Inhibitors | 2004 |
[A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2004 |
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; NF-kappa B; Stomach Neoplasms | 2004 |
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Antidiarrheals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Loperamide; Neomycin | 2004 |
Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Endodeoxyribonucleases; Fluorescence Resonance Energy Transfer; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Single Nucleotide | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver; Liver Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2004 |
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Female; Gene Frequency; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Thymidylate Synthase; Topoisomerase I Inhibitors | 2004 |
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
Topics: Abdominal Neoplasms; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Topoisomerase I Inhibitors; Transplantation, Heterologous | 2004 |
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Colorectal Neoplasms; DNA Primers; Female; Fluorouracil; Genetic Vectors; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Polymerase Chain Reaction; Polymorphism, Genetic; Risk; Sequence Analysis, DNA | 2004 |
Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Topics: Animals; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Intestinal Mucosa; Irinotecan; Kinetics; Liver; Models, Chemical; Nitrophenols; Protein Biosynthesis; Rabbits; Recombinant Proteins; Transfection | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Catheter Ablation; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplastic Syndromes, Hereditary; Pancreatectomy; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Reoperation; Splenectomy; Stomach Neoplasms; Taxoids | 2004 |
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Baculoviridae; Benzimidazoles; Biological Transport; Camptothecin; Cell Line; DNA, Complementary; Dogs; Drug Interactions; Enzyme Inhibitors; Humans; Irinotecan; Membrane Transport Proteins; Methotrexate; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Omeprazole; Pantoprazole; Spodoptera; Sulfoxides; Topotecan; Transfection | 2004 |
[Present-day potential of medication for disseminated cervical carcinoma].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Uterine Cervical Neoplasms | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Remission Induction | 2004 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colon, Sigmoid; Combined Modality Therapy; Drug Administration Schedule; Electrocoagulation; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Microwaves; Middle Aged; Sigmoid Neoplasms; Survivors | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Data Interpretation, Statistical; Fluorouracil; Gastrointestinal Neoplasms; Irinotecan; Male; Mitomycin; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Rats; Time Factors; Tumor Cells, Cultured | 2004 |
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Black People; Camptothecin; Drug Resistance, Multiple; Female; Gene Frequency; Genotype; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; White People | 2004 |
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan | 2004 |
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastroph
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA Replication; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; G2 Phase; HCT116 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Mitosis; S Phase; Staurosporine; Topoisomerase I Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2004 |
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Taiwan | 2004 |
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resista
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Intramolecular Oxidoreductases; Irinotecan; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Ornithine Decarboxylase; Oxaliplatin; Paclitaxel; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Survival Rate; Transplantation, Heterologous; Vault Ribonucleoprotein Particles | 2004 |
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Pyrimidines; Retrospective Studies; Survival Rate | 2004 |
[A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase 2; Drug Administration Schedule; Female; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwelling; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male | 2004 |
[A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Male; Quality of Life | 2004 |
Excited-state proton transfer reactions of 10-hydroxycamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Protons; Spectrometry, Fluorescence; Structure-Activity Relationship; Titrimetry | 2004 |
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Choline; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Hydrocarbons; Irinotecan; Magnetic Resonance Spectroscopy; Matched-Pair Analysis; Methane; Neuroblastoma; Predictive Value of Tests; Protons; Rats; Rats, Nude; Reproducibility of Results; Transplantation, Heterologous | 2004 |
Circadian rhythm of irinotecan tolerability in mice.
Topics: Agranulocytosis; Animals; Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Chronotherapy; Circadian Rhythm; Drug Tolerance; Enzyme Inhibitors; Intestines; Irinotecan; Leukopenia; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Photoperiod; Topoisomerase I Inhibitors; Weight Loss | 2004 |
Cetuximab in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Costs; Humans; Irinotecan; Quality of Life; Topoisomerase I Inhibitors | 2004 |
Cetuximab in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Outcome Assessment, Health Care; Topoisomerase I Inhibitors | 2004 |
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Topics: Animals; Camptothecin; Capsules; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Irinotecan; Liposomes; Liver Neoplasms; Male; Mice; Mice, SCID; Survival Analysis; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Colony-Forming Units Assay; Dogs; Granulocyte Precursor Cells; Granulocytes; Humans; Inhibitory Concentration 50; Irinotecan; Macrophages; Maximum Tolerated Dose; Mice; Models, Biological | 2004 |
Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Alleles; Camptothecin; Carboxylesterase; Enzyme Inhibitors; Exons; Gene Frequency; Genetic Variation; Genome; Genotype; Haplotypes; Homozygote; Humans; Hydrolysis; Introns; Irinotecan; Linkage Disequilibrium; Liver; Models, Genetic; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Procaine; Prodrugs; RNA, Messenger; Tissue Distribution | 2004 |
Bevacizumab in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality-Adjusted Life Years; Research Design | 2004 |
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays | 2004 |
Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Topics: Animals; Biomedical Enhancement; Camptothecin; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Colonic Neoplasms; Disease Models, Animal; Drug Carriers; Female; HT29 Cells; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, SCID; Technology, Pharmaceutical; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2004 |
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Irinotecan; Mice; Mice, Inbred ICR; Sesquiterpenes; Treatment Failure; Xenograft Model Antitumor Assays | 2005 |
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Breath Tests; Camptothecin; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Confidence Intervals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Erythromycin; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Male; Midazolam; Middle Aged; Phenotype; Predictive Value of Tests; Prospective Studies | 2004 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Likelihood Functions; Longitudinal Studies; Mice; Mice, SCID; Models, Biological; Models, Statistical; Neoplasms, Experimental; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2005 |
[Chemotherapy using nedaplatin for advanced gynecologic cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Combined Modality Therapy; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11).
Topics: Acetylcholinesterase; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinesterase Inhibitors; Erythrocytes; Humans; Irinotecan | 2004 |
In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aorta; Camptothecin; Cell Line, Tumor; Cisplatin; Drug Therapy, Combination; Endothelial Cells; Genes, Reporter; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Neoplasms; Retroviridae; Simplexvirus; Survival Rate; Swine; Thymidine Kinase; Transcription, Genetic; Treatment Outcome | 2005 |
Suppressive effect of CPT-11 on rat esophageal tumorigenesis induced by N-nitrosomethylbenzylamine.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Dimethylnitrosamine; Disease Models, Animal; DNA, Single-Stranded; Esophageal Neoplasms; Immunohistochemistry; Irinotecan; Male; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Rats; Tumor Suppressor Protein p53 | 2004 |
Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Parity; Treatment Outcome | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms | 2004 |
[Case report--Complete response of liver metastasis of rectal cancer after combination chemotherapy of CPT-11 + UFT-E].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tegafur; Uracil | 2004 |
[CPT-11 hepatic arterial infusion chemotherapy for metastatic liver tumor from gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2004 |
[Evaluation of bronchial arterial infusion (BAI) for metastatic lung tumor from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Cisplatin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Length of Stay; Lung Neoplasms; Male; Middle Aged | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cecal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Seeding; Peritoneal Neoplasms; Reoperation | 2004 |
Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Caco-2 Cells; Camptothecin; Coloring Agents; Enzyme Inhibitors; Flavonoids; Humans; Intestinal Mucosa; Intestines; Irinotecan; Sulfobromophthalein; Tumor Cells, Cultured | 2005 |
Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deaminase; Disease Models, Animal; Drug Delivery Systems; Female; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasms, Glandular and Epithelial; Promoter Regions, Genetic; Ribosomes; RNA, Messenger; Thymidylate Synthase; Time Factors; Transcription, Genetic | 2004 |
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindications; Enzyme Inhibitors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Topoisomerase I Inhibitors | 2004 |
[A case of liver metastatic recurrence of gastric cancer effectively treated by combined chemotherapy of CPT-11 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Gastrectomy; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Quality of Life; Stomach Neoplasms | 2004 |
Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.
Topics: Animals; Asian People; Black or African American; Camptothecin; Chlorocebus aethiops; COS Cells; Gene Frequency; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Polymorphism, Single Nucleotide; RNA, Messenger; White People | 2005 |
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Camptothecin; Cell Communication; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lymphoma; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stromal Cells; Up-Regulation | 2004 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; RNA, Messenger; Transcription Factors; Vascular Endothelial Growth Factor A | 2005 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypoxia; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Nude; Microcirculation; Oxygen; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylic Ester Hydrolases; Chromatography, High Pressure Liquid; Databases, Genetic; DNA; DNA Primers; Exons; Humans; Irinotecan; Liver; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; RNA | 2004 |
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; Complement System Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Survival Rate; Transplantation, Heterologous | 2005 |
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Camptothecin; Colonic Neoplasms; Drug Synergism; Female; HCT116 Cells; Humans; Irinotecan; Janus Kinase 2; Liver Neoplasms; Membrane Glycoproteins; Mice; Mice, Nude; Protein-Tyrosine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2004 |
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha | 2004 |
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cells, Cultured; Estrone; Female; Glucuronides; Humans; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Oocytes; Polymorphism, Single Nucleotide; Topoisomerase I Inhibitors; Xenopus | 2005 |
Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Logistic Models; Male; Mesothelioma; Middle Aged; Mitomycin; Models, Theoretical; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2005 |
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Nervous System Neoplasms; Neuroblastoma; Palliative Care; Quality of Life; Retrospective Studies; Treatment Outcome | 2005 |
Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
Topics: Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Camptothecin; In Vitro Techniques; Irinotecan; Liver; Loperamide; Male; Rats; Rats, Sprague-Dawley | 2005 |
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2004 |
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Primers; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Monitoring, Physiologic; Neutropenia; Reproducibility of Results | 2005 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).
Topics: Animals; Camptothecin; Chromatography, Liquid; Irinotecan; Liposomes; Mass Spectrometry; Mice; Tissue Distribution | 2005 |
Limited potential of hepatic arterial infusion of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms | 2004 |
[A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Survivors | 2005 |
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Male; Medical Records Systems, Computerized; Middle Aged | 2005 |
Irinotecan and other agents in the management of multiple tumor types. Highlights from the 6th University of Texas M. D. Anderson Cancer Center Investigators' Workshop. July 16-20, 2003, Amelia Island, Florida, USA.
Topics: Animals; Antineoplastic Agents; Camptothecin; Humans; Irinotecan | 2004 |
Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.
Topics: Animals; Antineoplastic Agents; Calotropis; Camptothecin; Cardenolides; Cell Line, Tumor; Cell Proliferation; Cerebral Cortex; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Maximum Tolerated Dose; Mice; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Sodium-Potassium-Exchanging ATPase; Structure-Activity Relationship; Swine; Thiazoles | 2005 |
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Phenazines; Transplantation, Heterologous | 2005 |
Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells: the role of nuclear factor-kappaB pathway activation.
Topics: Apoptosis; bcl-X Protein; Camptothecin; Caspases; Cell Cycle; Cell Survival; Cytochromes c; DNA Damage; DNA Fragmentation; Drug Synergism; Humans; Irinotecan; Mesothelioma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Necrosis Factors | 2005 |
From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Damage; DNA Replication; Drug Resistance, Multiple; HL-60 Cells; Humans; Irinotecan; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Translocation, Genetic | 2005 |
Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Transport, Active; Camptothecin; Coloring Agents; Intestine, Small; Irinotecan; Male; Mitoxantrone; Rats; Rats, Wistar; Sulfobromophthalein | 2005 |
Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Sodium Bicarbonate; Surveys and Questionnaires | 2004 |
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Cytokines; Drug Resistance, Neoplasm; Humans; Irinotecan; Kidney Neoplasms; Mitomycin; Neoplasm Metastasis; Prognosis | 2005 |
New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Evidence-Based Medicine; Female; Humans; Irinotecan; Male; Medical Oncology; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Thiophenes; Treatment Outcome | 2005 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Fluorouracil; HT29 Cells; Humans; Ibuprofen; Irinotecan; Lactones; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Xenograft Model Antitumor Assays | 2005 |
MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Body Weight; Camptothecin; Cell Line, Tumor; Dextrans; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Time Factors; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspases; Cell Division; Colonic Neoplasms; HT29 Cells; Humans; Irinotecan; Pentacyclic Triterpenes; Triterpenes | 2005 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspases; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Liver Neoplasms; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Skin; Tumor Cells, Cultured; Vorinostat | 2005 |
Gene expression profiling of the irinotecan pathway in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tumor Cells, Cultured | 2005 |
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms | 2005 |
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cluster Analysis; Computational Biology; Databases as Topic; DNA, Complementary; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mitomycin; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phylogeny; Sensitivity and Specificity; Tissue Distribution; Transfection; Vinblastine; Vinorelbine | 2005 |
The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinesterase Inhibitors; Crystallization; Crystallography, X-Ray; Humans; Irinotecan; Prodrugs; Torpedo | 2005 |
Gastrointestinal Cancers--Second Annual Symposium. 27-29 January 2005, Hollywood, FL, USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Floxuridine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms | 2005 |
Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints.
Topics: Camptothecin; cdc25 Phosphatases; Cell Line, Tumor; Cyclin B; DNA Damage; Female; G2 Phase; Humans; Irinotecan; Repressor Proteins; S Phase; Staurosporine; Transcriptional Activation; Tumor Suppressor Protein p53 | 2005 |
[Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Kidney Failure, Chronic; Leukopenia; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rectal Neoplasms; Renal Dialysis | 2005 |
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Fibroblast Growth Factor 7; Fibroblast Growth Factors; Irinotecan; Keratinocytes; Mammary Neoplasms, Animal; Rats; Survival Analysis | 2005 |
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glucosides; Humans; In Vitro Techniques; Indoles; Irinotecan; Mice; Microsomes, Liver; Topoisomerase I Inhibitors; Transplantation, Heterologous | 2005 |
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Female; Genes, MDR; Genotype; Heterozygote; Homozygote; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Nasopharyngeal Neoplasms; Neoplasm Proteins; Phenotype; Polymorphism, Single Nucleotide | 2005 |
Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Irinotecan; Liver Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2005 |
The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide.
Topics: Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Granisetron; Humans; Irinotecan; Microsomes, Liver | 2005 |
Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dietary Supplements; Dinoprostone; Drug Synergism; ErbB Receptors; Humans; Irinotecan; Membrane Proteins; Models, Biological; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Protein Processing, Post-Translational; Selenium; Selenomethionine; Signal Transduction | 2005 |
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; DNA, Complementary; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Vitro Techniques; Irinotecan; Multidrug Resistance-Associated Proteins; Neuroblastoma; Polymerase Chain Reaction; Prognosis; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Female; Humans; Hyperthermia, Induced; Irinotecan; Liver Neoplasms; Male; Melphalan; Middle Aged; Neoplasm Staging; Treatment Failure; Treatment Outcome | 2005 |
Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Mutation; Syndrome; Treatment Outcome | 2005 |
Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.
Topics: Animals; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lactones; Microsomes, Liver; Rats; Recombinant Proteins | 2005 |
Complete response of brain metastases to irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Esophageal Neoplasms; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Parotid Neoplasms | 2005 |
[A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Mastectomy, Segmental; Medroxyprogesterone Acetate; Middle Aged; Pancytopenia; Quality of Life | 2005 |
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Heterozygote; Humans; Irinotecan; Mutation; Nausea; Sigmoid Neoplasms; Vomiting | 2005 |
Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
Topics: Adult; Aged; Alleles; Camptothecin; Enhancer Elements, Genetic; Excitatory Amino Acid Antagonists; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Linkage Disequilibrium; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pharmacogenetics; Phenobarbital; Polymorphism, Genetic; Promoter Regions, Genetic; Risk; Time Factors | 2005 |
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.
Topics: Asian People; Camptothecin; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9; White People | 2005 |
Irinotecan-induced colitis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Biopsy; Brain Neoplasms; Camptothecin; Colitis; Colon; Diarrhea; Glioblastoma; Humans; Ileum; Immunoenzyme Techniques; Irinotecan; Male; Topoisomerase I Inhibitors | 2005 |
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2005 |
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Growth Processes; Colonic Neoplasms; ErbB Receptors; Growth Substances; HT29 Cells; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Metastasis; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Surface morphology control of polylactide microspheres enclosing irinotecan hydrochloride.
Topics: Camptothecin; Irinotecan; Microspheres; Polyesters; Surface Properties | 2005 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Quality of Life | 2005 |
The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; HT29 Cells; Humans; Irinotecan; Superoxide Dismutase | 2005 |
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cysteine; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Selenocysteine; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Osteonectin; Transplantation, Heterologous | 2005 |
[Systemic therapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mass Spectrometry; Mice; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2005 |
[A young patient with invasive small cell carcinoma of the urinary bladder: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Drug Administration Schedule; Female; Humans; Hysterectomy; Irinotecan; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2005 |
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Dose-Response Relationship, Drug; Esterases; Gastrointestinal Tract; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Transplantation; Rhabdomyosarcoma; Sarcoma, Experimental | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Risk Factors; Topoisomerase I Inhibitors | 2005 |
A long-term survival case of small cell lung cancer in an HIV-infected patient.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed | 2005 |
Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Liver; Male; Neutropenia; Pharmacogenetics; Polymorphism, Genetic | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Topics: Animals; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Irinotecan; Lactones; Quaternary Ammonium Compounds; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Thalidomide | 2005 |
Whither irinotecan?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Research Design | 2005 |
A mouse model for developing treatment for secondary liver tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Humans; Immunohistochemistry; Irinotecan; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Metastasis; Time Factors | 2005 |
Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.
Topics: Animals; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Interleukin-6; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Combinations; Drug Incompatibility; Drug Stability; Epirubicin; Infusions, Intravenous; Irinotecan; Pharmaceutical Solutions; Spectrophotometry, Ultraviolet | 2005 |
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Body Weight; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Interactions; Half-Life; Hypericum; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results | 2005 |
Synthesis and antitumor activity of A-ring modified hexacyclic analogues of camptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplasm Transplantation; Polycyclic Compounds | 2005 |
In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.
Topics: Apoptosis; Camptothecin; Cell Cycle; Cluster Analysis; DNA, Complementary; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Irinotecan; Kinetics; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; RNA, Messenger; Transcription, Genetic; Up-Regulation | 2005 |
[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quality of Life; Remission Induction; Stomach Neoplasms | 2005 |
[Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma].
Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Folliculitis; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Skin | 2006 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Prognosis; Thymidylate Synthase; Treatment Outcome | 2005 |
pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cardiolipins; Cholesterol; Chromatography, Gel; Diphenylhexatriene; Fluorescence Polarization; Fluorescent Dyes; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lipid Bilayers; Liposomes; Particle Size; Phosphatidylcholines; Temperature; Topoisomerase I Inhibitors | 2005 |
Characterization of secretory intestinal transport of the lactone form of CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport, Active; Camptothecin; In Vitro Techniques; Irinotecan; Jejunum; Lactones; Male; Rats; Rats, Wistar; Tissue Distribution | 2006 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors | 2005 |
[New oncolytic agents and immunomodulators and their application].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2005 |
Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.
Topics: Antineoplastic Agents; Calibration; Camptothecin; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Densitometry; Drug Industry; Drug Stability; Irinotecan; Models, Chemical; Pharmaceutical Preparations; Quality Control; Reproducibility of Results; Spectrometry, Fluorescence; Technology, Pharmaceutical; Topotecan | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Thyroid Neoplasms | 2005 |
Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
Topics: Animals; Asian People; Camptothecin; Carboxylesterase; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Humans; Irinotecan; Nitrophenols; Polymorphism, Single Nucleotide; RNA Splicing; Umbelliferones | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Hydrogen-Ion Concentration; Intestines; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Rectal Neoplasms | 2005 |
[Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
Topics: Adenocarcinoma; Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Mitomycin; Peritoneal Neoplasms; Survivors | 2005 |
[A case report of bowel obstruction due to peritonitis carcinomatosa using combined administration with CPT-11 and CDDP].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms | 2005 |
Modeling antitumor activity in xenograft tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Computer-Assisted; Irinotecan; Mice; Models, Biological; Models, Statistical; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cyclophosphamide; Cytochrome P-450 CYP2B1; Genetic Therapy; Glioma; Herpesvirus 1, Human; Humans; Irinotecan; Prodrugs; Virus Replication | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Female; Fluorouracil; Galanin; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Serotonin; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Thymidylate Synthase | 2005 |
Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Inhibitory Concentration 50; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2005 |
[Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Sensitivity and Specificity; Survival Rate | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Edaravone; Electrophoretic Mobility Shift Assay; Free Radical Scavengers; In Situ Nick-End Labeling; Irinotecan; Lung Neoplasms; Male; Mice; NF-kappa B; Reactive Oxygen Species | 2005 |
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dioxoles; DNA Topoisomerases, Type I; Humans; In Vitro Techniques; Irinotecan; Isoquinolines; Male; Mice; Mice, Nude; Rhabdomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Erythrocytes; Female; Humans; In Vitro Techniques; Irinotecan; Male; Sex Distribution; Smoking; Spectrometry, Fluorescence; Topoisomerase I Inhibitors | 2005 |
Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2005 |
MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate).
Topics: Base Sequence; Camptothecin; Cell Line; Chromatography, High Pressure Liquid; DNA Primers; Estradiol; Humans; Irinotecan; Leukotriene C4; Multidrug Resistance-Associated Proteins; Photoaffinity Labels | 2005 |
Transfection assays with allele-specific constructs: functional analysis of UDP-glucuronosyltransferase variants.
Topics: Adult; Alleles; Animals; Biological Assay; Blotting, Western; Camptothecin; Chlorocebus aethiops; COS Cells; Enzyme Stability; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Liver; Mutagenesis, Site-Directed; Plasmids; Polymorphism, Single Nucleotide; Transfection | 2005 |
Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA-Binding Proteins; Drug Synergism; HCT116 Cells; Humans; Interferon Regulatory Factors; Interferon-beta; Irinotecan; Phosphorylation; Signal Transduction; Transcription Factors; Transfection; Tumor Suppressor Protein p53 | 2005 |
[Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; Blood; Camptothecin; Colonic Neoplasms; Female; Humans; Immunologic Tests; Infusions, Intravenous; Irinotecan; Lipopolysaccharides; Male; Middle Aged; Monocytes; Stomach Neoplasms; Tumor Necrosis Factor-alpha | 2005 |
Analysis of incomplete quality of life data in advanced stage cancer: a practical application of multiple imputation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Female; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Staging; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Selection Bias; Surveys and Questionnaires; Vindesine | 2005 |
Dendritic supramolecular assemblies for drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Dendrimers; Drug Delivery Systems; Excipients; HT29 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Molecular Conformation; Polyethylene Glycols; Succinates | 2005 |
[Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Kidney Diseases; Lung Neoplasms; Male | 2005 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Krukenberg Tumor; Lymphangitis; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.
Topics: Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Gefitinib; Humans; Irinotecan; Microsomes, Liver; Midazolam; Quinazolines | 2005 |
Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Drug Resistance, Neoplasm; Glutathione; Humans; Irinotecan; Methotrexate; Multidrug Resistance-Associated Proteins; Organophosphonates; Paclitaxel | 2005 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2005 |
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan | 2005 |
Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents.
Topics: Amides; Camptothecin; Cell Line; Cell Survival; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Esters; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Topoisomerase I Inhibitors; Topotecan | 2005 |
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Topics: Camptothecin; Dose-Response Relationship, Drug; Glucuronates; Glucuronosyltransferase; Hepatocytes; Humans; Indinavir; Irinotecan; Isoenzymes; Ketoconazole; Kinetics; Microsomes, Liver; Substrate Specificity | 2005 |
Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis.
Topics: Adenocarcinoma; Camptothecin; Colorectal Neoplasms; Diabetic Nephropathies; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Risk Assessment; Treatment Outcome | 2005 |
Irinotecan (CPT-11) combined with cisplatin for small cell carcinoma of the nasal cavity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Nasal Cavity; Neoadjuvant Therapy; Nose Neoplasms | 2006 |
Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Colonic Neoplasms; DNA Damage; Female; Flow Cytometry; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Necrosis; Ploidies; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
[Utilizing synergism].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; Humans; Irinotecan; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2006 |
Regulation of hepatocyte engraftment and proliferation after cytotoxic drug-induced perturbation of the rat liver.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon Tetrachloride; Cell Division; Chemical and Drug Induced Liver Injury; Dipeptidyl Peptidase 4; Doxorubicin; Endothelium; Graft Survival; Hepatectomy; Hepatocytes; Irinotecan; Kupffer Cells; Rats; Rats, Inbred F344; Rats, Mutant Strains; Vincristine | 2005 |
Liposomalization of SN-38 as active metabolite of CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Carriers; Drug Compounding; Excipients; Freeze Drying; Freezing; Irinotecan; Liposomes; Prodrugs | 2005 |
[Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase | 2005 |
[A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Quality of Life; Sigmoid Neoplasms | 2005 |
Patient with angina secondary to capecitabine.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Sigmoid Neoplasms | 2005 |
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
Topics: Antineoplastic Agents, Phytogenic; Brain Stem Neoplasms; Camptothecin; Child; Diarrhea; Female; Glioma; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Magnetic Resonance Imaging; Polymorphism, Genetic | 2005 |
Clinical trial designs for prospective validation of biomarkers.
Topics: Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Genotype; Humans; Inactivation, Metabolic; Irinotecan; Neoplasms; Outcome Assessment, Health Care; Predictive Value of Tests; Reproducibility of Results; Research Design | 2005 |
Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Retrospective Studies; Treatment Outcome | 2005 |
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Kinetics; Leucovorin; Leukocytes, Mononuclear; Male; Middle Aged; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; fas Receptor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; RNA, Messenger; STAT1 Transcription Factor; Thiophenes; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Radiation Tolerance; Radiotherapy; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin E; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2005 |
Irinotecan (CPT-11) in the treatment of mycosis fungoides.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms | 2005 |
Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Arthritis, Rheumatoid; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Topoisomerase I Inhibitors | 2005 |
[A case of advanced gastric cancer with obstructive jaundice that responded to TS-1/CPT-11 combination therapy after percutaneous transhepatic cholangio drainage].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Camptothecin; Combined Modality Therapy; Drainage; Drug Administration Schedule; Drug Combinations; Gastroscopy; Humans; Irinotecan; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of small cell carcinoma of the stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Rupture, Spontaneous; Stomach Neoplasms; Stomach Rupture | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Tegafur; Uracil | 2005 |
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Prodrugs; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Topics: Analysis of Variance; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Length of Stay; Logistic Models; Lung; Male; Pneumonia; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Respiratory Distress Syndrome; Retrospective Studies; Sex Factors; Statistics, Nonparametric | 2006 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Taxoids | 2005 |
Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.
Topics: Adolescent; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cell Death; Cell Survival; Colon; Drug Combinations; Female; Fluorescence; Fluorouracil; Humans; Image Processing, Computer-Assisted; Irinotecan; Membrane Glycoproteins; Organ Culture Techniques; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome | 2005 |
Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
Topics: Acetylcholinesterase; Antineoplastic Agents; Butyrylcholinesterase; Camptothecin; Cholinesterase Inhibitors; Enzyme Activation; Humans; Irinotecan; Molecular Structure; Structure-Activity Relationship | 2005 |
Are there any better camptothecins than the ones we have?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors | 2003 |
Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Camptothecin; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Irinotecan; Lopinavir; Male; Pyrimidinones; Ritonavir; Sarcoma, Kaposi | 2005 |
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carbazoles; Carcinoma, Medullary; cdc25 Phosphatases; Cell Cycle; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Enzyme Inhibitors; Histones; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinases; Protein-Tyrosine Kinases; S Phase; Signal Transduction; Thyroid Neoplasms; Transplantation, Heterologous | 2006 |
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Enzyme Inhibitors; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Pharmacogenetics; Polymorphism, Genetic; Prodrugs; Promoter Regions, Genetic; Topoisomerase I Inhibitors | 2005 |
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carcinoma; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Plant Extracts; Silybum marianum; Time Factors | 2005 |
High salt culture conditions suppress proliferation of rat C6 glioma cell by arresting cell-cycle progression at S-phase.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Early Growth Response Protein 1; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glioma; Hypertonic Solutions; Irinotecan; Osmolar Concentration; Rats; Resveratrol; S Phase; Sodium Chloride; Stilbenes | 2005 |
[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cecal Neoplasms; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged | 2005 |
[A case of rectal cancer treated by preoperative chemoradiation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colostomy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Preoperative Care; Rectal Neoplasms; Rectum; Remission Induction; Tegafur; Uracil | 2005 |
Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Retroperitoneal Neoplasms; Topoisomerase I Inhibitors | 2005 |
The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents; Butyrylcholinesterase; Camptothecin; Carboxylesterase; Cholinesterase Inhibitors; Crystallography, X-Ray; Hydrolysis; Irinotecan; Liver; Models, Molecular; Protein Structure, Tertiary; Rabbits; Torpedo | 2005 |
Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Leukemia, Promyelocytic, Acute; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2006 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2005 |
The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2006 |
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2005 |
[Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2005 |
[Host immunity in colorectal cancer patients treated with TS-1 plus CPT-11].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Silicates; Titanium | 2005 |
[Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[Chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2005 |
[A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Seeding; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Tegafur | 2005 |
[A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Preoperative Care; Pyridines; Rectal Neoplasms; Tegafur | 2005 |
[A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2005 |
[A case of chemoradiation with tissue expander for local reccurence of rectal cancer].
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Floxuridine; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Radiotherapy Dosage; Rectal Neoplasms; Tissue Expansion Devices | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2005 |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Dacarbazine; Female; Humans; Injections, Intravenous; Irinotecan; Male; Neoplasm Metastasis; Sarcoma, Ewing; Temozolomide | 2007 |
[CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Pyrazoles; Quality of Life; Stomach Neoplasms | 2005 |
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Models, Theoretical; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2005 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Veins; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Liver Regeneration; Male; Rectal Neoplasms; Vena Cava, Inferior | 2006 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Unresectable hepatic colorectal metastases: need for new surgical strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Intravenous irinotecan plus oral ciclosporin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclosporine; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 2005 |
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2005 |
Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Enzyme Inhibitors; Infusions, Parenteral; Irinotecan; Male; Models, Animal; Neoplasm Transplantation; Neoplasms, Experimental; Peritoneal Neoplasms; Postoperative Period; Rats | 2006 |
HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38.
Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Irinotecan; Liposomes; Reproducibility of Results; Temperature | 2006 |
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; CpG Islands; Dendritic Cells; Disease Models, Animal; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Mice; Mice, Inbred BALB C; Oligonucleotides | 2006 |
Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Thyroid Neoplasms | 2006 |
in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Phosphorylation | 2005 |
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Blotting, Southern; Brain Neoplasms; Camptothecin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Enzyme Inhibitors; Fibroblasts; Gene Deletion; Gene Expression; Gentian Violet; Glioblastoma; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Irinotecan; Oncolytic Viruses; Protein Synthesis Inhibitors; Receptors, Virus; Tumor Cells, Cultured | 2006 |
[Management of chemotherapy-induced mucositis and diarrhea].
Topics: Allopurinol; Antineoplastic Agents; Camptothecin; Diarrhea; Free Radical Scavengers; Histamine H2 Antagonists; Humans; Irinotecan; Neoplasms; Proton Pump Inhibitors; Quality of Life; Stomatitis | 2006 |
[A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Oxonic Acid; Pyridines; Sigmoid Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Glyceric Acids; Glycerides; Irinotecan; Kinetics; Liquid Crystals; Octreotide; Paclitaxel; Solubility; Surface-Active Agents; Water | 2006 |
PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.
Topics: Adolescent; Adult; Aged; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatocytes; Humans; Infant; Irinotecan; Liver; Male; Middle Aged; Pharmacogenetics; Phenobarbital; Polymorphism, Single Nucleotide | 2006 |
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Synergism; Flow Cytometry; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; S Phase; Survival Rate; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma; Cell Adhesion; Cell Proliferation; Cetuximab; Drug Interactions; Drug Synergism; Humans; Irinotecan; Lymphatic Metastasis; Male; Mice; Mice, Nude; Survival Rate; Thyroid Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid.
Topics: Apoptosis; Camptothecin; Caspases; Cell Cycle; Cell Death; DNA Fragmentation; Drug Synergism; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Mitochondria; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Ursodeoxycholic Acid | 2006 |
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Cisplatin; ErbB Receptors; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2006 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chorionic Gonadotropin; Drug Administration Schedule; Enterocolitis, Neutropenic; gamma-Globulins; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Radiography, Abdominal; Testicular Neoplasms; Tomography, X-Ray Computed | 2006 |
Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Topics: Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Enzyme Inhibitors; Flavonoids; Glucuronidase; Intestines; Irinotecan; Male; Medicine, Kampo; Penicillins; Rats; Rats, Wistar; Streptomycin | 2006 |
[Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Remission Induction; Salvage Therapy; Treatment Outcome | 2005 |
Identification and immunotherapeutic targeting of antigens induced by chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Base Sequence; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Immunotherapy; Irinotecan; Membrane Proteins; Mice; Mice, Nude; Molecular Sequence Data; Treatment Outcome | 2006 |
DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Flow Cytometry; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Irinotecan; Models, Biological; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53 | 2006 |
Central nervous system toxicity induced by irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Central Nervous System; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Sigmoid Neoplasms; Tachyphylaxis | 2006 |
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Disease Progression; Hepatic Artery; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Rectal Neoplasms; Remission Induction; Starch; Stomach Neoplasms; Topoisomerase I Inhibitors | 2006 |
Designer combination therapy for cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Drug Design; Female; Humans; Immunotherapy; Irinotecan; Membrane Proteins; Mice; Mice, Nude; Treatment Outcome | 2006 |
Direct activation of the human major vault protein gene by DNA-damaging agents.
Topics: Antineoplastic Agents; Binding Sites; Butyrates; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Irinotecan; Luciferases; Promoter Regions, Genetic; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Transfection; Vault Ribonucleoprotein Particles | 2006 |
A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Male; Tomography, X-Ray Computed | 2005 |
Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.
Topics: Adrenalectomy; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Circadian Rhythm; DNA Topoisomerases, Type I; Gene Expression Regulation, Neoplastic; Glucocorticoids; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Neoplasms, Experimental; Receptors, Glucocorticoid; Topoisomerase I Inhibitors | 2006 |
[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Male; Mitomycin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2006 |
Intestinal microflora and digestive toxicity of irinotecan in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cecum; Colon; Diarrhea; Dose-Response Relationship, Drug; Ileum; Intestinal Mucosa; Intestines; Irinotecan; Jejunum; Mice; Mice, Inbred C3H; Microscopy, Electron, Scanning; Necrosis; Specific Pathogen-Free Organisms; Survival Analysis; Time Factors | 2006 |
UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Retrospective Studies | 2005 |
Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; HT29 Cells; Humans; Irinotecan; Membrane Potentials; Mitochondrial Membranes | 2005 |
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
Topics: Animals; Camptothecin; Carrier Proteins; Child, Preschool; Cytokines; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation; Humans; Irinotecan; Male; Mice; Neovascularization, Pathologic; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Interferon-gamma; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
Topics: Animals; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Male; Nanostructures; Phospholipids; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2006 |
[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Germany; Guideline Adherence; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Radiotherapy, Adjuvant; Survival Rate | 2006 |
[New chances in therapy of gastrointestinal tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Randomized Controlled Trials as Topic | 2005 |
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous | 2006 |
[The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Signal Transduction; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.
Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Blotting, Western; Cadherins; Camptothecin; Carcinoembryonic Antigen; Catenins; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Delta Catenin; Dose-Response Relationship, Drug; Drug Synergism; Fibronectins; G1 Phase; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Mice; Mice, Inbred ICR; Mice, Nude; Phosphoproteins; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2006 |
The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
Topics: Anthracyclines; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms | 2006 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
[A case of small-cell lung cancer responding remarkably to CPT-11 and CDDP combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cranial Irradiation; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Pleural Effusion, Malignant; Remission Induction; Tomography, X-Ray Computed | 2006 |
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Topics: Animals; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Nude; Nanostructures; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2006 |
Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Topics: Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Glycine; Humans; Irinotecan; Mutation, Missense; Protein Conformation; Serine | 2006 |
Novel single nucleotide polymorphism of UGT1A7 gene in Japanese.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; DNA; Exons; Female; Gene Frequency; Glucuronosyltransferase; Humans; Irinotecan; Japan; Male; Molecular Sequence Data; Neoplasms; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Novel single nucleotide polymorphism of UGT1A9 gene in Japanese.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; DNA, Neoplasm; Exons; Gene Frequency; Glucuronosyltransferase; Humans; Introns; Irinotecan; Japan; Molecular Sequence Data; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; UDP-Glucuronosyltransferase 1A9 | 2006 |
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Technology Transfer; Technology, Pharmaceutical | 2006 |
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
Topics: Azacitidine; Camptothecin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronides; Glucuronosyltransferase; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan | 2006 |
Correspondence re: Cecchin et al., Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005;11:6901-7.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoenzymes; Leukocytes, Mononuclear; Predictive Value of Tests; RNA, Messenger | 2006 |
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Irinotecan; Pancreatic Neoplasms; Protein Synthesis Inhibitors | 2006 |
The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Topics: Camptothecin; Gene Expression Regulation, Enzymologic; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Introns; Irinotecan; Linkage Disequilibrium; Liver; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; UDP-Glucuronosyltransferase 1A9 | 2006 |
Irinotecan as a new agent for urachal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Urachus | 2006 |
Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Topics: Adenosine Triphosphate; Alleles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Survival; Chlorophyll; Daunorubicin; Doxorubicin; Drug Resistance; Hematoporphyrins; Humans; Irinotecan; Kinetics; Methotrexate; Mitoxantrone; Mutant Proteins; Mutation; Neoplasm Proteins; Polymorphism, Single Nucleotide; Porphyrins; Spodoptera; Transfection | 2006 |
[A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Hexosomes formed from glycerate surfactants--formulation as a colloidal carrier for irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Colloids; Drug Carriers; Drug Delivery Systems; Drug Storage; Glyceric Acids; Irinotecan; Osmolar Concentration; Particle Size; Poloxamer; Solubility; Sorbitol; Surface-Active Agents; Water | 2006 |
Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; DNA Repair; Follow-Up Studies; Gene Silencing; Hepatectomy; Humans; Irinotecan; Liver; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms; Remission Induction; Retrospective Studies; Topoisomerase I Inhibitors | 2006 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2006 |
Irinogenetics: what is the right star?
Topics: Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type I; Drug-Related Side Effects and Adverse Reactions; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2006 |
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Korea; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; Survival Analysis; Treatment Outcome | 2006 |
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gemcitabine; Gene Expression; GPI-Linked Proteins; Hepatocytes; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Organoplatinum Compounds; Oxaliplatin; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
Individualizing chemotherapeutic treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; United States | 2006 |
Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.
Topics: Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; CD83 Antigen; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunoglobulins; Irinotecan; Lymph Nodes; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2006 |
[The present state and future of home care for gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Forecasting; Home Care Services, Hospital-Based; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Parenteral Nutrition, Home; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Home Care Services, Hospital-Based; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Quality of Life | 2006 |
[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cisplatin; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Oxazines; Retrospective Studies; Vomiting, Anticipatory | 2006 |
[A case of gastric cancer presenting with obstructive jaundice and responding to biweekly CPT-11 and CDDP combination administration].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drainage; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Jaundice, Obstructive; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Stomach Neoplasms | 2006 |
[Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carrier State; CD8-Positive T-Lymphocytes; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hepatitis B; HTLV-I Antibodies; Humans; Irinotecan; Lamivudine; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Pentostatin; Prednisone; Vincristine | 2006 |
Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics | 2006 |
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Celecoxib; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasms; NF-kappa B; Pyrazoles; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha | 2007 |
[A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Endodermal Sinus Tumor; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasms, Multiple Primary; Remission Induction; Salvage Therapy; Seminoma; Testicular Neoplasms | 2006 |
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; DNA; Genetic Variation; Haplotypes; Humans; Irinotecan; Japan; Linkage Disequilibrium; Neoplasm Proteins; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Celecoxib; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Neuroblastoma; Promoter Regions, Genetic; Pyrazoles; Sulfonamides; Survivin; Transcription, Genetic; Transfection; Xenograft Model Antitumor Assays | 2006 |
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured | 2006 |
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Enzyme Inhibitors; Female; HT29 Cells; Humans; Indoles; Irinotecan; Mice; Neoplasm Proteins; Neoplasms, Experimental; Staining and Labeling; Topotecan; Vacuolar Proton-Translocating ATPases | 2006 |
[Is small cell lung cancer an orphan disease?].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
Topics: Aging, Premature; Animals; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; DNA Helicases; DNA Methylation; Epigenesis, Genetic; Exodeoxyribonucleases; Female; Genes, Tumor Suppressor; Humans; Irinotecan; Mice; Mice, Nude; Promoter Regions, Genetic; RecQ Helicases; RNA, Messenger; Topoisomerase I Inhibitors; Werner Syndrome; Werner Syndrome Helicase | 2006 |
Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Cell Line, Tumor; Diarrhea; Drug Interactions; Glucuronides; Hydrolysis; Intestines; Irinotecan; Leukocyte Count; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Buthionine Sulfoximine; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Death; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Gene Expression Regulation, Leukemic; Glutathione; Humans; Irinotecan; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2006 |
Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate | 2006 |
Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Camptothecin; Cell Proliferation; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Hypercholesterolemia; Inflammation; Irinotecan; Necrosis; Phosphorylcholine; Rabbits; Research Design; Stents; Tunica Intima | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leucovorin; Leukopenia; Lung Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Neutropenia; Remission Induction; Tegafur; Uracil; Vomiting, Anticipatory | 2006 |
[A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Quality of Life; Tegafur | 2006 |
[Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report].
Topics: Adenocarcinoma; Administration, Oral; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colostomy; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Omentum; Peritoneal Neoplasms; Rectal Neoplasms; Remission Induction; Tegafur; Uracil | 2006 |
Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
Topics: Administration, Oral; Adsorption; Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon; Chromatography, High Pressure Liquid; Diarrhea; Hydrogen-Ion Concentration; Intestinal Mucosa; Irinotecan; Male; Oxides; Rats; Rats, Wistar | 2007 |
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bevacizumab; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Thromboembolism; Tomography, X-Ray Computed | 2006 |
[Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Pneumonectomy | 2006 |
Mechanism of central nervous system toxicity by irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Central Nervous System; Colorectal Neoplasms; Electrochemistry; Humans; Irinotecan; Models, Biological | 2006 |
Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 1; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Irinotecan; Jejunum; Mammary Neoplasms, Experimental; Mitogen-Activated Protein Kinase Kinases; Mucositis; Oligonucleotide Array Sequence Analysis; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2007 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden | 2006 |
Comparison of antitumor activities in tumor xenograft treatment.
Topics: Algorithms; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease Models, Animal; Humans; Irinotecan; Mice; Sesquiterpenes; Transplantation, Heterologous; Treatment Outcome | 2007 |
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Blood Proteins; Bone Marrow; Caco-2 Cells; Camptothecin; Diarrhea; Hepatocytes; Humans; Intestines; Irinotecan; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thalidomide; Tumor Necrosis Factor-alpha; Weight Loss | 2006 |
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Topics: Animals; Camptothecin; Carboxylesterase; Catalysis; Cell Division; Etoposide; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Neuroblastoma; Prodrugs; Rabbits; Tumor Cells, Cultured | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Tegafur; Uracil | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Glucuronidase; Humans; Hydroxyquinolines; Irinotecan; Nitrophenols; Tumor Cells, Cultured | 2006 |
Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Small Interfering | 2006 |
Turning point for colorectal cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2006 |
Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Hepatoblastoma; Humans; Irinotecan; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Neoplasm Recurrence, Local | 2006 |
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Humans; Image Processing, Computer-Assisted; Irinotecan; Luciferases; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Photons; Stomach Neoplasms; Transfection | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma; Colonic Neoplasms; Dacarbazine; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Floxuridine; Humans; Irinotecan; Liposomes; Mice; Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Molecular determinants of irinotecan efficacy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Irinotecan; Male; Middle Aged; Peptide Termination Factors; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Polymorphism, Single Nucleotide; Predictive Value of Tests; Radionuclide Imaging | 2006 |
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Female; Gene Frequency; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Radionuclide Imaging; Radiopharmaceuticals; Regression Analysis; Technetium Tc 99m Diethyl-iminodiacetic Acid; Technetium Tc 99m Disofenin; Technetium Tc 99m Sestamibi | 2006 |
[Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Tegafur | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Irinotecan; Paclitaxel; Structure-Activity Relationship; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vincristine | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
[A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Ductal, Breast; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intralesional; Irinotecan; Pericardial Effusion; Pericardiocentesis; Pleural Effusion, Malignant; Pleural Neoplasms | 2006 |
[Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Oxonic Acid; Remission Induction; Tegafur | 2006 |
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Poly A; RNA, Messenger | 2005 |
A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breath Tests; Camptothecin; Cyclophosphamide; Disease Models, Animal; DNA Topoisomerases, Type I; Doxorubicin; Etoposide; Female; Intestine, Small; Irinotecan; Mucositis; Rats; Sucrase; Sucrose; Topoisomerase I Inhibitors | 2006 |
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Transplantation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous | 2007 |
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement by Bartlett et al.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2006 |
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Clinical Trials as Topic; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Risk Factors; Topoisomerase I Inhibitors | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Quality of Life; Rectal Neoplasms | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of non-curatively resected colon cancer with liver and lymph node metastases treated by TS-1/CPT-11 combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur | 2006 |
[A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Combined Modality Therapy; Drug Administration Schedule; Floxuridine; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Rectal Neoplasms; Remission Induction | 2006 |
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Bile Ducts; Biliary Tract; Camptothecin; Drainage; Feces; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Pancreatic Neoplasms; Prodrugs | 2006 |
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; DNA Fragmentation; Dose-Response Relationship, Drug; Glucuronidase; Glucuronides; Humans; Hybridomas; Hydrogen-Ion Concentration; Hydrolysis; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Lactones; Molecular Structure; Prodrugs; Serum Albumin; Thymidine; Time Factors; Topotecan; Tritium | 2007 |
Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Irinotecan; Male; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2006 |
Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Topics: Animals; Camptothecin; Carboxylic Ester Hydrolases; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Humans; Intestines; Irinotecan; Liver; Phenylglyoxal; Prodrugs; Rabbits | 2006 |
Morphology control of polylactide microspheres enclosing irinotecan hydrochloride with polylactide based polymer surfactant for reduction of initial burst.
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Delayed-Action Preparations; Drug Delivery Systems; Irinotecan; Microscopy, Electron, Scanning; Microspheres; Polyesters; Polyethylene Glycols | 2007 |
The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Diarrhea; Female; Glucuronides; Glucuronosyltransferase; Intestines; Irinotecan; Male; Rats; Rats, Gunn | 2007 |
A case report and discussion of cetuximab-induced folliculitis.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clindamycin; Colorectal Neoplasms; ErbB Receptors; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male; Remission Induction | 2006 |
Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Adducts; DNA Damage; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Irinotecan; Lactones; Lung Neoplasms; Time Factors | 2007 |
Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2006 |
Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Middle Aged; Oxonic Acid; Tegafur; Time Factors | 2006 |
St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cytokines; Diarrhea; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Hypericum; Intestinal Mucosa; Irinotecan; Male; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley | 2006 |
Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2006 |
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Immunoglobulin M; Irinotecan; Lymphocytes, Tumor-Infiltrating; Lymphotoxin beta Receptor; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Recombinant Fusion Proteins; Single-Blind Method; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Treatment Outcome | 2006 |
Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; United States | 2006 |
Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Drug Carriers; Drug Compounding; Drug Delivery Systems; Female; Irinotecan; Liver; Male; Microspheres; Particle Size; Solubility; Swine | 2007 |
[A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Mitomycin; Rectal Neoplasms; Starch | 2006 |
[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Diseases; Cisplatin; Colonoscopy; Drainage; Drug Administration Schedule; Fatal Outcome; Female; Humans; Intestinal Perforation; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pleural Effusion, Malignant | 2006 |
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Topics: Animals; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Polyethylene Glycols; Polyglutamic Acid; Random Allocation; Tissue Distribution; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Topics: Antimetabolites; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Flow Cytometry; Humans; Irinotecan; Trifluridine | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fibrosis; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2007 |
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
Topics: Adult; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Bone Marrow Diseases; Camptothecin; China; Ethnicity; Exons; Female; Gastrointestinal Diseases; Gene Frequency; Genetic Predisposition to Disease; Glucuronosyltransferase; Haplotypes; Heterozygote; Homozygote; Humans; Hyperbilirubinemia; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Reference Values; TATA Box | 2007 |
Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Copper; Cryoelectron Microscopy; Drug Carriers; Drug Compounding; Hydrogen-Ion Concentration; Irinotecan; Lactones; Liposomes; Transition Elements | 2006 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Retrospective Studies; Treatment Outcome | 2007 |
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Searching for the Holy Grail of oncology.
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Assessment | 2006 |
Fractionated administration of irinotecan and cisplatin in Japanese patients with extensive-stage-disease small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Humans; Irinotecan; Japan; Lung Neoplasms; Salvage Therapy; Sample Size; Time Factors | 2006 |
Effects of green tea compounds on irinotecan metabolism.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Catechin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Glucuronates; Glucuronosyltransferase; Hepatocytes; Humans; Hydroxytestosterones; Irinotecan; RNA, Messenger; Tea | 2007 |
Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Cisplatin; Female; Humans; Infant; Irinotecan; Male; Spinal Cord Neoplasms; Treatment Outcome | 2007 |
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colostomy; Drug Administration Schedule; Fluorouracil; Humans; Ileus; Irinotecan; Leucovorin; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Approval; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Quality of Life; Temozolomide; Treatment Outcome | 2006 |
Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colonoscopy; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Prodrugs; Tegafur; Tomography, X-Ray Computed; Uracil | 2006 |
A bacterial protein enhances the release and efficacy of liposomal cancer drugs.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bacterial Proteins; Base Sequence; Camptothecin; Cell Line, Tumor; Cloning, Molecular; Clostridium; Colorectal Neoplasms; Doxorubicin; Drug Carriers; Humans; Irinotecan; Lipase; Lipid Bilayers; Liposomes; Mice; Molecular Sequence Data; Mutation; Neoplasm Transplantation; Protein Structure, Tertiary | 2006 |
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Irinotecan; Middle Aged; Models, Theoretical; Neoplasm Metastasis; Sensitivity and Specificity | 2006 |
Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Crohn Disease; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Intestine, Small; Irinotecan; Jejunal Neoplasms; Leucovorin; Male; Remission Induction; Survival Analysis | 2006 |
Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Injections, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Pancreatic Neoplasms; Portal Vein; Rats; Rats, Nude; Transplantation, Heterologous | 2006 |
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Pleural Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2007 |
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carcinoma; Cecum; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Humans; Imatinib Mesylate; Irinotecan; Liver; Male; Mice; Mice, Nude; Pericytes; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells; Transplantation, Heterologous | 2006 |
Role of p53 in irinotecan-induced intestinal cell death and mucosal damage.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzothiazoles; Blotting, Western; Camptothecin; Cell Adhesion; Cell Count; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; Colon; Cyclin-Dependent Kinase Inhibitor p21; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Immunohistochemistry; Intestinal Mucosa; Irinotecan; Proliferating Cell Nuclear Antigen; Rats; Toluene; Tumor Suppressor Protein p53 | 2007 |
Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Cleavage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental | 2007 |
Development of a tumor-selective approach to treat metastatic cancer.
Topics: Animals; Base Sequence; Camptothecin; Carboxylic Ester Hydrolases; Cell Line; Cell Line, Tumor; DNA Primers; Embryonic Stem Cells; Humans; Irinotecan; Mice; Mice, SCID; Multipotent Stem Cells; Neoplasm Metastasis; Neoplasm Transplantation; Neuroblastoma; Prodrugs; Rabbits; Recombinant Proteins; Transduction, Genetic; Transplantation, Heterologous | 2006 |
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Pharmacogenetics | 2006 |
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide | 2007 |
Thrombotic microangiopathy and anti-VEGF agents.
Topics: Biopsy; Camptothecin; Drug Therapy, Combination; Female; Humans; Irinotecan; Kidney Glomerulus; Middle Aged; Ovarian Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Thrombosis; Vascular Endothelial Growth Factor A | 2007 |
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma; Male; Models, Biological; Neutropenia; Polymorphism, Genetic; Regression Analysis | 2007 |
Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Protein p14ARF | 2007 |
[A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms | 2006 |
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Bacterial Typing Techniques; Biodiversity; Camptothecin; Colon; Colony Count, Microbial; Diarrhea; Feces; Female; Gastric Mucosa; Gastrointestinal Tract; Histocytochemistry; Intestinal Mucosa; Irinotecan; Jejunum; Rats; Rats, Inbred Strains; Stomach; Time Factors | 2007 |
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2006 |
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Drug Combinations; Drug Compounding; Drug Delivery Systems; Female; Floxuridine; Hydrogen-Ion Concentration; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C | 2007 |
Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Drug Combinations; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2007 |
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; DNA, Complementary; Genetic Therapy; Humans; Irinotecan; Mice; Neuroblastoma; Prodrugs; Telencephalon; Transduction, Genetic; Xenograft Model Antitumor Assays | 2007 |
[Evaluation of bronchial arterial infusion (BAI) for lung cancer with brain metastasis].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bronchial Arteries; Camptothecin; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged; Quality of Life | 2006 |
[A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2006 |
[A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].
Topics: Aged; Camptothecin; Carcinoma; Colectomy; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Remission Induction; Sigmoid Neoplasms | 2006 |
[A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Pneumonectomy | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
[Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagoscopes; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Mucous Membrane | 2007 |
[A case of stage IV gastric cancer treated sequentially for over two years by TS-1, paclitaxel, and CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Kidney Failure, Chronic; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Remission Induction | 2007 |
[A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Aorta; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Quality of Life; Remission Induction; Sigmoid Neoplasms; Splenic Neoplasms; Urinary Bladder Neoplasms | 2007 |
[CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report].
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Remission Induction; Tegafur | 2007 |
Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Bone Neoplasms; Calcinosis; Camptothecin; Child; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Hematuria; Hemorrhage; Humans; Iatrogenic Disease; Ilium; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Methotrexate; Osteosarcoma; Radiography; Tibia; Ultrasonography, Interventional | 2008 |
Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Interleukin-1alpha; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptors, Thyrotropin-Releasing Hormone | 2006 |
[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Bacillaceae; Binding Sites; Camptothecin; Carboxylesterase; Crystallization; Crystallography; Cysteine; Iodine; Irinotecan; Models, Molecular; Prodrugs; Protein Conformation | 2007 |
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine | 2007 |
Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Iodine Radioisotopes; Irinotecan; Neuroblastoma; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2008 |
Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Female; Humans; Irinotecan; Middle Aged; Tomography, X-Ray Computed | 2007 |
Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Cloning, Molecular; Genotype; Humans; Irinotecan; Models, Biological; Models, Genetic; Promoter Regions, Genetic; Protein Isoforms; RNA, Messenger; Transcription, Genetic | 2007 |
Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Circular Dichroism; Drug Compounding; Ethanolamines; Gluconates; Hydrogen Bonding; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Liposomes; Solubility; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Temperature | 2007 |
Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Culture Media; Irinotecan; Rats; Spectrometry, Fluorescence | 2007 |
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Pyrophosphatases; Thymidylate Synthase; X-ray Repair Cross Complementing Protein 1 | 2007 |
Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.
Topics: Animals; Antimycin A; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Camptothecin; Cell Death; Colonic Neoplasms; Down-Regulation; Doxorubicin; HCT116 Cells; Humans; Irinotecan; Mice; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2007 |
St. John's wort and irinotecan-induced diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Interactions; Humans; Hypericum; Irinotecan; Phytotherapy; Plant Extracts | 2007 |
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Drug Resistance, Neoplasm; Drug Utilization; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; National Health Programs; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Practice Patterns, Physicians'; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Sex Distribution; Survival Analysis | 2007 |
Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; HL-60 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Models, Molecular; Topotecan | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Tumor Cells, Cultured | 2006 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neutropenia; Quality of Life; Rectal Neoplasms | 2007 |
A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.
Topics: Animals; Anthracenes; Antineoplastic Agents, Phytogenic; Bridged Bicyclo Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Glucuronides; Hypericum; Irinotecan; Male; Microsomes, Liver; Perylene; Phloroglucinol; Plant Extracts; Quercetin; Rats; Rats, Sprague-Dawley; Terpenes | 2007 |
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Risk Factors | 2007 |
Green tea polyphenol administration partly ameliorates chemotherapy-induced side effects in the small intestine of mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Flavonoids; Inflammation; Intestinal Mucosa; Intestine, Small; Irinotecan; Mice; Mice, Inbred BALB C; Oxidative Stress; Phenols; Polyphenols; Tea | 2007 |
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2007 |
[Small cell carcinoma of the urinary bladder treated with neo-adjuvant cp chemotherapy (CPT-11 and CDDP): a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Male; Urinary Bladder Neoplasms | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vomiting, Anticipatory | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies | 2007 |
[A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; CA-125 Antigen; Camptothecin; Carcinoma, Endometrioid; Cisplatin; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Laparotomy; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 2007 |
Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2007 |
Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Disease Models, Animal; Irinotecan; Male; Meningioma; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Soft Tissue Neoplasms; Subcutaneous Tissue | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
The thermodynamic dissociation constants of the anticancer drugs camptothecine, 7-ethyl-10-hydroxycamptothecine, 10-hydroxycamptothecine and 7-ethylcamptothecine by the least-squares nonlinear regression of multiwavelength spectrophotometric pH-titration
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Hydrogen-Ion Concentration; Irinotecan; Least-Squares Analysis; Spectrophotometry, Ultraviolet; Thermodynamics; Titrimetry | 2007 |
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Unknown Primary; Organoplatinum Compounds; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Unknown Primary; Organoplatinum Compounds; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Cyclooxygenase 2; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Intestinal Mucosa; Intestinal Neoplasms; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Rats; Signal Transduction; Tumor Cells, Cultured | 2007 |
Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Heat-Shock Proteins; Humans; Immunohistochemistry; Irinotecan; Up-Regulation | 2007 |
Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Hypoxia; Cell Line; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Neoplasms; Rabbits; Transplantation, Heterologous | 2007 |
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cannabinoids; Cytochrome P-450 CYP3A; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Taxoids | 2007 |
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Camptothecin; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2007 |
[A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Female; Genetic Markers; Genetic Variation; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neutropenia; Risk | 2007 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Irinotecan; Lung Neoplasms; Temozolomide | 2006 |
Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ehrlich Tumor; Drug Synergism; Drug Therapy, Combination; Flavanones; Flavonoids; Irinotecan; Male; Mice; Phenols; Polyphenols; Propolis; Quercetin | 2007 |
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, Nude; Pancreatic Neoplasms; Pemetrexed; Transplantation, Heterologous | 2007 |
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Activation; Humans; Irinotecan; Ligands; Male; Mice; Prostatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Receptors, TNF-Related Apoptosis-Inducing Ligand; S Phase; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous; Tumor Suppressor Proteins | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
[A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Jaundice, Obstructive; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Routes; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Oxonic Acid; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Oxonic Acid; Pancreas; Splenectomy; Stomach Neoplasms; Tegafur | 2007 |
[Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2007 |
[A case of effective regimen of tegafur and uracil (UFT)/leucovorin (LV) plus irinotecan (CPT-11) for advanced rectal carcinoma with severe pelvic infiltration to be performed curative resection].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Pelvic Neoplasms; Quality of Life; Rectal Neoplasms; Tegafur; Uracil | 2007 |
DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA-Activated Protein Kinase; Enzyme Inhibitors; Etoposide; GC Rich Sequence; Humans; Irinotecan; Phosphorylation; Promoter Regions, Genetic; Sp1 Transcription Factor; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms; Vitamin B Complex | 2007 |
Developing strategies for liver metastases from colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catheter Ablation; Chemotherapy, Adjuvant; Colonic Neoplasms; Cryosurgery; Embolization, Therapeutic; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Rectal Neoplasms; Remission Induction; Survival Rate; Time Factors; Topoisomerase I Inhibitors | 2007 |
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lewis X Antigen; Male; Middle Aged; Oligosaccharides; Orotate Phosphoribosyltransferase; Prognosis; Sialyl Lewis X Antigen; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Vitamin B Complex | 2007 |
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Diarrhea; Fibroblast Growth Factors; Gastroenteritis; Irinotecan; Mucositis; Rats; Rats, Inbred Strains | 2007 |
Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism.
Topics: Alleles; Black or African American; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic; Sequence Analysis, DNA; Time Factors | 2007 |
Size matters. What can we learn from a small randomized trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2007 |
[Outpatient chemotherapy in gynecologic oncology].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms | 2006 |
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dacarbazine; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Temozolomide; Treatment Outcome | 2007 |
Validation of rapid polymerase chain reaction-based detection of all length polymorphisms in the UGT 1A1 gene promoter.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA; Glucuronosyltransferase; Humans; Irinotecan; Polymerase Chain Reaction; Polymorphism, Genetic; Prodrugs; Promoter Regions, Genetic | 2007 |
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Topics: Acridines; Aminoacridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Amplification; Gene Expression Regulation, Neoplastic; Heterozygote; Humans; Indoles; Irinotecan; Mitoxantrone; Neoplasm Proteins; RNA, Messenger; Triazoles | 2007 |
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Colorectal Neoplasms; DNA; Genotype; Humans; Irinotecan; Liver; Paraffin Embedding; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis | 2008 |
The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; In Situ Nick-End Labeling; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA Precursors | 2007 |
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 2007 |
Panitumumab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Epidermal Growth Factor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab | 2007 |
[A case of ascending colon cancer with enlarged metastatic lymph nodes around superior mesenteric arterial root that responded dramatically to S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Oxonic Acid; Remission Induction; Tegafur | 2007 |
Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; Brefeldin A; Camptothecin; Cation Transport Proteins; Cell Membrane; CHO Cells; Cisplatin; Colonic Neoplasms; Copper; Copper-Transporting ATPases; Cricetinae; Cricetulus; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Golgi Apparatus; Humans; Irinotecan; Monensin; Transfection | 2007 |
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone | 2007 |
A case of small cell carcinoma of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Piperidines | 2007 |
Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers.
Topics: Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Camptothecin; Cholinesterase Inhibitors; Chromosomes, Human, 1-3; Chromosomes, Human, 4-5; Comet Assay; Cytogenetic Analysis; Dose-Response Relationship, Drug; Erythrocytes; Female; Humans; In Vitro Techniques; Irinotecan; Lymphocytes; Sister Chromatid Exchange | 2007 |
Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Cell Fusion; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Genetic Therapy; Humans; Irinotecan; Measles virus; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oncolytic Virotherapy; T-Lymphocytes, Cytotoxic; Viral Fusion Proteins | 2007 |
Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin.
Topics: Aged; Antineoplastic Agents; Camptothecin; Cisplatin; Colon; Diagnosis, Differential; Embolism, Air; Esophageal Neoplasms; Follow-Up Studies; Humans; Intestine, Small; Irinotecan; Ischemia; Laparotomy; Male; Pneumatosis Cystoides Intestinalis; Portal Vein; Prodrugs; Tomography, X-Ray Computed | 2008 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Polymorphism, Genetic | 2007 |
Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Clopidogrel; Dose-Response Relationship, Drug; Female; Hepatocytes; Humans; Interleukin-6; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oseltamivir; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine | 2007 |
Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Blotting, Western; Camptothecin; Cell Line, Tumor; Drug Interactions; Hydrolysis; Irinotecan; Liver; Male; Membrane Transport Proteins; Microsomes, Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Rats; Rats, Sprague-Dawley; Up-Regulation | 2007 |
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2007 |
Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
Topics: Adenocarcinoma, Mucinous; Adult; Animals; Antigens, Tumor-Associated, Carbohydrate; Ascitic Fluid; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Chorionic Gonadotropin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Somatostatin; Stomach Neoplasms | 2007 |
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Profiling; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies | 2008 |
Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Polymerase Chain Reaction; Stomach Neoplasms; Topoisomerase I Inhibitors | 2007 |
Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diarrhea; Glucuronosyltransferase; Hyperbilirubinemia; Intestines; Irinotecan; Rats; Rats, Gunn; Rats, Wistar | 2008 |
Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
Isolated metastasis of lung cancer to the thyroid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Small Cell; CD56 Antigen; Chemotherapy, Adjuvant; Chromogranin A; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Thyroid Neoplasms | 2007 |
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Exons; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2007 |
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2007 |
Cigarette smoking and the personalization of irinotecan therapy.
Topics: Antineoplastic Agents; Camptothecin; Genetic Testing; Genotype; Humans; Irinotecan; Kinetics; Lung Neoplasms; Medical Oncology; Smoking; Topoisomerase I Inhibitors | 2007 |
[Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Stomach Neoplasms | 2007 |
[A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Camptothecin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Tegafur | 2007 |
[Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Sigmoid Neoplasms; Survivors; Tegafur | 2007 |
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Topics: Camptothecin; Cisplatin; Cytotoxins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Melphalan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Peritoneal Neoplasms; Tumor Cells, Cultured | 2008 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Reoperation; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2007 |
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chi-Square Distribution; Child; Child, Preschool; Clinical Trials as Topic; DNA, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Promoter Regions, Genetic; Risk Factors | 2007 |
Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Proteins; Colon; Female; Gastric Mucosa; Gastrointestinal Tract; Gene Expression Profiling; Gene Expression Regulation; Irinotecan; Jejunum; Mucositis; Oligonucleotide Array Sequence Analysis; Rats; Signal Transduction; Stomach; Time Factors; Transcription Factors | 2007 |
Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; DNA Probes; Electrophoretic Mobility Shift Assay; Humans; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Oligonucleotides; Tumor Suppressor Protein p53 | 2007 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diarrhea; Fluorouracil; Gastric Mucosa; Gastrointestinal Tract; Humans; Infusions, Intravenous; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Leucovorin; Loperamide; Mice; Mucositis; Organoplatinum Compounds; Rats | 2007 |
Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemokines; Diarrhea; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Injections, Intraperitoneal; Interleukin-1beta; Intestine, Small; Irinotecan; Male; Mice; Mucositis; Pentoxifylline; Peroxidase; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
[Role of pharmacogenetics in chemotherapy of colorectal cancers].
Topics: Acetylcholinesterase; Antineoplastic Agents; Butyrylcholinesterase; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic | 2007 |
In vitro simulation study of individualized chemotherapy in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2007 |
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; India; Irinotecan; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Singapore; Urogenital Neoplasms | 2007 |
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2007 |
[Preparation and characterization of 7-ethyl-10-hydroxycamptothecin-loaded hypomicron of amphiphilic block copolymer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Carriers; Irinotecan; Lactic Acid; Microspheres; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Solubility; Technology, Pharmaceutical | 2007 |
Expression and characterization of a human carboxylesterase 2 splice variant.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Carboxylesterase; Cloning, Molecular; Colon; Colonic Neoplasms; Humans; Irinotecan; Isoenzymes; Molecular Sequence Data; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
[Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Quality of Life; Radiosurgery; Radiotherapy Dosage; Remission Induction; Splenectomy; Stomach Neoplasms | 2007 |
[Complete remission of hepatic metastasis of gastric cancer with CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colitis, Ischemic; Colonoscopy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Rectal Neoplasms | 2007 |
Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotin; Camptothecin; CHO Cells; Cricetinae; Cricetulus; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; HT29 Cells; Humans; Irinotecan; Prodrugs; Shiga Toxin; Shiga Toxins; Topoisomerase II Inhibitors; Trihexosylceramides | 2007 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Doxorubicin; Drug Synergism; Half-Life; Humans; Irinotecan; Liposomes; Male; Nanoparticles; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Topics: Acetamides; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Deoxycytidine; Drug Screening Assays, Antitumor; Erythrocyte Count; Female; Gemcitabine; Humans; Imides; Irinotecan; Isoquinolines; Leukocyte Count; Maximum Tolerated Dose; Mice; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Platelet Count; Structure-Activity Relationship; Topoisomerase I Inhibitors; Urea | 2007 |
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Microscopy, Fluorescence; Oligonucleotides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tumor Suppressor Protein p53 | 2007 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Fluorouracil; Granulomatosis with Polyangiitis; Hemorrhage; Humans; Irinotecan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2007 |
Acute toxicity of irinotecan in the ex-vivo isolated perfused human lung model--high-dose therapy during isolated perfusion without acute toxic lung edema.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Capillaries; Dose-Response Relationship, Drug; Humans; Irinotecan; Lung; Lung Neoplasms; Lymph Nodes; Organ Culture Techniques; Organ Size; Oxygen; Perfusion; Pulmonary Circulation; Pulmonary Edema; Pulmonary Gas Exchange; Time Factors | 2007 |
[A case of small cell carcinoma of the esophagus with remarkable response to chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Remission Induction | 2007 |
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Prodrugs; Promoter Regions, Genetic | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethics, Medical; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukemia; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Uncertainty | 2007 |
[Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2007 |
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Death; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; Humans; Irinotecan; Mice; Phthalimides; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
Topics: Adult; Aged; Asian People; Camptothecin; Female; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Introns; Irinotecan; Liver; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2008 |
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2007 |
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Coloring Agents; Cytokines; Diarrhea; Digestive System; Eosine Yellowish-(YS); Female; Fluorescent Dyes; Gastric Mucosa; Hematoxylin; Immunohistochemistry; Intestinal Mucosa; Irinotecan; Jejunum; Mouth Mucosa; Mucositis; NF-kappa B; Rats | 2008 |
Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Cisplatin; Dacarbazine; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Temozolomide | 2007 |
Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Mucoepidermoid; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Male; Thymus Neoplasms | 2008 |
Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
Topics: Animals; Body Weight; Camptothecin; Diarrhea; Disease Models, Animal; Female; Irinotecan; Mucositis; Neoplasm Transplantation; Organ Size; Rats; Survival Rate | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro.
Topics: Acetylcholinesterase; Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cells, Cultured; Cholinesterase Inhibitors; Chromosome Aberrations; Female; Humans; Irinotecan; Lymphocytes; Molecular Structure; Oximes; Pyridinium Compounds | 2007 |
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Camptothecin; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Metastasis; Nuclear Proteins; Treatment Outcome | 2007 |
Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Drug Delivery Systems; Hepatic Artery; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Swine | 2006 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Mutation; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured; Up-Regulation | 2007 |
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan | 2007 |
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; NF-kappa B; Survival Rate | 2007 |
Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Asian; Camptothecin; China; Female; Gene Frequency; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Male; Metabolic Clearance Rate; Middle Aged; Philippines; Polymorphism, Genetic; United States; White People | 2007 |
Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Ileal Neoplasms; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2006 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Line, Tumor; Collagen Type II; Colonic Neoplasms; Female; Fibronectins; Floxuridine; Fluorouracil; Humans; Irinotecan; Laminin; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2007 |
Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; bcl-Associated Death Protein; Betulinic Acid; Camptothecin; Caspases; Cell Death; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Mitochondria; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Pentacyclic Triterpenes; Triterpenes | 2007 |
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chromatography, High Pressure Liquid; Female; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Liver; Middle Aged; Models, Biological; Transaminases; Treatment Outcome; Valproic Acid | 2007 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Quinazolines; Rectal Neoplasms; Thiophenes | 2007 |
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Irinotecan; Mice; Mice, SCID; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neuroblastoma; Nuclear Proteins; Temozolomide; Tumor Suppressor Proteins | 2007 |
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Combined Modality Therapy; Female; Humans; Irinotecan; Membrane Potential, Mitochondrial; Mice; Mice, SCID; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survival Rate; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2007 |
[A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
Hydroxycamptothecin deactivation rates and binding to model membranes and HSA determined by fluorescence spectra analysis.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Kinetics; Lipid Bilayers; Membranes, Artificial; Models, Biological; Protein Binding; Serum Albumin; Spectrometry, Fluorescence | 2007 |
Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Humans; Irinotecan; Japan; Liver-Specific Organic Anion Transporter 1; Lung Neoplasms; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic | 2007 |
A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcimycin; Camptothecin; Chemistry, Pharmaceutical; Copper Sulfate; Female; Hydrogen-Ion Concentration; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C | 2008 |
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Compounding; Drug Evaluation, Preclinical; Drug Synergism; Female; Floxuridine; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Neoplasms; Pharmaceutical Vehicles; Survival Rate; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2007 |
[A case of unresectable gastric cancer complicated by serious pyloric stenosis in which S-1 administration after gastrojejunostomy proved effective].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastric Bypass; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyloric Antrum; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2007 |
[Neoadjuvant chemotherapy with combination of S-1 and CPT-11 in advanced rectal cancer - a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Rectal Neoplasms; Tegafur | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dogs; Drug Resistance, Neoplasm; Gene Expression; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Topotecan; Transfection | 2008 |
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Europe; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Staging; Nuclear Proteins; Thymidylate Synthase; Treatment Outcome | 2008 |
Taming glioblastoma: targeting angiogenesis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Survival Rate | 2007 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Proliferation; Female; Fluorine Radioisotopes; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiography; Radiopharmaceuticals; Survival Rate; Thymidine | 2007 |
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan | 2007 |
Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Renal Dialysis; Treatment Outcome | 2007 |
Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2007 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Body Surface Area; Body Weight; Camptothecin; Digestive System Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Reproducibility of Results | 2007 |
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cytochrome P-450 CYP3A; Female; Haplotypes; Humans; Irinotecan; Japan; Male; Metabolic Clearance Rate; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Prodrugs; Sex Factors | 2008 |
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed | 2008 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Quality of Life | 2007 |
[Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[A case of cytology-positive, stage IV gastric cancer, alive with no recurrence for 4 years, curatively treated with combination chemotherapy using S-1, CPT-11 and subsequent total gastrectomy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms | 2007 |
AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle Proteins; Clinical Trials as Topic; Humans; Irinotecan; Janus Kinase 2; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Protein Serine-Threonine Kinases | 2007 |
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.
Topics: Animals; Camptothecin; Colonic Neoplasms; Diarrhea; Diet; Fatty Acids, Omega-3; Female; Food-Drug Interactions; Glutamine; Irinotecan; Oligosaccharides; Probiotics; Rats | 2007 |
[Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoid Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Rectal Neoplasms; Rectum; Remission Induction; Soft Tissue Neoplasms; Time Factors; Treatment Outcome | 2007 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; HT29 Cells; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2007 |
Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2007 |
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Immunosuppressive Agents; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
[A case report--combination chemotherapy with oral UFT and CPT-11, 5-FU, l-LV by hepatic arterial infusion for multiple hepatic metastasis from sigmoid colon cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Sigmoid Neoplasms; Tegafur; Uracil | 2007 |
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Retrospective Studies | 2008 |
Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.
Topics: Antineoplastic Agents; Camptothecin; Chenodeoxycholic Acid; Dactinomycin; Docetaxel; Fluorescent Dyes; Humans; Irinotecan; Kinetics; Lysine; Mitoxantrone; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Signal Processing, Computer-Assisted; Solute Carrier Organic Anion Transporter Family Member 1B3; Spectrometry, Fluorescence; Taxoids; Transfection | 2008 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Endothelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Purines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Treatment of metastatic urachal carcinoma in an elderly woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Cystectomy; Diagnosis, Differential; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Neoplasm Recurrence, Local; Pelvic Neoplasms; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2008 |
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Tumor Lysis Syndrome | 2008 |
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prodrugs; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2008 |
Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carcinoembryonic Antigen; Dose-Response Relationship, Immunologic; Gene Targeting; HeLa Cells; Humans; Immunoglobulin Variable Region; Irinotecan; Recombinant Fusion Proteins | 2008 |
Local-regional approach to diffuse malignant peritoneal mesothelioma.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Humans; Hyperthermia, Induced; Irinotecan; Mesothelioma; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prodrugs; Second-Look Surgery | 2007 |
Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Clinical Trials as Topic; Female; France; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prodrugs; Prognosis; Prospective Studies; Retrospective Studies | 2007 |
Cetuximab efficacy in patients treated routinely in university hospitals.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; France; Hospitals, University; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Registries | 2007 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis | 2008 |
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; HT29 Cells; Humans; I-kappa B Kinase; Irinotecan; Mice; Mice, Nude; NF-kappa B; Protein Kinase Inhibitors; Pyrimidines; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Topics: Adenoviridae; Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylesterase; Cell Proliferation; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Crystallography, X-Ray; Genetic Therapy; Humans; Irinotecan; Mice; Mice, SCID; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Prodrugs; Protein Structure, Secondary; Protein Structure, Tertiary; Sequence Homology, Amino Acid; Transfection; Xenograft Model Antitumor Assays | 2008 |
Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Docetaxel; Esthesioneuroblastoma, Olfactory; Female; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Taxoids | 2008 |
[Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Tomography, X-Ray Computed | 2008 |
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Rate | 2008 |
[An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Synergism; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers; Transplantation, Heterologous | 2008 |
[A long-term surviving patient with unresectable lung metastasis from colon cancer treated with intravenous administration of activated autologous lymphocytes and low-dose chemotherapy--a case report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Immunotherapy; Injections, Intravenous; Irinotecan; Lung Neoplasms; Lymphocyte Activation; Lymphocyte Transfusion; Lymphocytes; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Uracil | 2007 |
[Transarterial chemoembolization with irinotecan (CPT-11) and degradable starch microspheres (DSM) in patients with liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Middle Aged; Neoplasm Staging; Starch; Survival Rate | 2007 |
[An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonoscopy; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tomography, X-Ray Computed | 2007 |
[Carboplatin and CPT-11 chemotherapy in a hemodialysis patient with small-cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
[Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of unresectable gastric cancer successfully treated with combination chemotherapy of S-1 + CPT-11].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Gastroscopy; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of S-1 resistant multiple lung metastases after curative total gastrectomy for gastric cancer successfully treated by S-1 combined with CPT-11 as the third-line chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Drug Resistance, Neoplasm; Female; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2007 |
Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Primers; Female; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Multidrug Resistance-Associated Protein 2; Multivariate Analysis; Polymorphism, Genetic; Regression Analysis; Sex Factors; Treatment Outcome | 2009 |
Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Retrospective Studies; Survival Analysis | 2007 |
Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia | 2008 |
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA Primers; DNA-Binding Proteins; Drug Combinations; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxonic Acid; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Survival Rate | 2008 |
Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Drug Stability; Humans; Hydrogels; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Lactones; Liver Neoplasms; Microspheres; Models, Chemical; Particle Size; Solubility | 2008 |
The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition.
Topics: Camptothecin; DNA Damage; Endodeoxyribonucleases; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Phosphorylation; Promoter Regions, Genetic; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Topoisomerase I Inhibitors; Up-Regulation | 2008 |
Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavanones; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Irinotecan; Liver Neoplasms; Neoplasm Proteins; RNA, Messenger; Tetrahydroisoquinolines; Transfection | 2008 |
Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; beta-Galactosidase; Blotting, Western; Camptothecin; Cell Proliferation; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Drug Delivery Systems; Irinotecan; Liver Neoplasms; Male; Microspheres; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Prodrugs; Rats | 2008 |
Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Disease Progression; Down-Regulation; Humans; Immunoglobulin G; Irinotecan; Mice; Neoplasm Staging; Topoisomerase I Inhibitors | 2008 |
Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Humans; Hyperthermia, Induced; Irinotecan | 2007 |
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Bilirubin; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Computer Simulation; Cytochrome P-450 CYP3A; Female; Glucuronates; Glucuronosyltransferase; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Models, Biological; Multicenter Studies as Topic; Neoplasms | 2008 |
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Failure; Treatment Outcome | 2008 |
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2008 |
Bevacizumab plus irinotecan in recurrent glioblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2008 |
[CPT-11 (Irinotecan)].
Topics: Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2008 |
[Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Tomography Scanners, X-Ray Computed | 2008 |
[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Radiosurgery; Time Factors; Tomography, X-Ray Computed | 2008 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Renal function as a predictor of irinotecan-induced neutropenia.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Creatinine; Drug Administration Schedule; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucuronosyltransferase; Humans; Irinotecan; Kidney; Linear Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Prospective Studies; Research Design; Retrospective Studies | 2008 |
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2008 |
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Calorimetry; Camptothecin; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Cholesterol; Copper; Drug Carriers; Drug Compounding; Excipients; Floxuridine; Gluconates; Irinotecan; Liposomes; Magnetic Resonance Spectroscopy; Microscopy, Electron, Transmission; Phosphatidylcholines; Phosphatidylglycerols; Solubility; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2008 |
Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Ethmoid Bone; Humans; Irinotecan; Male; Neuroendocrine Tumors; Organization and Administration; Radiotherapy, Adjuvant; Skull Neoplasms | 2008 |
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate | 2008 |
Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Micelles; Prodrugs; Xenograft Model Antitumor Assays | 2008 |
Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Interferons; Irinotecan; Oligonucleotide Array Sequence Analysis; Time Factors | 2008 |
Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies | 2008 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Keratin-19; Keratins; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[A long survival case of advanced colon cancer with lung metastasis and cancerous pleuritis responding to CPT-11 and S-1 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pleurisy; Positron-Emission Tomography; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Chi-Square Distribution; Female; Genetic Predisposition to Disease; Genotype; Gilbert Disease; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Single Nucleotide; Risk; Statistics, Nonparametric | 2008 |
Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Data Interpretation, Statistical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Irinotecan; Polymorphism, Genetic; Research Design; Salvage Therapy | 2008 |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Haplotypes; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Signal Transduction | 2008 |
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Topics: Animals; Antineoplastic Agents; Camptothecin; Colon; Female; Fluorouracil; Immunohistochemistry; Interleukin-1; Interleukin-6; Intestinal Mucosa; Irinotecan; Jejunum; Methotrexate; Mouth Mucosa; Mucositis; NF-kappa B; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2009 |
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Colon; Colonic Neoplasms; Cytoprotection; Diarrhea; Female; Glutamine; Irinotecan; Neoplasms, Experimental; Rats | 2008 |
Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Topics: Amidohydrolases; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Thymidylate Synthase | 2008 |
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2008 |
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Tegafur; Uracil | 2007 |
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Polyethylene Glycols; Prodrugs; Solubility; Temperature | 2008 |
Spectrofluorimetric determination of irinotecan in the presence of oxidant agents and metal ions.
Topics: Camptothecin; Drug Monitoring; Humans; Hydrogen-Ion Concentration; Irinotecan; Iron; Spectrometry, Fluorescence | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; Female; Fluorouracil; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Seeding; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Care; Retrospective Studies; Treatment Outcome | 2009 |
Small cell carcinoma of the extrahepatic bile duct diagnosed with EUS-FNA and effectively treated with chemoradiation.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Biopsy, Fine-Needle; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Therapy, Combination; Endosonography; Humans; Irinotecan; Male | 2008 |
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Flavonoids; HCT116 Cells; Humans; Irinotecan; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Rad51 Recombinase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2008 |
DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cations; Dogs; Drug Carriers; Humans; Irinotecan; Neoplasms, Experimental; Peptides; Prodrugs; Xenograft Model Antitumor Assays | 2008 |
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Humans; Irinotecan; Mice; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xenograft Model Antitumor Assays | 2008 |
Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Immunoenzyme Techniques; Infant; Irinotecan; Male; Mice; Neovascularization, Pathologic; Neuroblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Irinotecan; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Registries; Retrospective Studies; Treatment Outcome | 2008 |
[Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recurrence; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2008 |
[Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Pharmacogenetic pathway analysis of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enterohepatic Circulation; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Multidrug Resistance-Associated Protein 2; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2008 |
Determination of anticarcinogenic and rescue therapy drugs in urine by photoinduced spectrofluorimetry using multivariate calibration: comparison of several second-order methods.
Topics: Anticarcinogenic Agents; Calibration; Camptothecin; Fluorometry; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Irinotecan; Leucovorin; Molecular Structure; Photochemistry; Salvage Therapy | 2008 |
Sequential vs combination colorectal cancer therapy sparks debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2008 |
Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Japan; Neoplasm Recurrence, Local; Survival Rate; Topoisomerase I Inhibitors | 2008 |
A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Disease Models, Animal; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Female; Granulosa Cells; Immunohistochemistry; In Situ Nick-End Labeling; Injections, Intraperitoneal; Irinotecan; Mice; Organ Culture Techniques; Primary Ovarian Insufficiency; Recombinant Proteins; Topoisomerase I Inhibitors; Up-Regulation | 2008 |
Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Ovary; Perimenopause; Premenopause; Primary Ovarian Insufficiency; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Collagen Type I; Delayed-Action Preparations; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Pancreatic Neoplasms; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Glioma; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.
Topics: Antineoplastic Agents, Phytogenic; Caco-2 Cells; Camptothecin; Cell Survival; Chemical Phenomena; Chemistry, Physical; Dendrimers; Drug Carriers; Drug Delivery Systems; Epithelium; Humans; Injections, Intravenous; Irinotecan; Isotope Labeling; Magnetic Resonance Spectroscopy; Polyamines | 2008 |
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Immunoenzyme Techniques; Immunohistochemistry; Indoles; Irinotecan; Male; Mice; Mice, Nude; Microcirculation; Pyrroles; Thrombospondin 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.
Topics: Animals; Brain; Camptothecin; Dogs; Environmental Monitoring; Female; Fluorescence; Gadolinium; Irinotecan; Liposomes; Magnetic Resonance Imaging; Nanoparticles | 2008 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Retrospective Studies | 2008 |
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.
Topics: Camptothecin; Cohort Studies; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Genotype; Glucuronosyltransferase; Humans; Irinotecan | 2008 |
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cecum; Cell Proliferation; Colonic Neoplasms; Drug Therapy, Combination; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Irinotecan; Lymphatic Metastasis; Male; Mice; Mice, Nude; Necrosis; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; RNA, Small Interfering; Topoisomerase I Inhibitors; Transforming Growth Factor alpha | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Pilot Projects; Randomized Controlled Trials as Topic | 2007 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Case-Control Studies; China; Colorectal Neoplasms; Diarrhea; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Young Adult | 2007 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Enterohepatic Circulation; Female; Glioma; Half-Life; Humans; Irinotecan; Male | 2009 |
Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; Flow Cytometry; G2 Phase; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Irinotecan; Microtubule-Associated Proteins; Neoplasm Proteins; S Phase; Survivin; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2008 |
Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Melanoma; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2008 |
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2009 |
Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Treatment Outcome | 2008 |
Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Drug Synergism; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Signal Transduction; Transplantation, Heterologous | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Irinotecan; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; RNA, Small Interfering; S Phase; Tumor Stem Cell Assay | 2008 |
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Management and survival trends in advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2008 |
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytokines; Epithelium; Female; Fluorouracil; Gastrointestinal Tract; Gene Expression Regulation; Inflammation; Interleukin-1beta; Interleukin-6; Irinotecan; Methotrexate; NF-kappa B; Rats; Tumor Necrosis Factor-alpha | 2008 |
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Exons; Female; Gene Dosage; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Protein Structure, Tertiary; Retrospective Studies; Treatment Outcome | 2008 |
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; Humans; Irinotecan; Mice; Neoplastic Stem Cells | 2008 |
Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Area Under Curve; Bile; Biological Transport; Camptothecin; Catechin; Chromatography, High Pressure Liquid; Contraindications; Dietary Supplements; Food-Drug Interactions; Glucuronides; Injections, Intravenous; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Specific Pathogen-Free Organisms | 2008 |
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Magnesium; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2008 |
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Camptothecin; Colorectal Neoplasms; Fluorouracil; HIV Infections; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Skin; Skin Diseases; Weight Loss | 2008 |
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; ErbB Receptors; fas Receptor; Fluorouracil; Humans; Irinotecan; Myeloid Cell Leukemia Sequence 1 Protein; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Availability; Biological Transport; Caco-2 Cells; Camptothecin; Drug Screening Assays, Antitumor; Female; Humans; Intestinal Absorption; Irinotecan; Quercetin; Rats; Rats, Wistar | 2008 |
Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Immunohistochemistry; Irinotecan; Mutation; Panitumumab; Proto-Oncogene Proteins; ras Proteins | 2008 |
Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Interactions; Fluorodeoxyglucose F18; Fluorouracil; Glucose; Hexokinase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiopharmaceuticals | 2008 |
[Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats].
Topics: Administration, Oral; Animals; Body Weight; Camptothecin; Diarrhea; Feeding Behavior; Irinotecan; Lacticaseibacillus casei; Male; Rats; Rats, Wistar; Time Factors | 2008 |
[CR obtained by CPT-11 and CDDP combination-therapy in a small-cell lung-cancer patient through effective pharmaceutical care].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Radiography; Remission Induction; Time Factors | 2008 |
[A case of interstitial pneumonia induced by S-1/irinotecan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Diseases, Interstitial; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2008 |
[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
Topics: Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Multigene Family; Neoplasms; Polymorphism, Genetic | 2008 |
[Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Irinotecan; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Radiography | 2008 |
[A case of small cell carcinoma of the ureter].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Irinotecan; Male; Ureteral Neoplasms | 2008 |
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cell Line, Tumor; Cell Survival; Ceramides; Drug Therapy, Combination; Green Fluorescent Proteins; Humans; Irinotecan; Lysophospholipids; Male; Mice; Neoplasm Metastasis; para-Aminobenzoates; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Sphingosine; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
PEGylated nanographene oxide for delivery of water-insoluble cancer drugs.
Topics: Antineoplastic Agents; Camptothecin; Carbon; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Irinotecan; Molecular Structure; Nanostructures; Oxides; Particle Size; Polyethylene Glycols; Solubility; Surface Properties; Water | 2008 |
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays | 2008 |
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2008 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2008 |
Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Camptothecin; Cell Proliferation; Chemotherapy, Adjuvant; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Neovascularization, Pathologic; Postoperative Care; Rats; Rats, Inbred F344; Rats, Nude; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
[Case report of malignant sertoli cell tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Combined Modality Therapy; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Orchiectomy; Organoplatinum Compounds; Salvage Therapy; Sertoli Cell Tumor; Testicular Neoplasms; Tomography, X-Ray Computed | 2008 |
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Immunoblotting; In Situ Nick-End Labeling; Irinotecan; Male; Mesothelioma; Mice; Mice, Nude; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2008 |
Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Synergism; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, SCID; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies.
Topics: Animals; Bile; Camptothecin; Chromatography, High Pressure Liquid; Female; Irinotecan; Linear Models; Rats; Reference Standards; Sensitivity and Specificity; Time Factors; Ultraviolet Rays | 2008 |
Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA-Binding Proteins; Humans; Irinotecan; Mice; Mice, Nude; Microsatellite Instability; MRE11 Homologue Protein; Mutation; Thymidine; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
Bortezomib as a therapeutic candidate for neuroblastoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines | 2008 |
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Male; Mice; Mice, SCID; Multiple Myeloma; Topoisomerase I Inhibitors; Transfection; Xenograft Model Antitumor Assays | 2008 |
An autopsy case of acute pulmonary toxicity related to irinotecan.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Autopsy; Camptothecin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Irinotecan; Laryngeal Neoplasms; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Staging; Radiography, Thoracic; Respiratory Distress Syndrome; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2008 |
How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?
Topics: Camptothecin; Cephalosporins; Child; Diarrhea; Humans; Irinotecan; Male; Neuroblastoma; Patient Compliance | 2009 |
[Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastroscopy; Humans; Intestinal Neoplasms; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Drug Combinations; Female; Gastroscopy; Humans; Irinotecan; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Computer Simulation; Humans; Irinotecan; Models, Statistical; Multiple Sclerosis; Pharmacology; Probability; Receptors, Antigen, T-Cell, alpha-beta; Treatment Outcome | 2008 |
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 2008 |
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Topics: Apoptosis; Benzoquinones; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Survival; Checkpoint Kinase 1; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Interactions; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lactams, Macrocyclic; Nuclear Proteins; Protein Kinases; Protein-Tyrosine Kinases; Time Factors; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2009 |
New lessons from "old" chemotherapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pyrimidines | 2008 |
Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.
Topics: Administration, Oral; Animals; Biliary Tract; Camptothecin; Gefitinib; Irinotecan; Male; Quinazolines; Rats; Rats, Wistar | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Italy; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays | 2008 |
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Models, Statistical; Placebos; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2008 |
Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Profiling; HCT116 Cells; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Topoisomerase I Inhibitors | 2008 |
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Escherichia coli; Feces; Gastrointestinal Tract; Gene Expression Regulation, Enzymologic; Glucuronidase; Immunohistochemistry; Intestines; Irinotecan; Jejunum; Lactobacillus; Rats; Staphylococcus | 2008 |
Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Female; Flow Cytometry; Humans; Irinotecan; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2009 |
Efficient one-cycle affinity selection of binding proteins or peptides specific for a small-molecule using a T7 phage display pool.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Bacteriophage T7; Biosensing Techniques; Camptothecin; Carrier Proteins; Drug Evaluation, Preclinical; Electrodes; Gold; Irinotecan; Ligands; Molecular Sequence Data; Peptide Library; Peptides; Protein Structure, Tertiary; Structure-Activity Relationship; Tacrolimus Binding Proteins | 2008 |
[A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Differentiation; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatal Outcome; Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Treatment Failure | 2008 |
[A case of successful control for primary duodenal cancer with combined CPT-11, CDDP and DOC chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Duodenal Neoplasms; Duodenoscopy; Humans; Irinotecan; Male; Middle Aged; Taxoids; Time Factors; Tomography, X-Ray Computed | 2008 |
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.
Topics: Acetylene; Antibodies; Antineoplastic Agents; Azides; Camptothecin; Cell Line, Tumor; Cell Survival; Humans; Irinotecan; Kinetics; Molecular Structure; Structure-Activity Relationship | 2008 |
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.
Topics: Acid Anhydride Hydrolases; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Cytotoxins; DNA Repair Enzymes; DNA-Binding Proteins; Humans; Irinotecan; Microsatellite Instability; MRE11 Homologue Protein; MutL Protein Homolog 1; Nuclear Proteins | 2008 |
Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Chitosan; Cholesterol; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Stability; Electrochemistry; Freeze Fracturing; Gelatin; Irinotecan; Liposomes; Phosphatidylcholines | 2009 |
A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, Liquid; Drug Stability; Humans; Irinotecan; Microsomes, Liver; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2008 |
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms; Polymorphism, Genetic | 2008 |
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunoblotting; Irinotecan; Leupeptins; Lysosomes; Macrolides; Microscopy, Fluorescence; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; RNA, Messenger; Time Factors; Ubiquitin | 2009 |
Semi-synthesis and biological activity of gamma-lactones analogs of camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Irinotecan; Lactones; Models, Chemical; Molecular Structure; Solubility; Structure-Activity Relationship | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retreatment; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2008 |
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Glioblastoma; Glioma; Humans; Irinotecan | 2008 |
Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Female; Humans; Infant; Irinotecan; Magnetic Resonance Imaging; Neuroblastoma; Palliative Care; Radiography; Treatment Outcome | 2008 |
In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pharmacogenetics; Pharyngeal Neoplasms | 2009 |
Irinotecan-induced mucositis is associated with changes in intestinal mucins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Gene Expression Regulation; Goblet Cells; Immunohistochemistry; Intestinal Mucosa; Irinotecan; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mucin-2; Mucin-4; Mucins; Mucositis; Rats; Statistics, Nonparametric; Time Factors | 2009 |
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Prescriptions; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Epidermal Growth Factor; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Thymidylate Synthase | 2008 |
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Doxorubicin; Fluorouracil; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Irinotecan; Liposomes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Nanocapsules; Neoplasms, Experimental; Neovascularization, Pathologic; Tissue Distribution; Xenograft Model Antitumor Assays | 2008 |
Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Micelles; Microscopy, Fluorescence; Peritoneal Neoplasms; Stomach Neoplasms; Tissue Distribution | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[Marked response to combination chemotherapy using S-1, CPT-11 for lymph node metastasis of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Humans; Irinotecan; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2008 |
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome; Vitamin B Complex | 2008 |
Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?
Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Mice; Myocardium; Tandem Mass Spectrometry; Topotecan | 2009 |
Race does not explain genetic heterogeneity in pharmacogenomic pathways.
Topics: Camptothecin; Cluster Analysis; Databases, Genetic; Fluorouracil; Genetic Heterogeneity; Humans; Insulin; Irinotecan; Metabolic Clearance Rate; Pharmacogenetics; Polymorphism, Single Nucleotide; Principal Component Analysis; Racial Groups | 2008 |
Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modality Therapy; Female; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Histocytochemistry; Irinotecan; Leukocytes; Mucositis; Rats; Saccharomyces; Weight Loss | 2009 |
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Topics: Apoptosis; bcl-X Protein; Biphenyl Compounds; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Humans; Irinotecan; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2008 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2008 |
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate | 2009 |
[Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2008 |
[A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Camptothecin; Cell Proliferation; Drug Combinations; Gastroscopy; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
[A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Positron-Emission Tomography; Sigmoid Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of ovarian cancer in which a remarkable effect was seen with intrathoracic administration of CDDP and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Injections; Irinotecan; Middle Aged; Ovarian Neoplasms; Thorax; Tomography, X-Ray Computed | 2008 |
[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure | 2009 |
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Topics: Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Models, Biological; Neoplasm Metastasis; Neutropenia | 2009 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Vitamin B Complex | 2009 |
Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Intestinal Neoplasms; Irinotecan; Jejunal Neoplasms; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis | 2008 |
Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Biliary Tract; Caco-2 Cells; Calcium Channel Blockers; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Rats; Rats, Wistar; Spectrophotometry, Ultraviolet; Verapamil | 2009 |
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Radiotherapy | 2009 |
[Advanced gastric cancer showing complete response to neoadjuvant chemotherapy with CPT-11 and S-1-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of simultaneous double cancers with multiple liver metastases responding to S-1+CPT-11].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Endoscopy, Gastrointestinal; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Camptothecin; Cytogenetics; DNA Probes; DNA, Satellite; In Situ Hybridization, Fluorescence; Injections, Intraperitoneal; Irinotecan; Male; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Topotecan | 2009 |
Can cetuximab affect paraneoplastic myopathy?
Topics: Adenocarcinoma; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Candidiasis; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Klebsiella Infections; Liver Neoplasms; Male; Methylprednisolone; Middle Aged; Muscular Diseases; Paraneoplastic Syndromes; Tuberculosis | 2009 |
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Mutation; Polymorphism, Genetic; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Retrospective Studies; Survival Analysis | 2009 |
Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Female; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Peritoneal Neoplasms | 2009 |
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2009 |
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Patient Selection; Polymorphism, Single Nucleotide; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Organoplatinum Compounds; Pyridines; Regression Analysis; Tumor Cells, Cultured | 2009 |
Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Capillary Permeability; Cell Line, Tumor; Glioma; Humans; Irinotecan; Mice; Micelles; Xenograft Model Antitumor Assays | 2009 |
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Male; MAP Kinase Signaling System; Mice; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; DNA Primers; Humans; Irinotecan; Kidney Neoplasms; Melphalan; Organic Cation Transport Proteins; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Vincristine | 2009 |
Irinotecan in cancer patients with end-stage renal failure.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronates; Humans; Irinotecan; Kidney Failure, Chronic; Male; Middle Aged; Palliative Care; Renal Dialysis | 2009 |
Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Tolerance; HeLa Cells; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Irinotecan; Male; Middle Aged; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Phenotype; RNA, Messenger; Transfection; Up-Regulation | 2009 |
[A case of recurrence after curative total gastrectomy for gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Positron-Emission Tomography; Recurrence; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2009 |
Different inhibitory effects in rat and human carboxylesterases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Camptothecin; Carboxylic Ester Hydrolases; Cytosol; Enzyme Inhibitors; Humans; Imidazolidines; In Vitro Techniques; Irinotecan; Jejunum; Liver; Microsomes, Liver; Pharmaceutical Preparations; Rats; Rats, Wistar; Species Specificity | 2009 |
Role of glucocorticoid receptor in the regulation of cellular sensitivity to irinotecan hydrochloride.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Dexamethasone; Drug Synergism; Irinotecan; Phosphoinositide-3 Kinase Inhibitors; Rats; Receptors, Glucocorticoid; Topoisomerase I Inhibitors; Transfection | 2009 |
Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Meningeal Carcinomatosis; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Dietary Supplements; Fatty Acids, Omega-3; Female; Fluorouracil; Glutamine; Immune Tolerance; Irinotecan; Leukocyte Count; Nutritional Status; Rats; Rats, Inbred F344; Treatment Failure; Xenograft Model Antitumor Assays | 2009 |
The CAIRO and FOCUS studies: which lesson is to be learned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Microsatellite Instability; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2009 |
Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; G2 Phase; Gene Expression Regulation; Humans; Irinotecan; Ovarian Neoplasms; Taxoids | 2009 |
Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.
Topics: Animals; Anticholesteremic Agents; Apigenin; Azetidines; Bile; Camptothecin; Enzyme Inhibitors; Ezetimibe; Flavonoids; Genistein; Glucuronic Acid; Glucuronosyltransferase; Indomethacin; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Isoflavones; Liver; Male; Microsomes; Microsomes, Liver; Protein Isoforms; Rats; Rats, Gunn; Rats, Wistar; Recombinant Proteins; Testosterone; Up-Regulation | 2009 |
Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Follow-Up Studies; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Renal Dialysis; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors | 2009 |
Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Nucleus; Cell Survival; Comet Assay; DNA Damage; DNA Repair; Epirubicin; Female; HeLa Cells; Humans; Immunohistochemistry; Irinotecan; Leupeptins; Oligopeptides; Proteasome Inhibitors; Ubiquitin | 2009 |
The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Mice; Organophosphates; Polyploidy; Protein Serine-Threonine Kinases; Quinazolines; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2009 |
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Death-Associated Protein Kinases; Fas Ligand Protein; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Granulosa Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Models, Biological; Ovarian Follicle; Ovarian Neoplasms; Ovary | 2009 |
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan | 2009 |
Irinotecan toxicity: genes or intestinal microflora?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Glucuronosyltransferase; Humans; Intestines; Irinotecan | 2009 |
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Risk Factors; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2009 |
Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Beckwith-Wiedemann Syndrome; Bone Marrow Transplantation; Camptothecin; Cyclophosphamide; Dactinomycin; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infant, Newborn; Irinotecan; Potassium Channels, Voltage-Gated; Rhabdomyosarcoma, Alveolar; Skin Neoplasms; Transcription, Genetic; Vincristine | 2009 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Down-Regulation; Doxorubicin; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Protein Kinase C-delta; RNA, Small Interfering; Topotecan; Transcription, Genetic; U937 Cells | 2009 |
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2009 |
Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Phytic Acid | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
Irinogenetics: how many stars are there in the sky?
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Genetic Predisposition to Disease; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Multivariate Analysis; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Dogs; Haplorhini; Humans; Hydrogen-Ion Concentration; Irinotecan; Mice; Mice, Nude; Prodrugs; Rats; Topoisomerase I Inhibitors; Transplantation, Heterologous; Water | 2009 |
UGT1A and irinotecan toxicity: keeping it in the family.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan | 2009 |
Intracellular dynamics of topoisomerase I inhibitor, CPT-11, by slit-scanning confocal Raman microscopy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Irinotecan; Microscopy, Confocal; Spectrum Analysis, Raman; Topoisomerase I Inhibitors | 2009 |
Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Proliferation; Female; Flow Cytometry; Glucuronates; Glucuronidase; Humans; Irinotecan; Mice; Mice, SCID; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2009 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Cisplatin; Drug Combinations; Hematopoiesis; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Risk Factors; Stomach Neoplasms; Tegafur | 2009 |
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Genetic | 2009 |
Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Inbred BALB C; Micelles; Molecular Structure; Photochemotherapy; Polymers; Porphyrins; Xenograft Model Antitumor Assays | 2009 |
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Italy; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Mutation; Patient Selection; Phosphorylation; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies | 2009 |
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Ciprofloxacin; Colorectal Neoplasms; Diarrhea; Female; Immunity, Mucosal; Intestinal Mucosa; Irinotecan; Lymphatic Metastasis; Neoplasm Transplantation; Rats; Rats, Inbred F344; Spleen; Survival Analysis | 2009 |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyrimidines; Retrospective Studies; Tegafur | 2009 |
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Patient Compliance; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
High therapeutic effectiveness of postoperative irinotecan chemotherapy in a typical case of radiographically and pathologically diagnosed pleuropulmonary blastoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Child, Preschool; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Pleura; Pulmonary Blastoma; Thoracic Neoplasms; Vincristine | 2009 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prodrugs; Tegafur | 2009 |
Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Liver Diseases; Liver Neoplasms; Male; Quinazolines; Thiophenes | 2008 |
Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitory Concentration 50; Irinotecan; Mitoxantrone; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Receptor, TIE-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation | 2009 |
Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Drug Therapy, Combination; Fluorouracil; Gene Expression; Humans; Irinotecan; Leucovorin; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Stomach Neoplasms | 2009 |
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; DNA; DNA, Neoplasm; Ethnicity; Female; Gastrointestinal Tract; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Young Adult | 2009 |
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Orotate Phosphoribosyltransferase; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2009 |
[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Progression; Humans; Immunotherapy; Irinotecan; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab; Treatment Outcome | 2009 |
[A case of recurrent endocrine cell carcinoma of the common bile duct successfully treated by hepatic artery infusion with CPT-11 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Camptothecin; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed | 2009 |
[CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Esophagoscopy; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Tomography, X-Ray Computed | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Peritoneal Neoplasms; Plant Preparations; Prunus; Triterpenes; Xenograft Model Antitumor Assays | 2009 |
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Screening Assays, Antitumor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Models, Molecular; Neoplasm Proteins; Protein Conformation; Sulindac; Xenograft Model Antitumor Assays | 2009 |
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Mastectomy, Segmental; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.
Topics: Adolescent; Adult; Aged; Aging; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Child; Child, Preschool; Female; Human Growth Hormone; Humans; Hydrolysis; Infant; Infant, Newborn; Irinotecan; Liver; Male; Methylphenidate; Mice; Middle Aged; Sex Characteristics; Subcellular Fractions; Young Adult | 2009 |
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Combined Modality Therapy; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms; Taxoids; Tumor Suppressor Protein p53 | 2009 |
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Prodrugs; Solubility; Water; Xenograft Model Antitumor Assays | 2010 |
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Time Factors | 2010 |
Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Intestinal Mucosa; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Small Cell Lung Carcinoma; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
Topics: Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Trees; Genetic Testing; Genetic Variation; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Quality of Life | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Flow Cytometry; Fluorouracil; G1 Phase; G2 Phase; Humans; Irinotecan; Thymidylate Synthase; Tumor Cells, Cultured | 2009 |
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Topics: 14-3-3 Proteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Camptothecin; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; DNA Methylation; DNA Topoisomerases, Type I; Drug Therapy, Combination; Epigenesis, Genetic; Humans; Irinotecan; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Rate | 2009 |
Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Topics: Camptothecin; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Intestines; Irinotecan; Molecular Structure; Quantitative Structure-Activity Relationship; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Substrate Specificity | 2009 |
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk; Smoking; Treatment Outcome | 2009 |
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Hydrolysis; Inhibitory Concentration 50; Irinotecan; Models, Chemical; Rhodamines; Structure-Activity Relationship; Topotecan | 2009 |
[A case of marked response to CPT-11+CDDP neoadjuvant chemotherapy for advanced gastric cancer with paraaortic lymph node metastasis enabling curative resection and over 10-year survival].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2009 |
[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclodextrins; Female; Humans; Irinotecan; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Polymers; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.
Topics: Animals; Camptothecin; Cell Line, Tumor; Gangliosides; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Glioma; Glycomics; Humans; Irinotecan; Lipids; Mice; Phosphatidylglycerols; Sulfoglycosphingolipids; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2010 |
Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Stability; Female; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2009 |
Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity.
Topics: Camptothecin; Estradiol; Glucuronosyltransferase; Herbal Medicine; Humans; Irinotecan; Medicine, Kampo | 2009 |
Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan.
Topics: Adolescent; Adult; Amifostine; Antimutagenic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; DNA Repair; Dose-Response Relationship, Drug; Drug Antagonism; Enzyme Inhibitors; Humans; Irinotecan; Lymphocytes; Male; Mitotic Index; Radiation-Protective Agents; Sister Chromatid Exchange; Young Adult | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chi-Square Distribution; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Survival Rate | 2009 |
Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Glycolysis; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Proteome; Pyruvate Kinase; Reproducibility of Results; Up-Regulation | 2009 |
Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fanconi Syndrome; Female; Fluorouracil; Humans; Irinotecan | 2009 |
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Risk Factors | 2009 |
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Nasopharyngeal Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Single Nucleotide; Rhabdomyosarcoma, Alveolar | 2009 |
Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Chromatography, High Pressure Liquid; Contrast Media; Drug Compounding; Drug Delivery Systems; Drug Stability; Drug Storage; Infusions, Intra-Arterial; Irinotecan; Microspheres; Particle Size; Solubility; Temperature; Time Factors | 2010 |
Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Individuality; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 2009 |
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Leucovorin; Male; Polymorphism, Genetic | 2009 |
[A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Consciousness Disorders; Fluorouracil; Humans; Hyperammonemia; Irinotecan; Leucovorin; Male; Middle Aged | 2009 |
Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Camptothecin; Colonic Neoplasms; DNA, Antisense; Down-Regulation; GTP-Binding Proteins; HCT116 Cells; Humans; Irinotecan; Membrane Proteins; Proteasome Endopeptidase Complex; Protein Binding; Proto-Oncogene Proteins; RNA, Small Interfering | 2009 |
Irinotecan use during pregnancy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Care | 2009 |
Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; DNA Mutational Analysis; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cause of Death; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Middle Aged; Multicenter Studies as Topic; Netherlands; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Humans; Irinotecan; Macaca mulatta; Mice; Models, Statistical; Nonlinear Dynamics; Rats; Species Specificity; Topoisomerase I Inhibitors | 2009 |
Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2009 |
Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging | 2009 |
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Vitamin B Complex | 2009 |
Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, Liquid; Glucuronates; Glucuronidase; Humans; Irinotecan; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Maximum Tolerated Dose; Microspheres; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Yttrium Isotopes | 2009 |
Irinotecan side effects relieved by the use of HI-6 oxime: in vivo experimental approach.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Brain; Camptothecin; Cholinesterase Inhibitors; Cholinesterase Reactivators; Cholinesterases; DNA Damage; Drug Interactions; Erythrocytes; Free Radical Scavengers; Irinotecan; Leukocytes; Lipid Peroxidation; Liver; Male; Mutagenicity Tests; Oximes; Pyridinium Compounds; Random Allocation; Rats; Rats, Wistar; Time Factors | 2009 |
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Calcium-Binding Proteins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chaperonin 60; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Receptors, Notch; Secondary Prevention; Xenograft Model Antitumor Assays | 2009 |
[Pre-clinical study of combined aranosa, cisplatin and irinotecan in the treatment of experimental lung cancer].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Lewis Lung; Cisplatin; Drug Administration Schedule; Glycosides; Irinotecan; Male; Methylnitrosourea; Mice; Mice, Inbred C57BL; Mice, Inbred Strains | 2009 |
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Humans; Irinotecan; Mice; Mice, Nude | 2009 |
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Celecoxib; Cell Proliferation; Child, Preschool; Cyclooxygenase 2 Inhibitors; Female; Humans; Infant; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neuroblastoma; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Neoplastic Stem Cells; Quinolines | 2009 |
[Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Paclitaxel; Splenectomy; Stomach Neoplasms; Tegafur | 2009 |
[A case of advanced colon cancer treated with preoperative chemotherapy (IRIS) leading to clinical complete response].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Preoperative Care; Rectal Neoplasms; Tegafur; Treatment Outcome | 2009 |
[Effectiveness of S-1 plus CPT-11 therapy for an elderly patient with recurrent colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Tegafur | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line; Cell Proliferation; Colorectal Neoplasms; Drug Administration Schedule; Endothelial Cells; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Microvessels; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2009 |
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Camptothecin; Case-Control Studies; Female; Humans; Immune Tolerance; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies | 2009 |
Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Interactions; Glucuronides; Irinotecan; Liver; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2010 |
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Fluorouracil; Interleukins; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes | 2009 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).
Topics: Alleles; Antineoplastic Agents; Camptothecin; Gene Frequency; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Pharmacogenetics; Polymorphism, Genetic | 2009 |
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; In Situ Hybridization, Fluorescence; Irinotecan; Male; Middle Aged; Mutation; ras Proteins; Retrospective Studies; Treatment Failure | 2009 |
Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Treatment Outcome | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Child; Colonic Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Remission Induction; Young Adult | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pneumonectomy; Survival Rate; Treatment Outcome | 2009 |
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Expression; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Ligands; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA, Messenger; Survival Analysis | 2009 |
The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Skin | 2009 |
Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; DNA Damage; DNA Mismatch Repair; G1 Phase; Humans; Irinotecan; MutL Protein Homolog 1; Neoplasms; Nuclear Proteins; Phosphorylation; Ploidies; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2010 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Sirolimus; Treatment Outcome | 2009 |
[Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Female; Glucuronates; Humans; Individuality; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2009 |
[A case of superficial small cell carcinoma of the esophagus].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male | 2009 |
[Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Decontamination; Doxorubicin; Drug Compounding; Electrosurgery; Hot Temperature; Humans; Irinotecan; Mitomycin; Occupational Exposure; Operating Rooms; Organoplatinum Compounds; Peritoneal Neoplasms; Protective Clothing; Pyridines; Smoke; Ventilation | 2009 |
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Diarrhea; Feces; Female; Glucuronidase; Goblet Cells; Intestinal Mucosa; Irinotecan; Jejunum; Mucins; Mucositis; Rats | 2009 |
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Male; Middle Aged; Thymidylate Synthase; Treatment Outcome; Young Adult | 2009 |
False-positive interpretations in respiratory cytopathology.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Diagnostic Errors; Docetaxel; False Positive Reactions; Granulomatosis with Polyangiitis; Humans; Irinotecan; Lung Neoplasms; Male; Radiography, Thoracic; Remission Induction; Taxoids; Treatment Outcome | 2013 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Drug Delivery Systems; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Models, Biological; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids | 2010 |
Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2009 |
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Humans; Irinotecan; Mice; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11).
Topics: Adolescent; Adult; Animals; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cells, Cultured; Erythropoietin; Humans; In Vitro Techniques; Irinotecan; Leukemia P388; Lymphocytes; Mice; Mitosis; Mutagens; Recombinant Proteins; Sister Chromatid Exchange; Young Adult | 2010 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Retrospective Studies; Survival Analysis; Vitamin B Complex | 2010 |
Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines.
Topics: Buffers; Camptothecin; Cell Death; Drug Delivery Systems; Folic Acid; HT29 Cells; Humans; Irinotecan; Lactic Acid; Microscopy, Fluorescence; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2010 |
[A case of recurrent rectal cancer with multiple lung metastases successfully treated with S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Radiography; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2010 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Flavonoids; Genes, cdc; Growth Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Piperidines; Predictive Value of Tests; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Genotoxicity of irinotecan and its modulation by vitamins A, C and E in human lymphocytes from healthy individuals and cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Ascorbic Acid; Camptothecin; Comet Assay; DNA Damage; DNA Repair; Female; Humans; Irinotecan; Lymphocytes; Male; Middle Aged; Mutagens; Vitamin A; Vitamin E | 2010 |
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Neoplasm Recurrence, Local; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Spinal Puncture; Treatment Outcome | 2009 |
Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Proton Therapy; Survivors | 2009 |
Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; SUMO-1 Protein; Survival Analysis; Ubiquitin-Conjugating Enzymes; Up-Regulation | 2010 |
UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2009 |
Small cell carcinoma of the breast.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2009 |
Comeback for the camptothecins?
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2009 |
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2010 |
MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Cytokeratin expression patterns in multiple infundibulocystic basal cell carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Basal Cell; Docetaxel; Female; Humans; Immunohistochemistry; Irinotecan; Keratins; Lung Neoplasms; Neoplasms, Second Primary; Skin Neoplasms; Taxoids | 2011 |
No effect of irinotecan in patients with resistant desmoplastic small round cell tumor.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Fibroma, Desmoplastic; Humans; Irinotecan; Male; Prognosis; Sarcoma, Small Cell | 2010 |
Treatment of gastric cancer in Asia: the missing link.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Oxonic Acid; Patient Selection; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2009 |
The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Adhesion; Cell Survival; Colonic Neoplasms; Drug Synergism; HT29 Cells; Humans; Irinotecan; Protein Kinase C; Sphingosine | 2009 |
Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.
Topics: Acetaminophen; Animals; Biological Transport; Camptothecin; Glucuronides; Hymecromone; Intestine, Small; Irinotecan; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tissue Distribution | 2010 |
An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate.
Topics: Animals; Bile Acids and Salts; Camptothecin; Disease Models, Animal; Fatty Acids; Fatty Liver; Irinotecan; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin | 2010 |
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardenolides; Colonic Neoplasms; Digitoxin; Digoxin; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Irinotecan; NF-kappa B; Proscillaridin; Strophanthins | 2009 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Models, Theoretical; Radiosurgery; Regression Analysis; Statistics as Topic; Temozolomide; Tumor Burden | 2009 |
Hypoxia-induced downregulation of autophagy mediator Beclin 1 reduces the susceptibility of malignant intestinal epithelial cells to hypoxia-dependent apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Camptothecin; Caspases; Cell Hypoxia; Cytochromes c; Down-Regulation; Drug Screening Assays, Antitumor; Epithelial Cells; Fas-Associated Death Domain Protein; High-Temperature Requirement A Serine Peptidase 2; Intestines; Intracellular Signaling Peptides and Proteins; Irinotecan; Microtubule-Associated Proteins; Mitochondria; Mitochondrial Proteins; Oxygen; Rats; Serine Endopeptidases; Vacuoles | 2009 |
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Survival Analysis; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2010 |
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Genes, ras; Genetic Testing; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Precision Medicine; Protein Kinase Inhibitors; ras Proteins; Signal Transduction; Treatment Outcome | 2009 |
[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
[A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
[Huge ascending colon carcinoma, treated successfully with S-1 plus CPT-11, followed by significant tumor reduction and curative resection--a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced rectal cancer that responded to S-1 with an extended complete response].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.
Topics: Animals; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; Gene Expression; Glucuronosyltransferase; Irinotecan; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred DBA; Mice, Inbred Strains; Sex Factors; Species Specificity | 2010 |
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Young Adult | 2010 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2009 |
Irinotecan and mismatch repair deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Carcinoma; Colorectal Neoplasms; DNA Mismatch Repair; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Humans; Irinotecan; Liver Neoplasms; Postoperative Period; Prognosis | 2010 |
Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cytokines; Enzyme Inhibitors; Humans; Irinotecan; Melanoma; Neurons; Rabbits; Stem Cells | 2010 |
PTEN status in advanced colorectal cancer treated with cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gene Deletion; Gene Dosage; Gene Expression Profiling; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Salvage Therapy; Signal Transduction; Treatment Outcome | 2010 |
CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Drug Combinations; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Silencing; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Proto-Oncogene Proteins; Tegafur | 2010 |
[Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Exanthema; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Remission Induction; Retrospective Studies | 2009 |
Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Failure | 2010 |
[Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2009 |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Metastasis; Stomach Neoplasms; Tegafur; Uracil | 2009 |
[A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Sigmoid Neoplasms | 2009 |
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colony-Forming Units Assay; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; DNA; Drug Synergism; Enzyme Induction; Female; Flavonoids; Humans; Irinotecan; Paclitaxel | 2010 |
Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression.
Topics: alpha-Crystallin B Chain; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Immunohistochemistry; Irinotecan; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor C | 2010 |
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Treatment Outcome; Vitamin B Complex | 2010 |
Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cells; Camptothecin; Carcinoma, Ehrlich Tumor; Cells, Cultured; Flavonoids; Immunologic Factors; Injections, Intraperitoneal; Irinotecan; Kidney; Liver; Macrophages, Peritoneal; Male; Mice; Micronucleus Tests; Phenols; Propolis | 2010 |
Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Drug Delivery Systems; Enzyme Inhibitors; Female; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Pancreatic Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2010 |
Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Genetic Variation; Humans; In Vitro Techniques; Irinotecan; Liver Neoplasms; Loss of Heterozygosity; Polyhydroxyethyl Methacrylate; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors | 2010 |
[Combination with SN-38 on human colon cancer LoVo cells].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; RNA, Messenger; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays | 2010 |
[Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Genes, ras; Humans; Irinotecan; Panitumumab | 2009 |
[A case of rectal cancer with lung metastases responding to cetuximab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Humans; Irinotecan; Lung Neoplasms; Male; Quality of Life; Rectal Neoplasms | 2009 |
[A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Rectal Neoplasms; Sigmoid Neoplasms | 2009 |
[Intermittent hepatic arterial infusion with systemic chemotherapy for metastatic colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intravenous; Irinotecan; Liver Neoplasms; Middle Aged | 2009 |
[A case report of multiple liver metastases from colorectal cancer effectively treated with systemic chemotherapy and hepatic arterial infusion].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Sigmoid Neoplasms; Tegafur; Uracil | 2009 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Portal Vein | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Postoperative Period; Tegafur | 2009 |
[Treatment for intrapelvic recurrence of rectal cancer--resection versus chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Pelvis; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
[A long term survivor of advanced gastric cancer treated with multi-drug combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Floxuridine; Humans; Irinotecan; Male; Paclitaxel; Stomach Neoplasms | 2009 |
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of bilateral pulmonary metastasis from gastric cancer performed radical thoracoscopic lobectomy after neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Oxonic Acid; Pneumonectomy; Stomach Neoplasms; Tegafur; Thoracoscopy | 2009 |
En bloc resection for right colon cancer directly invading duodenum or pancreatic head.
Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin.
Topics: Camptothecin; Cations; Chitosan; Drug Carriers; Irinotecan; Micelles; Nanostructures; Particle Size; Polyesters; Surface Properties | 2010 |
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Synergism; G2 Phase; Gemcitabine; Humans; Irinotecan; Isoquinolines; Mice; Mice, Nude; Mutagens; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
Irinotecan as maintenance therapy in high-risk hepatoblastoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Disease-Free Survival; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms | 2010 |
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chromosomes, Human, Pair 1; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Mutation; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Rate; Treatment Outcome | 2010 |
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Cell Hypoxia; Cysteine; Drug Delivery Systems; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Reactive Oxygen Species; RNA, Small Interfering; Selenocysteine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Individualizing dosing of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Dosage Calculations; Humans; Irinotecan; Metabolic Clearance Rate; Models, Biological; Neoplasms; Precision Medicine; Randomized Controlled Trials as Topic | 2010 |
Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers; Xenograft Model Antitumor Assays | 2010 |
Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Child; Child, Preschool; Diarrhea; Female; Gastric Mucosa; Humans; Infant; Intestinal Mucosa; Irinotecan; Male; Predictive Value of Tests; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2009 |
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cholestasis, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Duodenoscopy; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Hematoporphyrins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Photochemotherapy; Photosensitizing Agents; Stents; Treatment Outcome | 2010 |
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Topics: Animals; Autoimmune Diseases; Camptothecin; Crosses, Genetic; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Irinotecan; Lupus Nephritis; Mice; Mice, Inbred NZB; Proteinuria; Random Allocation; Survival Analysis; Time Factors; Topoisomerase I Inhibitors | 2010 |
Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; ErbB Receptors; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Vascular Endothelial Growth Factor A | 2010 |
[Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
[A case of advanced gastric cancer with a complete response to S-1 plus CPT-11 chemotherapy for eight years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Male; Oxonic Acid; Pyloric Antrum; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
[Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[S-1 + CPT-11 combination therapy with continuing 30-month CR in a recurrent gastric cancer with para-aortic lymph node metastasis in adjuvant chemotherapy with S-1--a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[A case of S-1-resistant gastric cancer with multiple bone metastases and disseminated intravascular coagulation--effective treatment by combined chemotherapy with CDDP and CPT-11].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Palliative Care; Pulmonary Embolism | 2010 |
[A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2010 |
Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Rhabdomyosarcoma; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Coculture Techniques; Colonic Neoplasms; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Interleukin-6; Irinotecan; Nitric Oxide; Recombinant Proteins; Spheroids, Cellular; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2009 |
Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract.
Topics: Animals; Camptothecin; Female; Gastrointestinal Tract; Gene Expression Profiling; Irinotecan; Oligonucleotide Array Sequence Analysis; Rats; Signal Transduction | 2010 |
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Immunoenzyme Techniques; Insulin-Like Growth Factor I; Irinotecan; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2010 |
An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Endocytosis; Fluorescent Dyes; Humans; Irinotecan; Microscopy, Electron, Transmission; Nanoparticles; Silicon Dioxide; Surface-Active Agents; X-Ray Diffraction | 2010 |
Usefulness of staging laparoscopy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Irinotecan; Maximum Tolerated Dose | 2010 |
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2010 |
A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.
Topics: Alleles; Animals; Anticholesteremic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Azetidines; Biocatalysis; Camptothecin; Dimethyl Sulfoxide; Enzyme Induction; Ezetimibe; Gene Expression; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Kinetics; Liver; Male; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Naloxone; Pharmaceutical Preparations; Phenobarbital; UDP-Glucuronosyltransferase 1A9 | 2010 |
Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Medicare; Neoplasm Metastasis; Retrospective Studies; SEER Program; Treatment Outcome; United States | 2009 |
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Proliferation; Comet Assay; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Hydroxamic Acids; Irinotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vorinostat | 2010 |
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2010 |
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Histamine H1 Antagonists; Humans; Hypersensitivity; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Premedication; Retreatment | 2010 |
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2010 |
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
[A case of early poorly-differentiated neuroendocrine carcinoma of stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Delivery Systems; Female; Glioma; Injections, Intralesional; Irinotecan; Male; Microspheres; Pilot Projects; Rats; Survival Analysis | 2010 |
Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cellular Senescence; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; Humans; Irinotecan; Mice; Osteonectin; Tumor Suppressor Protein p53 | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Simple liquid chromatography method for the quantification of irinotecan and SN38 in sheep plasma: application to in vivo pharmacokinetics after pulmonary artery chemoembolization using drug eluting beads.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Chromatography, Liquid; Drug Delivery Systems; Drug Monitoring; Humans; Irinotecan; Models, Animal; Pulmonary Artery; Sheep | 2010 |
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Neoplasms; Neutropenia; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index | 2010 |
Gene expression profile of colon cancer cell lines treated with SN-38.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis | 2010 |
[Clinical features of patients with brain metastasis from testicular germ cell tumor].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Retrospective Studies; Testicular Neoplasms; Treatment Outcome | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tongue Neoplasms | 2010 |
Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Topics: Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Pregnane X Receptor; Receptors, Steroid; Rifampin; RNA, Messenger; RNA, Small Interfering; Transfection | 2010 |
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Delivery Systems; Drug Synergism; Female; Humans; Intestinal Mucosa; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxonic Acid; RNA, Messenger; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
[Prognostic analysis of patients with liver metastases from colorectal cancer treated with different modes of therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Survival Rate; Young Adult | 2010 |
In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Comet Assay; DNA; DNA Breaks; DNA Topoisomerases, Type I; Enzyme Inhibitors; Gastrointestinal Tract; Irinotecan; Liver; Macromolecular Substances; Male; Pilot Projects; Rats; Rats, Wistar; Reproducibility of Results; Topoisomerase I Inhibitors | 2010 |
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2010 |
[Allicin enhances cytotoxicity of CPT-11 to colon cancer LoVo cell in vitro].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disulfides; Humans; Irinotecan; Models, Biological; Sulfinic Acids | 2009 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Duodenal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Ileal Neoplasms; Intestine, Small; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2010 |
Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Disease-Free Survival; Humans; Irinotecan; Patient Selection; Precision Medicine; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
[A case of small cell lung cancer (extensive disease) with liver metastasis acquiring stable disease by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma | 2010 |
[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
[A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
Assessment of cyto/genotoxicity of irinotecan in v79 cells using the comet, micronucleus, and chromosome aberration assay.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cells, Cultured; Chromosome Aberrations; Comet Assay; Cricetinae; Cricetulus; Irinotecan; Micronucleus Tests; Mutagenicity Tests | 2010 |
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Glucuronidase; Glucuronosyltransferase; Intestinal Mucosa; Irinotecan; Male; Penicillin G; Rats; Rats, Gunn; Rats, Wistar; Streptomycin; Time Factors | 2011 |
Bevacizumab in recurrent high-grade pediatric gliomas.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Young Adult | 2010 |
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Disease Progression; DNA-Binding Proteins; Female; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tissue Array Analysis; Topoisomerase I Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2010 |
Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Hydrogen-Ion Concentration; Irinotecan; Particle Size; Porosity; Silicon Dioxide; Solubility; Solutions; Thermodynamics | 2010 |
[Prognostic factors and survival of metastatic colorectal cancer in the Sousse University Hospital (Tunisia): comparative study of two treatment period of 200 patients].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tunisia; Young Adult | 2010 |
Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Choroid Neoplasms; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2010 |
Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Inhibitory Concentration 50; Irinotecan; Nitrogen; Solubility; Water | 2010 |
Establishment and characterization of multidrug-resistant gastric cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Cell Cycle; Cell Line, Tumor; Death-Associated Protein Kinases; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2010 |
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Deoxycytidine; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Irinotecan; Killer Cells, Lymphokine-Activated; Mutation; Panitumumab; Up-Regulation | 2010 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Squamous Cell; Survival Rate; Uterine Cervical Neoplasms | 2010 |
[A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoplasm Staging; Recurrence; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Implants; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Survival Analysis; Tissue Distribution | 2011 |
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Competence; Colorectal Neoplasms; Dermatology; Drug Eruptions; Humans; Irinotecan; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Pilot Projects | 2010 |
Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fatty Liver; Female; Humans; Irinotecan; Liver Circulation; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Recovery of Function; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Different DNA immobilization strategies for the interaction of anticancer drug irinotecan with DNA based on electrochemical DNA biosensors.
Topics: Adsorption; Animals; Antineoplastic Agents; Biosensing Techniques; Camptothecin; DNA; Electrochemistry; Electrodes; Fishes; Graphite; High-Throughput Screening Assays; Irinotecan; Male; Oligonucleotides; Oxidation-Reduction; Sensitivity and Specificity; Spermatozoa; Surface Properties | 2010 |
Pharmacokinetics of intraperitoneal irinotecan in a pig model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Dose-Response Relationship, Drug; Female; Irinotecan; Peritoneal Neoplasms; Swine | 2010 |
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
Topics: Apoptosis; Benzimidazoles; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; I-kappa B Proteins; Irinotecan; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Simvastatin; Staining and Labeling; Substrate Specificity | 2011 |
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Disease Models, Animal; Dogs; Drug Delivery Systems; Glioma; Irinotecan; Liposomes; Magnetic Resonance Imaging; Nanoparticles | 2010 |
[A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-11 proved very effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Gastroscopy; Humans; Irinotecan; Male; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
Topics: Adult; Aged; Alabama; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Czech Republic; Female; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Kentucky; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Registries; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Quebec; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Neoplasm; Indoles; Irinotecan; Mice; Mitoxantrone; Polymorphism, Single Nucleotide; Protein Multimerization; Transfection | 2010 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Epidermal Growth Factor; Fluorouracil; Glutathione; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrrolidonecarboxylic Acid; Thiazolidines; Vascular Endothelial Growth Factor A | 2010 |
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Gene Frequency; Genotype; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Panitumumab; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Skin; Treatment Outcome | 2010 |
Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.
Topics: Amino Acid Transport Systems; Animals; Camptothecin; Cell Line, Tumor; Cystine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2010 |
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Pancreatic Neoplasms; Topotecan | 2010 |
[Third-line CPT-11 chemotherapy for gastric cancer cases of non-curative gastrectomy or recurrence].
Topics: Aged; Antineoplastic Agents; Camptothecin; Female; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Recurrence; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2010 |
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].
Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy | 2010 |
The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Micelles; Xenograft Model Antitumor Assays | 2010 |
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Incidence; Intestinal Diseases; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Drug Combinations; Erlotinib Hydrochloride; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2010 |
P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Biotransformation; Camptothecin; Carboxylic Acids; Female; Genotype; Injections, Intravenous; Irinotecan; Lactones; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Multidrug Resistance-Associated Proteins; Phenotype | 2010 |
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Genotype; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome | 2011 |
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan | 2010 |
Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Transplantation, Heterologous | 2010 |
Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan.
Topics: Absorption; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capsules; Delayed-Action Preparations; Diffusion; Doxorubicin; Drug Combinations; Drug Compounding; Embolization, Therapeutic; Hardness; Irinotecan | 2010 |
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Compassionate Use Trials; Denmark; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sunitinib; Treatment Outcome | 2010 |
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Failure | 2011 |
Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes.
Topics: Amino Acid Sequence; Animals; Camptothecin; Coumarins; Estradiol; Gene Expression; Glucuronosyltransferase; Humans; Irinotecan; Macaca fascicularis; Molecular Sequence Data; Recombinant Proteins; Sequence Alignment | 2010 |
Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comet Assay; DNA Repair; Humans; Irinotecan; Lung Neoplasms; Mutagens; Organoplatinum Compounds | 2010 |
[A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Irinotecan; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.
Topics: Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chromatography; Cocaine; Heroin; Humans; Hydrolysis; Intestines; Irinotecan; Kinetics; Liver; Models, Molecular; Molecular Structure; Protein Conformation; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2010 |
Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cetuximab; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies | 2010 |
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Enzyme Inhibitors; Gene Frequency; Genotype; Humans; Irinotecan; Japan; Multivariate Analysis; Neoplasms; Polymorphism, Single Nucleotide | 2010 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Glucuronosyltransferase; Health Surveys; Humans; Irinotecan; Mitomycin; Neutropenia; Organoplatinum Compounds; Pyridines; Risk Factors; State Medicine; United Kingdom | 2010 |
Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Biological Availability; Biological Transport; Biotransformation; Camptothecin; Cell Line; Chemistry, Pharmaceutical; Dogs; Drug Carriers; Drug Compounding; Epithelial Cells; Injections, Intravenous; Intestinal Mucosa; Intestines; Irinotecan; Lecithins; Male; Micelles; Novobiocin; Polyethylene Glycols; Propylene Glycols; Rats; Rats, Sprague-Dawley; Transfection | 2010 |
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Brain Neoplasms; Camptothecin; Cell Hypoxia; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prospective Studies | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
Effects of methimazole on the elimination of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antithyroid Agents; Camptothecin; Colorectal Neoplasms; Drug Interactions; Glucuronides; Glucuronosyltransferase; Graves Disease; Humans; Irinotecan; Male; Methimazole; Middle Aged | 2011 |
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Colon; DNA Primers; Female; Gastroenteritis; Gene Expression; Inflammation Mediators; Intestinal Mucosa; Irinotecan; Jejunum; Matrix Metalloproteinases; Mucositis; Plasminogen; Rats; RNA, Messenger; Tissue Inhibitor of Metalloproteinases | 2010 |
Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, Liquid; Drug Monitoring; Glucuronides; Humans; Irinotecan; Reproducibility of Results; Tandem Mass Spectrometry | 2010 |
When more is worse in clinical research and clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomedical Research; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Panitumumab; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reproducibility of Results | 2010 |
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs.
Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dehydroascorbic Acid; Docetaxel; Drug Synergism; Epirubicin; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2011 |
Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
Topics: Acetonitriles; Camptothecin; Chromatography, Liquid; Colorectal Neoplasms; Drugs, Chinese Herbal; Formates; Humans; Irinotecan; Tandem Mass Spectrometry | 2010 |
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Retrospective Studies | 2010 |
Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Administration Schedule; Endocrine Gland Neoplasms; Etoposide; Gemcitabine; Humans; Ileus; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Neuroblastoma; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors | 2010 |
Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Caseins; Colloids; Docetaxel; Drug Carriers; Drug Compounding; Drug Stability; Hydrogen-Ion Concentration; Irinotecan; Molecular Structure; Nanoparticles; Paclitaxel; Particle Size; Structure-Activity Relationship; Taxoids; Vinblastine | 2010 |
Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Medullary; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, Nude; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Proto-Oncogenes; RNA, Small Interfering; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
Topics: Animals; Antimetabolites; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cell Line, Tumor; Cytosine Deaminase; Female; Flucytosine; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Ovarian Neoplasms; Prodrugs; Stem Cells | 2010 |
Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
Topics: Antineoplastic Agents; Biotransformation; Camptothecin; Carboxylesterase; Chronic Disease; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Down-Regulation; Humans; Irinotecan; Liver Diseases; Microsomes, Liver | 2010 |
[A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
[A case of irinotecan-induced interstitial pneumonia during treatment of recurrent colon cancer].
Topics: Aged; Camptothecin; Fatal Outcome; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Rectal Neoplasms; Recurrence; Tomography, X-Ray Computed | 2010 |
Are herbal medicines ripe for the cancer clinic?
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Complementary Therapies; Gastrointestinal Tract; Herbal Medicine; Humans; Irinotecan; Mice; Neoplasms | 2010 |
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; beta Catenin; Biomarkers, Tumor; Bromodeoxyuridine; Camptothecin; Cell Proliferation; DNA Damage; Drugs, Chinese Herbal; Gastrointestinal Tract; Glucuronidase; Humans; Inflammation; Irinotecan; Medicine, Chinese Traditional; Mice; Proliferating Cell Nuclear Antigen; Recovery of Function; Signal Transduction; Stem Cells; Transplantation, Homologous; Weight Loss; Wnt Proteins; Wnt3 Protein; Wnt3A Protein | 2010 |
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Delivery Systems; Feasibility Studies; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
[Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Male; Neoplasm Recurrence, Local; Sensitivity and Specificity; Vascular Endothelial Growth Factor A | 2010 |
Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Chromatography, High Pressure Liquid; Colonic Neoplasms; Disease Models, Animal; Humans; Irinotecan; Kaplan-Meier Estimate; Liver; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Colonic Neoplasms; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Interactions; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2011 |
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Disease Progression; Drug Combinations; Female; Health Status Indicators; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Treatment Failure | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2010 |
Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Female; Humans; Infusions, Parenteral; Irinotecan; Male; Models, Theoretical; Neoplasm Seeding; Stomach Neoplasms | 2010 |
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Intestine, Small; Irinotecan; Kidney; Microsomes; Organ Specificity | 2011 |
Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Nucleus; Cell Proliferation; Dendrimers; Drug Stability; HCT116 Cells; Humans; Irinotecan; Rats | 2010 |
Cetuximab in small bowel adenocarcinoma: a new friend?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Female; Humans; Immunotherapy; Intestinal Neoplasms; Intestine, Small; Irinotecan; Male; Middle Aged; Survival | 2010 |
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine | 2010 |
Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Follow-Up Studies; Humans; Irinotecan; Leukocyte Count; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platelet Count; Sigmoid Neoplasms; Thrombocytopenia | 2011 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2011 |
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dietary Supplements; Drug-Related Side Effects and Adverse Reactions; Fatty Liver; Female; Fluorouracil; Glycine; Immunohistochemistry; Irinotecan; Kupffer Cells; Leucovorin; Liver; Microcirculation; Neoadjuvant Therapy; Nitric Oxide Synthase Type II; Organoplatinum Compounds; Oxaliplatin; Phagocytosis; Rats; Rats, Sprague-Dawley; Transaminases | 2011 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Female; Follow-Up Studies; Hepatic Artery; Humans; Irinotecan; Male; Middle Aged; Prodrugs; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8.
Topics: Animals; Camptothecin; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Irinotecan; Lung Neoplasms; Mesoderm; Mice; Mice, Inbred C3H; Osteosarcoma; Signal Transduction | 2010 |
18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colectomy; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Period; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; ROC Curve; Treatment Outcome | 2011 |
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Guanine; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fever; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Irinotecan; Male; Mannose-Binding Lectin; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic | 2010 |
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infant; Irinotecan; Male; Neuroblastoma; Retrospective Studies; Vincristine | 2011 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Use of irinotecan for treatment of small cell carcinoma of the prostate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Therapy, Combination; Humans; Irinotecan; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Subrenal Capsule Assay | 2011 |
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Association Studies; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Japan; Leucovorin; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prodrugs; Retrospective Studies; Survival Analysis; Topoisomerase I Inhibitors | 2011 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Research Design; Survival Rate; Tomography, X-Ray Computed | 2010 |
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Focal Nodular Hyperplasia; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2011 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection | 2010 |
Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome | 2010 |
Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fluorescence; Irinotecan; Lasers; Pharmaceutical Preparations; Photochemistry; Sensitivity and Specificity; Spectrometry, Fluorescence; Topotecan | 2010 |
Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; Lymphoma, T-Cell; Mice; Protein Kinases; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Models, Biological; Naphthalenes; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays | 2010 |
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Female; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Prodrugs; Random Allocation; Sulfonamides; Topoisomerase I Inhibitors; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2011 |
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome | 2011 |
Cancer. Targeting bacteria to improve cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Glucuronidase; Intestinal Mucosa; Irinotecan; Mice | 2010 |
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria, Anaerobic; Camptothecin; Cell Line, Tumor; Colon; Crystallography, X-Ray; Diarrhea; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Female; Glucuronidase; Humans; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred BALB C; Models, Molecular; Prodrugs; Protein Conformation | 2010 |
Guesstimates are not good enough for determining what is happening in routine care.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan | 2010 |
[A rare case of large cell neuroendocrine carcinoma of the thymus].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Thymus Neoplasms | 2010 |
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Treatment Outcome | 2011 |
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy; Survival Rate; Treatment Outcome | 2011 |
[Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Antagonism; Drug Synergism; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2010 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Hematologic Diseases; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Risk Factors; Tegafur | 2010 |
[A case of complete resection of a squamous cell lung cancer invading diaphragm after neoadjuvant chemotherapy of nedaplatin and irinotecan].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Diaphragm; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pneumonectomy | 2010 |
[Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron after chemotherapy including irinotecan].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Iron; Transferrin | 2010 |
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Irinotecan; Male; Matrix Metalloproteinase 7; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Colorectal Neoplasms; Dendrimers; Humans; Irinotecan | 2011 |
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Genotype; Humans; Irinotecan; Kaplan-Meier Estimate; Magnesium; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2011 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Failure | 2011 |
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.
Topics: Adenocarcinoma, Clear Cell; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Postoperative Period; Purpura, Thrombocytopenic, Idiopathic | 2011 |
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endocytosis; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; MicroRNAs; National Cancer Institute (U.S.); Nucleosides; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; United States | 2010 |
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; HCT116 Cells; Humans; Imidazoles; Immunohistochemistry; Irinotecan; Isoenzymes; Leucovorin; MAP Kinase Signaling System; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Xenograft Model Antitumor Assays | 2011 |
Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Body Weight; Brain; Camptothecin; Dose-Response Relationship, Radiation; Half-Life; Irinotecan; Male; Models, Statistical; Nonlinear Dynamics; Rats; Rats, Sprague-Dawley | 2011 |
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Topics: Acneiform Eruptions; Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; ras Proteins; Rectal Neoplasms; Remission Induction; Survival Rate | 2010 |
Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Camptothecin; Carcinoma, Neuroendocrine; Cell Proliferation; Drug Carriers; Female; Flow Cytometry; Gastrointestinal Agents; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred ICR; Mice, Nude; Octreotide; Receptors, Somatostatin; Thyroid Neoplasms; Tumor Cells, Cultured | 2011 |
Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2-dimethyl hydrazine induced colorectal carcinoma in rats.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Camptothecin; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Irinotecan; Kaempferols; Lipid Peroxidation; Male; Rats; Rats, Wistar; Species Specificity | 2011 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany; Health Status Indicators; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Irinotecan injures tight junction and causes bacterial translocation in rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Translocation; Camptothecin; Claudin-1; Diarrhea; Intestinal Mucosa; Irinotecan; Male; Membrane Proteins; Occludin; Permeability; Rats; Rats, Wistar; RNA, Messenger; Tight Junctions; Weight Loss | 2012 |
The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.
Topics: Animals; Antineoplastic Agents; Calcimycin; Camptothecin; Cell Membrane Permeability; Chemistry, Pharmaceutical; Cholesterol; Chromatography, High Pressure Liquid; Copper; Female; Ionophores; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Phosphatidylcholines | 2011 |
Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Carriers; Folic Acid; Injections, Intravenous; Irinotecan; Lactic Acid; Molecular Structure; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Surface Properties; Tissue Distribution | 2011 |
Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Retrospective Studies; Treatment Outcome | 2010 |
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proportional Hazards Models; Radiography; Vascular Endothelial Growth Factor A | 2011 |
Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Camptothecin; Cell Separation; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice; Mice, SCID; Mutation; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2011 |
Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Drug Administration Schedule; Female; Flow Cytometry; Humans; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Sarcoma; Ultrasonic Therapy; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Rate; Treatment Outcome | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Genes, ras; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Mutation; Prognosis; Receptor, ErbB-3; Retrospective Studies; Treatment Outcome | 2011 |
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Topics: Acridines; Acridones; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Transplantation, Heterologous | 2011 |
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
Topics: Acridones; Antineoplastic Agents; Camptothecin; Cell Cycle Checkpoints; Cell Survival; Chromones; Cisplatin; Colonic Neoplasms; Comet Assay; DNA-Activated Protein Kinase; Drug Synergism; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Morpholines; Organoplatinum Compounds; Protein Kinase Inhibitors; Pyridines; Topoisomerase I Inhibitors | 2012 |
A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Heart Arrest; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Panitumumab | 2010 |
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Anisotropy; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Diffusion Tensor Imaging; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2012 |
[Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged | 2010 |
[A case of small cell carcinoma of esophagus treated by chemotherapy with CDDP plus CPT-11 and radiotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Irinotecan; Lymphatic Metastasis | 2010 |
[A case of pneumocystis pneumonia during chemotherapy for gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dexamethasone; Drug Combinations; Fatal Outcome; Glucocorticoids; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pneumonia, Pneumocystis; Stomach Neoplasms; Tegafur; Trimethoprim, Sulfamethoxazole Drug Combination | 2010 |
[A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A successful case with CPT-11 + CDDP chemotherapy for recurrent gastric cancer of the remnant stomach].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastrectomy; Gastric Stump; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Stomach Neoplasms | 2010 |
[A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[Two cases of gastric endocrine cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Endocrine Gland Neoplasms; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of gastric endocrine cell carcinoma with liver metastases treated with S-1/CDDP].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Endocrine Gland Neoplasms; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[The efficacy of cetuximab for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Rectal Neoplasms; Sigmoid Neoplasms | 2010 |
[A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
[Adrenalectomy for solitary adrenal metastasis from colorectal cancer].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Humans; Irinotecan; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2010 |
[A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Tegafur; Uracil | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
[Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Hepatectomy; Humans; Irinotecan; Length of Stay; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Tegafur; Uracil | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxonic Acid; Tegafur; Tumor Burden | 2010 |
[A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Pelvis; Rectal Neoplasms; Tegafur; Vitamin B Complex | 2010 |
[An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Length of Stay; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Rectal Neoplasms; Sacrum; Tegafur; Uracil; Vitamin B Complex | 2010 |
[A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Colostomy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Pyrimidines; Radiotherapy, Adjuvant; Survival Rate | 2011 |
Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-κB pathway.
Topics: Animals; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Survival; Cells, Cultured; Clopidogrel; Down-Regulation; Enzyme Inhibitors; Genes, Reporter; Humans; Hydrolysis; Irinotecan; Lipopolysaccharides; Male; Mice; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Platelet Aggregation Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Subcellular Fractions; Ticlopidine; Transfection | 2011 |
Feasibility of EUS-guided injection of irinotecan-loaded microspheres into the swine pancreas.
Topics: Animals; Camptothecin; Feasibility Studies; Injections; Irinotecan; Microspheres; Necrosis; Pancreas; Swine; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Ultrasonography, Interventional | 2011 |
Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Small Cell; Female; Fever; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Neutropenia; Renal Dialysis; Treatment Outcome | 2011 |
Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Microspheres; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2011 |
Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Fatal Outcome; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Angiography; Male; Neoplasm Recurrence, Local; Spin Labels | 2011 |
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis.
Topics: 14-3-3 Proteins; Actins; Animals; Camptothecin; Colon; Disease Models, Animal; Gene Expression Regulation; Glyceraldehyde-3-Phosphate Dehydrogenases; Irinotecan; Jejunum; Male; Matrix Metalloproteinase 2; Molecular Chaperones; Mucositis; Rats; Succinate Dehydrogenase; Ubiquitin C; Up-Regulation | 2011 |
Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cetuximab; Cyclin-Dependent Kinase Inhibitor p16; Down-Regulation; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Signal Transduction; Stomach Neoplasms; Tumor Suppressor Protein p53; Up-Regulation | 2011 |
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Genetic | 2011 |
Proteomic analysis of cell lines to identify the irinotecan resistance proteins.
Topics: Aldehyde Reductase; Amino Acid Sequence; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Irinotecan; Molecular Sequence Data; Prodrugs; Proteome; Two-Dimensional Difference Gel Electrophoresis | 2010 |
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Preoperative Period; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Time Factors | 2012 |
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Body Fluids; Caco-2 Cells; Camptothecin; Drug Compounding; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Stability; Electric Conductivity; Excipients; Humans; Irinotecan; Lipids; Nanocapsules; Particle Size; Solubility; Topoisomerase I Inhibitors; Transendothelial and Transepithelial Migration | 2011 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Epistaxis; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Proteinuria; Retrospective Studies; Tegafur; Thrombosis; Treatment Outcome | 2011 |
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Disease-Free Survival; Female; History, 17th Century; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Retrospective Studies; Stomach Neoplasms | 2011 |
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Palliative Care; Proportional Hazards Models; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Platinum Compounds; Retrospective Studies; Stomach Neoplasms; Taxoids | 2011 |
Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Bystander Effect; Camptothecin; Combined Modality Therapy; Genetic Therapy; Genetic Vectors; Glucuronates; Glucuronidase; Humans; Irinotecan; Neoplasms; Prodrugs; Tumor Cells, Cultured | 2011 |
Spectrofluorimetric determination of SN-38, a promising new anti-tumor agent, in the presence and absence of organized media.
Topics: Antineoplastic Agents; Camptothecin; Cyclodextrins; Humans; Irinotecan; Spectrometry, Fluorescence; Surface-Active Agents | 2011 |
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA Damage; Drug Synergism; G-Quadruplexes; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Telomere; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
[Analysis of gene expression patterns in an irinotecan-resistance colon cancer cell by cDNA microarray].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Transcriptome; Zinc Fingers | 2011 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Disorders; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Stomach Neoplasms | 2011 |
Barking up the wrong genome--we are not alone.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Mice; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs; Topoisomerase I Inhibitors | 2011 |
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Macaca fascicularis; Male; Mice; Mice, Nude; Models, Biological; Monkey Diseases; Neoplasms, Glandular and Epithelial; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Three-drug combination regimen in pancreatic cancer treatment: are we there yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Camptothecin; Cell Proliferation; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Blotting, Western; Camptothecin; Cation Transport Proteins; Cell Proliferation; Cells, Cultured; Copper-Transporting ATPases; Drug Synergism; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Indazoles; Irinotecan; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
[A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Camptothecin; Carcinoma; Fatal Outcome; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Respiratory Insufficiency; Tomography, X-Ray Computed | 2011 |
[Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Irinotecan; Kidney Failure, Chronic; Male; Neoplasm Staging; Palliative Care; Renal Dialysis; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of drug-induced interstitial pneumonia caused by S-1 and CPT-11 combination therapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Fatal Outcome; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2011 |
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Topics: Animals; Antigens; Antineoplastic Agents; Benzimidazoles; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Etoposide; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Peptides; T-Lymphocytes, Cytotoxic | 2011 |
Few positives for triple-negative breast cancer.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Chemistry, Pharmaceutical; Disease-Free Survival; Epothilones; Female; Genes, BRCA1; Humans; Irinotecan; Parity; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Treatment Outcome; Tubulin Modulators | 2011 |
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies | 2011 |
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Salvage Therapy | 2011 |
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2011 |
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin D1; Drug Therapy, Combination; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2011 |
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Differentiation; Colonic Neoplasms; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Spheroids, Cellular; Time Factors; Topoisomerase I Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Proliferation; Collagen Type IV; Colon; Dose-Response Relationship, Drug; Extracellular Matrix; Female; Fibronectins; Irinotecan; Jejunum; Laminin; Models, Animal; Rats; Rats, Inbred Strains; Time Factors | 2011 |
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Camptothecin; Cell Line, Tumor; Female; Humans; Immunotoxins; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2011 |
A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Automation; Camptothecin; Cytochrome P-450 CYP2C19; Diagnostic Tests, Routine; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Point-of-Care Systems; Polymorphism, Single Nucleotide; Proton Pump Inhibitors | 2011 |
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Capillary Permeability; Cell Line, Tumor; Chemistry, Pharmaceutical; DNA-Binding Proteins; Doxorubicin; Glioblastoma; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Knockout; Nanoparticles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays | 2011 |
New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Drug Design; Female; Fibrin; Immunotoxins; Irinotecan; Mice; Neoplasms, Experimental | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Topics: Abdominal Wall; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Hyaluronan Receptors; Hyaluronic Acid; Inhibitory Concentration 50; Injections, Intraperitoneal; Irinotecan; Male; Neoplasm Transplantation; Peritoneal Neoplasms; Random Allocation; Rats; Rats, Inbred Strains | 2011 |
Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Line, Tumor; Cetuximab; Contrast Media; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, SCID; Pancreatic Neoplasms; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Acneiform eruption following molecular targeted chemotherapy.
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Gene Targeting; Humans; Irinotecan; Male; Middle Aged | 2011 |
[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Self Evaluation; Fatigue; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Surveys and Questionnaires | 2011 |
APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Genetic Association Studies; Humans; Irinotecan; Linkage Disequilibrium; Methotrexate; Neoplasms; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Slovakia | 2011 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Palliative Care; Prognosis; Radionuclide Imaging; Stomach Neoplasms; Treatment Outcome | 2011 |
Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fibromatosis, Abdominal; Fibromatosis, Aggressive; Fluorouracil; Humans; Irinotecan; Leucovorin; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Methylation; Female; Genes, erbB-1; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Promoter Regions, Genetic; Treatment Outcome | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Hypersensitivity; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasms; Pneumonia; Product Surveillance, Postmarketing; Pulmonary Alveoli; Steroids; Tomography, X-Ray Computed | 2011 |
Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Topics: Acrylonitrile; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; HCT116 Cells; Humans; Irinotecan; K562 Cells; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Proteins; Neoplasms; Xenograft Model Antitumor Assays | 2011 |
[A resected case of advanced gastric cancer with multiple liver metastasis successfully treated by preoperative and postoperative S-1/CPT-11 combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Transplantation; DNA Primers; Drug Carriers; Drug Evaluation, Preclinical; Female; Genes, Transgenic, Suicide; Irinotecan; Lung Neoplasms; Magnetics; Melanoma; Mice; Mice, Inbred C57BL; Monocyte-Macrophage Precursor Cells; Nanoparticles; Prodrugs | 2012 |
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Interactions; Drugs, Chinese Herbal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Immunity; Immunohistochemistry; Inflammation; Irinotecan; Liver; Macrophages; Medicine, Chinese Traditional; Mice; Organ Size; Polymerase Chain Reaction; Reproducibility of Results; RNA, Messenger; Signal Transduction; Spleen; Tumor Microenvironment | 2011 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Development of thermosensitive poly(n-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release.
Topics: Absorption; Animals; Antineoplastic Agents; Camptothecin; Cell Death; Delayed-Action Preparations; Endocytosis; Female; Fluorescence; HT29 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Methacrylates; Mice; Mice, Inbred BALB C; Nanoparticles; Nanotechnology; Particle Size; Polymethacrylic Acids; Static Electricity; Temperature; Thermogravimetry | 2011 |
Esophageal small-cell carcinoma with syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Fatal Outcome; Humans; Hyponatremia; Inappropriate ADH Syndrome; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Paraneoplastic Endocrine Syndromes | 2011 |
Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Capsules; Female; Half-Life; Irinotecan; Lipids; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polyethylene Glycols; Prostatic Neoplasms; Technology, Pharmaceutical | 2011 |
Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Colonic Neoplasms; Drug Combinations; Drug Compounding; Drug Synergism; HT29 Cells; Humans; Irinotecan; Liposomes; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Orotic Acid; Particle Size; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Colorectal Neoplasms; Culture Media; Ethanol; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Plant Extracts; Seaweed; Undaria; Xanthophylls | 2012 |
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; Retrospective Studies; Tumor Burden | 2012 |
Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Camptothecin; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Humans; Irinotecan; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors | 2011 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2011 |
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Risk; Survival Analysis; Vitamin B Complex | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Activity of aspirin analogues and vanillin in a human colorectal cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Benzaldehydes; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Humans; Inhibitory Concentration 50; Irinotecan | 2011 |
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography | 2011 |
Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ehrlich Tumor; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Flavanones; Hepatocytes; Injections, Intraperitoneal; Irinotecan; Kidney; Male; Mice; Peritoneal Cavity; Quercetin | 2011 |
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms | 2011 |
Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart.
Topics: Actin Depolymerizing Factors; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Image Processing, Computer-Assisted; Irinotecan; Molecular Sequence Data; Neoplasm Proteins; Phosphopyruvate Hydratase; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; CDC2 Protein Kinase; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myb; Pyrimidines; Recombinant Proteins; RNA, Small Interfering; Thiazoles; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Pulmonary artery chemoembolization in a sheep model: Evaluation of performance and safety of irinotecan eluting beads (DEB-IRI).
Topics: Animals; Camptothecin; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Irinotecan; Microspheres; Pharmacokinetics; Pulmonary Artery; Sheep; Tissue Distribution; Topoisomerase I Inhibitors | 2011 |
Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Diagnosis, Differential; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis; Thymus Neoplasms; Treatment Outcome | 2011 |
The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum.
Topics: Animals; Antineoplastic Agents; Camptothecin; Circadian Rhythm; Female; Gene Expression Regulation; Ileum; Intestinal Mucosa; Irinotecan; Male; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; RNA, Messenger; Sex Characteristics; Species Specificity | 2011 |
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Statistics as Topic | 2011 |
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Research Design | 2011 |
[Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Recurrence; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2011 |
[Primary adenocarcinoma of small intestine with peritoneal dissemination treated with S-1 and CPT-11 combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Duodenal Neoplasms; Fatal Outcome; Female; Humans; Irinotecan; Jejunal Neoplasms; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Humans; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Treatment Outcome | 2011 |
Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colonic Neoplasms; Fatal Outcome; Genotype; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Risk Factors | 2011 |
Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; Female; Humans; Irinotecan; Keratitis; Lung Neoplasms; Ophthalmic Solutions | 2011 |
Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Methotrexate; Organophosphorus Compounds; Surface Properties; Tandem Mass Spectrometry; Vincristine | 2012 |
Sex and dosing-time dependencies in irinotecan-induced circadian disruption.
Topics: Animals; Antineoplastic Agents; Body Temperature; Camptothecin; Circadian Rhythm; CLOCK Proteins; Corticosterone; Drug Administration Schedule; Female; Gene Expression Regulation; Irinotecan; Liver; Male; Mice; Motor Activity; Sex Characteristics | 2011 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; HCT116 Cells; Hep G2 Cells; Humans; Inactivation, Metabolic; Irinotecan; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Signal Transduction; Up-Regulation; Xenobiotics | 2011 |
In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stability; Intestinal Absorption; Intestinal Mucosa; Intestines; Irinotecan; Male; Perfusion; Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Verapamil | 2011 |
Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins B-raf; Xenograft Model Antitumor Assays | 2011 |
Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Gene Expression; Glutamates; Guanine; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Vinblastine; Vinorelbine | 2011 |
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Silencing; Humans; Irinotecan; MAP Kinase Kinase Kinases; Mice; Mice, Nude; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
First-order multivariate calibration applied to the simultaneous fluorometric determination of the anticancer agents CPT-11 and SN-38 in serum and urine samples.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Calibration; Camptothecin; Fluorometry; Humans; Irinotecan; Multivariate Analysis; Time Factors; Urinalysis | 2011 |
Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Collagen; Endothelium, Vascular; Female; Immunoconjugates; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms; Polyethylene Glycols; Stromal Cells; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Genes, ras; Humans; Irinotecan; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Pyridines; Treatment Failure; Vascular Endothelial Growth Factor A | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Treatment Outcome | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur | 2011 |
[Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Camptothecin; Chlorpheniramine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2011 |
[A case of interstitial pneumonia induced by CPT-11 for local recurrence of rectal cancer].
Topics: Camptothecin; Combined Modality Therapy; Fatal Outcome; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Rectal Neoplasms; Recurrence | 2011 |
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Neoplasm Seeding; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Second-Look Surgery; Tumor Burden; Young Adult | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Camptothecin; Cell Line, Tumor; Female; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Shiga Toxins; Topoisomerase I Inhibitors | 2011 |
Irinotecan as a second-line monotherapy for small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Using bevacizumab in the fight against malignant glioma: first results in Asian patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asian People; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2011 |
PDZK1 regulates breast cancer resistance protein in small intestine.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cimetidine; Intestinal Absorption; Intestine, Small; Intracellular Signaling Peptides and Proteins; Irinotecan; Kidney; Male; Membrane Proteins; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Protein Interaction Domains and Motifs | 2011 |
[Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy | 2011 |
[A case of advanced gastric cancer with multiple liver metastasis responding to S-1 and irinotecan combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Comparative Effectiveness Research; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Analysis; Treatment Outcome; United States | 2011 |
The polypyrimidine/polypurine motif in the mouse mu opioid receptor gene promoter is a supercoiling-regulatory element.
Topics: Animals; Binding Sites; Camptothecin; Cell Line, Tumor; DNA; Gene Expression Regulation; Humans; Irinotecan; Luciferases; Mice; Microscopy, Atomic Force; Nucleic Acid Conformation; Promoter Regions, Genetic; Purine Nucleotides; Pyrimidine Nucleotides; Receptors, Opioid, mu; Regulatory Sequences, Nucleic Acid; Reverse Transcriptase Polymerase Chain Reaction; Spectrum Analysis, Raman; Topoisomerase I Inhibitors | 2011 |
Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.
Topics: Antineoplastic Agents; Camptothecin; Carboxylesterase; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Glucuronosyltransferase; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Irinotecan; Phosphorylation; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Transcriptional Activation | 2011 |
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Comorbidity; Drug Approval; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2011 |
Total synthesis of 7-ethyl-10-hydroxycamptothecin (SN38) and its application to the development of C18-functionalized camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Female; HCT116 Cells; HeLa Cells; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Prodrugs; Structure-Activity Relationship | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Rectal Neoplasms; Statistics, Nonparametric; Transketolase; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Body Surface Area; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Five hundred patients with Merkel cell carcinoma evaluated at a single institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Merkel Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Infusion Pumps; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Research Design; Skin Neoplasms; Treatment Outcome | 2011 |
Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
Topics: Animals; Camptothecin; Glucuronides; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Thienamycins | 2011 |
Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radionuclide Imaging | 2011 |
Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase.
Topics: Animals; Camptothecin; Carboxylesterase; Cerebellar Neoplasms; Genetic Therapy; Humans; Irinotecan; Male; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neural Stem Cells; Prognosis; Rabbits; Random Allocation; Xenograft Model Antitumor Assays | 2011 |
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Chromatography, High Pressure Liquid; Cysteine; Drug Synergism; Female; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Organoselenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays | 2011 |
Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Interactions; Drug Monitoring; Female; Genital Neoplasms, Female; Humans; International Normalized Ratio; Irinotecan; Middle Aged; Thromboembolism; Treatment Outcome; Venous Thrombosis; Warfarin | 2011 |
Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.
Topics: Animals; ATP-Binding Cassette Transporters; Base Sequence; Body Weight; Camptothecin; Cell Line; DNA Primers; Fluorouracil; Humans; Intestinal Absorption; Irinotecan; Male; Phosphorylation; Polymerase Chain Reaction; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger | 2011 |
Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study.
Topics: Anastomosis, Surgical; Anastomotic Leak; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Fluorouracil; Hydroxyproline; Irinotecan; Male; Neovascularization, Physiologic; Pressure; Rats; Rats, Wistar; Rupture; Tissue Adhesions; Wound Healing | 2011 |
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Topics: Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Female; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide | 2011 |
Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathepsins; Cell Line, Tumor; Colon; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Gene Expression; Humans; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Genetic Testing; Germany; Humans; Irinotecan; Leucovorin; Markov Chains; Monte Carlo Method; Mutation; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States | 2012 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Case-Control Studies; Cell Line, Tumor; Colonic Neoplasms; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Knockdown Techniques; HCT116 Cells; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger | 2012 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Female; Fluorouracil; High-Throughput Screening Assays; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
[CPT-11 chemotherapy for a hemodialysis patient with small-cell lung cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Male; Renal Dialysis; Small Cell Lung Carcinoma | 2011 |
[Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Salvage Therapy; Stomach Neoplasms | 2011 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Fluorouracil; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Transcription Factors; Treatment Outcome | 2012 |
A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.
Topics: Antineoplastic Agents, Phytogenic; Caco-2 Cells; Camptothecin; Circadian Rhythm; Circadian Rhythm Signaling Peptides and Proteins; Computational Biology; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Chronotherapy; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Models, Biological; Multidrug Resistance-Associated Protein 2; RNA, Messenger | 2011 |
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Nude; Neoplasms, Experimental; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2012 |
NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines.
Topics: Androgens; Camptothecin; Cell Line, Tumor; DNA Damage; Histones; Homeodomain Proteins; Humans; Irinotecan; Male; Prostatic Neoplasms; S Phase; Transcription Factors | 2011 |
Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Tegafur | 2011 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Premedication; Survival Rate | 2012 |
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line; Colonic Neoplasms; Cyclooxygenase 2; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; MicroRNAs; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
ERas enhances resistance to CPT-11 in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Irinotecan; Models, Biological; NF-kappa B; Protein Binding; ras Proteins; Sirolimus; Stomach Neoplasms; Up-Regulation | 2011 |
A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cats; Doxorubicin; Female; Glioma; Infusion Pumps, Implantable; Injections, Intraventricular; Irinotecan; Male; Microspheres; Necrosis; Safety; Treatment Outcome | 2011 |
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dexamethasone; Drug Therapy, Combination; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Nausea; Prospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Etoposide; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Simplexvirus; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies | 2012 |
Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.
Topics: Apoptosis; Camptothecin; Cell Line; Coculture Techniques; Colon; Gene Expression Regulation, Enzymologic; Humans; Inflammation; Intracellular Space; Irinotecan; Macrophages; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Reactive Oxygen Species; TNF-Related Apoptosis-Inducing Ligand | 2011 |
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Choline Kinase; Choline-Phosphate Cytidylyltransferase; Colorectal Neoplasms; Female; Flavonoids; HCT116 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mice; Phosphorus Isotopes; Piperidines; Protons; Saccharomyces cerevisiae; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Looking through the vascular normalization window: timing antiangiogenic treatment and chemotherapy with (99m)Tc-annexin A5.
Topics: Animals; Annexin A5; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Irinotecan; Neovascularization, Pathologic; Organotechnetium Compounds; Tomography, Emission-Computed, Single-Photon | 2011 |
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms | 2011 |
Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Lymphoma, B-Cell; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2012 |
Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Humans; Irinotecan; Liposomes; Mice; Nanoparticles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Fatal Outcome; Glioblastoma; Humans; Irinotecan; Male; Methylprednisolone Hemisuccinate; Necrosis; Skin; Striae Distensae | 2011 |
In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Docetaxel; ErbB Receptors; Genes, ras; Humans; Irinotecan; Male; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2012 |
High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Brain; Camptothecin; Coumarins; Doxorubicin; Female; Heart; Irinotecan; Kidney; Mice, Inbred BALB C; Myocardium; Phenylenediamines; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Sulfasalazine; Toxicogenetics; Transcriptome; Xenobiotics | 2011 |
Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cell Line, Tumor; Humans; Irinotecan; Liposomes; Mice; Octreotide; Phosphorylation; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Survival Analysis | 2012 |
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Ribonucleoproteins, Small Nuclear; RNA Interference; RNA, Small Interfering; Systems Biology | 2012 |
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclodextrins; Drug Carriers; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Nanoparticles; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2012 |
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2012 |
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Sialic Acid Binding Ig-like Lectin 2 | 2012 |
Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Xenopus laevis | 2011 |
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Topics: Actins; Angiopoietin-1; Animals; Annexin A5; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Camptothecin; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms; Female; Irinotecan; Mice; Microvessels; Neovascularization, Pathologic; Organotechnetium Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Tomography, Emission-Computed, Single-Photon; Transcription, Genetic; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Matched-Pair Analysis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Propensity Score; Young Adult | 2012 |
Kampo medicine "Dai-kenchu-to" prevents CPT-11-induced small-intestinal injury in rats.
Topics: Animals; Apoptosis; Camptothecin; Diarrhea; In Situ Nick-End Labeling; Interferon-gamma; Interleukin-12; Interleukin-1beta; Intestine, Small; Irinotecan; Male; Medicine, Kampo; Panax; Plant Extracts; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Tumor Necrosis Factor-alpha; Zanthoxylum; Zingiberaceae | 2012 |
Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
Topics: Animals; Annexin A2; Antineoplastic Agents; Apoptosis; Calpain; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; I-kappa B Proteins; Irinotecan; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Pyrimidines; S100 Proteins; Transfection; Xenograft Model Antitumor Assays | 2012 |
[A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoradiotherapy; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Peripheral Blood Stem Cell Transplantation; Recurrence; Small Cell Lung Carcinoma; Time Factors | 2011 |
Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Humans; Irinotecan; Lipids; Liposomes; Models, Biological; Models, Chemical; Neoplasms | 2011 |
Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Ethnicity; Genetic Predisposition to Disease; Genetic Variation; Genotype; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Risk Factors; Singapore | 2011 |
Human neural stem cell tropism to metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Delivery Systems; Female; Humans; Interleukin-6; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Invasiveness; Neural Stem Cells; Prodrugs; Rabbits; Xenograft Model Antitumor Assays | 2012 |
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Disease Models, Animal; Enzyme Activation; Immunohistochemistry; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred C57BL; Mice, Knockout; Mucositis; Nitric Oxide; Nitric Oxide Synthase Type II | 2012 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.
Topics: Abdominal Neoplasms; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Desmoplastic Small Round Cell Tumor; Erythrocyte Transfusion; Feasibility Studies; Humans; Hyperthermia, Induced; Interferons; Irinotecan; Liver Neoplasms; Male; Pelvic Neoplasms; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide; Thrombocytopenia; Vinblastine; Vinorelbine; Young Adult | 2012 |
The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2012 |
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gene Dosage; Humans; Insulin-Like Growth Factor I; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; NF-kappa B; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor, ErbB-3; Retrospective Studies; Treatment Outcome | 2012 |
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Topics: Amino Acid Sequence; Animals; Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbohydrates; Cell Line, Tumor; Drug Delivery Systems; HCT116 Cells; Humans; Hydrazines; Injections, Intravenous; Irinotecan; Luminescent Measurements; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Mimicry; Molecular Sequence Data; Neoplasms; Neovascularization, Pathologic; Peptides; Protein Binding; Xenograft Model Antitumor Assays | 2011 |
Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Synergism; Humans; Irinotecan; Male; Mice; Neuroblastoma; Pyrazoles; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Contrast-enhanced ultrasonography with intraarterial administration of SonoVue for guidance of transarterial chemoembolization: an initial experience.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cholangiocarcinoma; Contrast Media; Doxorubicin; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Phospholipids; Prospective Studies; Sulfur Hexafluoride; Treatment Outcome; Ultrasonography, Interventional | 2011 |
RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide) (HPMA)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugates.
Topics: Acrylamides; Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Survival; Humans; Irinotecan; Mice; Polymers; Solubility | 2012 |
Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Interactions; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Irinotecan; Mitoxantrone; Organic Cation Transport Proteins; Transfection | 2011 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Total synthesis of camptothecin and SN-38.
Topics: Alkaloids; Camptothecin; Irinotecan; Molecular Structure; Stereoisomerism | 2012 |
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.
Topics: Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Statistics, Nonparametric | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Death, Sudden; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2012 |
When do you need a validated assay?
Topics: Biomarkers; Camptothecin; Government Regulation; Humans; Irinotecan; Validation Studies as Topic | 2011 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
Neurodevelopmental disorders. New hope for a devastating neurological disorder.
Topics: Angelman Syndrome; Animals; Brain; Camptothecin; Drug Evaluation, Preclinical; Gene Expression Regulation; Genetic Therapy; Humans; Irinotecan; Mice; Neurons; Topotecan; Transcriptional Activation; Ubiquitin-Protein Ligases | 2011 |
Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2011 |
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: 3' Flanking Region; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Dosage; Genetic Association Studies; Glucuronosyltransferase; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Retrospective Studies; Survival Analysis | 2012 |
Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lymphoma; Organic Cation Transporter 1; Paclitaxel | 2012 |
[A case of advanced gastric cancer with splenic vein thrombus successfully treated with S-1 plus CPT-11 neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Splenic Vein; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Venous Thrombosis | 2011 |
[A case report of pathologically complete response of rectal cancer after preoperative treatment of CPT-11, S-1, and radiation therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs.
Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Biotransformation; Blotting, Western; Camptothecin; Carboxylic Ester Hydrolases; Constitutive Androstane Receptor; Esters; Hydrolysis; Imidazolidines; Intestines; Irinotecan; Male; Nitrophenols; Organophosphorus Compounds; Parasympathomimetics; Pregnane X Receptor; Prodrugs; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger | 2011 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; DNA Breaks, Double-Stranded; Drug Administration Schedule; Flow Cytometry; Humans; Irinotecan; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured | 2012 |
Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Volume; Blood Volume Determination; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cerebrovascular Circulation; Irinotecan; Magnetic Resonance Imaging; Male; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
[Importance and practice of UGT1A1 polymorphisms].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2.
Topics: Biological Transport; Caco-2 Cells; Camptotheca; Camptothecin; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; Epithelial Cells; Estrone; Flavonoids; Humans; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Lactones; Sulfobromophthalein; Taurocholic Acid | 2012 |
Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.
Topics: Camptothecin; Carcinogens; Case-Control Studies; Chromosome Mapping; Genetic Predisposition to Disease; Genome-Wide Association Study; Glucuronosyltransferase; Humans; Irinotecan; Liver; Phenotype; Polymorphism, Single Nucleotide; Protein Isoforms; Risk Factors; RNA, Messenger; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2012 |
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.
Topics: Animals; Body Weight; Camptothecin; Endothelial Cells; Irinotecan; Male; Mesentery; Mitoxantrone; Neovascularization, Pathologic; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Topoisomerase Inhibitors; Vascular Endothelial Growth Factor A | 2012 |
Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters.
Topics: Amino Acid Transport System A; Amino Acid Transport System ASC; Amino Acid Transport Systems; Antineoplastic Agents; Biological Transport; Camptothecin; Esters; HEK293 Cells; Humans; Irinotecan; Minor Histocompatibility Antigens; Prodrugs; Valine | 2012 |
Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Glucuronosyltransferase; Inactivation, Metabolic; Irinotecan; Maximum Tolerated Dose; Organoselenium Compounds; Rats; Rats, Gunn; Rats, Inbred F344 | 2012 |
A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.
Topics: Animals; Camptothecin; Dextrans; Disease Models, Animal; Irinotecan; Mice; Pancreatic Neoplasms; Prodrugs; Rabbits | 2012 |
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dealkylation; Death-Associated Protein Kinases; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Uterine Cervical Neoplasms | 2012 |
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Comorbidity; Female; Humans; Intestinal Perforation; Irinotecan; Kaplan-Meier Estimate; Male; Medicare; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stroke; Survival Rate; United States | 2012 |
SN-38:β-cyclodextrin inclusion complex for in situ solidifying injectable polymer implants.
Topics: Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Camptothecin; Drug Implants; Irinotecan; Polymers | 2011 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
Viewing metastatic colorectal cancer as a curable chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Bevacizumab; Camptothecin; Cetuximab; Chronic Disease; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Recurrence; Reoperation; Survival Rate | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distribution; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.
Topics: Alginates; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Doxorubicin; Drug Delivery Systems; Female; Glioma; Glucuronic Acid; Hexuronic Acids; Irinotecan; Male; Materials Testing; Microspheres; Rats; Survival Rate; Suspensions; Tumor Burden | 2012 |
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Markov Chains; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quality-Adjusted Life Years; Risk Factors; State Medicine; Survival Analysis; United Kingdom | 2012 |
Comparison of the predictive ability of several second-order multivariate methods in the simultaneous determination of two therapeutic drugs in human urine.
Topics: Algorithms; Antineoplastic Agents; Calibration; Camptothecin; Chloroform; Factor Analysis, Statistical; Fluorescence; Humans; Irinotecan; Least-Squares Analysis; Liquid-Liquid Extraction; Multivariate Analysis; Spectrometry, Fluorescence; Thalidomide | 2012 |
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Indoles; Irinotecan; Mutation; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Purines; ras Proteins; TOR Serine-Threonine Kinases; Transcription Factors | 2012 |
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Retrospective Studies | 2012 |
[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2012 |
Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Chemoembolization, Therapeutic; Chromatography, High Pressure Liquid; Glucuronides; Humans; Irinotecan; Liver; Reference Standards; Swine; Tandem Mass Spectrometry | 2012 |
Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics.
Topics: Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Fluorescence; Humans; Irinotecan; Kinetics; Mitoxantrone; Reactive Oxygen Species; Single-Cell Analysis | 2012 |
Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG | 2012 |
Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Topics: Adult; Alleles; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Uterine Cervical Neoplasms | 2011 |
[A case of cecal cancer with abdominal wall abscess].
Topics: Abdominal Wall; Abscess; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Cecal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2012 |
Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Mice; Mice, Nude; Microarray Analysis; Sulfonamides; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Bilirubin; Camptothecin; Chemoembolization, Therapeutic; Drug Delivery Systems; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Rabbits; Statistics, Nonparametric | 2012 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Pilot Projects; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2012 |
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Fluorodeoxyglucose F18; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2012 |
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Topics: Acetals; Animals; Camptothecin; Chromatography, Liquid; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Mice; Mice, Nude; Polymers; Tandem Mass Spectrometry; Tissue Distribution; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Survival Rate | 2012 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2012 |
Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cerebellar Neoplasms; Gene Transfer Techniques; Genetic Therapy; Humans; Irinotecan; Medulloblastoma; Mice; Mice, Nude; Mice, Transgenic; Neural Stem Cells; Prodrugs; Stem Cell Transplantation; Treatment Outcome | 2013 |
Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Indocyanine Green; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Prognosis; Risk Factors; Survival Rate | 2012 |
Modulation of irinotecan-induced genomic DNA damage by theanine.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromosome Aberrations; DNA Damage; Dose-Response Relationship, Drug; Glutamates; Irinotecan; Male; Mice; Micronucleus Tests; Oxidative Stress | 2012 |
[A case of S-1-resistant resected advanced gastric cancer with para-aortic lymph node recurrence responding to bi-weekly CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2012 |
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Irinotecan; Mice; Mice, Knockout; Protein Kinase Inhibitors; Protein Kinases; Tumor Suppressor Protein p53 | 2013 |
Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Receptors, Androgen; RNA Interference; RNA, Small Interfering; Sex Characteristics; Steroid 17-alpha-Hydroxylase; Treatment Outcome; Tubulin | 2012 |
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2012 |
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Irinotecan; Neoplastic Stem Cells; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Receptor, ErbB-2 | 2014 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 9; Caspases; Colorectal Neoplasms; Drug Synergism; G1 Phase; Ginsenosides; HCT116 Cells; Humans; Irinotecan; Panax; Phytotherapy; Plant Extracts | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fibrosis; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Mucins; Multivariate Analysis; Necrosis; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Retrospective Studies; Single-Blind Method | 2012 |
[Successful management of liver metastasis from gastric adenosquamous carcinoma with adjuvant chemotherapy and radiofrequency ablation].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Catheter Ablation; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2012 |
MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Polymers | 2012 |
Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; England; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Proto-Oncogene Proteins c-akt; Treatment Outcome | 2012 |
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Imaging; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2012 |
[Monitoring and evaluation tools for irinotecan and bevacizumab in glioblastoma: from prescription to patient's information].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Contraindications; Drug Monitoring; Family; France; General Practice; Glioblastoma; Humans; Irinotecan; Medical Oncology; Off-Label Use; Pamphlets; Patient Education as Topic; Pharmaceutical Services; Pharmacovigilance; Prescription Drugs | 2012 |
Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.
Topics: Camptothecin; Cell Cycle Checkpoints; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Gene Expression Regulation, Neoplastic; Half-Life; HCT116 Cells; Humans; Irinotecan; Kinetics; Phosphorylation; Polyribosomes; Protein Biosynthesis; Protein Kinases; Pyrazoles; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
Topics: Aldehyde Dehydrogenase; Amyloid Precursor Protein Secretases; Animals; Camptothecin; Colorectal Neoplasms; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Mice; Mice, Nude; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2012 |
Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.
Topics: Amoxapine; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Discovery; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Glucuronidase; Irinotecan; Isocarboxazid; Mefloquine; Monoamine Oxidase Inhibitors; Nialamide; Phenelzine | 2012 |
SN-38 loaded polymeric micelles to enhance cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Diffusion; Humans; Irinotecan; Micelles; Nanocapsules; Neoplasms, Experimental; Tumor Cells, Cultured | 2012 |
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Imidazoles; Irinotecan; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a straw?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Humans; Irinotecan; Prognosis; Salvage Therapy; Stomach Neoplasms; Taxoids | 2012 |
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Topics: Animals; Antineoplastic Agents; Binding Sites; Camptothecin; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; DNA Damage; Drug Design; Drug Synergism; Gemcitabine; High-Throughput Screening Assays; Irinotecan; Mice; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2012 |
A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Calibration; Camptothecin; Chromatography, Liquid; Female; Injections, Intraperitoneal; Irinotecan; Limit of Detection; Mice; Reproducibility of Results; Specimen Handling; Tandem Mass Spectrometry; Tissue Distribution; Zinc Sulfate | 2012 |
N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells.
Topics: Blotting, Western; Caco-2 Cells; Camptothecin; Cell Movement; Cell Survival; Cisplatin; Colorectal Neoplasms; Flow Cytometry; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Polysaccharides; Swainsonine; Tunicamycin | 2012 |
[A case of an advanced gastric cancer patient on hemodialysis achieving long-term progression-free survival after CPT-11+CDDP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Disease-Free Survival; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Renal Dialysis; Stomach Neoplasms; Time Factors | 2012 |
[A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Recurrence; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2012 |
[Two cases of CPT-11 and CDDP chemotherapy for advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2012 |
Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Japan; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Retrospective Studies | 2012 |
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Contraindications; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tumor Burden | 2012 |
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Combined portal vein embolization and preoperative chemotherapy prior to liver resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Blood Loss, Surgical; Blood Volume; Camptothecin; Carcinoma; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Embolization, Therapeutic; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Operative Time; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Retrospective Studies; Statistics, Nonparametric | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies | 2013 |
Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Folic Acid; Irinotecan; Liposomes; Mice; Mice, Inbred ICR; Random Allocation; Rats; Xenograft Model Antitumor Assays | 2012 |
Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Japan; Laparotomy; Middle Aged; Ovarian Neoplasms; Proportional Hazards Models; Retrospective Studies; Second-Look Surgery | 2012 |
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.
Topics: Autophagy; Camptothecin; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Knockout Techniques; HCT116 Cells; Humans; Irinotecan; Mitogen-Activated Protein Kinase 14; Tumor Suppressor Protein p53; Vacuoles | 2012 |
UPLC and LC-MS studies on degradation behavior of irinotecan hydrochloride and development of a validated stability-indicating ultra-performance liquid chromatographic method for determination of irinotecan hydrochloride and its impurities in pharmaceutic
Topics: Camptothecin; Chromatography, High Pressure Liquid; Dosage Forms; Drug Contamination; Drug Stability; Humidity; Irinotecan; Limit of Detection; Linear Models; Mass Spectrometry; Methanol; Models, Molecular; Reproducibility of Results; Temperature | 2012 |
A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Genome-Wide Association Study; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies | 2013 |
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mitogen-Activated Protein Kinases; Reproducibility of Results; Signal Transduction; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2012 |
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.
Topics: Animals; Camptothecin; Female; Humans; Irinotecan; Killer Cells, Natural; Mice; Mice, SCID; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Sindbis Virus; Topoisomerase Inhibitors | 2012 |
Fertility-sparing management for bulky cervical cancer using neoadjuvant transuterine arterial chemotherapy followed by vaginal trachelectomy.
Topics: Adult; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Organoplatinum Compounds; Pregnancy; Retrospective Studies; Uterine Artery Embolization; Uterine Cervical Neoplasms; Vagina | 2012 |
3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Delivery Systems; Glycerol; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Monoglycerides; Polyesters; Stearates | 2012 |
Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Everolimus; Female; Humans; Immunosuppressive Agents; Irinotecan; Liposomes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Sirolimus; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Young Adult | 2012 |
Infused chemotherapy use in the elderly after patent expiration.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cost Savings; Cross-Sectional Studies; Female; Health Services for the Aged; Humans; Irinotecan; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patents as Topic; Practice Patterns, Physicians'; Time Factors; United States | 2012 |
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Blood Coagulation Tests; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Thrombelastography | 2012 |
Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Chemokine CCL22; Cohort Studies; Colorectal Neoplasms; Epidermal Growth Factor; Female; Humans; Interleukins; Irinotecan; Male; Middle Aged | 2012 |
Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies | 2012 |
The role of autophagic cell death and apoptosis in irinotecan-treated p53 null colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Tumor Suppressor Protein p53 | 2013 |
Bradycardia associated with drug-eluting beads loaded with irinotecan (DEBIRI) infusion for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bradycardia; Camptothecin; Colorectal Neoplasms; Cone-Beam Computed Tomography; Drug Delivery Systems; Electrocardiography; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2013 |
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2012 |
Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Irinotecan; Male; Rhabdomyosarcoma, Alveolar; Temozolomide; Vincristine | 2013 |
Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Topics: Animals; Antineoplastic Agents; Bombesin; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gastrin-Releasing Peptide; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Peptide Fragments; Receptors, Bombesin; Transplantation, Heterologous | 2012 |
A case of successful preoperative chemotherapy with cisplatin and irinotecan followed by curative-intent surgery for locally advanced thymic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Preoperative Period; Thymoma; Thymus Neoplasms | 2013 |
Fabrication of biodegradable micelles with sheddable poly(ethylene glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Camptothecin; Cell Line; Cell Survival; Delayed-Action Preparations; Disulfides; Dithiothreitol; Drug Carriers; Drug Compounding; Freeze Drying; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Kinetics; Mice; Micelles; Oxidation-Reduction; Polyethylene Glycols; Polyglutamic Acid; Solubility; Water | 2012 |
Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Camptothecin; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Escherichia coli Proteins; Fluorouracil; Genetic Therapy; Humans; Irinotecan; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin | 2012 |
Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Caproates; Cell Line, Tumor; Drug Delivery Systems; Drug Stability; Glioblastoma; Humans; Irinotecan; Kinetics; Lactones; Polyesters; Polyethylene Glycols; Polymers | 2012 |
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2012 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Male; Oxonic Acid; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms; Werner Syndrome Helicase | 2012 |
Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cohort Studies; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Hyperthermia, Induced; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome; United States | 2013 |
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Mice; Microsatellite Instability; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rats; Xenograft Model Antitumor Assays | 2012 |
Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.
Topics: Antineoplastic Agents; Camptothecin; HT29 Cells; Humans; Irinotecan; Liposomes; Polyethylene Glycols | 2012 |
First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI).
Topics: Aged; Aged, 80 and over; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2012 |
Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cecum; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Feces; Female; Intestines; Irinotecan; Metagenome; Neoplasms; Rats | 2012 |
Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; Xenograft Model Antitumor Assays | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Dietary Supplements; Drug Resistance, Neoplasm; Emulsions; Fatty Acids, Omega-3; Fish Oils; Fluorouracil; Food-Drug Interactions; Humans; Irinotecan; Membrane Potential, Mitochondrial; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Triglycerides | 2013 |
A template model for studying anticancer drug efflux transporter inhibitors in vitro.
Topics: Acridones; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Membrane; Diffusion; Drug Evaluation, Preclinical; Drug Interactions; Drug Resistance; HEK293 Cells; Humans; Intracellular Fluid; Irinotecan; Kinetics; Membrane Transport Modulators; Mitoxantrone; Models, Biological; Neoplasm Proteins; Osmolar Concentration; Recombinant Proteins; Reproducibility of Results | 2013 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide | 2012 |
Irinotecan induces senescence and apoptosis in colonic cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; Cellular Senescence; Colon; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; Fibroblasts; Gene Expression Regulation; Gene Knockdown Techniques; HCT116 Cells; Humans; Irinotecan; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
p53 Dimers associate with a head-to-tail response element to repress cyclin B transcription.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Nucleus; Chromatin Immunoprecipitation; Cross-Linking Reagents; Cyclin B; Dimerization; DNA Damage; Gene Expression Regulation, Neoplastic; Genes, p53; Glutaral; Humans; Irinotecan; Response Elements; Transcription, Genetic; Tumor Suppressor Protein p53 | 2012 |
Preclinical combination therapy of thiarabine plus various clinical anticancer agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Camptothecin; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Female; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins B-raf | 2012 |
The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 9; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Office Visits; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Palliative Care; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Retrospective Studies; Scandinavian and Nordic Countries; Sweden | 2012 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Turkey | 2012 |
Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Colonic Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Sarcosine; Temozolomide | 2013 |
Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.
Topics: Biomarkers, Pharmacological; Camptothecin; Ethnicity; Gene Frequency; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Malaysia; Pharmacogenetics; Polymorphism, Genetic; Sequence Analysis, DNA | 2012 |
Creation of pure nanodrugs and their anticancer properties.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Dimerization; Drug Carriers; Drug Design; Hep G2 Cells; Humans; Irinotecan; Nanofibers; Nanoparticles; Water | 2012 |
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiation Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Molecular structure and vibrational spectra of Irinotecan: a density functional theoretical study.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Irinotecan; Models, Molecular; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Static Electricity; Topoisomerase I Inhibitors | 2012 |
Current stages of adjuvant treatment of colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Cisplatin; Colon, Ascending; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Tomography, X-Ray Computed | 2012 |
[A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Neoplasm Invasiveness; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2012 |
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Camptothecin; Female; Hematologic Diseases; Humans; Irinotecan; Kidney; Liver; Male; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyenes; Rats; Rats, Sprague-Dawley; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cerebellar Neoplasms; Child; Comet Assay; DNA Damage; Drug Synergism; Humans; Irinotecan; Medulloblastoma; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Platinum Compounds; Xenograft Model Antitumor Assays | 2012 |
Colorectal cancer targeted Irinotecan-Assam Bora rice starch based microspheres: a mechanistic, pharmacokinetic and biochemical investigation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Colon; Colorectal Neoplasms; Emulsions; Gastrointestinal Tract; Irinotecan; Liver; Male; Microspheres; Oryza; Rats; Solvents; Starch; Time Factors; Tissue Distribution | 2013 |
Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Feasibility Studies; Irinotecan; Liver; Models, Animal; Swine | 2013 |
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate | 2013 |
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2012 |
Progress in pancreatic cancer: moving beyond gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies | 2013 |
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neutropenia; Platinum Compounds; Remission Induction; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2012 |
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Prognosis; Promoter Regions, Genetic; Stem Cell Transplantation; Temozolomide; Transplantation, Autologous; Tumor Suppressor Proteins | 2013 |
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil | 2012 |
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Female; Humans; Irinotecan; Liposomes; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2012 |
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Immunohistochemistry; Indoles; Irinotecan; Liposomes; Mice; Mice, Nude; PC12 Cells; Pyrroles; Rats; Sunitinib; Tissue Distribution | 2012 |
Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchronous peritoneal carcinomatosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Flow Cytometry; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Cells, Cultured | 2013 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Analysis | 2012 |
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
Topics: Antigens, Surface; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Synergism; Glutamate Carboxypeptidase II; Humans; Irinotecan; Male; Nanoparticles; Polymers; Prostate; Prostatic Neoplasms | 2013 |
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Signal Transduction; STAT3 Transcription Factor; Survival Rate | 2013 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Irinotecan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Propensity Score; Proportional Hazards Models; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Fluorouracil; Growth Hormone-Releasing Hormone; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; S Phase Cell Cycle Checkpoints; Sermorelin; Transplantation, Heterologous | 2012 |
Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Uterine Cervical Neoplasms | 2013 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Fatty acid synthase inhibitor cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis.
Topics: Apoptosis; Camptothecin; Cell Survival; Cerulenin; Chromones; DNA Topoisomerases, Type I; Drug Synergism; Fatty Acid Synthases; Humans; Irinotecan; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2013 |
Tailored immunoconjugate therapy depending on a quantity of tumor stroma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Collagen; Female; Humans; Immunoconjugates; Irinotecan; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Topoisomerase I Inhibitors | 2013 |
The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Topics: Adenocarcinoma; Adult; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damage; DNA Repair; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Lung Neoplasms; Lymphocytes; Melatonin; Young Adult | 2013 |
Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Humans; Irinotecan; Lactic Acid; Materials Testing; Nanocapsules; Nanoparticles; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Vitamin E | 2012 |
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Fragmentation; HL-60 Cells; Humans; In Situ Nick-End Labeling; Irinotecan; Mouth Neoplasms; Topoisomerase Inhibitors | 2012 |
[Severe diarrhea].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal Motility; Gout Suppressants; Humans; Immunosuppressive Agents; Irinotecan; Molecular Targeted Therapy | 2012 |
Double pancreatic and gastric adenocarcinomas: a rare association.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rare Diseases; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
[Effects of isorhamnetin on CYP3A4 and herb-drug interaction].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Hep G2 Cells; Herb-Drug Interactions; Humans; Irinotecan; Pregnane X Receptor; Quercetin; Receptors, Steroid; RNA, Messenger; Transcriptional Activation; Up-Regulation | 2012 |
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2013 |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Humans; Irinotecan; Leucovorin; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Survival Analysis | 2013 |
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Coculture Techniques; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Interferon-beta; Irinotecan; Male; Prodrugs; Prostatic Neoplasms; Rabbits; Stem Cells | 2012 |
KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA-Binding Proteins; Endonucleases; Fluorouracil; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology.
Topics: Camptothecin; Drug Carriers; Drug Delivery Systems; Irinotecan; Light; Lipids; Nanostructures; Particle Size; Regression Analysis; Reproducibility of Results; Scattering, Radiation; Static Electricity | 2013 |
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2012 |
Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.
Topics: Animals; Anti-Obesity Agents; Antineoplastic Agents; Camptothecin; Carboxylic Ester Hydrolases; Cell Line; Cell Survival; Doxorubicin; Drug Interactions; Female; Humans; Irinotecan; Lactones; Liver; Male; Mice; Orlistat; Oxazoles; Prodrugs; Rats; Species Specificity | 2013 |
Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms; Serum Albumin, Bovine; Solubility; Xenograft Model Antitumor Assays | 2013 |
Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2012 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus fumigatus; Camptothecin; Fluorouracil; Humans; Invasive Pulmonary Aspergillosis; Irinotecan; Male; Middle Aged; Neutropenia; Opportunistic Infections; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pneumocystis carinii; Pneumonia, Pneumocystis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Drug Administration Routes; Drug Delivery Systems; Female; Glioblastoma; History, Ancient; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Irinotecan; Liposomes; Mice; Mice, Nude; Nanoparticles; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles; Nanoparticles; Prodrugs; Solubility; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
[Neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2012 |
[A case of recurrent gastric cancer responding to CPT-11].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Stomach Neoplasms | 2012 |
[A case of recurrent gastric cancer successfully treated by a combination of CPT-11 and CDDP as the third-line chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Salvage Therapy; Stomach Neoplasms | 2012 |
[Chemotherapy-mediated tumor regression in a patient with stage IV stomach small cell cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of gastric endocrine cell carcinoma that responded to chemotherapy with CPT-11+CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Endocrine Gland Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2012 |
Anthocyanins suppress the cleavable complex formation by irinotecan and diminish its DNA-strand-breaking activity in the colon of Wistar rats.
Topics: Animals; Anthocyanins; Camptothecin; Colon; DNA Breaks; DNA Damage; DNA Topoisomerases, Type I; Fruit; Glucosides; Irinotecan; Male; Plant Extracts; Rats; Rats, Wistar | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Topics: Alkaline Phosphatase; Animals; Biliary Tract; Body Weight; Camptothecin; Diarrhea; Drug Interactions; Genistein; Glucuronates; Glucuronides; Intestinal Mucosa; Intestines; Irinotecan; Kidney; Liver; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Probenecid; Rats; Rats, Sprague-Dawley | 2013 |
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
Topics: Abietanes; Algorithms; Camptothecin; Carboxylesterase; Clinical Trials, Phase I as Topic; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; Irinotecan; Medicine, Chinese Traditional; Molecular Structure; Phenanthrolines; Plant Roots; Salvia miltiorrhiza | 2013 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Medulloblastoma; Recurrence; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retreatment; Young Adult | 2013 |
Preclinical antitumor activity of a nanoparticulate SN38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Female; HCT116 Cells; Humans; Irinotecan; Mice; Mitomycin; Nanoparticles; Neoplasms; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.
Topics: Animals; BRCA2 Protein; Camptothecin; Cytochrome P-450 Enzyme System; DNA Damage; DNA Primers; DNA Repair; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Genetic Complementation Test; Insect Proteins; Irinotecan; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topotecan | 2013 |
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Sodium Compounds; Telomere | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan].
Topics: Animals; Camptothecin; Drug Interactions; Glucuronides; Humans; Irinotecan; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Tacrolimus | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Retrospective Studies; Temozolomide | 2013 |
Pleural tuberculosis following lung cancer chemotherapy: a report of two cases proven pathologically by pleural biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Small Cell Lung Carcinoma; Tuberculosis, Pleural | 2013 |
Higher lung accumulation of intravenously injected organic nanotubes.
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Carriers; Female; Gadolinium; Hydrogen-Ion Concentration; Injections, Intravenous; Irinotecan; Liver; Lung; Mice; Nanotubes; Particle Size; Tissue Distribution | 2013 |
Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Herpesvirus 1, Human; Humans; Irinotecan; Methotrexate; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Transcriptional Activation; Tumor Necrosis Factor-alpha; Virus Replication | 2013 |
[Importance and practice of UGT1A1 polymorphisms].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2012 |
Activation of a PGC-1-related coactivator (PRC)-dependent inflammatory stress program linked to apoptosis and premature senescence.
Topics: Acetylcysteine; Antioxidants; Apoptosis; Camptothecin; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Line, Tumor; Cell Survival; Cellular Senescence; Cornified Envelope Proline-Rich Proteins; Gene Expression; Gene Knockdown Techniques; Histamine H1 Antagonists; Humans; Inflammation; Irinotecan; Kinetics; Meclizine; Oxidants; Oxidative Stress; Proto-Oncogene Proteins c-myc; Proton Ionophores; RNA, Small Interfering; Topoisomerase I Inhibitors; Transcription Factors; Transcriptional Activation; Vitamin K 3 | 2013 |
Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Mice; Oxazoles; RNA Stability; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cetrimonium; Cetrimonium Compounds; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Middle Aged; Prostatic Neoplasms; RNA, Small Interfering; Surface-Active Agents | 2013 |
Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.
Topics: Acridones; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Neoplasm; Drug Synergism; Female; HEK293 Cells; Humans; Irinotecan; Mice; Mice, SCID; Models, Biological; Neoplasm Proteins; Transfection; Xenograft Model Antitumor Assays | 2014 |
[Preparation and characterization of irinotecan hydrochloride loaded PEO-PPO-PEO micelles and its mechanism of decreasing drug intestinal toxicity].
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Biological Transport; Camptothecin; Cells, Cultured; Diarrhea; Dogs; Drug Carriers; Intestines; Irinotecan; Madin Darby Canine Kidney Cells; Male; Micelles; Neoplasm Proteins; Polyethylene Glycols; Propylene Glycols; Rats; Rats, Sprague-Dawley | 2012 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cesarean Section; Colectomy; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Gestational Age; Humans; Infant, Newborn; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Failure | 2012 |
Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Dihydroxycholecalciferols; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vitamin D; Xenograft Model Antitumor Assays | 2013 |
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Doxorubicin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histocompatibility Antigens Class II; Humans; Irinotecan; Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.
Topics: Adsorption; Animals; Caco-2 Cells; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lactic Acid; Male; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Propylene Glycols; Rats; Rats, Wistar; Structure-Activity Relationship; Surface Properties; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2013 |
Aflibercept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placenta Growth Factor; Pregnancy Proteins; Protein Binding; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2013 |
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Topics: Acridines; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tetrahydroisoquinolines; Topotecan | 2013 |
Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cells, Cultured; DNA Topoisomerases, Type I; Genes, Reporter; Inhibitory Concentration 50; Irinotecan; Kinetics; Leishmania infantum; Life Cycle Stages; Luminescent Proteins; Mice; Prodrugs; Protozoan Proteins; Red Fluorescent Protein; Spleen; Topoisomerase I Inhibitors; Trypanocidal Agents | 2013 |
A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Small Cell Lung Carcinoma | 2014 |
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2013 |
Clinical implications of CES2 RNA expression in neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Neuroblastoma; RNA; Tumor Cells, Cultured | 2013 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome | 2013 |
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Topics: Aminopyridines; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Respiration; Cisplatin; Doxorubicin; Everolimus; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2013 |
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Synergism; Female; Fluorouracil; Gene Amplification; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2013 |
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms | 2014 |
Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression; Humans; Irinotecan; Isoenzymes; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Uterine Cervical Neoplasms | 2014 |
[Determination of 7-ethyl-10-hydroxycamptothecin in microdialysates from rat brain with LC-MS/MS].
Topics: Animals; Brain Chemistry; Camptothecin; Chromatography, Liquid; Irinotecan; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2013 |
A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Biomarkers, Tumor; Camptothecin; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Methylation; Mice; Middle Aged; Models, Genetic; Neoplasm Proteins; Reproducibility of Results; Stomach Neoplasms; Sulfatases; Sulfotransferases; Xenograft Model Antitumor Assays | 2013 |
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Irinotecan; Metabolome; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mice, SCID; Microscopy, Confocal; Neoplasm Transplantation; Random Allocation; Real-Time Polymerase Chain Reaction; Spheroids, Cellular; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Comet Assay; DNA Damage; Female; Fluorouracil; HCT116 Cells; Histones; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Irinotecan; Microsatellite Instability; S Phase | 2013 |
ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Topics: Acrylonitrile; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Side-Population Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Localized skin necrosis by bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Drug Eruptions; Humans; Irinotecan; Male; Middle Aged; Necrosis; Skin | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Selecting regimens in advanced colon cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Synthesis, metabolite analysis, and in vivo evaluation of [(11)C]irinotecan as a novel positron emission tomography (PET) probe.
Topics: Animals; Camptothecin; Carbon Radioisotopes; Chemistry Techniques, Synthetic; Irinotecan; Kinetics; Male; Mice; Positron-Emission Tomography | 2013 |
Cell diameter measurements obtained with a handheld cell counter could be used as a surrogate marker of G2/M arrest and apoptosis in colon cancer cell lines exposed to SN-38.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Count; Cell Proliferation; Cell Size; Cell Survival; Colonic Neoplasms; Cytological Techniques; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Reproducibility of Results | 2013 |
Triggered drug release from superhydrophobic meshes using high-intensity focused ultrasound.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; MCF-7 Cells; Polyesters; Ultrasonics | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation.
Topics: Antigen Presentation; Antineoplastic Agents; Camptothecin; Cell Differentiation; Cells, Cultured; Cisplatin; Cytokines; Dendritic Cells; Dexamethasone; Doxorubicin; Humans; Immunotherapy; Interferon-beta; Irinotecan; Monocytes; RNA, Messenger; T-Lymphocytes | 2013 |
Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic | 2014 |
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; HT29 Cells; Humans; Irinotecan; Liposomes; Male; Mice; Tumor Burden | 2013 |
Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Follow-Up Studies; Freezing; Humans; Irinotecan; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate | 2013 |
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evidence-Based Medicine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Patient Selection; Platinum Compounds; Positron-Emission Tomography | 2013 |
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Longitudinal Studies; Male; Models, Biological; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome; Tumor Burden | 2013 |
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Camptothecin; Checkpoint Kinase 1; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; MutL Protein Homolog 1; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinases; Topoisomerase I Inhibitors | 2013 |
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Carriers; Female; Humans; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Polymers; Prospective Studies; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Preliminary study on pH-sensitive lipid bilayer-coated mesoporous silica nanoparticles as a novel drug carrier for antitumor drug].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Drug Carriers; Humans; Hydrogen-Ion Concentration; Irinotecan; Lipid Bilayers; MCF-7 Cells; Nanoparticles; Particle Size; Porosity; Silicon Dioxide | 2013 |
Irinotecan delivery by microbubble-assisted ultrasound: in vitro validation and a pilot preclinical study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Glioblastoma; Humans; Irinotecan; Male; Mice, Nude; Microbubbles; Ultrasonics | 2013 |
Effect of maternal smoking during pregnancy on fetus: a cytogenetic perspective.
Topics: Adolescent; Adult; Camptothecin; Cell Proliferation; Cells, Cultured; Cytogenetic Analysis; DNA Damage; Female; Fetal Blood; Humans; Infant, Newborn; Irinotecan; Lymphocytes; Maternal-Fetal Exchange; Mitotic Index; Mutagens; Pregnancy; Sister Chromatid Exchange; Smoking; Young Adult | 2014 |
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2013 |
Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity.
Topics: Animals; Camptothecin; Cattle; Drug Interactions; Enzyme Inhibitors; Escherichia coli; Female; Glucuronidase; Glycoproteins; Irinotecan; Liver; Mice; Mice, Inbred BALB C | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
Topics: Absorption; Animals; Caco-2 Cells; Calorimetry, Differential Scanning; Camptothecin; Cell Death; Chitosan; Coated Materials, Biocompatible; Coumarins; Enterocytes; HT29 Cells; Humans; Intestines; Irinotecan; Kinetics; Lactic Acid; Male; Nanoparticles; Particle Size; Perfusion; Permeability; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Rhodamine 123; Spectroscopy, Fourier Transform Infrared; Static Electricity; X-Ray Diffraction | 2013 |
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?
Topics: Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras) | 2013 |
EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Structure, Tertiary | 2013 |
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzofurans; Camptothecin; Cell Death; Cell Nucleus; Cell Survival; Colonic Neoplasms; DNA Damage; DNA Mismatch Repair; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Fluorescent Antibody Technique; Fluorouracil; Gene Knockdown Techniques; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; MutL Protein Homolog 1; MutS Homolog 3 Protein; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Rad51 Recombinase | 2013 |
Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Drug Evaluation, Preclinical; HCT116 Cells; Humans; Irinotecan; Mass Spectrometry; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Will PICCOLO affect metastatic colorectal cancer therapy?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colectomy; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2013 |
Effects of herbal supplements on the bioactivation of chemotherapeutic agents.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Cimicifuga; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hypericum; Inhibitory Concentration 50; Irinotecan; Microsomes, Liver; Plant Extracts; Regression Analysis; Tamoxifen; Tandem Mass Spectrometry; Zingiber officinale | 2013 |
Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Molecular Structure; Nanocapsules; Neoplasms; Oxidation-Reduction; Prodrugs; Structure-Activity Relationship | 2013 |
Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Radiotherapy; Retrospective Studies; Salvage Therapy; Vincristine; Young Adult | 2013 |
Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Topics: Animals; Biological Transport; Camptothecin; Cell Line, Tumor; CHO Cells; Cricetinae; Drug Carriers; Emulsions; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Nanoparticles; Ovarian Neoplasms; Particle Size; Polyethylene Glycols; Polyglactin 910; Topoisomerase I Inhibitors | 2013 |
A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Camptothecin; Drug Resistance, Neoplasm; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2013 |
Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Steroids; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Predicting therapy response in live tumor cells isolated with the flexible micro spring array device.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Agents; Camptothecin; Cell Separation; Cell Survival; Drug Screening Assays, Antitumor; Female; Fluorouracil; HCT116 Cells; High-Throughput Screening Assays; Humans; Irinotecan; Mice; Mice, SCID; Microfluidic Analytical Techniques; Neoplasm Transplantation; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prostheses and Implants; Treatment Outcome | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
Irinotecan combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice.
Topics: Animals; Antibodies, Blocking; Antibodies, Monoclonal; Camptothecin; CD40 Ligand; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Graft Rejection; Graft Survival; Heart Transplantation; Immunologic Memory; Interferon-gamma; Interleukin-10; Interleukin-2; Irinotecan; Isoantigens; Lymphocyte Function-Associated Antigen-1; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Transforming Growth Factor beta; Transplantation, Homologous | 2013 |
A high-throughput yeast assay identifies synergistic drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Humans; Irinotecan; Mitomycin; Neoplasms; Two-Hybrid System Techniques | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Micelles; Multiple Myeloma; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Stomach Neoplasms; Young Adult | 2013 |
Dysarthria induced by irinotecan in a patient with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Dysarthria; Humans; Infusion Pumps; Irinotecan; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Sigmoid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Monte Carlo Method; Neoplasm Grading; Positron-Emission Tomography; Recurrence; Treatment Outcome; Tyrosine | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2014 |
Investigation of the mechanisms governing doxorubicin and irinotecan release from drug-eluting beads: mathematical modeling and experimental verification.
Topics: Antineoplastic Agents; Camptothecin; Diffusion; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Hydrogels; Irinotecan; Kinetics; Liver Neoplasms; Models, Theoretical; Particle Size; Time Factors; Water | 2013 |
Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Polymorphism, Genetic; Uterine Cervical Neoplasms | 2013 |
[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2013 |
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Ligands; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
mRMRe: an R package for parallelized mRMR ensemble feature selection.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Genomics; Irinotecan; Software | 2013 |
Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Glasgow Outcome Scale; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Polymorphism, Genetic; Severity of Illness Index; Treatment Outcome | 2013 |
Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Camptothecin; Drug Carriers; Drug Delivery Systems; Emulsifying Agents; Endocytosis; Enterocytes; Flow Cytometry; Humans; Irinotecan; Nanoparticles; Oils; Permeability; Phase Transition; Rats, Wistar; Suspensions | 2013 |
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Case-Control Studies; Female; Fluorouracil; Gastrointestinal Neoplasms; Genetic Predisposition to Disease; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Risk; Tumor Necrosis Factor-alpha; Venous Thromboembolism | 2013 |
Mitogen-activated protein kinase p38 and retinoblastoma protein signalling is required for DNA damage-mediated formation of senescence-associated heterochromatic foci in tumour cells.
Topics: Antibiotics, Antineoplastic; Camptothecin; Cell Line, Tumor; Cell Survival; Cellular Senescence; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterochromatin; High Mobility Group Proteins; Humans; Irinotecan; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Repressor Proteins; Retinoblastoma Protein; Signal Transduction | 2013 |
[Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recurrence; Retrospective Studies | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
[A case of synchronous liver metastasis originating from advanced gastric cancer treated with combination chemotherapy involving S-1 and surgical intervention].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaloacetates; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of recurrence after resection of gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stomach Neoplasms | 2013 |
Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged | 2013 |
[Preliminary study on the efficacy of irinotecan in the treatment of childhood relapsed hepatoblastoma].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Female; Hepatoblastoma; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2013 |
Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Cations; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Female; Irinotecan; Liposomes; Melanoma, Experimental; Mice; Mice, Nude; Nanocomposites; Particle Size; Phosphatidylcholines; Polyethylene Glycols; Quantum Dots; Spectrometry, Fluorescence; Static Electricity; Wound Healing | 2013 |
Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Survival; Drug Delivery Systems; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Leucovorin; Nanofibers; Nanotechnology; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tumor Cells, Cultured | 2013 |
Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; China; Colorectal Neoplasms; Female; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Tissue Distribution | 2013 |
Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Demography; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2013 |
Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors.
Topics: Adult; Antineoplastic Agents; Camptothecin; Female; Granulosa Cell Tumor; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2013 |
Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans.
Topics: Adult; Biological Transport; Camptothecin; Cell Line; Down-Regulation; Female; HEK293 Cells; Hepatocytes; Humans; Irinotecan; Liver; Male; Middle Aged; Organic Anion Transporters | 2014 |
Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Delayed-Action Preparations; Drug Carriers; ErbB Receptors; HCT116 Cells; HT29 Cells; Humans; Immunoconjugates; Irinotecan; Microscopy, Confocal; Nanotubes, Carbon | 2013 |
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Treatment Outcome | 2013 |
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Failure; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2013 |
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.
Topics: Amphiregulin; Base Sequence; Biomarkers; Camptothecin; Colorectal Neoplasms; DNA Primers; ErbB Receptors; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction | 2014 |
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Ultrasound-guided paravertebral block for management of abdominal pain after transarterial embolization using drug-eluting beads loaded with irinotecan.
Topics: Abdominal Pain; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Implants; Humans; Irinotecan; Male; Nerve Block; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Multimodal delivery of irinotecan from microparticles with two distinct compartments.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Delayed-Action Preparations; Dextrans; Hydrogen-Ion Concentration; Irinotecan; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oligonucleotides; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Female; Injections, Intravenous; Irinotecan; Male; Mice; Nanoparticles; Random Allocation; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Tissue Distribution | 2013 |
[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Genes, ras; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2013 |
Montmorillonite-alginate nanocomposite as a drug delivery system--incorporation and in vitro release of irinotecan.
Topics: Alginates; Antineoplastic Agents, Phytogenic; Bentonite; Camptothecin; Drug Carriers; Glucuronic Acid; Hexuronic Acids; Ion Exchange; Irinotecan; Microscopy, Electron, Scanning; Nanocomposites; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2014 |
Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Young Adult | 2014 |
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Topics: Adult; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Germany; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.
Topics: Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Product Surveillance, Postmarketing; Treatment Failure; Treatment Outcome | 2013 |
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Variation; Genotype; Humans; Irinotecan; Leucovorin; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Neoplasm Metastasis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
[A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer].
Topics: Adult; Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Female; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2013 |
[An elderly patient with large cell neuroendocrine carcinoma(LCNEC)for whom chemotherapy with irinotecan and split-dose cisplatin(CDDP)proved very effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Radiography; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Analytical application of polymethylene blue-multiwalled carbon nanotubes modified glassy carbon electrode on anticancer drug irinotecan and determination of its ionization constant value.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Chromatography, Reverse-Phase; Electrochemical Techniques; Electrodes; Hydrogen-Ion Concentration; Ions; Irinotecan; Limit of Detection; Methylene Blue; Microscopy, Electrochemical, Scanning; Nanotubes, Carbon; Oxidation-Reduction; Polymerization; Solutions | 2013 |
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Endothelial Cells; Female; Glioblastoma; GPI-Linked Proteins; Humans; Immunophenotyping; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Prognosis; Treatment Outcome; Young Adult | 2013 |
Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Gene Frequency; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Polymorphism, Genetic; Retrospective Studies | 2013 |
Etirinotecan pegol: an option for late-stage breast cancer?
Topics: Breast Neoplasms; Camptothecin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Polyethylene Glycols; Topoisomerase I Inhibitors | 2013 |
Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Male; Prognosis; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2013 |
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Dysarthria; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Recurrence; Time Factors | 2014 |
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leukocyte Common Antigens; Male; Middle Aged; Neutrophils; Prognosis; Programmed Cell Death 1 Receptor; Prospective Studies; Toll-Like Receptor 4 | 2013 |
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Temozolomide; Vincristine; Wilms Tumor | 2014 |
[Correlation between the methylation of SULF2 and WRN promoter and chemosensitivity to irinotecan in gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Methylation; Exodeoxyribonucleases; Humans; Irinotecan; Methylation; Promoter Regions, Genetic; RecQ Helicases; Stomach Neoplasms; Sulfatases; Sulfotransferases; Werner Syndrome Helicase | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
Development and validation of a microfluidic chip-based nano-liquid chromatography-triple quadrupole tandem mass spectrometry method for a sensitive and reliable quantification of 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma.
Topics: Animals; Camptothecin; Chromatography, Liquid; Irinotecan; Male; Mice; Mice, Inbred ICR; Microfluidics; Nanotechnology; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2013 |
A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
Topics: Antineoplastic Agents, Phytogenic; ATP Citrate (pro-S)-Lyase; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression; Gene Knockdown Techniques; HT29 Cells; Humans; Irinotecan; Models, Biological; Proto-Oncogene Proteins c-akt; RNA Interference | 2013 |
Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism.
Topics: Alternative Splicing; Antineoplastic Agents; Camptothecin; Catalase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Gene Expression Profiling; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Oxidative Stress; Peroxiredoxins; Reactive Oxygen Species; RNA, Small Interfering | 2014 |
A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Multidetector Computed Tomography; Neoadjuvant Therapy; Organoplatinum Compounds; Precision Medicine; Uterine Cervical Neoplasms | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
A circadian clock transcription model for the personalization of cancer chronotherapy.
Topics: Animals; ARNTL Transcription Factors; Camptothecin; Chronotherapy; Circadian Clocks; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Irinotecan; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred DBA; Models, Biological; Nuclear Receptor Subfamily 1, Group D, Member 1; Period Circadian Proteins; Precision Medicine; RNA, Messenger; Topoisomerase I Inhibitors | 2013 |
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Oxonic Acid; RNA Interference; RNA, Small Interfering; Tegafur; Thymidylate Synthase; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Pharmacogenetics and its relevance to clinical practice.
Topics: Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Asian People; Camptothecin; Carbamazepine; Clopidogrel; Cytochrome P-450 CYP2C19; Glucuronosyltransferase; HLA-A Antigens; HLA-B Antigens; Humans; Irinotecan; Platelet Aggregation Inhibitors; Stevens-Johnson Syndrome; Ticlopidine; Topoisomerase I Inhibitors | 2013 |
Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Topics: Adenoviridae; Animals; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Dose-Response Relationship, Drug; Feasibility Studies; Genetic Vectors; Glioma; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Neural Stem Cells; Rabbits; Time Factors; Tissue Distribution; Topoisomerase I Inhibitors; Transduction, Genetic; Transfection; Xenograft Model Antitumor Assays | 2013 |
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA; DNA Modification Methylases; Drug Synergism; Epigenesis, Genetic; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2014 |
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF‑κB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Berberine; Camptothecin; Colonic Neoplasms; Down-Regulation; Doxorubicin; Fluorouracil; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; NF-kappa B; RNA Interference; RNA, Small Interfering; Survivin; Transcription Factor RelA | 2014 |
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Spain; Time Factors; Treatment Outcome | 2014 |
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postoperative Period; Preoperative Period; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
P7 peptides targeting bFGF sensitize colorectal cancer cells to CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; HT29 Cells; Humans; Irinotecan; Keratin-8; Peptide Fragments; Proto-Oncogene Proteins c-akt; Ribonucleotide Reductases | 2014 |
Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).
Topics: Animals; Camptothecin; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Glucuronic Acid; Glucuronosyltransferase; Histological Techniques; Immunoblotting; Intestinal Mucosa; Irinotecan; Liver; Male; Mice; Mice, Knockout; Microscopy, Confocal; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.
Topics: Animals; Apoptosis; Area Under Curve; Camptothecin; Carboxylic Ester Hydrolases; Female; Gene Expression; Humans; Intestine, Small; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Mice, Knockout; Mice, Transgenic; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Thymus Gland; Up-Regulation | 2014 |
[A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Oxonic Acid; Pancreatic Neoplasms; Proteoglycans; Recurrence; Salvage Therapy; Tegafur | 2013 |
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; DNA-Binding Proteins; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Irinotecan; MRE11 Homologue Protein; Mutation; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Real-Time Polymerase Chain Reaction | 2014 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases | 2013 |
Trends in treatment and survival in older patients presenting with stage IV colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Humans; Irinotecan; Male; Medicare; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Registries; Survival Rate; Time Factors; United States | 2014 |
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sex Characteristics; Treatment Outcome | 2014 |
Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Treatment Outcome | 2014 |
Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Neuroblastoma; Renal Dialysis; Renal Insufficiency; Temozolomide; Treatment Outcome | 2014 |
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dioxoles; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Irinotecan; Mice; Oncogene Proteins, Fusion; Phenotype; Proto-Oncogene Protein c-fli-1; RecQ Helicases; RNA Interference; RNA-Binding Protein EWS; RNA, Small Interfering; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Werner Syndrome Helicase; Xenograft Model Antitumor Assays | 2014 |
The antioxidants, vitamin A and E but not vitamin C and melatonin enhance the proapoptotic effects of irinotecan in cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Ascorbic Acid; Camptothecin; Cell Line, Tumor; Coloring Agents; Flow Cytometry; HT29 Cells; Humans; In Situ Nick-End Labeling; Irinotecan; Melatonin; Necrosis; Vitamin A; Vitamin E | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; France; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Treatment Outcome; Young Adult | 2014 |
In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38.
Topics: Animals; Caco-2 Cells; Camptothecin; Cell Death; Hep G2 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Male; Polyethylene Glycols; Rats, Sprague-Dawley; Reproducibility of Results; Time Factors; Tissue Distribution | 2014 |
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Infant; Irinotecan; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2014 |
Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Claudin-1; Diarrhea; Female; Intestinal Mucosa; Intestine, Large; Intestine, Small; Irinotecan; Occludin; Rats; Tight Junctions; Zonula Occludens-1 Protein | 2014 |
Genetically-engineered human neural stem cells with rabbit carboxyl esterase can target CNS lymphoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Bystander Effect; Camptothecin; Carboxylesterase; Central Nervous System Neoplasms; DNA Primers; Genetic Engineering; Humans; Irinotecan; Lymphoma; Male; Mice; Mice, Inbred BALB C; Neural Stem Cells; Rabbits; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Topics: Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Indoles; Irinotecan; Middle Aged; Piperazines; Proto-Oncogene Proteins c-met; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Hepatectomy; Hospitals, General; Humans; Irinotecan; Kaplan-Meier Estimate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Operative Time; Organoplatinum Compounds; Oxaliplatin; Surgery Department, Hospital; Treatment Outcome | 2013 |
Versatile online SPE-HPLC method for the analysis of Irinotecan and its clinically relevant metabolites in biomaterials.
Topics: Biocompatible Materials; Camptothecin; Chromatography, High Pressure Liquid; Internet; Irinotecan; Molecular Conformation; Solid Phase Extraction; Time Factors | 2014 |
Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Carriers; Fatty Acids; Irinotecan; Lipids; Nanostructures; Oils; Poloxamer; Solubility; Surface-Active Agents; Transition Temperature; X-Ray Diffraction | 2014 |
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Random Allocation; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2014 |
Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Signet Ring Cell; DNA Methylation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Exodeoxyribonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; RecQ Helicases; Stomach Neoplasms; Sulfatases; Sulfotransferases; Werner Syndrome Helicase | 2013 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2014 |
Image-based evaluations of distribution and cytotoxicity of Irinotecan (CPT-11) in a multi-compartment micro-cell coculture device.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cell Survival; Coculture Techniques; Dimethylpolysiloxanes; Drug Screening Assays, Antitumor; Hepatocytes; Irinotecan; Mice; Microfluidic Analytical Techniques; Microscopy, Fluorescence; Rats | 2014 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Cancer Vaccines; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Doxorubicin; Drug Evaluation; Fatal Outcome; Ganglioglioma; Humans; Immunotherapy; Indoles; Infant; Irinotecan; Male; Mutation, Missense; Neoplasm Proteins; Point Mutation; Polyethylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Salvage Therapy; Sulfonamides; Temozolomide; Thalamus; Treatment Outcome; Vemurafenib | 2014 |
Biocatalytic polymer coatings: on-demand drug synthesis and localized therapeutic effect under dynamic cell culture conditions.
Topics: Biocatalysis; Camptothecin; Cell Culture Techniques; Cell Survival; Coated Materials, Biocompatible; Glucuronidase; Hep G2 Cells; Hepatocytes; Humans; Irinotecan; Perfusion; Pharmaceutical Preparations; Polymers; Prodrugs; Quartz Crystal Microbalance Techniques | 2014 |
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
Topics: Animals; Bone Marrow; Breast Neoplasms; Camptothecin; Cations; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Lipids; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Camptothecin; Cell Line, Tumor; Chronotherapy; Circadian Rhythm; Cyclosporins; Endpoint Determination; Female; Ileum; Irinotecan; Mice; Mucous Membrane; Osteosarcoma; RNA, Messenger; Time Factors | 2014 |
Addition of propolis to irinotecan therapy prolongs survival in ehrlich ascites tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ehrlich Tumor; Cell Growth Processes; Disease Models, Animal; Drug Synergism; Irinotecan; Male; Mice; Propolis; Survival Analysis | 2014 |
[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinosarcoma; Combined Modality Therapy; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms | 2014 |
[An appropriate distal resection margin for lower rectal cancer after preoperative chemoradiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Postoperative Complications; Rectal Neoplasms; Tegafur | 2013 |
[Multiple hepatic metastases from colon cancer successfully treated with irinotecan and S-1 plus panitumumab as second-line therapy-a case report].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Panitumumab; Salvage Therapy; Sigmoid Neoplasms; Tegafur | 2013 |
[An effective treatment by chemotherapy with CDDP+CPT-11 for recurrent gastric cancer which S-1 cannot be used owing to adverse effects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Contraindications; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2013 |
[A case of multiple distant lymph node metastases from advanced gastric cancer treated with adjuvant chemotherapy after total gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Female; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Stomach Neoplasms | 2013 |
[Multidisciplinary therapy for 3 patients with lymph node recurrence after curative gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Stomach Neoplasms | 2013 |
[A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Esophagogastric Junction; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Cases of three patients undergoing chemotherapy for gastric cancer who developed Trousseau's syndrome].
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Stroke; Tegafur | 2013 |
[Long-term survival after surgical resection of a cancer of unknown primary site-a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Neoplasms, Unknown Primary; Oxonic Acid; Tegafur; Time Factors | 2013 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cholangitis; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Sepsis | 2014 |
Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Irinotecan; Mice; Mice, Inbred BALB C; Mucositis; Receptors, Interleukin; Recombinant Proteins | 2014 |
Proteomic analysis identifies proteins associated with curcumin-enhancing efficacy of irinotecan-induced apoptosis of colorectal cancer LOVO cell.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Humans; Irinotecan; Proteomics; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.
Topics: Animals; Camptothecin; Drug Delivery Systems; Intercellular Signaling Peptides and Proteins; Interleukin-18; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mucositis; Organ Culture Techniques | 2014 |
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Approval; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplastic Stem Cells; Quinolines; Spheroids, Cellular; United States; United States Food and Drug Administration; Xenograft Model Antitumor Assays | 2014 |
DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors | 2014 |
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum | 2014 |
Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2014 |
Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cardiovascular Agents; Cell Death; Cell Line; Cell Survival; Dexrazoxane; Diltiazem; Doxorubicin; Humans; Inhibitory Concentration 50; Irinotecan; Losartan; Myoblasts; Rats | 2013 |
The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats.
Topics: Animals; Butyrates; Camptothecin; Cecum; Dietary Fiber; Fatty Acids; Female; Glucuronidase; Humans; Intestinal Mucosa; Intestines; Irinotecan; Microbiota; Rats | 2014 |
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Diarrhea; Drug Synergism; Drug Therapy, Combination; Female; Gefitinib; HEK293 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Quinazolines; RNA, Messenger; Transplantation, Heterologous | 2013 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
A rapid, simple and reliable HPLC-triple quadrupole tandem mass spectrometer method for a simultaneous quantification of irinotecan and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma.
Topics: Animals; Camptothecin; Chromatography, High Pressure Liquid; Female; Irinotecan; Linear Models; Male; Mice; Mice, Inbred ICR; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Irinotecan; Liposomes; Manganese; Mice; Mice, SCID; Ovarian Neoplasms; Ovary | 2013 |
Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme.
Topics: Antibodies, Anti-Idiotypic; Camptothecin; Drug Delivery Systems; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Particle Size; Polymers; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Intracellular Space; Irinotecan; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Proteins; Neoplasms; Particle Size; Polymers; Porosity; Silicon Dioxide; Static Electricity; Time Factors; X-Ray Diffraction; Xenograft Model Antitumor Assays | 2014 |
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Vitamin B Complex | 2014 |
FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Retrospective Studies; Survival Analysis | 2014 |
Irinotecan-induced immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Platelet Count; Thrombocytopenia | 2014 |
Antitumor effects with apoptotic death in human promyelocytic leukemia HL-60 cells and suppression of leukemia xenograft tumor growth by irinotecan HCl.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase 3; Cell Cycle Proteins; Disease Models, Animal; DNA Damage; Endoplasmic Reticulum Chaperone BiP; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Irinotecan; Leukemia, Promyelocytic, Acute; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Transplantation, Heterologous | 2015 |
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prognosis; Radiography, Thoracic; Retrospective Studies | 2014 |
SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cyclodextrins; Female; Humans; Irinotecan; Ovarian Neoplasms; Solubility | 2014 |
Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Female; Genes, Reporter; Humans; Irinotecan; Liver Neoplasms; Luciferases; Luminescent Measurements; Mice; Mice, SCID; Micelles; Stomach Neoplasms; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Irinotecan; Liposomes; Nanostructures; Rats | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Gene Frequency; Genetic Variation; Genotype; HLA Antigens; HLA-B Antigens; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptors, KIR; Receptors, KIR3DL1; Treatment Outcome | 2014 |
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Comorbidity; Disease-Free Survival; Female; Health Status; Humans; Irinotecan; Male; Middle Aged | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss | 2014 |
Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Care Facilities; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; United States | 2014 |
The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caco-2 Cells; Camptothecin; Colonic Neoplasms; Drug Synergism; Female; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sirtuin 1; Sirtuin 2; Sirtuins; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Introns; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Positron-Emission Tomography | 2014 |
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Proteasome Endopeptidase Complex; RNA Interference; Signal Transduction; Stomach Neoplasms; Thioredoxins; Time Factors; Transfection; Ubiquitination; X-ray Repair Cross Complementing Protein 1 | 2014 |
FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Molecular precision chemotherapy: overcoming resistance to targeted therapies?
Topics: Animals; Antineoplastic Agents; Camptothecin; Dioxoles; DNA Damage; Female; Humans; Irinotecan; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin | 2014 |
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan | 2014 |
Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models.
Topics: Algorithms; Antineoplastic Agents; Bile Duct Neoplasms; Camptothecin; Drug Discovery; Feasibility Studies; Humans; Irinotecan; Models, Biological | 2013 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
Cetuximab-induced esophageal ulcer: the first report in literature.
Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoradiotherapy; Colostomy; Esophagitis; Esophagoscopy; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Proctoscopy; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Treatment Outcome; Ulcer; Vascular Endothelial Growth Factor A; Vomiting | 2014 |
Lung cancer with sarcoid reaction in the lymph nodes following chemoradiotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Irinotecan; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiation Dosage; Radiopharmaceuticals; Sarcoidosis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Hepatectomy; Humans; Intraoperative Care; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2014 |
[Chemotherapy and targeted therapy in liver metastasis from gastric cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Stomach Neoplasms; Taxoids; Trastuzumab | 2014 |
The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Irinotecan; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations.
Topics: Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy; Drug-Eluting Stents; Humans; Injections, Intra-Arterial; Internationality; Irinotecan; Liver Neoplasms; Practice Guidelines as Topic | 2014 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2014 |
Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Data Interpretation, Statistical; Dideoxynucleosides; Dihydroxyphenylalanine; Female; Glioma; Humans; Irinotecan; Kinetics; Male; Middle Aged; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Recurrence; Tissue Distribution | 2014 |
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cytoprotection; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Rats; Rats, Inbred F344; Selenocysteine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Factors | 2014 |
Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Half-Life; HT29 Cells; Humans; Irinotecan; Male; Metabolic Clearance Rate; Nanoparticles; Particle Size; Phospholipids; Rats; Rats, Wistar; Xenograft Model Antitumor Assays | 2015 |
Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia.
Topics: Antineoplastic Agents; Base Sequence; Benzimidazoles; Camptothecin; Cell Hypoxia; Cell Line, Tumor; DNA Damage; DNA Primers; DNA, Neoplasm; E2F1 Transcription Factor; Humans; Irinotecan; Male; Polymerase Chain Reaction; Prostatic Neoplasms; Rad51 Recombinase; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Small cell carcinoma presenting with massive pleural spread mimicking malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Diagnosis, Differential; Fatal Outcome; Humans; Irinotecan; Male; Mesothelioma; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Pleural Neoplasms; Small Cell Lung Carcinoma | 2014 |
An activatable theranostic for targeted cancer therapy and imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Fluorescent Dyes; Humans; Irinotecan; Mice; Molecular Imaging; Neoplasms, Experimental; Prodrugs; Sulfhydryl Compounds; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Testicular Neoplasms | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Perfusion Imaging; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Chlorophyllides; Combined Modality Therapy; Disulfides; Doxorubicin; Drug Carriers; Female; HeLa Cells; Humans; Irinotecan; KB Cells; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Molybdenum; Nanostructures; Phototherapy; Pilot Projects; Polyethylene Glycols; Porphyrins; Radiation-Sensitizing Agents | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide | 2014 |
IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).
Topics: Animals; Antimetabolites, Antineoplastic; Camptothecin; Cell Line; Cell Line, Tumor; Colon; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epithelial Cells; Fluorouracil; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Irinotecan; Jejunum; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mucositis; Protective Agents; Recombinant Proteins; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2014 |
Modeling sustained treatment effects in tumor xenograft experiments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Interactions; Humans; Irinotecan; Mice; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Sepsis | 2014 |
Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Body Composition; Body Mass Index; Camptothecin; Cetuximab; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Intra-Abdominal Fat; Irinotecan; Male; Middle Aged; Muscle, Skeletal; Neoplasm Metastasis; Nutrition Assessment; Prospective Studies; Sarcopenia; Young Adult | 2014 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Caring for one of our own.
Topics: Camptothecin; Caregivers; Diphosphonates; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nurses; Organoplatinum Compounds; Oxaliplatin; Pain; Pain Management; Pancreatic Neoplasms; Patient-Centered Care; Physician-Patient Relations | 2014 |
Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells.
Topics: Autophagy; beta Catenin; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Humans; I-kappa B Kinase; Irinotecan; Neoplasm Metastasis; NF-kappa B; Signal Transduction; Topoisomerase I Inhibitors; Wnt Proteins | 2014 |
Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding.
Topics: Animals; Camptothecin; Disease Progression; DNA; Female; Irinotecan; Lupus Nephritis; Mice; Mice, Inbred NZB; Topoisomerase I Inhibitors | 2014 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2014 |
Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.
Topics: Amoxapine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Female; Glycoproteins; Irinotecan; Mice; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Protective Agents; Protein Binding; Xenograft Model Antitumor Assays | 2014 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
Combination of chemotherapy and photodynamic therapy using graphene oxide as drug delivery system.
Topics: Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Carriers; Graphite; Humans; Irinotecan; Oxides; Perylene; Phenol; Photochemotherapy; Photosensitizing Agents; Quinones; Singlet Oxygen | 2014 |
Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; Humans; Irinotecan; Microscopy, Electron, Scanning; Mutation; Oncolytic Virotherapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rats; Reoviridae; Tumor Cells, Cultured | 2014 |
Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Fatty Liver; Female; Fluorouracil; Humans; Irinotecan; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Probability; Retrospective Studies; Risk Factors | 2014 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Survival Rate | 2014 |
Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Denmark; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex | 2014 |
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Young Adult | 2014 |
A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.
Topics: Administration, Intravenous; Administration, Oral; Afatinib; Animals; Camptothecin; Erlotinib Hydrochloride; In Vitro Techniques; Irinotecan; Liver; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Animal; Molecular Structure; Pyridones; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Immunohistochemistry; In Situ Hybridization; Irinotecan; Male; Membrane Proteins; Mutation; Panitumumab; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biological Assay; Caco-2 Cells; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Irinotecan; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Organoids; Proto-Oncogene Proteins; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Retrospective Studies; Treatment Outcome | 2014 |
Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation.
Topics: Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Irinotecan; Male; Mice, 129 Strain | 2014 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2014 |
Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Camptothecin; Chemistry, Pharmaceutical; Chemoembolization, Therapeutic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Irinotecan; Liver Neoplasms, Experimental; Microspheres; Necrosis; Particle Size; Rabbits | 2014 |
Irinotecan and temozolomide brain distribution: a focus on ABCB1.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Blood-Brain Barrier; Brain; Camptothecin; Dacarbazine; Female; Half-Life; Injections, Intraperitoneal; Irinotecan; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Nerve Tissue Proteins; Neurons; Prodrugs; Temozolomide; Tissue Distribution; Topoisomerase I Inhibitors | 2014 |
SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Irinotecan; Lactic Acid; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Surface Properties; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Enzyme Activation; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Prognosis | 2014 |
Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.
Topics: Animals; Blood Cell Count; Camptothecin; Cell Death; Cell Survival; Drug Stability; Electrophoresis, Polyacrylamide Gel; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasms; Particle Size; Serum Albumin; Static Electricity; Tissue Distribution | 2014 |
Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
Topics: Alleles; Asian People; Camptothecin; Genetic Linkage; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Liver; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2014 |
MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Camptothecin; Cell Survival; Chitosan; CHO Cells; Cricetinae; Cricetulus; Drug Carriers; Esters; HT29 Cells; Humans; Irinotecan; Molecular Targeted Therapy; Mucin-1; Nanoparticles | 2014 |
[A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Rectal Neoplasms; Tegafur | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Irinotecan; Middle Aged; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Heterografts; Humans; Irinotecan; Mice, Nude; Neuroimaging; Positron-Emission Tomography; Tyrosine | 2014 |
Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Limit of Detection; Neoplasms; Rabbits; Reproducibility of Results; Tandem Mass Spectrometry | 2014 |
Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective stu
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Treatment Outcome | 2014 |
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice.
Topics: Animals; Camptothecin; Caspase 1; Ileum; Inflammasomes; Interleukin-18; Interleukin-1beta; Irinotecan; Male; Membrane Glycoproteins; Mice, Inbred C57BL; Mice, Knockout; Mucositis; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Reactive Oxygen Species | 2014 |
Irinotecan pharmacogenetics: a finished puzzle?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms | 2014 |
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Topics: Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Precision Medicine; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RNA, Neoplasm; Sequence Analysis, RNA; Topoisomerase I Inhibitors | 2014 |
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; NF-kappaB-Inducing Kinase; Oligopeptides; Protein Serine-Threonine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Oncology Nursing; Polymorphism, Single Nucleotide | 2014 |
Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel.
Topics: Animals; Camptothecin; Cell Line, Tumor; Diffusion; Hydrogels; Irinotecan; Mice; Mice, Nude; Nanocapsules; Neoplasms, Experimental; Particle Size; Polyesters; Polyethylene Glycols; Rabbits; Remission Induction; Solubility; Treatment Outcome | 2014 |
Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Cyclobutanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Glutamates; Humans; Inhibitory Concentration 50; Irinotecan; Malonates; Organoplatinum Compounds; Oxaliplatin | 2014 |
HPLC analysis and extraction method of SN-38 in brain tumor model after injected by polymeric drug delivery system.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Delivery Systems; Irinotecan; Mice, Nude; Polymers | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
Evaluation of the in vitro/in vivo potential of five berries (bilberry, blueberry, cranberry, elderberry, and raspberry ketones) commonly used as herbal supplements to inhibit uridine diphospho-glucuronosyltransferase.
Topics: Animals; Blueberry Plants; Butanones; Camptothecin; Chromatography, Liquid; Fruit; Glucuronosyltransferase; Herb-Drug Interactions; Humans; Inhibitory Concentration 50; Irinotecan; Ketones; Male; Microsomes, Liver; Plant Extracts; Rats; Rats, Sprague-Dawley; Rubus; Sambucus; Tandem Mass Spectrometry; Vaccinium macrocarpon; Vaccinium myrtillus | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fecal Incontinence; Female; Fluorouracil; Humans; Ileostomy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Rectal Neoplasms; Risk Factors; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2014 |
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2014 |
Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Cell Line; Cell Line, Tumor; Docetaxel; eIF-2 Kinase; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Irinotecan; MCF-7 Cells; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sirtuin 1; Stomach Neoplasms; Taxoids; Transcription Factor CHOP; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Survival Rate | 2014 |
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Irinotecan; Metformin; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Records; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma; Treatment Outcome; Vomiting | 2014 |
Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heparin-binding EGF-like Growth Factor; Humans; Irinotecan; Ovarian Neoplasms; Promoter Regions, Genetic; Protein Binding; Sp1 Transcription Factor | 2014 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |
Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Rats; Selenium | 2014 |
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Metastasectomy; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Peritoneal Neoplasms; Proto-Oncogene Proteins B-raf; Survival Rate | 2014 |
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome | 2014 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fatty Liver; Humans; Interleukin-1beta; Irinotecan; Liver; Male; Mice; Peroxidase; Time Factors; Tumor Necrosis Factor-alpha; Weight Loss | 2014 |
Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Female; Humans; Hyperthermia, Induced; Ileal Neoplasms; Infusions, Parenteral; Intestine, Small; Irinotecan; Jejunal Neoplasms; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Lavage; Peritoneal Neoplasms; Peritoneum; Retrospective Studies; Treatment Outcome | 2014 |
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Nuclear Proteins; RNA, Small Interfering; Topoisomerase Inhibitors; Transfection | 2014 |
Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Caco-2 Cells; Camptothecin; Humans; In Vitro Techniques; Irinotecan; Liposomes | 2014 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nutrition Assessment; Nutritional Status; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Topics: Adult; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Genome-Wide Association Study; Genome, Human; Genomics; Humans; Irinotecan; KCNQ Potassium Channels; Knowledge Bases; Male; Neoplasms; Polymorphism, Single Nucleotide; ROC Curve | 2014 |
[Neuroendocrine gallbladder cancer treated with cisplatin plus irinotecan - a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Diagnosis, Differential; Female; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Middle Aged | 2014 |
UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2014 |
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Staging; Posterior Leukoencephalopathy Syndrome | 2014 |
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Retrospective Studies; ROC Curve | 2014 |
[Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Drug Carriers; Drug Delivery Systems; Humans; Irinotecan; Lipid Bilayers; Liver Neoplasms; Nanoparticles; Particle Size; Silicon Dioxide | 2014 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism.
Topics: Camptothecin; Dose-Response Relationship, Drug; Herb-Drug Interactions; Humans; Irinotecan; Microsomes, Liver; Plant Preparations; Tamoxifen | 2014 |
Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Camptothecin; Digoxin; Doxorubicin; Drugs, Chinese Herbal; Furans; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Phenanthrenes; Quinones; Salvia miltiorrhiza | 2014 |
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
Topics: Aged; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2014 |
Gene signatures of drug resistance predict patient survival in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Survival Rate | 2015 |
Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method.
Topics: Acetonitriles; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Stability; HCT116 Cells; HT29 Cells; Humans; Intracellular Space; Irinotecan; Least-Squares Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Tandem Mass Spectrometry | 2014 |
Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery platforms for enhanced antitumor efficacy.
Topics: Antineoplastic Agents; Camptothecin; Drug Carriers; Irinotecan; Microscopy, Electron, Transmission; Polymers; Prodrugs | 2014 |
The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Liver Neoplasms; Microspheres; Mutation; Neutropenia; Polymorphism, Genetic | 2014 |
Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Humans; Irinotecan; KB Cells; Multidrug Resistance-Associated Proteins; Transfection; Vincristine | 2014 |
Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2014 |
Establishment of an orthotopic model of pancreatic cancer to evaluate the antitumor effects of irinotecan through the biomarker carbohydrate antigen 19-9 in mice.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2014 |
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Focal Adhesion Kinase 1; Hepatectomy; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins pp60(c-src); Survival Analysis; Treatment Outcome | 2014 |
Synthesis and self-assembly of amphiphilic poly(acrylicacid)-poly(ɛ-caprolactone)-poly(acrylicacid) block copolymer as novel carrier for 7-ethyl-10-hydroxy camptothecin.
Topics: Absorption, Physicochemical; Acrylic Resins; Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Diffusion; Humans; Irinotecan; Materials Testing; Nanocapsules; Particle Size; Polyesters; Treatment Outcome | 2015 |
Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis.
Topics: Analysis of Variance; Animals; Atrophy; Camptothecin; Disease Models, Animal; Female; Immunohistochemistry; Irinotecan; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Mouth Mucosa; Random Allocation; Rats; Stomatitis; Tongue | 2015 |
Herb-drug interaction between irinotecan and psoralidin-containing herbs.
Topics: Animals; Benzofurans; Camptothecin; Colon; Coumarins; Dose-Response Relationship, Drug; Herb-Drug Interactions; Humans; Irinotecan; Male; Mice; Mice, 129 Strain | 2015 |
Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma.
Topics: Adenocarcinoma; Camptothecin; Colonic Neoplasms; Coumarins; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Lipids; Nanoparticles; Thiazoles | 2015 |
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dogs; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Species Specificity; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
[Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, Liquid; Colon; Half-Life; Injections, Intravenous; Irinotecan; Lung; Mice; Nanoparticles; Rats; Tandem Mass Spectrometry; Tissue Distribution | 2014 |
An activatable prodrug for the treatment of metastatic tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; HeLa Cells; Humans; Hydrogen Peroxide; Irinotecan; Lung Neoplasms; Mice; Molecular Structure; Neoplasms, Experimental; Prodrugs; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
In vivo evaluation of irinotecan-loaded QuadraSphere microspheres for use in chemoembolization of VX2 liver tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Disease Models, Animal; Female; Irinotecan; Liver Neoplasms, Experimental; Microspheres; Rabbits; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Clinical efficacy of low-dose CDDP and CPT-11 therapy as second- or third-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Recurrence; Retrospective Studies; Stomach Neoplasms | 2014 |
Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Carboxylesterase; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; HCT116 Cells; HT29 Cells; Humans; Irinotecan; RNA, Small Interfering; Transfection | 2014 |
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan | 2014 |
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Treatment Outcome | 2014 |
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma; Colonic Neoplasms; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2015 |
Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2015 |
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Case-Control Studies; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Matrix Metalloproteinase 7; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Syndecan-1; Tumor Cells, Cultured | 2014 |
CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Burden | 2015 |
The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Israel; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2015 |
Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Lung Neoplasms; Methyltransferases; Reproducibility of Results; Tumor Suppressor Protein p53 | 2015 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Breast Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mutation; Neoplasm Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2014 |
Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Irinotecan; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Retrospective Studies; Young Adult | 2014 |
An on-chip small intestine-liver model for pharmacokinetic studies.
Topics: Animals; Caco-2 Cells; Camptothecin; Computer Simulation; Cyclophosphamide; Drug Screening Assays, Antitumor; Epirubicin; Hep G2 Cells; Humans; Intestine, Small; Irinotecan; Lab-On-A-Chip Devices; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Organ Culture Techniques; Stomach Neoplasms | 2015 |
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drugs, Investigational; Half-Life; Humans; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Receptor, trkB; Survival Analysis; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Seminoma; Testicular Neoplasms; Treatment Outcome; Young Adult | 2016 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Prospective Studies; Sex Factors; Treatment Outcome | 2015 |
Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Retrospective Studies | 2015 |
Interplay between the prostaglandin transporter OATP2A1 and prostaglandin E2-mediated cellular effects.
Topics: Camptothecin; Cell Movement; Cell Survival; Cyclic AMP; Dinoprostone; Gastric Mucosa; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Interleukin-8; Irinotecan; Organic Anion Transporters; Receptors, Prostaglandin E, EP4 Subtype; RNA, Messenger; S Phase Cell Cycle Checkpoints; Up-Regulation | 2015 |
Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Young Adult | 2015 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Synthesis and biological evaluation of novel 10-substituted-7-ethyl-10-hydroxycamptothecin (SN-38) prodrugs.
Topics: Animals; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; Cholinesterase Inhibitors; Colonic Neoplasms; Drug Stability; Humans; Hydrogen-Ion Concentration; Irinotecan; Mice, Nude; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Magnetic nanoparticles-serum proteins bioconjugates for binding of irinotecan.
Topics: Blood Proteins; Camptothecin; Drug Carriers; Drug Delivery Systems; Humans; Irinotecan; Magnetite Nanoparticles; Protein Binding; Spectroscopy, Fourier Transform Infrared; Thermodynamics; Thermogravimetry | 2015 |
Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polymorphism, Genetic; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Young Adult | 2014 |
Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Hyaluronic Acid; Irinotecan; Lipids; Nanoparticles; Nanostructures | 2014 |
Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation.
Topics: Alendronate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Flow Cytometry; HT29 Cells; Humans; Hyaluronan Receptors; Hyaluronic Acid; Inhibitory Concentration 50; Irinotecan; Lipids; Nanostructures | 2014 |
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Topics: Camptothecin; Dose-Response Relationship, Drug; Drug Approval; HEK293 Cells; High-Throughput Screening Assays; Humans; Irinotecan; Luciferases; Luminescent Measurements; Mercaptopurine; Multidrug Resistance-Associated Proteins; Small Molecule Libraries; United States | 2015 |
Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Chromatography, High Pressure Liquid; Chromones; HEK293 Cells; Humans; Indoles; Irinotecan; Mass Spectrometry; Mice; Neoplasm Proteins; Neoplasms, Experimental; Transfection; Xenograft Model Antitumor Assays | 2014 |
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Methylation; Drug Evaluation, Preclinical; Epigenesis, Genetic; Female; Histones; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Pyridines | 2015 |
Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs.
Topics: Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Biological Transport; Camptothecin; Cyclic GMP; Estrone; HEK293 Cells; Humans; Irinotecan; Nitrogen Mustard Compounds; Organic Anion Transporters, Sodium-Dependent; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Symporters | 2015 |
Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Vessels; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colonic Neoplasms; Drug Delivery Systems; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Nanostructures; Regional Blood Flow; Xenograft Model Antitumor Assays | 2015 |
Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats.
Topics: Animals; Camptothecin; Carboxylic Ester Hydrolases; Chemical and Drug Induced Liver Injury; Down-Regulation; Imidazolidines; Irinotecan; Lipopolysaccharides; Liver; Male; Mycobacterium bovis; Prodrugs; Rats; Rats, Sprague-Dawley; Substrate Specificity | 2015 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged | 2014 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Colonic Neoplasms; Drugs, Chinese Herbal; Female; Granulocyte Colony-Stimulating Factor; Humans; Intestinal Mucosa; Intestines; Irinotecan; Mice; Neutrophil Infiltration; Phytotherapy; Receptors, G-Protein-Coupled; RNA, Messenger; Tumor Necrosis Factor-alpha; Weight Loss | 2014 |
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Retreatment; Treatment Outcome | 2015 |
Vaginal carcinoma in a young woman who underwent fertility-sparing treatment involving chemotherapy and conservative surgery.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Organoplatinum Compounds; Remission Induction; Uterine Hemorrhage; Vagina; Vaginal Neoplasms | 2015 |
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Chromosomal Proteins, Non-Histone; Colorectal Neoplasms; Down-Regulation; Female; Gene Expression; Gene Knockdown Techniques; Humans; Irinotecan; Male; Middle Aged; Oncogene Proteins; Phenotype; Poly-ADP-Ribose Binding Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Databases, Factual; Feasibility Studies; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Melanoma; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Treatment Outcome; Uveal Neoplasms; Young Adult | 2015 |
Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan.
Topics: Biocatalysis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Phosphoric Diester Hydrolases; RNA, Messenger | 2015 |
A bioengineered murine model using CD24⁺CD44⁺ pancreatic cancer stem cells for chemotherapy study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomedical Engineering; Camptothecin; CD24 Antigen; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Tissue Scaffolds | 2014 |
New method and characterization of self-assembled gelatin-oleic nanoparticles using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction.
Topics: Antineoplastic Agents; Biocompatible Materials; Camptothecin; Carbodiimides; Drug Carriers; Drug Compounding; Gelatin; Irinotecan; Magnetic Resonance Spectroscopy; Microscopy, Electron, Transmission; Nanoparticles; Oleic Acid; Particle Size; Spectroscopy, Fourier Transform Infrared; Succinimides; Suspensions; Trinitrobenzenesulfonic Acid | 2015 |
Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Growth Processes; Cell Line, Tumor; Disease Models, Animal; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neural Stem Cells; Random Allocation; Xenograft Model Antitumor Assays | 2014 |
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Transformation, Neoplastic; Cellular Senescence; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Heterografts; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2015 |
Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcineurin; Camptothecin; Cell Line, Tumor; Diterpenes; Drug Synergism; Epoxy Compounds; Extracellular Signal-Regulated MAP Kinases; Humans; Irinotecan; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phenanthrenes; Proto-Oncogene Proteins c-akt; Signal Transduction | 2015 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cetuximab; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Retrospective Studies; Survival Rate; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Gene homozygosis and mitotic recombination induced by camptothecin and irinotecan in Aspergillus nidulans diploid cells.
Topics: Aspergillus nidulans; Camptothecin; Diploidy; Homozygote; Irinotecan; Mitosis; Mutagenicity Tests; Recombination, Genetic; Topoisomerase I Inhibitors | 2014 |
A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Enzyme Activation; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2015 |
[Complete resection of liver metastases of colorectal cancer after high efficacy bevacizumab, S-1, and CPT -11 combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2015 |
[A case of disease-free, long survival in a patient with mixed adenoneuroendocrine carcinoma of the gallbladder treated with induction CDDP/CPT-11 chemotherapy and resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Female; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Time Factors; Treatment Outcome | 2015 |
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Spiral Cone-Beam Computed Tomography; Treatment Outcome | 2015 |
Neoadjuvant therapy for localized pancreatic cancer: support is growing?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Receptor, ErbB-2; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2015 |
Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids.
Topics: Camptothecin; Chromatography, Liquid; Drug Stability; HCT116 Cells; Humans; Irinotecan; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spheroids, Cellular; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2015 |
Irinotecan as a palliative therapy for metastatic breast cancer patients after previous chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2014 |
TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tissue Inhibitor of Metalloproteinase-1 | 2015 |
Always look at the bright side of drugs?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2015 |
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Polymorphism, Single Nucleotide; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
TPGS2k/PLGA nanoparticles for overcoming multidrug resistance by interfering mitochondria of human alveolar adenocarcinoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lactic Acid; Mitochondria; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Vitamin E | 2015 |
Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albumin.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Thin Layer; Humans; Irinotecan; Serum Albumin; Solutions; Spectrum Analysis, Raman | 2015 |
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, SCID; Purines; RNA, Neoplasm; Roscovitine; Treatment Outcome | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Peduncle; Child; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infratentorial Neoplasms; Irinotecan; Laser Therapy; Male; Neoplasms, Multiple Primary; Neurofibromatosis 1; Neuroimaging; Optic Nerve Glioma; Supratentorial Neoplasms; Temozolomide | 2015 |
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2015 |
Selective anticancer activity of hirsutine against HER2‑positive breast cancer cells by inducing DNA damage.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspases; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Irinotecan; MCF-7 Cells; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2015 |
Targeting the adaptability of heterogeneous aneuploids.
Topics: Aneuploidy; Antifungal Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Candida albicans; Cell Line, Tumor; Drug Resistance, Fungal; Drug Resistance, Neoplasm; ErbB Receptors; Fluconazole; Glioblastoma; Humans; Hygromycin B; Irinotecan; Saccharomyces cerevisiae | 2015 |
Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Humans; Irinotecan; Mice; Mice, Nude; Nanoparticles; Neuroblastoma; Prodrugs; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Escherichia coli; Fluorescent Dyes; Genetic Engineering; Genetic Therapy; Glucuronidase; Humans; Hydrolysis; Irinotecan; Mice; Transformation, Genetic | 2015 |
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study.
Topics: Blood Chemical Analysis; Camptothecin; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Irinotecan; Tandem Mass Spectrometry | 2015 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Evaluation of the plasmatic and parenchymal elution kinetics of two different irinotecan-loaded drug-eluting embolics in a pig model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Disease Models, Animal; Female; Irinotecan; Liver Neoplasms; Swine | 2015 |
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Panitumumab; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins | 2015 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur | 2015 |
Fatty acid synthase-positive hepatocytes and subsequent steatosis in rat livers by irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Fatty Acid Synthases; Fatty Liver; Hepatocytes; Immunohistochemistry; Irinotecan; Liver; Male; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction | 2015 |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Irinotecan; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2015 |
Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prodrugs; Time Factors; Tomography, X-Ray Computed | 2015 |
Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Drug Monitoring; Glioblastoma; Humans; Infusions, Parenteral; Irinotecan; Liposomes; Rats; Sirolimus; Topoisomerase I Inhibitors; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Proliferation; Doxorubicin; Drug Combinations; HeLa Cells; Humans; Irinotecan; Lecithins; Lipid Bilayers; MCF-7 Cells; Mice; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Polymers; Structure-Activity Relationship | 2015 |
Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Hypersensitivity; Emergency Treatment; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Glioma; Humans; Irinotecan; Mice; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Xenograft Model Antitumor Assays | 2015 |
[A case of advanced rectal cancer with irinotecan (CPT-11)-induced delayed emesis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Humans; Irinotecan; Middle Aged; Quality of Life; Rectal Neoplasms; Vomiting | 2014 |
[Mixed adenoneuroendocrine carcinoma with multiple liver metastases successfully treated by cetuximab/CPT-11 chemotherapy followed by curative resection - a case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Humans; Irinotecan; Liver Neoplasms; Male; Rectal Neoplasms | 2014 |
[A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur | 2014 |
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Humans; Irinotecan; Liposomes; Macrophages; Mice; Nuclear Proteins; Sarcoma, Ewing; Sucrose; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Impact of the spheroid model complexity on drug response.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cetuximab; Coculture Techniques; Everolimus; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Spheroids, Cellular; Stromal Cells; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Vorinostat | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
The Influence of Aging on Hepatic Regeneration and Early Outcome after Portal Vein Occlusion: A Case-Control Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Diabetes Complications; Embolization, Therapeutic; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Neoadjuvant Therapy; Organ Size; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Preoperative Care; Radiography; Sex Factors; Young Adult | 2015 |
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
Topics: Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Models, Biological; Organoplatinum Compounds; Oxaliplatin | 2015 |
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Biosynthesis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.
Topics: Animals; Camptothecin; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Drug Approval; HT29 Cells; Humans; Intracellular Space; Irinotecan; Mice; Models, Molecular; Multidrug Resistance-Associated Proteins; Protein Conformation; United States; United States Food and Drug Administration | 2015 |
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.
Topics: alpha-Tocopherol; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Irinotecan; Mice, Nude; Nanoparticles; Neuroblastoma; Particle Size; Prodrugs; Treatment Outcome | 2015 |
Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Heterografts; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Mice; Mice, Nude; Microdialysis; Neuroblastoma | 2015 |
Irinotecan as a second-line chemotherapy for small cell lung cancer: a systemic analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Small Cell Lung Carcinoma | 2015 |
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Canada; Colorectal Neoplasms; Female; Genetic Testing; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide | 2015 |
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Topics: Animals; Benzamidines; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Immunomodulation; Irinotecan; Lupus Nephritis; Mice; Mice, Inbred NZB; Phosphoric Diester Hydrolases; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
Therapy-related leukemia with Inv(16)(p13.1q22) and type D CBFB/MYH11 developing after exposure to irinotecan-containing chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoradiotherapy; Chromosomes, Human, Pair 16; Female; Humans; Irinotecan; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Treatment Outcome | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2015 |
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
Topics: Adult; Camptothecin; Dioxoles; Humans; Irinotecan; Male; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Malaysia; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Topics: Activation, Metabolic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Polo-Like Kinase 1; Prodrugs; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Proteins; Pteridines; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Skin Neoplasms; Topoisomerase I Inhibitors; Ubiquitination; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[Biomarkers for the prediction of adverse events].
Topics: Antineoplastic Agents; Biomarkers; Camptothecin; Fluorouracil; Humans; Irinotecan; Mercaptopurine; Tamoxifen | 2015 |
[DNA topoisomerase I--targeting drugs].
Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2015 |
Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Contrast Media; Drug Delivery Systems; Female; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Melanoma; Middle Aged; Radiographic Image Enhancement; Retrospective Studies; Therapeutics; Tomography, X-Ray Computed; Uveal Neoplasms; Young Adult | 2015 |
Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caco-2 Cells; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Irinotecan; Male; Mice, Nude; Necrosis; Neoplasms; Tumor Burden | 2015 |
CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; History, 20th Century; History, 21st Century; Humans; Irinotecan; Medical Oncology | 2015 |
Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chitosan; Irinotecan; Macromolecular Substances; Male; Mice; Mice, Inbred BALB C; Micelles; Particle Size; Prodrugs; Rats; Rats, Sprague-Dawley; Solubility; Xenograft Model Antitumor Assays | 2015 |
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; DNA; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Prognosis; Retreatment; Retrospective Studies; Survival Rate; Turkey | 2015 |
Oral delivery of nanoparticles containing anticancer SN38 and hSET1 antisense for dual therapy of colon cancer.
Topics: Administration, Oral; Animals; Camptothecin; Cell Line, Tumor; Chitosan; Colonic Neoplasms; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Stability; Histone-Lysine N-Methyltransferase; Humans; Irinotecan; Mice; Nanoparticles; Oligonucleotides, Antisense; Spectroscopy, Fourier Transform Infrared; Xenograft Model Antitumor Assays | 2015 |
The rapidly escalating cost of treating colorectal cancer in Australia.
Topics: Aged, 80 and over; Antineoplastic Agents; Australia; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2016 |
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Genetic Markers; Genotype; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia | 2016 |
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Topics: Aged; Alleles; Asian People; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Neutrophils; Nomograms; Prospective Studies | 2015 |
Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Dipeptides; Female; Humans; Immunoenzyme Techniques; Indoles; Irinotecan; Lymphatic Metastasis; Mice; Mice, Nude; Necrosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2015 |
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Male; Membrane Transport Proteins; Mice, SCID; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Receptor, ErbB-2; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2015 |
Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability.
Topics: Camptothecin; Cell Line, Transformed; Chromosomal Instability; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Etoposide; Humans; Irinotecan; Mitosis; Mutation; Organoplatinum Compounds; Oxaliplatin; Recombinant Proteins; Telomerase; Telomere | 2016 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
Inferior mesenteric artery chemoembolization and chemotherapy for advanced rectal cancer: report of a clinical case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mesenteric Artery, Inferior; Microspheres; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome; Tumor Burden | 2015 |
Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Coumarins; Dendrimers; Drug Carriers; Humans; Irinotecan; Molecular Dynamics Simulation; Nanostructures | 2015 |
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Apoptosis; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Clinical Trials as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Irinotecan; Mice; Pancreatic Neoplasms; Signal Transduction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2015 |
ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Camptothecin; Cell Line, Tumor; Chemoradiotherapy; Cyclin G1; Doxycycline; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Osteosarcoma; Peptides; Phosphorylation; Protein Binding; Protein Phosphatase 2; Tumor Suppressor Protein p53 | 2015 |
Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Combinations; Drug Interactions; Gefitinib; Glucuronosyltransferase; Humans; Irinotecan; Microsomes, Liver; Quinazolines | 2015 |
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Colorectal Neoplasms; Female; Gene Expression; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Middle Aged; Prognosis; Ubiquitin-Conjugating Enzymes | 2016 |
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzodioxoles; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Indolizines; Irinotecan; Lung Neoplasms; Mice, SCID; Neoplasm Proteins; Topoisomerase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Azoxymethane; Camptothecin; Cell Line, Tumor; Colitis; Colonic Neoplasms; Dextrans; Drug Delivery Systems; Drug Screening Assays, Antitumor; Endoscopy; Free Radical Scavengers; Inflammation; Irinotecan; Male; Mice; Mice, Inbred ICR; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Nitrogen Oxides; Oxidation-Reduction; Reactive Oxygen Species; Sulfates | 2015 |
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; GTP Phosphohydrolases; Humans; In Situ Hybridization, Fluorescence; Insulin-Like Growth Factor I; Irinotecan; Male; Membrane Proteins; Middle Aged; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-3; Treatment Outcome | 2015 |
Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Survival Analysis; Treatment Outcome | 2015 |
Safety and efficacy compared between irinotecan-loaded microspheres HepaSphere and DC bead in a model of VX2 liver metastases in the rabbit.
Topics: Activation, Metabolic; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Carriers; Gene Expression Regulation, Neoplastic; Hepatic Artery; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms, Experimental; Male; Microspheres; Necrosis; Particle Size; Rabbits; Tissue Distribution | 2015 |
Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice.
Topics: Adenomatous Polyposis Coli Protein; Animals; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Fasting; G2 Phase Cell Cycle Checkpoints; Irinotecan; Mice; Mice, Inbred C57BL; Mice, Knockout; S Phase Cell Cycle Checkpoints; Topoisomerase I Inhibitors | 2015 |
[Long-term survival and effective treatment of synchronous liver metastases in a case of primary gastric choriocarcinoma by using hepatic arterial infusion chemotherapy, irinotecan, and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Choriocarcinoma; Cisplatin; Fatal Outcome; Gastrectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2015 |
Prevalence of the UGT1A1*6 (c.211G>A) Polymorphism and Prediction of Irinotecan Toxicity in Iranian Populations of Different Ethnicities.
Topics: Camptothecin; Ethnicity; Gene Frequency; Glucuronosyltransferase; Humans; Iran; Irinotecan; Polymorphism, Genetic; Population Surveillance; Predictive Value of Tests; Prevalence | 2014 |
Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2015 |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; HCT116 Cells; Heat-Shock Proteins; Humans; Irinotecan; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Transcriptome | 2015 |
Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Camptothecin; Chemistry, Pharmaceutical; Chlorophyll; Dogs; Doxorubicin; Irinotecan; Madin Darby Canine Kidney Cells; Microscopy, Confocal; Nanoparticles; Neoplasm Proteins; Rhodamine 123 | 2015 |
Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Diseases; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Drug Carriers; Female; Humans; Infarction; Irinotecan; Liver Neoplasms; Male; Middle Aged; Particle Size; Patient Safety; Portal Vein; Retrospective Studies; Risk Assessment; Risk Factors; Texas; Time Factors; Treatment Outcome; Tumor Burden; Venous Thrombosis | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Topics: Amino Acid Transport System X-AG; Antineoplastic Agents; Aspartic Acid; Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Copper; Drug Resistance, Neoplasm; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 3; Gene Expression; Gene Knockdown Techniques; Glutathione; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Transport; Tumor Suppressor Protein p53 | 2015 |
[Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2015 |
Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
Design and synthesis of novel PEG-conjugated 20(S)-camptothecin sulfonylamidine derivatives with potent in vitro antitumor activity via Cu-catalyzed three-component reaction.
Topics: Antineoplastic Agents; Camptothecin; Catalysis; Cell Line, Tumor; Cell Proliferation; Copper; Drug Design; Drug Screening Assays, Antitumor; Humans; Irinotecan; KB Cells; Polyethylene Glycols; Structure-Activity Relationship | 2015 |
The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Topics: Alu Elements; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; SOX Transcription Factors | 2015 |
Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cells, Cultured; Chlorocebus aethiops; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Organoplatinum Compounds; Oxaliplatin; Vaccinia virus | 2015 |
Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients.
Topics: Adult; Camptothecin; Carcinoma, Hepatocellular; Genistein; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Liver Neoplasms; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Propofol; Tamoxifen; Zidovudine | 2015 |
Structure-inhibition relationship of podophyllotoxin (PT) analogues towards UDP-glucuronosyltransferase (UGT) isoforms.
Topics: Binding, Competitive; Camptothecin; Drug Interactions; Enzyme Inhibitors; Estradiol; Glucuronides; Glucuronosyltransferase; Humans; Hymecromone; In Vitro Techniques; Irinotecan; Isoenzymes; Microsomes, Liver; Podophyllotoxin; Structure-Activity Relationship; Substrate Specificity; Trifluoperazine | 2015 |
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Diphenylamine; Drug Synergism; ErbB Receptors; Female; Humans; Irinotecan; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Genes, Dominant; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 8; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Transfection; Xenograft Model Antitumor Assays | 2015 |
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboxylesterase; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Mass Spectrometry; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, RNA; Tissue Array Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Topics: Antineoplastic Agents; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Protein Isoforms; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Triazines; Wnt Signaling Pathway | 2015 |
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Irinotecan in a Patient With Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Irinotecan; Neoplasm Metastasis | 2015 |
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy | 2015 |
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.
Topics: Animals; Antineoplastic Agents; Bystander Effect; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytotoxicity, Immunologic; Drug Delivery Systems; Humans; Interleukin-2; Irinotecan; Lymph Nodes; Lymphoma; Mice; Nanocapsules; Nanoparticles; Receptors, Lymphocyte Homing; Sirolimus; T-Lymphocytes; Treatment Outcome | 2015 |
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Diabetes Mellitus, Type 2; Etoposide; Female; Humans; Hypoglycemic Agents; Irinotecan; Lung Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Platinum Compounds; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Antitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Blood Proteins; Body Weight; Camptothecin; Cattle; Colitis; Diarrhea; Enteritis; Female; Immunoglobulins; Injections, Intraperitoneal; Irinotecan; Jejunal Diseases; Mucositis; Random Allocation; Rats | 2016 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Genetic; Thrombocytopenia | 2015 |
Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Culture Media, Conditioned; Drug Resistance, Neoplasm; Enzyme Activation; Fibroblasts; HCT116 Cells; Hepatocyte Growth Factor; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-met | 2015 |
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Follow-Up Studies; Genotype; Germany; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Insurance, Health; Irinotecan; Leucovorin; Neoplasm Staging; Prognosis; Quality of Life; Quality-Adjusted Life Years; Survival Rate | 2016 |
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Female; Humans; Immunoconjugates; Irinotecan; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Humans; Immunoconjugates; Irinotecan; Mice; Pancreatic Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Comet Assay; Disease Progression; DNA Damage; DNA Repair; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Repetitive Sequences, Nucleic Acid; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
Cellular backpackers deliver lymphoma drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Delivery Systems; Humans; Irinotecan; Lymphoma; T-Lymphocytes | 2015 |
Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Camptothecin; Cisplatin; Etoposide; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retreatment; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Cisplatin; Diarrhea; DNA-Binding Proteins; Endonucleases; Female; Gene Expression; Gene Frequency; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polymorphism, Genetic; Treatment Outcome | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
A pH-Responsive Carrier System that Generates NO Bubbles to Trigger Drug Release and Reverse P-Glycoprotein-Mediated Multidrug Resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Nitric Oxide | 2015 |
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Prospective Studies; Remission Induction | 2015 |
Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Circadian Clocks; DNA Topoisomerases, Type I; Drug Chronotherapy; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Models, Theoretical; Neoplasms | 2015 |
Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Thymidylate Synthase; Treatment Outcome | 2015 |
The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles | 2015 |
Layered superhydrophobic meshes for controlled drug release.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Lewis Lung; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Hydrophobic and Hydrophilic Interactions; Irinotecan; Neoplasm Recurrence, Local; Polyesters; Rats; Rats, Inbred Lew; Solubility; Surface Properties | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Camptothecin; Eligibility Determination; Female; Fluorouracil; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Insufficiency; Retrospective Studies | 2017 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Pseudomyxoma Peritonei; Tumor Cells, Cultured; Young Adult | 2015 |
SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Adhesion; Cell Count; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Receptors, G-Protein-Coupled; Transfection | 2015 |
Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Irinotecan; Isoenzymes; Neoplasm Proteins; Phthalazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins | 2015 |
KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.
Topics: Acetylation; Animals; Antineoplastic Agents, Alkylating; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Gene Deletion; Gene Expression Profiling; Genes, Tumor Suppressor; Heterografts; Histone Acetyltransferases; Histones; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Protein Processing, Post-Translational; RNA Interference; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering | 2015 |
Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Glioblastoma; In Vitro Techniques; Irinotecan; Nanofibers; Rats; Rats, Wistar | 2015 |
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Polycomb Repressive Complex 1; RNA, Messenger | 2015 |
Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice.
Topics: Animals; Antineoplastic Agents; Bacteria; Camptothecin; Gastrointestinal Microbiome; Germ-Free Life; Intestinal Mucosa; Irinotecan; Mice; Mucositis | 2015 |
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index; Young Adult | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Complex and Mixed; Neutrophils; Platelet Count; Platinum Compounds; Pneumonectomy; Prognosis; Radiotherapy; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Gene Knockout Techniques; Genomics; Herpesvirus 1, Human; Humans; Irinotecan; Lentivirus; Oncolytic Virotherapy; Phosphorylation; RNA, Small Interfering; Serine-Arginine Splicing Factors; Virus Replication | 2016 |
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice, Inbred ICR; Mice, SCID; Microscopy, Fluorescence; Molecular Targeted Therapy; Neoplasms; Resorcinols; Topoisomerase I Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Taiwan; Treatment Outcome | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Female; Glioblastoma; Humans; Irinotecan; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Portugal; Prevalence; Procarbazine; Retrospective Studies; Risk Assessment; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2015 |
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Epiregulin; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; RNA, Messenger | 2016 |
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockdown Techniques; Genes, p53; Humans; Irinotecan; Neoplasm Proteins; Nitrofurans; Nuclear Proteins; Piperazines; Proteolysis; Proto-Oncogene Mas; Recombinant Fusion Proteins; RNA, Small Interfering; Signal Transduction; Tumor Protein p73; Tumor Stem Cell Assay; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
Biophysical and molecular docking insight into interaction mechanism and thermal stability of human serum albumin isoforms with a semi-synthetic water-soluble camptothecin analog irinotecan hydrochloride.
Topics: Camptothecin; Humans; Irinotecan; Kinetics; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Protein Stability; Serum Albumin; Spectrum Analysis; Thermodynamics | 2016 |
Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles.
Topics: Animals; Apoptosis; Aptamers, Nucleotide; Calorimetry, Differential Scanning; Camptothecin; Cell Line, Tumor; Cell Survival; Chitosan; Cricetinae; Drug Carriers; Drug Liberation; Humans; Hyaluronic Acid; Irinotecan; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Mucin-1; Nanoparticles; Particle Size; Protein Corona | 2015 |
An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cell Adhesion Molecule; Flow Cytometry; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Leucovorin; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Vitamin B Complex; Xenograft Model Antitumor Assays | 2015 |
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pakistan; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2015 |
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Fluorouracil; Genetic Markers; Humans; Irinotecan; Liver Neoplasms; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Predictive Value of Tests; Prognosis; Survival Analysis | 2015 |
[A Case of Esophageal Neuroendocrine Carcinoma for Which Irinotecan and Cisplatin Combination Therapy Was Effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Tomography, X-Ray Computed | 2015 |
Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
Topics: Animals; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Drug Delivery Systems; Gadolinium; Glioma; Humans; Irinotecan; Male; Mice; Micelles; Polymers; Rats; Rats, Inbred F344; Rats, Nude | 2016 |
Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Colonic Neoplasms; Diarrhea; Fasting; Glucuronides; Irinotecan; Leukopenia; Liver; Male; Mice, Inbred BALB C; RNA, Messenger; Treatment Outcome; Tumor Burden; Weight Loss | 2016 |
Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Feces; Glucuronates; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Necrosis Factor-alpha | 2015 |
Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.
Topics: Acute Kidney Injury; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Kidney; Models, Biological; Neoplasms; Protein Binding | 2016 |
Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Endocytosis; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Intracellular Space; Irinotecan; Lactic Acid; Male; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spheroids, Cellular; Tissue Distribution | 2015 |
The development of a matrix-assisted laser desorption/ionization (MALDI)-based analytical method for determination of irinotecan levels in human plasma: preliminary results.
Topics: Camptothecin; Humans; Irinotecan; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Long-term survival in small-cell carcinoma of the endometrium with liver and brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Endometrial Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms | 2016 |
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genetic Markers; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies | 2015 |
Clinicopathological outcomes of preoperative chemoradiotherapy using S-1 plus Irinotecan for T4 lower rectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Digestive System Surgical Procedures; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Preoperative Period; Rectal Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2016 |
Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bacterial Proteins; Bacteroides fragilis; Camptothecin; Clostridium perfringens; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Escherichia coli; Glucuronidase; Irinotecan; Mice; Mice, Inbred BALB C; Microbiota; Models, Molecular; Molecular Sequence Data; Streptococcus agalactiae | 2015 |
Synergistic Antiproliferative Effects of a New Cucurbitacin B Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549.
Topics: Actins; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Paclitaxel; Reactive Oxygen Species; Survivin; Triterpenes; Tumor Suppressor Protein p53 | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2015 |
SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lactic Acid; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; RNA, Messenger | 2015 |
MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Irinotecan; Male; MicroRNAs; Multicenter Studies as Topic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2015 |
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glycoproteins; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Peptides; Polymorphism, Genetic; Prognosis; Survival Rate | 2015 |
Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Hemangioma; Humans; Irinotecan; Male; Mutation; Ramucirumab; Rectal Neoplasms; Skin Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings.
Topics: Animals; Anti-Inflammatory Agents; Camptothecin; Carrier Proteins; Caspase 1; Cell Line, Tumor; Colitis; Colon; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Inflammation Mediators; Interleukin-1beta; Interleukin-8; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Mice, Inbred C57BL; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Permeability; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Topoisomerase I Inhibitors | 2015 |
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Colonic Neoplasms; Drug Design; Drug Synergism; Female; Humans; Indoles; Irinotecan; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein Kinases; Pyridones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |
Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Topics: Animals; Camptothecin; Cell Line, Tumor; Female; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Topics: Animals; Bacteremia; Camptothecin; Diarrhea; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Mice, Knockout; Mucositis; Myeloid Differentiation Factor 88; Peroxidase; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 9 | 2015 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide | 2016 |
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2015 |
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Irinotecan; Luminescent Measurements; Mice; Molecular Structure; Permeability; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Excipients; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Mice; Mice, Inbred ICR; Nanoparticles; Surface-Active Agents | 2015 |
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azepines; Azocines; Benzhydryl Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Signal Transduction; Taxoids; Time Factors; Topoisomerase Inhibitors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cellular Senescence; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Gene Knockdown Techniques; Humans; Immunoprecipitation; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Oxadiazoles; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2015 |
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Cluster Analysis; Colorectal Neoplasms; Female; Gene Expression; Gene Expression Profiling; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins B-raf; ras Proteins; Transcription Factors; Treatment Outcome | 2015 |
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colitis, Microscopic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Promoter Regions, Genetic | 2016 |
Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; HCT116 Cells; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Quinolones | 2015 |
Loss of Nek11 Prevents G2/M Arrest and Promotes Cell Death in HCT116 Colorectal Cancer Cells Exposed to Therapeutic DNA Damaging Agents.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Death; Cell Survival; Colorectal Neoplasms; DNA Damage; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Irinotecan; M Phase Cell Cycle Checkpoints; NIMA-Related Kinases; Protein Kinases; RNA Interference | 2015 |
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Cetuximab; Colonic Neoplasms; Drug Synergism; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylation; Signal Transduction | 2015 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Immunoassay; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Anti-Neoplastic Cytotoxicity of SN-38-Loaded PCL/Gelatin Electrospun Composite Nanofiber Scaffolds against Human Glioblastoma Cells In Vitro.
Topics: Antineoplastic Agents; Biocompatible Materials; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Liberation; Gelatin; Glioblastoma; Humans; Irinotecan; Membranes; Nanofibers; Polyesters; Tissue Engineering; Tissue Scaffolds | 2015 |
Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Proliferation; Cumulus Cells; Green Fluorescent Proteins; HCT116 Cells; Humans; Hydrolysis; Irinotecan; Mice | 2015 |
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Models, Genetic; Oligonucleotide Array Sequence Analysis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Signal Transduction | 2015 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Ciprofloxacin; Dose-Response Relationship, Drug; Enterohepatic Circulation; Glucuronidase; Glucuronides; Irinotecan; Time Factors | 2016 |
Successful Multidisciplinary Therapy for Small Cell Carcinomas Arising from the Extrahepatic Bile Duct.
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Carcinoma, Small Cell; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Common Bile Duct; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Treatment Outcome | 2015 |
Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bacteria; Bacterial Proteins; Camptothecin; Cefixime; Diarrhea; Enzyme Inhibitors; Female; Flavonoids; Food-Drug Interactions; Fruit and Vegetable Juices; Gastrointestinal Microbiome; Gene Transfer Techniques; Glucuronidase; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Intestines; Irinotecan; Kinetics; Malus; Mice, Inbred C57BL; Oocytes; Organic Anion Transporters; Xenopus laevis | 2016 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Compounding; Glioblastoma; Humans; Irinotecan; Liposomes; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Screening Assays, Antitumor; Female; Humans; Intramolecular Oxidoreductases; Irinotecan; Lipocalins; Mice; Mice, Inbred BALB C; Solubility | 2015 |
Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Drug Screening Assays, Antitumor; Enteritis; Female; Injections, Intraperitoneal; Irinotecan; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; RAW 264.7 Cells | 2016 |
Development and characterization of pH responsive polymeric nanoparticles of SN-38 for colon cancer.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Humans; Hydrogen-Ion Concentration; Irinotecan; Nanoparticles | 2016 |
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Dosage; Gene Expression; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Staging; Prognosis; RNA, Messenger; Topoisomerase I Inhibitors | 2016 |
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Computer Simulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, ras; Humans; Immune System; Irinotecan; Lymphocytes; Models, Theoretical; Mutation; ras Proteins; Stochastic Processes | 2016 |
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Lineage; Cell Movement; Chemokine CXCL12; Colonic Neoplasms; Dipeptidyl Peptidase 4; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplasm Metastasis; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2015 |
Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemokines; Chemoradiotherapy; Colonic Neoplasms; Computational Biology; Cytokines; Databases, Genetic; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Heterozygote; Humans; Inhibitory Concentration 50; Irinotecan; MicroRNAs; Mutation; Radiation Dosage; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Protein p53 | 2015 |
Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits.
Topics: Animals; Antineoplastic Agents; Blood Chemical Analysis; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Dacarbazine; Irinotecan; Male; Microbubbles; Rabbits; Reproducibility of Results; Temozolomide; Ultrasonography | 2016 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; G1 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sarcoma, Ewing; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53; Vorinostat | 2015 |
Determination of irinotecan and SN38 in human plasma by TurboFlow™ liquid chromatography-tandem mass spectrometry.
Topics: Camptothecin; Chromatography, Liquid; Humans; Irinotecan; Prodrugs; Tandem Mass Spectrometry | 2016 |
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celecoxib; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; p38 Mitogen-Activated Protein Kinases; Stomach Neoplasms; Sulfides; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Drug Screening Assays, Antitumor; Female; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy.
Topics: Camptothecin; Cell Survival; Drug Delivery Systems; HCT116 Cells; Humans; Irinotecan; Prodrugs; Tandem Mass Spectrometry | 2016 |
Systematic Protein Level Regulation via Degradation Machinery Induced by Genotoxic Drugs.
Topics: Apoptosis; Camptothecin; Cisplatin; DNA Damage; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Leupeptins; Mutagens; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Proteome | 2016 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Young Adult | 2016 |
5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Delayed-Action Preparations; Fluorouracil; Gastric Emptying; HCT116 Cells; Humans; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Tissue Distribution | 2016 |
Langmuir monolayers and Differential Scanning Calorimetry for the study of the interactions between camptothecin drugs and biomembrane models.
Topics: Biomimetic Materials; Calorimetry, Differential Scanning; Camptothecin; Irinotecan; Membranes, Artificial | 2016 |
A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Interleukin-6; Intestinal Mucosa; Irinotecan; Male; Mice; Mice, Inbred C57BL; Models, Animal; Mucositis; Peroxidase; Tumor Necrosis Factor-alpha | 2016 |
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Panitumumab; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2016 |
DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Catheters; Doxorubicin; Drug Carriers; Irinotecan; Liver Neoplasms, Experimental; Rabbits; X-Ray Microtomography | 2016 |
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peptide Synthases; Prognosis; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidine Phosphorylase | 2016 |
[Effect of Shengjiang Xiexin Decoction on the Repair of Damaged Rat Intestinal Mucosa after Irinotecan Chemotherapy].
Topics: Animals; Apoptosis; Camptothecin; Colon; Diarrhea; Drug Therapy; Drugs, Chinese Herbal; Ileum; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Wound Healing | 2015 |
Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholangiocarcinoma; Humans; Indoles; Irinotecan; Male; Mutation; Panitumumab; Sulfonamides; Vemurafenib | 2016 |
SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Child, Preschool; Diffusion; Female; Humans; Irinotecan; Male; Mice; Nanocapsules; Nanofibers; Neoplasm Recurrence, Local; Neoplasms, Experimental; Particle Size; Postoperative Care; Tissue Distribution; Treatment Outcome | 2016 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 2016 |
Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Acids and Salts; Camptothecin; Cells, Cultured; Gene Expression Regulation; Interleukin-10; Irinotecan; Male; Mice; Mice, Inbred C57BL | 2016 |
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Body Fluids; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Prospective Studies; Risk Factors | 2016 |
Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Delivery Systems; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2016 |
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; Irinotecan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
Topics: Adult; Aged; Aged, 80 and over; Australia; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Genetic Testing; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome; Young Adult | 2016 |
Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Stability; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Liposomes; Male; Mice; Monocarboxylic Acid Transporters; Muscle Proteins; Nanoparticles; Neoplasm Proteins; Pancreatic Neoplasms; Photochemotherapy; Porphyrins; Survivin; Treatment Outcome | 2016 |
The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions.
Topics: Adsorption; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Design; Humans; Irinotecan; Nanoparticles; Polyesters; Polyethylene Glycols; Propylene Glycols; Serum Albumin, Bovine; Solubility | 2016 |
Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Fees, Medical; Female; Financing, Personal; Health Care Costs; Hospital Charges; Humans; Irinotecan; Japan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2016 |
Possibility of Müller Cell Dysfunction as the Pathogenesis of Paclitaxel Maculopathy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Substitution; Electroretinography; Ependymoglial Cells; Fluorescein Angiography; Humans; Irinotecan; Macular Edema; Male; Paclitaxel; Stomach Neoplasms; Tomography, Optical Coherence | 2016 |
Multi-responsive photothermal-chemotherapy with drug-loaded melanin-like nanoparticles for synergetic tumor ablation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Death; Doxorubicin; Drug Liberation; Drug Stability; Endocytosis; HeLa Cells; Humans; Hyperthermia, Induced; Indoles; Inhibitory Concentration 50; Irinotecan; Male; MCF-7 Cells; Melanins; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; NIH 3T3 Cells; Phototherapy; Polyethylene Glycols; Polymers | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2.
Topics: Antineoplastic Agents; Apoptosis; Biotransformation; Camptothecin; Carboxylesterase; Clopidogrel; Down-Regulation; Irinotecan; Ticlopidine; Xanthones | 2016 |
Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Topoisomerase I Inhibitors | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Metastasectomy; Microsatellite Instability; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Singapore | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Phosphoproteins; Protein Transport; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Epirubicin; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovariectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Irinotecan; Medulloblastoma; Temozolomide; Young Adult | 2016 |
Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Female; HCT116 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Male; Middle Aged; Phosphorylation; Retinoblastoma Protein; Retrospective Studies; RNA, Small Interfering | 2016 |
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Humans; Indazoles; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; MCF-7 Cells; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Taxoids | 2016 |
[Pre-Operative Treatment with Transcatheter Arterial Chemoembolization (TACE) and Hepatic Arterial Infusion (HAI) for Liver Metastasis from Gastric Cancer--A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Combined Modality Therapy; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2015 |
[A Case of Successful Treatment of Metachronous Liver Metastasis from Gastric Cancer with Hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[A Case of Advanced Gastric Cancer with Long-Term Survival after Chemotherapy with Combined S-1 and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Prognosis; Splenectomy; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[A Case of Signet-Ring Cell Carcinoma of the Sigmoid Colon with Disseminated Carcinomatosis Successfully Treated with CPT-11/Panitumumab].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Camptothecin; Carcinoma, Signet Ring Cell; Disseminated Intravascular Coagulation; Humans; Irinotecan; Male; Panitumumab; Sigmoid Neoplasms | 2015 |
Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; China; Genotype; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2016 |
Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Luminescent Proteins; Mice; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Red Fluorescent Protein; Xenograft Model Antitumor Assays | 2016 |
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan | 2016 |
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Young Adult | 2016 |
Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Risk; Thailand | 2016 |
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Glioma; Humans; Irinotecan; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Wound Healing | 2016 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Young Adult | 2016 |
Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Gamma Rays; Humans; Hysterectomy; Injections, Intravenous; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC-MS/MS Method.
Topics: Animals; Area Under Curve; Camptothecin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dogs; Irinotecan; Liposomes; Mice; Solubility; Tandem Mass Spectrometry; Tissue Distribution | 2016 |
Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Liberation; Female; Irinotecan; Lipid Bilayers; Liposomes; Mice; Nanoparticles; Pancreatic Neoplasms; Silicon Dioxide | 2016 |
Detection of low-quantity anticancer drugs by surface-enhanced Raman scattering.
Topics: Antineoplastic Agents; Camptothecin; Doxorubicin; Humans; Indoles; Irinotecan; Limit of Detection; Paclitaxel; Pyrroles; Spectrum Analysis, Raman; Sunitinib; Surface Properties | 2016 |
Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic | 2016 |
Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Risk Factors | 2016 |
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Deoxycytidine; DNA Damage; Down-Regulation; Gemcitabine; Genes, Viral; Humans; Irinotecan; MRE11 Homologue Protein; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2016 |
Mesenchymal stem cells exhibit resistance to topoisomerase inhibition.
Topics: Apoptosis; Camptothecin; Cell Adhesion; Cell Differentiation; Cell Movement; Cells, Cultured; Drug Resistance; Etoposide; Fibroblasts; Humans; Irinotecan; MCF-7 Cells; Mesenchymal Stem Cells; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2016 |
Spontaneous arrangement of a tumor targeting hyaluronic acid shell on irinotecan loaded PLGA nanoparticles.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Liberation; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Lactic Acid; Molecular Targeted Therapy; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2016 |
Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.
Topics: Animals; Camptothecin; Chromatography, High Pressure Liquid; Feces; Glucuronides; Irinotecan; Kidney; Linear Models; Liver; Male; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colon; Colorectal Neoplasms; Dextrans; Drug Carriers; Drug Delivery Systems; Female; Humans; Irinotecan; Magnetite Nanoparticles; Methacrylates; Mice, Inbred BALB C; Mice, Nude; Micelles; Polyesters; Polyethylene Glycols; Rectum; RNA, Small Interfering; RNAi Therapeutics; Theranostic Nanomedicine; Vascular Endothelial Growth Factor A | 2016 |
Irinotecan-induced dysarthria: A case report and review of the literature.
Topics: Adult; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Dysarthria; Female; Humans; Irinotecan | 2017 |
Gastrointestinal cancer: PICCOLO--changing the tune of anti-EGFR therapy.
Topics: Amphiregulin; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; EGF Family of Proteins; Epiregulin; Humans; Irinotecan; Molecular Targeted Therapy; Panitumumab; RNA, Messenger | 2016 |
MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Grading; Neoplasm Metastasis; Pilot Projects; Prognosis; Survival Analysis | 2016 |
Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromosomes; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Expression; Humans; Irinotecan; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transcription Factors | 2016 |
The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Fullerenes; Glutathione; Ileum; Interleukin-1beta; Intestinal Mucosa; Irinotecan; Leukopenia; Male; Melanoma; Mice, Inbred C57BL; Mice, Transgenic; Mucositis; Nanocomposites; Oxidative Stress; Peroxidase; Thiobarbituric Acid Reactive Substances; Tumor Burden | 2016 |
Complete regression of xenograft tumors using biodegradable mPEG-PLA-SN38 block copolymer micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Carriers; Drug Liberation; Female; HCT116 Cells; Hepatocytes; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Injections, Subcutaneous; Irinotecan; Mice; Mice, Nude; Micelles; Particle Size; Polyesters; Polyethylene Glycols; Structure-Activity Relationship; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diagnostic Imaging; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Peritoneal Neoplasms; Photosensitizing Agents; Stomach Neoplasms | 2016 |
Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Irinotecan; Mice; Neoplasm Transplantation; Neural Stem Cells; Prodrugs; Urinary Bladder Neoplasms | 2016 |
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tertiary Care Centers; Treatment Outcome | 2016 |
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Topics: Benzodioxoles; Binding Sites; Camptothecin; Cell Line, Tumor; Chromosome Deletion; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Gene Dosage; Guanidines; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Irinotecan; Isoquinolines; Mutation | 2016 |
Potential treatment for a subtype of glioblastoma tumours.
Topics: Bevacizumab; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Randomized Controlled Trials as Topic | 2016 |
A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options.
Topics: Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chromatography, Liquid; Claudin-1; Electric Impedance; Fluorescent Antibody Technique; Gastrointestinal Diseases; Humans; In Vitro Techniques; Intestinal Mucosa; Irinotecan; Membranes, Artificial; Microscopy, Electron, Transmission; Occludin; Tight Junctions; Toll-Like Receptor 4 | 2016 |
Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
Topics: Administration, Metronomic; Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Combined Modality Therapy; Disease Progression; Female; Glioma; Humans; Irinotecan; Maintenance Chemotherapy; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment; Retrospective Studies; Vinblastine | 2016 |
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Safety | 2016 |
The influence of mPEG-PCL and mPEG-PLGA on encapsulation efficiency and drug-loading of SN-38 NPs.
Topics: Camptothecin; Drug Carriers; Irinotecan; Nanoparticles; Polyesters; Polyethylene Glycols | 2017 |
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38.
Topics: Antineoplastic Agents, Phytogenic; Benzoquinones; Camptothecin; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Transcription Factor RelA | 2017 |
Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Embolization, Therapeutic; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Retrospective Studies; Yttrium Radioisotopes | 2016 |
10-Boronic acid substituted camptothecin as prodrug of SN-38.
Topics: Antineoplastic Agents; Boronic Acids; Camptothecin; Cell Line, Tumor; Drug Liberation; Humans; Hydrogen Peroxide; Irinotecan; Oxidation-Reduction; Prodrugs; Topoisomerase I Inhibitors | 2016 |
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Axin Protein; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Middle Aged; Tankyrases; Xenograft Model Antitumor Assays | 2016 |
Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker.
Topics: Animals; Antineoplastic Agents; Biological Transport; Camptothecin; Cathepsin B; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Drug Stability; Humans; Irinotecan; Mice; Nanoparticles; Prodrugs; Solubility; Xenograft Model Antitumor Assays | 2016 |
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2016 |
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Female; Fucose; Humans; Immunochemistry; Irinotecan; Lectins; Liposomes; Male; Mice; Middle Aged; Nanoparticles; Neoplasm Transplantation; Proteins | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2016 |
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Male; Middle Aged; Palliative Care; Retrospective Studies; Treatment Outcome | 2016 |
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neoplasms, Second Primary; Urologic Neoplasms | 2016 |
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Camptothecin; Cell Line, Tumor; Heterografts; Humans; In Vitro Techniques; Irinotecan; Lipids; Mice; Microscopy, Electron, Transmission; Nanoparticles; Survival Rate | 2016 |
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; DNA Methylation; Gene Expression; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Werner Syndrome Helicase | 2016 |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome; Turkey | 2016 |
Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis.
Topics: Animals; Camptothecin; Disease Models, Animal; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Irinotecan; Jejunum; Lipid Peroxidation; Male; Mice; Mucositis; Oxidative Stress; Probiotics; Saccharomyces cerevisiae; Weight Loss | 2016 |
Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Humans; Irinotecan; Lung Neoplasms; Mice; NAD(P)H Dehydrogenase (Quinone); Prodrugs; Uterine Cervical Neoplasms | 2016 |
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Camptothecin; Cell Death; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Leucovorin; Mice; Panitumumab; Phagocytosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Unfolded Protein Response; Vemurafenib; X-Box Binding Protein 1 | 2016 |
Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Biotin; Camptothecin; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Lactic Acid; MCF-7 Cells; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2017 |
A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Computational Biology; Data Mining; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Retrospective Studies; Treatment Outcome | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2016 |
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; France; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis | 2016 |
A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Transforming Growth Factor beta; Young Adult | 2016 |
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Topics: Camptothecin; Cell Line, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cohort Studies; Colonic Neoplasms; Disease-Free Survival; Drug Evaluation, Preclinical; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Prognosis | 2016 |
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; Young Adult | 2017 |
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bacteria; Camptothecin; Feces; Female; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Deletion; Gene Expression Regulation; Irinotecan; Mice; Mice, Inbred BALB C; Pain; Sequence Analysis, DNA; Signal Transduction; Toll-Like Receptor 4 | 2016 |
Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry.
Topics: Camptothecin; Cell Culture Techniques; Colonic Neoplasms; HCT116 Cells; Humans; Irinotecan; Lab-On-A-Chip Devices; Printing, Three-Dimensional; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spheroids, Cellular | 2016 |
Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Mice; Mice, Nude; Nanoparticles; Receptor, ErbB-2; Stomach Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression; Humans; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Mice; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Incompatibility between irinotecan and fluorouracil injections.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Incompatibility; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan | 2016 |
Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Liberation; Endocytosis; Fluorescein-5-isothiocyanate; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Polyesters; Polyethylene Glycols; Tissue Distribution; Treatment Outcome | 2016 |
UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Facilitating gastrointestinal solubilisation and enhanced oral absorption of SN38 using a molecularly complexed silica-lipid hybrid delivery system.
Topics: Administration, Oral; Animals; Biological Availability; Camptothecin; Drug Delivery Systems; Female; Gastrointestinal Tract; Irinotecan; Lipids; Rats; Silicon Dioxide; Solubility | 2016 |
BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Synergism; HCT116 Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Nitrogen Mustard Compounds; Phenylurea Compounds; Sarcoma; Xenograft Model Antitumor Assays | 2016 |
In brief: liposomal irinotecan (Onivyde) for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Compounding; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Preparation and Characterization of SN-38-Encapsulated Phytantriol Cubosomes Containing α-Monoglyceride Additives.
Topics: Camptothecin; Fatty Alcohols; Irinotecan; Molecular Conformation; Monoglycerides; Nanoparticles; Particle Size; Surface Properties | 2016 |
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Heterografts; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Retrospective Studies; Xenograft Model Antitumor Assays | 2016 |
A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; Drug Delivery Systems; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, SCID; Resorcinols; Signal Transduction; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2016 |
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Carbolines; Cell Line; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Proteins; Neoplasms | 2016 |
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; DNA Damage; Drug Synergism; HCT116 Cells; Humans; Irinotecan; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2016 |
Assessment of the chemotherapeutic potential of a new camptothecin derivative, ZBH-1205.
Topics: Antineoplastic Agents; Apoptosis; Camptotheca; Camptothecin; Caspase 3; Cell Cycle; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Inhibitory Concentration 50; Irinotecan; K562 Cells; Kinetics; Plant Extracts | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy, Adjuvant; Re-Irradiation; Retrospective Studies; Temozolomide | 2016 |
Knockdown of NDRG1 promote epithelial-mesenchymal transition of colorectal cancer via NF-κB signaling.
Topics: Adult; Aged; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Female; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; NF-kappa B; Signal Transduction; Vimentin | 2016 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Diseases; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Female; Fluorouracil; Humans; Intestinal Perforation; Irinotecan; Leucovorin | 2016 |
Digital Glissonectomy: A Safe Perihepatic Peritonectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Pseudomyxoma Peritonei; Young Adult | 2016 |
Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
Topics: AC133 Antigen; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; HCT116 Cells; HT29 Cells; Humans; Immunotoxins; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Neoplastic Stem Cells; Random Allocation; Xenograft Model Antitumor Assays | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Camptothecin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Operative Time; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Sarcopenia | 2016 |
[Research hotspot and progress of preoperative chemoradiotherapy for rectal cancer].
Topics: Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms | 2016 |
Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Delayed-Action Preparations; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Retrospective Studies; Treatment Outcome | 2016 |
Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Colorectal Neoplasms; Delayed-Action Preparations; Disease-Free Survival; Doxorubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Polyethylene Glycols; Retrospective Studies; Treatment Outcome | 2016 |
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cell Line; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Heterografts; Humans; Irinotecan; Lasers; Mice, Inbred BALB C; Photosensitizing Agents; Prodrugs; Topoisomerase I Inhibitors | 2016 |
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Comorbidity; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras) | 2016 |
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Azepines; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Irinotecan; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study.
Topics: Antineoplastic Agents; Camptothecin; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Compounding; Drug Contamination; Fluorouracil; Ganciclovir; Gemcitabine; Humans; Ifosfamide; Irinotecan; Methotrexate; Occupational Exposure; Prospective Studies | 2016 |
[Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Anxiety; Camptothecin; Cognitive Dysfunction; Depression; Drug Therapy, Combination; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Hemoglobins; Humans; Irinotecan; Male; Memory; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Surveys and Questionnaires; Translating | 2016 |
An in-vitro evaluation of three types of drug-eluting microspheres loaded with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Drug Stability; Irinotecan; Microspheres; Suspensions | 2016 |
GSK-3 inhibition overcomes chemoresistance in human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Irinotecan; Maleimides; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2017 |
Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colon; Colorectal Neoplasms; Drug Delivery Systems; Female; HCT116 Cells; Humans; Irinotecan; Liposomes; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Rectum | 2016 |
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; CpG Islands; Disease-Free Survival; Female; Genes, erbB-1; Humans; Irinotecan; Japan; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenomic Testing; Proto-Oncogene Proteins B-raf; ras Proteins; Statistics as Topic; Treatment Outcome | 2016 |
Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Fluorouracil; Fractals; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Risk Factors; ROC Curve; Technetium Tc 99m Aggregated Albumin; Technetium Tc 99m Pentetate | 2016 |
Primary cultures of human colon cancer as a model to study cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Mice; Neoplastic Stem Cells; Octamer Transcription Factor-3; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Fluorescent Dyes; HeLa Cells; Humans; Irinotecan; Neoplasms, Experimental; Oxygen; Theranostic Nanomedicine; Treatment Outcome; Tumor Hypoxia | 2016 |
Drug Resistance in Colorectal Cancer Cell Lines is Partially Associated with Aneuploidy Status in Light of Profiling Gene Expression.
Topics: Aneuploidy; Camptothecin; Cell Line, Tumor; Chromosomes, Human, Pair 14; Colorectal Neoplasms; Drug Resistance; Gene Dosage; Gene Expression Profiling; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2016 |
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cytochrome P-450 CYP3A; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Mice; MicroRNAs; Neoplasms; Pharmacogenetics; RNA Interference; Vitamin D; Xenograft Model Antitumor Assays | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.
Topics: Animals; Apoptosis; Camptothecin; Cell Proliferation; Female; Fluorescent Antibody Technique; Germ Cells; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Inbred C57BL; Oocytes; Organ Culture Techniques; Ovary; Spermatogonia; Testis | 2016 |
Passage of irinotecan and its active metabolite, SN-38, into human milk.
Topics: Adult; Camptothecin; Female; Humans; Irinotecan; Milk, Human | 2016 |
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Brain; Brain Neoplasms; Camptothecin; Cisplatin; Disease Models, Animal; Drug Delivery Systems; Ethylnitrosourea; Glioblastoma; Glioma; Humans; Irinotecan; Lactic Acid; Male; Nanofibers; Neurosurgical Procedures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tumor Burden | 2016 |
Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Delivery Systems; Drug Liberation; Female; Glioblastoma; Heterografts; Humans; Injections; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Polyesters; Polyethylene Glycols | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Ramucirumab | 2016 |
Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Bile; Camptothecin; Hesperidin; Irinotecan; Liver; Male; Rats, Wistar | 2016 |
Evaluation of ion exchange processes in drug-eluting embolization beads by use of an improved flow-through elution method.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Doxorubicin; Drug Delivery Systems; Drug Liberation; Ion Exchange; Irinotecan; Polyvinyl Alcohol; Sulfonic Acids | 2016 |
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Topics: Biomarkers, Tumor; Camptothecin; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Pathology, Molecular | 2016 |
Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Irinotecan; Liposomes; Macrophages; Mice; Nanoparticles; Prodrugs; Xenograft Model Antitumor Assays | 2016 |
Development of polymeric irinotecan nanoparticles using a novel lactone preservation strategy.
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Liberation; Drug Stability; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lactones; Male; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Rats; Solubility | 2016 |
Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Contrast Media; Doxorubicin; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
Folate-Mediated Targeted Delivery of Combination Chemotherapeutics Loaded Reduced Graphene Oxide for Synergistic Chemo-Photothermal Therapy of Cancers.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Drug Synergism; Female; Folic Acid; Graphite; Hep G2 Cells; Humans; Irinotecan; MCF-7 Cells; Nanoparticles; Particle Size; Phototherapy; Surface Properties; Taxoids | 2016 |
Preliminary study of mechanism of action of SN38 derivatives. Physicochemical data, evidence of interaction and alkylation of DNA octamer d(GCGATCGC)
Topics: Alkylation; Antineoplastic Agents; Base Sequence; Camptothecin; DNA; Drug Stability; Irinotecan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Polydeoxyribonucleotides; Structure-Activity Relationship | 2017 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2016 |
Enabling Oral SN38-Based Chemotherapy with a Combined Lipophilic Prodrug and Self-Microemulsifying Drug Delivery System.
Topics: Administration, Oral; Animals; Camptothecin; Chromatography, Liquid; Drug Delivery Systems; Emulsions; Excipients; Female; Irinotecan; Molecular Structure; Prodrugs; Rats; Tandem Mass Spectrometry | 2016 |
Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.
Topics: Amino Acid Sequence; Camptothecin; Cell Differentiation; DNA Topoisomerases, Type I; Enzyme Stability; Genes, Reporter; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; HMGA2 Protein; Humans; Irinotecan; Luciferases, Renilla; Netropsin; Promoter Regions, Genetic; Topoisomerase I Inhibitors; Transcription, Genetic; Transcriptional Activation | 2016 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cholera Toxin; Colon; Contrast Media; Diarrhea; Fluorouracil; Gastrointestinal Diseases; Haptoglobins; Intestinal Mucosa; Iohexol; Irinotecan; Jejunum; Male; Organoplatinum Compounds; Oxaliplatin; Permeability; Protein Precursors; Rats; Rats, Sprague-Dawley | 2016 |
Sequential designs for individualized dosing in phase I cancer clinical trials.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplasms; Phenotype | 2017 |
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Resorcinols; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbocyanines; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Female; Fucose; Humans; Immunohistochemistry; Irinotecan; Liposomes; Male; Mannose; Mice; Middle Aged; Nanoparticles; Neoplasm Transplantation; Proteins | 2016 |
ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Histones; Humans; Inhibitory Concentration 50; Irinotecan; Oncogene Protein p21(ras); Phosphorylation; Proto-Oncogene Proteins; Stomach Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion Molecules; Female; Immunohistochemistry; Intestinal Mucosa; Irinotecan; Jejunum; Mucositis; Rats | 2017 |
Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
Topics: Animals; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Oncogene Proteins; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Retreatment; Stomach Neoplasms; Survival Rate; Vomiting; White People | 2016 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Spain; Survival Rate | 2017 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Mice; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib; Xenograft Model Antitumor Assays | 2016 |
Gap junction composed of connexin43 modulates 5‑fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Connexin 43; Drug Resistance, Neoplasm; Fluorouracil; Gap Junctions; Gene Knockdown Techniques; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2016 |
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Topics: Animals; Antibodies, Antinuclear; Camptothecin; Disease Models, Animal; DNA; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Female; Flow Cytometry; Irinotecan; Kidney; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; Random Allocation; Skin; Topoisomerase I Inhibitors | 2016 |
Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; MicroRNAs; Organoplatinum Compounds; Oxaliplatin; RNA, Neoplasm; Signal Transduction; Stress, Physiological | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
[Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colon, Transverse; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectum; Retrospective Studies | 2016 |
[Second-line treatment for metastatic or locally advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids | 2016 |
The use of surfactants to enhance the solubility and stability of the water-insoluble anticancer drug SN38 into liquid crystalline phase nanoparticles.
Topics: Antineoplastic Agents; Bromides; Camptothecin; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Stability; Irinotecan; Liquid Crystals; Nanoparticles; Particle Size; Quaternary Ammonium Compounds; Sodium Dodecyl Sulfate; Solubility; Surface-Active Agents; Water | 2016 |
Unusual case of hyperpigmentation secondary to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Female; Humans; Hyperpigmentation; Irinotecan; Middle Aged; Mouth Mucosa; Nails; Neoplasm Recurrence, Local | 2016 |
Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drugs, Generic; Humans; Irinotecan; Therapeutic Equivalency | 2016 |
Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Real-Time Polymerase Chain Reaction | 2016 |
Late-stage inhibition of autophagy enhances calreticulin surface exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein-1 Homolog; Beclin-1; Calreticulin; Camptothecin; Cell Membrane; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Fluorouracil; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Transport; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases | 2016 |
Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.
Topics: Animals; Antioxidants; Body Weight; Camptothecin; Cyclooxygenase 2; Cymenes; Female; Immunohistochemistry; Inflammation; Intestines; Irinotecan; Leukocyte Count; Mice; Molecular Docking Simulation; Monoterpenes; Mucositis; NF-kappa B; Oxidative Stress; Peroxidase; Survival Analysis; Transient Receptor Potential Channels; TRPA1 Cation Channel | 2016 |
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Platinum Compounds; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2017 |
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Disease Progression; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate; Thymidylate Synthase | 2017 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Drug Carriers; Heterografts; Infrared Rays; Irinotecan; Liposomes; Mice; Pancreatic Neoplasms; Phospholipids; Porphyrins; Sphingomyelins; Treatment Outcome | 2016 |
SN38 increases IL-8 expression through the MAPK pathways in HCT8 cells.
Topics: Berberine; Camptothecin; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Interleukin-8; Irinotecan; Janus Kinase 2; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Up-Regulation | 2017 |
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, ras; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2017 |
RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Membrane Transport Proteins; Proto-Oncogene Proteins c-bcl-2; rhoA GTP-Binding Protein; Signal Transduction | 2016 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex | 2017 |
Side-Effects of Irinotecan (CPT-11), the Clinically Used Drug for Colon Cancer Therapy, Are Eliminated in Experimental Animals Treated with Latex Proteins from Calotropis procera (Apocynaceae).
Topics: Animals; Apocynaceae; Calotropis; Camptothecin; Colonic Neoplasms; Disease Models, Animal; Irinotecan; Latex; Male; Mice | 2017 |
SN-38 loading capacity of hydrophobic polymer blend nanoparticles: formulation, optimization and efficacy evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Compounding; Drug Evaluation, Preclinical; Female; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Nanoparticles; Particle Size; Polymers; Rats; Rats, Wistar; Treatment Outcome | 2017 |
Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations.
Topics: Camptothecin; Humans; Irinotecan; Medical Oncology; Pancreatic Neoplasms; United States | 2017 |
Tumor Microenvironment-Responsive Nanoparticle Delivery of Chemotherapy for Enhanced Selective Cellular Uptake and Transportation within Tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Drug Delivery Systems; Hyaluronic Acid; Irinotecan; Macrophages; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polyglycolic Acid; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment | 2016 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Pyridines; Retreatment; Treatment Outcome | 2017 |
New Insight into a Cancer Theranostic Probe: Efficient Cell-Specific Delivery of SN-38 Guided by Biotinylated Poly(vinyl alcohol).
Topics: Animals; Camptothecin; Cell Line; Humans; Irinotecan; Mice; Theranostic Nanomedicine | 2016 |
UGT1A10 Is a High Activity and Important Extrahepatic Enzyme: Why Has Its Role in Intestinal Glucuronidation Been Frequently Underestimated?
Topics: Animals; Blotting, Western; Camptothecin; Chromatography, High Pressure Liquid; Coumarins; Diclofenac; Estradiol; Estrone; Flavonoids; Glucuronosyltransferase; Humans; Hymecromone; Intestinal Mucosa; Irinotecan; Kinetics; Microsomes, Liver | 2017 |
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Camptothecin; Caspases; Cell Nucleus; DNA Topoisomerases, Type I; Drug Interactions; Egtazic Acid; Fluorouracil; HeLa Cells; Humans; Irinotecan; Neoplasm Proteins; Nuclear Pore; Permeability; ran GTP-Binding Protein; Topotecan; Tumor Suppressor Protein p53 | 2017 |
Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Receptors, Granulocyte Colony-Stimulating Factor; Tomography Scanners, X-Ray Computed | 2017 |
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Topics: Animals; Camptothecin; Cancer Pain; Diarrhea; Female; Irinotecan; Naloxone; Rats; Toll-Like Receptor 4 | 2017 |
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Gene Amplification; Genes, p53; Humans; Irinotecan; Male; Middle Aged; Mutation; ras Proteins | 2017 |
Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Texas | 2017 |
Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Gastrointestinal Neoplasms; Genomics; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Pancreatectomy; Precision Medicine; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate | 2017 |
Intraarterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rabbit Liver Tumor Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Area Under Curve; Camptothecin; Drug Carriers; Drug Compounding; Female; Femoral Vein; Hepatic Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Micelles; Nanoparticles; Necrosis; Rabbits; Tissue Distribution | 2017 |
Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colorectal Neoplasms; Delayed-Action Preparations; Dendrimers; Female; Irinotecan; Mice; Mice, Nude; Oxazoles; Rats, Wistar; Rectum | 2017 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2017 |
ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autophagy; Camptothecin; Disease Models, Animal; Fatty Liver; Hepatocytes; Humans; In Vitro Techniques; Irinotecan; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Preoperative Care | 2018 |
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoplasm Staging; Patient Care Management; Pharmacogenomic Testing; Pharmacogenomic Variants; Retrospective Studies; Topoisomerase I Inhibitors | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; CD3 Complex; CD56 Antigen; CD8 Antigens; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2017 |
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Gene Dosage; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2017 |
TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Mice; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Tumor Necrosis Factor-alpha | 2017 |
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
Topics: Camptothecin; Carboxylic Ester Hydrolases; Cell Line; Enzyme Inhibitors; Humans; Hydrolysis; Irinotecan; Liver; Molecular Docking Simulation; Naphthoquinones; Oseltamivir | 2017 |
2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Blotting, Western; Camptothecin; Cell Survival; Drug Resistance, Multiple; HEK293 Cells; Humans; Irinotecan; Mitoxantrone | 2017 |
CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk.
Topics: Animals; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cell Survival; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lysosomes; Mice; Mitochondria; Reactive Oxygen Species; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
[Curative Resection for Chemorefractory Advanced Gastric Cancer with Pancreatic Invasion by Pancreatoduodenectomy - A Case Report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Invasiveness; Oxonic Acid; Pancreas; Pancreaticoduodenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[Lymph Node Recurrence of Small Cell Carcinoma of the Extrahepatic Bile Ducts Effectively Treated with Cisplatin plus Irinotecan Chemotherapy - Report of a Case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Treatment Outcome | 2016 |
[A Case of Multiple Liver Metastasis from Gastric Cancer Successfully Treated with CPT-11 as Third-Line Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Fatal Outcome; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms; Time Factors | 2016 |
[Effectiveness of Irinotecan, S-1, and Bevacizumab for Rectal Cancer with Lung and Skin Metastases after Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Oxonic Acid; Rectal Neoplasms; Skin Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Recurrent Gastric Cancer with Recurrent Celiac Lymph Node Metastasis Successfully Treated with Chemoradiotherapy and CPT-11 plus CDDP Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Stomach Neoplasms; Treatment Outcome | 2016 |
Drug Combo Beats Vemurafenib Alone for Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Indoles; Irinotecan; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vemurafenib | 2017 |
Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chromatography, Liquid; Drug Interactions; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mass Spectrometry; Microsomes, Liver; Sulfonamides | 2017 |
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies | 2017 |
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis | 2017 |
Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Topics: Acetylation; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; Humans; Irinotecan; Models, Biological; Phosphoric Diester Hydrolases; Topoisomerase I Inhibitors | 2017 |
Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration.
Topics: Administration, Intravenous; Administration, Rectal; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Female; Humans; Hydrogels; Irinotecan; Lipids; Male; Mice, Nude; Nanomedicine; Nanoparticles; Phase Transition; Poloxamer; Rats, Sprague-Dawley; Solubility; Technology, Pharmaceutical; Transition Temperature; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™.
Topics: Animals; Antineoplastic Agents; Benzaldehydes; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Liberation; Female; Humans; Iodobenzenes; Ion Exchange; Irinotecan; Liver Neoplasms; Microspheres; Optical Imaging; Particle Size; Polyvinyl Alcohol; Rabbits; Surface Properties; Tomography, X-Ray Computed | 2017 |
Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Down-Regulation; Epoxy Compounds; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Irinotecan; Mice, Nude; Organophosphates; Phenanthrenes; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Brain; Camptothecin; Chromones; Drug Interactions; Female; Indoles; Irinotecan; Mice, SCID; Models, Biological | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Exons; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2017 |
Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Camptothecin; Carboxylesterase; Cells, Cultured; Cytochrome P-450 CYP3A; Cytokines; Drug Interactions; Gene Expression Regulation; Glucuronosyltransferase; Hepatocytes; Irinotecan; Male; Membrane Proteins; Mice, Inbred C3H; Mice, Mutant Strains; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; Toll-Like Receptor 4 | 2017 |
Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line.
Topics: Adenocarcinoma, Scirrhous; Apoptosis; Camptothecin; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Necrosis; Reactive Oxygen Species; Stomach Neoplasms | 2017 |
Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Retrospective Studies | 2017 |
Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Dasatinib; Drug Synergism; Female; Flow Cytometry; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Polo-Like Kinase 1; Protein Biosynthesis; Protein Serine-Threonine Kinases; Protein Synthesis Inhibitors; Proto-Oncogene Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Elastic Modulus; Elasticity Imaging Techniques; Humans; Irinotecan; Mice, Nude; Random Allocation; Treatment Outcome; Tumor Burden; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2017 |
Irinotecan binds to the internal cavity of beta-lactoglobulin: A multi-spectroscopic and computational investigation.
Topics: Animals; Binding Sites; Camptothecin; Cattle; Fluorescence Resonance Energy Transfer; Irinotecan; Lactoglobulins; Molecular Docking Simulation; Protein Structure, Secondary; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Survival Rate; Transcriptome; Treatment Outcome | 2017 |
Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Hydrogels; Injections, Intramuscular; Irinotecan; Lipids; Mice; Mice, Nude; Nanoparticles; Neoplasms, Experimental | 2017 |
Irinotecan-induced bile acid malabsorption is associated with down-regulation of ileal Asbt (Slc10a2) in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Acids and Salts; Camptothecin; Cholestanetriol 26-Monooxygenase; Cholesterol 7-alpha-Hydroxylase; Colon; Diarrhea; Down-Regulation; Feces; Gallbladder; Ileum; Irinotecan; Liver; Male; Membrane Transport Proteins; Mice; Organic Anion Transporters, Sodium-Dependent; RNA, Messenger; Symporters | 2017 |
Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Islet Cell; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Period; Treatment Outcome | 2017 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Half-Life; HEK293 Cells; Humans; Irinotecan; Kidney Failure, Chronic; Liver; Liver-Specific Organic Anion Transporter 1; Renal Dialysis; Serum Albumin; Toxins, Biological; Uremia | 2017 |
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2017 |
Crystal Structures and Vapor-Induced Crystalline Transformation of 7-Ethyl-10-Hydroxycamptothecin Pseudopolymorphs.
Topics: Antineoplastic Agents; Camptothecin; Crystallization; Crystallography, X-Ray; Dimethylformamide; Hydrogen Bonding; Irinotecan; Methanol; Solvents; X-Ray Diffraction | 2017 |
Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Ether; Humans; Hypoxia; Irinotecan; Methods; Mice; Microsomes, Liver; Prodrugs; Structure-Activity Relationship | 2017 |
Effect of antitumor drugs in low concentrationson the biological, immunophenotypic and cytogenetic characteristics of human colon cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Endonucleases; Epithelial-Mesenchymal Transition; HT29 Cells; Humans; Hyaluronan Receptors; Immunohistochemistry; Immunophenotyping; Interferons; Irinotecan; Snail Family Transcription Factors; Time Factors; Vimentin | 2017 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
The involvement of mast cells in the irinotecan-induced enteric neurons loss and reactive gliosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Count; Enteric Nervous System; Gliosis; Intestine, Small; Irinotecan; Mast Cells; Mice; Neurons; Random Allocation | 2017 |
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Colostomy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Kidney Pelvis; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Treatment Outcome; Ureterostomy; Urologic Neoplasms; Urothelium | 2017 |
Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Monitoring; Glucuronides; Humans; Irinotecan; Precision Medicine; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Ind
Topics: Antineoplastic Agents; Area Under Curve; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Models, Biological; Polymorphism, Genetic; Probability | 2017 |
Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcium; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Curcumin; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Irinotecan; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Transcription Factor CHOP | 2017 |
Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cetuximab; Colonic Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Panitumumab; Postoperative Care; Preoperative Care; Prospective Studies; Rectal Neoplasms; Registries | 2017 |
Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation.
Topics: Animals; Camptothecin; DNA; DNA-Binding Proteins; Exosomes; Immunity, Innate; Inflammasomes; Interleukin-18; Interleukin-1beta; Intestinal Mucosa; Intestines; Irinotecan; Mice; Nuclear Proteins | 2017 |
Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Child, Preschool; Drug Liberation; Extracellular Fluid; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Irinotecan; Male; Mice, Nude; N-Acetylgalactosaminyltransferases; Nanoparticles; Neuroblastoma; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Humans; Irinotecan; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasms, Experimental; Oligopeptides; Silicon Dioxide; Transcytosis; Xenograft Model Antitumor Assays | 2017 |
TU-100 exerts a protective effect against bacterial translocation by maintaining the tight junction.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Translocation; Camptothecin; Cells, Cultured; Claudin-4; Cytokines; Diarrhea; Humans; Inflammation Mediators; Irinotecan; Male; Naphthoquinones; Occludin; Phytotherapy; Rats, Wistar; Tight Junctions; Toll-Like Receptors; Zonula Occludens-1 Protein | 2017 |
Efficient co-delivery of immiscible hydrophilic/hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Emulsions; Female; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lipids; Mice, Inbred BALB C; Microscopy, Confocal; Organoplatinum Compounds; Oxaliplatin; Particle Size; Phospholipids; Tissue Distribution | 2017 |
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cost-Benefit Analysis; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells.
Topics: Acetylation; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Irinotecan; Matrix Metalloproteinase 9; MCF-7 Cells; Poly(ADP-ribose) Polymerases | 2017 |
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Azacitidine; Caco-2 Cells; Camptothecin; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA Methylation; DNA Repair; Gene Expression; Gene Expression Profiling; HCT116 Cells; Humans; Irinotecan; Long Interspersed Nucleotide Elements; Mice; Mice, Inbred NOD; Mice, SCID | 2017 |
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Damage; Drug Evaluation, Preclinical; Epithelial-Mesenchymal Transition; Humans; Irinotecan; Lung Neoplasms; MAP Kinase Signaling System; Mice, Transgenic; Neoplasm Staging; Phosphorylation; Proto-Oncogene Proteins p21(ras); Resorcinols; Tumor Burden; Tumor Suppressor Protein p53 | 2017 |
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Piperazines; Retreatment; Treatment Outcome | 2017 |
Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Bacterial Infections; Biomarkers; Camptothecin; Cytokines; Female; Irinotecan; Lipid Metabolism; Liver; Liver Function Tests; Mice; Neutrophil Infiltration; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silymarin; Sulfhydryl Compounds | 2017 |
MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells.
Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HEK293 Cells; HT29 Cells; Humans; Irinotecan; Lentivirus; Leukocytes, Mononuclear; MicroRNAs; T-Lymphocytes, Regulatory; Transfection | 2017 |
Ionic Liquid Dispersive Liquid-Liquid Microextraction Method for the Determination of Irinotecan, an Anticancer Drug, in Water and Urine Samples Using UV-Vis Spectrophotometry.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Ionic Liquids; Irinotecan; Liquid Phase Microextraction; Spectrophotometry; Water; Water Pollutants, Chemical | 2017 |
Crypt Organoid Culture as an in Vitro Model in Drug Metabolism and Cytotoxicity Studies.
Topics: Animals; Apoptosis; Camptothecin; Cell Culture Techniques; Cytochrome P-450 CYP3A; Gene Expression; Inactivation, Metabolic; Intestinal Mucosa; Irinotecan; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Organoids; Xenobiotics | 2017 |
Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide | 2017 |
Synthesis and Characterization of Micelle-Forming PEG-Poly(Amino Acid) Copolymers with Iron-Hydroxamate Cross-Linkable Blocks for Encapsulation and Release of Hydrophobic Drugs.
Topics: Amino Acids; Anhydrides; Animals; Antineoplastic Agents; Camptothecin; Daunorubicin; Drug Compounding; Drug Delivery Systems; Drug Liberation; Ferric Compounds; Hydrophobic and Hydrophilic Interactions; Hydroxamic Acids; Irinotecan; Micelles; Polyethylene Glycols; Polymerization; Rats; Rats, Inbred F344; Stereoisomerism | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult | 2017 |
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Hypoxia; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Screening Assays, Antitumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3 beta; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitory Concentration 50; Irinotecan; MAP Kinase Signaling System; Piperazines; Protein Stability; Proto-Oncogene Proteins c-akt; Pyridines | 2017 |
Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901.
Topics: Aged; Camptothecin; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrins; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phosphorylation; Proteolysis; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Stomach Neoplasms | 2017 |
Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Camptothecin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Retrospective Studies | 2017 |
Terminal Acetylated/Acrylated Poly(ethylene glycol) Fabricated Drug Carriers: Design, Synthesis, and Biological Evaluation.
Topics: A549 Cells; Acetylation; Acrylates; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Female; Flocculation; Fungal Proteins; Humans; Hydrogen Bonding; Irinotecan; Kinetics; Lipase; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Polyethylene Glycols; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
An evolving function of DNA-containing exosomes in chemotherapy-induced immune response.
Topics: Animals; Camptothecin; Colorectal Neoplasms; Diarrhea; DNA; Exosomes; Humans; Irinotecan; Models, Biological | 2017 |
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
[A Case of Effective Chemoradiotherapy Using mFOLFOX6 for Locally Advanced Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2017 |
The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite outgrowth and signal via protein kinase C.
Topics: Animals; Camptothecin; Cell Differentiation; Cell Movement; Cells, Cultured; Idarubicin; Irinotecan; Neural Cell Adhesion Molecules; Neuronal Outgrowth; Neuronal Plasticity; Neurons; Protein Kinase C; Rats, Sprague-Dawley; Sialic Acids; Stem Cells | 2017 |
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Stem Neoplasms; Camptothecin; Cetuximab; Chemoradiotherapy; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2017 |
Efficacy assessment of self-assembled PLGA-PEG-PLGA nanoparticles: Correlation of nano-bio interface interactions, biodistribution, internalization and gene expression studies.
Topics: Adsorption; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Fibroblast Growth Factor 3; Gene Expression Regulation, Neoplastic; Histones; Humans; Irinotecan; Molecular Weight; Muscle Proteins; Nanoparticles; Nerve Tissue Proteins; Particle Size; Polyethylene Glycols; Polyglactin 910; Rats, Wistar; Serum Albumin, Bovine; Surface Properties; Tissue Distribution; Ubiquitins | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib | 2017 |
[Chemotherapy for colorectal cancer: Pragmatic assessment of prescription changes and relative dose intensity].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Substitution; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2017 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HeLa Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Knockout; Mutation; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan.
Topics: Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Lactic Acid; Liver Neoplasms; Micelles; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tretinoin | 2018 |
Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer.
Topics: Camptothecin; Cell Movement; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Neoplasm Invasiveness; Neoplastic Stem Cells; Nuclear Proteins; RNA, Small Interfering; Transfection; Twist-Related Protein 1 | 2017 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Retreatment; Retrospective Studies; Survival Rate | 2017 |
Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Models, Biological; Molecular Structure | 2017 |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Topics: Adult; Aged; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged | 2017 |
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Feces; Fluorouracil; Gastrointestinal Diseases; Inflammation; Intestinal Mucosa; Irinotecan; Magnetic Resonance Spectroscopy; Male; Metabolome; Microbiota; Organoplatinum Compounds; Oxaliplatin; Permeability; Rats; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Severity of Illness Index | 2017 |
Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; HSP27 Heat-Shock Proteins; Humans; Irinotecan; Janus Kinase 2; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Signal Transduction; STAT3 Transcription Factor; Tyrphostins | 2017 |
Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bronchoalveolar Lavage Fluid; Camptothecin; Female; Hemorrhage; Humans; Irinotecan; Lung Diseases; Pulmonary Alveoli; Thymoma; Thymus Neoplasms | 2017 |
Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics.
Topics: Biocatalysis; Camptothecin; Cell Proliferation; Delayed-Action Preparations; Drug Delivery Systems; Enzyme Stability; Glucuronidase; HeLa Cells; Humans; Irinotecan; Liposomes; Particle Size; Polyvinyl Alcohol; Porosity; Prodrugs | 2017 |
Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Delivery Systems; HT29 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Male; Mice; Mice, Nude; Micelles; Nanoparticles; Particle Size; Photons; Photosensitizing Agents; Phototherapy; Rats; Rats, Sprague-Dawley; Time Factors; Xenograft Model Antitumor Assays | 2017 |
Photothermal, Targeting, Theranostic Near-Infrared Nanoagent with SN38 against Colorectal Cancer for Chemothermal Therapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Humans; Indoles; Irinotecan; Nanoparticles; Phototherapy; Theranostic Nanomedicine | 2017 |
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clarithromycin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies | 2017 |
Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2017 |
Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Caco-2 Cells; Camptothecin; Cell Survival; Drug Delivery Systems; Drug Liberation; HEK293 Cells; Humans; Irinotecan; Mice; Nanoparticles; NIH 3T3 Cells; Peptides; Polylysine | 2017 |
Improved selectivity and cytotoxic effects of irinotecan via liposomal delivery: A comparative study on Hs68 and HeLa cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line; Cell Survival; DNA Damage; Endocytosis; HeLa Cells; Humans; Irinotecan; Liposomes | 2017 |
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Doxycycline; Heterografts; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Neuroblastoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
Irinotecan-induced muscle twitching from a possible drug interaction: A case report.
Topics: Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Drug Interactions; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Spasm | 2018 |
Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Topics: Camptothecin; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Genes, Neoplasm; HCT116 Cells; Humans; Irinotecan; Kaplan-Meier Estimate; MAP Kinase Signaling System; Protein Interaction Maps; Signal Transduction; Up-Regulation | 2017 |
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Immunohistochemistry; Irinotecan; Ki-67 Antigen; M Phase Cell Cycle Checkpoints; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tissue Array Analysis | 2017 |
Aggressive large-cell neuroendocrine carcinoma of the sigmoid colon in a patient with ulcerative colitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Colitis, Ulcerative; Fatal Outcome; Female; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Precancerous Conditions; Risk Factors; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2017 |
Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death: Potential use as adjunctive to chemotherapy.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cell Survival; Drug Screening Assays, Antitumor; Fibroblasts; Gene Expression; Humans; Irinotecan; Protective Agents; Pyruvates | 2017 |
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms | 2018 |
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Rats, Sprague-Dawley; Solubility; Tissue Distribution; X-Ray Diffraction; Xenograft Model Antitumor Assays | 2017 |
Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child, Preschool; Cyclophosphamide; Dacarbazine; Dactinomycin; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Humans; Irinotecan; Male; MicroRNAs; Neoplasm Metastasis; Promoter Regions, Genetic; Rhabdomyosarcoma, Alveolar; RNA, Neoplasm; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2018 |
Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Mice, Inbred NOD; Mice, SCID; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance.
Topics: Anilides; Animals; Antineoplastic Agents; Camptothecin; Coculture Techniques; Drug Resistance, Neoplasm; Drug Synergism; Female; Fibroblasts; Hedgehog Proteins; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Pyridines; Rats, Sprague-Dawley; Signal Transduction | 2017 |
Effects of an irinotecan derivative, ZBH‑1208, on the immune system in a mouse model of brain tumor and its antitumor mechanism.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Germ-Free Life; Immunity, Innate; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Nuclear Proteins; Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53 | 2017 |
Orthotopic patient-derived xenografts of paediatric solid tumours.
Topics: Animals; Bortezomib; Camptothecin; Cell Cycle Proteins; Child; Clone Cells; Drug Therapy, Combination; Epigenesis, Genetic; Female; Heterografts; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Indoles; Irinotecan; Mice; Neoplasms; Nuclear Proteins; Panobinostat; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Sensitivity to
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Etoposide; Gene Expression Profiling; Glioblastoma; Humans; Irinotecan; Protein Serine-Threonine Kinases; RNA, Messenger | 2017 |
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Random Allocation; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2017 |
A Pancreatic Predicament.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed; Tumor Burden | 2017 |
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic | 2017 |
Synthesis and evaluation of asymmetric curcuminoid analogs as potential anticancer agents that downregulate NF-κB activation and enhance the sensitivity of gastric cancer cell lines to irinotecan chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Humans; Irinotecan; Molecular Structure; NF-kappa B; Stomach Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Medical Oncology; Nanostructures; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Treatment Outcome | 2018 |
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2017 |
Solubility-Improved 10-O-Substituted SN-38 Derivatives with Antitumor Activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Male; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Structure-Activity Relationship | 2017 |
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Pneumonectomy; Prognosis; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2017 |
Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Azides; Benzene Derivatives; Biological Availability; Biological Transport; Camptothecin; Cell Line, Tumor; Curcumin; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Irinotecan; Ketones; Mitoxantrone; Neoplasm Proteins; Prazosin | 2017 |
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stomach Neoplasms | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
Carvacryl acetate, a novel semisynthetic monoterpene ester, binds to the TRPA1 receptor and is effective in attenuating irinotecan-induced intestinal mucositis in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Bacteremia; Camptothecin; Cytokines; Female; Intestinal Mucosa; Irinotecan; Jejunum; Mice; Molecular Docking Simulation; Monoterpenes; Mucositis; Neutropenia; TRPA1 Cation Channel | 2017 |
Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment.
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Camptothecin; Drug Monitoring; Humans; Irinotecan; Models, Molecular; Peptides; Protein Binding; Spectrometry, Fluorescence; Surface Plasmon Resonance | 2018 |
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Irinotecan; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Thyroid Carcinoma, Anaplastic | 2017 |
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dihydroorotase; DNA Damage; Doxorubicin; Enzyme Activation; Humans; Irinotecan; Mutagenesis; Mutation; Neoplasms; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Vincristine | 2017 |
Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic"
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylidene Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Hydrogen Peroxide; Irinotecan; Magnetic Resonance Imaging; Male; Melatonin; Mice, Inbred BALB C; Mice, Nude; Oncogenes; Oxidative Stress; Piperidones; Reactive Oxygen Species; Signal Transduction; Superoxides; Time Factors; Tumor Burden | 2017 |
How to Assess Drug Resistance in Cancer Stem Cells.
Topics: Animals; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplastic Stem Cells | 2018 |
Estimation of the future remnant liver function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Glycine; Hepatectomy; Humans; Imino Acids; Irinotecan; Liver Failure; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Organotechnetium Compounds; Oxaliplatin; Platelet Function Tests; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome | 2017 |
Liposome-loaded thermo-sensitive hydrogel for stabilization of SN-38 via intratumoral injection: optimization, characterization, and antitumor activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Hydrogel, Polyethylene Glycol Dimethacrylate; Injections, Intralesional; Irinotecan; Liposomes; Male; Mice; Particle Size; Solubility; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |
Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; DNA; DNA Helicases; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Irinotecan; Protein Binding; RNA-Binding Proteins | 2017 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatectomy; Humans; Inflammation Mediators; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Remission Induction | 2017 |
Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic | 2018 |
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2017 |
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Retreatment; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9.
Topics: Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Camptothecin; Enzyme Inhibitors; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Lignans; Metabolic Networks and Pathways; Microsomes, Liver; Recombinant Proteins; Serum Albumin, Bovine; UDP-Glucuronosyltransferase 1A9 | 2018 |
Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Complement Activation; Complement C3; Dextrans; Doxorubicin; Female; Ferrosoferric Oxide; Humans; Irinotecan; Liposomes; Magnetite Nanoparticles; Male; Middle Aged; Polyethylene Glycols; Surface Properties | 2017 |
Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Screening Assays, Antitumor; Escherichia coli; Glucuronidase; High-Throughput Screening Assays; Humans; Hydrogen-Ion Concentration; Intestines; Irinotecan; Mice; Molecular Docking Simulation; Protective Agents; Pyrazoles; Quinolines; Structure-Activity Relationship | 2017 |
Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Injections, Intraperitoneal; Irinotecan; Mice, Nude; Neoplasm Proteins; Quercetin; Random Allocation; Specific Pathogen-Free Organisms; Stomach Neoplasms; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan.
Topics: Antineoplastic Agents; Camptothecin; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Nanoparticles; Particle Size; Polysorbates; Serum Albumin, Human; Solubility | 2018 |
Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local | 2017 |
Liposomal
Topics: Animals; Bevacizumab; Camptothecin; Colonic Neoplasms; Copper Radioisotopes; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, SCID; Positron-Emission Tomography; Vascular Endothelial Growth Factor A | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
17β-estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes.
Topics: Animals; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Clopidogrel; Enzyme Inhibitors; Estradiol; Female; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrolysis; Irinotecan; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred ICR; Receptors, Estrogen; Ticlopidine; Transcription Factor AP-1; Transcription, Genetic | 2018 |
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Proliferation; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Photochemotherapy; Receptors, CXCR4; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Databases, Factual; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Taiwan | 2017 |
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |
Comparison of three-way and four-way calibration for the real-time quantitative analysis of drug hydrolysis in complex dynamic samples by excitation-emission matrix fluorescence.
Topics: Calibration; Camptothecin; Humans; Hydrolysis; Irinotecan; Kinetics; Models, Theoretical; Spectrometry, Fluorescence; Thermodynamics | 2018 |
Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Monitoring; Drug Stability; Fluorescence; Humans; Irinotecan; Reproducibility of Results; Temperature; Time Factors | 2018 |
Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
Topics: Acetylcholinesterase; Antineoplastic Agents; Camptothecin; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Irinotecan; Neoplasms; Poly(ADP-ribose) Polymerases; Prodrugs | 2018 |
Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Damage; Enzyme Inhibitors; Humans; Irinotecan; Mutation; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Suppressor Protein p53 | 2018 |
Chemotherapy diminishes lipid storage capacity of adipose tissue in a preclinical model of colon cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Size; Colonic Neoplasms; Disease Models, Animal; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Omega-3; Female; Fluorouracil; Humans; Irinotecan; Lipogenesis; Mitochondria; Mitochondrial Proteins; Phospholipids; Proteome; Rats; Rats, Inbred F344; Triglycerides | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
Role of regulatory T cells in irinotecan-induced intestinal mucositis.
Topics: Animals; Camptothecin; Cyclophosphamide; Cytokines; Diarrhea; Ileum; Inflammation; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred C57BL; Mucositis; Neutrophil Infiltration; Peroxidase; T-Lymphocytes, Regulatory; Th17 Cells | 2018 |
CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon.
Topics: Animals; Aquaporin 3; Aquaporin 4; Aquaporins; Camptothecin; Celecoxib; Cell Survival; Colon; Cyclooxygenase 2; Cytokines; Diarrhea; Feces; Gene Expression; Irinotecan; Male; Mice; Nitric Oxide Synthase Type II; Rats; Rats, Wistar; RAW 264.7 Cells | 2018 |
Chemical decontamination of iPS cell-derived neural cell mixtures.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Cell Membrane Permeability; DNA Damage; Humans; Induced Pluripotent Stem Cells; Irinotecan; Neural Stem Cells; Neurons; Phosphorylation | 2018 |
pH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fluorometry; Humans; Hydrogen-Ion Concentration; Irinotecan; Prodrugs | 2018 |
[A Case of Triple Negative Spindle Cell Carcinoma of the Breast and Improved Quality of Life Following Irinotecan Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Camptothecin; Carcinoma; Female; Humans; Irinotecan; Middle Aged; Quality of Life; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Topics: Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
[A Case of Locally Advanced Neuroendocrine Carcinoma of the Stomach Could be Curably Resected after Chemotherapy with CPT-11/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2017 |
[A Case of Successful CDDP plus CPT-11 Therapy for Recurrent Carcinomatous Lymphangiosis Occurring during Postoperative Adjuvant Therapy for Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Gastrectomy; Humans; Irinotecan; Lymphangitis; Male; Recurrence; Stomach Neoplasms | 2017 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Overexpression of Nitrogen Permease Regulator Like-2 (NPRL2) Enhances Sensitivity to Irinotecan (CPT-11) in Colon Cancer Cells by Activating the DNA Damage Checkpoint Pathway.
Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Movement; Colonic Neoplasms; DNA Damage; Down-Regulation; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histones; Humans; Irinotecan; Lentivirus; Membrane Potential, Mitochondrial; Mitosis; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Transduction, Genetic; Tumor Suppressor Proteins | 2018 |
Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer.
Topics: Adult; Antineoplastic Agents, Immunological; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Female; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Posterior Leukoencephalopathy Syndrome; Treatment Outcome | 2018 |
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.
Topics: Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2018 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Glucuronosyltransferase; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GTP Phosphohydrolases; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate | 2018 |
Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Ethanol; Fluorouracil; Garcinia; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Random Allocation; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
Topics: Antineoplastic Agents; Cadherins; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chitosan; Claudin-1; Drug Delivery Systems; Humans; Irinotecan; Male; Nanoparticles; Prostatic Neoplasms; RNA, Small Interfering; Snail Family Transcription Factors | 2018 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |
Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
Topics: Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Hedgehog Proteins; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Organoids; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; Zinc Finger Protein GLI1 | 2018 |
Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems.
Topics: Acridines; Aminoacridines; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Glucuronides; Glucuronosyltransferase; Hep G2 Cells; HT29 Cells; Humans; Irinotecan; Isoenzymes; Microsomes, Liver; Triazoles | 2018 |
[A Case Report of Neuroendocrine Carcinoma in the Gall Bladder Showing Recurrence Shortly after Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Female; Gallbladder Neoplasms; Humans; Irinotecan; Middle Aged; Recurrence; Time Factors | 2018 |
[A Case of Resected Esophageal Endocrine Cell Carcinoma That Responded to Combination Therapy Comprising Irinotecan and Cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Endocrine Cells; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Female; Humans; Irinotecan; Neoadjuvant Therapy | 2018 |
Reality of the emetogenic level of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Emetics; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Outpatients; Quality of Life; Retrospective Studies; Severity of Illness Index; Vomiting | 2018 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Quality of Life; Retrospective Studies; Salivation; Syndrome; Young Adult | 2018 |
Curcumin protects heart tissue against irinotecan-induced damage in terms of cytokine level alterations, oxidative stress, and histological damage in rats.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Camptothecin; Cardiotonic Agents; Cardiotoxicity; Curcumin; Cytokines; Irinotecan; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2018 |
Structural and photodynamic properties of the anti-cancer drug irinotecan in aqueous solutions of different pHs.
Topics: Antineoplastic Agents; Camptothecin; Hydrogen-Ion Concentration; Irinotecan; Light; Models, Chemical; Molecular Structure; Photochemistry; Water | 2018 |
SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Liberation; Humans; Irinotecan; Liposomes; Male; MCF-7 Cells; Mice, Inbred BALB C; Molecular Imaging; Nanoparticles; Particle Size; Solubility; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |
Retinoblastoma Cell Culturing and Evaluation of Their Drug Resistance.
Topics: Antineoplastic Agents; Ascorbic Acid; Camptothecin; Cell Survival; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infant; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Retinoblastoma; Tumor Cells, Cultured | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
How should BRAF V600E-mutated colorectal cancer be treated?
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type I; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan | 2018 |
Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Body Weight; Camptothecin; DNA Damage; Dose-Response Relationship, Drug; Dronabinol; Irinotecan; Liver; Liver Function Tests; Male; Mutagenicity Tests; Organ Size; Oxidative Stress; Rats, Wistar | 2018 |
Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Brain; Caco-2 Cells; Camptothecin; Chitosan; Drug Carriers; Humans; Intestinal Absorption; Irinotecan; Lactic Acid; Male; MCF-7 Cells; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2018 |
Improved lymphatic targeting: effect and mechanism of synthetic borneol on lymph node uptake of 7-ethyl-10-hydroxycamptothecin nanoliposomes following subcutaneous administration.
Topics: Administration, Cutaneous; Animals; Biological Transport; Camptothecin; Irinotecan; Liposomes; Lymph Nodes; Lymphatic System; Male; Mice; Nanoparticles; Rats; RAW 264.7 Cells; Tissue Distribution | 2018 |
Impact of diet on irinotecan toxicity in mice.
Topics: Animals; Body Weight; Camptothecin; Carboxylesterase; Diarrhea; Diet; Fatty Liver; Glucuronidase; Irinotecan; Male; Metabolome; Mice, Inbred C57BL; Toxicity Tests | 2018 |
Carboxylesterase and UDP-glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra-performance liquid chromatography-mass spectrometry analysis.
Topics: Animals; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Glucuronosyltransferase; Humans; Irinotecan; Linear Models; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Curcumin; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplastic Stem Cells; Spheroids, Cellular | 2018 |
Irinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biocompatible Materials; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Injections, Intravenous; Irinotecan; MCF-7 Cells; Mice; Micelles; Molecular Structure; Neoplasms, Experimental; Oxidation-Reduction; Particle Size; Polymers; Prodrugs; Structure-Activity Relationship; Surface Properties | 2018 |
Practical fluorimetric assay for the detection of anticancer drug SN-38 in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Monitoring; Fluorometry; Humans; Irinotecan; Reproducibility of Results | 2018 |
Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride in rat plasma by using high performance liquid chromatography-diode array detector.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Injections, Intravenous; Irinotecan; Rats; Rats, Sprague-Dawley | 2018 |
Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Folate Receptors, GPI-Anchored; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pentacyclic Triterpenes; Structure-Activity Relationship; Triterpenes; Tumor Cells, Cultured | 2018 |
Plasma citrulline is a sensitive safety biomarker for small intestinal injury in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Biomarkers; Camptothecin; Citrulline; Down-Regulation; Ileum; Intestinal Diseases; Irinotecan; Jejunum; Male; Metabolomics; Rats, Sprague-Dawley; Time Factors | 2018 |
[A Case of Advanced Gastric Cancer Treated with Curative Resection after Preoperative Secondary Chemotherapy with Irinotecan after Primary Chemotherapy with Docetaxel, Cisplatin, and S-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2018 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
[Factors Affecting Development of Cholinergic Symptoms after Irinotecan Administration].
Topics: Abdominal Pain; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Retrospective Studies; Sweat | 2018 |
A highly GSH-sensitive SN-38 prodrug with an "OFF-to-ON" fluorescence switch as a bifunctional anticancer agent.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Nucleus; Fluorescence; Fluorescent Dyes; Glutathione; Humans; Irinotecan; Kinetics; Mice; Microscopy, Confocal; Prodrugs | 2018 |
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.
Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Cholagogues and Choleretics; Diarrhea; Female; Humans; Intestines; Irinotecan; Magnesium Oxide; Male; Middle Aged; Neutropenia; Retrospective Studies; Sodium Bicarbonate; Topoisomerase I Inhibitors; Ursodeoxycholic Acid; Uterine Cervical Neoplasms; Uterine Neoplasms | 2019 |
Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.
Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Hodgkin Disease; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Mice; Mice, SCID; Pharmacokinetics | 2018 |
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
Topics: A549 Cells; ADAM17 Protein; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Fluorouracil; HeLa Cells; Hep G2 Cells; Humans; Irinotecan; MCF-7 Cells; Receptors, Notch; Signal Transduction | 2018 |
Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Proto-Oncogene Proteins pp60(c-src); Radiation-Sensitizing Agents; Signal Transduction; Tumor Suppressor Protein p53 | 2018 |
Pro-guest and acyclic cucurbit[n]uril conjugated polymers for the controlled release of anti-tumor drugs.
Topics: Antineoplastic Agents; Berberine; Bridged-Ring Compounds; Camptothecin; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Irinotecan; Mitoxantrone; Polymers; Topotecan | 2018 |
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Topics: Aminopyridines; Animals; Benzimidazoles; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; HT29 Cells; Humans; Irinotecan; MAP Kinase Kinase 1; Mice; Molecular Targeted Therapy; Morpholines; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes | 2018 |
Chemoembolization in Conjunction with Bevacizumab: Preliminary Results.
Topics: Administration, Intravenous; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Humans; Irinotecan; Italy; Liver Neoplasms; Male; Middle Aged; Preliminary Data; Prospective Studies; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chickens; Female; Humans; Integrin alphaVbeta3; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Peptides, Cyclic; Polyethylene Glycols; Rats, Sprague-Dawley | 2018 |
Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinergic Agents; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Risk Factors; Syndrome | 2019 |
A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines.
Topics: Caco-2 Cells; Camptothecin; Cell Cycle; Cell Death; Cell Survival; Chemistry, Pharmaceutical; Colorectal Neoplasms; Flow Cytometry; Freeze Drying; HeLa Cells; Humans; Irinotecan; L-Lactate Dehydrogenase; Liposomes; Microfluidics; Suspensions; Topoisomerase I Inhibitors | 2018 |
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Injury; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies; Risk Factors | 2018 |
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GPI-Linked Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Purinergic P1; Survival Rate | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Topics: Animals; Apoptosis; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Endocytosis; Female; Gene Silencing; Gene Transfer Techniques; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Liposomes; Mice, Nude; Neoplasms; Particle Size; Prodrugs; RNA, Small Interfering; Survivin; Tissue Distribution; Transferrin | 2018 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Camptothecin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Monodisperse oligoethylene glycols modified Camptothecin, 10-Hydroxycamptothecin and SN38 prodrugs.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Liberation; Ethylene Glycols; Humans; Irinotecan; Prodrugs | 2019 |
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronates; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Forecasting; Glucuronates; Humans; Irinotecan; Leucovorin; Leukopenia; Machine Learning; Male; Middle Aged; Models, Biological; Neutropenia; Oxaliplatin; Topoisomerase I Inhibitors | 2019 |
A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drugs, Chinese Herbal; Humans; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Oxaliplatin; Phytotherapy; Xenograft Model Antitumor Assays | 2019 |
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nomograms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
[FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Sarcopenia; Survival Analysis | 2019 |
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Etoposide; Hepatoblastoma; Humans; Ifosfamide; Infant; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Remission Induction | 2020 |
Biodegradable Polymeric Micelle-Mediated Delivery of a pH-Activatable Prodrug of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) to Enhance Anti-Angiogenesis and Anti-Tumor Activity.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Hydrogen-Ion Concentration; Irinotecan; Micelles; Prodrugs | 2018 |
Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Liberation; Female; HT29 Cells; Humans; Irinotecan; Lipids; Liposomes; Mice, Nude; Molecular Dynamics Simulation; Nanoparticles; Prodrugs; Rats, Sprague-Dawley; Solubility; Tissue Distribution; Xenograft Model Antitumor Assays | 2019 |
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Topics: Aged; Alternative Splicing; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Prognosis; Prospective Studies; Protein Isoforms; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2019 |
Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2019 |
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Germ Cells; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Ribosomal Proteins; Survival Rate; Tumor Cells, Cultured | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
The pharmacokinetic interaction between irinotecan and sunitinib.
Topics: Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Kinetics; Microsomes, Liver; Sunitinib | 2020 |
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2020 |
PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
Topics: Animals; Bile; Camptothecin; Gene Expression Regulation; Glucuronates; Glucuronosyltransferase; Irinotecan; Liver; Polyethylene Glycols; Prodrugs; Rats; Rats, Gunn; Tissue Distribution; Topoisomerase I Inhibitors | 2020 |
Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
Topics: Administration, Intravenous; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Immunoconjugates; Indicator Dilution Techniques; Irinotecan; Mass Spectrometry; Mice; Mice, SCID; Molecular Structure; Neoplasms, Experimental | 2020 |
Identify old drugs as selective bacterial β-GUS inhibitors by structural-based virtual screening and bio-evaluations.
Topics: Antidiarrheals; Aspartame; Bacteria; Bacterial Proteins; Camptothecin; Clozapine; Diarrhea; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Gemifloxacin; Glucuronates; Glucuronidase; Humans; Irinotecan; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Structure-Activity Relationship | 2020 |
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Endometrioid; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Survival; Endometrial Neoplasms; Female; Humans; Immunoconjugates; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2020 |
Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Camptothecin; Intestinal Mucosa; Irinotecan; Luteolin; Mice; Mucositis | 2020 |
Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Diarrhea; Disease Models, Animal; Glycerol; Heterografts; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2020 |
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2020 |
Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence.
Topics: Animals; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Limit of Detection; Linear Models; Mice; Reproducibility of Results; Spectrometry, Fluorescence; Tissue Distribution | 2020 |
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; HLA-G Antigens; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Molecular; Protein Binding; Protein Conformation; Protein Isoforms; Solubility; Spectrometry, Fluorescence | 2020 |
[Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Europe; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Pancreatic Neoplasms; Quality of Life | 2020 |
The coffee ingredients caffeic acid and caffeic acid phenylethyl ester protect against irinotecan-induced leukopenia and oxidative stress response.
Topics: Animals; Caffeic Acids; Camptothecin; Coffee; Esters; Glucuronosyltransferase; Irinotecan; Leukopenia; Mice; Oxidative Stress | 2020 |
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Microenvironment | 2020 |
FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Retrospective Studies | 2020 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Incidence; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; United States | 2020 |
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Tomography, X-Ray Computed | 2020 |
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2021 |
Modulation of Immune Checkpoints by Chemotherapy in Human Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Hepatitis A Virus Cellular Receptor 2; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2020 |
Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Esterases; Irinotecan; Nanoparticles; Prodrugs | 2021 |
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Fluorouracil; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic | 2021 |
UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Platinum; Polymorphism, Genetic; Prospective Studies; Small Cell Lung Carcinoma | 2021 |
[The Efficacy of topo Ⅰ-pS10 Expression in Gastric Cancer as a Predictive Biomarker for Irinotecan Use].
Topics: Biomarkers; Camptothecin; DNA Topoisomerases, Type I; Humans; Irinotecan; Stomach Neoplasms | 2021 |
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2021 |
[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Consensus; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2021 |
Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Irinotecan; Lysophospholipids; Oxidation-Reduction | 2021 |
Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Benzodioxoles; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Chromones; Dactinomycin; Datasets as Topic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Neoplasms; Prognosis; Pyridines; Triazoles | 2021 |
Antitumor Mechanism of Hydroxycamptothecin via the Metabolic Perturbation of Ribonucleotide and Deoxyribonucleotide in Human Colorectal Carcinoma Cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Survival; Colorectal Neoplasms; DNA; DNA Damage; HCT116 Cells; Humans; Irinotecan; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Ribonucleotides | 2021 |
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Microbubbles; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; Uridine | 2021 |
SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy.
Topics: Albumins; Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Irinotecan; Mice; Neoplasms; Prodrugs | 2021 |
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Progression-Free Survival; Pyrimidines; Retrospective Studies; Time Factors | 2021 |
A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins | 2022 |
Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2022 |
All You Need to Know About
Topics: Camptothecin; Genetic Testing; Glucuronosyltransferase; Humans; Irinotecan; Pancreatic Neoplasms; Polymorphism, Genetic; United States | 2022 |
Eosinophil plays a crucial role in intestinal mucositis induced by antineoplastic chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Eosinophils; Humans; Intestinal Mucosa; Irinotecan; Mice; Mucositis | 2022 |
Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboxylesterase; Colorectal Neoplasms; Drug Interactions; Fluorouracil; Irinotecan; Rats | 2022 |
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Topics: Camptothecin; Costs and Cost Analysis; Febrile Neutropenia; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Prospective Studies | 2022 |
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2022 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies | 2022 |
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Neoplasm Recurrence, Local; Retrospective Studies; Young Adult | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2022 |
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronates; Glucuronides; Humans; Irinotecan | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting | 2022 |
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma, Ewing; Temozolomide | 2022 |
Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Glucuronosyltransferase; Inflammation; Irinotecan; Mice | 2022 |
Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Costs and Cost Analysis; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic; Prospective Studies | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Diarrhea; Genotype; Humans; Irinotecan; Neoplasms | 2023 |
A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |
Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Dacarbazine; Humans; Irinotecan; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Topics: Camptothecin; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia | 2023 |
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Provider imaging practices and outcomes of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxicity; Cardiotoxins; Colorectal Neoplasms; Coronary Vasospasm; Diltiazem; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Nitrates | 2022 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms | 2023 |
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan | 2022 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan.
Topics: Camptothecin; Catalysis; Drug Stability; Irinotecan; Liposomes; Phospholipids; Tissue Distribution | 2023 |
Comment on: Irinotecan dose schedule for the treatment of Ewing sarcoma-protracted/metronomic schedule-wording matters!
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing | 2023 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan.
Topics: Camptothecin; Genotype; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic | 2023 |
Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.
Topics: Analgesics, Opioid; Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Disease Models, Animal; Dysbiosis; Glucuronidase; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Morphine Derivatives; Neoplasms; RNA, Ribosomal, 16S | 2023 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2022 |
Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Humans; Irinotecan | 2023 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Study on the solubilization effect of 7-ethyl-10-hydroxycamptothecin based on molecular docking and molecular dynamics simulation.
Topics: Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation | 2023 |
Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Treatment Outcome | 2023 |
Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy.
Topics: Camptothecin; Cell Line, Tumor; Disulfides; Drug Delivery Systems; Drug Liberation; Humans; Irinotecan; Nanoparticles; Pancreatic Neoplasms; Prodrugs | 2023 |
Green tea extract prevents CPT-11-induced diarrhea by regulating the gut microbiota.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Bacteria; Camptothecin; Diarrhea; Gastrointestinal Microbiome; Glucuronidase; Irinotecan; Rats; Tea | 2023 |
Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
Topics: Apoptosis; Camptothecin; Caspase 8; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Humans; Irinotecan | 2023 |
Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity.
Topics: Animals; Artesunate; Camptothecin; Cellular Senescence; Humans; Intestinal Diseases; Irinotecan; Mice; Neoplasms; TOR Serine-Threonine Kinases | 2023 |
Synthesis and Antitumor Evaluation of Biotin-SN38-Valproic Acid Conjugates.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotin; Camptothecin; Cell Line, Tumor; Fibroblasts; HeLa Cells; Humans; Irinotecan; Mice; NIH 3T3 Cells; Valproic Acid | 2023 |
A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Topics: Animals; Camptothecin; Cell Line, Tumor; Chitosan; Hyaluronic Acid; Irinotecan; Mice; Neoplasms; Polymers; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks.
Topics: Camptothecin; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Irinotecan; Mutation; Neoplasms | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2023 |
Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemical and Drug Induced Liver Injury, Chronic; Cross-Sectional Studies; Humans; Irinotecan; Liver Neoplasms; Retrospective Studies; Risk Factors | 2023 |
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Radiation-Sensitizing Agents; Treatment Outcome | 2023 |
Design, Synthesis, and Evaluation of Glucose Transporter Inhibitor-SN38 Conjugates for Targeting Colorectal Cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Irinotecan; Mice; Prodrugs; Tissue Distribution; Tumor Microenvironment | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Patient Safety | 2023 |
Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Prognosis; Topoisomerase I Inhibitors; Treatment Outcome | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Liposomes; Male; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis.
Topics: Camptothecin; Carboxylesterase; Colitis, Ulcerative; Diarrhea; Humans; Intestines; Irinotecan; Structure-Activity Relationship | 2023 |
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Pharmacogenomic Testing; Quality of Life | 2023 |
Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Caffeine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; DNA; Humans; Irinotecan | 2023 |
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2023 |